Selegiline	Selegiline	s040204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
postural	postural	p0230604	JJ	I-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
longitudinal	longitudinal	l05203030504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
Kingdom	Kingdom	k052305	NNP	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
Disease	Disease	d02020	NN	I-NP	I-Disease
Research	Research	r020620	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
(	(	(000	(	O	O
UKPDRG	UKPDRG	u21362	NNP	O	O
)	)	)000	)	O	O
trial	trial	t604	NN	B-NP	O
found	find	f053	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
randomized	randomize	r053050203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
selegiline	selegiline	s040204050	NN	I-NP	B-Chemical
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
and	and	a530	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
taking	take	t02052	VBG	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	B-Disease
orthostatic	orthostatic	o630230302	JJ	I-NP	I-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
unwanted	unwanted	u505303	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
postural	postural	p0230604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
autonomic	autonomic	a03050502	JJ	B-NP	O
failure	failure	f04060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aims	aim	a052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
confirm	confirm	c051065	VB	I-VP	O
our	our	o060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expectation	expectation	e210230305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
might	might	m0203	MD	B-VP	O
shed	shed	s030	VB	I-VP	O
light	light	l0203	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-VP	O
standing	standing	s3053052	VB	I-VP	O
and	and	a530	CC	I-VP	O
head	head	h030	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
tilt	tilt	t043	NN	B-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Head	Head	h030	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
tilt	tilt	t043	NN	B-NP	O
caused	cause	c0203	VBD	B-VP	O
systolic	systolic	s0230402	JJ	B-NP	B-Disease
orthostatic	orthostatic	o630230302	JJ	I-NP	I-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
marked	mark	m06203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	I-NP	O
20	20	0000	CD	I-NP	O
PD	PD	p300	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
lost	lose	l023	VBD	B-VP	O
consciousness	consciousness	c05202502	NN	B-NP	O
with	with	w030	IN	B-PP	O
unrecordable	unrecordable	u56020630140	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
standing	standing	s3053052	NN	B-NP	O
.	.	.000	.	O	O

Orthostatic	Orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
totally	totally	t03040	RB	B-VP	O
abolished	abolish	a1040203	VBD	I-VP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Stopping	Stop	s301052	VBG	B-VP	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	B-Disease
the	the	t000	DT	B-NP	I-Disease
supine	supine	s01050	NN	I-NP	I-Disease
systolic	systolic	s0230402	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
diastolic	diastolic	d0230402	JJ	I-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressures	pressure	p6020602	NNS	I-NP	I-Disease
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
undescribed	undescribed	u530260103	JJ	I-NP	O
supine	supine	s01050	NN	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
confirms	confirm	c0510652	VBZ	B-VP	O
our	our	o060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
selegiline	selegiline	s040204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
orthostatic	orthostatic	o630230302	JJ	I-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibilities	possibility	p0201040302	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
monoamine	monoamine	m0505050	NN	B-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
or	or	o600	CC	B-PP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
metamphetamine	metamphetamine	m030510305050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
irrigation	irrigation	i6020305	NN	B-NP	O
solutions	solution	s0403052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
bladders	bladder	b403062	NNS	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
irrigating	irrigate	i60203052	VBG	I-NP	O
fluids	fluid	f4032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
degradation	degradation	d026030305	NN	I-NP	O
product	product	p603023	NN	I-NP	O
p	p	p000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
choloroaniline	choloroaniline	c04060504050	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
chlorhexidine	chlorhexidine	c04060203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
digluconate	digluconate	d0240205030	NN	I-NP	I-Chemical
associated	associate	a2020303	VBN	B-VP	O
erosive	erosive	e602010	JJ	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
colistin	colistin	c0402305	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
povidone	povidone	p0103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
iodine	iodine	i03050	NN	I-NP	I-Chemical
irrigations	irrigation	i60203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
erosive	erosive	e602010	JJ	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
suggested	suggest	s0202303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
usage	usage	u2020	NN	I-NP	O
.	.	.000	.	O	O

Picloxydine	Picloxydine	p0240203050	NN	B-NP	B-Chemical
irrigations	irrigation	i60203052	NNS	I-NP	O
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
erosive	erosive	e602010	JJ	B-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
but	but	b030	CC	O	O
further	further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
would	would	w043	MD	B-VP	O
have	have	h010	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
before	before	b01060	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
urological	urological	u604020204	JJ	B-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
tetrandrine	tetrandrine	t0360536050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fangchinoline	fangchinoline	f0520504050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
and	and	a530	CC	O	O
human	human	h0505	JJ	B-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tetrandrine	Tetrandrine	t0360536050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TET	TET	t030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
fangchinoline	fangchinoline	f0520504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FAN	FAN	f050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
two	two	t000	CD	B-NP	O
naturally	naturally	n0306040	RB	I-NP	O
occurring	occur	o206052	VBG	I-NP	O
analogues	analogue	a5040202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
bisbenzylisoquinoline	bisbenzylisoquinoline	b0210520402020504050	NN	I-NP	B-Chemical
structure	structure	s36023060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TET	TET	t030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FAN	FAN	f050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
collagen	collagen	c040205	NN	B-NP	O
plus	plus	p402	CC	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
EP	EP	e100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
platelet	platelet	p4030403	NN	B-NP	B-Disease
aggregation	aggregation	a26020305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
TET	TET	t030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FAN	FAN	f050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
acetylsalicylic	acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
ASA	ASA	a200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
human	human	h0505	JJ	I-NP	O
platelet	platelet	p4030403	NN	I-NP	B-Disease
aggregations	aggregation	a260203052	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
tests	test	t0232	NNS	B-NP	O
,	,	,000	,	I-NP	O
TET	TET	t030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
FAN	FAN	f050	NN	I-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
inhibitions	inhibition	i50103052	NNS	I-NP	O
dose	dose	d020	NN	I-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
neither	neither	n0306	CC	O	O
TET	TET	t030	NN	B-NP	B-Chemical
nor	nor	n060	CC	I-NP	O
FAN	FAN	f050	NN	I-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
any	any	a500	DT	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
activated	activate	a23010303	VBN	I-NP	O
partial	partial	p06304	JJ	I-NP	O
thromboplastin	thromboplastin	t0605101402305	NN	I-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
APTT	APTT	a130	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
prothrombin	prothrombin	p6030605105	NN	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
PT	PT	p300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
thrombin	thrombin	t0605105	NN	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
TT	TT	t300	NN	B-NP	O
)	)	)000	)	O	O
using	use	u2052	VBG	B-VP	O
human	human	h0505	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
citrated	citrate	c0360303	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
antithrombosis	antithrombosis	a5303060510202	NN	B-NP	O
of	of	o100	IN	B-PP	O
TET	TET	t030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FAN	FAN	f050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
mainly	mainly	m0540	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
antiplatelet	antiplatelet	a53014030403	JJ	I-NP	O
aggregation	aggregation	a26020305	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
.	.	.000	.	O	O

Angioedema	Angioedema	a5203050	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
ACE	ACE	a200	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
:	:	:000	:	O	O
common	common	c0505	JJ	B-ADJP	O
and	and	a530	CC	O	O
inadequately	inadequately	i5030203040	RB	B-ADJP	O
diagnosed	diagnose	d0250203	VBN	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
angioedema	angioedema	a5203050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
(	(	(000	(	O	I-Chemical
ACE	ACE	a200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
inhibitor	inhibitor	i5010306	NN	B-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
between	between	b0305	IN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
per	per	p060	IN	B-PP	O
thousand	thousand	t02053	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
minor	minor	m0506	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
warning	warning	w065052	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
:	:	:000	:	O	O
prevalence	prevalence	p601040520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
and	and	a530	CC	O	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
sample	sample	s05140	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
attempts	attempt	a305132	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
and	and	a530	CC	I-VP	O
compare	compare	c051060	VB	I-VP	O
prevalence	prevalence	p601040520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
and	and	a530	CC	O	O
symptom	symptom	s051305	NN	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DSM	DSM	d250	NN	B-NP	O
substance	substance	s01230520	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
and	and	a530	CC	I-NP	O
other	other	o306	JJ	I-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

243	243	0000	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
outpatients	outpatient	o031030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
CIMD	CIMD	c053	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
no	no	n000	DT	B-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
measures	measure	m020602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
CIMD	CIMD	c053	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Introduction	Introduction	i5360302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DSM	DSM	d250	NN	I-NP	O
-	-	-000	HYPH	O	O
IV	IV	i100	CD	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
CIMD	CIMD	c053	NN	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
substantially	substantially	s0123053040	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
rates	rate	r0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CIMD	CIMD	c053	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
symptom	symptom	s051305	NN	B-NP	O
severity	severity	s0106030	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
without	without	w0303	IN	I-PP	O
a	a	a000	DT	B-NP	O
mood	mood	m030	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
some	some	s050	DT	B-NP	O
validity	validity	v0403030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
DSM	DSM	d250	NN	I-NP	O
-	-	-000	HYPH	O	O
IV	IV	i100	CD	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
CIMD	CIMD	c053	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
requires	require	r020602	VBZ	B-VP	O
further	further	f06306	JJ	B-NP	O
specification	specification	s10201020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
replication	replication	r014020305	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
fucoidan	fucoidan	f020305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
collagenase	collagenase	c040205020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
intracerebral	intracerebral	i536020601604	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Inflammatory	Inflammatory	i5140503060	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
mediate	mediate	m03030	VB	I-VP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intracerebral	Intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
more	more	m060	JJR	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
sulfated	sulfated	s0410303	JJ	I-NP	O
polysaccharide	polysaccharide	p04020206030	NN	I-NP	O
fucoidan	fucoidan	f020305	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
brain	brain	b605	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bacterial	bacterial	b0230604	JJ	B-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
caudate	caudate	c03030	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
day	day	d000	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
fucoidan	fucoidan	f020305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
h	h	h000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
by	by	b000	IN	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
.	.	.000	.	O	O

Motor	Motor	m0306	NNP	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
,	,	,000	,	O	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
skilled	skille	s20403	VBD	B-VP	O
forelimb	forelimb	f0604051	NN	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
six	six	s020	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Fucoidan	Fucoidan	f020305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
blood	blood	b403	NN	I-NP	I-Disease
clotting	clotting	c403052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hemodilution	hemodilution	h0503040305	NN	I-NP	B-Disease
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
larger	large	l06206	JJR	B-NP	O
hematomas	hematoma	h05030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
less	less	l020	JJR	B-NP	O
inflammation	inflammation	i514050305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vicinity	vicinity	v0205030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
three	three	t060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
showed	show	s030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	RBR	I-NP	O
rapid	rapid	r0103	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
week	week	w020	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
better	good	b0306	JJR	B-NP	O
memory	memory	m05060	NN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
white	white	w030	JJ	I-NP	B-Disease
matter	matter	m0306	NN	I-NP	I-Disease
edema	edema	e3050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
eventual	eventual	e105304	JJ	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
adjacent	adjacent	a3202053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Investigation	Investigation	i51023020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	RBR	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
hemodiluting	hemodilute	h05030403052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Recurarization	Recurarization	r020606020305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
room	room	r050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
recurarization	recurarization	r020606020305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
room	room	r050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Accumulation	Accumulation	a205040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
atracurium	atracurium	a36020605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
line	line	l050	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
recurarization	recurarization	r020606020305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
flushing	flush	f402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
line	line	l050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
room	room	r050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
desaturation	desaturation	d0203060305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Circumstances	Circumstance	c062052305202	NNS	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
event	event	e1053	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
enabling	enable	e5014052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	B-Disease
blockade	blockade	b402030	NN	I-NP	I-Disease
to	to	t000	TO	B-VP	O
occur	occur	o206	VB	I-VP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
relaxant	relaxant	r0402053	NN	B-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
ASA	ASA	a200	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
and	and	a530	CC	O	O
negative	negative	n0203010	JJ	B-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
disadvantages	disadvantage	d020310530202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
frail	frail	f604	NN	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adding	add	a3052	VBG	B-VP	O
different	different	d0106053	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
obtund	obtund	o13053	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
haemodynamic	haemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adding	add	a3052	VBG	B-VP	O
15	15	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
20	20	0000	CD	I-NP	O
or	or	o600	CC	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
control	control	c053604	VB	I-VP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
ASA	ASA	a200	NN	I-NP	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
over	over	o106	IN	B-PP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
genito	genito	g05030	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
obtunding	obtund	o13053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
all	all	a400	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
marked	marked	m06203	JJ	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
reaching	reach	r02052	VBG	B-VP	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Due	Due	d000	JJ	B-PP	O
to	to	t000	TO	I-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
inducing	induce	i5302052	VBG	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
would	would	w043	MD	B-VP	O
not	not	n030	RB	I-VP	O
recommend	recommend	r0205053	VB	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ephedrine	ephedrine	e1036050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
propofol	propofol	p6010104	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
mixtures	mixture	m0230602	NNS	B-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

Gemcitabine	Gemcitabine	g0520301050	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
vinorelbine	vinorelbine	v0506041050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
nonsmall	nonsmall	n052504	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
age	age	a200	NN	I-NP	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
or	or	o600	CC	O	O
older	old	o4306	JJR	B-ADJP	O
or	or	o600	CC	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
receive	receive	r02010	VB	I-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Oncopaz	Oncopaz	o520102	NNP	B-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonsmall	nonsmall	n052504	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
high	high	h020	JJ	B-ADJP	O
among	among	a5052	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
few	few	f000	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
single	single	s05240	JJ	B-NP	O
agent	agent	a2053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
vinorelbine	vinorelbine	v0506041050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VNB	VNB	v510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
GEM	GEM	g050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
a	a	a000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
acceptable	acceptable	a20130140	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
VNB	VNB	v510	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
or	or	o600	CC	O	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
some	some	s050	DT	B-NP	O
contraindication	contraindication	c0536053020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	O	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
,	,	,000	,	O	O
38	38	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
age	age	a200	NN	I-VP	O
>	>	>000	SYM	O	O
/	/	/000	SYM	B-NP	O
=	=	=000	SYM	B-VP	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
age	age	a200	NN	B-NP	O
<	<	<000	SYM	O	O
70	70	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
but	but	b030	CC	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
contraindication	contraindication	c0536053020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
comprised	comprise	c05160203	VBN	I-VP	O
of	of	o100	IN	B-PP	O
VNB	VNB	v510	NN	B-NP	B-Chemical
,	,	,000	,	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
plus	plus	p402	CC	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
both	both	b030	DT	O	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
every	every	e1060	DT	B-NP	O
28	28	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
unless	unless	u5402	IN	B-SBAR	O
progressive	progressive	p602602010	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
sixty	sixty	s0230	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
per	per	p060	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
41	41	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
attained	attain	a30503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Eastern	Eastern	e023065	NNP	B-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
value	value	v040	NN	I-NP	O
>	>	>000	SYM	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
relief	relief	r0401	NN	B-NP	O
of	of	o100	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
1	1	1000	CD	I-NP	O
symptom	symptom	s051305	NN	I-NP	O
without	without	w0303	IN	B-PP	O
worsening	worsen	w06205052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
27	27	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
progression	progression	p60260205	NN	B-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Toxicity	Toxicity	t0202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
World	World	w0643	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
Grade	Grade	g6030	NNP	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
sepsis	sepsis	s01202	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developing	develop	d010401052	VBG	B-VP	O
Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
vs	vs	v200	IN	B-ADVP	O
.	.	.000	.	O	O
72	72	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
047	047	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GEM	GEM	g050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
VNB	VNB	v510	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
moderately	moderately	m030603040	RB	B-ADJP	O
active	active	a23010	JJ	I-ADJP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
except	except	e2013	IN	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
age	age	a200	NN	I-NP	O
>	>	>000	SYM	O	O
/	/	/000	SYM	B-NP	O
=	=	=000	SYM	B-VP	O
75	75	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
age	age	a200	NN	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
granulocyte	granulocyte	g6050402030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
colony	colony	c04050	NN	I-NP	O
stimulating	stimulating	s3050403052	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

New	New	n000	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
advanced	advanced	a3105203	JJ	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D4	D4	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
preclinical	preclinical	p6024050204	JJ	I-NP	O
neuropharmacological	neuropharmacological	n06010650204020204	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorobenzylidene	fluorobenzylidene	f406010520403050	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
piperidin	piperidin	p01060305	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
yl	yl	y400	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorophenyl	fluorophenyl	f406010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
thiazole	thiazole	t02040	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxamide	carboxamide	c0610205030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
for	for	f060	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
cloned	clone	c40503	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D4	D4	0000	NN	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
D4	D4	0000	NN	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
D4	D4	0000	NN	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
Ki	Ki	k000	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
over	over	o106	IN	B-PP	O
20	20	0000	CD	B-NP	O
,	,	,000	,	O	O
000fold	000fold	0000	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D4	D4	0000	NN	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
cloned	clone	c40503	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2L	D2L	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
negligible	negligible	n024020140	JJ	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
cloned	clone	c40503	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D3	D3	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
Ki	Ki	k000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
39	39	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rat	rat	r030	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
2A	2A	2000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
Ki	Ki	k000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
180	180	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
rat	rat	r030	NN	B-NP	O
alpha1	alpha1	0000	NN	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
(	(	(000	(	O	O
Ki	Ki	k000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
237	237	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
antagonized	antagonize	a5302050203	VBD	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
antagonized	antagonize	a5302050203	VBD	B-VP	O
MAP	MAP	m010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
stereotyped	stereotype	s306030103	VBN	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
exceed	exceed	e203	VB	I-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
exceed	exceed	e203	VB	I-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
induction	induction	i5302305	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prepulse	prepulse	p6010420	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
(	(	(000	(	O	O
PPI	PPI	p100	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
shortened	shorten	s0630503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
phencyclidine	phencyclidine	p05202403050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
PCP	PCP	p210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
prolonged	prolong	p60405203	VBN	I-VP	O
swimming	swim	s05052	VBG	B-VP	O
latency	latency	l030520	NN	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
task	task	t020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
NRA0160	NRA0160	0000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
unique	unique	u5020	JJ	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
liability	liability	l0104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
typical	typical	t010204	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
classical	classical	c4020204	JJ	B-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
.	.	.000	.	O	O

Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
accelerated	accelerate	a204060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
growth	growth	g6030	NN	B-NP	O
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
growth	growth	g6030	NN	B-NP	O
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
enhance	enhance	e50520	VBP	B-VP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
sufficient	sufficient	s0102053	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Warfarin	Warfarin	w0610605	NNP	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
gamma	gamma	g050	NN	B-NP	O
-	-	-000	HYPH	O	O
carboxylation	carboxylation	c06102040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
matrix	matrix	m03602	NN	B-NP	O
Gla	Gla	g400	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
inhibitor	inhibitor	i5010306	NN	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
expressed	express	e2160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
smooth	smooth	s5030	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
macrophages	macrophage	m026010202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
artery	artery	a63060	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
examined	examine	e2050503	VBN	B-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
growth	growth	g6030	NN	I-NP	O
status	status	s30302	NN	I-NP	O
on	on	o500	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
massive	massive	m02010	JJ	B-NP	O
focal	focal	f0204	JJ	I-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
media	medium	m030	NNS	I-NP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
less	less	l020	RBR	B-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
focal	focal	f0204	JJ	I-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
42	42	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
adult	adult	a3043	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
even	even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
directly	directly	d0602340	RB	I-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
growth	growth	g6030	NN	B-NP	O
to	to	t000	TO	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
either	either	e0306	CC	O	O
an	an	a500	DT	B-NP	O
ad	ad	a300	NN	I-NP	O
libitum	libitum	l010305	NN	I-NP	O
diet	diet	d030	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
d	d	d000	NN	I-NP	O
restricted	restricted	r023602303	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
that	that	t030	WDT	B-NP	O
maintains	maintain	m053052	VBZ	B-VP	O
weight	weight	w0203	NN	B-NP	O
but	but	b030	CC	O	O
prevents	prevent	p6010532	VBZ	B-VP	O
growth	growth	g6030	NN	B-NP	O
.	.	.000	.	O	O

Concurrent	Concurrent	c05206053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
dietary	dietary	d03060	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
massive	massive	m02010	JJ	B-NP	O
focal	focal	f0204	JJ	I-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
media	medium	m030	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ad	ad	a300	NN	I-NP	O
libitum	libitum	l010305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
fed	feed	f030	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
detectable	detectable	d030230140	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
restricted	restricted	r023602303	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
growth	growth	g6030	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
inhibited	inhibit	i5010303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
explanation	explanation	e214050305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
growth	growth	g6030	NN	B-NP	O
status	status	s30302	NN	I-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
serum	serum	s0605	NN	I-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
higher	high	h0206	JJR	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
,	,	,000	,	O	O
ad	ad	a300	NN	B-NP	O
libitum	libitum	l010305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
fed	feed	f030	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
either	either	e0306	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
resistant	resistant	r02023053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
,	,	,000	,	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
restricted	restricted	r023602303	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
growth	growth	g6030	NN	B-NP	O
-	-	-000	HYPH	O	O
inhibited	inhibit	i5010303	VBN	B-NP	O
young	young	y052	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
increased	increase	i5260203	VBN	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
artery	artery	a63060	NN	I-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
higher	high	h0206	JJR	B-NP	O
serum	serum	s0605	NN	I-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
set	set	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
synergy	synergy	s050620	NN	I-NP	O
between	between	b0305	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
Warfarin	Warfarin	w0610605	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
calcification	calcification	c04201020305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
media	medium	m030	NNS	I-NP	O
in	in	i500	IN	B-PP	O
as	as	a200	RB	B-NP	O
little	little	l0340	JJ	I-NP	O
as	as	a200	IN	I-NP	O
3	3	3000	CD	I-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
K	K	k000	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
Warfarin	Warfarin	w0610605	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
calcification	calcification	c04201020305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
artery	artery	a63060	NN	I-NP	I-Disease
media	medium	m030	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
at	at	a300	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
or	or	o600	CC	O	O
longer	long	l05206	JJR	B-ADJP	O
yet	yet	y030	CC	O	O
not	not	n030	RB	O	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
synergy	synergy	s050620	NN	I-NP	O
between	between	b0305	IN	B-PP	O
these	these	t020	DT	B-NP	O
2	2	2000	CD	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
and	and	a530	CC	O	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
concurrent	concurrent	c05206053	JJ	B-NP	O
Warfarin	Warfarin	w0610605	NNP	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
dramatically	dramatically	d6050302040	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcification	calcification	c04201020305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
parallel	parallel	p060404	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
dose	dose	d020	NN	I-NP	O
on	on	o500	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
dose	dose	d020	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
synergy	synergy	s050620	NN	I-NP	O
between	between	b0305	IN	B-PP	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
probably	probably	p6010140	RB	I-VP	O
best	well	b023	RBS	I-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
matrix	matrix	m03602	NN	B-NP	O
Gla	Gla	g400	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
matrix	matrix	m03602	NN	B-NP	O
Gla	Gla	g400	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
found	find	f053	VBN	I-VP	O
at	at	a300	IN	B-PP	O
sites	site	s0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
artery	artery	a63060	NN	B-NP	B-Disease
calcification	calcification	c04201020305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D	D	d000	NN	I-NP	I-Chemical
plus	plus	p402	CC	O	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
chemical	chemical	c050204	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
accumulated	accumulate	a205040303	VBD	B-VP	O
was	be	w020	VBD	B-VP	O
indeed	indeed	i5303	RB	B-ADVP	O
not	not	n030	RB	B-NP	O
gamma	gamma	g050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
carboxylated	carboxylate	c06102040303	VBN	B-VP	I-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxyglutamate	carboxyglutamate	c061020240305030	NN	I-NP	I-Chemical
residues	residue	r020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
matrix	matrix	m03602	NN	B-NP	O
Gla	Gla	g400	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
apparently	apparently	a10605340	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
function	function	f052305	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
calcification	calcification	c04201020305	NN	I-NP	B-Disease
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
at	at	a300	IN	B-PP	O
calcification	calcification	c04201020305	NN	B-NP	B-Disease
sites	site	s0302	NNS	I-NP	O
.	.	.000	.	O	O

Test	Test	t023	NN	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
influence	influence	i5140520	VBP	B-VP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
under	under	u5306	IN	B-PP	O
varied	varied	v0603	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
test	test	t023	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
routinely	routinely	r0305040	RB	B-VP	O
employed	employ	e51403	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
behavioral	behavioral	b010604	NN	I-NP	O
and	and	a530	CC	I-NP	O
neurophysiological	neurophysiological	n06010204020204	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

Apomorphine	Apomorphine	a105061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
nonselective	nonselective	n05204023010	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	I-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
biphasic	biphasic	b010202	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
hypothermia	hypothermia	h01030650	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
distinct	distinct	d0230523	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
turnover	turnover	t0650106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rodent	rodent	r03053	NN	I-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
such	such	s020	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
characterization	characterization	c0602306020305	NN	B-NP	O
and	and	a530	CC	I-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
critically	critically	c60302040	RB	B-ADVP	O
depends	depend	d010532	VBZ	B-VP	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
employed	employ	e51403	VBN	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
facilitated	facilitate	f0204030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
acclimatization	acclimatization	a240503020305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
test	test	t023	NN	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
can	can	c050	MD	B-VP	O
impact	impact	i51023	VB	I-VP	O
upon	upon	u105	IN	B-PP	O
other	other	o306	JJ	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
qualitatively	qualitatively	q04030301040	RB	B-NP	O
different	different	d0106053	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
novel	novel	n0104	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
elicited	elicit	e4020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
home	home	h050	NN	I-NP	O
test	test	t023	NN	I-NP	O
cage	cage	c020	NN	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
gross	gross	g602	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
exploratory	exploratory	e2140603060	NN	I-NP	O
box	box	b020	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
measures	measure	m020602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
stereotypic	stereotypic	s306030102	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
prominent	prominent	p60505053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
exploratory	exploratory	e2140603060	NN	I-NP	O
box	box	b020	NN	I-NP	O
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
turnover	turnover	t0650106	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
(	(	(000	(	O	O
DOPAC	DOPAC	d0102	NN	B-NP	B-Chemical
:	:	:000	:	O	O
DA	DA	d000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
HVA	HVA	h100	NN	I-NP	B-Chemical
:	:	:000	:	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
exploratory	exploratory	e2140603060	NN	I-NP	O
box	box	b020	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
home	home	h050	NN	I-NP	O
cage	cage	c020	NN	I-NP	O
counterparts	counterpart	c0530610632	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
turnover	turnover	t0650106	NN	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
novel	novel	n0104	JJ	I-NP	O
and	and	a530	CC	I-NP	O
home	home	h050	NN	I-NP	O
cage	cage	c020	NN	I-NP	O
environments	environment	e5106050532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
emphasis	emphasis	e510202	NN	I-NP	O
upon	upon	u105	IN	B-PP	O
conducting	conduct	c053023052	VBG	B-VP	O
psychopharmacological	psychopharmacological	p202010650204020204	JJ	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
.	.	.000	.	O	O

Hemolysis	Hemolysis	h05040202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
erythrocytes	erythrocyte	e60306020302	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
tamoxifen	tamoxifen	t05020105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
membrane	membrane	m0516050	NN	B-NP	O
structure	structure	s36023060	NN	I-NP	O
.	.	.000	.	O	O

Tamoxifen	Tamoxifen	t05020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TAM	TAM	t050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
antiestrogenic	antiestrogenic	a530236020502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
most	most	m023	RBS	B-VP	O
widely	widely	w03040	RB	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
of	of	o100	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
discoid	discoid	d0203	JJ	I-NP	O
shape	shape	s010	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
and	and	a530	CC	O	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
evaluates	evaluate	e1040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
human	human	h0505	JJ	I-NP	O
erythrocytes	erythrocyte	e60306020302	NNS	I-NP	O
,	,	,000	,	O	O
attempting	attempt	a30513052	VBG	B-VP	O
to	to	t000	TO	I-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
on	on	o500	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
biomembranes	biomembrane	b0505160502	NNS	B-NP	O
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
cytostatic	cytostatic	c030230302	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

TAM	TAM	t050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
concentration	concentration	c05205360305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extension	extension	e2305205	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
variable	variable	v060140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
erythrocyte	erythrocyte	e6030602030	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
TAM	TAM	t050	NN	I-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
total	total	t0304	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
tested	test	t02303	VBN	I-NP	O
suspensions	suspension	s021052052	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
lysis	lysis	l0202	NN	I-NP	O
,	,	,000	,	O	O
TAM	TAM	t050	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
shift	shift	s013	VB	I-VP	O
the	the	t000	DT	B-NP	O
osmotic	osmotic	o250302	JJ	I-NP	O
fragility	fragility	f60204030	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
erythrocytes	erythrocyte	e60306020302	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
low	low	l000	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tocopherol	tocopherol	t02010604	NN	B-NP	I-Chemical
(	(	(000	(	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
T	T	t000	NN	B-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tocopherol	tocopherol	t02010604	NN	B-NP	I-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
TAc	TAc	t020	NN	B-NP	I-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
inactivated	inactivate	i5023010303	VBN	B-VP	O
functional	functional	f05230504	JJ	B-NP	O
hydroxyl	hydroxyl	h0360204	NN	I-NP	B-Chemical
)	)	)000	)	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
TAM	TAM	t050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
membrane	membrane	m0516050	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
further	further	f06306	RB	I-VP	O
evidenced	evidence	e10305203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
absence	absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
and	and	a530	CC	O	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
oxidation	oxidation	o2030305	NN	I-NP	O
both	both	b030	CC	O	O
determined	determine	d030650503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
parallel	parallel	p060404	NN	B-NP	O
with	with	w030	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
TAM	TAM	t050	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
erythrocytes	erythrocyte	e60306020302	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
AAPH	AAPH	a010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
ruling	rule	r04052	VBG	B-VP	O
out	out	o030	RP	B-PRT	O
TAM	TAM	t050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cell	cell	c040	NN	I-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Hemolysis	Hemolysis	h05040202	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
leakage	leakage	l02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
also	also	a420	RB	B-ADVP	O
excluding	exclude	e2403052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
colloid	colloid	c0403	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
osmotic	osmotic	o250302	JJ	I-NP	O
type	type	t010	NN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
osmotic	osmotic	o250302	JJ	B-NP	O
fragility	fragility	f60204030	NN	I-NP	O
curves	curve	c06102	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
TAM	TAM	t050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
membrane	membrane	m0516050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
cytoskeleton	cytoskeleton	c0302040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
cytosol	cytosol	c030204	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
essentially	essentially	e2053040	RB	B-ADVP	O
bound	bind	b053	VBD	B-VP	O
to	to	t000	TO	B-PP	O
band	band	b053	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

Either	Either	e0306	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
T	T	t000	NN	B-NP	I-Chemical
or	or	o600	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
TAc	TAc	t020	NN	B-NP	I-Chemical
increases	increase	i5260202	VBZ	B-VP	O
membrane	membrane	m0516050	NN	B-NP	O
packing	packing	p02052	NN	I-NP	O
and	and	a530	CC	O	O
prevents	prevent	p6010532	VBZ	B-VP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
partition	partition	p0630305	NN	I-NP	O
into	into	i530	IN	B-PP	O
model	model	m0304	NN	B-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
from	from	f605	IN	B-PP	O
hemolysis	hemolysis	h05040202	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
tocopherols	tocopherol	t020106042	NNS	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
TAM	TAM	t050	NN	I-NP	B-Chemical
incorporation	incorporation	i52061060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
condensed	condense	c05305203	VBN	B-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
consequently	consequently	c0520205340	RB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
TAM	TAM	t050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
results	result	r020432	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
perturbation	perturbation	p0630610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
red	red	r030	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
framework	framework	f605062	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
cytoskeleton	cytoskeleton	c0302040305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
high	high	h020	JJ	I-NP	O
partition	partition	p0630305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
membrane	membrane	m0516050	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
defects	defect	d010232	NNS	I-NP	O
explain	explain	e21405	VBP	B-VP	O
the	the	t000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
erythrocyte	erythrocyte	e6030602030	NN	I-NP	O
shape	shape	s010	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
stability	stability	s30104030	NN	I-NP	O
promoted	promote	p6050303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
membrane	membrane	m0516050	NN	B-NP	O
leakage	leakage	l02020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytotoxicity	cytotoxicity	c03030202030	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
biomembranes	biomembrane	b0505160502	NNS	B-NP	O
by	by	b000	IN	B-PP	O
TAM	TAM	t050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
anticancer	anticancer	a530205206	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
affinities	affinity	a1050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
K	K	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
deficient	deficient	d0102053	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
NO	NO	n000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
functions	function	f0523052	NNS	B-NP	O
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
induces	induce	i530202	VBZ	B-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
disturbances	disturbance	d02306105202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
transmembraneous	transmembraneous	t6052505160502	JJ	B-NP	O
transport	transport	t60521063	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
K	K	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
to	to	t000	TO	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
synthase	synthase	s053020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
with	with	w030	IN	B-PP	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	O	O
day	day	d000	NN	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
G	G	g000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
nitro	nitro	n0360	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
four	four	f060	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
week	week	w020	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
terminating	terminate	t0650503052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
SBP	SBP	s100	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
value	value	v040	NN	B-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
activating	activate	a230103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
with	with	w030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
substrate	substrate	s01236030	NN	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Km	Km	k500	NN	B-NP	O
and	and	a530	CC	I-NP	O
Vmax	Vmax	v502	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
activation	activation	a23010305	NN	B-NP	O
with	with	w030	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Vmax	Vmax	v502	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
profound	profound	p601053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
-	-	-000	HYPH	O	O
binding	bind	b053052	VBG	B-VP	O
site	site	s030	NN	B-NP	O
in	in	i500	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
from	from	f605	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
K	K	k000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
higher	high	h0206	JJR	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
binding	bind	b053052	VBG	B-NP	O
site	site	s030	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
revealed	reveal	r010403	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
lowered	lowered	l0603	JJ	I-NP	O
Km	Km	k500	NN	I-NP	O
value	value	v040	NN	I-NP	O
for	for	f060	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
K	K	k000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
value	value	v040	NN	B-NP	O
for	for	f060	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
control	control	c053604	VB	I-VP	O
value	value	v040	NN	B-NP	O
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
synthase	synthase	s053020	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
depressed	depressed	d0160203	JJ	B-NP	B-Disease
Na	Na	n000	NN	I-NP	B-Chemical
+	+	+000	SYM	O	O
-	-	-000	HYPH	O	O
extrusion	extrusion	e2360205	NN	B-NP	O
from	from	f605	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
deteriorated	deteriorate	d0306060303	VBN	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
binding	bind	b053052	VBG	B-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
extrusion	extrusion	e2360205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
from	from	f605	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
normalized	normalize	n065040203	VBN	I-VP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
revealed	reveal	r010403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
restoration	restoration	r023060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
(	(	(000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
persisted	persist	p06202303	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
adrenalectomy	adrenalectomy	a360504023050	NN	B-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
ii	ii	i000	LS	I-LST	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
,	,	,000	,	O	O
supporting	support	s01063052	VBG	B-VP	O
therefore	therefore	t0601060	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
outflow	outflow	o03140	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
prolonged	prolong	p60405203	VBN	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
abolish	abolish	a104020	VB	I-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
hypertrophy	hypertrophy	h010636010	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
affecting	affect	a1023052	VBG	B-VP	O
baseline	baseline	b0204050	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
bromocriptine	bromocriptine	b605026013050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

Bromocriptine	Bromocriptine	b605026013050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
partly	partly	p06340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
domperidone	domperidone	d0510603050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
vagal	vagal	v0204	JJ	I-NP	O
nor	nor	n060	CC	I-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
altered	alter	a430603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
perfused	perfuse	p0610203	VBN	I-NP	O
heart	heart	h063	NN	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pretreated	pretreate	p60360303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pretreated	pretreate	p60360303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
EC50	EC50	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
22	22	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
abolished	abolish	a1040203	VBD	B-VP	O
but	but	b030	CC	I-VP	O
reversed	reverse	r0106203	VBD	I-VP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
mainly	mainly	m0540	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
further	further	f06306	VB	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
desensitization	desensitization	d0205203020305	NN	I-NP	O
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
to	to	t000	TO	B-PP	O
impairment	impairment	i51065053	NN	B-NP	O
of	of	o100	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
conscious	conscious	c05202	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
predominate	predominate	p6030505030	VB	I-VP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
mask	mask	m020	VB	I-VP	O
the	the	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
at	at	a300	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
infant	infant	i51053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
infant	infant	i51053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
emit	emit	e503	VBP	B-VP	O
ultrasonic	ultrasonic	u436020502	JJ	B-NP	O
vocalizations	vocalization	v02040203052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
extreme	extreme	e236050	JJ	B-NP	O
cold	cold	c043	JJ	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	B-PP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
adrenoceptor	adrenoceptor	a36050201306	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
ultrasound	ultrasound	u43602053	NN	B-NP	O
production	production	p60302305	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
2nd	2nd	2530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
week	week	w020	NN	I-NP	O
postpartum	postpartum	p023106305	NN	I-NP	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-VP	O
that	that	t030	IN	B-SBAR	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
neural	neural	n0604	JJ	I-NP	O
dominance	dominance	d05050520	NN	I-NP	O
exhibits	exhibit	e201032	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
given	give	g0105	VBN	B-VP	O
that	that	t030	IN	B-SBAR	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
developmental	developmental	d010401505304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
would	would	w043	MD	B-VP	O
mirror	mirror	m0606	VB	I-VP	O
each	each	e020	DT	B-NP	O
other	other	o306	JJ	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
ultrasound	ultrasound	u43602053	JJ	B-NP	O
production	production	p60302305	NN	I-NP	O
corresponded	correspond	c0602105303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
ultrasound	ultrasound	u43602053	JJ	B-NP	O
production	production	p60302305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
acoustic	acoustic	a202302	NN	I-NP	O
by	by	b000	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
product	product	p603023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
maneuver	maneuver	m050106	NN	I-NP	O
that	that	t030	WDT	B-NP	O
compensates	compensate	c0510520302	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
detrimental	detrimental	d0360505304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
newer	new	n060	JJR	B-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
epidemiological	epidemiological	e1030504020204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
VTE	VTE	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
newer	new	n060	JJR	B-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
OC	OC	o200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
distinguish	distinguish	d023052020	VB	I-VP	O
between	between	b0305	IN	B-PP	O
patterns	pattern	p030652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
OC	OC	o200	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
namely	namely	n05040	RB	B-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
repeaters	repeater	r0103062	NNS	B-NP	O
and	and	a530	CC	I-NP	O
switchers	switcher	s032062	NNS	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
Transnational	Transnational	t60525030504	JJ	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
accounting	account	a2053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
use	use	u200	NN	B-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
1993	1993	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1996	1996	0000	CD	I-NP	O
,	,	,000	,	O	O
551	551	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Germany	Germany	g065050	NNP	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
UK	UK	u200	NNP	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
2066	2066	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Totals	Total	t03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
128	128	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
650	650	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
135	135	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
622	622	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
patterns	pattern	p030652	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
for	for	f060	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
users	user	u2062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
generation	generation	g05060305	NN	I-NP	O
OC	OC	o200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
relative	relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
repeat	repeat	r0103	VB	I-VP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
generation	generation	g05060305	NN	I-NP	O
pills	pill	p042	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
switchers	switcher	s032062	NNS	B-NP	O
from	from	f605	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
to	to	t000	TO	B-PP	O
third	third	t063	JJ	B-NP	O
generation	generation	g05060305	NN	I-NP	O
pills	pill	p042	NNS	I-NP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
switchers	switcher	s032062	NNS	B-NP	O
from	from	f605	IN	B-PP	O
third	third	t063	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
second	second	s02053	JJ	B-NP	O
generation	generation	g05060305	NN	I-NP	O
pills	pill	p042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
second	second	s02053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
third	third	t063	JJ	I-NP	O
generation	generation	g05060305	NN	I-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
equivalent	equivalent	e20104053	JJ	B-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
interruption	interruption	i530601305	NN	B-NP	O
periods	period	p06032	NNS	I-NP	O
or	or	o600	CC	O	O
when	when	w050	WRB	B-ADVP	O
users	user	u2062	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
switched	switch	s03203	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
generations	generation	g050603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pills	pill	p042	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
newer	new	n060	JJR	I-NP	O
OC	OC	o200	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
inadequate	inadequate	i50302030	JJ	B-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pill	pill	p040	NN	B-NP	O
users	user	u2062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pill	pill	p040	NN	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
systemically	systemically	s0230502040	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
dynamic	dynamic	d050502	JJ	B-NP	O
and	and	a530	CC	I-NP	O
static	static	s30302	JJ	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
brush	brush	b6020	NN	B-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-VP	O
(	(	(000	(	O	O
dynamic	dynamic	d050502	JJ	O	O
)	)	)000	)	O	O
pain	pain	p050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
punctate	punctate	p0523030	NN	I-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-VP	O
(	(	(000	(	O	O
static	static	s30302	JJ	O	O
)	)	)000	)	O	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	NN	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
12	12	0000	CD	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
intradermally	intradermally	i53603065040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
volar	volar	v0406	JJ	I-NP	O
forearm	forearm	f06065	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
bolus	bolus	b0402	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
over	over	o106	IN	I-NP	O
10	10	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	O	O
1	1	1000	CD	B-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
for	for	f060	IN	B-PP	O
50	50	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Infusion	Infusion	i510205	NN	B-NP	O
started	start	s306303	VBD	B-VP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
:	:	:000	:	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
pain	pain	p050	NN	B-NP	B-Disease
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
punctate	punctate	p0523030	NN	B-NP	O
and	and	a530	CC	I-NP	O
brush	brush	b6020	NN	I-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
(	(	(000	(	O	O
VAS	VAS	v020	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
areas	area	a602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
brush	brush	b6020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
evoked	evoke	e10203	VBN	B-VP	O
and	and	a530	CC	O	O
punctate	punctate	p0523030	NN	B-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
brush	brush	b6020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
evoked	evoke	e10203	VBN	B-VP	O
and	and	a530	CC	O	O
punctate	punctate	p0523030	NN	B-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
brush	brush	b6020	NN	B-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Lidocaine	Lidocaine	l0302050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
punctate	punctate	p0523030	NN	B-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
VAS	VAS	v020	NNP	B-NP	O
scores	score	s20602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
evoked	evoke	e10203	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
static	static	s30302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
dynamic	dynamic	d050502	JJ	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
separate	separate	s0106030	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
and	and	a530	CC	O	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
distinct	distinct	d0230523	JJ	I-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
:	:	:000	:	O	O
comparison	comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
once	once	o520	RB	O	O
daily	daily	d040	JJ	B-ADJP	O
)	)	)000	)	O	O
aggressive	aggressive	a2602010	JJ	B-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
breeder	breeder	b60306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
sets	set	s032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
repeated	repeat	r010303	VBN	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
as	as	a200	IN	B-SBAR	O
evidenced	evidence	e10305203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
aggressiveness	aggressiveness	a2602010502	NN	B-NP	B-Disease
and	and	a530	CC	O	O
shortened	shorten	s0630503	VBD	B-VP	O
latency	latency	l030520	NN	B-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
attack	attack	a302	NN	I-NP	O
toward	toward	t063	IN	B-PP	O
the	the	t000	DT	B-NP	O
opponent	opponent	o105053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
weak	weak	w020	JJ	I-NP	O
tendency	tendency	t0530520	NN	I-NP	O
toward	toward	t063	IN	B-PP	O
aggressiveness	aggressiveness	a2602010502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
gender	gender	g05306	NN	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
aggressive	aggressive	a2602010	JJ	I-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
and	and	a530	CC	O	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
fill	fill	f040	VB	I-VP	O
the	the	t000	DT	B-NP	O
validation	validation	v04030305	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Intracranial	Intracranial	i5360260504	JJ	B-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
:	:	:000	:	O	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
prognostic	prognostic	p602502302	JJ	B-NP	O
indicators	indicator	i530203062	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
of	of	o100	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reportedly	reportedly	r010630340	RB	B-ADJP	O
poor	poor	p060	JJ	I-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
analyze	analyze	a504020	VB	I-VP	O
the	the	t000	DT	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
influence	influence	i5140520	VBP	B-VP	O
outcome	outcome	o032050	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
admissions	admission	a3502052	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
aneurysms	aneurysm	a5060252	NNS	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
135	135	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ruptured	ruptured	r0130603	JJ	B-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
of	of	o100	IN	B-PP	O
ictus	ictus	i2302	NN	B-NP	O
after	after	a1306	IN	B-PP	O
intoxication	intoxication	i5302020305	NN	B-NP	O
,	,	,000	,	O	O
Hunt	Hunt	h053	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Hess	Hess	h020	NNP	I-NP	O
grade	grade	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
size	size	s020	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aneurysm	aneurysm	a506025	NN	I-NP	B-Disease
,	,	,000	,	O	O
location	location	l020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aneurysm	aneurysm	a506025	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Glasgow	Glasgow	g4020	NNP	I-NP	O
Outcome	Outcome	o032050	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
score	score	s2060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
younger	young	y05206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
aneurysms	aneurysm	a5060252	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
located	locate	l020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
aneurysms	aneurysm	a5060252	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mortality	mortality	m06304030	NN	B-NP	O
and	and	a530	CC	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

Hunt	Hunt	h053	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Hess	Hess	h020	NNP	I-NP	O
grade	grade	g6030	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
007	007	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
predictors	predictor	p603023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
outcome	outcome	o032050	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
aneurysms	aneurysm	a5060252	NNS	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
predisposed	predispose	p6030210203	VBD	B-VP	O
aneurysmal	aneurysmal	a50602504	JJ	B-NP	B-Disease
rupture	rupture	r013060	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
earlier	early	e06406	JJR	I-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
much	much	m020	RB	B-NP	O
smaller	small	s50406	JJR	I-NP	O
aneurysms	aneurysm	a5060252	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Contrary	Contrary	c0536060	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
published	publish	p0140203	VBN	I-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
did	do	d030	VBD	B-VP	O
reasonably	reasonably	r02050140	RB	B-ADVP	O
well	well	w040	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
aggressive	aggressive	a2602010	JJ	B-NP	O
management	management	m050205053	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
nimodipine	nimodipine	n050301050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
PURPOSE	PURPOSE	p061020	NN	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
Intravenous	Intravenous	i536010502	JJ	I-NP	O
Nimodipine	Nimodipine	n050301050	NNP	I-NP	B-Chemical
West	West	w023	NNP	I-NP	O
European	European	e060105	NNP	I-NP	O
Stroke	Stroke	s36020	NNP	I-NP	B-Disease
Trial	Trial	t604	NNP	I-NP	O
(	(	(000	(	O	O
INWEST	INWEST	i5023	NN	B-NP	O
)	)	)000	)	O	O
found	find	f053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
unfavorable	unfavorable	u5101060140	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
confirm	confirm	c051065	VB	I-VP	O
this	this	t020	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	B-PP	O
without	without	w0303	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
prognostic	prognostic	p602502302	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
outcome	outcome	o032050	NN	B-NP	O
in	in	i500	IN	B-PP	O
subgroups	subgroup	s0126012	NNS	B-NP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BP	BP	b100	NN	B-NP	B-Disease
reduction	reduction	r0302305	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
(	(	(000	(	O	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
consecutively	consecutively	c052020301040	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
100	100	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
h	h	h000	NN	I-NP	O
(	(	(000	(	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
101	101	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
h	h	h000	NN	I-NP	O
(	(	(000	(	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
94	94	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
average	average	a106020	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
change	change	c0520	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
21	21	0000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
sixty	sixty	s0230	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
five	five	f010	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
92	92	0000	CD	B-NP	O
,	,	,000	,	O	O
93	93	0000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
80	80	0000	CD	B-NP	O
for	for	f060	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nimodipine	Nimodipine	n050301050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
systolic	systolic	s0230402	JJ	B-NP	I-Disease
BP	BP	b100	NN	I-NP	I-Disease
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
diastolic	diastolic	d0230402	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
(	(	(000	(	O	O
DBP	DBP	d100	NN	B-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
DBP	DBP	d100	NN	B-NP	B-Disease
reduction	reduction	r0302305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
worsening	worsen	w06205052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
beta	beta	b030	SYM	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
49	49	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
048	048	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
DBP	DBP	d100	NN	I-NP	B-Disease
reduction	reduction	r0302305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
OR	OR	o600	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
variable	variable	v060140	JJ	I-NP	O
death	death	d030	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
dependency	dependency	d010530520	NN	I-NP	O
(	(	(000	(	O	O
Barthel	Barthel	b06304	NNP	B-NP	O
Index	Index	i5302	NNP	I-NP	O
<	<	<000	SYM	B-NP	O
60	60	0000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
/	/	/000	SYM	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
/	/	/000	SYM	O	O
26	26	0000	CD	B-NP	O
,	,	,000	,	O	O
OR	OR	o600	NN	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	O	O
16	16	0000	CD	B-NP	O
,	,	,000	,	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
101	101	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
74	74	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	B-Disease
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
/	/	/000	SYM	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
/	/	/000	SYM	O	O
26	26	0000	CD	B-NP	O
,	,	,000	,	O	O
OR	OR	o600	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
336	336	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
131	131	0000	CD	B-NP	O
16	16	0000	CD	I-NP	O
.	.	.000	.	O	O
619	619	0000	CD	O	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
all	all	a400	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
N	N	n000	NN	I-NP	O
=	=	=000	SYM	B-VP	O
62	62	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
92	92	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
92	92	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
SBP	SBP	s100	NN	B-NP	O
change	change	c0520	NN	I-NP	O
and	and	a530	CC	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
DBP	DBP	d100	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
SBP	SBP	s100	NN	B-NP	O
,	,	,000	,	O	O
reduction	reduction	r0302305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
worsening	worsen	w06205052	VBG	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
nimodipine	nimodipine	n050301050	NN	I-NP	B-Chemical
after	after	a1306	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
nimodipine	nimodipine	n050301050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
conclusive	conclusive	c052402010	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
confirm	confirm	c051065	VB	I-VP	O
or	or	o600	CC	I-VP	O
exclude	exclude	e24030	VB	I-VP	O
a	a	a000	DT	B-NP	O
neuroprotective	neuroprotective	n0601603023010	JJ	I-NP	O
property	property	p6010630	NN	I-NP	O
of	of	o100	IN	B-PP	O
nimodipine	nimodipine	n050301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Neonatal	Neonatal	n050304	JJ	B-NP	O
pyridoxine	pyridoxine	p060302050	NN	I-NP	B-Chemical
responsive	responsive	r021052010	JJ	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
17	17	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
infant	infant	i51053	NN	I-NP	O
on	on	o500	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
13	13	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
birth	birth	b0630	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
tuberculosis	tuberculosis	t01062040202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonic	clonic	c40502	JJ	B-NP	B-Disease
fits	fit	f032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
infective	infective	i51023010	JJ	I-NP	O
or	or	o600	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fits	fit	f032	NNS	I-NP	B-Disease
ceased	cease	c0203	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
administering	administer	a350502306052	VBG	B-VP	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
pyridoxine	pyridoxine	p060302050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
aetiology	aetiology	a0304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
deficiency	deficiency	d01020520	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
sedation	sedation	s030305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
fractures	fracture	f60230602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
recently	recently	r0205340	RB	B-ADVP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
resurgence	resurgence	r020620520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
utilization	utilization	u304020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
emergency	emergency	e50620520	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
department	department	d010635053	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
requiring	require	r0206052	VBG	B-VP	O
sedation	sedation	s030305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
fractures	fracture	f60230602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
fourteen	fourteen	f06305	CD	I-NP	O
children	child	c043605	NNS	I-NP	O
(	(	(000	(	O	O
average	average	a106020	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
twelve	twelve	t0410	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
ten	ten	t050	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
ten	ten	t050	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
closed	close	c40203	VBN	B-VP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
fracture	fracture	f6023060	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
dislocation	dislocation	d024020305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
trauma	trauma	t6050	NN	I-NP	B-Disease
center	center	c05306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
prospectively	prospectively	p602102301040	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
milligrams	milligram	m04026052	NNS	I-NP	O
per	per	p060	IN	B-PP	O
kilogram	kilogram	k0402605	NN	B-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
ninety	ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
milligrams	milligram	m04026052	NNS	I-NP	O
per	per	p060	IN	B-PP	O
kilogram	kilogram	k0402605	NN	B-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
fifteen	fifteen	f01305	CD	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
board	board	b063	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
certified	certify	c0630103	VBN	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
physician	physician	p020205	NN	I-NP	O
skilled	skille	s20403	VBN	B-VP	O
in	in	i500	IN	B-PP	O
airway	airway	a060	NN	B-NP	O
management	management	m050205053	NN	I-NP	O
supervised	supervise	s010610203	VBD	B-VP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
registered	register	r020230603	VBN	I-NP	O
nurse	nurse	n0620	NN	I-NP	O
.	.	.000	.	O	O

Any	Any	a500	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
rated	rat	r0303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
orthopaedic	orthopaedic	o63010302	JJ	I-NP	O
surgeon	surgeon	s06205	NN	I-NP	O
treating	treat	t603052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Eastern	Eastern	e023065	NNP	B-NP	O
Ontario	Ontario	o53060	NNP	I-NP	O
Pain	Pain	p050	NNP	I-NP	B-Disease
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
CHEOPS	CHEOPS	c012	NNP	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
time	time	t050	NN	I-NP	O
from	from	f605	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
manipulation	manipulation	m0501040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fracture	fracture	f6023060	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
dislocation	dislocation	d024020305	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
one	one	o500	CD	B-NP	O
minute	minute	m05030	NN	I-NP	O
and	and	a530	CC	O	O
thirty	thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
seconds	second	s020532	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
twenty	twenty	t0530	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
five	five	f010	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
time	time	t050	NN	I-NP	O
from	from	f605	IN	B-PP	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
manipulation	manipulation	m0501040305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
four	four	f060	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
forty	forty	f0630	NN	I-NP	O
-	-	-000	HYPH	O	O
two	two	t000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
sixty	sixty	s0230	JJ	B-NP	O
seconds	second	s020532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
fifteen	fifteen	f01305	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Children	Children	c043605	NNP	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Eastern	Eastern	e023065	NNP	B-NP	O
Ontario	Ontario	o53060	NNP	I-NP	O
Pain	Pain	p050	NNP	I-NP	B-Disease
Scale	Scale	s2040	NNP	I-NP	O
was	be	w020	VBD	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
points	point	p0532	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
points	point	p0532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
reflecting	reflect	r014023052	VBG	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
no	no	n000	DT	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
fracture	fracture	f6023060	NN	B-NP	B-Disease
reduction	reduction	r0302305	NN	I-NP	O
.	.	.000	.	O	O

Adequate	Adequate	a302030	JJ	B-NP	O
fracture	fracture	f6023060	NN	I-NP	B-Disease
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
111	111	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Ninety	Ninety	n05030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
sixty	sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sixty	sixty	s0230	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
parents	parent	p060532	NNS	I-NP	O
present	present	p602053	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
pleased	please	p40203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
and	and	a530	CC	O	O
would	would	w043	MD	B-VP	O
allow	allow	a400	VB	I-VP	O
it	it	i300	PRP	B-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
again	again	a205	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
situation	situation	s030305	NN	I-NP	O
.	.	.000	.	O	O

Patency	Patency	p030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
airway	airway	a060	NN	I-NP	O
and	and	a530	CC	O	O
independent	independent	i5301053053	JJ	B-NP	O
respiration	respiration	r021060305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
.	.	.000	.	O	O

Minor	Minor	m0506	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
(	(	(000	(	O	O
thirteen	thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
emesis	emesis	e50202	NN	B-NP	B-Disease
(	(	(000	(	O	O
eight	eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
thirteen	thirteen	t06305	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
clumsiness	clumsiness	c40520502	NN	B-NP	B-Disease
(	(	(000	(	O	O
evident	evident	e103053	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
ataxic	ataxic	a30202	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
dysphoric	dysphoric	d0210602	JJ	B-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
hallucinations	hallucination	h04020503052	NNS	B-NP	B-Disease
or	or	o600	CC	I-NP	O
nightmares	nightmare	n020350602	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
reliably	reliably	r040140	RB	B-ADVP	O
,	,	,000	,	O	O
safely	safely	s01040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
quickly	quickly	q0240	RB	B-VP	O
provided	provide	p6010303	VBD	I-VP	O
adequate	adequate	a302030	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
to	to	t000	TO	B-VP	O
effectively	effectively	e102301040	RB	I-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
fractures	fracture	f60230602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
institution	institution	i523030305	NN	I-NP	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
only	only	o540	RB	I-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
environment	environment	e510605053	NN	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
proper	proper	p60106	JJ	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	B-ADVP	O
on	on	o500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
one	one	o500	CD	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
and	and	a530	CC	O	O
board	board	b063	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
certified	certify	c0630103	VBN	I-NP	O
physicians	physician	p0202052	NNS	I-NP	O
skilled	skille	s20403	VBD	B-VP	O
in	in	i500	IN	B-PP	O
airway	airway	a060	NN	B-NP	O
management	management	m050205053	NN	I-NP	O
are	be	a600	VBP	B-VP	O
directly	directly	d0602340	RB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
care	care	c060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Cyclosporine	Cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
(	(	(000	(	O	O
TMA	TMA	t500	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
well	well	w040	RB	I-VP	O
documented	document	d020505303	VBN	I-VP	O
.	.	.000	.	O	O

Treatments	Treatment	t60350532	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
included	include	i5240303	VBN	I-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
or	or	o600	CC	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
exchange	exchange	e20520	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
immunoglobulin	immunoglobulin	i505024010405	NN	I-NP	O
G	G	g000	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
recipients	recipient	r02010532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
removing	remove	r0501052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
inciting	incite	i5203052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
attendant	attendant	a3053053	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
precipitating	precipitate	p602010303052	VBG	B-VP	O
acute	acute	a2030	JJ	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
and	and	a530	CC	I-NP	O
graft	graft	g6013	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
decade	decade	d02030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
seen	see	s050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
with	with	w030	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
virtually	virtually	v063040	RB	B-ADJP	O
identical	identical	i30530204	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
,	,	,000	,	O	O
switching	switch	s032052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
viable	viable	v0140	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
option	option	o1305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
TMA	TMA	t500	NN	I-NP	B-Disease
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
TMA	TMA	t500	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
literature	literature	l030603060	NN	B-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TMA	TMA	t500	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
sequentially	sequentially	s02053040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
living	live	l01052	VBG	I-NP	O
donor	donor	d0506	NN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipient	recipient	r0201053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
TMA	TMA	t500	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
plasmapheresis	plasmapheresis	p402501060202	NN	B-NP	O
and	and	a530	CC	O	O
fresh	fresh	f6020	JJ	B-NP	O
frozen	frozen	f60205	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Introduction	Introduction	i5360302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TMA	TMA	t500	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
allograft	allograft	a4026013	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
switched	switch	s03203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
vice	vice	v020	NN	I-NP	O
versa	versa	v0620	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
closely	closely	c402040	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
TMA	TMA	t500	NN	I-NP	B-Disease
.	.	.000	.	O	O

Analgesic	Analgesic	a50420202	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
crossover	crossover	c6020106	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
not	not	n030	RB	B-ADJP	O
responsive	responsive	r021052010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	B-ADVP	O
problematic	problematic	p6014050302	JJ	B-ADJP	O
.	.	.000	.	O	O

Animal	Animal	a50504	NN	B-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
opioid	opioid	o103	JJ	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
in	in	i500	IN	B-PP	O
difficult	difficult	d0102043	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
syndromes	syndrome	s05360502	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
slow	slow	s400	JJ	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
subhypnotic	subhypnotic	s010150302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
unrelieved	unrelieved	u56040103	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
crossover	crossover	c6020106	JJ	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
0	0	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
10	10	0000	CD	I-NP	O
numerical	numerical	n05060204	JJ	I-NP	O
scale	scale	s2040	NN	I-NP	O
;	;	;000	:	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	O	O
drowsiness	drowsiness	d6020502	NN	B-NP	O
,	,	,000	,	O	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dry	dry	d600	JJ	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
scale	scale	s2040	NN	I-NP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
(	(	(000	(	O	O
not	not	n030	RB	O	O
at	at	a300	IN	B-ADVP	O
all	all	a400	DT	I-ADVP	O
,	,	,000	,	O	O
slight	slight	s40203	JJ	B-ADJP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
lot	lot	l030	NN	I-NP	O
,	,	,000	,	O	O
awful	awful	a0104	JJ	B-ADJP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
Mini	Mini	m050	NNP	B-NP	O
-	-	-000	:	O	O
Mental	Mental	m05304	NNP	B-NP	O
State	State	s3030	NNP	I-NP	O
Examination	Examination	e205050305	NNP	I-NP	O
(	(	(000	(	O	O
MMSE	MMSE	m520	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
(	(	(000	(	O	O
T0	T0	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
(	(	(000	(	O	O
T30	T30	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
(	(	(000	(	O	O
T60	T60	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
120	120	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
(	(	(000	(	O	O
T120	T120	0000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
180	180	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
(	(	(000	(	O	O
T180	T180	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
saline	saline	s04050	NN	B-NP	O
solution	solution	s040305	NN	I-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
all	all	a400	PDT	I-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
both	both	b030	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
relevant	relevant	r0401053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Hallucinations	Hallucination	h04020503052	NNS	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
unpleasant	unpleasant	u51402053	JJ	I-NP	O
sensation	sensation	s0520305	NN	I-NP	O
(	(	(000	(	O	O
"	"	"000	``	O	O
empty	empty	e5130	JJ	B-NP	O
head	head	h030	NN	I-NP	O
"	"	"000	''	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
1	1	1000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
drowsiness	drowsiness	d6020502	NN	B-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
groups	group	g6012	NNS	B-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
marked	marked	m06203	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
MMSE	MMSE	m520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
T30	T30	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ketamine	ketamine	k0305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Ketamine	Ketamine	k0305050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
analgesia	analgesia	a5042020	NN	I-NP	O
in	in	i500	IN	B-PP	O
difficult	difficult	d0102043	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
syndromes	syndrome	s05360502	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
taken	take	t0205	VBN	I-VP	O
into	into	i530	IN	B-PP	O
account	account	a2053	NN	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
using	use	u2052	VBG	B-VP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
ketamine	ketamine	k0305050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
multidisciplinary	multidisciplinary	m043030201405060	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
nonsmall	nonsmall	n052504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cisplatin	Cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
improve	improve	i516010	VBP	B-VP	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
and	and	a530	CC	I-NP	O
survival	survival	s0610104	NN	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
nonsmall	nonsmall	n052504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
active	active	a23010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
translate	translate	t60524030	VB	I-VP	O
into	into	i530	IN	B-PP	O
more	more	m060	RBR	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
feasibility	feasibility	f020104030	NN	I-NP	O
,	,	,000	,	O	O
response	response	r0210520	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
,	,	,000	,	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
-	-	-000	HYPH	O	O
naive	naive	n010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Stage	Stage	s3020	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
Eastern	Eastern	e023065	NNP	I-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
135	135	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
120	120	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
Day	Day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
given	give	g0105	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
responding	respond	r021053052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
scheduled	schedule	s2030403	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
consolidation	consolidation	c05204030305	NN	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
preplanned	preplanne	p60140503	VBN	I-VP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
after	after	a1306	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
rates	rate	r0302	NNS	I-NP	O
reported	report	r0106303	VBN	B-VP	O
refer	refer	r0106	VBP	B-VP	O
only	only	o540	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
;	;	;000	:	O	O
34	34	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
examinable	examinable	e205050140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
73	73	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
55	55	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
87	87	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
4	4	4000	CD	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

According	Accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
intention	intention	i5305305	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
treat	treat	t603	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
71	71	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
53	53	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	:	O	O
85	85	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
154	154	0000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
131	131	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
97	97	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
117	117	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
97	97	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1378	1378	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
86	86	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

World	World	w0643	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
Grade	Grade	g6030	NNP	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
39	39	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
one	one	o500	CD	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
death	death	d030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Nonhematologic	Nonhematologic	n050503040202	JJ	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
progression	progression	p60260205	NN	I-NP	O
free	free	f600	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
survival	survival	s0610104	NN	I-NP	O
time	time	t050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
gemcitabine	gemcitabine	g0520301050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
shows	show	s020	VBZ	B-VP	O
high	high	h020	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
NSCLC	NSCLC	n242	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
merits	merit	m06032	VBZ	B-VP	O
further	far	f06306	JJR	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Serotonergic	Serotonergic	s06030506202	JJ	B-NP	B-Chemical
antidepressants	antidepressant	a5303016020532	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
new	new	n000	JJ	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	B-Chemical
antidepressants	antidepressant	a5303016020532	NNS	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
introduced	introduce	i536030203	VBN	I-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
decade	decade	d02030	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
listed	list	l02303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
package	package	p02020	NN	I-NP	O
inserts	insert	i520632	VBZ	B-VP	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
report	report	r01063	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
concerns	concern	c0520652	VBZ	B-VP	O
2	2	2000	CD	B-NP	O
male	male	m040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
incontinence	incontinence	i52053050520	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
paper	paper	p0106	NN	I-NP	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
describe	describe	d026010	VBP	B-VP	O
2	2	2000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
incontinence	incontinence	i52053050520	NN	B-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
paroxetine	paroxetine	p060203050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
sertraline	sertraline	s063604050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
taking	take	t02052	VBG	I-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
carbonate	carbonate	c06105030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
blockers	blocker	b402062	NNS	B-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
incontinence	incontinence	i52053050520	NN	I-NP	B-Disease
.	.	.000	.	O	O

Animal	Animal	a50504	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
incontinence	incontinence	i52053050520	NN	B-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
serotonergic	serotonergic	s06030506202	JJ	B-NP	B-Chemical
antidepressants	antidepressant	a5303016020532	NNS	I-NP	I-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
5HT4	5HT4	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
found	find	f053	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
delineate	delineate	d0405030	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
troubling	troubling	t6014052	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
how	how	h000	WRB	B-ADVP	O
best	good	b023	JJS	O	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
:	:	:000	:	O	O
differential	differential	d010605304	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
inbred	inbred	i51603	JJ	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

Mature	Mature	m03060	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
female	female	f05040	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
from	from	f605	IN	B-PP	O
six	six	s020	CD	B-NP	O
inbred	inbred	i51603	JJ	I-NP	O
stains	stain	s3052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
ip	ip	i100	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
behavior	behavior	b0106	NN	B-NP	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
20	20	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
forelimb	forelimb	f0604051	NN	B-NP	O
or	or	o600	CC	I-NP	O
hindlimb	hindlimb	h0534051	NN	I-NP	O
clonus	clonus	c40502	NN	I-NP	O
,	,	,000	,	O	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
clonic	clonic	c40502	JJ	B-NP	O
running	run	r05052	VBG	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
latency	latency	l030520	NN	I-NP	O
to	to	t000	TO	B-PP	O
jumping	jump	j051052	VBG	B-VP	O
bouncing	bounce	b052052	VBG	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
strain	strain	s3605	NN	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
sensitivities	sensitivity	s05203010302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
A	A	a000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
and	and	a530	CC	I-NP	O
SJL	SJL	s240	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
being	be	b052	VBG	B-VP	O
most	most	m023	RBS	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
6J	6J	6200	NN	I-NP	O
most	most	m023	RBS	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
.	.	.000	.	O	O

DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
2J	2J	2000	NN	I-NP	O
,	,	,000	,	O	O
BALB	BALB	b041	NN	B-NP	O
/	/	/000	SYM	B-NP	O
cByJ	cByJ	c102	NN	I-NP	O
and	and	a530	CC	I-NP	O
NZW	NZW	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
LacJ	LacJ	l020	NN	B-NP	O
strains	strain	s36052	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
intermediate	intermediate	i5306503030	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
.	.	.000	.	O	O

EEG	EEG	e020	NN	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
in	in	i500	IN	B-PP	O
SJL	SJL	s240	NN	B-NP	O
,	,	,000	,	O	O
A	A	a000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
and	and	a530	CC	I-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
6J	6J	6200	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
revealing	reveal	r0104052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
correspondence	correspondence	c060210530520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	I-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
determined	determine	d030650503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
hippocampus	hippocampus	h010205102	NN	B-NP	O
and	and	a530	CC	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
between	between	b0305	IN	B-PP	O
sensitive	sensitive	s05203010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

Additional	Additional	a3030504	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
investigating	investigate	i510230203052	VBG	B-VP	O
genetic	genetic	g050302	JJ	B-NP	O
influences	influence	i51405202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Hypotension	Hypotension	h010305205	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tizanidine	tizanidine	t020503050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Centrally	Centrally	c0536040	RB	B-ADVP	O
acting	act	a23052	VBG	B-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
pharmacologic	pharmacologic	p06502040202	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spasticity	spasticity	s102302030	NN	B-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
disorders	disorder	d02063062	NNS	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
central	central	c053604	JJ	I-NP	I-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
spasticity	spasticity	s102302030	NN	B-NP	B-Disease
,	,	,000	,	O	O
certain	certain	c06305	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Adults	Adult	a30432	NNS	B-NP	O
chronically	chronically	c060502040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
limited	limit	l050303	VBN	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
respond	respond	r021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
simultaneously	simultaneously	s05043050240	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
chronically	chronically	c060502040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lisinopril	lisinopril	l020501604	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tizanidine	tizanidine	t020503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spasticity	spasticity	s102302030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tizanidine	tizanidine	t020503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
kept	keep	k013	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mind	mind	m053	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
either	either	e0306	CC	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
spasticity	spasticity	s102302030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
mouse	mouse	m020	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
selected	select	s0402303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
differential	differential	d010605304	JJ	B-NP	O
sensitivities	sensitivity	s05203010302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
also	also	a420	RB	B-ADVP	O
differentially	differentially	d0106053040	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	I-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
mouse	mouse	m020	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
selectively	selectively	s0402301040	RB	I-VP	O
bred	breed	b603	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
(	(	(000	(	O	O
BS	BS	b200	NN	B-NP	O
line	line	l050	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
resistance	resistance	r020230520	NN	B-NP	O
(	(	(000	(	O	O
BR	BR	b600	NN	B-NP	O
line	line	l050	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methyl	methyl	m0304	NN	B-NP	B-Chemical
beta	beta	b030	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
carboline	carboline	c06104050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxylate	carboxylate	c0610204030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
beta	beta	b030	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
CCM	CCM	c250	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inverse	inverse	i510620	JJ	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
benzodiazepine	benzodiazepine	b052030201050	NN	I-NP	B-Chemical
site	site	s030	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
aim	aim	a050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
characterize	characterize	c0602306020	VB	I-VP	O
both	both	b030	DT	B-NP	O
lines	line	l0502	NNS	I-NP	O
'	'	'000	POS	B-NP	O
sensitivities	sensitivity	s05203010302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
ligands	ligand	l020532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
anxiolysis	anxiolysis	a52040202	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
plus	plus	p402	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
maze	maze	m020	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
by	by	b000	IN	B-PP	O
recording	record	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
pentylenetetrazol	pentylenetetrazol	p0530405030360204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
presented	present	p60205303	VBN	B-VP	O
here	here	h060	RB	B-ADVP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
sensitivities	sensitivity	s05203010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BS	BS	b200	NN	B-NP	O
and	and	a530	CC	I-NP	O
BR	BR	b600	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
CCM	CCM	c250	NN	B-NP	I-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
extended	extend	e2305303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
picrotoxin	picrotoxin	p026030205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
pentylenetetrazol	pentylenetetrazol	p0530405030360204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
selection	selection	s0402305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
and	and	a530	CC	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
to	to	t000	TO	B-PP	O
several	several	s010604	JJ	B-NP	O
ligands	ligand	l020532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
.	.	.000	.	O	O

Propylthiouracil	Propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
perinuclear	perinuclear	p060502406	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
staining	staining	s305052	NN	I-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
autoantibody	autoantibody	a0305301030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
pericarditis	pericarditis	p06020630302	NN	B-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
manifesting	manifest	m0501023052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
pericarditis	pericarditis	p06020630302	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
a	a	a000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
of	of	o100	IN	B-PP	O
pericarditis	pericarditis	p06020630302	NN	B-NP	B-Disease
,	,	,000	,	O	O
fever	fever	f0106	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
.	.	.000	.	O	O

Serologic	Serologic	s06040202	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
and	and	a530	CC	O	O
immunologic	immunologic	i505040202	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
pericardial	pericardial	p060206304	JJ	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
Graves	Graves	g60102	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
febrile	febrile	f016040	JJ	I-NP	B-Disease
illness	illness	i4502	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pericarditis	pericarditis	p06020630302	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
biopsy	biopsy	b0120	NN	B-NP	O
.	.	.000	.	O	O

Serologic	Serologic	s06040202	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
perinuclear	perinuclear	p060502406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
staining	staining	s305052	NN	I-NP	O
antineutrophil	antineutrophil	a53050360104	NN	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
autoantibodies	autoantibody	a03053010302	NNS	I-NP	O
(	(	(000	(	O	O
pANCA	pANCA	p0520	NN	B-NP	O
)	)	)000	)	O	O
against	against	a20523	IN	B-PP	O
myeloperoxidase	myeloperoxidase	m0401060203020	NN	B-NP	O
(	(	(000	(	O	O
MPO	MPO	m100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Propylthiouracil	Propylthiouracil	p601043060204	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
prednisone	prednisone	p603502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
alleviated	alleviate	a4010303	VBD	B-VP	O
her	her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
review	review	r010	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pericarditis	pericarditis	p06020630302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
MPO	MPO	m100	NN	I-NP	O
pANCA	pANCA	p0520	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
propylthio	propylthio	p6010430	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
uracil	uracil	u60204	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Pericarditis	Pericarditis	p06020630302	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
propylthio	propylthio	p6010430	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
uracil	uracil	u60204	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
solitary	solitary	s0403060	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
solitary	solitary	s0403060	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
two	two	t000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
hospitalized	hospitalize	h02103040203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
diuretics	diuretic	d060302	NNS	I-NP	O
.	.	.000	.	O	O

Due	Due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
losartan	losartan	l0206305	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
.	.	.000	.	O	O

Surprisingly	Surprisingly	s06160205240	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
sudden	sudden	s0305	JJ	I-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
lasted	last	l02303	VBD	B-VP	O
eight	eight	e0203	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
despite	despite	d021030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
furosemide	furosemide	f060205030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
amine	amine	a5050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
mistake	mistake	m023020	NN	B-NP	O
,	,	,000	,	O	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
again	again	a205	RB	B-ADVP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
anuria	anuria	a5060	NN	I-NP	B-Disease
lasting	last	l023052	VBG	B-VP	O
10	10	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
,	,	,000	,	O	O
his	his	h020	PRP$	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
diminished	diminish	d05050203	VBD	B-VP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Ultimately	Ultimately	u430503040	RB	B-ADVP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
arteriography	arteriography	a6306026010	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
80	80	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
diuretic	diuretic	d060302	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
certainly	certainly	c0630540	RB	B-ADVP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
RAS	RAS	r020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
such	such	s020	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
by	by	b000	IN	B-PP	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
probably	probably	p6010140	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
losartan	losartan	l0206305	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
serious	serious	s0602	JJ	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renovascular	renovascular	r0501020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
extreme	extreme	e236050	JJ	B-NP	O
caution	caution	c0305	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

Calcineurin	Calcineurin	c042050605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
induced	induce	i530203	VBN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
(	(	(000	(	O	O
CIPS	CIPS	c012	NN	B-NP	B-Disease
)	)	)000	)	O	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
disabling	disable	d02014052	VBG	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Bone	Bone	b050	NN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
diseases	disease	d020202	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
depend	depend	d01053	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
correct	correct	c06023	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
feet	foot	f030	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
registered	register	r020230603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Bone	Bone	b050	NN	B-NP	O
scans	scan	s2052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
tracer	tracer	t60206	NN	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
foot	foot	f030	NN	I-NP	O
bones	bone	b0502	NNS	I-NP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
bone	bone	b050	NN	B-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
oedema	oedema	o03050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
painful	painful	p05104	JJ	I-NP	O
bones	bone	b0502	NNS	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
other	other	o306	JJ	B-NP	O
diseases	disease	d020202	NNS	I-NP	O
causing	cause	c02052	VBG	B-VP	O
foot	foot	f030	NN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
reflex	reflex	r01402	NN	B-NP	B-Disease
sympathetic	sympathetic	s051030302	JJ	I-NP	I-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
,	,	,000	,	O	O
polyneuropathy	polyneuropathy	p04050601030	NN	B-NP	B-Disease
,	,	,000	,	O	O
Morton	Morton	m06305	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
neuralgia	neuralgia	n060420	NN	I-NP	I-Disease
,	,	,000	,	O	O
gout	gout	g030	NN	B-NP	B-Disease
,	,	,000	,	O	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
avascular	avascular	a1020406	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
,	,	,000	,	O	O
intermittent	intermittent	i5306503053	JJ	B-NP	B-Disease
claudication	claudication	c403020305	NN	I-NP	I-Disease
,	,	,000	,	O	O
orthopaedic	orthopaedic	o63010302	JJ	B-NP	O
foot	foot	f030	NN	I-NP	B-Disease
deformities	deformity	d010650302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
stress	stress	s3602	NN	B-NP	B-Disease
fractures	fracture	f60230602	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hyperparathyroidism	hyperparathyroidism	h0106106030603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
trough	trough	t6020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
relief	relief	r0401	NN	B-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Calcineurin	Calcineurin	c042050605	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
Induced	Induce	i530203	VBN	I-NP	O
Pain	Pain	p050	NN	I-NP	B-Disease
Syndrome	Syndrome	s0536050	NN	I-NP	O
(	(	(000	(	O	O
CIPS	CIPS	c012	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
severe	severe	s01060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
accurately	accurately	a20603040	RB	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
typical	typical	t010204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
,	,	,000	,	O	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
and	and	a530	CC	I-NP	O
bone	bone	b050	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
.	.	.000	.	O	O

Incorrect	Incorrect	i5206023	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
will	will	w040	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
quality	quality	q04030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
CIPS	CIPS	c012	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
predictor	predictor	p60302306	NN	I-NP	O
of	of	o100	IN	B-PP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Anthracyclines	Anthracycline	a5306020240502	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
effective	effective	e1023010	JJ	B-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
they	they	t000	PRP	B-NP	O
frequently	frequently	f60205340	RB	B-ADVP	O
cause	cause	c020	VBP	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
anthracycline	anthracycline	a530602024050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
search	search	s0620	VB	I-VP	O
for	for	f060	IN	B-PP	O
methods	method	m03032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
and	and	a530	CC	I-ADJP	O
capable	capable	c010140	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
predicting	predict	p603023052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
(	(	(000	(	O	O
BNP	BNP	b510	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
BNP	BNP	b510	NN	B-NP	O
might	might	m0203	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
simple	simple	s05140	JJ	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
daunorubicin	daunorubicin	d0506010205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DNR	DNR	d560	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimen	regimen	r020505	NN	B-NP	O
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
DNR	DNR	d560	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimen	regimen	r020505	NN	B-NP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
radionuclide	radionuclide	r0305024030	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
before	before	b01060	IN	B-PP	O
chemotherapies	chemotherapy	c0503060102	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
(	(	(000	(	O	O
ANP	ANP	a510	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
BNP	BNP	b510	NN	B-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
radionuclide	radionuclide	r0305024030	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
subclinical	subclinical	s0124050204	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BNP	BNP	b510	NN	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
subclinical	subclinical	s0124050204	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
increased	increase	i5260203	VBD	B-VP	O
above	above	a1010	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
or	or	o600	CC	I-NP	O
subclinical	subclinical	s0124050204	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
radionuclide	radionuclide	r0305024030	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
BNP	BNP	b510	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
given	give	g0105	VBN	B-PP	O
DNR	DNR	d560	NN	B-NP	B-Chemical
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
700	700	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m	m	m000	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
ANP	ANP	a510	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
always	always	a402	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
subclinical	subclinical	s0124050204	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
BNP	BNP	b510	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
cephalothin	cephalothin	c01040305	JJ	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
,	,	,000	,	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
oliguric	oliguric	o4020602	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cephalothin	cephalothin	c01040305	JJ	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
given	give	g0105	VBN	I-VP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
very	very	v060	RB	B-ADVP	O
carefully	carefully	c0601040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
this	this	t020	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
protection	protection	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dna	dna	d500	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
necrotic	necrotic	n0260302	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	O
deaths	death	d0302	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lung	lung	l052	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
IH636	IH636	0000	NN	I-NP	B-Chemical
grape	grape	g6010	NN	I-NP	I-Chemical
seed	seed	s030	NN	I-NP	I-Chemical
proanthocyanidin	proanthocyanidin	p605302050305	NN	I-NP	I-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Grape	Grape	g6010	NN	B-NP	B-Chemical
seed	seed	s030	NN	I-NP	I-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
,	,	,000	,	O	O
primarily	primarily	p60506040	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
proanthocyanidins	proanthocyanidin	p6053020503052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
modulate	modulate	m0304030	VB	I-VP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
biological	biological	b04020204	JJ	B-NP	O
,	,	,000	,	I-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
toxicological	toxicological	t020204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
mainly	mainly	m0540	RB	B-ADJP	O
cytoprotective	cytoprotective	c0301603023010	JJ	I-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
IH636	IH636	0000	NN	B-NP	B-Chemical
grape	grape	g6010	NN	I-NP	I-Chemical
seed	seed	s030	NN	I-NP	I-Chemical
proanthocyanidin	proanthocyanidin	p605302050305	NN	I-NP	I-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AAP	AAP	a010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AMI	AMI	a500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lung	lung	l052	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
design	design	d02025	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
vehicle	vehicle	v0240	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
drug	drug	d602	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytoprotection	cytoprotection	c030160302305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
orally	orally	o6040	RB	I-VP	O
gavaged	gavage	g010203	VBN	I-VP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
Kg	Kg	k200	NN	I-NP	O
GSPE	GSPE	g210	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
specific	specific	s1020102	JJ	B-NP	O
three	three	t060	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
AAP	AAP	a010	NN	B-NP	B-Chemical
:	:	:000	:	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
Kg	Kg	k200	NN	B-NP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
;	;	;000	:	O	O
AMI	AMI	a500	NN	B-NP	B-Chemical
:	:	:000	:	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
Kg	Kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
;	;	;000	:	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
:	:	:000	:	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
Kg	Kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Parameters	Parameter	p060503062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
included	include	i5240303	VBD	B-VP	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
chemistry	chemistry	c0502360	NN	I-NP	O
(	(	(000	(	O	O
ALT	ALT	a430	NN	B-NP	O
,	,	,000	,	O	O
BUN	BUN	b050	NN	B-NP	O
and	and	a530	CC	O	O
CPK	CPK	c120	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
orderly	orderly	o630640	JJ	B-NP	O
fragmentation	fragmentation	f60250530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
genomic	genomic	g050502	JJ	B-NP	O
DNA	DNA	d500	NN	I-NP	O
(	(	(000	(	O	O
both	both	b030	CC	O	O
endonuclease	endonuclease	e5305024020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
independent	independent	i5301053053	JJ	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
microscopic	microscopic	m026020102	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
damage	damage	d05020	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
protection	protection	p60302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
PAS	PAS	p020	NN	B-NP	O
stained	stain	s30503	VBD	B-VP	O
tissues	tissue	t0202	NNS	B-NP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
preexposure	preexposure	p602102060	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
AAP	AAP	a010	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
AMI	AMI	a500	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
provided	provide	p6010303	VBN	B-PP	O
near	near	n060	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
chemistry	chemistry	c0502360	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
(	(	(000	(	O	O
ALT	ALT	a430	NN	B-NP	O
,	,	,000	,	O	O
BUN	BUN	b050	NN	B-NP	O
and	and	a530	CC	O	O
CPK	CPK	c120	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
DNA	DNA	d500	NN	B-NP	O
fragmentation	fragmentation	f60250530305	NN	I-NP	O
.	.	.000	.	O	O

Histopathological	Histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
,	,	,000	,	I-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	I-NP	O
lung	lung	l052	NN	I-NP	O
sections	section	s023052	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
massive	massive	m02010	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphological	morphological	m06104020204	JJ	B-NP	O
aberrations	aberration	a10603052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
three	three	t060	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
preexposure	preexposure	p602102060	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
presence	presence	p6020520	NN	I-NP	O
.	.	.000	.	O	O

GSPE	GSPE	g210	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
drug	drug	d602	NN	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
tissues	tissue	t0202	NNS	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
minor	minor	m0506	JJ	B-NP	O
residual	residual	r020304	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
or	or	o600	CC	B-PP	O
near	near	n060	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
mirrored	mirror	m060603	VBD	B-VP	O
both	both	b030	CC	O	O
serum	serum	s0605	NN	B-NP	O
chemistry	chemistry	c0502360	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
fragmentation	fragmentation	f60250530305	NN	I-NP	O
.	.	.000	.	O	O

Interestingly	Interestingly	i530602305240	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
,	,	,000	,	O	O
AAP	AAP	a010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
AMI	AMI	a500	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
organs	organ	o62052	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
very	very	v060	RB	I-VP	O
effectively	effectively	e102301040	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Since	Since	s0520	IN	B-PP	O
AAP	AAP	a010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
AMI	AMI	a500	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
undergo	undergo	u530620	VBP	B-VP	O
biotransformation	biotransformation	b03605210650305	NN	B-NP	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
produce	produce	p603020	VB	I-VP	O
damaging	damaging	d0502052	JJ	B-NP	O
radicals	radical	r0302042	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
linked	link	l05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
metabolism	metabolism	m030104025	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
detoxification	detoxification	d030201020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
radicals	radical	r0302042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
'	'	'000	``	I-NP	O
presumed	presumed	p6020503	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
to	to	t000	TO	B-PP	O
DNA	DNA	d500	NN	B-NP	O
repair	repair	r0106	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
another	another	a50306	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
attribute	attribute	a3601030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
played	play	p403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
chemoprevention	chemoprevention	c050160105305	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
on	on	o500	IN	B-PP	O
AMI	AMI	a500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
apoptotic	apoptotic	a10130302	JJ	I-NP	O
death	death	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lung	lung	l052	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
.	.	.000	.	O	O

Taken	Take	t0205	VBN	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
events	event	e10532	NNS	I-NP	O
undoubtedly	undoubtedly	u530130340	RB	B-VP	O
establish	establish	e23014020	VBP	I-VP	O
GSPE	GSPE	g210	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
abundant	abundant	a1053053	JJ	B-NP	O
bioavailability	bioavailability	b01040104030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
power	power	p060	NN	I-NP	O
to	to	t000	TO	B-VP	O
defend	defend	d01053	VB	I-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
target	target	t06203	NN	I-NP	O
organs	organ	o62052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
assaults	assault	a20432	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
structurally	structurally	s3602306040	RB	B-NP	O
diverse	diverse	d010620	JJ	I-NP	O
and	and	a530	CC	I-NP	O
functionally	functionally	f052305040	RB	I-NP	O
different	different	d0106053	JJ	I-NP	O
entities	entity	e530302	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

Antidepressant	Antidepressant	a530301602053	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
mania	mania	m050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
:	:	:000	:	O	O
identification	identification	i305301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Concerns	Concern	c0520652	NNS	B-NP	O
about	about	a103	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
mania	mania	m050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	B-Chemical
continue	continue	c053050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
establishment	establishment	e230140205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
for	for	f060	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
44	44	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
meeting	meet	m03052	VBG	B-VP	O
DSM	DSM	d250	NN	B-NP	O
-	-	-000	HYPH	O	O
IV	IV	i100	CD	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
naturalistic	naturalistic	n03060402302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
6	6	6000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Montgomery	Montgomery	m053205060	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Asberg	Asberg	a21062	NNP	I-NP	O
Depression	Depression	d0160205	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Bech	Bech	b020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Rafaelson	Rafaelson	r0104205	NNP	I-NP	O
Mania	Mania	m050	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
manic	manic	m0502	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	O
hypomanic	hypomanic	h01050502	JJ	I-NP	B-Disease
switch	switch	s0320	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	O	O
on	on	o500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
(	(	(000	(	O	O
DSM	DSM	d250	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
IV	IV	i100	CD	B-NP	I-Disease
bipolar	bipolar	b010406	JJ	I-NP	I-Disease
I	I	i000	NN	I-NP	I-Disease
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
II	II	i000	NN	I-NP	I-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
number	number	n05106	NN	B-NP	O
of	of	o100	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
manic	manic	m0502	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
,	,	,000	,	O	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
antidepressant	antidepressant	a530301602053	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
used	use	u203	VBN	B-VP	O
(	(	(000	(	O	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
antidepressant	antidepressant	a530301602053	JJ	B-NP	B-Chemical
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
more	more	m060	RBR	B-ADVP	O
particularly	particularly	p06302040640	RB	I-ADVP	O
,	,	,000	,	O	O
selective	selective	s04023010	JJ	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
reuptake	reuptake	r013020	NN	I-NP	I-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	I-Chemical
[	[	[000	(	O	O
SSRIs	SSRI	s2602	NNS	B-NP	B-Chemical
]	]	]000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
and	and	a530	CC	I-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
stabilizers	stabilizer	s3010402062	NNS	I-NP	O
(	(	(000	(	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
temperament	temperament	t0510605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
assessed	assess	a20203	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
normothymic	normothymic	n065030502	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
hyperthymia	hyperthymia	h01063050	NN	I-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Semi	Semi	s050	NN	I-NP	O
-	-	-000	HYPH	O	O
structured	structure	s360230603	VBN	B-VP	O
Affective	Affective	a1023010	JJ	B-NP	O
Temperament	Temperament	t0510605053	NNP	I-NP	O
Interview	Interview	i530610	NNP	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Switches	Switch	s03202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
hypomania	hypomania	h0105050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
mania	mania	m050	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
SSRIs	SSRI	s2602	NNS	B-NP	B-Chemical
[	[	[000	(	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
33	33	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
;	;	;000	:	O	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
experienced	experience	e210605203	VBD	B-VP	O
manic	manic	m0502	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
experienced	experience	e210605203	VBD	B-VP	O
hypomanic	hypomanic	h01050502	JJ	B-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
.	.	.000	.	O	O

Sex	Sex	s020	NN	B-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
(	(	(000	(	O	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
I	I	i000	NN	I-NP	I-Disease
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
II	II	i000	NN	I-NP	I-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
additional	additional	a3030504	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
switching	switching	s032052	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
switches	switch	s03202	NNS	I-NP	O
seemed	seem	s0503	VBD	B-VP	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	NN	I-NP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
no	no	n000	DT	B-NP	O
mood	mood	m030	NN	I-NP	O
stabilizer	stabilizer	s301040206	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
mood	mood	m030	NN	B-NP	O
switches	switch	s03202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
26	26	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
not	not	n030	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
18	18	0000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
manic	manic	m0502	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
probability	probability	p6010104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
switching	switching	s032052	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hyperthymia	hyperthymia	h01063050	NN	I-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Semistructured	Semistructured	s0502360230603	JJ	I-NP	O
Affective	Affective	a1023010	JJ	I-NP	O
Temperament	Temperament	t0510605053	NN	I-NP	O
Interview	Interview	i530610	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
switching	switching	s032052	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
008	008	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
switching	switching	s032052	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Particular	Particular	p063020406	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
paid	pay	p030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
hyperthymic	hyperthymic	h010630502	JJ	I-NP	O
temperament	temperament	t0510605053	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
mood	mood	m030	NN	B-NP	O
switches	switch	s03202	NNS	I-NP	O
.	.	.000	.	O	O

Peritubular	Peritubular	p0603010406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
reduplication	reduplication	r03014020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
allografts	allograft	a40260132	NNS	B-NP	O
and	and	a530	CC	O	O
native	native	n03010	JJ	B-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
clinicopathologic	clinicopathologic	c405020103040202	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
278	278	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	B-Disease
glomerulopathy	glomerulopathy	g405060401030	NN	I-NP	I-Disease
(	(	(000	(	O	O
TG	TG	t200	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
reduplication	reduplication	r03014020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
peritubular	peritubular	p0603010406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
(	(	(000	(	O	O
PTCR	PTCR	p326	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
such	such	s020	JJ	B-NP	O
an	an	a500	DT	I-NP	O
association	association	a2020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
practical	practical	p60230204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
theoretical	theoretical	t06030204	JJ	I-NP	O
importance	importance	i510630520	NN	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
tried	try	t603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
confirm	confirm	c051065	VB	I-VP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
278	278	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
135	135	0000	CD	B-NP	O
transplants	transplant	t6052140532	NNS	I-NP	O
and	and	a530	CC	O	O
143	143	0000	CD	B-NP	O
native	native	n03010	JJ	I-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
ultrastructural	ultrastructural	u43602360230604	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PTCR	PTCR	p326	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
allografts	allograft	a40260132	NNS	I-NP	O
with	with	w030	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
grafts	graft	g60132	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
,	,	,000	,	O	O
recurrent	recurrent	r0206053	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
,	,	,000	,	O	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
allograft	allograft	a4026013	NN	I-NP	I-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
stable	stable	s30140	JJ	B-NP	O
grafts	graft	g60132	NNS	I-NP	O
(	(	(000	(	O	O
"	"	"000	``	O	O
protocol	protocol	p6030204	NN	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
"	"	"000	''	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Native	Native	n03010	JJ	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
wide	wide	w030	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerulopathies	glomerulopathy	g4050604010302	NNS	B-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
,	,	,000	,	O	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
tubular	tubular	t010406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
PTCR	PTCR	p326	NN	B-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
143	143	0000	CD	B-NP	O
native	native	n03010	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
13	13	0000	CD	I-NP	O
included	include	i5240303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
,	,	,000	,	O	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
,	,	,000	,	O	O
lupus	lupus	l0102	NN	B-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
Henoch	Henoch	h05020	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Schonlein	Schonlein	s205405	NNP	I-NP	I-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
crescentic	crescentic	c60205302	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mild	Mild	m043	JJ	B-NP	O
PTCR	PTCR	p326	NN	I-NP	O
in	in	i500	IN	B-PP	O
allografts	allograft	a40260132	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
predict	predict	p603023	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
or	or	o600	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
periods	period	p06032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
between	between	b0305	IN	B-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
transplants	transplant	t6052140532	NNS	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
well	well	w040	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
developed	develop	d01040103	VBN	I-NP	O
PTCR	PTCR	p326	NN	I-NP	O
and	and	a530	CC	I-NP	O
TG	TG	t200	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
PTCR	PTCR	p326	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

PTCR	PTCR	p326	NN	B-NP	O
also	also	a420	RB	B-ADVP	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
native	native	n03010	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
as	as	a200	RB	B-ADJP	O
strong	strong	s36052	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
that	that	t030	DT	B-NP	O
for	for	f060	IN	B-PP	O
TG	TG	t200	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
repeated	repeat	r010303	VBN	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
immunologic	immunologic	i505040202	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
both	both	b030	CC	B-PP	O
in	in	i500	IN	B-PP	O
allografts	allograft	a40260132	NNS	B-NP	O
and	and	a530	CC	O	O
native	native	n03010	JJ	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
.	.	.000	.	O	O

Caffeine	Caffeine	c01050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmia	arrhythmia	a603050	NN	I-NP	I-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
unrecognised	unrecognised	u56020250203	JJ	I-NP	O
danger	danger	d05206	NN	I-NP	O
of	of	o100	IN	B-PP	O
healthfood	healthfood	h0430103	NN	B-NP	O
products	product	p6030232	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-VP	O
existing	exist	e2023052	VBG	B-NP	O
mitral	mitral	m03604	JJ	I-NP	B-Disease
valve	valve	v0410	NN	I-NP	I-Disease
prolapse	prolapse	p6040120	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
intractable	intractable	i5360230140	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
consuming	consume	c05205052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
"	"	"000	``	I-NP	O
natural	natural	n030604	JJ	I-NP	O
energy	energy	e50620	NN	I-NP	O
"	"	"000	``	O	O
guarana	guarana	g06050	NN	B-NP	O
health	health	h0430	NN	I-NP	O
drink	drink	d6052	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
highlights	highlight	h020402032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
labelling	labelling	l0104052	NN	I-NP	O
and	and	a530	CC	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
products	product	p6030232	NNS	I-NP	O
.	.	.000	.	O	O

Conformationally	Conformationally	c0510650305040	RB	B-NP	O
restricted	restrict	r023602303	VBN	I-NP	O
analogs	analog	a50402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BD1008	BD1008	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
antisense	antisense	a53020520	JJ	I-NP	O
oligodeoxynucleotide	oligodeoxynucleotide	o40203020502403030	NN	I-NP	B-Chemical
targeting	target	t06203052	VBG	B-VP	O
sigma1	sigma1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
produce	produce	p603020	VBP	B-VP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
interact	interact	i5306023	VB	I-VP	O
with	with	w030	IN	B-PP	O
sigma	sigma	s0250	SYM	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
mediate	mediate	m03030	VBP	B-VP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
novel	novel	n0104	JJ	I-NP	O
sigma	sigma	s0250	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
antagonist	antagonist	a530205023	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Swiss	Swiss	s020	NNP	B-NP	O
Webster	Webster	w012306	NNP	I-NP	O
mice	mouse	m020	NNS	I-NP	O
:	:	:000	:	O	O
BD1018	BD1018	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3S	3S	3200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dichlorophenyl	dichlorophenyl	d020406010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diazabicyclo	diazabicyclo	d0201020240	NN	I-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
.	.	.000	.	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
.	.	.000	.	O	I-Chemical
0	0	0000	CD	O	I-Chemical
]	]	]000	)	O	I-Chemical
nonane	nonane	n05050	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
BD1063	BD1063	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dichlorophenyl	dichlorophenyl	d020406010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylpiperazine	methylpiperazine	m03041010602050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
LR132	LR132	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1R	1R	1600	NN	B-NP	O
,	,	,000	,	O	O
2S	2S	2000	NN	B-NP	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
cis	cis	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
N	N	n000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
[	[	[000	(	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dichlorophenyl	dichlorophenyl	d020406010504	NN	I-NP	O
)	)	)000	)	O	O
ethyl	ethyl	e304	NN	B-NP	O
]	]	]000	)	O	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	O	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
pyrrolidinyl	pyrrolidinyl	p0604030504	NN	I-NP	O
)	)	)000	)	O	O
cyclohexylamine	cyclohexylamine	c024020405050	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Competition	Competition	c051030305	NN	B-NP	O
binding	binding	b053052	NN	I-NP	O
assays	assay	a202	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
compounds	compound	c0510532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
high	high	h020	JJ	B-NP	O
affinities	affinity	a1050302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
sigma1	sigma1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
compounds	compound	c0510532	NNS	I-NP	O
vary	vary	v060	VBP	B-VP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
affinities	affinity	a1050302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
sigma2	sigma2	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
exhibit	exhibit	e20103	VBP	B-VP	O
negligible	negligible	n024020140	JJ	B-NP	O
affinities	affinity	a1050302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
opioid	opioid	o103	NN	B-NP	O
,	,	,000	,	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
BD1018	BD1018	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
BD1063	BD1063	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
LR132	LR132	0000	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
lethality	lethality	l0304030	NN	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
LR132	LR132	0000	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
lethality	lethality	l0304030	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
provided	provide	p6010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
putative	putative	p0303010	JJ	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
characterized	characterize	c06023060203	VBN	I-NP	O
sigma	sigma	s0250	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
di	di	d000	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
o	o	o000	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
tolylguanidine	tolylguanidine	t040420503050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
DTG	DTG	d320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
sigma	sigma	s0250	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
BD1031	BD1031	0000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
3R	3R	3600	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dichlorophenyl	dichlorophenyl	d020406010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diazabicyclo	diazabicyclo	d0201020240	NN	I-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
.	.	.000	.	I-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
.	.	.000	.	O	I-Chemical
0	0	0000	CD	O	I-Chemical
]	]	]000	)	O	I-Chemical
nonane	nonane	n05050	NN	B-NP	I-Chemical
)	)	)000	)	O	O
each	each	e020	DT	B-NP	O
worsened	worsen	w0620503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
where	where	w060	WRB	B-ADVP	O
alone	alone	a4050	RB	I-ADVP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
locomotion	locomotion	l02050305	NN	B-NP	O
,	,	,000	,	O	O
BD1018	BD1018	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
BD1063	BD1063	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
LR132	LR132	0000	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
further	further	f06306	RB	I-VP	O
validate	validate	v0403030	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
involved	involve	i5104103	VBD	B-VP	O
antagonism	antagonism	a530205025	NN	B-NP	O
of	of	o100	IN	B-PP	O
sigma	sigma	s0250	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
antisense	antisense	a53020520	JJ	I-NP	O
oligodeoxynucleotide	oligodeoxynucleotide	o40203020502403030	NN	I-NP	B-Chemical
against	against	a20523	IN	B-PP	O
sigma1	sigma1	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Together	Together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
functional	functional	f05230504	JJ	B-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
sigma	sigma	s0250	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
attenuating	attenuate	a30503052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
.	.	.000	.	O	O

Ranitidine	Ranitidine	r050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
cadaveric	cadaveric	c03010602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
allograft	allograft	a4026013	NN	I-NP	O
.	.	.000	.	O	O

Ranitidine	Ranitidine	r050303050	NN	B-NP	B-Chemical
frequently	frequently	f60205340	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
peptic	peptic	p01302	JJ	B-NP	O
ulceration	ulceration	u42060305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
native	native	n03010	JJ	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
no	no	n000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
recipient	recipient	r0201053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cadaveric	cadaveric	c03010602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
allograft	allograft	a4026013	NN	I-NP	O
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
allograft	allograft	a4026013	NN	I-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
48	48	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimen	specimen	s1020505	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
pathognomonic	pathognomonic	p03025050502	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
eosinophilic	eosinophilic	e0205010402	JJ	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
.	.	.000	.	O	O

Allograft	Allograft	a4026013	NN	B-NP	O
function	function	f052305	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
and	and	a530	CC	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
presents	present	p6020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
,	,	,000	,	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
light	light	l0203	NN	B-NP	O
and	and	a530	CC	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
active	active	a23010	JJ	I-NP	I-Disease
(	(	(000	(	O	I-Disease
aggressive	aggressive	a2602010	JJ	B-ADJP	I-Disease
)	)	)000	)	O	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
propylthiouracil	propylthiouracil	p601043060204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
list	list	l023	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Withdrawal	Withdrawal	w0303604	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
emergent	emergent	e5062053	JJ	I-NP	I-Disease
rabbit	rabbit	r0103	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Rabbit	Rabbit	r0103	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
RS	RS	r200	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
emergent	emergent	e5062053	JJ	I-NP	I-Disease
RS	RS	r200	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
kind	kind	k053	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
RS	RS	r200	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
trihexyphenidyl	trihexyphenidyl	t60201050304	NN	B-NP	B-Chemical
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
emergent	emergent	e5062053	JJ	I-NP	I-Disease
RS	RS	r200	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
pathophysiologic	pathophysiologic	p030102040202	JJ	I-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
RS	RS	r200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
E4031	E4031	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
terfenadine	terfenadine	t0610503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
terodiline	terodiline	t060304050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
monophasic	monophasic	m05010202	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
dog	dog	d020	NN	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

Torsades	Torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TDP	TDP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
and	and	a530	CC	O	O
monophasic	monophasic	m05010202	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
MAPD	MAPD	m013	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

TDP	TDP	t310	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
effect	effect	e1023	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
market	market	m06203	NN	I-NP	O
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
terfenadine	terfenadine	t0610503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
terodiline	terodiline	t060304050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
TDP	TDP	t310	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
monitoring	monitor	m050306052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
MAPD	MAPD	m013	NN	B-NP	O
in	in	i500	IN	B-PP	O
dog	dog	d020	NN	B-NP	O
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
increase	increase	i526020	VB	I-VP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
and	and	a530	CC	O	O
cause	cause	c020	NN	B-NP	O
TDP	TDP	t310	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
:	:	:000	:	O	O
terfenadine	terfenadine	t0610503050	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
terodiline	terodiline	t060304050	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
cisapride	cisapride	c02016030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
E4031	E4031	0000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
only	only	o540	RB	B-NP	O
free	free	f600	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
will	will	w040	MD	B-VP	O
elicit	elicit	e40203	VB	I-VP	O
a	a	a000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
target	target	t06203	NN	I-NP	O
,	,	,000	,	O	O
free	free	f600	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
mimic	mimic	m0502	VB	I-VP	O
the	the	t000	DT	B-NP	O
free	free	f600	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Infusion	Infusion	i510205	NN	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
achieved	achieve	a20103	VBD	B-VP	O
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBD	B-VP	O
target	target	t06203	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
free	free	f600	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
MAPD	MAPD	m013	NN	B-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
free	free	f600	JJ	I-NP	O
ED50	ED50	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
for	for	f060	IN	B-PP	O
terfenadine	terfenadine	t0610503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
terodiline	terodiline	t060304050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
76	76	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
E4031	E4031	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
closely	closely	c402040	RB	B-ADVP	O
correlate	correlate	c0604030	VBP	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
free	free	f600	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
causing	cause	c02052	VBG	B-VP	O
QT	QT	q300	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
TDP	TDP	t310	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinic	clinic	c40502	NN	I-NP	O
(	(	(000	(	O	O
terfenadine	terfenadine	t0610503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
terodiline	terodiline	t060304050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
cisapride	cisapride	c02016030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
little	little	l0340	JJ	B-NP	O
differentiation	differentiation	d01060530305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
ED50	ED50	0000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
efficacious	efficacious	e1020202	JJ	I-NP	O
free	free	f600	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
)	)	)000	)	O	O
reflecting	reflect	r014023052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
limited	limit	l050303	VBN	I-NP	O
safety	safety	s01030	NN	I-NP	O
margins	margin	m062052	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
underline	underline	u53064050	VBP	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
maximize	maximize	m0205020	VB	I-VP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
ratio	ratio	r030	NN	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
TDP	TDP	t310	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
candidates	candidate	c053030302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
free	free	f600	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pharmacokinetic	pharmacokinetic	p0650202050302	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Bladder	Bladder	b40306	NN	B-NP	O
retention	retention	r0305305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
urine	urine	u6050	NN	B-NP	I-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
.	.	.000	.	O	O

Sedation	Sedation	s030305	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
commonly	commonly	c050540	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neonate	neonate	n05030	NN	I-NP	O
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
the	the	t000	DT	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
noxious	noxious	n0202	JJ	I-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
and	and	a530	CC	O	O
invasive	invasive	i5102010	JJ	B-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neonatal	neonatal	n050304	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
to	to	t000	TO	B-VP	O
facilitate	facilitate	f020403030	VB	I-VP	O
synchrony	synchrony	s05206050	NN	B-NP	O
between	between	b0305	IN	B-PP	O
ventilator	ventilator	v053040306	NN	B-NP	O
and	and	a530	CC	O	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
breaths	breath	b60302	NNS	I-NP	O
.	.	.000	.	O	O

Fentanyl	Fentanyl	f0530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
analgesic	analgesic	a50420202	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neonatal	neonatal	n050304	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
setting	set	s03052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
very	very	v060	JJ	I-NP	O
purposes	purpose	p0610202	NNS	I-NP	O
.	.	.000	.	O	O

Various	Various	v0602	NNP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
include	include	i524030	VBP	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
wall	wall	w040	NN	I-NP	I-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
retention	retention	r0305305	NN	I-NP	I-Disease
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
pelvocalyceal	pelvocalyceal	p04102040204	JJ	I-NP	O
dilatation	dilatation	d04030305	NN	I-NP	O
mimicking	mimic	m0502052	VBG	B-VP	O
hydronephrosis	hydronephrosis	h0360501060202	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
myeloencephalopathy	myeloencephalopathy	m04052010401030	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
accidental	accidental	a20305304	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
vincristin	vincristin	v052602305	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
accidental	accidental	a20305304	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
vincristine	vincristine	v0526023050	NN	I-NP	B-Chemical
instillation	instillation	i523040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leucemia	leucemia	l02050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
57	57	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
lymphoblastic	lymphoblastic	l05101402302	JJ	B-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
girl	girl	g064	NN	I-NP	O
died	die	d030	VBD	B-VP	O
seven	seven	s0105	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
man	man	m050	NN	I-NP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Clinically	Clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
opistothonus	opistothonus	o1023030502	NN	B-NP	B-Disease
,	,	,000	,	O	I-Disease
sensory	sensory	s052060	NN	B-NP	I-Disease
and	and	a530	CC	O	I-Disease
motor	motor	m0306	NN	B-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
ascending	ascend	a2053052	VBG	B-VP	O
paralysis	paralysis	p06040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
(	(	(000	(	O	O
HE	HE	h000	NN	B-NP	O
-	-	-000	HYPH	O	O
LFB	LFB	l100	NN	B-NP	O
,	,	,000	,	O	O
CD	CD	c300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
68	68	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
Neurofilament	Neurofilament	n06010405053	NN	I-NP	O
)	)	)000	)	O	O
revealed	reveal	r010403	VBD	B-VP	O
degeneration	degeneration	d0205060305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
myelin	myelin	m0405	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
axons	axon	a2052	NNS	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
pseudocystic	pseudocystic	p2030202302	JJ	B-NP	B-Disease
transformation	transformation	t605210650305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
areas	area	a602	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
numerous	numerous	n050602	JJ	B-NP	O
prominent	prominent	p60505053	JJ	I-NP	O
macrophages	macrophage	m026010202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
given	give	g0105	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
better	good	b0306	JJR	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
administering	administer	a350502306052	VBG	B-VP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

Palpebral	Palpebral	p04101604	JJ	B-NP	B-Disease
twitching	twitching	t032052	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
adolescent	adolescent	a30402053	NN	I-NP	O
on	on	o500	IN	B-PP	O
citalopram	citalopram	c030401605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
estimates	estimate	e23050302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
between	between	b0305	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	I-NP	O
adolescents	adolescent	a304020532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
citalopram	citalopram	c030401605	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
with	with	w030	IN	B-PP	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
palpebral	palpebral	p04101604	JJ	B-NP	B-Disease
twitching	twitching	t032052	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
citalopram	citalopram	c030401605	NN	B-NP	B-Chemical
as	as	a200	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
remitted	remit	r050303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
redistribution	redistribution	r030236010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
sulphasalazine	sulphasalazine	s041020402050	NN	I-NP	B-Chemical
syndrome	syndrome	s0536050	NN	I-NP	O
strikes	strike	s360202	VBZ	B-VP	O
again	again	a205	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
34	34	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
lady	lady	l030	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
constellation	constellation	c0523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dermatitis	dermatitis	d065030302	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
fever	fever	f0106	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
lymphadenopathy	lymphadenopathy	l051030501030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
beginning	begin	b0205052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
17th	17th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
sulphasalazine	sulphasalazine	s041020402050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
sero	sero	s060	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
rheumatoid	rheumatoid	r050303	JJ	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cervical	Cervical	c0610204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
inguinal	inguinal	i520504	JJ	I-NP	O
lymph	lymph	l0510	NN	I-NP	O
node	node	n030	NN	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
necrotising	necrotising	n0260302052	NN	I-NP	O
lymphadenitis	lymphadenitis	l05103050302	NN	I-NP	B-Disease
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
erythrophagocytosis	erythrophagocytosis	e60306010202030202	NN	B-NP	O
and	and	a530	CC	O	O
prominent	prominent	p60505053	JJ	B-NP	O
eosinophilic	eosinophilic	e0205010402	JJ	I-NP	O
infiltrates	infiltrate	i5104360302	NNS	I-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
viral	viral	v0604	JJ	B-NP	O
inclusion	inclusion	i5240205	NN	I-NP	O
bodies	body	b0302	NNS	I-NP	O
,	,	,000	,	O	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
.	.	.000	.	O	O
A	A	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
fulminant	fulminant	f04505053	JJ	B-NP	O
drug	drug	d602	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
induced	induce	i530203	VBN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
nuclear	nuclear	n02406	JJ	I-NP	O
autoantibodies	autoantibody	a03053010302	NNS	I-NP	O
(	(	(000	(	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
other	other	o306	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
autoimmunity	autoimmunity	a030505030	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
multi	multi	m0430	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
organ	organ	o6205	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
sepsis	sepsis	s01202	NN	I-NP	B-Disease
,	,	,000	,	O	O
supervened	supervene	s010610503	VBD	B-VP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
subsequently	subsequently	s0120205340	RB	B-ADVP	O
died	die	d030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
5	5	5000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
commencement	commencement	c0505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O
Post	Post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
mortem	mortem	m06305	NN	I-NP	O
examination	examination	e205050305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	B-Disease
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	O
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
,	,	,000	,	O	O
focal	focal	f0204	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	O
tubulo	tubulo	t01040	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
nephritis	nephritis	n01060302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
extensive	extensive	e23052010	JJ	B-NP	O
bone	bone	b050	NN	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
malignancy	malignancy	m040250520	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
thought	think	t0203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
clinico	clinico	c405020	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
and	and	a530	CC	O	O
chronology	chronology	c060504020	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
bore	bear	b060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hallmarks	hallmark	h045062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
so	so	s000	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
called	call	c0403	VBN	B-VP	O
"	"	"000	``	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
sulphasalazine	sulphasalazine	s041020402050	NN	I-NP	B-Chemical
syndrome	syndrome	s0536050	NN	I-NP	O
"	"	"000	''	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
often	often	o1305	RB	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
,	,	,000	,	I-NP	O
immunoallergic	immunoallergic	i5050406202	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
or	or	o600	CC	O	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
city	city	c030	NN	I-NP	O
teaching	teaching	t02052	NN	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
aged	age	a203	VBN	B-ADJP	O
18	18	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
or	or	o600	CC	O	O
older	old	o4306	JJR	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
eligible	eligible	e4020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
inclusion	inclusion	i5240205	NN	B-NP	O
.	.	.000	.	O	O

Study	Study	s3030	NN	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
push	push	p020	NN	I-NP	O
(	(	(000	(	O	O
bolus	bolus	b0402	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
diluted	dilute	d040303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
50	50	0000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
infusion	infusion	i510205	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
participants	participant	p06302010532	NNS	I-NP	O
experiencing	experience	e2106052052	VBG	B-VP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
within	within	w0305	IN	B-PP	O
60	60	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
.	.	.000	.	O	O

Akathisia	Akathisia	a203020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
either	either	e0306	CC	O	O
a	a	a000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
restlessness	restlessness	r023402502	NN	B-NP	O
or	or	o600	CC	I-NP	O
agitation	agitation	a2030305	NN	I-NP	B-Disease
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
reported	report	r0106303	VBN	B-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
rating	rating	r03052	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
1	1	1000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
investigator	investigator	i51023020306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
observed	observe	o1206103	VBN	B-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
rating	rating	r03052	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
intensity	intensity	i53052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
100	100	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mm	mm	m500	NN	I-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
study	study	s3030	NN	I-NP	O
participant	participant	p0630201053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
protocol	protocol	p6030204	NN	B-NP	O
violation	violation	v040305	NN	I-NP	O
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
(	(	(000	(	O	O
73	73	0000	CD	B-NP	O
/	/	/000	SYM	O	O
99	99	0000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
99	99	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
13	13	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
50	50	0000	CD	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
49	49	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
Delta	Delta	d0430	NN	B-NP	O
=	=	=000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
-	-	-000	SYM	B-NP	O
24	24	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
and	and	a530	CC	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
participants	participant	p06302010532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
saw	see	s000	VBD	B-VP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
within	within	w0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
29	29	0000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
means	mean	m052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	JJ	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
push	push	p020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
prochlorperazine	prochlorperazine	p602040610602050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
likewise	likewise	l02020	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
formal	formal	f06504	JJ	I-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
.	.	.000	.	O	O

Combined	Combine	c0510503	VBN	B-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
elevates	elevate	e4010302	VBZ	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
transgenic	transgenic	t60520502	JJ	B-NP	O
AIDS	AIDS	a032	NN	I-NP	B-Disease
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Highly	Highly	h02040	RB	B-NP	O
active	active	a23010	JJ	I-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
HAART	HAART	h063	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
(	(	(000	(	O	O
CM	CM	c500	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
elevated	elevate	e4010303	VBN	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
lactate	lactate	l023030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
LA	LA	l000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
through	through	t06020	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
HAART	HAART	h063	NN	B-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
hemizygous	hemizygous	h05020202	JJ	I-NP	O
transgenic	transgenic	t60520502	JJ	I-NP	O
AIDS	AIDS	a032	NN	I-NP	B-Disease
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
NL4	NL4	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3Delta	3Delta	30430	SYM	I-NP	O
gag	gag	g020	NN	I-NP	O
/	/	/000	SYM	I-NP	O
pol	pol	p040	NN	I-NP	O
;	;	;000	:	O	O
TG	TG	t200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
FVB	FVB	f100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
n	n	n000	NN	I-NP	O
littermates	littermate	l030650302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
HAART	HAART	h063	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
indinavir	indinavir	i53050106	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
control	control	c053604	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
or	or	o600	CC	O	O
35	35	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
termination	termination	t065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
,	,	,000	,	O	O
mice	mouse	m020	NNS	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
,	,	,000	,	O	O
quantitation	quantitation	q053030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
abundance	abundance	a10530520	NN	B-NP	O
of	of	o100	IN	B-PP	O
molecular	molecular	m04020406	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CM	CM	c500	NN	B-NP	B-Disease
(	(	(000	(	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
encoding	encode	e5203052	VBG	B-VP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
[	[	[000	(	O	O
ANF	ANF	a510	NN	B-NP	O
]	]	]000	)	O	O
and	and	a530	CC	O	O
sarcoplasmic	sarcoplasmic	s06201402502	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
ATPase	ATPase	a31020	NN	I-NP	O
[	[	[000	(	O	O
SERCA2	SERCA2	0000	NN	B-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
LA	LA	l000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
semiquantitatively	semiquantitatively	s0502053030301040	RB	B-ADVP	O
and	and	a530	CC	O	O
results	result	r020432	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
transmission	transmission	t605250205	NN	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
35	35	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TG	TG	t200	NN	I-NP	O
+	+	+000	SYM	B-NP	O
HAART	HAART	h063	NNP	I-NP	O
cohort	cohort	c063	NN	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
mass	mass	m020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
160	160	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
.	.	.000	.	O	O

Molecularly	Molecularly	m0402040640	RB	B-ADVP	O
,	,	,000	,	O	O
ANF	ANF	a510	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
250	250	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
SERCA2	SERCA2	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Biochemically	Biochemically	b020502040	RB	B-ADVP	O
,	,	,000	,	O	O
LA	LA	l000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mM	mM	m500	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pathologically	Pathologically	p03040202040	RB	B-ADVP	O
,	,	,000	,	O	O
granular	granular	g6050406	JJ	B-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
myocytes	myocyte	m020302	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
enlarged	enlarge	e5406203	VBN	I-VP	O
,	,	,000	,	O	O
damaged	damage	d050203	VBN	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
.	.	.000	.	O	O

Findings	Finding	f053052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
ultrastructurally	ultrastructurally	u436023602306040	RB	B-ADVP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
cohorts	cohort	c0632	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
ANF	ANF	a510	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TG	TG	t200	NN	I-NP	O
+	+	+000	SYM	B-NP	O
HAART	HAART	h063	NNP	I-NP	O
cohort	cohort	c063	JJ	B-ADJP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cumulative	cumulative	c050403010	JJ	B-NP	O
HAART	HAART	h063	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
CM	CM	c500	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
LA	LA	l000	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
transgenic	transgenic	t60520502	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Phase	Phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
WR	WR	w600	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
2721	2721	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
amifostine	amifostine	a501023050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
Eastern	Eastern	e023065	NNP	I-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
(	(	(000	(	O	O
E8188	E8188	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cisplatin	Cisplatin	c02140305	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
antitumor	antitumor	a53030506	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
or	or	o600	CC	I-NP	O
third	third	t063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Older	Old	o4306	JJR	B-NP	O
reports	report	r010632	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
an	an	a500	DT	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
60	60	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxicities	toxicity	t02020302	NNS	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
limited	limit	l050303	VBN	I-VP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

WR	WR	w600	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
2721	2721	0000	CD	B-NP	I-Chemical
or	or	o600	CC	O	O
amifostine	amifostine	a501023050	NN	B-NP	B-Chemical
initially	initially	i503040	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
military	military	m0403060	JJ	B-NP	O
personnel	personnel	p0620504	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nuclear	nuclear	n02406	JJ	B-NP	O
war	war	w060	NN	I-NP	O
.	.	.000	.	O	O

Amifostine	Amifostine	a501023050	NN	B-NP	B-Chemical
subsequently	subsequently	s0120205340	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
normal	normal	n06504	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alkylating	alkylate	a420403052	VBG	B-NP	B-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
without	without	w0303	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
antitumor	antitumor	a53030506	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amifostine	amifostine	a501023050	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
neuropathy	neuropathy	n0601030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
Phase	Phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
amifostine	amifostine	a501023050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
one	one	o500	CD	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
,	,	,000	,	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
amifostine	amifostine	a501023050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
910	910	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
intravenously	intravenously	i53601050240	RB	B-NP	O
over	over	o106	IN	I-NP	O
15	15	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
completion	completion	c05140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
amifostine	amifostine	a501023050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
over	over	o106	IN	B-NP	O
30	30	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
hydration	hydration	h0360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
mannitol	mannitol	m050304	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
until	until	u5304	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
7	7	7000	CD	B-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
ineligible	ineligible	i504020140	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
37	37	0000	CD	I-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
partial	partial	p06304	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
stopped	stop	s30103	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
disease	disease	d02020	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

Neurologic	Neurologic	n06040202	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
52	52	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
life	life	l010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
threatening	threaten	t060305052	VBG	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amifostine	amifostine	a501023050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
a	a	a000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
nor	nor	n060	CC	O	O
reduced	reduced	r030203	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amifostine	amifostine	a501023050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-NP	O
all	all	a400	DT	I-NP	O
,	,	,000	,	O	O
studies	study	s30302	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
this	this	t020	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
progestagen	progestagen	p6020230205	NN	B-NP	B-Chemical
included	include	i5240303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
desogestrel	desogestrel	d0202023604	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
gestodene	gestodene	g02303050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	O	O
generation	generation	g05060305	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
levonorgestrel	levonorgestrel	l0105062023604	NN	B-NP	B-Chemical
)	)	)000	)	O	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
prothrombotic	prothrombotic	p603060510302	JJ	B-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
nationwide	nationwide	n0305030	JJ	I-NP	O
,	,	,000	,	I-NP	O
population	population	p01040305	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
based	base	b0203	VBN	B-VP	O
,	,	,000	,	O	O
case	case	c020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
identified	identify	i30530103	VBD	B-VP	O
and	and	a530	CC	O	O
enrolled	enrol	e560403	VBD	B-VP	O
248	248	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
18	18	0000	CD	B-NP	O
through	through	t06020	IN	B-PP	O
49	49	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
had	have	h030	VBN	I-VP	O
a	a	a000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
between	between	b0305	IN	B-PP	O
1990	1990	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1995	1995	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
925	925	0000	CD	I-NP	O
control	control	c053604	NN	I-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
had	have	h030	VBN	I-VP	O
a	a	a000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
matched	match	m03203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
calendar	calendar	c0405306	NN	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
index	index	i5302	NN	I-NP	O
event	event	e1053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
area	area	a600	NN	B-NP	O
of	of	o100	IN	B-PP	O
residence	residence	r02030520	NN	B-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
supplied	supply	s01403	VBD	B-VP	O
information	information	i510650305	NN	B-NP	O
on	on	o500	IN	B-PP	O
oral	oral	o604	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
contraceptive	contraceptive	c053602013010	JJ	I-NP	I-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
major	major	m0206	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
factor	factor	f02306	NN	B-NP	O
V	V	v000	NNP	I-NP	O
Leiden	Leiden	l0305	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
G20210A	G20210A	0000	NN	I-NP	O
mutation	mutation	m030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prothrombin	prothrombin	p6030605105	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
217	217	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
763	763	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
any	any	a500	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptive	contraceptive	c053602013010	NN	I-NP	I-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
nonusers	nonuser	n0502062	NNS	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
those	those	t020	DT	B-NP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
prothrombotic	prothrombotic	p603060510302	JJ	I-NP	O
mutation	mutation	m030305	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
CONCLUSIONS	CONCLUSIONS	c052402052	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
third	third	t063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
inconclusive	inconclusive	i52052402010	JJ	B-ADJP	O
but	but	b030	CC	O	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
among	among	a5052	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
whether	whether	w0306	IN	B-SBAR	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
they	they	t000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
prothrombotic	prothrombotic	p603060510302	JJ	I-NP	O
mutation	mutation	m030305	NN	I-NP	O
.	.	.000	.	O	O

End	End	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
orthotopic	orthotopic	o63030102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
OLTX	OLTX	o432	NN	B-NP	O
)	)	)000	)	O	O
using	use	u2052	VBG	B-VP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
immunotherapy	immunotherapy	i5050306010	NN	I-NP	O
:	:	:000	:	O	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
cyclosporine	cyclosporine	c02402106050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
both	both	b030	DT	O	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-ADJP	B-Disease
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
orthotopic	orthotopic	o63030102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
(	(	(000	(	O	O
OLTX	OLTX	o432	NN	B-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
dramatically	dramatically	d6050302040	RB	I-VP	O
improved	improve	i5160103	VBN	B-NP	O
success	success	s0202	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
had	have	h030	VBN	I-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
presenting	present	p602053052	VBG	I-VP	O
after	after	a1306	IN	B-PP	O
OLTX	OLTX	o432	NN	B-NP	O
with	with	w030	IN	B-PP	O
end	end	e530	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examines	examine	e2050502	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CRF	CRF	c610	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
OLTX	OLTX	o432	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
OLTX	OLTX	o432	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
June	June	j050	NNP	B-NP	O
1985	1985	0000	CD	I-NP	O
through	through	t06020	IN	B-PP	O
December	December	d0205106	NNP	B-NP	O
of	of	o100	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
who	who	w000	WP	B-NP	O
survived	survive	s0610103	VBD	B-VP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
834	834	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
prospectively	prospectively	p602102301040	RB	I-NP	O
collected	collect	c0402303	VBN	I-NP	O
database	database	d0301020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
source	source	s0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
information	information	i510650305	NN	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
Controls	Control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
CRF	CRF	c610	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
748	748	0000	CD	B-NP	O
;	;	;000	:	O	O
CRF	CRF	c610	NN	B-NP	B-Disease
,	,	,000	,	O	O
sustained	sustain	s0230503	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
>	>	>000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
41	41	0000	CD	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
,	,	,000	,	O	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
,	,	,000	,	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
,	,	,000	,	O	O
survival	survival	s0610104	NN	B-NP	O
,	,	,000	,	O	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
survival	survival	s0610104	NN	B-NP	O
from	from	f605	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
At	At	a300	IN	B-PP	O
13	13	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
OLTX	OLTX	o432	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
CRF	CRF	c610	NN	B-NP	B-Disease
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
CRF	CRF	c610	NN	B-NP	B-Disease
and	and	a530	CC	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
preoperative	preoperative	p6010603010	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hepatorenal	hepatorenal	h0103060504	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
higher	high	h0206	JJR	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
requirement	requirement	r020605053	NN	I-NP	O
for	for	f060	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
stepwise	stepwise	s301020	JJ	I-NP	O
logistic	logistic	l0202302	JJ	I-NP	O
regression	regression	r0260205	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
identified	identify	i30530103	VBN	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
average	average	a106020	NN	B-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
independent	independent	i5301053053	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
CRF	CRF	c610	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
odds	odd	o320	NNS	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Overall	Overall	o10604	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
OLTX	OLTX	o432	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
by	by	b000	IN	B-PP	O
year	year	y060	NN	B-NP	O
13	13	0000	CD	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
survival	survival	s0610104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
only	only	o540	RB	B-NP	O
28	28	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
developing	develop	d010401052	VBG	B-VP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
after	after	a1306	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
71	71	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developing	develop	d010401052	VBG	B-VP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
who	who	w000	WP	B-NP	O
subsequently	subsequently	s0120205340	RB	B-VP	O
received	receive	r020103	VBD	I-VP	O
kidney	kidney	k0350	NN	B-NP	O
transplants	transplant	t6052140532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
10	10	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
OLTX	OLTX	o432	NN	B-NP	O
have	have	h010	VBP	B-VP	O
CRF	CRF	c610	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
decreases	decrease	d0260202	VBZ	B-VP	O
survival	survival	s0610104	NN	B-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
develop	develop	d010401	VBP	B-VP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
preoperative	preoperative	p6010603010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
hepatorenal	hepatorenal	h0103060504	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
times	time	t0502	NNS	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
predictive	predictive	p603023010	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
CRF	CRF	c610	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
.	.	.000	.	O	O

New	New	n000	JJ	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Epileptic	Epileptic	e10401302	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrin	fibrin	f01605	NN	B-NP	O
sealants	sealant	s040532	NNS	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Fibrin	Fibrin	f01605	NN	B-NP	O
sealants	sealant	s040532	NNS	I-NP	O
(	(	(000	(	O	O
FS	FS	f200	NNS	B-NP	O
)	)	)000	)	O	O
derived	derive	d060103	VBN	B-VP	O
from	from	f605	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
are	be	a600	VBP	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
neurosurgery	neurosurgery	n0602062060	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
increase	increase	i526020	VB	I-VP	O
clot	clot	c403	NN	B-NP	O
stability	stability	s30104030	NN	I-NP	O
,	,	,000	,	O	O
FS	FS	f200	NN	B-NP	O
typically	typically	t0102040	RB	B-ADVP	O
contain	contain	c05305	VBP	B-VP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
natural	natural	n030604	JJ	I-NP	O
fibrinolysis	fibrinolysis	f01605040202	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
synthetic	synthetic	s0530302	JJ	B-NP	O
fibrinolysis	fibrinolysis	f01605040202	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
substitutes	substitute	s0123030302	NNS	B-NP	O
for	for	f060	IN	B-PP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
wanted	want	w05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
study	study	s3030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
retains	retain	r03052	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
if	if	i100	IN	B-SBAR	O
incorporated	incorporate	i52061060303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
a	a	a000	DT	B-NP	O
FS	FS	f200	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
FS	FS	f200	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
or	or	o600	CC	O	O
different	different	d0106053	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
47	47	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pial	pial	p040	JJ	I-NP	O
surface	surface	s061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
of	of	o100	IN	B-PP	O
anaesthetized	anaesthetize	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
electroencephalography	electroencephalography	e402360520104026010	NN	B-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
monitoring	monitor	m050306052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
recovery	recovery	r0201060	NN	B-NP	O
from	from	f605	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
FS	FS	f200	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
paroxysmal	paroxysmal	p060202504	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
distinct	distinct	d0230523	JJ	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
behaviours	behaviour	b01062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
FS	FS	f200	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
47	47	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
tAMCA	tAMCA	t0520	NN	I-NP	B-Chemical
evoked	evoke	e10203	VBD	B-VP	O
generalized	generalize	g0506040203	VBN	B-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
tested	test	t02303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
lowest	low	l023	JJS	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
only	only	o540	RB	B-ADVP	O
evoked	evoke	e10203	VBD	B-VP	O
brief	brief	b601	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
jerk	jerk	j062	NN	B-NP	O
-	-	-000	HYPH	O	O
correlated	correlate	c06040303	VBN	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
potentials	potential	p03053042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
FS	FS	f200	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
aprotinin	aprotinin	a16030505	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
evoke	evoke	e1020	VB	I-VP	O
any	any	a500	DT	B-NP	O
paroxysmal	paroxysmal	p060202504	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

INTERPRETATION	INTERPRETATION	i530616030305	NN	B-NP	O
:	:	:000	:	O	O
Tranexamic	Tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
retains	retain	r03052	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
FS	FS	f200	NN	B-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
FS	FS	f200	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
tAMCA	tAMCA	t0520	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
within	within	w0305	IN	B-PP	O
or	or	o600	CC	O	O
close	close	c4020	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
may	may	m000	MD	B-VP	O
pose	pose	p020	VB	I-VP	O
a	a	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Sequential	Sequential	s0205304	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-NP	B-Disease
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
by	by	b000	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
exo	exo	e200	NN	I-NP	O
utero	utero	u3060	NN	I-NP	O
development	development	d0104015053	NN	I-NP	O
system	system	s02305	NN	I-NP	O
:	:	:000	:	O	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
transformation	transformation	t605210650305	NN	B-NP	O
from	from	f605	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-ADVP	B-Disease
to	to	t000	TO	B-PP	O
anencephaly	anencephaly	a505201040	RB	B-NP	B-Disease
.	.	.000	.	O	O

Anencephaly	Anencephaly	a505201040	RB	B-ADVP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
develop	develop	d010401	VB	I-VP	O
from	from	f605	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-NP	B-Disease
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
little	little	l0340	JJ	B-NP	O
direct	direct	d06023	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
to	to	t000	TO	B-VP	O
support	support	s01063	VB	I-VP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
transformation	transformation	t605210650305	NN	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
this	this	t020	DT	B-NP	O
theory	theory	t060	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
exo	exo	e200	NN	I-NP	O
utero	utero	u3060	NN	I-NP	O
development	development	d0104015053	NN	I-NP	O
system	system	s02305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
allows	allow	a402	VBZ	B-VP	O
direct	direct	d06023	JJ	B-NP	O
and	and	a530	CC	I-NP	O
sequential	sequential	s0205304	JJ	I-NP	O
observations	observation	o1206103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mid	mid	m030	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
gestation	gestation	g0230305	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
embryos	embryo	e51602	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
exencephaly	exencephaly	e205201040	RB	I-NP	B-Disease
induced	induce	i530203	VBN	I-NP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azacytidine	azacytidine	a2020303050	NN	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
embryonic	embryonic	e5160502	JJ	B-NP	O
day	day	d000	NN	I-NP	O
13	13	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
E13	E13	0000	NN	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
let	let	l030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
embryos	embryo	e51602	NNS	I-NP	O
develop	develop	d010401	VBP	B-VP	O
exo	exo	e200	NN	B-NP	O
utero	utero	u3060	NN	I-NP	O
until	until	u5304	IN	B-PP	O
E18	E18	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
re	re	r000	NN	B-NP	O
-	-	-000	HYPH	O	O
observed	observe	o1206103	VBN	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
embryos	embryo	e51602	NNS	I-NP	O
at	at	a300	IN	B-PP	O
E18	E18	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
several	several	s010604	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transformation	transformation	t605210650305	NN	B-NP	O
from	from	f605	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-ADVP	B-Disease
to	to	t000	TO	B-PP	O
anencephaly	anencephaly	a505201040	RB	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
brain	brain	b605	NN	I-NP	O
tissue	tissue	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
more	more	m060	JJR	B-NP	O
or	or	o600	CC	I-NP	O
less	less	l020	JJR	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
this	this	t020	DT	B-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
analyze	analyze	a504020	VB	I-VP	O
the	the	t000	DT	B-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
classified	classify	c4020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
exencephaly	exencephaly	e205201040	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
size	size	s020	NN	B-NP	O
and	and	a530	CC	I-NP	O
shape	shape	s010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
into	into	i530	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
at	at	a300	IN	B-PP	O
E13	E13	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
E18	E18	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
transformation	transformation	t605210650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
exencephalic	exencephalic	e2052010402	JJ	B-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
simply	simply	s05140	RB	B-ADVP	O
size	size	s020	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anencephaly	anencephaly	a505201040	RB	B-ADVP	B-Disease
at	at	a300	IN	B-PP	O
E18	E18	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
embryos	embryo	e51602	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
exencephalic	exencephalic	e2052010402	JJ	B-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
at	at	a300	IN	B-PP	O
E13	E13	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O

Microscopic	Microscopic	m026020102	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
configuration	configuration	c05102060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-ADVP	B-Disease
at	at	a300	IN	B-PP	O
E13	E13	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
frequent	frequent	f602053	JJ	B-NP	O
hemorrhaging	hemorrhaging	h050602052	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
detachment	detachment	d030205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neural	neural	n0604	JJ	I-NP	O
plate	plate	p4030	NN	I-NP	O
from	from	f605	IN	B-PP	O
surface	surface	s061020	NN	B-NP	O
ectoderm	ectoderm	e2303065	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
head	head	h030	NN	I-NP	O
at	at	a300	IN	B-PP	O
E15	E15	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
multiple	multiple	m0430140	JJ	B-NP	O
modes	mode	m0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
at	at	a300	IN	B-PP	O
E18	E18	0000	NN	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
observations	observation	o1206103052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasculature	vasculature	v020403060	NN	I-NP	O
,	,	,000	,	O	O
altered	altered	a430603	JJ	B-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vessels	vessel	v02042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
head	head	h030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
overgrowth	overgrowth	o10626030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
neural	neural	n0604	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
altered	alter	a430603	VBN	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vessels	vessel	v02042	NNS	B-NP	O
,	,	,000	,	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
circulatory	circulatory	c0620403060	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
hemorrhaging	hemorrhaging	h050602052	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
parts	part	p0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exencephalic	exencephalic	e2052010402	JJ	I-NP	B-Disease
head	head	h030	NN	I-NP	O
,	,	,000	,	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
modes	mode	m0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tissue	tissue	t020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
transformation	transformation	t605210650305	NN	B-NP	O
from	from	f605	IN	B-PP	O
exencephaly	exencephaly	e205201040	RB	B-ADVP	B-Disease
to	to	t000	TO	B-PP	O
anencephaly	anencephaly	a505201040	RB	B-NP	B-Disease
.	.	.000	.	O	O

99mTc	99mTc	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
glucarate	glucarate	g40206030	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Infarct	Infarct	i510623	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
avid	avid	a103	JJ	I-NP	O
radiopharmaceuticals	radiopharmaceutical	r0301065020302042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
and	and	a530	CC	I-NP	O
timely	timely	t05040	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
infarction	infarction	i51062305	NN	B-NP	B-Disease
implies	imply	i51402	VBZ	B-VP	O
artery	artery	a63060	NN	B-NP	O
ligation	ligation	l020305	NN	I-NP	O
but	but	b030	CC	O	O
chemical	chemical	c050204	JJ	B-NP	O
induction	induction	i5302305	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
easily	easily	e02040	RB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
infarct	infarct	i510623	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	O
avid	avid	a103	NN	I-NP	O
radiopharmaceutical	radiopharmaceutical	r030106502030204	NN	I-NP	O
based	base	b0203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
glucaric	glucaric	g4020602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
prepared	prepare	p6010603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
radiopharmacy	radiopharmacy	r0301065020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
INCMNSZ	INCMNSZ	i5252	NN	I-NP	O
.	.	.000	.	O	O

99mTc	99mTc	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
glucarate	glucarate	g40206030	NN	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
easy	easy	e020	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
prepare	prepare	p601060	VB	I-VP	O
,	,	,000	,	O	O
stable	stable	s30140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
96	96	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
biodistribution	biodistribution	b030236010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
infarct	infarct	i510623	NN	I-NP	B-Disease
18	18	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
biodistribution	biodistribution	b030236010305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
99mTc	99mTc	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glucarate	glucarate	g40206030	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
the	the	t000	DT	B-NP	O
standardised	standardised	s30530630203	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
uptake	uptake	u13020	NN	I-NP	O
value	value	v040	NN	I-NP	O
S	S	s000	NN	I-NP	O
(	(	(000	(	O	O
h	h	h000	NN	B-NP	O
)	)	)000	)	O	O
UV	UV	u100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
in	in	i500	IN	B-PP	O
infarcted	infarcte	i51062303	VBN	B-NP	O
rat	rat	r030	NN	I-NP	O
heart	heart	h063	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
six	six	s020	CD	B-ADJP	O
times	time	t0502	NNS	I-ADJP	O
more	more	m060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

ROIs	ROI	r020	NNS	B-NP	O
drawn	draw	d605	VBN	B-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	NN	I-NP	O
camera	camera	c05060	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
image	image	i5020	NN	I-NP	O
quality	quality	q04030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
high	high	h020	JJ	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
96	96	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
stability	stability	s30104030	NN	I-NP	O
makes	make	m0202	VBZ	B-VP	O
it	it	i300	PRP	B-NP	O
an	an	a500	DT	B-NP	O
ideal	ideal	i304	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
early	early	e0640	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Bupropion	Bupropion	b0160105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Zyban	Zyban	z0105	NN	B-NP	B-Chemical
)	)	)000	)	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Bupropion	Bupropion	b0160105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
monocyclic	monocyclic	m050202402	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
structurally	structurally	s3602306040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Zyban	Zyban	z0105	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
formulation	formulation	f065040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
recently	recently	r0205340	RB	I-VP	O
released	release	r040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Ireland	Ireland	i604053	NNP	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
cessation	cessation	c020305	NN	I-NP	O
aid	aid	a030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
since	since	s0520	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
'	'	'000	``	O	O
s	s	s000	JJ	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
overdose	overdose	o1063020	JJ	I-NP	B-Disease
cases	case	c0202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
The	The	t000	DT	B-NP	O
National	National	n030504	NNP	I-NP	O
Poisons	Poisons	p02052	NNP	I-NP	O
Information	Information	i510650305	NNP	I-NP	O
Centre	Centre	c05360	NNP	I-NP	O
.	.	.000	.	O	O

8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Common	Common	c0505	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
drowsiness	drowsiness	d6020502	NN	I-NP	O
,	,	,000	,	I-NP	O
hallucinations	hallucination	h04020503052	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
resuscitated	resuscitate	r0202030303	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
sequelae	sequela	s02040	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
31	31	0000	CD	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
who	who	w000	WP	B-NP	O
required	require	r020603	VBD	B-VP	O
admission	admission	a350205	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Intensive	Intensive	i53052010	JJ	I-NP	O
Care	Care	c060	NNP	I-NP	O
Unit	Unit	u503	NNP	I-NP	O
for	for	f060	IN	B-PP	O
ventilation	ventilation	v053040305	NN	B-NP	O
and	and	a530	CC	O	O
full	full	f040	JJ	B-NP	O
supportive	supportive	s01063010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
5g	5g	5200	CD	B-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
broad	broad	b603	JJ	B-NP	O
complex	complex	c051402	JJ	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Zyban	Zyban	z0105	NNP	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
overdose	overdose	o1063020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
it	it	i300	PRP	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
cessation	cessation	c020305	NN	I-NP	O
aid	aid	a030	NN	I-NP	O
.	.	.000	.	O	O

GLEPP1	GLEPP1	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
tyrosine	tyrosine	t0602050	NN	I-NP	B-Chemical
phosphatase	phosphatase	p02103020	NN	I-NP	O
(	(	(000	(	O	O
Ptpro	Ptpro	p3160	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
PAN	PAN	p050	NN	I-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
podocyte	podocyte	p0302030	NN	I-NP	O
injury	injury	i52060	NN	I-NP	O
.	.	.000	.	O	O

Glomerular	Glomerular	g405060406	JJ	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
podocyte	podocyte	p0302030	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
tyrosine	tyrosine	t0602050	NN	I-NP	B-Chemical
phosphatase	phosphatase	p02103020	NN	I-NP	O
located	located	l020303	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
of	of	o100	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
and	and	a530	CC	I-NP	O
foot	foot	f030	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
regulating	regulate	r020403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
structure	structure	s36023060	NN	I-NP	O
and	and	a530	CC	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocyte	podocyte	p0302030	NN	B-NP	O
foot	foot	f030	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
better	well	b0306	RBR	I-VP	O
understand	understand	u530623053	VB	I-VP	O
the	the	t000	DT	B-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
and	and	a530	CC	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	O	O
mRNA	mRNA	m650	NN	B-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
,	,	,000	,	O	O
Western	Western	w023065	NN	B-NP	O
blot	blot	b403	NN	I-NP	O
and	and	a530	CC	O	O
RNase	RNase	r5020	NN	B-NP	O
protection	protection	p60302305	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocyte	podocyte	p0302030	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Puromycin	Puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100g	100g	0000	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Tissues	Tissue	t0202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
11	11	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
21	21	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
45	45	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
80	80	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
126	126	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
so	so	s000	RB	B-SBAR	O
as	as	a200	IN	I-SBAR	O
to	to	t000	TO	B-VP	O
include	include	i524030	VB	I-VP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
foot	foot	f030	NN	B-NP	O
process	process	p60202	NN	I-NP	O
effacement	effacement	e10205053	NN	I-NP	O
(	(	(000	(	O	O
days	day	d020	NNS	B-NP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
11	11	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
(	(	(000	(	O	O
days	day	d020	NNS	B-NP	O
45	45	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
126	126	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	O	O
mRNA	mRNA	m650	NN	B-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
(	(	(000	(	O	O
265	265	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
79	79	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
moles	mole	m0402	NNS	B-NP	O
/	/	/000	SYM	B-NP	O
glomerulus	glomerulus	g405060402	NN	I-NP	O
and	and	a530	CC	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
moles	mole	m0402	NNS	B-NP	O
/	/	/000	SYM	B-VP	O
glomerulus	glomerulus	g405060402	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
005	005	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
content	content	c053053	NN	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
99	99	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
61	61	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
podocalyxin	podocalyxin	p0302040205	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
11	11	0000	CD	I-NP	O
,	,	,000	,	O	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
and	and	a530	CC	O	O
mRNA	mRNA	m650	NN	B-NP	O
had	have	h030	VBD	B-VP	O
begun	begin	b0205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
return	return	r03065	VB	I-VP	O
towards	towards	t0632	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
126	126	0000	CD	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
scarring	scarring	s206052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
,	,	,000	,	O	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
absent	absent	a12053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
glomerulosclerotic	glomerulosclerotic	g4050604024060302	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GLEPP1	GLEPP1	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
unlike	unlike	u54020	IN	B-PP	O
podocalyxin	podocalyxin	p0302040205	NN	B-NP	O
,	,	,000	,	O	O
reflects	reflect	r0140232	VBZ	B-VP	O
podocyte	podocyte	p0302030	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

GLEPP1	GLEPP1	0000	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
podocyte	podocyte	p0302030	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
.	.	.000	.	O	O

Antithymocyte	Antithymocyte	a53030502030	NN	B-NP	B-Chemical
globulin	globulin	g4010405	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
antithymocyte	antithymocyte	a53030502030	JJ	B-NP	B-Chemical
globulin	globulin	g4010405	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Bone	Bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
1	1	1000	CD	I-NP	O
month	month	m0530	NN	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
blood	blood	b403	NN	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
therapies	therapy	t060102	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
necessary	necessary	n0202060	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	I-NP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
antithymocyte	antithymocyte	a53030502030	JJ	B-NP	B-Chemical
globulin	globulin	g4010405	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Metamizol	Metamizol	m03050204	NN	B-NP	B-Chemical
potentiates	potentiate	p030530302	VBZ	B-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
antinociception	antinociception	a5305020201305	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
constipation	constipation	c0523010305	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
evaluates	evaluate	e1040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
constipating	constipating	c05230103052	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
177	177	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
metamizol	metamizol	m03050204	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
acutely	acutely	a203040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
chronically	chronically	c060502040	RB	I-ADVP	O
treated	treat	t60303	VBN	B-VP	O
(	(	(000	(	O	O
once	once	o520	RB	O	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
13th	13th	0000	JJ	I-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
antinociceptive	antinociceptive	a53050202013010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
nociception	nociception	n020201305	NN	I-NP	O
,	,	,000	,	O	O
pain	pain	p050	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
impairment	impairment	i51065053	NN	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
charcoal	charcoal	c06204	NN	I-NP	B-Chemical
meal	meal	m040	JJ	I-NP	O
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
transit	transit	t605203	NN	I-NP	O
.	.	.000	.	O	O

Simultaneous	Simultaneous	s050430502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
metamizol	metamizol	m03050204	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
markedly	markedly	m0620340	RB	I-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increasing	increasing	i52602052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
(	(	(000	(	O	O
298	298	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
139	139	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
36	36	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
area	area	a600	NN	B-NP	O
(	(	(000	(	O	O
ua	ua	u000	NN	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
repeated	repeat	r010303	VBN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
280	280	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
17	17	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
131	131	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
22	22	0000	CD	B-NP	O
ua	ua	u000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Antinociceptive	Antinociceptive	a53050202013010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
39	39	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
18	18	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
au	au	a000	SYM	B-NP	O
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
antinociception	antinociception	a5305020201305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
remained	remain	r050503	VBN	I-VP	O
similar	similar	s050406	JJ	B-ADJP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
(	(	(000	(	O	O
298	298	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
280	280	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
17	17	0000	CD	B-NP	O
au	au	a000	SYM	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
partially	partially	p063040	RB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
opioidergic	opioidergic	o10306202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
synergism	synergism	s05062025	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
independent	independent	i5301053053	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
transit	transit	t605203	NN	I-NP	O
in	in	i500	IN	B-PP	O
48	48	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
38	38	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
tolerance	tolerance	t04060520	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
develop	develop	d010401	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
constipating	constipate	c05230103052	VBG	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
intestinal	intestinal	i530230504	JJ	B-NP	O
transit	transit	t605203	NN	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
metamizol	metamizol	m03050204	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
constipation	constipation	c0523010305	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
metamizol	metamizol	m03050204	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
chronically	chronically	c060502040	RB	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ifosfamide	Ifosfamide	i102105030	NN	B-NP	B-Chemical
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
asterixis	asterixis	a23060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

CNS	CNS	c520	NN	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antineoplastic	antineoplastic	a530501402302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
IFX	IFX	i120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
and	and	a530	CC	O	O
include	include	i524030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
limit	limit	l0503	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
51	51	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-ADJP	O
,	,	,000	,	O	O
disabling	disable	d02014052	VBG	B-VP	O
negative	negative	n0203010	JJ	B-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
upper	upper	u106	JJ	I-NP	O
and	and	a530	CC	I-NP	O
lower	low	l060	JJR	I-NP	O
extremities	extremity	e236050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
plasmacytoma	plasmacytoma	p40250203050	NN	B-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
awake	awake	a020	NN	B-NP	O
,	,	,000	,	O	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
rest	rest	r023	NN	B-NP	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
motor	motor	m0306	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Cranial	Cranial	c60504	JJ	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
and	and	a530	CC	O	O
extensive	extensive	e23052010	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
reveal	reveal	r0104	VB	I-VP	O
structural	structural	s360230604	JJ	B-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
brain	brain	b605	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
continuous	continuous	c0530502	JJ	B-ADJP	O
,	,	,000	,	O	O
generalized	generalize	g0506040203	VBN	B-VP	O
irregular	irregular	i6020406	JJ	B-NP	O
slowing	slowing	s4052	NN	I-NP	O
with	with	w030	IN	B-PP	O
admixed	admix	a350203	VBN	B-NP	O
periodic	periodic	p060302	JJ	I-NP	O
triphasic	triphasic	t6010202	JJ	I-NP	O
waves	wave	w0102	NNS	I-NP	O
indicating	indicate	i530203052	VBG	B-VP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
within	within	w0305	IN	B-PP	O
12	12	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
the	the	t000	DT	B-NP	O
asterixis	asterixis	a23060202	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
asterixis	asterixis	a23060202	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
and	and	a530	CC	O	O
imaging	imaging	i502052	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
negative	negative	n0203010	JJ	B-NP	O
myoclonus	myoclonus	m0240502	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
IFX	IFX	i120	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Antagonism	Antagonism	a530205025	NN	B-NP	O
between	between	b0305	IN	B-PP	O
interleukin	interleukin	i530640205	NN	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
erythropoietin	erythropoietin	e60306010305	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
azidothymidine	azidothymidine	a203030503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Azidothymidine	Azidothymidine	a203030503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	NN	I-NP	O
fusion	fusion	f0205	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
of	of	o100	IN	B-PP	O
insulin	insulin	i520405	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
II	II	i000	CD	I-NP	O
(	(	(000	(	O	O
IGF	IGF	i210	NN	B-NP	O
II	II	i000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
interleukin	interleukin	i530640205	NN	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
interleukin	interleukin	i530640205	NN	B-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
erythropoietin	erythropoietin	e60306010305	NN	B-NP	O
(	(	(000	(	O	O
EPO	EPO	e100	NN	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
act	act	a230	VB	I-VP	O
synergistically	synergistically	s0506202302040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
hematopoietic	hematopoietic	h0503010302	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
EPO	EPO	e100	NN	B-NP	O
in	in	i500	IN	B-PP	O
AZT	AZT	a230	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
red	red	r030	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
EPO	EPO	e100	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
EPO	EPO	e100	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
IL	IL	i400	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
EPO	EPO	e100	NN	B-NP	O
on	on	o500	IN	B-PP	O
erythroid	erythroid	e6030603	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Bovine	Bovine	b01050	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
erythroid	erythroid	e6030603	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
cultured	culture	c0430603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
monolayers	monolayer	m0504062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
bone	bone	b050	NN	I-NP	O
marrow	marrow	m060	NN	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
previously	previously	p6010240	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
and	and	a530	CC	I-NP	O
IGF	IGF	i210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thymidine	thymidine	t0503050	NN	B-NP	B-Chemical
incorporation	incorporation	i52061060305	NN	I-NP	O
into	into	i530	IN	B-PP	O
both	both	b030	CC	O	O
erythroid	erythroid	e6030603	JJ	B-NP	O
and	and	a530	CC	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
cultures	culture	c0430602	NNS	B-NP	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
EPO	EPO	e100	NNP	B-NP	O
.	.	.000	.	O	O

Endothelial	Endothelial	e53030404	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
culture	culture	c043060	NN	I-NP	O
supernatants	supernatant	s01065030532	NNS	I-NP	O
separated	separate	s01060303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ultrafiltration	ultrafiltration	u4360104360305	NN	B-NP	O
and	and	a530	CC	I-NP	O
ultracentrifugation	ultracentrifugation	u43602053601020305	NN	I-NP	O
from	from	f605	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
thymidine	thymidine	t0503050	NN	B-NP	B-Chemical
incorporation	incorporation	i52061060305	NN	I-NP	O
into	into	i530	IN	B-PP	O
erythroid	erythroid	e6030603	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
identical	identical	i30530204	JJ	B-NP	O
fractions	fraction	f6023052	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
cultured	culture	c0430603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
endothelial	endothelial	e53030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
EPO	EPO	e100	NN	B-NP	O
and	and	a530	CC	I-NP	O
IL	IL	i400	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
erythroid	erythroid	e6030603	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
and	and	a530	CC	O	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
prone	prone	p6050	NN	I-NP	O
and	and	a530	CC	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
-	-	-000	HYPH	B-ADJP	O
resistant	resistant	r02023053	JJ	B-NP	O
selected	select	s0402303	VBN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
lines	line	l0502	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
septo	septo	s0130	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
pathway	pathway	p030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
genetic	genetic	g050302	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
influence	influence	i5140520	VBP	B-VP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
limited	limited	l050303	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
responsiveness	responsiveness	r021052010502	NN	B-NP	O
and	and	a530	CC	I-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Cholinergic	Cholinergic	c040506202	JJ	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
na	na	n000	NN	I-NP	O
ve	ve	v000	NN	I-NP	O
Withdrawal	Withdrawal	w0303604	NN	I-NP	O
Seizure	Seizure	s02060	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
Prone	Prone	p6050	NN	B-NP	O
(	(	(000	(	O	O
WSP	WSP	w210	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
-	-	-000	HYPH	O	O
Resistant	Resistant	r02023053	JJ	O	O
(	(	(000	(	O	O
WSR	WSR	w260	JJ	B-ADJP	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Animals	Animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
neostigmine	neostigmine	n023025050	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
timed	time	t0503	VBN	B-NP	O
tail	tail	t040	NN	I-NP	O
vein	vein	v050	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
latencies	latency	l0305202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
clonus	clonus	c40502	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
and	and	a530	CC	O	O
converted	convert	c05106303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
threshold	threshold	t0602043	VB	I-VP	O
dose	dose	d020	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
used	use	u203	VBD	B-VP	O
microdialysis	microdialysis	m02603040202	NN	B-NP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
basal	basal	b0204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
stimulated	stimulate	s305040303	VBN	B-VP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACh	ACh	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
release	release	r04020	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CA1	CA1	0000	NN	I-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
.	.	.000	.	O	O

Potassium	Potassium	p030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
reverse	reverse	r010620	JJ	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
,	,	,000	,	O	O
separated	separate	s01060303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
75	75	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Hippocampal	Hippocampal	h010205104	JJ	B-NP	O
ACh	ACh	a200	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
testing	testing	t023052	NN	B-NP	O
for	for	f060	IN	B-PP	O
handling	handling	h0534052	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Sensitivity	Sensitivity	s0520301030	NN	B-NP	O
to	to	t000	TO	B-PP	O
several	several	s010604	JJ	B-NP	O
convulsion	convulsion	c05104205	NN	I-NP	B-Disease
endpoints	endpoint	e5310532	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
neostigmine	neostigmine	n023025050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
WSR	WSR	w260	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
WSP	WSP	w210	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
microdialysis	microdialysis	m02603040202	NN	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
lines	line	l0502	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
in	in	i500	IN	B-PP	O
basal	basal	b0204	JJ	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ACh	ACh	a200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
KCl	KCl	k240	NN	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
ACh	ACh	a200	NN	B-NP	B-Chemical
output	output	o03103	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
lines	line	l0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
release	release	r04020	NN	B-NP	O
of	of	o100	IN	B-PP	O
ACh	ACh	a200	NN	B-NP	B-Chemical
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
KCl	KCl	k240	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
fold	fold	f043	RB	I-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
WSP	WSP	w210	NN	B-NP	O
versus	versus	v06202	IN	B-PP	O
WSR	WSR	w260	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
ACh	ACh	a200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
testing	testing	t023052	NN	B-NP	O
for	for	f060	IN	B-PP	O
handling	handling	h0534052	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
,	,	,000	,	O	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
ACh	ACh	a200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
(	(	(000	(	O	O
192	192	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
WSP	WSP	w210	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
nonsignificantly	nonsignificantly	n052025010205340	RB	I-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
(	(	(000	(	O	O
59	59	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
WSR	WSR	w260	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
convulsants	convulsant	c0510420532	NNS	I-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ethanol	ethanol	e30504	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
severity	severity	s0106030	NN	I-NP	O
and	and	a530	CC	O	O
implicate	implicate	i51402030	VBP	B-VP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Specifically	Specifically	s1020102040	RB	B-ADVP	O
,	,	,000	,	O	O
WSP	WSP	w210	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
lower	low	l060	JJR	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
convulsants	convulsant	c0510420532	NNS	I-NP	B-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
WSR	WSR	w260	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
desensitization	desensitization	d0205203020305	NN	I-NP	O
brought	bring	b60203	VBD	B-VP	O
on	on	o500	RP	B-PRT	O
by	by	b000	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
alters	alter	a43062	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
jaw	jaw	j000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
stretch	stretch	s360320	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
painful	painful	p05104	JJ	B-NP	O
temporomandibular	temporomandibular	t0510605053010406	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
fully	fully	f040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
evidence	evidence	e1030520	NN	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
muscle	muscle	m0240	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
modulates	modulate	m03040302	VBZ	B-VP	O
motor	motor	m0306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
ways	way	w020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
afferent	afferent	a106053	JJ	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
linked	link	l05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
excitability	excitability	e2030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
jaw	jaw	j000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
stretch	stretch	s360320	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
and	and	a530	CC	O	O
whether	whether	w0306	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
process	process	p60202	NN	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
sensitive	sensitive	s05203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
length	length	l05230	NN	B-NP	O
and	and	a530	CC	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
stretch	stretch	s360320	NN	I-NP	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
micro	micro	m0260	NN	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
masseter	masseter	m020306	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
.	.	.000	.	O	O

Short	Short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
latency	latency	l030520	NN	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evoked	evoke	e10203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
masseter	masseter	m020306	NN	I-NP	O
and	and	a530	CC	I-NP	O
temporalis	temporalis	t051060402	NN	I-NP	O
muscles	muscle	m02402	NNS	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
stretch	stretch	s360320	NN	I-NP	O
device	device	d01020	NN	I-NP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
velocities	velocity	v04020302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
displacements	displacement	d021402050532	NNS	I-NP	O
before	before	b01060	RB	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
normalized	normalized	n065040203	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
velocity	velocity	v0402030	NN	B-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
given	give	g0105	VBN	I-NP	O
displacement	displacement	d02140205053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
remained	remain	r050503	VBD	B-VP	O
constant	constant	c0523053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
displacements	displacement	d021402050532	NNS	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
given	give	g0105	VBN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
normalized	normalized	n065040203	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
during	during	d06052	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
faster	fast	f02306	JJR	B-NP	O
stretches	stretch	s3603202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
painful	painful	p05104	JJ	I-NP	B-Disease
muscle	muscle	m0240	NN	I-NP	I-Disease
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fusimotor	fusimotor	f02050306	NN	I-NP	O
system	system	s02305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
one	one	o500	CD	B-NP	O
likely	likely	l02040	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
to	to	t000	TO	B-VP	O
explain	explain	e21405	VB	I-VP	O
the	the	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
microinjected	microinjecte	m02605202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
accumbal	accumbal	a205104	JJ	I-NP	O
shell	shell	s040	NN	I-NP	O
or	or	o600	CC	I-NP	O
core	core	c060	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
microinjected	microinjecte	m02605202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
subregions	subregion	s01602052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
accumbens	accumbens	a2051052	NN	I-NP	O
(	(	(000	(	O	O
the	the	t000	DT	B-NP	O
shell	shell	s040	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
core	core	c060	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
implanted	implant	i51405303	VBN	I-VP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
cannulae	cannulae	c05040	NNS	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
accumbens	accumben	a2051052	NNS	I-NP	O
shell	shell	s040	NN	I-NP	O
or	or	o600	CC	I-NP	O
core	core	c060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
were	be	w060	VBD	B-VP	O
locally	locally	l02040	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
CP	CP	c100	NN	B-NP	B-Chemical
93129	93129	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
an	an	a500	DT	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
any	any	a500	DT	B-NP	O
accumbal	accumbal	a205104	JJ	I-NP	O
subregion	subregion	s0160205	NN	I-NP	O
,	,	,000	,	O	O
GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	I-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
CP	CP	c100	NN	B-NP	B-Chemical
93129	93129	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	I-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
basal	basal	b0204	JJ	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Systemic	Systemic	s0230502	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	I-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
intra	intra	i5360	AFX	O	O
-	-	-000	HYPH	O	O
accumbens	accumben	a2051052	VBZ	B-VP	O
shell	shell	s040	NN	B-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependently	dependently	d0105305340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
psychostimulant	psychostimulant	p2020230504053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	B-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
attenuation	attenuation	a3050305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
accumbens	accumben	a2051052	NNS	I-NP	O
core	core	c060	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
injected	inject	i5202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
accumbens	accumben	a2051052	NNS	I-NP	O
shell	shell	s040	NN	I-NP	O
(	(	(000	(	O	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
the	the	t000	DT	B-NP	O
core	core	c060	NN	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
CP	CP	c100	NN	B-NP	B-Chemical
93129	93129	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	I-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
being	be	b052	VBG	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	I-NP	O
side	side	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	B-NP	O
accumbens	accumben	a2051052	VBZ	B-VP	O
shell	shell	s040	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
side	side	s030	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
induced	induced	i530203	JJ	I-NP	O
hyperlocomotion	hyperlocomotion	h0106402050305	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
modified	modify	m030103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
microinjected	microinjecte	m02605202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
accumbens	accumben	a2051052	NNS	I-NP	O
shell	shell	s040	NN	I-NP	O
,	,	,000	,	B-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
core	core	c060	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
modification	modification	m0301020305	NN	I-NP	O
consisting	consist	c052023052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
facilitatory	facilitatory	f02040303060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
(	(	(000	(	O	O
GR	GR	g600	NN	B-NP	B-Chemical
55562	55562	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
agonist	agonist	a205023	NN	B-NP	O
(	(	(000	(	O	O
CP	CP	c100	NN	B-NP	B-Chemical
93129	93129	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
words	word	w0632	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
accumbal	accumbal	a205104	JJ	I-NP	O
shell	shell	s040	NN	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT1B	HT1B	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
permissive	permissive	p06502010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
psychostimulant	psychostimulant	p2020230504053	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
related	related	r040303	JJ	I-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
:	:	:000	:	O	O
are	be	a600	VBP	B-VP	O
we	we	w000	PRP	B-NP	O
seeing	see	s052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
tip	tip	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
iceberg	iceberg	i201062	NN	I-NP	O
?	?	?000	.	O	O

The	The	t000	DT	B-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
nurse	nurse	n0620	NN	I-NP	O
ought	ought	o0203	MD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
familiar	familiar	f050406	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
tendency	tendency	t0530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
ought	ought	o0203	MD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mind	mind	m053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
nurse	nurse	n0620	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
faced	face	f0203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
victim	victim	v02305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
is	be	i200	VBZ	B-VP	O
otherwise	otherwise	o306020	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
dilemmas	dilemma	d040502	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
moral	moral	m0604	JJ	B-NP	O
issues	issue	i202	NNS	I-NP	O
relating	relate	r0403052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
testing	testing	t023052	NN	I-NP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
addressed	address	a360203	VBN	I-VP	O
.	.	.000	.	O	O

Crossover	Crossover	c6020106	NN	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
preference	preference	p601060520	NN	I-NP	O
for	for	f060	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Rizatriptan	Rizatriptan	r0203601305	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1B	1B	1000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
1D	1D	1300	NN	I-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
agonist	agonist	a205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
absorption	absorption	a12061305	NN	I-NP	O
and	and	a530	CC	O	O
early	early	e0640	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
randomized	randomize	r053050203	VBD	B-VP	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
study	study	s3030	NN	I-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
preference	preference	p601060520	NN	I-NP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
rizatriptan	rizatriptan	r0203601305	NN	I-NP	B-Chemical
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
tablet	tablet	t01403	NN	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
ergotamine	ergotamine	e620305050	NN	I-NP	B-Chemical
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-VP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
439	439	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treating	treat	t603052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
with	with	w030	IN	B-PP	O
each	each	e020	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
expressing	express	e21602052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
preference	preference	p601060520	NN	I-NP	O
(	(	(000	(	O	O
89	89	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
twice	twice	t020	RB	I-NP	O
as	as	a200	RB	I-NP	O
many	many	m050	JJ	I-NP	O
preferred	prefer	p6010603	VBN	I-NP	O
rizatriptan	rizatriptan	r0203601305	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
69	69	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Faster	Faster	f02306	NN	B-NP	O
relief	relief	r0401	NN	I-NP	O
of	of	o100	IN	B-PP	O
headache	headache	h03020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
important	important	i51063053	JJ	I-NP	O
reason	reason	r0205	NN	I-NP	O
for	for	f060	IN	B-PP	O
preference	preference	p601060520	NN	B-NP	O
,	,	,000	,	O	O
cited	cite	c0303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
preferring	prefer	p60106052	VBG	B-VP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
preferred	prefer	p6010603	VBD	B-VP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
primary	primary	p605060	JJ	I-NP	O
endpoint	endpoint	e531053	NN	I-NP	O
of	of	o100	IN	B-PP	O
being	be	b052	VBG	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
free	free	f600	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
favor	favor	f0106	NN	B-NP	O
of	of	o100	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
free	free	f600	JJ	I-NP	O
2	2	2000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
being	be	b052	VBG	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Headache	Headache	h03020	NN	B-NP	B-Disease
relief	relief	r0401	NN	I-NP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
75	75	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
47	47	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
being	be	b052	VBG	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
within	within	w0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
dosing	dosing	d02052	NN	B-NP	O
.	.	.000	.	O	O

Almost	Almost	a45023	RB	B-NP	O
36	36	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
free	free	f600	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
or	or	o600	CC	I-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Rizatriptan	Rizatriptan	r0203601305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
proportions	proportion	p601063052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
phonophobia	phonophobia	p0501010	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
photophobia	photophobia	p0301010	NN	I-NP	B-Disease
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
2	2	2000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

More	More	m060	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
(	(	(000	(	O	O
completely	completely	c051403040	RB	B-ADVP	O
,	,	,000	,	O	O
very	very	v060	RB	B-ADVP	O
or	or	o600	CC	I-ADVP	O
somewhat	somewhat	s0503	RB	I-ADVP	O
)	)	)000	)	O	O
satisfied	satisfy	s0302103	VBD	B-VP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
69	69	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
38	38	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Recurrence	Recurrence	r02060520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
31	31	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
ergotamine	ergotamine	e620305050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
(	(	(000	(	O	O
incidence	incidence	i52030520	NN	B-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
rizatriptan	rizatriptan	r0203601305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ergotamine	ergotamine	e620305050	NN	I-NP	B-Chemical
/	/	/000	SYM	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
somnolence	somnolence	s05040520	NN	B-NP	B-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
orbital	orbital	o610304	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intracarotid	intracarotid	i53602060303	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
glioblastomas	glioblastoma	g40140230502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Glioblastoma	Glioblastoma	g4014023050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
malignant	malignant	m04025053	JJ	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebrum	cerebrum	c0601605	NN	I-NP	O
during	during	d06052	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	I-NP	O
radiation	radiation	r030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
life	life	l010	NN	I-NP	O
expectancy	expectancy	e210230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
1	1	1000	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
glioblastoma	glioblastoma	g4014023050	NN	B-NP	B-Disease
sometimes	sometimes	s05030502	RB	B-ADVP	O
have	have	h010	VBP	B-VP	O
intracarotid	intracarotid	i53602060303	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carcinostatics	carcinostatic	c062050230302	NNS	B-NP	O
added	add	a303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

Generally	Generally	g0506040	RB	B-ADVP	O
,	,	,000	,	O	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
said	say	s030	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
milder	mild	m04306	JJR	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whose	whose	w020	WP$	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
orbital	orbital	o610304	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
well	well	w040	RB	B-ADJP	O
known	know	k505	VBN	I-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
orbital	orbital	o610304	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
intracarotid	intracarotid	i53602060303	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
infrequently	infrequently	i5160205340	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
58	58	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
intracarotid	intracarotid	i53602060303	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
glioblastomas	glioblastoma	g40140230502	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
left	left	l013	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
lobe	lobe	l010	NN	I-NP	O
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
and	and	a530	CC	O	I-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
ipsilateral	ipsilateral	i1204030604	JJ	I-NP	I-Disease
eye	eye	e000	NN	I-NP	I-Disease
30	30	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Various	Various	v0602	JJ	B-NP	O
ocular	ocular	o20406	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
findings	finding	f053052	NNS	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
He	He	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
and	and	a530	CC	O	O
glycerin	glycerin	g4020605	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
intraocular	intraocular	i536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	O
angle	angle	a5240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
closure	closure	c402060	NN	I-NP	O
glaucoma	glaucoma	g402050	NN	I-NP	B-Disease
decreased	decrease	d0260203	VBD	B-VP	O
and	and	a530	CC	O	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
diminished	diminish	d05050203	VBD	B-VP	O
,	,	,000	,	O	O
inexorable	inexorable	i502060140	JJ	B-NP	O
papilledema	papilledema	p010403050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
exudative	exudative	e20303010	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
detachment	detachment	d030205053	NN	I-NP	I-Disease
continued	continue	c0530503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
diffuse	diffuse	d01020	JJ	B-NP	O
chorioretinal	chorioretinal	c0606030504	JJ	I-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
optic	optic	o1302	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
vision	vision	v0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
left	left	l013	JJ	I-NP	O
eye	eye	e000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
When	When	w050	WRB	B-ADVP	O
performing	perform	p061065052	VBG	B-VP	O
intracarotid	intracarotid	i53602060303	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
blinding	blind	b4053052	VBG	I-NP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
further	further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effort	effort	e1063	NN	I-NP	O
to	to	t000	TO	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
such	such	s020	JJ	B-NP	O
severe	severe	s01060	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
zonisamide	zonisamide	z050205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Zonisamide	Zonisamide	z050205030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
broad	broad	b603	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
various	various	v0602	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
complex	complex	c051402	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
altered	alter	a430603	VBN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
after	after	a1306	IN	B-PP	O
zonisamide	zonisamide	z050205030	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
begun	begin	b0205	VBN	I-VP	O
or	or	o600	CC	O	O
its	its	i320	PRP$	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
earlier	earlier	e06406	RBR	B-ADVP	O
with	with	w030	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	I-NP	O
(	(	(000	(	O	O
EEG	EEG	e020	NN	B-NP	O
)	)	)000	)	O	O
findings	finding	f053052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-ADJP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
monitoring	monitoring	m050306052	NN	B-NP	O
,	,	,000	,	O	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
readings	reading	r03052	NNS	I-NP	O
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
did	do	d030	VBD	O	O
video	video	v030	NN	B-NP	O
recording	record	r02063052	VBG	B-VP	O
capture	capture	c013060	NN	B-NP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
described	describe	d0260103	VBN	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
visual	visual	v0204	JJ	B-NP	B-Disease
hallucinations	hallucination	h04020503052	NNS	I-NP	I-Disease
before	before	b01060	IN	B-PP	O
this	this	t020	DT	B-NP	O
event	event	e1053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
recent	recent	r02053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
or	or	o600	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
zonisamide	zonisamide	z050205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
either	either	e0306	CC	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
or	or	o600	CC	O	O
decreased	decrease	d0260203	VBN	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
disappeared	disappear	d02010603	VBD	B-VP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
recur	recur	r0206	VB	I-VP	O
.	.	.000	.	O	O

Further	Far	f06306	JJR	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
reports	report	r010632	NNS	I-NP	O
will	will	w040	MD	B-VP	O
help	help	h041	VB	I-VP	O
clarify	clarify	c406010	VB	I-VP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Until	Until	u5304	IN	B-PP	O
then	then	t050	RB	B-NP	O
,	,	,000	,	O	O
clinicians	clinician	c40502052	NNS	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
zonisamide	zonisamide	z050205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Anti	Anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
present	present	p602053	VBP	B-VP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
de	de	d000	FW	B-NP	O
novo	novo	n010	FW	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
vigabatrin	vigabatrin	v020103605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
diseases	disease	d020202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
for	for	f060	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
good	good	g030	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
subsides	subside	s0120302	VBZ	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
offending	offend	o1053052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
gamma	gamma	g050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
transmitted	transmit	t605250303	VBN	B-VP	O
thalamocortical	thalamocortical	t0405020630204	JJ	B-NP	O
circuitry	circuitry	c0620360	NN	I-NP	O
accounts	account	a20532	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
neurophysiology	neurophysiology	n06010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
,	,	,000	,	O	O
pro	pro	p600	AFX	O	O
-	-	-000	HYPH	O	O
absence	absence	a120520	NN	B-NP	O
drugs	drug	d602	NNS	I-NP	O
can	can	c050	MD	B-VP	O
only	only	o540	RB	I-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
promoting	promote	p60503052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
epileptogenecity	epileptogenecity	e104013020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
accompanying	accompany	a205105052	VBG	I-NP	O
drugs	drug	d602	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
trigger	trigger	t60206	VB	I-VP	O
the	the	t000	DT	B-NP	O
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizure	seizure	s02060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aggravation	aggravation	a26010305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
whenever	whenever	w050106	WRB	B-ADVP	O
an	an	a500	DT	B-NP	O
unexpected	unexpected	u502102303	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
new	new	n000	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
types	type	t0102	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
following	follow	f04052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
understanding	understand	u530623053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
absence	absence	a120520	NN	B-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
can	can	c050	MD	B-VP	O
avoid	avoid	a103	VB	I-VP	O
the	the	t000	DT	B-NP	O
inappropriate	inappropriate	i5016016030	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
and	and	a530	CC	O	O
prevent	prevent	p601053	VBP	B-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
programs	program	p6026052	NNS	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
developing	develop	d010401052	VBG	I-NP	O
fetus	fetus	f0302	NN	I-NP	O
to	to	t000	TO	B-VP	O
accelerate	accelerate	a20406030	VB	I-VP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
development	development	d0104015053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
programmed	program	p60260503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Pregnant	Pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
either	either	e0306	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
or	or	o600	CC	O	O
2	2	2000	CD	B-NP	O
daily	daily	d040	JJ	I-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
gestational	gestational	g023030504	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
11	11	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
13	13	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
17	17	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
18	18	0000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
19	19	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O

Offspring	Offspring	o1216052	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
administered	administer	a35050230603	VBN	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
gestation	gestation	g0230305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
20	20	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
glomerular	glomerular	g405060406	JJ	B-NP	I-Disease
number	number	n05106	NN	I-NP	I-Disease
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
9	9	9000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
527	527	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
509	509	0000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
28	28	0000	CD	B-NP	O
050	050	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
561	561	0000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
percent	percent	p062053	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
measured	measure	m020603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
old	old	o430	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
prenatal	prenatal	p6050304	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
17	17	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
18	18	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
17	17	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
(	(	(000	(	O	O
23	23	0000	CD	B-NP	O
380	380	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
587	587	0000	CD	B-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
prenatal	prenatal	p6050304	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
17	17	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
18	18	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
13	13	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
14	14	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
had	have	h030	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	B-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressures	pressure	p6020602	NNS	I-NP	I-Disease
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
glomerular	glomerular	g405060406	JJ	B-NP	I-Disease
number	number	n05106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Adult	Adult	a3043	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
given	give	g0105	VBN	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
15	15	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
had	have	h030	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
glomeruli	glomeruli	g40506040	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
dexamethasone	dexamethasone	d02050302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
glomerular	glomerular	g405060406	JJ	B-NP	I-Disease
number	number	n05106	NN	I-NP	I-Disease
,	,	,000	,	O	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
points	point	p0532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
.	.	.000	.	O	O

Hypertension	Hypertension	h0106305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
glomerular	glomerular	g405060406	JJ	B-NP	I-Disease
number	number	n05106	NN	I-NP	I-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
glomerular	glomerular	g405060406	JJ	B-NP	I-Disease
number	number	n05106	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
sole	sole	s040	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Kidney	Kidney	k0350	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
morphology	morphology	m06104020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sirolimus	sirolimus	s06040502	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
supplement	supplement	s01405053	VB	I-VP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
organ	organ	o6205	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
are	be	a600	VBP	B-VP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-ADJP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
act	act	a230	VB	I-VP	O
differently	differently	d010605340	RB	B-ADVP	O
displaying	display	d0214052	VBG	B-VP	O
only	only	o540	RB	B-NP	O
minor	minor	m0506	JJ	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
question	question	q02305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
open	open	o105	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
calcineurin	calcineurin	c042050605	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
indications	indication	i530203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
further	further	f06306	RBR	B-ADVP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
morphological	morphological	m06104020204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
monotherapies	monotherapy	m0503060102	NNS	B-NP	O
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
For	For	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
15	15	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-ADVP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
given	give	g0105	VBN	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
once	once	o520	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
as	as	a200	IN	B-PP	O
these	these	t020	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
earlier	earlier	e06406	RBR	I-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
achieve	achieve	a2010	VB	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
'	'	'000	``	I-NP	O
conscious	conscious	c05202	JJ	I-NP	O
catheterized	catheterize	c0303060203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
'	'	'000	''	I-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
GFR	GFR	g160	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
Cr	Cr	c600	NN	B-NP	O
(	(	(000	(	O	O
EDTA	EDTA	e300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
semi	semi	s050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
scoring	scoring	s206052	NN	I-NP	O
system	system	s02305	NN	I-NP	O
analysing	analyse	a50402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
striped	strip	s360103	VBN	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
,	,	,000	,	O	O
subcapsular	subcapsular	s0120120406	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
basophilic	basophilic	b02010402	JJ	B-NP	O
tubules	tubule	t010402	NNS	I-NP	O
,	,	,000	,	O	O
plus	plus	p402	CC	B-PP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
stereological	stereological	s30604020204	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
stained	stain	s30503	VBD	B-VP	O
with	with	w030	IN	B-PP	O
Sirius	Sirius	s0602	NNP	B-NP	O
Red	Red	r030	NNP	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
CsA	CsA	c200	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
SRL	SRL	s640	NN	I-NP	B-Chemical
all	all	a400	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	I-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
GFR	GFR	g160	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
GFR	GFR	g160	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
FK506	FK506	0000	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
substances	substance	s012305202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
semi	semi	s050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
scoring	scoring	s206052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
worst	worst	w0623	JJS	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
SRL	SRL	s640	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
marginally	marginally	m06205040	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrosis	fibrosis	f0160202	NN	B-NP	B-Disease
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
study	study	s3030	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CsA	CsA	c200	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
better	well	b0306	RBR	B-ADJP	O
tolerated	tolerate	t04060303	VBN	I-ADJP	O
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
troponin	troponin	t6010505	NN	I-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
T	T	t000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
as	as	a200	IN	B-PP	O
markers	marker	m062062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
with	with	w030	IN	B-PP	O
echocardiographic	echocardiographic	e2020630260102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
histological	histological	h02304020204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cardiac	Cardiac	c06302	JJ	B-NP	O
troponins	troponin	t60105052	NNS	I-NP	O
I	I	i000	NN	I-NP	O
(	(	(000	(	O	O
cTnI	cTnI	c350	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
T	T	t000	NN	B-NP	O
(	(	(000	(	O	O
cTnT	cTnT	c353	NN	B-NP	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
highly	highly	h02040	RB	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
cTnI	cTnI	c350	NN	B-NP	O
and	and	a530	CC	I-NP	O
cTnT	cTnT	c353	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DOX	DOX	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
cTnI	cTnI	c350	NN	I-NP	O
and	and	a530	CC	I-NP	O
cTnT	cTnT	c353	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
monitored	monitor	m05030603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
and	and	a530	CC	O	O
histological	histological	h02304020204	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
weekly	weekly	w0240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
saline	saline	s04050	NN	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

cTnI	cTnI	c350	NN	B-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
Access	Access	a202	NN	B-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
ng	ng	n200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
research	research	r020620	NN	I-NP	O
immunoassay	immunoassay	i505020	NN	I-NP	O
(	(	(000	(	O	O
pg	pg	p200	NN	B-NP	O
/	/	/000	SYM	O	O
ml	ml	m400	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
cTnT	cTnT	c353	NN	B-NP	O
,	,	,000	,	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
MB	MB	m100	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
and	and	a530	CC	I-NP	O
CK	CK	c200	NN	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
transthoracic	transthoracic	t60523060202	JJ	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
,	,	,000	,	O	O
anterior	anterior	a530606	JJ	B-NP	O
and	and	a530	CC	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
,	,	,000	,	O	O
LV	LV	l100	NN	B-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
and	and	a530	CC	O	O
LV	LV	l100	NN	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
shortening	shortening	s06305052	NN	I-NP	O
(	(	(000	(	O	O
FS	FS	f200	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
at	at	a300	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
9	9	9000	CD	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
surviving	survive	s06101052	VBG	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Histology	Histology	h02304020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
rats	rat	r032	NNS	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
9	9	9000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Eighteen	Eighteen	e020305	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
prematurely	prematurely	p6050306040	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
9	9	9000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

End	End	e530	NN	B-NP	O
-	-	-000	HYPH	O	O
diastolic	diastolic	d0230402	JJ	O	O
(	(	(000	(	O	O
ED	ED	e300	JJ	B-ADJP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
end	end	e530	NN	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
systolic	systolic	s0230402	JJ	I-ADJP	O
(	(	(000	(	O	O
ES	ES	e200	NN	B-NP	O
)	)	)000	)	O	O
LV	LV	l100	NN	B-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
/	/	/000	SYM	O	O
BW	BW	b000	NN	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
LV	LV	l100	NN	B-NP	O
FS	FS	f200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
9	9	9000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Histological	Histological	h02304020204	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearts	heart	h0632	NNS	B-NP	O
from	from	f605	IN	B-PP	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
given	give	g0105	VBN	B-VP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
revealed	reveal	r010403	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
slight	slight	s40203	JJ	I-NP	O
degrees	degree	d02602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
perivascular	perivascular	p0601020406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
18	18	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
degeneration	degeneration	d0205060305	NN	B-NP	O
and	and	a530	CC	I-NP	O
myocyte	myocyte	m02030	NN	I-NP	O
vacuolisation	vacuolisation	v0204020305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
five	five	f010	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
very	very	v060	RB	B-NP	O
slight	slight	s40203	JJ	I-NP	O
perivascular	perivascular	p0601020406	JJ	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
cTnT	cTnT	c353	NN	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

cTnT	cTnT	c353	NN	B-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
found	find	f053	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
DOX	DOX	d020	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Maximal	Maximal	m020504	JJ	B-NP	O
cTnI	cTnI	c350	NN	I-NP	O
(	(	(000	(	O	O
pg	pg	p200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
cTnT	cTnT	c353	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
006	006	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
007	007	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

cTnI	cTnI	c350	NN	B-NP	O
(	(	(000	(	O	O
ng	ng	n200	NN	B-NP	O
/	/	/000	SYM	O	O
ml	ml	m400	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
CK	CK	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
MB	MB	m100	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
and	and	a530	CC	I-NP	O
CK	CK	c200	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
markers	marker	m062062	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
data	datum	d030	NNS	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
cTnT	cTnT	c353	NN	I-NP	O
and	and	a530	CC	I-NP	O
ED	ED	e300	NN	I-NP	O
and	and	a530	CC	I-NP	O
ES	ES	e200	NN	I-NP	O
LV	LV	l100	NN	I-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
/	/	/000	SYM	O	O
BW	BW	b000	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
81	81	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
65	65	0000	CD	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
cTnT	cTnT	c353	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
between	between	b0305	IN	B-PP	O
LV	LV	l100	NN	B-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
BW	BW	b000	NN	I-NP	O
and	and	a530	CC	O	O
histological	histological	h02304020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-PP	O
markers	marker	m062062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ischemic	ischemic	i20502	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
cTnT	cTnT	c353	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
assessed	assess	a20203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
echocardiographic	echocardiographic	e2020630260102	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
and	and	a530	CC	O	O
histological	histological	h02304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
discrepancy	discrepancy	d026010520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cTnI	cTnI	c350	NN	B-NP	O
and	and	a530	CC	I-NP	O
cTnT	cTnT	c353	NN	I-NP	O
after	after	a1306	IN	B-PP	O
DOX	DOX	d020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
heterogeneity	heterogeneity	h03060205030	NN	B-NP	O
in	in	i500	IN	B-PP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
reactivities	reactivity	r023010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mAbs	mAb	m012	NNS	B-NP	O
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
cTnI	cTnI	c350	NN	I-NP	O
and	and	a530	CC	I-NP	O
cTnT	cTnT	c353	NN	I-NP	O
forms	form	f0652	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
cTnT	cTnT	c353	NN	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
after	after	a1306	IN	B-SBAR	O
DOX	DOX	d020	NN	B-NP	B-Chemical
indicates	indicate	i53020302	VBZ	B-VP	O
cell	cell	c040	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
injury	injury	i52060	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
cTnT	cTnT	c353	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
marker	marker	m06206	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prediction	prediction	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
possibly	possibly	p020140	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
cardioprotective	cardioprotective	c06301603023010	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
.	.	.000	.	O	O

Octreotide	Octreotide	o23603030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypoxemia	hypoxemia	h0102050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
premature	premature	p60503060	JJ	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
report	report	r01063	VBP	B-VP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
premature	premature	p60503060	JJ	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
enterocutaneous	enterocutaneous	e530602030502	JJ	B-NP	O
fistula	fistula	f023040	NN	I-NP	B-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
necrotizing	necrotize	n0260302052	VBG	B-NP	B-Disease
enterocolitis	enterocolitis	e530602040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pulmonary	Pulmonary	p04505060	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
somatostatin	somatostatin	s05030230305	NN	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
,	,	,000	,	O	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
resolution	resolution	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fistula	fistula	f023040	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
and	and	a530	CC	O	O
recommend	recommend	r0205053	VB	B-VP	O
caution	caution	c0305	NN	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
premature	premature	p60503060	JJ	I-NP	O
neonates	neonate	n050302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
prescribed	prescribe	p60260103	VBD	B-VP	O
cyproterone	cyproterone	c0160306050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
nested	nested	n02303	JJ	I-NP	O
cohort	cohort	c063	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cyproterone	Cyproterone	c0160306050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
licensed	license	l0205203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
UK	UK	u200	NNP	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acne	acne	a250	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hirsutism	hirsutism	h06203025	NN	I-NP	B-Disease
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
option	option	o1305	NN	I-NP	O
for	for	f060	IN	B-PP	O
polycystic	polycystic	p040202302	JJ	B-NP	B-Disease
ovary	ovary	o1060	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
PCOS	PCOS	p202	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
VTE	VTE	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
COCs	COC	c020	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
believe	believe	b04010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
residual	residual	r020304	JJ	B-NP	O
confounding	confounding	c051053052	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Using	Use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
General	General	g050604	NNP	I-NP	O
Practice	Practice	p6023020	NNP	I-NP	O
Research	Research	r020620	NNP	I-NP	O
Database	Database	d0301020	NNP	I-NP	O
we	we	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
and	and	a530	CC	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
nested	nest	n02303	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
aged	aged	a203	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
15	15	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
39	39	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acne	acne	a250	NN	B-NP	B-Disease
,	,	,000	,	O	O
hirsutism	hirsutism	h06203025	NN	B-NP	B-Disease
or	or	o600	CC	O	O
PCOS	PCOS	p202	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
adjusted	adjust	a3202303	VBN	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
versus	versus	v06202	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
COCs	COC	c020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
20	20	0000	CD	I-NP	O
[	[	[000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
58	58	0000	CD	I-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
group	group	g601	NN	I-NP	O
women	woman	w0505	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
using	use	u2052	VBG	I-VP	O
oral	oral	o604	JJ	B-NP	O
contraception	contraception	c05360201305	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recent	recent	r02053	JJ	I-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
or	or	o600	CC	I-NP	O
menopausal	menopausal	m05010204	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
gave	give	g010	VBD	B-VP	O
an	an	a500	DT	B-NP	O
adjusted	adjust	a3202303	VBN	I-NP	O
odds	odd	o320	NNS	I-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
(	(	(000	(	O	O
adj	adj	a320	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
44	44	0000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
67	67	0000	CD	I-NP	O
-	-	-000	:	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
08	08	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
OR	OR	o600	NN	I-NP	O
(	(	(000	(	O	O
adj	adj	a320	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
58	58	0000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
60	60	0000	CD	I-NP	O
-	-	-000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
18	18	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
conventional	conventional	c0510530504	JJ	B-NP	O
COCs	COC	c020	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acne	acne	a250	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
hirsutism	hirsutism	h06203025	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
PCOS	PCOS	p202	NN	I-NP	B-Disease
although	although	a43020	IN	B-SBAR	O
residual	residual	r020304	JJ	B-NP	O
confounding	confounding	c051053052	NN	I-NP	O
by	by	b000	IN	B-PP	O
indication	indication	i53020305	NN	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	B-ADJP	I-Chemical
on	on	o500	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
work	work	w062	NN	I-NP	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	B-ADJP	I-Chemical
on	on	o500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
GM	GM	g500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
distilled	distilled	d0230403	JJ	B-NP	O
water	water	w0306	NN	I-NP	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
w	w	w000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
v	v	v000	NN	I-NP	O
cellulose	cellulose	c0404020	NN	I-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	B-ADJP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
w	w	w000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
v	v	v000	NN	I-NP	O
aqueous	aqueous	a202	JJ	I-NP	O
suspension	suspension	s02105205	NN	I-NP	O
of	of	o100	IN	B-PP	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	I-NP	I-Chemical
powder	powder	p0306	NN	I-NP	O
,	,	,000	,	O	O
orally	orally	o6040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	NNP	I-NP	I-Chemical
concomitantly	concomitantly	c052050305340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
80mg	80mg	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
day	day	d000	NN	I-NP	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
six	six	s020	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nephrotoxicity	Nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
GSH	GSH	g200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
light	light	l0203	NN	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
sections	section	s023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	NNP	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
GM	GM	g500	NNP	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
about	about	a103	RB	B-NP	O
183	183	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
239	239	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
432	432	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
346	346	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cellulose	cellulose	c0404020	NN	B-NP	O
and	and	a530	CC	O	O
GM	GM	g500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
of	of	o100	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
GSH	GSH	g200	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cellulose	cellulose	c0404020	NN	I-NP	O
plus	plus	p402	CC	O	O
GM	GM	g500	NNP	B-NP	B-Chemical
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
The	The	t000	DT	B-NP	O
GM	GM	g500	NNP	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
slightly	slightly	s4020340	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
GM	GM	g500	NNP	B-NP	B-Chemical
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	B-ADJP	I-Chemical
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
given	give	g0105	VBN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
and	and	a530	CC	O	O
cellulose	cellulose	c0404020	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
inferred	infer	i510603	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
gum	gum	g050	NN	B-NP	B-Chemical
Arabic	Arabic	a60102	JJ	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
induced	induce	i530203	VBN	I-VP	O
a	a	a000	DT	B-NP	O
modest	modest	m03023	JJ	I-NP	O
amelioration	amelioration	a504060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
histological	histological	h02304020204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
indices	index	i530202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
GM	GM	g500	NNP	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
work	work	w062	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
aspects	aspect	a210232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
involved	involve	i5104103	VBN	B-VP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
docetaxel	docetaxel	d02030204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
androgen	androgen	a5360205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
VTE	VTE	v300	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
androgen	androgen	a5360205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
docetaxel	docetaxel	d02030204	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
National	National	n030504	NNP	B-NP	O
Institutes	Institute	i523030302	NNPS	I-NP	O
of	of	o100	IN	B-PP	O
Health	Health	h0430	NNP	B-NP	O
clinical	clinical	c4050204	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
center	center	c05306	NN	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
:	:	:000	:	O	O
Seventy	Seventy	s010530	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
80	80	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
androgen	androgen	a5360205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
prostate	prostate	p6023030	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

INTERVENTION	INTERVENTION	i5306105305	NN	B-NP	O
:	:	:000	:	O	O
Each	Each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
docetaxel	docetaxel	d02030204	NN	I-NP	B-Chemical
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
off	off	o100	RB	B-ADVP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
every	every	e1060	DT	B-NP	O
evening	evening	e105052	NN	I-NP	O
plus	plus	p402	CC	O	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
docetaxel	docetaxel	d02030204	NN	I-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
until	until	u5304	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
excessive	excessive	e202010	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
disease	disease	d02020	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

MEASUREMENTS	MEASUREMENTS	m0206050532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
MAIN	MAIN	m050	NN	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
23	23	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
docetaxel	docetaxel	d02030204	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
VTE	VTE	v300	NNP	B-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
9	9	9000	CD	B-NP	O
of	of	o100	IN	B-PP	O
47	47	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
docetaxel	docetaxel	d02030204	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
VTE	VTE	v300	NN	B-NP	B-Disease
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
docetaxel	docetaxel	d02030204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
VTE	VTE	v300	NN	B-NP	B-Disease
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
adding	add	a3052	VBG	B-VP	O
thalidomide	thalidomide	t040305030	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Ticlopidine	Ticlopidine	t0240103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
investigate	investigate	i5102302030	VB	B-VP	O
its	its	i320	PRP$	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
compare	compare	c051060	VBP	B-VP	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
main	main	m050	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
published	publish	p0140203	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARIES	SUMMARIES	s050602	NNS	I-NP	O
:	:	:000	:	O	O
Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
following	follow	f04052	VBG	B-PP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angioplasty	angioplasty	a520140230	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
.	.	.000	.	O	O

T	T	t000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
by	by	b000	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
healthy	healthy	h0430	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Cholestatic	Cholestatic	c040230302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiplatelet	antiplatelet	a53014030403	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
ticlopidine	ticlopidine	t0240103050	NN	I-NP	B-Chemical
;	;	;000	:	O	O
several	several	s010604	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
but	but	b030	CC	O	O
few	few	f000	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
English	English	e524020	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
weeks	week	w020	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
run	run	r050	VB	I-VP	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
course	course	c0620	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
causality	causality	c0204030	NN	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
event	event	e1053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
probably	probably	p6010140	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
ticlopidine	ticlopidine	t0240103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

Immune	Immune	i5050	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
suggested	suggest	s0202303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
here	here	h060	RB	B-ADVP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Cholestatic	Cholestatic	c040230302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
immune	immune	i5050	JJ	B-ADJP	O
mediated	mediate	m030303	VBN	B-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
even	even	e105	RB	B-ADVP	O
less	less	l020	RBR	I-ADVP	O
often	often	o1305	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
future	future	f03060	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
being	be	b052	VBG	I-VP	O
replaced	replace	r0140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
newer	new	n060	JJR	I-NP	O
antiplatelet	antiplatelet	a53014030403	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
clopidogrel	clopidogrel	c4010302604	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Epithelial	Epithelial	e1030404	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
(	(	(000	(	O	O
ENaC	ENaC	e502	NN	B-NP	O
)	)	)000	)	O	O
subunit	subunit	s010503	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
salt	salt	s043	NN	B-NP	O
retention	retention	r0305305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
completely	completely	c051403040	RB	B-ADJP	O
elucidated	elucidate	e402030303	VBN	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
constituent	constituent	c052303053	NN	B-NP	O
of	of	o100	IN	B-PP	O
collecting	collect	c04023052	VBG	B-VP	O
duct	duct	d023	NN	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
transport	transport	t60521063	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
(	(	(000	(	O	O
ENaC	ENaC	e502	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
abundance	abundance	a10530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ENaC	ENaC	e502	NN	B-NP	O
subunit	subunit	s010503	NN	I-NP	O
mRNAs	mRNA	m6502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alphaENaC	alphaENaC	a410502	NN	B-NP	O
,	,	,000	,	I-NP	O
betaENaC	betaENaC	b030502	NN	I-NP	O
and	and	a530	CC	I-NP	O
gammaENaC	gammaENaC	g050502	NN	I-NP	O
mRNAs	mRNA	m6502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
kidneys	kidney	k03502	NNS	B-NP	O
from	from	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
by	by	b000	IN	B-PP	O
real	real	r040	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
TaqMan	TaqMan	t02505	NNP	I-NP	O
PCR	PCR	p260	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
proteins	protein	p603052	NNS	B-NP	O
by	by	b000	IN	B-PP	O
Western	Western	w023065	JJ	B-NP	O
blot	blot	b403	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
kinetics	kinetic	k050302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
reported	report	r0106303	VBN	B-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
after	after	a1306	IN	B-SBAR	O
PAN	PAN	p050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
up	up	u100	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
alphaENaC	alphaENaC	a410502	NN	B-NP	O
and	and	a530	CC	I-NP	O
betaENaC	betaENaC	b030502	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
abundance	abundance	a10530520	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
preceded	preceded	p6020303	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
down	down	d050	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alphaENaC	alphaENaC	a410502	NN	B-NP	O
,	,	,000	,	O	O
betaENaC	betaENaC	b030502	NN	B-NP	O
and	and	a530	CC	O	O
gammaENaC	gammaENaC	g050502	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
return	return	r03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alphaENaC	alphaENaC	a410502	NN	B-NP	O
,	,	,000	,	I-NP	O
betaENaC	betaENaC	b030502	NN	I-NP	O
and	and	a530	CC	I-NP	O
gammaENaC	gammaENaC	g050502	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
retention	retention	r0305305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
ENaC	ENaC	e502	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
alphaENaC	alphaENaC	a410502	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
very	very	v060	RB	I-NP	O
early	early	e0640	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
escape	escape	e2010	VB	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
by	by	b000	IN	B-PP	O
aldosterone	aldosterone	a4302306050	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
day	day	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

Sub	Sub	s010	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
vinyl	vinyl	v0504	NN	B-NP	I-Chemical
GABA	GABA	g010	NN	I-NP	I-Chemical
(	(	(000	(	O	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
)	)	)000	)	O	O
inhibits	inhibit	i501032	VBZ	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
nucleus	nucleus	n02402	NN	B-NP	O
accumbens	accumbens	a2051052	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

RATIONALE	RATIONALE	r0305040	NN	B-NP	O
:	:	:000	:	O	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Vinyl	Vinyl	v0504	NN	B-NP	I-Chemical
GABA	GABA	g010	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GVG	GVG	g120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
irreversibly	irreversibly	i6010620140	RB	B-ADVP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
transaminase	transaminase	t60520505020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
requires	require	r020602	VBZ	B-VP	O
de	de	d000	FW	B-NP	O
novo	novo	n010	FW	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
for	for	f060	IN	B-PP	O
restoration	restoration	r023060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
catabolism	catabolism	c030104025	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Given	Give	g0105	VBN	B-VP	O
its	its	i320	PRP$	B-NP	O
preclinical	preclinical	p6024050204	JJ	I-NP	O
success	success	s0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
substance	substance	s01230520	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
field	field	f043	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
(	(	(000	(	O	O
VFD	VFD	v130	NN	B-NP	B-Disease
)	)	)000	)	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
lifetime	lifetime	l0103050	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
explored	explore	e2140603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
GVG	GVG	g120	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
nucleus	nucleus	n02402	NN	B-NP	O
accumbens	accumbens	a2051052	NN	I-NP	O
(	(	(000	(	O	O
NAcc	NAcc	n020	NN	B-NP	O
)	)	)000	)	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Using	Use	u2052	VBG	B-VP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
microdialysis	microdialysis	m02603040202	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
(	(	(000	(	O	O
450	450	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	B-VP	O
or	or	o600	CC	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
washout	washout	w0203	NN	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
)	)	)000	)	O	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
washout	washout	w0203	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Sub	Sub	s010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
GVG	GVG	g120	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
magnitude	magnitude	m02503030	NN	B-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
the	the	t000	DT	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Sub	Sub	s010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
GVG	GVG	g120	NN	I-NP	B-Chemical
potentiates	potentiate	p030530302	VBZ	B-VP	O
and	and	a530	CC	I-VP	O
extends	extend	e230532	VBZ	I-VP	O
the	the	t000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
effectively	effectively	e102301040	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
VFDS	VFDS	v132	NN	B-NP	O
.	.	.000	.	O	O

MR	MR	m600	NN	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
with	with	w030	IN	B-PP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
mapping	mapping	m01052	NN	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
objective	objective	o12023010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
brain	brain	b605	NN	B-NP	O
MR	MR	m600	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
diffusion	diffusion	d010205	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
(	(	(000	(	O	O
DW	DW	d000	NN	B-NP	O
)	)	)000	)	O	O
imaging	imaging	i502052	NN	B-NP	O
in	in	i500	IN	B-PP	O
organ	organ	o6205	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
neurologic	neurologic	n06040202	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
MR	MR	m600	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
DW	DW	d000	NN	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
prospectively	prospectively	p602102301040	RB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
organ	organ	o6205	NN	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
neurologic	neurologic	n06040202	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
MR	MR	m600	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
MR	MR	m600	NN	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Apparent	Apparent	a106053	JJ	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
coefficient	coefficient	c0102053	NN	I-NP	O
(	(	(000	(	O	O
ADC	ADC	a320	NN	B-NP	O
)	)	)000	)	O	O
values	value	v0402	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
MR	MR	m600	NN	I-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
reversibility	reversibility	r010620104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
14	14	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
white	white	w030	JJ	B-NP	B-Disease
matter	matter	m0306	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
putaminal	putaminal	p03050504	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
(	(	(000	(	O	O
57	57	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
MR	MR	m600	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
white	white	w030	JJ	B-NP	B-Disease
matter	matter	m0306	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
higher	high	h0206	JJR	B-ADVP	O
than	than	t050	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
ADC	ADC	a320	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
on	on	o500	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
MR	MR	m600	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
showed	show	s030	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
on	on	o500	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
images	image	i50202	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
1	1	1000	CD	I-NP	O
patient	patient	p03053	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
lower	low	l060	JJR	B-ADVP	O
than	than	t050	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
ADC	ADC	a320	NN	I-NP	O
value	value	v040	NN	I-NP	O
and	and	a530	CC	O	O
showed	show	s030	VBD	B-VP	O
incomplete	incomplete	i520514030	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	B-Disease
laminar	laminar	l050506	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Diffusion	Diffusion	d010205	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
weighted	weight	w020303	VBN	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
predicting	predict	p603023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
transport	transport	t60521063	NN	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
system	system	s02305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigate	investigate	i5102302030	VBP	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
uptake	uptake	u13020	NN	I-NP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
.	.	.000	.	O	O

Hydrocortisone	Hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
6	6	6000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
fixed	fix	f0203	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
salt	salt	s043	NN	I-NP	O
diet	diet	d030	NN	I-NP	O
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Crossover	Crossover	c6020106	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
apart	apart	a1063	RB	B-ADVP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
milliliters	milliliter	m040403062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
isolation	isolation	i2040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
mononuclear	mononuclear	m050502406	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
uptake	uptake	u13020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mononuclear	mononuclear	m050502406	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
incubated	incubate	i52010303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	O	O
300	300	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
incorporating	incorporate	i520610603052	VBG	B-VP	O
100	100	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
l	l	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
at	at	a300	IN	B-PP	O
37	37	0000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
C	C	c000	JJ	B-ADJP	O
.	.	.000	.	O	O

Forearm	Forearm	f06065	NN	B-NP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
extraction	extraction	e23602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
arginine	arginine	a6205050	NN	B-NP	I-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
brachial	brachial	b60204	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
nCi	nCi	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
for	for	f060	IN	B-PP	O
80	80	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Deep	Deep	d010	JJ	B-NP	O
forearm	forearm	f06065	NN	I-NP	O
venous	venous	v0502	JJ	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
extraction	extraction	e23602305	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
raised	raise	r0203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
(	(	(000	(	O	O
323	323	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
43	43	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1082	1082	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
245	245	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	O	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
transport	transport	t60521063	NN	I-NP	O
into	into	i530	IN	B-PP	O
mononuclear	mononuclear	m050502406	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
vs	vs	v200	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
,	,	,000	,	I-NP	O
26	26	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
vs	vs	v200	IN	I-NP	O
29	29	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
pmol	pmol	p504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
000	000	0000	CD	I-NP	O
cells	cell	c042	NNS	I-NP	O
per	per	p060	IN	B-PP	O
5	5	5000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
l	l	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
nor	nor	n060	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
extraction	extraction	e23602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forearm	forearm	f06065	NN	I-NP	O
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
80	80	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
placebo	placebo	p402010	NN	B-NP	O
vs	vs	v200	IN	B-PP	O
active	active	a23010	JJ	B-ADJP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
868	868	0000	CD	I-NP	O
904	904	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
434	434	0000	CD	B-NP	O
962	962	0000	CD	I-NP	O
vs	vs	v200	IN	B-NP	O
2	2	2000	CD	I-NP	O
013	013	0000	CD	I-NP	O
910	910	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
770	770	0000	CD	B-NP	O
619	619	0000	CD	I-NP	O
disintegrations	disintegration	d0205302603052	NNS	I-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
;	;	;000	:	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
that	that	t030	IN	B-SBAR	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
uptake	uptake	u13020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
cortisol	cortisol	c0630204	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
l	l	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
transport	transport	t60521063	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Amount	Amount	a5053	NN	B-NP	O
of	of	o100	IN	B-PP	O
bleeding	bleeding	b403052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
size	size	s020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
intracerebral	intracerebral	i536020601604	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aggravated	aggravated	a26010303	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
on	on	o500	IN	B-PP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ICH	ICH	i200	NN	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
used	use	u203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
carefully	carefully	c0601040	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
established	establish	e230140203	VBD	B-VP	O
sensitive	sensitive	s05203010	JJ	B-NP	O
quantification	quantification	q05301020305	NN	I-NP	O
methods	method	m03032	NNS	I-NP	O
and	and	a530	CC	O	O
provided	provide	p6010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
intrastriatally	intrastriatally	i536023603040	RB	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
014	014	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
unit	unit	u503	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
070	070	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
unit	unit	u503	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
350	350	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
unit	unit	u503	NN	I-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
bleeding	bleeding	b403052	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
morphologically	morphologically	m061040202040	RB	I-NP	O
determined	determine	d030650503	VBN	I-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
amounts	amount	a50532	NNS	I-NP	O
and	and	a530	CC	O	O
hematoma	hematoma	h0503050	NN	B-NP	B-Disease
volumes	volume	v040502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
014	014	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
unit	unit	u503	NN	I-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
adequate	adequate	a302030	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
ICH	ICH	i200	NN	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
induction	induction	i5302305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
014	014	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
unit	unit	u503	NN	I-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
,	,	,000	,	O	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
that	that	t030	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
7	7	7000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-ADVP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
useful	useful	u20104	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
ICH	ICH	i200	NN	B-NP	B-Disease
detection	detection	d0302305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
ICH	ICH	i200	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
collagenase	collagenase	c040205020	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
evaluation	evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
affect	affect	a1023	VB	I-VP	O
ICH	ICH	i200	NN	B-NP	B-Disease
.	.	.000	.	O	O

Estradiol	Estradiol	e2360304	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
ovariectomized	ovariectomize	o106023050203	VBN	B-NP	O
female	female	f05040	JJ	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
male	male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Estrogens	Estrogen	e23602052	NNS	B-NP	O
protect	protect	p603023	VBP	B-VP	O
ovariectomized	ovariectomize	o106023050203	VBN	I-VP	O
rats	rat	r032	NNS	B-NP	O
from	from	f605	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SE	SE	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
ovariectomized	ovariectomize	o106023050203	VBN	I-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
SE	SE	s000	NN	I-NP	B-Disease
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
received	receive	r020103	VBD	B-VP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
rat	rat	r030	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
oil	oil	o040	NN	B-NP	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

SE	SE	s000	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
20	20	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
and	and	a530	CC	O	O
terminated	terminate	t065050303	VBN	B-VP	O
3	3	3000	CD	B-NP	O
h	h	h000	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
silver	silver	s04106	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
stained	stain	s30503	VBN	I-NP	O
CA3	CA3	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
CA1	CA1	0000	NN	I-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Estradiol	Estradiol	e2360304	NN	B-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
clonus	clonus	c40502	NN	I-NP	O
in	in	i500	IN	B-PP	O
ovariectomized	ovariectomize	o106023050203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
but	but	b030	CC	O	O
accelerated	accelerate	a204060303	VBD	B-VP	O
it	it	i300	PRP	B-NP	O
in	in	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
.	.	.000	.	O	O

17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
Estradiol	Estradiol	e2360304	NN	I-NP	I-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
argyrophilic	argyrophilic	a6206010402	JJ	I-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CA1	CA1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
CA3	CA3	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
C	C	c000	NN	I-NP	O
sectors	sector	s023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ovariectomized	ovariectomize	o106023050203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
,	,	,000	,	O	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
score	score	s2060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
and	and	a530	CC	I-NP	O
damage	damage	d05020	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
altered	alter	a430603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
sex	sex	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hormonal	hormonal	h0650504	JJ	I-NP	O
environment	environment	e510605053	NN	I-NP	O
.	.	.000	.	O	O

Pseudoacromegaly	Pseudoacromegaly	p2030260502040	RB	B-ADVP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
minoxidil	minoxidil	m05020304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Acromegaly	Acromegaly	a260502040	RB	B-ADVP	B-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
endocrine	endocrine	e53026050	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
excessive	excessive	e202010	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	O
gland	gland	g4053	NN	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
disfiguring	disfiguring	d0210206052	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
occur	occur	o206	VBP	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
,	,	,000	,	O	O
cartilage	cartilage	c06304020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
soft	soft	s013	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
hypertrophy	hypertrophy	h010636010	NN	I-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
thickening	thickening	t0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
,	,	,000	,	O	O
coarsening	coarsening	c06205052	NN	B-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cutis	cutis	c0302	NN	B-NP	B-Disease
verticis	verticis	v0630202	NN	I-NP	I-Disease
gyrata	gyrata	g06030	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Pseudoacromegaly	Pseudoacromegaly	p2030260502040	RB	B-ADVP	B-Disease
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
acromegaloid	acromegaloid	a2605020403	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
or	or	o600	CC	I-NP	O
insulin	insulin	i520405	NN	I-NP	O
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
pseudoacromegaly	pseudoacromegaly	p2030260502040	NN	B-NP	B-Disease
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
minoxidil	minoxidil	m05020304	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
unusually	unusually	u502040	RB	I-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
pseudoacromegaly	pseudoacromegaly	p2030260502040	RB	B-ADVP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
minoxidil	minoxidil	m05020304	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Combined	Combine	c0510503	VBN	B-NP	O
androgen	androgen	a5360205	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	I-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
androgen	androgen	a5360205	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
(	(	(000	(	O	O
CAB	CAB	c010	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	O	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
biopsy	biopsy	b0120	NN	B-NP	O
-	-	-000	HYPH	O	O
proven	prove	p60105	VBN	B-VP	O
prostatic	prostatic	p60230302	JJ	B-NP	B-Disease
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	I-Disease
[	[	[000	(	O	O
26	26	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
T3N0M0	T3N0M0	0000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
D1	D1	0000	NN	I-NP	O
(	(	(000	(	O	O
T3N1M0	T3N1M0	0000	NN	B-NP	O
)	)	)000	)	O	O
]	]	]000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
CAB	CAB	c010	NN	B-NP	O
[	[	[000	(	O	O
leuprolide	leuprolide	l01604030	NN	B-NP	B-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
LHRH	LHRH	l060	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
,	,	,000	,	O	O
every	every	e1060	DT	B-NP	O
28	28	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
plus	plus	p402	CC	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
flutamide	flutamide	f40305030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
tid	tid	t030	NN	B-NP	O
,	,	,000	,	O	O
per	per	p060	IN	B-PP	O
Os	O	o200	NNS	B-NP	O
]	]	]000	)	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
CAB	CAB	c010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Hb	Hb	h100	NN	B-NP	O
,	,	,000	,	I-NP	O
PSA	PSA	p200	NN	I-NP	O
and	and	a530	CC	I-NP	O
Testosterone	Testosterone	t02302306050	NN	I-NP	B-Chemical
measurements	measurement	m0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
D2	D2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
disease	disease	d02020	NN	I-NP	O
,	,	,000	,	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
level	level	l0104	NN	I-NP	O
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-ADJP	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
upper	upper	u106	JJ	I-NP	O
limits	limit	l05032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
(	(	(000	(	O	O
Hb	Hb	h100	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
declined	decline	d0240503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
CAB	CAB	c010	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinically	clinically	c40502040	RB	I-NP	O
evident	evident	e103053	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
Hb	Hb	h100	NN	B-NP	O
<	<	<000	SYM	O	O
11	11	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
CAB	CAB	c010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
normochromic	normochromic	n06502060502	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
normocytic	normocytic	n065020302	JJ	I-ADJP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
CAB	CAB	c010	NN	B-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
Hb	Hb	h100	NN	I-NP	O
mean	mean	m050	NN	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	O	O
dl	dl	d400	NN	B-NP	O
(	(	(000	(	O	O
X	X	x000	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
mild	mild	m043	JJ	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
Hb	Hb	h100	NN	B-NP	O
mean	mean	m050	NN	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
X	X	x000	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
CAB	CAB	c010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
predictable	predictable	p6030230140	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Hb	Hb	h100	NN	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CAB	CAB	c010	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
CAB	CAB	c010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
T	T	t000	NN	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
(	(	(000	(	O	O
T	T	t000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
T	T	t000	NN	B-NP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
76	76	0000	CD	B-NP	O
yrs	yr	y620	NNS	I-NP	O
versus	versus	v06202	CC	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
76	76	0000	CD	B-NP	O
yrs	yr	y620	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
stage	stage	s3020	NN	I-NP	O
(	(	(000	(	O	O
stage	stage	s3020	NN	B-NP	O
C	C	c000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
stage	stage	s3020	NN	B-NP	O
D1	D1	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinically	clinically	c40502040	RB	I-NP	O
evident	evident	e103053	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
easily	easily	e02040	RB	I-VP	O
corrected	correct	c0602303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
week	week	w020	NN	I-NP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
erythropoietin	erythropoietin	e60306010305	NN	I-NP	O
(	(	(000	(	O	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
rHuEPO	rHuEPO	r010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
beta	beta	b030	NN	I-NP	O
correctable	correctable	c060230140	JJ	I-NP	O
CAB	CAB	c010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostate	prostate	p6023030	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
:	:	:000	:	O	O
incidence	incidence	i52030520	NN	B-NP	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-VP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Incidence	Incidence	i52030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
require	require	r02060	VBP	B-VP	O
further	far	f06306	JJR	B-NP	O
clarification	clarification	c40601020305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
computerized	computerized	c05103060203	JJ	B-NP	O
pharmacy	pharmacy	p065020	NN	I-NP	O
records	record	r020632	NNS	I-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
all	all	a400	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
inpatients	inpatient	i51030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1995	1995	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
96	96	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
reviewed	review	r0103	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
medical	medical	m030204	JJ	I-NP	O
records	record	r020632	NNS	I-NP	O
to	to	t000	TO	B-VP	O
score	score	s2060	VB	I-VP	O
incidence	incidence	i52030520	NN	B-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
delirium	delirium	d040605	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
tested	test	t02303	VBN	B-VP	O
associations	association	a20203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Subjects	Subject	s0120232	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
139	139	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
72	72	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
67	67	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
40	40	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
12	12	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
hospitalized	hospitalize	h02103040203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
23	23	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
given	give	g0105	VBN	B-VP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
gradually	gradually	g603040	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
282	282	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
203	203	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
45	45	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
45	45	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
48	48	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
person	person	p06205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
71	71	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
.	.	.000	.	O	O

Associated	Associate	a2020303	VBN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
centrally	centrally	c0536040	RB	I-NP	O
antimuscarinic	antimuscarinic	a530502060502	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
poor	poor	p060	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
,	,	,000	,	O	O
older	old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
longer	long	l05206	JJR	B-NP	O
hospitalization	hospitalization	h0210304020305	NN	I-NP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
cost	cost	c023	NN	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
or	or	o600	CC	I-NP	O
medical	medical	m030204	JJ	I-NP	O
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
morbidity	morbidity	m06103030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
daily	daily	d040	JJ	B-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
fell	fall	f040	VBD	B-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
unrelated	unrelated	u56040303	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Delirium	Delirium	d040605	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
inpatients	inpatient	i51030532	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
anticholinergics	anticholinergic	a5302040506202	NNS	I-NP	O
.	.	.000	.	O	O

Delirium	Delirium	d040605	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
inconsistently	inconsistently	i5205202305340	RB	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
milder	mild	m04306	JJR	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
length	length	l05230	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
stay	stay	s300	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
costs	cost	c0232	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
inferior	inferior	i510606	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

Neuroprotective	Neuroprotective	n0601603023010	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPEP	MPEP	m101	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
mGluR5	mGluR5	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
outflow	outflow	o03140	NN	I-NP	O
and	and	a530	CC	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperthermia	hyperthermia	h010630650	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
metabotropic	metabotropic	m03010360102	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
mGluR5	mGluR5	0000	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurones	neurone	n060502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
five	five	f010	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
measured	measure	m020603	VBN	B-VP	O
72	72	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
mGluR5	mGluR5	0000	NN	B-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
phenylethynyl	phenylethynyl	p0504030504	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
pyridine	pyridine	p0603050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
MPEP	MPEP	m101	NN	B-NP	B-Chemical
;	;	;000	:	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
five	five	f010	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
before	before	b01060	IN	B-SBAR	O
each	each	e020	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
MPEP	MPEP	m101	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
stimulated	stimulate	s305040303	VBD	B-VP	O
either	either	e0306	CC	O	O
by	by	b000	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
intrastriatally	intrastriatally	i536023603040	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
veratridine	veratridine	v0603603050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
transiently	transiently	t605205340	RB	B-ADVP	O
diminished	diminish	d05050203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
sc	sc	s200	NN	I-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
basal	basal	b0204	JJ	I-NP	O
body	body	b030	NN	I-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
.	.	.000	.	O	O

MPEP	MPEP	m101	NN	B-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
lower	low	l060	JJR	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
microM	microM	m02605	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
devoid	devoid	d0103	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
mGluR5	mGluR5	0000	NN	B-NP	O
by	by	b000	IN	B-PP	O
MPEP	MPEP	m101	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
protect	protect	p603023	VB	I-VP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurones	neurone	n060502	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Neuroprotection	Neuroprotection	n060160302305	NN	B-NP	O
rendered	render	r0530603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
MPEP	MPEP	m101	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
efflux	efflux	e1402	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrastriatal	extrastriatal	e23602360304	JJ	B-NP	O
mGluR5	mGluR5	0000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hyperthermia	hyperthermia	h010630650	NN	B-NP	B-Disease
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuroactive	neuroactive	n06023010	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
against	against	a20523	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
kindled	kindle	k053403	VBD	B-VP	O
-	-	-000	HYPH	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Neuroactive	Neuroactive	n06023010	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
actions	action	a23052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
relevance	relevance	r04010520	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
host	host	h023	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
psychiatric	psychiatric	p20203602	JJ	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
offer	offer	o106	VBP	B-VP	O
protection	protection	p60302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
and	and	a530	CC	O	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
certain	certain	c06305	JJ	B-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
dependence	dependence	d010530520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
preclinical	preclinical	p6024050204	JJ	B-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
two	two	t000	CD	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
neuroactive	neuroactive	n06023010	JJ	I-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
that	that	t030	WDT	B-NP	O
positively	positively	p020301040	RB	B-ADVP	O
modulate	modulate	m0304030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
engendered	engender	e520530603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
kindling	kindling	k0534052	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Allopregnanolone	Allopregnanolone	a40160250504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3alpha	3alpha	30410	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5alpha	5alpha	50410	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pregnan	pregnan	p602505	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
20	20	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
one	one	o500	CD	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
pregnanolone	pregnanolone	p60250504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3alpha	3alpha	30410	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5beta	5beta	51030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pregnan	pregnan	p602505	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
20	20	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
one	one	o500	CD	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
ganaxolone	ganaxolone	g050204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
allopregnanolone	allopregnanolone	a40160250504050	NN	B-NP	B-Chemical
3alpha	3alpha	30410	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3beta	3beta	31030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5alpha	5alpha	50410	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pregnan	pregnan	p602505	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
20	20	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
one	one	o500	CD	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
suppress	suppress	s01602	VB	I-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
(	(	(000	(	O	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
development	development	d0104015053	NN	B-NP	O
(	(	(000	(	O	O
antiepileptogenic	antiepileptogenic	a530104013020502	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
kindled	kindle	k053403	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
,	,	,000	,	I-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
Webster	Webster	w012306	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Kindled	Kindle	k053403	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
)	)	)000	)	O	O
modulators	modulator	m030403062	NNS	B-NP	O
suppressed	suppress	s0160203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
kindled	kindled	k053403	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
only	only	o540	RB	B-NP	O
allopregnanolone	allopregnanolone	a40160250504050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
ganaxolone	ganaxolone	g050204050	NN	I-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
kindling	kindling	k0534052	NN	B-NP	O
.	.	.000	.	O	O

Allopregnanolone	Allopregnanolone	a40160250504050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pregnanolone	pregnanolone	p60250504050	NN	I-NP	B-Chemical
,	,	,000	,	B-NP	O
but	but	b030	CC	I-NP	O
not	not	n030	RB	I-NP	O
ganaxolone	ganaxolone	g050204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
also	also	a420	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
lethality	lethality	l0304030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
kindling	kindling	k0534052	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
neuroactive	neuroactive	n06023010	JJ	I-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
attenuate	attenuate	a305030	VBP	B-VP	O
convulsant	convulsant	c051042053	NN	B-NP	O
and	and	a530	CC	O	O
sensitizing	sensitize	s0520302052	VBG	B-VP	O
properties	property	p60106302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
add	add	a300	VB	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
growing	grow	g6052	VBG	I-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
abuse	abuse	a1020	NN	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
humoral	humoral	h050604	JJ	B-NP	O
modulators	modulator	m030403062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
locomotor	locomotor	l02050306	NN	B-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
humoral	humoral	h050604	JJ	B-NP	O
modulators	modulator	m030403062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
locomotor	locomotor	l02050306	NN	B-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
HC1	HC1	0000	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
locomotor	locomotor	l02050306	NN	B-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
attenuated	attenuate	a3050303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
physostigmine	physostigmine	p02023025050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
methscopolamine	methscopolamine	m0302010405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
neostigmine	neostigmine	n023025050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
penetrate	penetrate	p05036030	VB	I-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyltyrosine	methyltyrosine	m030430602050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
tyrosine	tyrosine	t0602050	NN	B-NP	B-Chemical
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
decreased	decrease	d0260203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
-	-	-000	HYPH	O	O
increasing	increase	i52602052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
hand	hand	h053	NN	I-NP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
p	p	p000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
chlorophenylalamine	chlorophenylalamine	c04060105040405050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
X	X	x000	SYM	I-NP	O
320	320	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
depletor	depletor	d0140306	NN	I-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
-	-	-000	HYPH	O	O
increasing	increase	i52602052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
adrenergic	adrenergic	a360506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

And	And	a530	CC	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
acts	act	a232	VBZ	B-VP	O
by	by	b000	IN	B-PP	O
retarding	retard	r03063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
some	some	s050	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
synapses	synapsis	s0501202	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
collected	collect	c0402303	VBN	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
-	-	-000	HYPH	O	O
increasing	increase	i52602052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
which	which	w020	WDT	B-NP	O
mediate	mediate	m03030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
-	-	-000	HYPH	O	O
increasing	increase	i52602052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
uninephrectomy	uninephrectomy	u5050106023050	JJ	B-NP	O
and	and	a530	CC	I-NP	O
high	high	h020	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
feeding	feeding	f03052	NN	I-NP	O
on	on	o500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
high	high	h020	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
HP	HP	h100	NN	B-NP	O
)	)	)000	)	O	O
feeding	feeding	f03052	NN	B-NP	O
,	,	,000	,	O	O
uninephrectomy	uninephrectomy	u5050106023050	NN	B-NP	O
(	(	(000	(	O	O
NX	NX	n200	NN	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
hyperfiltration	hyperfiltration	h0106104360305	NN	I-NP	O
and	and	a530	CC	O	O
further	further	f06306	JJ	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Newborn	Newborn	n01065	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
a	a	a000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
diet	diet	d030	NN	B-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
randomized	randomize	r053050203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
HP	HP	h100	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
NX	NX	n200	NN	B-NP	O
or	or	o600	CC	I-NP	O
HP	HP	h100	NN	I-NP	O
+	+	+000	SYM	B-NP	O
NX	NX	n200	NN	I-NP	O
for	for	f060	IN	B-PP	O
another	another	a50306	DT	B-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Corresponding	Correspond	c06021053052	VBG	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
pretreated	pretreate	p60360303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
comparing	compare	c05106052	VBG	B-VP	O
all	all	a400	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
versus	versus	v06202	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
GFR	GFR	g160	NN	B-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
effective	effective	e1023010	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
secreted	secrete	s0260303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubules	tubule	t010402	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
.	.	.000	.	O	O

Consequently	Consequently	c0520205340	RB	B-ADVP	O
,	,	,000	,	O	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
filtration	filtration	f04360305	NN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
fractional	fractional	f60230504	JJ	B-NP	O
Li	Li	l000	NNP	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
systolic	systolic	s0230402	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
absence	absence	a120520	NN	B-NP	O
of	of	o100	IN	B-PP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

HP	HP	h100	NN	B-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
accentuante	accentuante	a20530530	VB	I-VP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
fact	fact	f023	NN	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
GFR	GFR	g160	NN	B-NP	O
and	and	a530	CC	O	O
decrease	decrease	d026020	VB	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
pretreated	pretreate	p60360303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

NX	NX	n200	NN	B-NP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
additive	additive	a303010	JJ	I-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
which	which	w020	WDT	B-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
HP	HP	h100	NN	B-NP	O
.	.	.000	.	O	O

NX	NX	n200	NN	B-NP	O
+	+	+000	SYM	I-NP	O
HP	HP	h100	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
Li	Li	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pretreated	pretreate	p60360303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
Li	Li	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
when	when	w050	WRB	I-ADVP	O
the	the	t000	DT	B-NP	O
GFR	GFR	g160	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
only	only	o540	RB	I-VP	O
modestly	modestly	m0302340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
the	the	t000	DT	B-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
corresponding	corresponding	c06021053052	JJ	I-NP	O
fall	fall	f040	NN	I-NP	O
in	in	i500	IN	B-PP	O
effective	effective	e1023010	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonfiltrating	nonfiltrating	n051043603052	JJ	B-NP	O
atubular	atubular	a3010406	JJ	I-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fractional	fractional	f60230504	JJ	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tubular	tubular	t010406	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
proximal	proximal	p6020504	JJ	I-NP	O
tubules	tubule	t010402	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
leaving	leave	l01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
Crohn	Crohn	c605	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
fusidic	fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
antibiotic	antibiotic	a53010302	NN	I-NP	O
with	with	w030	IN	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fusidic	Fusidic	f020302	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antibiotic	antibiotic	a53010302	NN	I-NP	O
with	with	w030	IN	B-PP	O
T	T	t000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
Crohn	Crohn	c605	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
pharmacodynamics	pharmacodynamic	p0650203050502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fusidic	fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
active	active	a23010	JJ	I-NP	O
,	,	,000	,	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
resistant	resistant	r02023053	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
Crohn	Crohn	c605	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
.	.	.000	.	O	O

Fusidic	Fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
d	d	d000	NN	B-NP	O
.	.	.000	.	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
planned	plan	p40503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
last	last	l023	VB	I-VP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
primarily	primarily	p60506040	RB	I-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
modified	modify	m030103	VBN	I-NP	O
individual	individual	i53010304	JJ	I-NP	O
grading	grading	g603052	NN	I-NP	O
score	score	s2060	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
improved	improve	i5160103	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
fusidic	fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	O
at	at	a300	IN	B-PP	O
two	two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
after	after	a1306	IN	I-NP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
required	require	r020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
.	.	.000	.	O	O

Biochemically	Biochemically	b020502040	RB	B-ADVP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
alkaline	alkaline	a4204050	NN	B-NP	O
phosphatases	phosphatas	p021030202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
levels	level	l01042	NNS	B-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
fusidic	fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
of	of	o100	IN	B-PP	O
benefit	benefit	b050103	NN	B-NP	O
in	in	i500	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
active	active	a23010	JJ	I-NP	O
Crohn	Crohn	c605	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
conventional	conventional	c0510530504	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
exist	exist	e2023	VB	I-VP	O
a	a	a000	DT	B-NP	O
scientific	scientific	s20530102	JJ	I-NP	O
rationale	rationale	r0305040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
fusidic	fusidic	f020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytokine	cytokine	c0302050	NN	I-NP	O
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
further	further	f06306	RBR	B-ADJP	O
investigated	investigate	i51023020303	VBN	I-ADJP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
status	status	s30302	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

Depression	Depression	d0160205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
any	any	a500	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
non	non	n050	JJ	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
blocker	blocker	b40206	NN	B-NP	O
(	(	(000	(	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	B-NP	O
(	(	(000	(	O	O
betaxolol	betaxolol	b03020404	NN	B-NP	B-Chemical
)	)	)000	)	O	O
regarding	regard	r02063052	VBG	B-VP	O
CNS	CNS	c520	NN	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
glaucomatous	glaucomatous	g402050302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
chronically	chronically	c060502040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
12h	12h	0000	NN	I-NP	O
,	,	,000	,	O	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
diagnosed	diagnose	d0250203	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
DMS	DMS	d520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
III	III	i000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
R	R	r000	NN	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
six	six	s020	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
depression	depression	d0160205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
quantified	quantify	q0530103	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
Beck	Beck	b020	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Zung	Zung	z052	NNP	I-NP	O
-	-	-000	HYPH	O	O
Conde	Conde	c0530	NNP	B-NP	O
scales	scale	s20402	VBZ	B-VP	O
every	every	e1060	DT	B-NP	O
two	two	t000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
cross	cross	c602	AFX	O	O
-	-	-000	HYPH	O	O
over	over	o106	IN	B-PP	O
study	study	s3030	NN	B-NP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
values	value	v0402	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
Beck	Beck	b020	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Zung	Zung	z052	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
Conde	Conde	c0530	NN	I-NP	O
scales	scale	s20402	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
vs	vs	v200	CC	O	O
control	control	c053604	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
betaxolol	betaxolol	b03020404	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
less	less	l020	JJR	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
inducer	inducer	i530206	NN	B-NP	O
than	than	t050	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
predisposed	predispose	p6030210203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Protection	Protection	p60302305	NN	B-NP	O
against	against	a20523	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
toward	toward	t063	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
by	by	b000	IN	B-PP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
excitatory	excitatory	e20303060	JJ	I-NP	O
amino	amino	a5050	NN	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
.	.	.000	.	O	O

LY274614	LY274614	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
3SR	3SR	3260	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
4aRS	4aRS	4062	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
6SR	6SR	6260	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
8aRS	8aRS	8062	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	I-NP	I-Chemical
phosphonomethyl	phosphonomethyl	p02105050304	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
decahydr	decahydr	d02036	NN	B-NP	I-Chemical
oisoquinoline	oisoquinoline	o02020504050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxylic	carboxylic	c061020402	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
subtype	subtype	s013010	NN	B-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
its	its	i320	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
the	the	t000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
by	by	b000	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
iprindole	iprindole	i16053040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
hemisulfate	hemisulfate	h0502041030	NN	I-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
iprindole	iprindole	i16053040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
1	1	1000	CD	I-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
dizocilpine	dizocilpine	d0202041050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
,	,	,000	,	O	O
being	be	b052	VBG	B-VP	O
maximum	maximum	m020505	NN	B-NP	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
mgkg	mgkg	m200	NN	I-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
antagonizing	antagonize	a53020502052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
as	as	a200	RB	B-ADVP	O
long	long	l052	RB	I-ADVP	O
as	as	a200	IN	B-SBAR	O
8	8	8000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
not	not	n030	RB	O	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Depletion	Depletion	d0140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
;	;	;000	:	O	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
protected	protect	p60302303	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
8	8	8000	CD	B-NP	O
or	or	o600	CC	I-NP	O
24	24	0000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
depletion	depletion	d0140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
completely	completely	c051403040	RB	I-ADVP	O
by	by	b000	IN	B-PP	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
strengthen	strengthen	s36052305	VBP	B-VP	O
the	the	t000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
related	relate	r040303	VBN	I-NP	O
compounds	compound	c0510532	NNS	I-NP	O
toward	toward	t063	IN	B-PP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
involves	involve	i5104102	VBZ	B-VP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
LY274614	LY274614	0000	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
lasting	last	l023052	VBG	B-VP	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Ketoconazole	Ketoconazole	k03020502040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	B-Disease
sequelae	sequela	s02040	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
77	77	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
y	y	y000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
old	old	o430	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
weakness	weakness	w02502	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
extremities	extremity	e236050302	NNS	B-NP	I-Disease
,	,	,000	,	O	O
legs	leg	l020	NNS	B-NP	B-Disease
paralysis	paralysis	p06040202	NN	I-NP	I-Disease
,	,	,000	,	O	O
dysarthria	dysarthria	d02063060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
tremor	tremor	t60506	NN	B-NP	B-Disease
1	1	1000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
ketoconazole	ketoconazole	k03020502040	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
life	life	l010	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
complaints	complaint	c05140532	NNS	I-NP	O
faded	fade	f0303	VBD	B-VP	O
away	away	a000	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Few	Few	f000	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
used	use	u203	VBD	B-VP	O
another	another	a50306	DT	B-NP	O
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
ketoconazole	ketoconazole	k03020502040	NN	I-NP	B-Chemical
tablet	tablet	t01403	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
within	within	w0305	IN	B-PP	O
an	an	a500	DT	B-NP	O
hour	hour	h060	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
again	again	a205	RB	B-ADVP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
hours	hour	h062	NNS	B-NP	O
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
evaluations	evaluation	e10403052	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
head	head	h030	NN	B-NP	O
CT	CT	c300	NN	I-NP	O
scan	scan	s205	NN	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
close	close	c4020	JJ	B-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
monkeys	monkey	m05202	NNS	I-NP	O
may	may	m000	MD	B-VP	O
depend	depend	d01053	VB	I-VP	O
upon	upon	u105	IN	B-PP	O
rate	rate	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptom	symptom	s051305	NN	B-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
(	(	(000	(	O	O
LIDs	LID	l032	NNS	B-NP	B-Disease
)	)	)000	)	O	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Due	Due	d000	JJ	B-PP	O
to	to	t000	TO	I-PP	O
the	the	t000	DT	B-NP	O
interdependence	interdependence	i53063010530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
populations	population	p010403052	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
difficult	difficult	d0102043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
independently	independently	i530105305340	RB	I-VP	O
examine	examine	e205050	VB	I-VP	O
factors	factor	f023062	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
influence	influence	i5140520	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
macaque	macaque	m02020	JJ	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
to	to	t000	TO	B-PP	O
which	which	w020	WDT	B-NP	O
rate	rate	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptom	symptom	s051305	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
,	,	,000	,	O	O
symptom	symptom	s051305	NN	B-NP	O
severity	severity	s0106030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
and	and	a530	CC	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Monkeys	Monkey	m05202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	O	O
(	(	(000	(	O	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
)	)	)000	)	O	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
rapid	rapid	r0103	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	O	O
short	short	s063	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
between	between	b0305	IN	B-PP	O
11	11	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
24	24	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
monkeys	monkey	m05202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
MPTP	MPTP	m131	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
slow	slow	s400	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
long	long	l052	JJ	B-NP	O
symptom	symptom	s051305	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
no	no	n000	DT	B-NP	O
sooner	sooner	s0506	RBR	I-NP	O
than	than	t050	IN	I-NP	O
146	146	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similarly	similarly	s05040640	RB	B-ADJP	O
symptomatic	symptomatic	s0513050302	JJ	I-ADJP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
distinct	distinct	d0230523	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
propensity	propensity	p601052030	NN	I-NP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
monkeys	monkey	m05202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
symptom	symptom	s051305	NN	B-NP	O
progression	progression	p60260205	NN	I-NP	O
or	or	o600	CC	I-NP	O
symptom	symptom	s051305	NN	I-NP	O
durations	duration	d0603052	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
models	model	m03042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
further	further	f06306	RB	B-ADVP	O
studying	study	s303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
LIDs	LID	l032	NNS	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
promoting	promote	p60503052	VBG	B-VP	O
sugar	sugar	s0206	NN	B-NP	B-Disease
dependency	dependency	d010530520	NN	I-NP	I-Disease
causes	cause	c0202	VBZ	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	B-Disease
cross	cross	c602	AFX	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
sensitization	sensitization	s05203020305	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
of	of	o100	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
excessive	excessive	e202010	JJ	I-NP	O
sugar	sugar	s0206	NN	I-NP	O
consumption	consumption	c052051305	NN	I-NP	O
produces	produce	p6030202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
state	state	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
neurochemical	neurochemical	n0602050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
similarities	similarity	s0504060302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
dependency	dependency	d010530520	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sugar	sugar	s0206	NN	B-NP	O
access	access	a202	NN	I-NP	O
would	would	w043	MD	B-VP	O
show	show	s000	VB	I-VP	O
behavioral	behavioral	b010604	JJ	B-ADJP	B-Disease
cross	cross	c602	AFX	B-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
sensitization	sensitization	s05203020305	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
baseline	baseline	b0204050	NN	I-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
cyclic	cyclic	c02402	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
access	access	a202	NN	I-NP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sucrose	sucrose	s026020	NN	I-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
chow	chow	c000	NN	I-NP	O
pellets	pellet	p04032	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
access	access	a202	NN	I-NP	O
starting	start	s3063052	VBG	B-VP	O
4	4	4000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dark	dark	d062	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
21	21	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Locomotor	Locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
again	again	a205	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
21	21	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
sugar	sugar	s0206	NN	B-NP	O
access	access	a202	NN	I-NP	O
.	.	.000	.	O	O

Beginning	Begin	b0205052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
22	22	0000	CD	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
ad	ad	a300	NN	B-NP	O
libitum	libitum	l010305	NN	I-NP	O
chow	chow	c000	NN	I-NP	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
cyclic	cyclic	c02402	JJ	B-NP	O
sucrose	sucrose	s026020	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
chow	chow	c000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
hyperactive	hyperactive	h0106023010	JJ	B-ADJP	B-Disease
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
four	four	f060	CD	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
ad	ad	a300	NN	B-NP	O
libitum	libitum	l010305	NN	I-NP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sucrose	sucrose	s026020	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
chow	chow	c000	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
cyclic	cyclic	c02402	JJ	B-NP	O
chow	chow	c000	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
ad	ad	a300	NN	B-NP	O
libitum	libitum	l010305	NN	I-NP	O
chow	chow	c000	NN	I-NP	O
with	with	w030	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
cyclic	cyclic	c02402	JJ	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
sucrose	sucrose	s026020	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
chow	chow	c000	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
comprised	comprise	c05160203	VBN	B-VP	O
of	of	o100	IN	B-PP	O
alternating	alternate	a4306503052	VBG	B-VP	O
deprivation	deprivation	d016010305	NN	B-NP	O
and	and	a530	CC	I-NP	O
access	access	a202	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
sugar	sugar	s0206	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
and	and	a530	CC	I-NP	O
chow	chow	c000	NN	I-NP	O
produces	produce	p6030202	VBZ	B-VP	O
bingeing	binge	b052052	VBG	I-VP	O
on	on	o500	IN	B-PP	O
sugar	sugar	s0206	NN	B-NP	O
that	that	t030	WDT	B-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
lasting	lasting	l023052	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lasting	lasting	l023052	JJ	I-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
dilated	dilated	d040303	JJ	I-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
dilated	dilate	d040303	VBN	I-VP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	I-Disease
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AmB	AmB	a510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
disseminated	disseminate	d0205050303	VBN	B-NP	O
coccidioidomycosis	coccidioidomycosis	c02030305020202	NN	I-NP	B-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
echocardiographic	echocardiographic	e2020630260102	JJ	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
posaconazole	posaconazole	p02020502040	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
substituted	substitute	s0123030303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
recognize	recognize	r02025020	VB	I-VP	O
the	the	t000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
potentially	potentially	p03053040	RB	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
AmB	AmB	a510	NN	B-NP	B-Chemical
.	.	.000	.	O	O

NO	NO	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
:	:	:000	:	O	O
strong	strong	s36052	JJ	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	B-Chemical
gene	gene	g050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
related	relate	r040303	VBN	B-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CGRP	CGRP	c261	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
and	and	a530	CC	O	O
negative	negative	n0203010	JJ	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
with	with	w030	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	B-Chemical
gene	gene	g050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
related	relate	r040303	VBN	B-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CGRP	CGRP	c261	NN	B-NP	B-Chemical
)	)	)000	)	O	O
concentration	concentration	c05205360305	NN	B-NP	O
and	and	a530	CC	O	O
platelet	platelet	p4030403	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytriptamine	hydroxytriptamine	h0360203601305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
)	)	)000	)	O	O
content	content	c053053	NN	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
genuine	genuine	g05050	JJ	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
provoked	provoke	p6010203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
migraineurs	migraineur	m02605062	NNS	I-NP	B-Disease
(	(	(000	(	O	I-Disease
without	without	w0303	IN	B-PP	I-Disease
aura	aura	a060	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	O
eight	eight	e0203	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
participated	participate	p06302010303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Sublingual	Sublingual	s01405204	JJ	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
was	be	w020	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
antecubital	antecubital	a5302010304	JJ	I-NP	O
vein	vein	v050	NN	I-NP	O
four	four	f060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
:	:	:000	:	O	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
application	application	a14020305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
344	344	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
404	404	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
;	;	;000	:	O	O
12	12	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
time	time	t050	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
CGRP	CGRP	c261	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
and	and	a530	CC	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
cessation	cessation	c020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
both	both	b030	CC	O	O
change	change	c0520	NN	B-NP	O
and	and	a530	CC	I-NP	O
peak	peak	p020	NN	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
correlations	correlation	c060403052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
CGRP	CGRP	c261	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
change	change	c0520	VB	I-VP	O
during	during	d06052	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

Basal	Basal	b0204	JJ	B-NP	O
CGRP	CGRP	c261	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
and	and	a530	CC	O	O
platelet	platelet	p4030403	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
content	content	c053053	NN	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
who	who	w000	WP	B-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

Platelet	Platelet	p4030403	NN	B-NP	O
serotonin	serotonin	s06030505	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
consistent	consistent	c052023053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
plasma	plasma	p40250	NN	B-NP	O
CGRP	CGRP	c261	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
timing	timing	t05052	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
headache	headache	h03020	NN	I-NP	B-Disease
suggests	suggest	s020232	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
CGRP	CGRP	c261	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
from	from	f605	IN	B-PP	O
platelets	platelet	p40304032	NNS	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
provoke	provoke	p601020	VB	I-VP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
even	even	e105	RB	I-VP	O
counteract	counteract	c05306023	VB	I-VP	O
the	the	t000	DT	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
CGRP	CGRP	c261	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Hyperbaric	Hyperbaric	h010610602	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
intractable	intractable	i5360230140	JJ	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
intractable	intractable	i5360230140	JJ	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Conservative	Conservative	c05206103010	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
bladder	bladder	b40306	NN	B-NP	O
irrigation	irrigation	i6020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
physiological	physiological	p0204020204	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
and	and	a530	CC	I-NP	O
instillation	instillation	i523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
F2	F2	0000	NN	I-NP	I-Chemical
alpha	alpha	a410	NN	I-NP	I-Chemical
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
totally	totally	t03040	RB	I-VP	O
control	control	c053604	VB	I-VP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
used	use	u203	VBD	B-VP	O
hyperbaric	hyperbaric	h010610602	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
atm	atm	a350	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
ceased	cease	c0203	VBN	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
hematuria	hematuria	h0503060	NN	B-NP	B-Disease
thereafter	thereafter	t0601306	RB	B-ADVP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
future	future	f03060	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
can	can	c050	MD	B-VP	O
offer	offer	o106	VB	I-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
psychosis	psychosis	p2020202	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
nonepileptic	nonepileptic	n05010401302	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
antiepileptic	antiepileptic	a53010401302	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
brain	brain	b605	NN	I-NP	O
substratum	substratum	s012360305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
nonepileptic	nonepileptic	n05010401302	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
trigeminal	trigeminal	t602050504	JJ	B-NP	B-Disease
neuralgia	neuralgia	n060420	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
psychotic	psychotic	p2020302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
occur	occur	o206	VBP	B-VP	O
following	follow	f04052	VBG	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
,	,	,000	,	O	O
unrelated	unrelated	u56040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Risks	Risk	r020	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
consumption	consumption	c052051305	NN	I-NP	O
of	of	o100	IN	B-PP	O
beverages	beverage	b01060202	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
Food	Food	f030	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
banned	ban	b0503	VBD	B-VP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
for	for	f060	IN	B-PP	O
nocturnal	nocturnal	n02306504	JJ	B-NP	B-Disease
leg	leg	l020	NN	I-NP	I-Disease
cramps	cramp	c60512	NNS	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
safety	safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
,	,	,000	,	O	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
widely	widely	w03040	RB	B-ADJP	O
available	available	a1040140	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
beverages	beverage	b01060202	NNS	B-NP	O
including	include	i52403052	VBG	B-PP	O
tonic	tonic	t0502	JJ	B-NP	O
water	water	w0306	NN	I-NP	O
and	and	a530	CC	O	O
bitter	bitter	b0306	JJ	B-NP	O
lemon	lemon	l0505	NN	I-NP	O
.	.	.000	.	O	O

Numerous	Numerous	n050602	JJ	B-NP	O
anecdotal	anecdotal	a50230304	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
products	product	p6030232	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
,	,	,000	,	O	O
altered	alter	a430603	VBN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
coma	coma	c050	NN	B-NP	B-Disease
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

Psychologists	Psychologist	p20204020232	NNS	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
inquire	inquire	i52060	VB	I-VP	O
about	about	a103	IN	B-PP	O
consumption	consumption	c052051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
quinine	quinine	q05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
beverages	beverage	b01060202	NNS	B-NP	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
platypnea	platypnea	p4030150	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
orthodeoxia	orthodeoxia	o6303020	NN	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
propafenone	propafenone	p6010105050	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
Ebstein	Ebstein	e12305	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
anomaly	anomaly	a505040	RB	B-ADVP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
Ebstein	Ebstein	e12305	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
anomaly	anomaly	a505040	RB	B-ADVP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
called	call	c0403	VBN	B-VP	O
platypnea	platypnea	p4030150	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
orthodeoxia	orthodeoxia	o6303020	NN	I-NP	I-Disease
,	,	,000	,	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
right	right	r0203	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
left	left	l013	JJ	I-NP	O
interatrial	interatrial	i530603604	JJ	I-NP	O
shunting	shunting	s053052	NN	I-NP	O
with	with	w030	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
profound	profound	p601053	JJ	I-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
cyanosis	cyanosis	c050202	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
shunt	shunt	s053	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
patent	patent	p03053	NN	I-NP	B-Disease
foramen	foraman	f060505	NNS	I-NP	I-Disease
ovale	ovale	o1040	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
probably	probably	p6010140	RB	I-VP	O
precipitated	precipitate	p60201030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
propafenone	propafenone	p6010105050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
biventricular	biventricular	b010536020406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
inotropic	inotropic	i50360102	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
vasodilatory	vasodilatory	v02030403060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
gave	give	g010	VBD	B-VP	O
rise	rise	r020	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
atrial	atrial	a3604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
one	one	o500	CD	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequent	consequent	c05202053	JJ	I-NP	O
stretching	stretching	s36032052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
foramen	foraman	f060505	NNS	I-NP	O
ovale	ovale	o1040	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
creation	creation	c60305	NN	I-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
right	right	r0203	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
left	left	l013	JJ	I-NP	O
shunting	shunting	s053052	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
this	this	t020	DT	B-NP	O
interatrial	interatrial	i530603604	JJ	I-NP	O
shunt	shunt	s053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
very	very	v060	RB	I-VP	O
accurately	accurately	a20603040	RB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
bubble	bubble	b0140	NN	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Noxious	Noxious	n0202	JJ	B-NP	O
chemical	chemical	c050204	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
facial	facial	f0204	JJ	I-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
trigemino	trigemino	t60205050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
parasympathetic	parasympathetic	p0602051030302	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
-	-	-000	HYPH	B-NP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
cluster	cluster	c402306	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cluster	Cluster	c402306	NNP	B-NP	B-Disease
headache	headache	h03020	PRP	B-NP	I-Disease
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
typical	typical	t010204	JJ	B-NP	O
autonomic	autonomic	a03050502	JJ	I-NP	O
dysfunctions	dysfunction	d0210523052	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
facial	facial	f0204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
the	the	t000	DT	B-NP	O
trigeminal	trigeminal	t602050504	JJ	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
cranial	cranial	c60504	JJ	I-NP	O
parasympathetic	parasympathetic	p0602051030302	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mediating	mediate	m0303052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
dysfunctions	dysfunction	d0210523052	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
lacrimation	lacrimation	l026050305	NN	B-NP	O
and	and	a530	CC	O	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
noxious	noxious	n0202	JJ	B-NP	O
chemical	chemical	c050204	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
arteries	artery	a630602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
cranial	cranial	c60504	JJ	I-NP	O
dura	dura	d060	NN	I-NP	O
mater	mater	m0306	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
parietal	parietal	p060304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
laser	laser	l0206	NN	B-NP	O
Doppler	Doppler	d01406	NNP	I-NP	O
flowmetry	flowmetry	f4050360	NN	I-NP	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
)	)	)000	)	O	O
applied	apply	a1403	VBD	B-VP	O
to	to	t000	TO	B-PP	O
oral	oral	o604	JJ	B-NP	O
or	or	o600	CC	I-NP	O
nasal	nasal	n0204	JJ	I-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
increases	increase	i5260202	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
dural	dural	d0604	JJ	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
cortical	cortical	c0630204	JJ	I-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
flow	flow	f400	NN	I-NP	I-Disease
and	and	a530	CC	O	O
provoked	provoked	p6010203	JJ	B-NP	O
lacrimation	lacrimation	l026050305	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hexamethonium	hexamethonium	h0205030505	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
dural	dural	d0604	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
flow	flow	f400	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
[	[	[000	(	O	O
Lys1	Lys1	0000	NN	B-NP	O
,	,	,000	,	O	O
Pro2	Pro2	0000	NN	B-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	O	O
Arg3	Arg3	0000	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
Tyr6	Tyr6	0000	NN	I-NP	O
]	]	]000	)	O	O
-	-	-000	HYPH	B-NP	O
VIP	VIP	v010	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
vasoactive	vasoactive	v02023010	JJ	I-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	O
polypeptide	polypeptide	p0401013030	NN	I-NP	O
(	(	(000	(	O	O
VIP	VIP	v010	NN	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
,	,	,000	,	O	O
onto	onto	o530	IN	B-PP	O
the	the	t000	DT	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
dura	dura	d060	NN	I-NP	O
mater	mater	m0306	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
noxious	noxious	n0202	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
mucosa	mucosa	m02020	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
intracranial	intracranial	i5360260504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
and	and	a530	CC	I-NP	O
lacrimation	lacrimation	l026050305	NN	I-NP	O
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
trigemino	trigemino	t60205050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
parasympathetic	parasympathetic	p0602051030302	JJ	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
VIP	VIP	v010	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
meninges	meninge	m0505202	NNS	I-NP	O
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
cluster	cluster	c402306	NN	B-NP	B-Disease
headache	headache	h03020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Organophosphate	Organophosphate	o620501021030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropathological	neuropathological	n06010304020204	JJ	B-NP	B-Disease
damages	damage	d050202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
organophosphorus	organophosphorus	o6205010210602	NN	I-NP	B-Chemical
(	(	(000	(	O	O
OP	OP	o100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
compounds	compound	c0510532	NNS	B-NP	O
as	as	a200	IN	B-PP	O
diisopropylfluorophosphate	diisopropylfluorophosphate	d020160104140601021030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DFP	DFP	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
sarin	sarin	s0605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
soman	soman	s0505	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
potent	potent	p03053	JJ	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acetylcholinesterases	acetylcholinesteras	a2030420405023060202	NNS	B-NP	O
(	(	(000	(	O	O
AChEs	AChE	a202	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
butyrylcholinesterases	butyrylcholinesteras	b03060420405023060202	NNS	B-NP	O
(	(	(000	(	O	O
BChEs	BChE	b202	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
OPs	OP	o120	NNS	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
binding	binding	b053052	NN	I-NP	O
with	with	w030	IN	B-PP	O
AChEs	AChE	a202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
CNS	CNS	c520	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
elevates	elevate	e4010302	VBZ	B-VP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACh	ACh	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
subcutaneously	subcutaneously	s01203050240	RB	B-NP	O
(	(	(000	(	O	O
SC	SC	s200	NN	B-NP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-NP	O
antidotes	antidote	a53030302	NNS	I-NP	O
or	or	o600	CC	O	O
their	their	t060	PRP$	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
intoxication	intoxication	i5302020305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
weeks	week	w020	NNS	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Han	Han	h050	NNP	I-NP	O
-	-	-000	HYPH	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
AChE	AChE	a200	NN	B-NP	O
reactivator	reactivator	r023010306	NN	I-NP	O
pralidoxime	pralidoxime	p6040302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2PAM	2PAM	2105	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	B-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
A	A	a000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
N	N	n000	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
6	6	6000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
cyclopentyl	cyclopentyl	c0240105304	NN	I-NP	I-Chemical
adenosine	adenosine	a30502050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
dizocilpine	dizocilpine	d0202041050	NN	I-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
MK801	MK801	0000	NN	I-NP	O
hydrogen	hydrogen	h0360205	NN	I-NP	O
maleate	maleate	m04030	NN	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
their	their	t060	PRP$	B-NP	O
combinations	combination	c0510503052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cholinolytic	cholinolytic	c0405040302	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
BW	BW	b000	NN	I-NP	O
)	)	)000	)	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
or	or	o600	CC	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
SC	SC	s200	NN	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
saline	saline	s04050	NN	B-NP	O
and	and	a530	CC	I-NP	O
olive	olive	o4010	NN	I-NP	O
oil	oil	o040	NN	I-NP	O
instead	instead	i52303	RB	B-PP	O
of	of	o100	IN	I-PP	O
other	other	o306	JJ	B-NP	O
antidotes	antidote	a53030302	NNS	I-NP	O
and	and	a530	CC	O	O
DFP	DFP	d100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
terminated	terminate	t065050303	VBN	I-VP	O
either	either	e0306	CC	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
or	or	o600	CC	O	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
DFP	DFP	d100	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
typical	typical	t010204	JJ	I-NP	O
OP	OP	o100	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
CPA	CPA	c100	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
diazepam	diazepam	d020105	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
2PAM	2PAM	2105	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
,	,	,000	,	O	O
delayed	delay	d0403	VBD	B-VP	O
or	or	o600	CC	I-VP	O
shortened	shorten	s0630503	VBD	I-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
poisoning	poisoning	p0205052	NN	B-NP	B-Disease
.	.	.000	.	O	O

Atropine	Atropine	a3601050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
MK801	MK801	0000	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
offer	offer	o106	VB	I-VP	O
any	any	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
CPA	CPA	c100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
2PAM	2PAM	2105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
poisoning	poisoning	p0205052	NN	B-NP	B-Disease
and	and	a530	CC	O	O
thus	thus	t020	RB	B-VP	O
reduced	reduce	r030203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
DFP	DFP	d100	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
pyridoxine	pyridoxine	p060302050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
unmasked	unmasked	u50203	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
girl	girl	g064	NN	I-NP	O
had	have	h030	VBD	B-VP	O
behavioral	behavioral	b010604	JJ	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
hyperkinesis	hyperkinesis	h01062050202	NN	B-NP	B-Disease
,	,	,000	,	O	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
sleeping	sleep	s401052	VBG	B-VP	B-Disease
difficulties	difficulty	d010204302	NNS	B-NP	I-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
isoniazid	isoniazid	i2050203	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
behavior	behavior	b0106	NN	B-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
controlled	control	c05360403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
niacinamide	niacinamide	n020505030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
as	as	a200	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Periodic	Periodic	p060302	JJ	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
return	return	r03065	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hyperkinesis	hyperkinesis	h01062050202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
pyridoxal	pyridoxal	p06030204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
periods	period	p06032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
relapse	relapse	r040120	NN	B-NP	O
.	.	.000	.	O	O

Metabolic	Metabolic	m03010402	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
block	block	b402	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kynurenine	kynurenine	k050605050	NN	I-NP	B-Chemical
pathway	pathway	p030	NN	I-NP	O
of	of	o100	IN	B-PP	O
tryptophan	tryptophan	t60130105	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
six	six	s020	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pyridoxine	pyridoxine	p060302050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
control	control	c053604	VB	I-VP	O
her	her	h060	PRP$	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
excitation	excitation	e2030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

Similar	Similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SE	SE	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
eventual	eventual	e105304	JJ	I-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
mossy	mossy	m020	NN	B-NP	O
fiber	fiber	f0106	NN	I-NP	O
sprouting	sprout	s1603052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
C57BL	C57BL	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
6	6	6000	CD	I-NP	O
and	and	a530	CC	I-NP	O
CD1	CD1	0000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
events	event	e10532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Population	Population	p01040305	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
granule	granule	g605040	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
transverse	transverse	t605210620	JJ	B-NP	O
slices	slice	s40202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
from	from	f605	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADVP	O
treated	treat	t60303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Mg	Mg	m200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
bathing	bathing	b03052	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
bicuculline	bicuculline	b020204050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
conditions	condition	c05303052	NNS	B-NP	O
designed	design	d0202503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
excitability	excitability	e2030104030	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
slices	slice	s40202	NNS	I-NP	O
,	,	,000	,	O	O
electrical	electrical	e402360204	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hilus	hilus	h0402	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
spike	spike	s1020	NN	I-NP	O
in	in	i500	IN	B-PP	O
granule	granule	g605040	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
and	and	a530	CC	I-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
experience	experience	e21060520	VB	I-VP	O
SE	SE	s000	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
survivors	survivor	s06101062	NNS	I-NP	O
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
spike	spike	s1020	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
variable	variable	v060140	JJ	I-NP	O
latency	latency	l030520	NN	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
DC	DC	d200	NN	I-NP	O
shifts	shift	s0132	NNS	I-NP	O
and	and	a530	CC	O	O
repetitive	repetitive	r010303010	JJ	B-NP	O
afterdischarges	afterdischarge	a130630206202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ionotropic	ionotropic	i050360102	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

Focal	Focal	f0204	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
photostimulation	photostimulation	p0302305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
granule	granule	g605040	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
at	at	a300	IN	B-PP	O
sites	site	s0302	NNS	B-NP	O
distant	distant	d023053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
recording	record	r02063052	VBG	I-NP	O
pipette	pipette	p01030	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
population	population	p01040305	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
s	s	s000	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
slices	slice	s40202	NNS	B-NP	O
from	from	f605	IN	B-PP	O
SE	SE	s000	NN	B-NP	B-Disease
survivors	survivor	s06101062	NNS	I-NP	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
other	other	o306	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
SE	SE	s000	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mossy	mossy	m020	NN	I-NP	O
fiber	fiber	f0106	NN	I-NP	O
sprouting	sprout	s1603052	VBG	B-VP	O
and	and	a530	CC	O	O
synaptic	synaptic	s0501302	JJ	B-NP	O
reorganization	reorganization	r06205020305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
relevant	relevant	r0401053	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
murine	murine	m06050	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
,	,	,000	,	O	O
resembling	resemble	r020514052	VBG	B-VP	O
rat	rat	r030	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
:	:	:000	:	O	O
risks	risk	r020	NNS	B-NP	O
and	and	a530	CC	O	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
and	and	a530	CC	I-VP	O
characterise	characterise	c0602306020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
relation	relation	r040305	NN	I-NP	O
to	to	t000	TO	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
based	base	b0203	VBN	B-VP	O
,	,	,000	,	O	O
nationwide	nationwide	n0305030	JJ	B-NP	O
Swedish	Swedish	s03020	NNP	I-NP	O
Inpatient	Inpatient	i5103053	NNP	I-NP	O
Register	Register	r0202306	NNP	I-NP	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
1065	1065	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
1969	1969	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
95	95	0000	CD	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Through	Through	t06020	IN	B-PP	O
linkage	linkage	l052020	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
Swedish	Swedish	s03020	NNP	I-NP	O
Cancer	Cancer	c05206	NNP	I-NP	B-Disease
Register	Register	r0202306	NNP	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
diagnosed	diagnose	d0250203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Nested	Nest	n02303	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
matched	match	m03203	VBN	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
using	use	u2052	VBG	B-VP	O
odds	odd	o320	NNS	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
(	(	(000	(	O	O
ORs	OR	o620	NNS	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
relative	relative	r0403010	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cohort	cohort	c063	NN	I-NP	O
the	the	t000	DT	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
among	among	a5052	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
113	113	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
and	and	a530	CC	O	O
25	25	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
doubled	double	d01403	VBD	B-VP	O
for	for	f060	IN	B-PP	O
every	every	e1060	DT	B-NP	O
10	10	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
increment	increment	i52605053	NN	I-NP	O
in	in	i500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
(	(	(000	(	O	O
CI	CI	c000	NN	B-NP	O
)	)	)000	)	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
duration	duration	d060305	NN	I-NP	O
longer	long	l05206	JJR	B-ADVP	O
than	than	t050	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
eightfold	eightfold	e02031043	RB	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
to	to	t000	TO	B-PP	O
69	69	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
absolute	absolute	a1204030	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cohort	cohort	c063	JJ	I-NP	O
reached	reach	r0203	VBD	B-VP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
16	16	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
(	(	(000	(	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
significantly	significantly	s025010205340	RB	O	O
)	)	)000	)	O	O
twice	twice	t020	RB	B-ADJP	O
as	as	a200	RB	I-ADJP	O
common	common	c0505	JJ	I-ADJP	O
as	as	a200	IN	B-SBAR	O
expected	expect	e2102303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
operating	operate	o10603052	VBG	B-VP	O
even	even	e105	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
Wegener	Wegener	w020506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
granulomatosis	granulomatosis	g6050405030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
by	by	b000	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
alpha2	alpha2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
I1	I1	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
imidazoline	imidazoline	i5030204050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
recently	recently	r0205340	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
negatively	negatively	n020301040	RB	B-ADVP	O
modulates	modulate	m03040302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mixed	mix	m0203	VBN	B-NP	O
alpha2	alpha2	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	B-NP	O
I1	I1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
implicates	implicate	i514020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
autonomic	autonomic	a03050502	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
involves	involve	i5104102	VBZ	B-VP	O
interaction	interaction	i530602305	NN	B-NP	O
with	with	w030	IN	B-PP	O
alpha2	alpha2	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
I1	I1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
rilmenidine	rilmenidine	r0450503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
600	600	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
selective	selective	s04023010	JJ	B-NP	O
I1	I1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
alpha2	alpha2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
hemodynamic	hemodynamic	h0503050502	JJ	B-NP	O
variability	variability	v060104030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
radiotelemetered	radiotelemetere	r03030405030603	VBN	B-NP	O
sham	sham	s050	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
operated	operate	o1060303	VBN	I-VP	O
and	and	a530	CC	I-VP	O
ovariectomized	ovariectomize	o106023050203	VBN	I-VP	O
(	(	(000	(	O	O
Ovx	Ovx	o120	NN	B-NP	O
)	)	)000	)	O	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
wk	wk	w200	NN	I-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
replacement	replacement	r0140205053	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
time	time	t050	NN	I-NP	O
domain	domain	d0505	NN	B-NP	O
indexes	index	i530202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hemodynamic	hemodynamic	h0503050502	JJ	B-NP	O
variability	variability	v060104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
employed	employ	e51403	VBN	I-VP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
deviation	deviation	d010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
deviation	deviation	d010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
beat	beat	b030	NN	B-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
beat	beat	b030	JJ	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
(	(	(000	(	O	O
SDRR	SDRR	s360	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
root	root	r030	NN	I-NP	O
mean	mean	m050	JJ	I-NP	O
square	square	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
successive	successive	s0202010	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
R	R	r000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
wave	wave	w010	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
wave	wave	w010	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
as	as	a200	IN	B-PP	O
measures	measure	m020602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
operated	operate	o1060303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
rilmenidine	rilmenidine	r0450503050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
elicited	elicit	e4020303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
lasted	last	l02303	VBD	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
5	5	5000	CD	I-NP	O
h	h	h000	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
reductions	reduction	r03023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
deviation	deviation	d010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

SDRR	SDRR	s360	NN	B-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
.	.	.000	.	O	O

Ovx	Ovx	o120	NN	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
rilmenidine	rilmenidine	r0450503050	NN	B-NP	B-Chemical
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
alpha	alpha	a410	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyldopa	methyldopa	m03043010	NN	I-NP	I-Chemical
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Ovx	Ovx	o120	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
paralleled	parallel	p06040403	VBN	I-VP	O
with	with	w030	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
SDRR	SDRR	s360	NN	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	B-Disease
reduced	reduce	r030203	VBN	I-NP	I-Disease
locomotor	locomotor	l02050306	NN	I-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Estrogen	Estrogen	e2360205	NN	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
(	(	(000	(	O	O
17beta	17beta	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
pellet	pellet	p0403	NN	I-NP	O
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
Ovx	Ovx	o120	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
and	and	a530	CC	I-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
to	to	t000	TO	B-PP	O
sham	sham	s050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
operated	operate	o1060303	VBN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
downregulates	downregulate	d05602040302	VBZ	B-VP	O
alpha2	alpha2	0000	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
I1	I1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
highlight	highlight	h02040203	VBP	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
autonomic	autonomic	a03050502	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
in	in	i500	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyldopa	methyldopa	m03043010	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
left	left	l013	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
systolic	systolic	s0230402	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
diastolic	diastolic	d0230402	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
accidental	accidental	a20305304	JJ	B-NP	O
iatrogenic	iatrogenic	i036020502	JJ	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Catecholamine	Catecholamine	c03020405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
excess	excess	e202	NN	I-NP	O
of	of	o100	IN	B-PP	O
endogenous	endogenous	e53020502	JJ	B-NP	O
catecholamines	catecholamine	c030204050502	NNS	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
decades	decade	d020302	NNS	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
reports	report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
iatrogenic	iatrogenic	i036020502	JJ	I-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
35	35	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
whose	whose	w020	WP$	B-NP	O
cervix	cervix	c06102	NN	I-NP	O
uteri	uterus	u3060	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
inadvertently	inadvertently	i503106305340	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
stunning	stunning	s305052	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
compromise	compromise	c051605020	NN	I-NP	O
,	,	,000	,	O	O
profound	profound	p601053	NN	B-NP	O
,	,	,000	,	O	O
albeit	albeit	a4103	IN	B-PP	O
transient	transient	t6052053	JJ	B-ADJP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	B-Disease
ventricular	ventricular	v0536020406	JJ	B-NP	I-Disease
systolic	systolic	s0230402	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
diastolic	diastolic	d0230402	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
modestly	modestly	m0302340	RB	I-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
errors	error	e6062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
improved	improve	i5160103	VBN	B-NP	O
medication	medication	m03020305	NN	I-NP	O
labeling	labeling	l0104052	NN	I-NP	O
and	and	a530	CC	I-NP	O
staff	staff	s301	NN	I-NP	O
supervision	supervision	s010610205	NN	I-NP	O
.	.	.000	.	O	O

Cardioprotective	Cardioprotective	c06301603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
tincture	tincture	t0523060	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	I-Chemical
Crataegus	Crataegus	c6030202	NNP	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Tincture	Tincture	t0523060	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	I-Chemical
Crataegus	Crataegus	c6030202	NNP	B-NP	I-Chemical
(	(	(000	(	O	O
TCR	TCR	t260	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
alcoholic	alcoholic	a420402	JJ	I-NP	B-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
of	of	o100	IN	B-PP	I-Chemical
the	the	t000	DT	B-NP	I-Chemical
berries	berry	b0602	NNS	I-NP	I-Chemical
of	of	o100	IN	B-PP	I-Chemical
hawthorn	hawthorn	h03065	NN	B-NP	I-Chemical
(	(	(000	(	O	O
Crataegus	Crataegus	c6030202	NNP	B-NP	B-Chemical
oxycantha	oxycantha	o2020530	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
herbal	herbal	h06104	JJ	B-NP	O
and	and	a530	CC	I-NP	O
homeopathic	homeopathic	h05010302	JJ	I-NP	O
medicine	medicine	m0302050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
TCR	TCR	t260	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
TCR	TCR	t260	NN	B-NP	B-Chemical
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
bodyweight	bodyweight	b030203	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
orally	orally	o6040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
marker	marker	m06206	NN	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
85	85	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

TCR	TCR	t260	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
isoproterenol	isoproterenol	i201603060504	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heart	heart	h063	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
ADP	ADP	a310	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
stimulated	stimulate	s305040303	VBN	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
and	and	a530	CC	O	O
respiratory	respiratory	r0210603060	JJ	B-NP	O
coupling	coupling	c014052	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
.	.	.000	.	O	O

TCR	TCR	t260	NN	B-NP	B-Chemical
protected	protect	p60302303	VBD	B-VP	O
against	against	a20523	IN	B-PP	O
pathological	pathological	p0304020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
TCR	TCR	t260	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
damage	damage	d05020	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
tinnitus	tinnitus	t050302	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
intratympanic	intratympanic	i536030510502	JJ	B-NP	O
instillation	instillation	i523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lignocaine	lignocaine	l02502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
2	2	2000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
through	through	t06020	IN	B-PP	O
ventilation	ventilation	v053040305	NN	B-NP	O
tubes	tube	t0102	NNS	I-NP	O
.	.	.000	.	O	O

Idiopathic	Idiopathic	i3010302	JJ	B-NP	B-Disease
subjective	subjective	s012023010	JJ	I-NP	I-Disease
tinnitus	tinnitus	t050302	NN	I-NP	I-Disease
(	(	(000	(	O	O
IST	IST	i230	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
obscure	obscure	o12060	JJ	I-NP	O
otological	otological	o304020204	JJ	I-NP	O
pathologies	pathology	p03040202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
presents	present	p6020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
IST	IST	i230	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
intratympanic	intratympanic	i536030510502	JJ	B-NP	O
instillation	instillation	i523040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lignocaine	lignocaine	l02502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
2	2	2000	CD	B-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
grommet	grommet	g60503	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
weekly	weekly	w0240	JJ	I-NP	O
courses	course	c06202	NNS	I-NP	O
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
intractable	intractable	i5360230140	JJ	B-NP	O
tinnitus	tinnitus	t050302	NN	I-NP	B-Disease
entered	enter	e530603	VBD	B-VP	O
this	this	t020	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-NP	O
nine	nine	n050	CD	I-NP	O
finished	finish	f050203	VBD	B-VP	O
all	all	a400	DT	B-NP	O
five	five	f010	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
tinnitus	tinnitus	t050302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
almost	almost	a45023	RB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
nine	nine	n050	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
decompensated	decompensate	d020510520303	VBN	I-NP	O
tinnitus	tinnitus	t050302	NN	I-NP	B-Disease
changed	change	c05203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
compensated	compensate	c0510520303	VBN	I-NP	O
one	one	o500	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
this	this	t020	DT	B-NP	O
mode	mode	m030	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
,	,	,000	,	O	O
acupuncture	acupuncture	a2010523060	NN	B-NP	O
and	and	a530	CC	I-NP	O
biofeedback	biofeedback	b0103102	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
disappointing	disappointing	d0201053052	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
warned	warn	w06503	VBN	I-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vertigo	vertigo	v063020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
subsides	subside	s0120302	VBZ	B-VP	O
gradually	gradually	g603040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
every	every	e1060	DT	B-NP	O
new	new	n000	JJ	I-NP	O
instillation	instillation	i523040305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
tinnitus	tinnitus	t050302	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
disappear	disappear	d020106	VB	I-VP	O
but	but	b030	CC	O	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
alleviated	alleviate	a4010303	VBN	I-VP	O
,	,	,000	,	O	O
enabling	enable	e5014052	VBG	B-VP	O
them	them	t050	PRP	B-NP	O
to	to	t000	TO	B-VP	O
cope	cope	c010	VB	I-VP	O
more	more	m060	RBR	B-ADVP	O
easily	easily	e02040	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
and	and	a530	CC	O	O
lead	lead	l030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
normal	normal	n06504	JJ	I-NP	O
life	life	l010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
alpha3	alpha3	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
beta4	beta4	0000	NN	I-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypolocomotion	hypolocomotion	h010402050305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Binding	Binding	b053052	NN	B-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
nAChRs	nAChR	n02062	NNS	B-NP	O
)	)	)000	)	O	O
elicits	elicit	e402032	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
go	go	g000	VBP	B-VP	O
from	from	f605	IN	B-PP	O
altered	alter	a430603	VBN	B-NP	O
exploration	exploration	e214060305	NN	I-NP	O
,	,	,000	,	O	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
tremors	tremor	t605062	NNS	B-NP	B-Disease
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	B-Disease
.	.	.000	.	O	O

nAChRs	nAChR	n02062	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
pentameric	pentameric	p053050602	JJ	B-NP	O
ion	ion	i050	NN	I-NP	O
channels	channel	c05042	NNS	I-NP	O
usually	usually	u2040	RB	B-VP	O
composed	compose	c0510203	VBN	I-VP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	NN	B-NP	O
and	and	a530	CC	O	O
beta	beta	b030	NN	B-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
gene	gene	g050	NN	I-NP	O
cluster	cluster	c402306	NN	I-NP	O
comprises	comprise	c05160202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
alpha3	alpha3	0000	NN	I-NP	O
,	,	,000	,	I-NP	O
alpha5	alpha5	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
beta4	beta4	0000	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
coassemble	coassemble	c0205140	VBP	B-VP	O
to	to	t000	TO	I-VP	O
form	form	f065	VB	I-VP	O
functional	functional	f05230504	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta4	beta4	0000	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypolocomotion	hypolocomotion	h010402050305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
beta4	beta4	0000	NN	B-NP	O
homozygous	homozygous	h05020202	JJ	I-NP	O
null	null	n040	NN	I-NP	O
(	(	(000	(	O	O
beta4	beta4	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
alpha3	alpha3	0000	NN	B-NP	O
heterozygous	heterozygous	h0306020202	JJ	B-ADJP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

beta4	beta4	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
both	both	b030	CC	B-PP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
measured	measure	m020603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
exploration	exploration	e214060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
field	field	f043	NN	I-NP	O
,	,	,000	,	B-PP	O
and	and	a530	CC	I-PP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
measured	measure	m020603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
to	to	t000	TO	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
in	in	i500	FW	B-NP	O
situ	situ	s030	FW	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
probes	probe	p60102	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha3	alpha3	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
alpha5	alpha5	0000	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
alpha5	alpha5	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
alpha3	alpha3	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
selectively	selectively	s0402301040	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mitral	mitral	m03604	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
layer	layer	l060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
olfactory	olfactory	o41023060	JJ	I-NP	O
bulb	bulb	b041	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
inferior	inferior	i510606	JJ	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
superior	superior	s010606	JJ	I-NP	O
colliculus	colliculus	c04020402	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta4	beta4	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
brains	brain	b6052	NNS	B-NP	O
.	.	.000	.	O	O

alpha3	alpha3	0000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	HYPH	B-ADVP	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
partially	partially	p063040	RB	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
littermates	littermate	l030650302	NNS	I-NP	O
.	.	.000	.	O	O

mRNA	mRNA	m650	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
alpha5	alpha5	0000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
beta4	beta4	0000	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
alpha3	alpha3	0000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	HYPH	B-ADVP	O
brains	brain	b6052	NNS	B-NP	O
.	.	.000	.	O	O

Together	Together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
beta4	beta4	0000	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
alpha3	alpha3	0000	NN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
mediators	mediator	m0303062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypolocomotion	hypolocomotion	h010402050305	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
cats	cat	c032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
41	41	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

l	l	l000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
increasing	increase	i52602052	VBG	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
66	66	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

l	l	l000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
tidal	tidal	t0304	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
(	(	(000	(	O	O
61	61	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
8	8	8000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
l	l	l000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
during	during	d06052	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
celling	celling	c04052	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
between	between	b0305	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
became	become	b02050	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
marked	marked	m06203	JJ	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
higher	high	h0206	JJR	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
at	at	a300	IN	B-PP	O
convulsions	convulsion	c051042052	NNS	B-NP	B-Disease
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
enflurane	enflurane	e51406050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
became	become	b02050	VBD	B-VP	O
70	70	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
.	.	.000	.	O	O

Apamin	Apamin	a10505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
channels	channel	c05042	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intracerebroventricularly	intracerebroventricularly	i536020601601053602040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anticonvulsive	anticonvulsive	a5302051042010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Apamin	Apamin	a10505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
tendency	tendency	t0530520	NN	I-NP	O
to	to	t000	TO	B-VP	O
decrease	decrease	d026020	VB	I-VP	O
the	the	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	B-PP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
l	l	l000	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
convulsive	convulsive	c051042010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
but	but	b030	CC	O	O
carries	carry	c0602	VBZ	B-VP	O
some	some	s050	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
circulatory	circulatory	c0620403060	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
based	base	b0203	VBN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
alkylating	alkylate	a420403052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
given	give	g0105	VBN	B-VP	O
frequently	frequently	f60205340	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
many	many	m050	JJ	B-NP	O
conditioning	condition	c0530305052	VBG	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
its	its	i320	PRP$	B-NP	O
nonhematological	nonhematological	n05050304020204	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	B-NP	B-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
combined	combine	c0510503	VBD	B-VP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
melphalan	melphalan	m0410405	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
thiotepa	thiotepa	t03010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
carboplatin	carboplatin	c0610140305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
triple	triple	t60140	JJ	I-NP	O
sequential	sequential	s0205304	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
61	61	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
responsive	responsive	r021052010	JJ	I-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
receiving	receive	r0201052	VBG	B-VP	O
96	96	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
infusional	infusional	i51020504	JJ	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
triple	triple	t60140	JJ	I-NP	O
sequential	sequential	s0205304	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
association	association	a2020305	NN	B-NP	O
between	between	b0305	IN	B-PP	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
peritransplant	peritransplant	p0603605214053	NN	B-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHF	CHF	c010	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
:	:	:000	:	O	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
(	(	(000	(	O	O
EKG	EKG	e200	NN	B-NP	O
)	)	)000	)	O	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
prior	prior	p606	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
smoking	smoking	s502052	NN	B-NP	O
,	,	,000	,	O	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
prior	prior	p606	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
anthracyclines	anthracycline	a5306020240502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
left	left	l013	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
sided	sided	s0303	JJ	I-NP	O
chest	chest	c023	NN	I-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
61	61	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
grade	grade	g6030	NN	I-NP	O
3	3	3000	CD	I-NP	O
CHF	CHF	c010	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
infusional	infusional	i51020504	JJ	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
percent	percent	p062053	NN	I-NP	O
decline	decline	d024050	NN	I-NP	O
in	in	i500	IN	B-PP	O
ejection	ejection	e202305	NN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
previous	previous	p60102	JJ	B-NP	O
recorded	record	r0206303	VBN	I-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Older	Old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
CHF	CHF	c010	NN	I-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
;	;	;000	:	O	O
with	with	w030	IN	B-PP	O
median	median	m0305	JJ	B-NP	O
ages	age	a202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
developing	develop	d010401052	VBG	B-VP	O
CHF	CHF	c010	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
45	45	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
59	59	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
,	,	,000	,	O	O
oncologists	oncologist	o5204020232	NNS	B-NP	O
should	should	s043	MD	B-VP	O
carefully	carefully	c0601040	RB	I-VP	O
monitor	monitor	m050306	VB	I-VP	O
fluid	fluid	f403	NN	B-NP	O
balance	balance	b040520	NN	I-NP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Routine	Routine	r03050	NN	B-NP	O
EKG	EKG	e200	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
infusional	infusional	i51020504	JJ	B-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
predict	predict	p603023	VB	I-VP	O
CHF	CHF	c010	NN	B-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
.	.	.000	.	O	O

Tremor	Tremor	t60506	NN	B-NP	B-Disease
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
quantified	quantify	q0530103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
laser	laser	l0206	NN	I-NP	O
pointer	pointer	p05306	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
an	an	a500	DT	B-NP	O
easily	easily	e02040	RB	I-NP	O
applicable	applicable	a14020140	JJ	I-NP	O
,	,	,000	,	I-NP	O
quick	quick	q020	JJ	I-NP	O
and	and	a530	CC	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
priced	price	p60203	VBN	I-NP	O
method	method	m0303	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
commercially	commercially	c05062040	RB	I-NP	O
available	available	a1040140	JJ	B-ADJP	O
,	,	,000	,	O	O
pen	pen	p050	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
shaped	shape	s0103	VBN	B-NP	O
laser	laser	l0206	NN	I-NP	O
pointer	pointer	p05306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
.	.	.000	.	O	O

Aim	Aim	a050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
,	,	,000	,	O	O
reproducibility	reproducibility	r01603020104030	NN	B-NP	O
,	,	,000	,	O	O
reference	reference	r01060520	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
agreement	agreement	a2605053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Tremor	Tremor	t60506	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
laser	laser	l0206	NN	I-NP	O
pointer	pointer	p05306	NN	I-NP	O
technique	technique	t0205020	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
44	44	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
obstructive	obstructive	o1236023010	JJ	B-NP	B-Disease
lung	lung	l052	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cumulative	cumulative	c050403010	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
salbutamol	salbutamol	s041030504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
asked	ask	a203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
aim	aim	a050	VB	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
centre	centre	c05360	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
,	,	,000	,	O	O
subdivided	subdivide	s013010303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
concentric	concentric	c052053602	JJ	B-NP	O
circles	circle	c062402	NNS	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
5	5	5000	CD	B-NP	O
m	m	m000	NN	I-NP	O
distance	distance	d0230520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
circle	circle	c06240	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
participant	participant	p0630201053	NN	I-NP	O
succeeded	succeed	s020303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
aim	aim	a050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
millimetres	millimetre	m040503602	NNS	B-NP	O
radius	radius	r0302	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
measurements	measurement	m0206050532	NNS	B-NP	O
,	,	,000	,	O	O
reproducibility	reproducibility	r01603020104030	NN	B-NP	O
and	and	a530	CC	I-NP	O
reference	reference	r01060520	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
65	65	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
sessions	session	s02052	NNS	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
9	9	9000	CD	B-NP	O
a	a	a000	DT	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
a	a	a000	DT	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Postural	Postural	p0230604	JJ	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
arm	arm	a650	NN	I-NP	O
horizontally	horizontally	h0602053040	RB	B-ADVP	O
outstretched	outstretche	o0323603203	VBD	B-VP	O
rest	rest	r023	NN	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
arm	arm	a650	NN	I-NP	O
supported	support	s0106303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
armrest	armrest	a656023	NN	I-NP	O
and	and	a530	CC	O	O
finally	finally	f05040	RB	B-ADVP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
holding	hold	h043052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
kg	kg	k200	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
until	until	u5304	IN	B-PP	O
exhaustion	exhaustion	e202305	NN	B-NP	O
.	.	.000	.	O	O

Inter	Inter	i5306	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
observer	observer	o1206106	NN	I-NP	O
variability	variability	v060104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Tremor	Tremor	t60506	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
two	two	t000	CD	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
observers	observer	o12061062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Salbutamol	Salbutamol	s041030504	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
way	way	w000	NN	I-NP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
adults	adult	a30432	NNS	I-NP	O
no	no	n000	DT	B-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependency	dependency	d010530520	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
found	find	f053	VBN	I-VP	O
(	(	(000	(	O	O
b	b	b000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
262	262	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
/	/	/000	SYM	B-NP	O
year	year	y060	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
72	72	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
agreement	agreement	a2605053	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
and	and	a530	CC	I-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
093	093	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
53	53	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Postural	Postural	p0230604	JJ	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
and	and	a530	CC	I-NP	O
third	third	t063	JJ	I-NP	O
session	session	s0205	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
07	07	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Support	Support	s01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arm	arm	a650	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
,	,	,000	,	O	O
exhaustion	exhaustion	e202305	NN	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
good	good	g030	JJ	I-NP	O
agreement	agreement	a2605053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
two	two	t000	CD	B-NP	O
independent	independent	i5301053053	JJ	I-NP	O
observers	observer	o12061062	NNS	I-NP	O
(	(	(000	(	O	O
interclass	interclass	i53062402	NN	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
coefficient	coefficient	c0102053	JJ	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
72	72	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Quantifying	Quantify	q05301052	VBG	B-VP	O
tremor	tremor	t60506	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
inexpensive	inexpensive	i5021052010	JJ	I-NP	O
laser	laser	l0206	NN	I-NP	O
pointer	pointer	p05306	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
exception	exception	e201305	NN	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
12	12	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
reproducible	reproducible	r01603020140	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
multiple	multiple	m0430140	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
occur	occur	o206	VBP	B-VP	O
with	with	w030	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
or	or	o600	CC	I-NP	O
tamoxifen	tamoxifen	t05020105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
Multiple	Multiple	m0430140	JJ	I-NP	O
Outcomes	Outcomes	o0320502	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Raloxifene	Raloxifene	r040201050	NNP	B-NP	B-Chemical
Evaluation	Evaluation	e1040305	NNP	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
enrolled	enrol	e560403	VBD	B-VP	O
7	7	7000	CD	B-NP	O
,	,	,000	,	O	O
705	705	0000	CD	B-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
osteoporosis	osteoporosis	o2301060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Women	Woman	w0505	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
60	60	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
or	or	o600	CC	O	O
120	120	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	B-NP	O
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

Outcomes	Outcome	o0320502	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
,	,	,000	,	O	O
cataracts	cataract	c03060232	NNS	B-NP	B-Disease
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
During	During	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
(	(	(000	(	O	O
relative	relative	r0403010	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
[	[	[000	(	O	O
RR	RR	r600	NN	B-NP	O
]	]	]000	)	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
excess	excess	e202	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	O	O
per	per	p060	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
woman	woman	w0505	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
needed	need	n0303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
1	1	1000	CD	B-NP	O
event	event	e1053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
170	170	0000	CD	B-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
100	100	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
582	582	0000	CD	I-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
raloxifene	raloxifene	r040201050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
about	about	a103	IN	B-NP	O
the	the	t000	DT	I-NP	O
same	same	s050	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
as	as	a200	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
.	.	.000	.	O	O

Raloxifene	Raloxifene	r040201050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
cataracts	cataract	c03060232	NNS	B-NP	B-Disease
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
RR	RR	r600	NN	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Raloxifene	Raloxifene	r040201050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
cataracts	cataract	c03060232	NNS	B-NP	B-Disease
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
hyperplasia	hyperplasia	h010614020	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
endometrial	endometrial	e530503604	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

LEVEL	LEVEL	l0104	NN	B-NP	O
OF	OF	o100	IN	B-PP	O
EVIDENCE	EVIDENCE	e1030520	NN	B-NP	O
:	:	:000	:	O	O
I	I	i000	PRP	B-NP	O

Optimization	Optimization	o1305020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
correct	correct	c06023	JJ	I-NP	O
starting	starting	s3063052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
for	for	f060	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
many	many	m050	JJ	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
started	start	s306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
either	either	e0306	CC	O	O
the	the	t000	DT	B-NP	O
25	25	0000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
or	or	o600	CC	O	O
controlled	control	c05360403	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
release	release	r04020	NN	I-NP	O
formula	formula	f065040	NN	I-NP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
rule	rule	r040	NN	I-NP	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
attempt	attempt	a30513	VB	I-VP	O
to	to	t000	TO	I-VP	O
titrate	titrate	t036030	VB	I-VP	O
carbidopa	carbidopa	c06103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
point	point	p053	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
normality	normality	n06504030	NN	B-NP	O
,	,	,000	,	O	O
"	"	"000	''	O	O
which	which	w020	WDT	B-NP	O
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
physician	physician	p020205	NN	I-NP	O
should	should	s043	MD	B-VP	O
also	also	a420	RB	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
proper	proper	p60106	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
adjunctive	adjunctive	a320523010	JJ	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
;	;	;000	:	O	O
such	such	s020	JJ	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
become	become	b02050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
emerging	emerge	e5062052	VBG	B-VP	O
difficulties	difficulty	d010204302	NNS	B-NP	O
require	require	r02060	VBP	B-VP	O
a	a	a000	DT	B-NP	O
reassessment	reassessment	r02025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
approaches	approach	a160202	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
dosage	dosage	d02020	NN	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
or	or	o600	CC	I-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonist	agonist	a205023	NN	I-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
possible	possible	p020140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
,	,	,000	,	O	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
,	,	,000	,	O	O
sleep	sleep	s401	NN	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
or	or	o600	CC	I-NP	O
parasomnias	parasomnia	p06020502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
drug	drug	d602	NN	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
-	-	-000	:	O	O
-	-	-000	HYPH	B-NP	O
also	also	a420	RB	B-ADVP	O
require	require	r02060	VBP	B-VP	O
carefully	carefully	c0601040	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
individual	individual	i53010304	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Nonpharmacologic	Nonpharmacologic	n05106502040202	JJ	B-NP	O
concerns	concern	c0520652	NNS	I-NP	O
can	can	c050	MD	B-VP	O
help	help	h041	VB	I-VP	O
the	the	t000	DT	B-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
achieve	achieve	a2010	NN	I-NP	O
and	and	a530	CC	O	O
maintain	maintain	m05305	VBP	B-VP	O
optimal	optimal	o130504	JJ	B-NP	O
functioning	functioning	f052305052	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
daily	daily	d040	JJ	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
involvement	involvement	i5104105053	NN	B-NP	O
with	with	w030	IN	B-PP	O
support	support	s01063	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
audiological	audiological	a0304020204	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
thalassemic	thalassemic	t04020502	JJ	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
and	and	a530	CC	O	O
young	young	y052	JJ	B-NP	O
adults	adult	a30432	NNS	I-NP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
thalassemia	thalassemia	t0402050	NN	I-NP	I-Disease
major	major	m0206	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
four	four	f060	CD	I-NP	O
(	(	(000	(	O	O
104	104	0000	CD	B-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
aged	age	a203	VBN	B-ADJP	O
6	6	6000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
35	35	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
17	17	0000	CD	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
participated	participate	p06302010303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
regular	regular	r020406	JJ	I-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
chelation	chelation	c040305	NN	I-NP	O
program	program	p602605	NN	I-NP	O
maintaining	maintain	m05305052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
gr	gr	g600	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DFO	DFO	d100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
chelation	chelation	c040305	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
six	six	s020	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
then	then	t050	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
40	40	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
eight	eight	e0203	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
14	14	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Overall	Overall	o10604	JJ	B-ADVP	O
,	,	,000	,	O	O
21	21	0000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
104	104	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
sensorineural	sensorineural	s05206050604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
(	(	(000	(	O	O
SNHL	SNHL	s504	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
unilateral	unilateral	u504030604	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
bilateral	bilateral	b04030604	JJ	I-ADJP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
ototoxic	ototoxic	o3030202	JJ	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
DFO	DFO	d100	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SNHL	SNHL	s504	NN	B-NP	B-Disease
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
lower	low	l060	JJR	I-NP	O
serum	serum	s0605	NN	I-NP	O
ferritin	ferritin	f060305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
hearing	hearing	h06052	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
with	with	w030	IN	B-PP	O
SNHL	SNHL	s504	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
submitted	submit	s0150303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
DFO	DFO	d100	NN	B-NP	B-Chemical
reduction	reduction	r0302305	NN	I-NP	O
or	or	o600	CC	O	O
temporary	temporary	t05106060	JJ	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
intervention	intervention	i5306105305	NN	B-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
affected	affected	a102303	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
remained	remain	r050503	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
aggravation	aggravation	a26010305	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
DFO	DFO	d100	NNP	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
contributing	contribute	c05360103052	VBG	B-VP	O
role	role	r040	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hear	h06052	VBG	B-VP	B-Disease
impairment	impairment	i51065053	NN	B-NP	I-Disease
.	.	.000	.	O	O

Regular	Regular	r020406	JJ	B-NP	O
audiologic	audiologic	a03040202	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
imperative	imperative	i510603010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
thalassemic	thalassemic	t04020502	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
so	so	s000	IN	B-SBAR	O
that	that	t030	IN	I-SBAR	O
early	early	e0640	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
judiciously	judiciously	j03020240	RB	I-VP	O
adjusted	adjust	a3202303	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
or	or	o600	CC	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
hearing	hear	h06052	VBG	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Individual	Individual	i53010304	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
predict	predict	p603023	VBP	B-VP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
,	,	,000	,	O	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
,	,	,000	,	O	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
ACE	ACE	a200	NN	B-NP	O
(	(	(000	(	O	O
I	I	i000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
D	D	d000	NN	I-NP	O
)	)	)000	)	O	O
genotype	genotype	g0503010	NN	B-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
raises	raise	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
individual	individual	i53010304	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
inflicted	inflict	i51402303	VBN	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Renal	Renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
(	(	(000	(	O	O
Hip	Hip	h010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
His	His	h020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Leu	Leu	l000	NN	I-NP	I-Chemical
cleavage	cleavage	c401020	NN	I-NP	O
by	by	b000	IN	B-PP	O
cortical	cortical	c0630204	JJ	B-NP	O
homogenates	homogenate	h0502050302	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
in	in	i500	IN	B-PP	O
27	27	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
[	[	[000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
18	18	0000	CD	B-NP	O
;	;	;000	:	O	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
saline	saline	s04050	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
9	9	9000	CD	B-NP	O
]	]	]000	)	O	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
harvested	harvest	h06102303	VBN	B-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-SBAR	O
anticipated	anticipate	a5302010303	VBN	B-VP	O
,	,	,000	,	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
elicited	elicit	e4020303	VBD	B-VP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
range	range	r0520	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
interstitial	interstitial	i5306230304	JJ	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
mild	mild	m043	JJ	B-NP	O
focal	focal	f0204	JJ	I-NP	B-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	O
ACE	ACE	a200	NN	I-NP	O
positively	positively	p020301040	RB	B-ADVP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
62	62	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
actin	actin	a2305	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
49	49	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	O
macrophage	macrophage	m02601020	NN	I-NP	O
influx	influx	i51402	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
56	56	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	O
collagen	collagen	c040205	NN	I-NP	O
III	III	i000	CD	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
53	53	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-ADJP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
actin	actin	a2305	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
74	74	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
desmin	desmin	d02505	NN	I-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
48	48	0000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
renal	renal	r0504	JJ	I-NP	O
ACE	ACE	a200	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
22	22	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
NS	NS	n200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
values	value	v0402	NNS	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Individual	Individual	i53010304	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
predict	predict	p603023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
outbred	outbred	o031603	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
strain	strain	s3605	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
assumption	assumption	a2051305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
predispose	predispose	p603021020	VBP	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
less	less	l020	RBR	I-NP	O
favourable	favourable	f01060140	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
azithromycin	azithromycin	a20306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
14	14	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
girl	girl	g064	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
,	,	,000	,	I-NP	O
azithromycin	azithromycin	a20306050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
,	,	,000	,	I-NP	O
acute	acute	a2030	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
although	although	a43020	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-ADJP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
most	most	m023	JJS	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antibiotic	antibiotic	a53010302	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
benign	benign	b05025	JJ	B-ADJP	O
and	and	a530	CC	O	O
self	self	s041	AFX	B-VP	O
-	-	-000	HYPH	I-VP	O
limited	limit	l050303	VBN	I-VP	O
,	,	,000	,	O	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
permanent	permanent	p06505053	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Spironolactone	Spironolactone	s1060504023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
controlled	control	c05360403	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
treatments	treatment	t60350532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
changed	change	c05203	VBN	I-VP	O
since	since	s0520	IN	B-PP	O
the	the	t000	DT	B-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
differ	differ	d0106	VB	I-VP	O
in	in	i500	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
practice	practice	p6023020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
associations	association	a20203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
practice	practice	p6023020	NN	I-NP	O
.	.	.000	.	O	O

Cases	Case	c0202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
(	(	(000	(	O	O
K	K	k000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
)	)	)000	)	O	O
>	>	>000	SYM	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
(	(	(000	(	O	O
Cr	Cr	c600	NN	B-NP	B-Chemical
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
randomly	randomly	r0530540	RB	I-NP	O
selected	select	s0402303	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
per	per	p060	IN	B-PP	O
case	case	c020	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
,	,	,000	,	O	O
medications	medication	m030203052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
serum	serum	s0605	NN	B-NP	O
chemistries	chemistry	c05023602	NNS	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
time	time	t050	NN	B-NP	O
periods	period	p06032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
seven	seven	s0105	CD	I-NP	O
of	of	o100	IN	B-PP	O
926	926	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
required	require	r020603	VBD	B-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
spironolactone	spironolactone	s1060504023050	NN	B-NP	B-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
33	33	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
34	34	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
older	old	o4306	JJR	B-ADJP	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
supplement	supplement	s01405053	NN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
blockers	blocker	b402062	NNS	B-NP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
134	134	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
had	have	h030	VBD	B-VP	O
lower	low	l060	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
required	require	r020603	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
loop	loop	l010	NN	B-NP	O
diuretics	diuretic	d060302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
thiazide	thiazide	t02030	NN	B-NP	B-Chemical
diuretics	diuretic	d060302	NNS	I-NP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Spironolactone	Spironolactone	s1060504023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
reported	report	r0106303	VBN	B-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
explained	explain	e2140503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
comorbidities	comorbidity	c05061030302	NNS	I-NP	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
blockers	blocker	b402062	NNS	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
subchronic	subchronic	s012060502	JJ	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
treatments	treatment	t60350532	NNS	I-NP	O
change	change	c0520	VBP	B-VP	O
synaptosomal	synaptosomal	s05013020504	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
and	and	a530	CC	O	O
elicit	elicit	e40203	VB	B-VP	O
orofacial	orofacial	o6010204	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
orofacial	orofacial	o6010204	JJ	I-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
putative	putative	p0303010	JJ	B-NP	O
animal	animal	a50504	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
tardive	tardive	t063010	NN	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
(	(	(000	(	O	O
TD	TD	t300	NN	B-NP	B-Disease
)	)	)000	)	O	O
whose	whose	w020	WP$	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
induced	induce	i530203	VBD	B-VP	O
orofacial	orofacial	o6010204	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
subchronic	subchronic	s012060502	JJ	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Reserpine	Reserpine	r02061050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
every	every	e1060	DT	B-NP	O
other	other	o306	JJ	I-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
,	,	,000	,	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusion	protrusion	p60360205	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
twitching	twitching	t032052	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
once	once	o520	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
week	week	w020	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
,	,	,000	,	O	O
tongue	tongue	t0520	NN	B-NP	O
protrusion	protrusion	p60360205	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
facial	facial	f0204	JJ	B-NP	O
twitching	twitching	t032052	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
weekly	weekly	w0240	JJ	I-NP	O
evaluations	evaluation	e10403052	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
and	and	a530	CC	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
,	,	,000	,	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
by	by	b000	IN	B-PP	O
segments	segment	s0250532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subcortical	subcortical	s0120630204	JJ	I-NP	O
parts	part	p0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
reserpine	reserpine	r02061050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Importantly	Importantly	i5106305340	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
uptake	uptake	u13020	NN	I-NP	O
correlates	correlate	c06040302	VBZ	B-VP	O
negatively	negatively	n020301040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
orofacial	orofacial	o6010204	JJ	B-NP	B-Disease
diskinesia	diskinesia	d0205020	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
early	early	e0640	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
transport	transport	t60521063	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
vacuous	vacuous	v0202	JJ	B-NP	O
chewing	chewing	c052	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Ceftriaxone	Ceftriaxone	c013602050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
biliary	biliary	b04060	JJ	B-NP	B-Disease
pseudolithiasis	pseudolithiasis	p20304030202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
paediatric	paediatric	p0303602	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
ceftriaxone	ceftriaxone	c013602050	NN	B-NP	B-Chemical
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
situations	situation	s0303052	NNS	B-NP	O
causing	cause	c02052	VBG	B-VP	O
gallbladder	gallbladder	g04140306	NN	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
fasting	fast	f023052	VBG	B-VP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
paediatric	paediatric	p0303602	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
ceftriaxone	ceftriaxone	c013602050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
often	often	o1305	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
to	to	t000	TO	I-VP	O
fast	fast	f023	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
ceftriaxone	ceftriaxone	c013602050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
serial	serial	s0604	JJ	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
sonograms	sonogram	s05026052	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
biliary	biliary	b04060	JJ	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	I-NP	O
starvation	starvation	s30610305	NN	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
resolved	resolve	r0204103	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pseudolithiasis	pseudolithiasis	p20304030202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
fasting	fast	f023052	VBG	B-VP	O
.	.	.000	.	O	O

Coronary	Coronary	c0605060	JJ	B-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
implantation	implantation	i5140530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
eluting	elute	e403052	VBG	B-VP	O
stent	stent	s3053	NN	B-NP	O
.	.	.000	.	O	O

Formation	Formation	f0650305	NN	B-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
stenting	stente	s3053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
bare	bare	b060	JJ	B-NP	O
metal	metal	m0304	NN	I-NP	O
stents	stent	s30532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
eluting	elute	e403052	VBG	I-NP	O
stents	stent	s30532	NNS	I-NP	O
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
toxic	toxic	t0202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vessel	vessel	v0204	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
with	with	w030	IN	B-PP	O
incomplete	incomplete	i520514030	JJ	B-NP	O
stent	stent	s3053	JJ	I-NP	O
apposition	apposition	a1020305	NN	I-NP	O
,	,	,000	,	O	O
aneurysm	aneurysm	a506025	NN	B-NP	B-Disease
formation	formation	f0650305	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
stent	stent	s3053	JJ	B-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
or	or	o600	CC	O	O
vessel	vessel	v0204	NN	B-NP	B-Disease
rupture	rupture	r013060	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
43	43	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
eluting	elute	e403052	VBG	B-VP	O
stent	stent	s3053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
aneurysm	aneurysm	a506025	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
routine	routine	r03050	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Angiography	Angiography	a52026010	NN	B-NP	O
and	and	a530	CC	I-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
lack	lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
contact	contact	c053023	NN	B-NP	O
between	between	b0305	IN	B-PP	O
stent	stent	s3053	NN	B-NP	O
and	and	a530	CC	I-NP	O
vessel	vessel	v0204	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mm	mm	m500	NN	I-NP	O
long	long	l052	JJ	I-NP	O
segment	segment	s025053	NN	I-NP	O
with	with	w030	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
aneurysm	aneurysm	a506025	NN	I-NP	B-Disease
diameter	diameter	d050306	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
successfully	successfully	s02021040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
graft	graft	g6013	NN	I-NP	O
stent	stent	s3053	NN	I-NP	O
.	.	.000	.	O	O

Causes	Cause	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
kidney	kidney	k0350	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
Thrombotic	Thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
problem	problem	p601405	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
postrenal	postrenal	p02360504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
reflection	reflection	r01402305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
and	and	a530	CC	O	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
June	June	j050	NNP	B-NP	O
2003	2003	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
June	June	j050	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
King	King	k052	NNP	I-NP	O
Fahad	Fahad	f030	NNP	I-NP	O
National	National	n030504	NNP	I-NP	O
Guard	Guard	g063	NNP	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
in	in	i500	IN	B-PP	O
Riyadh	Riyadh	r030	NNP	B-NP	O
,	,	,000	,	O	O
Saudi	Saudi	s030	NNP	B-NP	O
Arabia	Arabia	a6010	NNP	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
reviewing	review	r01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
slides	slide	s40302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
)	)	)000	)	O	O
performed	perform	p06106503	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
this	this	t020	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
.	.	.000	.	O	O

Pre	Pre	p600	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
posttransplant	posttransplant	p023605214053	NN	I-NP	O
crossmatching	crossmatching	c6025032052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
possible	possible	p020140	JJ	B-ADJP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Five	Five	f010	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
25	25	0000	CD	I-NP	O
transplantations	transplantation	t60521405303052	NNS	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
King	King	k052	NNP	B-NP	O
Fahad	Fahad	f030	NNP	I-NP	O
National	National	n030504	NNP	I-NP	O
Guard	Guard	g063	NNP	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
2	2	2000	CD	I-NP	O
transplantations	transplantation	t60521405303052	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
abroad	abroad	a1603	RB	B-ADVP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
us	us	u200	PRP	B-NP	O
for	for	f060	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-PRT	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
case	case	c020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
tacrolimus	tacrolimus	t026040502	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fifth	fifth	f0130	JJ	I-NP	O
case	case	c020	NN	I-NP	O
had	have	h030	VBD	B-VP	O
features	feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
antiphospholipid	antiphospholipid	a5301021040103	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	B-Disease
lupus	lupus	l0102	NN	I-NP	I-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	JJS	I-NP	O
-	-	-000	HYPH	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recurrence	recurrence	r02060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
include	include	i524030	VBP	B-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-ADJP	O
(	(	(000	(	O	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
)	)	)000	)	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
procoagulant	procoagulant	p6020204053	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
antibody	antibody	a5301030	NN	B-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
most	most	m023	JJS	I-NP	O
-	-	-000	HYPH	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
drug	drug	d602	NN	B-NP	O
related	relate	r040303	VBN	B-ADJP	O
,	,	,000	,	O	O
secondary	secondary	s02053060	JJ	B-ADJP	O
mainly	mainly	m0540	RB	I-ADJP	O
to	to	t000	TO	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
developmental	developmental	d010401505304	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
selective	selective	s04023010	JJ	B-NP	O
cyclooxygenase	cyclooxygenase	c024020205020	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
CRL	CRL	c640	NN	B-NP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
WI	WI	w000	LS	I-LST	O
)	)	)000	)	O	O
WUBR	WUBR	w016	NNP	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
-	-	-000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
DFU	DFU	d100	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
piroxicam	piroxicam	p06020205	NN	I-NP	B-Chemical
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cyclooxygenase	Cyclooxygenase	c024020205020	NN	B-NP	O
(	(	(000	(	O	O
COX	COX	c020	NN	B-NP	O
)	)	)000	)	O	O
inhibitors	inhibitor	i50103062	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	O	O
most	most	m023	RBS	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
ingested	ingest	i5202303	VBN	B-VP	O
drugs	drug	d602	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Unlike	Unlike	u54020	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
prenatal	prenatal	p6050304	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
extensively	extensively	e2305201040	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
before	before	b01060	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
(	(	(000	(	O	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
selective	selective	s04023010	JJ	B-NP	O
(	(	(000	(	O	O
DFU	DFU	d100	NN	B-NP	B-Chemical
;	;	;000	:	O	O
5	5	5000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dimethyl	dimethyl	d050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorophenyl	fluorophenyl	f406010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylsulphonyl	methylsulphonyl	m030420410504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
phenyl	phenyl	p0504	NN	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
(	(	(000	(	O	I-Chemical
5H	5H	5000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
furanon	furanon	f060505	NN	I-NP	I-Chemical
)	)	)000	)	O	O
COX	COX	c020	NN	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Drugs	Drug	d602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
separately	separately	s010603040	RB	B-ADVP	O
,	,	,000	,	O	O
orally	orally	o6040	RB	B-ADVP	O
once	once	o520	RB	I-ADVP	O
daily	daily	d040	RB	B-ADVP	O
dosed	dose	d0203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
8	8	8000	CD	I-NP	O
to	to	t000	TO	I-NP	O
21	21	0000	CD	I-NP	O
(	(	(000	(	O	O
GD1	GD1	0000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
plug	plug	p402	NN	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Doses	Dose	d0202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
set	set	s030	VBN	I-VP	O
at	at	a300	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	O	O
0mg	0mg	0520	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O
0mg	0mg	0520	CD	B-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
for	for	f060	IN	B-PP	O
DFU	DFU	d100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fetuses	Fetus	f030202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
delivered	deliver	d04010603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
GD	GD	g300	NN	B-NP	O
21	21	0000	CD	I-NP	O
and	and	a530	CC	O	O
routinely	routinely	r0305040	RB	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

Comprehensive	Comprehensive	c0516052010	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
developmental	developmental	d010401505304	JJ	I-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pooled	pooled	p0403	JJ	I-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
(	(	(000	(	O	I-Disease
VSD	VSD	v230	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
midline	midline	m034050	NN	B-NP	I-Disease
(	(	(000	(	O	I-Disease
MD	MD	m300	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
defects	defect	d010232	NNS	B-NP	I-Disease
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
selective	selective	s04023010	JJ	B-ADJP	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
selective	selective	s04023010	JJ	B-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
present	present	p602053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
historic	historic	h0230602	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Maternal	Maternal	m0306504	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
intrauterine	intrauterine	i5360306050	JJ	B-NP	B-Disease
growth	growth	g6030	NN	I-NP	I-Disease
retardation	retardation	r030630305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
increase	increase	i526020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
external	external	e2306504	JJ	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
skeletal	skeletal	s2040304	JJ	I-NP	I-Disease
variations	variation	v0603052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Decrease	Decrease	d026020	NN	B-NP	O
of	of	o100	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
length	length	l05230	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
DFU	DFU	d100	NN	I-NP	B-Chemical
developmental	developmental	d010401505304	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pups	pup	p012	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
compound	compound	c051053	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Lack	Lack	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
teratogenicity	teratogenicity	t0603020502030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
DFU	DFU	d100	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
COX	COX	c020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
VSD	VSD	v230	NN	B-NP	O
and	and	a530	CC	I-NP	O
MD	MD	m300	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
historic	historic	h0230602	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
selective	selective	s04023010	JJ	B-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Both	Both	b030	CC	O	O
selective	selective	s04023010	JJ	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
selective	selective	s04023010	JJ	B-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
toxic	toxic	t0202	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Unlike	Unlike	u54020	IN	B-PP	O
DFU	DFU	d100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
piroxicam	piroxicam	p06020205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
highly	highly	h02040	RB	B-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
dams	dam	d052	NNS	I-NP	O
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
COX	COX	c020	NN	I-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
midline	midline	m034050	NN	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
selective	selective	s04023010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
historic	historic	h0230602	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Lone	Lone	l050	NN	B-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
monohydrate	monohydrate	m05036030	NN	I-NP	O
supplementation	supplementation	s014050530305	NN	I-NP	O
.	.	.000	.	O	O

Atrial	Atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
reversible	reversible	r010620140	JJ	B-NP	O
causes	cause	c0202	NNS	I-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
and	and	a530	CC	O	O
resolved	resolve	r0204103	VBN	B-VP	O
.	.	.000	.	O	O

Thyroid	Thyroid	t0603	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
illicit	illicit	i40203	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
or	or	o600	CC	I-NP	O
stimulant	stimulant	s30504053	NN	I-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
alcohol	alcohol	a4204	NN	I-NP	I-Disease
intoxication	intoxication	i5302020305	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
among	among	a5052	IN	B-PP	O
these	these	t020	DT	B-NP	O
causes	cause	c0202	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
came	come	c050	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
in	in	i500	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unremarkable	unremarkable	u56050620140	JJ	B-ADJP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
minor	minor	m0506	JJ	B-NP	O
fractures	fracture	f60230602	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
fingers	finger	f052062	NNS	I-NP	O
and	and	a530	CC	I-NP	O
foot	foot	f030	NN	I-NP	O
.	.	.000	.	O	O

Thyroid	Thyroid	t0603	NN	B-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
,	,	,000	,	O	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
limits	limit	l05032	NNS	I-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
drug	drug	d602	NN	I-NP	O
screen	screen	s2605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
denied	deny	d0503	VBN	I-VP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
questioned	question	q0230503	VBN	I-VP	O
about	about	a103	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
herbal	herbal	h06104	JJ	B-NP	O
products	product	p6030232	NNS	I-NP	O
and	and	a530	CC	I-NP	O
supplements	supplement	s014050532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
monohydrate	monohydrate	m05036030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
,	,	,000	,	O	O
anticoagulated	anticoagulate	a530202040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
unfractionated	unfractionated	u516023050303	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
given	give	g0105	VBN	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
rate	rate	r030	NN	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
rate	rate	r030	NN	B-NP	O
and	and	a530	CC	I-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
discharged	discharge	d0206203	VBN	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspirin	aspirin	a210605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
plans	plan	p4052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
echocardiography	echocardiography	e202063026010	NN	B-NP	O
and	and	a530	CC	O	O
nuclear	nuclear	n02406	JJ	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
perfusion	perfusion	p0610205	NN	B-NP	O
.	.	.000	.	O	O

Exogenous	Exogenous	e2020502	JJ	B-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
athletes	athlete	a3040302	NNS	B-NP	O
to	to	t000	TO	B-VP	O
theoretically	theoretically	t060302040	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
exercise	exercise	e2062020	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
.	.	.000	.	O	O

Vegetarians	Vegetarian	v020306052	NNS	B-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
take	take	t020	VB	I-VP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
replace	replace	r014020	VB	I-VP	O
what	what	w030	WP	B-NP	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
consuming	consume	c05205052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
meat	meat	m030	NN	B-NP	O
,	,	,000	,	O	O
fish	fish	f020	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
animal	animal	a50504	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
anecdotal	anecdotal	a50230304	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
linked	link	l05203	VBN	I-VP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
diligent	diligent	d0402053	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
interviewing	interview	i53061052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
about	about	a103	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
histories	history	h0230602	NNS	I-NP	O
and	and	a530	CC	O	O
include	include	i524030	VBP	B-VP	O
questions	question	q023052	NNS	B-NP	O
about	about	a103	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
herbal	herbal	h06104	JJ	B-NP	O
products	product	p6030232	NNS	I-NP	O
and	and	a530	CC	O	O
dietary	dietary	d03060	JJ	B-NP	O
supplements	supplement	s014050532	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
frequently	frequently	f60205340	RB	B-NP	O
consumed	consume	c0520503	VBN	I-NP	O
supplements	supplement	s014050532	NNS	I-NP	O
and	and	a530	CC	O	O
herbal	herbal	h06104	JJ	B-NP	O
products	product	p6030232	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Food	Food	f030	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	O	O
life	life	l010	NN	B-NP	O
(	(	(000	(	O	O
t1	t1	0000	NN	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
relatively	relatively	r040301040	RB	B-ADJP	O
short	short	s063	JJ	I-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	I-NP	O
strokes	stroke	s360202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
hours	hour	h062	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
led	lead	l030	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
hypothesize	hypothesize	h010302020	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
benzoylecgonine	benzoylecgonine	b052040205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
BE	BE	b000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
equimolar	equimolar	e2050406	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
BE	BE	b000	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
ventricularly	ventricularly	v053602040640	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
unanesthetized	unanesthetized	u505023030203	JJ	B-NP	O
juvenile	juvenile	j0105040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Treated	Treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
incidence	incidence	i52030520	NN	B-NP	O
,	,	,000	,	O	O
latency	latency	l030520	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
pattern	pattern	p03065	NN	I-NP	O
or	or	o600	CC	B-PP	O
for	for	f060	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

BE	BE	b000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
Induced	Induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
longer	long	l05206	JJR	I-NP	O
latencies	latency	l0305202	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
equimolar	equimolar	e2050406	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
best	well	b023	RBS	I-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
brief	brief	b601	NN	B-NP	O
,	,	,000	,	O	O
generalized	generalize	g0506040203	VBN	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
tonic	tonic	t0502	JJ	B-ADJP	O
and	and	a530	CC	O	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
,	,	,000	,	O	O
those	those	t020	DT	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
BE	BE	b000	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
prolonged	prolonged	p60405203	JJ	B-ADJP	O
,	,	,000	,	O	O
often	often	o1305	RB	B-ADVP	O
multiple	multiple	m0430140	JJ	B-ADJP	O
and	and	a530	CC	O	O
mixed	mixed	m0203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
type	type	t010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
rarely	rarely	r06040	RB	B-VP	O
resulted	result	r0204303	VBD	I-VP	O
in	in	i500	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Electrical	Electrical	e402360204	JJ	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rhythmic	rhythmic	r030502	JJ	I-NP	O
progression	progression	p60260205	NN	I-NP	O
in	in	i500	IN	B-PP	O
EEG	EEG	e020	NN	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
voltage	voltage	v043020	NN	I-NP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

BE	BE	b000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
Injected	Inject	i5202303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
more	more	m060	RBR	I-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
than	than	t050	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
BE	BE	b000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
differ	differ	d0106	VBP	B-VP	O
in	in	i500	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
respects	respect	r0210232	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
,	,	,000	,	O	O
BE	BE	b000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
HT6	HT6	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
Ro4368554	Ro4368554	0000	NN	I-NP	B-Chemical
restores	restore	r0230602	VBZ	B-VP	O
memory	memory	m05060	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
in	in	i500	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	B-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Antagonists	Antagonist	a5302050232	NNS	B-NP	O
at	at	a300	IN	B-PP	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
type	type	t010	NN	I-NP	O
6	6	6000	CD	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
show	show	s000	VBP	B-VP	O
activity	activity	a2301030	NN	B-NP	O
in	in	i500	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
(	(	(000	(	I-NP	O
s	s	s000	NNS	I-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
well	well	w040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
involve	involve	i510410	VB	I-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACh	ACh	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
sought	seek	s0203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
characterize	characterize	c0602306020	VB	I-VP	O
the	the	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
enhancing	enhance	e5052052	VBG	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
Ro4368554	Ro4368554	0000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
benzenesulfonyl	benzenesulfonyl	b05205020410504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
piperazin	piperazin	p01060205	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
yl	yl	y400	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
1H	1H	1000	NN	B-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
indole	indole	i53040	NN	B-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
object	object	o12023	NN	I-NP	O
recognition	recognition	r020250305	NN	I-NP	O
task	task	t020	NN	I-NP	O
employing	employ	e514052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
(	(	(000	(	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
(	(	(000	(	O	O
tryptophan	tryptophan	t60130105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TRP	TRP	t610	NN	B-NP	B-Chemical
)	)	)000	)	O	O
depletion	depletion	d0140305	NN	B-NP	O
)	)	)000	)	O	O
deficient	deficient	d0102053	JJ	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBD	B-VP	O
its	its	i320	PRP$	B-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
metrifonate	metrifonate	m0360105030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
forgetting	forget	f06203052	VBG	I-NP	O
task	task	t020	NN	I-NP	O
employing	employ	e514052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
delay	delay	d040	NN	I-NP	O
between	between	b0305	IN	B-PP	O
training	training	t605052	NN	B-NP	O
and	and	a530	CC	I-NP	O
testing	testing	t023052	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
metrifonate	metrifonate	m0360105030	NN	B-NP	B-Chemical
improved	improve	i5160103	VBD	B-VP	O
object	object	o12023	NN	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
(	(	(000	(	O	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
Ro4368554	Ro4368554	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
inactive	inactive	i5023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
,	,	,000	,	O	O
Ro4368554	Ro4368554	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
metrifonate	metrifonate	m0360105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
reversed	reverse	r0106203	VBD	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
TRP	TRP	t610	NN	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
p	p	p000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
Ro4368554	Ro4368554	0000	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
a	a	a000	DT	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
retention	retention	r0305305	NN	I-NP	O
deficit	deficit	d010203	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
serotonergic	serotonergic	s06030506202	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
facilitation	facilitation	f0204030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
object	object	o12023	NN	B-NP	O
memory	memory	m05060	NN	I-NP	O
by	by	b000	IN	B-PP	O
Ro4368554	Ro4368554	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT	HT	h300	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anticocaine	anticocaine	a530202050	NN	I-NP	O
monoclonal	monoclonal	m050240504	JJ	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
GNC92H2	GNC92H2	0000	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
immunotherapy	immunotherapy	i5050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
overdose	overdose	o1063020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
illicit	illicit	i40203	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
continues	continue	c0530502	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
epidemic	epidemic	e1030502	JJ	B-NP	O
proportions	proportion	p601063052	NNS	I-NP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
overdose	overdose	o1063020	NN	I-NP	I-Disease
remains	remain	r05052	VBZ	B-VP	O
elusive	elusive	e402010	JJ	B-ADJP	O
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
technology	technology	t020504020	NN	I-NP	O
offers	offer	o1062	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
venue	venue	v050	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
antibodies	antibody	a53010302	NNS	B-NP	O
bind	bind	b053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
stream	stream	s3605	NN	I-NP	O
,	,	,000	,	O	O
inactivating	inactivate	i50230103052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anticocaine	anticocaine	a530202050	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
GNC92H2	GNC92H2	0000	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
overdose	overdose	o1063020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Swiss	Swiss	s020	JJ	B-NP	O
albino	albino	a41050	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
prepared	prepare	p6010603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intrajugular	intrajugular	i53602020406	JJ	B-NP	O
catheters	catheter	c0303062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
photocell	photocell	p030204	NN	B-NP	O
cages	cage	c0202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
93	93	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
(	(	(000	(	O	O
LD50	LD50	0000	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
GNC92H2	GNC92H2	0000	NN	I-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
30	30	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
190	190	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

GNC92H2	GNC92H2	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
delivered	deliver	d04010603	VBN	I-VP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-ADVP	O
,	,	,000	,	O	O
concomitantly	concomitantly	c052050305340	RB	B-ADVP	O
or	or	o600	CC	O	O
3	3	3000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
GNC92H2	GNC92H2	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
190	190	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
premorbid	premorbid	p60506103	JJ	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
seizures	seizure	s020602	VBZ	B-VP	B-Disease
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
77	77	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
death	death	d030	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
72	72	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Importantly	Importantly	i5106305340	RB	B-ADVP	O
,	,	,000	,	O	O
GNC92H2	GNC92H2	0000	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
death	death	d030	NN	B-NP	B-Disease
even	even	e105	RB	B-ADVP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
GNC92H2	GNC92H2	0000	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
against	against	a20523	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
overdose	overdose	o1063020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Electrocardiographic	Electrocardiographic	e40236020630260102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
psychiatrically	psychiatrically	p20203602040	RB	B-NP	O
hospitalized	hospitalize	h02103040203	VBN	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
abusers	abuser	a102062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	I-NP	O
(	(	(000	(	O	O
ECG	ECG	e200	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
99	99	0000	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
abusing	abuse	a102052	VBG	B-VP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
ECGs	ECG	e200	NNS	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
abusers	abuser	a102062	NNS	I-NP	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
ECG	ECG	e200	NN	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
,	,	,000	,	O	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
bundle	bundle	b05340	NN	B-NP	B-Disease
branch	branch	b60520	NN	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
urotensin	urotensin	u60305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
centrally	centrally	c0536040	RB	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Urotensin	Urotensin	u60305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
II	II	i000	CD	O	I-Chemical
)	)	)000	)	O	O
receptors	receptor	r02013062	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
distributed	distribute	d0236010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Intracerebroventricular	Intracerebroventricular	i5360206016010536020406	JJ	O	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
causes	cause	c0202	NNS	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
stimulates	stimulate	s305040302	VBZ	B-VP	O
prolactin	prolactin	p60402305	NN	B-NP	O
and	and	a530	CC	I-NP	O
thyrotropin	thyrotropin	t060360105	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
centrally	centrally	c0536040	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
U	U	u000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
received	receive	r020103	VBN	I-VP	O
little	little	l0340	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
tested	test	t02303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
,	,	,000	,	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
endocrine	endocrine	e53026050	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
graded	grade	g60303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
II	II	i000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
)	)	)000	)	O	O
provoked	provoke	p6010203	VBD	B-VP	O
:	:	:000	:	O	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
head	head	h030	NN	B-NP	O
dips	dip	d012	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hole	hole	h040	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
board	board	b063	NN	I-NP	O
test	test	t023	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
entries	entry	e53602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
white	white	w030	JJ	I-NP	O
chamber	chamber	c05106	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
black	black	b402	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
white	white	w030	JJ	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
entries	entry	e53602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
platform	platform	p4031065	NN	I-NP	O
and	and	a530	CC	O	O
open	open	o105	JJ	B-NP	O
arms	arm	a652	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plus	plus	p402	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
maze	maze	m020	NN	I-NP	O
test	test	t023	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
immobility	immobility	i50104030	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forced	force	f06203	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
swimming	swim	s05052	VBG	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	I-NP	O
tail	tail	t040	NN	I-NP	O
suspension	suspension	s02105205	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Intracerebroventricular	Intracerebroventricular	i5360206016010536020406	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
II	II	i000	CD	B-NP	I-Chemical
also	also	a420	RB	B-ADVP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
:	:	:000	SYM	B-NP	O
food	food	f030	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	O	O
mouse	mouse	m020	NN	B-NP	O
,	,	,000	,	O	O
water	water	w0306	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
horizontal	horizontal	h060205304	JJ	B-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
.	.	.000	.	O	O

Whatever	Whatever	w030106	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
II	II	i000	CD	B-NP	I-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
body	body	b030	NN	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
,	,	,000	,	O	O
nociception	nociception	n020201305	NN	B-NP	O
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
penile	penile	p05040	JJ	I-NP	B-Disease
erection	erection	e602305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
climbing	climb	c4051052	VBG	B-VP	O
behavior	behavior	b0106	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
stress	stress	s3602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Taken	Take	t0205	VBN	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
II	II	i000	CD	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mouse	mouse	m020	NN	I-NP	O
induces	induce	i530202	VBZ	B-VP	O
anxiogenic	anxiogenic	a52020502	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
depressant	depressant	d01602053	NN	I-NP	O
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
U	U	u000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
II	II	i000	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
aspects	aspect	a210232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Learning	Learning	l065052	NN	B-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
under	under	u5306	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Dissociated	Dissociate	d02020303	VBN	B-NP	O
learning	learning	l065052	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
state	state	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
ip	ip	i100	JJ	B-ADJP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
approach	approach	a16020	VB	I-VP	O
a	a	a000	DT	B-NP	O
shelf	shelf	s041	NN	I-NP	O
where	where	w060	WRB	B-ADVP	O
they	they	t000	PRP	B-NP	O
received	receive	r020103	VBD	B-VP	O
food	food	f030	NN	B-NP	O
reinforcement	reinforcement	r05106205053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
1	1	1000	CD	I-NP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
run	run	r050	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
shelf	shelf	s041	NN	I-NP	O
as	as	a200	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
2	2	2000	CD	I-NP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
approach	approach	a16020	VB	I-VP	O
different	different	d0106053	JJ	B-NP	O
shelves	shelf	s04102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
memory	memory	m05060	NN	B-NP	B-Disease
dissociation	dissociation	d02020305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Differences	Difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
training	training	t605052	NN	B-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
between	between	b0305	IN	B-PP	O
Groups	Group	g6012	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
-	-	-000	HYPH	O	O
dissociated	dissociate	d02020303	VBN	B-NP	O
state	state	s3030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentobarbital	pentobarbital	p053010610304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
formed	form	f06503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
participation	participation	p06302010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
information	information	i510650305	NN	B-NP	O
perception	perception	p06201305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
raloxifene	raloxifene	r040201050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
on	on	o500	IN	B-PP	O
fibrinolysis	fibrinolysis	f01605040202	NN	B-NP	O
markers	marker	m062062	NNS	I-NP	O
:	:	:000	:	O	O
TAFI	TAFI	t010	NN	B-NP	O
,	,	,000	,	O	O
tPA	tPA	t100	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PAI	PAI	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Markers	Marker	m062062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
fibrinolysis	fibrinolysis	f01605040202	NN	B-NP	O
,	,	,000	,	O	O
thrombin	thrombin	t0605105	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
activatable	activatable	a2301030140	JJ	I-NP	O
fibrinolysis	fibrinolysis	f01605040202	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
TAFI	TAFI	t010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
tissue	tissue	t020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
plasminogen	plasminogen	p4025050205	NN	I-NP	O
activator	activator	a23010306	NN	I-NP	O
(	(	(000	(	O	O
tPA	tPA	t100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
plasminogen	plasminogen	p4025050205	NN	B-NP	O
activator	activator	a23010306	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
PAI	PAI	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
short	short	s063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
osteopenia	osteopenia	o2301050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
osteoporosis	osteoporosis	o2301060202	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
controlled	controlled	c05360403	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
plus	plus	p402	CC	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
matched	match	m03203	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
14	14	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
only	only	o540	RB	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
TAFI	TAFI	t010	NN	I-NP	O
,	,	,000	,	O	O
tPA	tPA	t100	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PAI	PAI	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
by	by	b000	IN	B-PP	O
commercially	commercially	c05062040	RB	B-NP	O
available	available	a1040140	JJ	I-NP	O
ELISA	ELISA	e4020	NN	I-NP	O
kits	kit	k032	NNS	I-NP	O
.	.	.000	.	O	O

Variations	Variation	v0603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Wilcoxon	Wilcoxon	w0420205	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Relationship	Relationship	r040305201	NN	B-NP	O
between	between	b0305	IN	B-PP	O
those	those	t020	DT	B-NP	O
markers	marker	m062062	NNS	I-NP	O
and	and	a530	CC	O	O
demographic	demographic	d050260102	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Three	Three	t060	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
TAFI	TAFI	t010	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
change	change	c0520	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
tPA	tPA	t100	NN	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
change	change	c0520	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
TAFI	TAFI	t010	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amenorrhea	amenorrhea	a505060	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
;	;	;000	:	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
33	33	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
thromboembolism	thromboembolism	t0605105104025	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
raloxifene	raloxifene	r040201050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
tPA	tPA	t100	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
TAFI	TAFI	t010	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Valproate	Valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
manifest	manifest	m0501023	VB	I-VP	O
in	in	i500	IN	B-PP	O
otherwise	otherwise	o306020	RB	B-NP	O
normal	normal	n06504	JJ	I-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
individuals	individual	i530103042	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
even	even	e105	RB	B-ADJP	O
present	present	p602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
this	this	t020	DT	B-NP	O
medicine	medicine	m0302050	NN	I-NP	O
well	well	w040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	I-VP	O
but	but	b030	CC	I-VP	O
not	not	n030	RB	I-VP	O
necessarily	necessarily	n020206040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
EEG	EEG	e020	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
triphasic	triphasic	t6010202	JJ	I-NP	O
waves	wave	w0102	NNS	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diagnosing	diagnose	d02502052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
dysphonia	dysphonia	d021050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
acitretin	acitretin	a20360305	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
complaining	complain	c051405052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
dysphonia	dysphonia	d021050	NN	B-NP	B-Disease
while	while	w040	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
acitretin	acitretin	a20360305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
totally	totally	t03040	RB	B-VP	O
regressed	regress	r0260203	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
and	and	a530	CC	O	O
reappeared	reappear	r010603	VBD	B-VP	O
when	when	w050	WRB	B-ADVP	O
acitretin	acitretin	a20360305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reintroduced	reintroduce	r0536030203	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acitretin	acitretin	a20360305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dysphonia	dysphonia	d021050	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
on	on	o500	IN	B-PP	O
mucous	mucous	m0202	JJ	B-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
.	.	.000	.	O	O

Nitro	Nitro	n0360	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
protector	protector	p60302306	NN	I-NP	O
against	against	a20523	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
inhibitor	inhibitor	i5010306	NN	B-NP	O
nitro	nitro	n0360	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
arginine	arginine	a6205050	NN	I-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
act	act	a230	VB	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
otoprotectant	otoprotectant	o301603023053	NN	I-NP	O
against	against	a20523	IN	B-PP	O
high	high	h020	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
frequency	frequency	f6020520	NN	I-NP	I-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
further	further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
confirm	confirm	c051065	VB	I-VP	O
this	this	t020	DT	B-NP	O
.	.	.000	.	I-NP	O
Aminoglycoside	Aminoglycoside	a5050240202030	NNP	I-NP	B-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
still	still	s304	RB	I-VP	O
widely	widely	w03040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
virtue	virtue	v0630	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
low	low	l000	JJ	I-NP	O
cost	cost	c023	NN	I-NP	O
.	.	.000	.	O	O

Their	Their	t060	PRP$	B-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
health	health	h0430	NN	I-NP	O
problem	problem	p601405	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
ototoxic	ototoxic	o3030202	JJ	I-NP	B-Disease
mechanism	mechanism	m0205025	NN	I-NP	O
involves	involve	i5104102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
need	need	n030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
inhibitors	inhibitor	i50103062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sensorineural	sensorineural	s05206050604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
we	we	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
30	30	0000	CD	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
27	27	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
instilled	instill	i5230403	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
middle	middle	m0340	JJ	I-NP	O
ear	ear	e060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
otoprotectant	otoprotectant	o301603023053	JJ	I-NP	O
L	L	l000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
topically	topically	t0102040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
12	12	0000	CD	B-NP	O
/	/	/000	SYM	O	O
27	27	0000	CD	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
attenuation	attenuation	a3050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
shifts	shift	s0132	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
NAME	NAME	n050	NN	B-NP	I-Chemical
reduced	reduce	r030203	VBD	B-VP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
gave	give	g010	VBD	B-VP	O
no	no	n000	DT	B-NP	O
protection	protection	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
middle	middle	m0340	JJ	I-NP	O
or	or	o600	CC	I-NP	O
low	low	l000	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
lozenge	lozenge	l020520	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
gum	gum	g050	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
medical	medical	m030204	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
polacrilex	polacrilex	p040260402	NN	I-NP	O
lozenges	lozenge	l0205202	VBZ	B-VP	O
deliver	deliver	d040106	VB	I-VP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
27	27	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
more	more	m060	JJR	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
equivalent	equivalent	e20104053	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
polacrilex	polacrilex	p040260402	NN	I-NP	O
gum	gum	g050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
raised	raise	r0203	VBN	I-VP	O
questions	question	q023052	NNS	B-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
gum	gum	g050	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
gum	gum	g050	NN	I-NP	O
in	in	i500	IN	B-PP	O
smokers	smoker	s502062	NNS	B-NP	O
with	with	w030	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
label	label	l0104	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
restricted	restrict	r023602303	VBN	I-NP	O
diseases	disease	d020202	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
not	not	n030	RB	B-VP	O
controlled	control	c05360403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
:	:	:000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
ratio	ratio	r030	NN	I-NP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
the	the	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
lozenge	lozenge	l020520	NN	I-NP	O
or	or	o600	CC	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
gum	gum	g050	NN	I-NP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
product	product	p603023	NN	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Nine	Nine	n050	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
one	one	o500	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
447	447	0000	CD	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	O	O
454	454	0000	CD	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
gum	gum	g050	NN	I-NP	O
(	(	(000	(	O	O
safety	safety	s01030	NN	B-NP	O
population	population	p01040305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
women	woman	w0505	NNS	B-NP	O
(	(	(000	(	O	O
52	52	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
53	53	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
mean	mean	m050	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
193	193	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
pounds	pound	p0532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
they	they	t000	PRP	B-NP	O
smoked	smoke	s50203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
cigarettes	cigarette	c02060302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
fifty	fifty	f0130	CD	I-NP	O
-	-	-000	HYPH	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
264	264	0000	CD	B-NP	O
taking	take	t02052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	O	O
289	289	0000	CD	B-NP	O
taking	take	t02052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
gum	gum	g050	NN	I-NP	O
,	,	,000	,	O	O
used	use	u203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
product	product	p603023	NN	I-NP	O
for	for	f060	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
per	per	p060	IN	B-PP	O
week	week	w020	NN	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
evaluable	evaluable	e1040140	JJ	B-NP	O
population	population	p01040305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
gum	gum	g050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
equally	equally	e2040	RB	I-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
product	product	p603023	NN	B-NP	O
use	use	u200	NN	I-NP	O
(	(	(000	(	O	O
evaluation	evaluation	e1040305	NN	B-NP	O
population	population	p01040305	NN	I-NP	O
:	:	:000	:	O	O
55	55	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
,	,	,000	,	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
gum	gum	g050	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
safety	safety	s01030	NN	B-NP	O
population	population	p01040305	NN	I-NP	O
:	:	:000	:	O	O
63	63	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Stratification	Stratification	s360301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
by	by	b000	IN	B-PP	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
extent	extent	e23053	NN	B-NP	O
of	of	o100	IN	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
,	,	,000	,	O	O
extent	extent	e23053	NN	B-NP	O
of	of	o100	IN	B-PP	O
product	product	p603023	NN	B-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
severity	severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
gum	gum	g050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hiccups	hiccup	h02012	NNS	B-NP	B-Disease
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
Cl	Cl	c400	NN	I-NP	O
,	,	,000	,	O	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Serious	Serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
respective	respective	r021023010	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Fewer	Few	f060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
group	group	g601	NN	I-NP	O
were	be	w060	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
investigator	investigator	i51023020306	NN	I-NP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
worsening	worsening	w06205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
overall	overall	o10604	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
condition	condition	c0530305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
experienced	experience	e210605203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
disease	disease	d02020	NN	I-NP	O
status	status	s30302	NN	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
4	4	4000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
lozenge	lozenge	l020520	NN	I-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
gum	gum	g050	NN	I-NP	O
had	have	h030	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-NP	O
safety	safety	s01030	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
label	label	l0104	NN	B-NP	O
-	-	-000	HYPH	O	O
restricted	restrict	r023602303	VBN	B-NP	O
medical	medical	m030204	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Pharmacological	Pharmacological	p0650204020204	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
brain	brain	b605	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Abnormal	Abnormal	a1506504	JJ	B-NP	O
processing	processing	p60202052	NN	I-NP	O
of	of	o100	IN	B-PP	O
somatosensory	somatosensory	s050302052060	JJ	B-NP	O
inputs	input	i51032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
(	(	(000	(	O	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
accounting	account	a2053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
surrounding	surround	s06053052	VBG	B-VP	O
tissue	tissue	t020	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
secondary	secondary	s02053060	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Secondary	Secondary	s02053060	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
shares	share	s0602	VBZ	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
neurogenic	neurogenic	n06020502	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Abnormal	Abnormal	a1506504	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
somatosensory	somatosensory	s050302052060	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
processing	processing	p60202052	NN	I-NP	O
of	of	o100	IN	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
central	central	c053604	JJ	I-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
states	state	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
functional	functional	f05230504	JJ	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
fMRI	fMRI	f560	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
gabapentin	gabapentin	g010105305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
skin	skin	s205	NN	I-NP	O
and	and	a530	CC	I-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
secondary	secondary	s02053060	JJ	I-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
800	800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
os	o	o200	NNS	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
(	(	(000	(	B-LST	O
i	i	i000	LS	I-LST	O
)	)	)000	)	O	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
activations	activation	a230103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
operculoinsular	operculoinsular	o1062040520406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
independently	independently	i530105305340	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
ii	ii	i000	LS	I-LST	O
)	)	)000	)	O	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
iii	iii	i000	LS	I-LST	O
)	)	)000	)	O	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
suppressed	suppress	s0160203	VBD	B-VP	O
stimulus	stimulus	s3050402	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
deactivations	deactivation	d0230103052	NNS	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
robust	robust	r01023	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
fMRI	fMRI	f560	NN	I-NP	O
signal	signal	s02504	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
measurable	measurable	m02060140	JJ	I-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
stronger	strong	s3605206	JJR	I-NP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
most	most	m023	RBS	B-ADJP	O
evident	evident	e103053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
deactivation	deactivation	d023010305	NN	B-NP	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
supporting	support	s01063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
concept	concept	c052013	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
gabapentin	gabapentin	g010105305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
modulating	modulate	m030403052	VBG	B-VP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
central	central	c053604	JJ	B-NP	O
sensitization	sensitization	s05203020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
present	present	p602053	JJ	B-ADJP	O
.	.	.000	.	O	O

Investigation	Investigation	i51023020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
aspects	aspect	a210232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
epileptogenesis	epileptogenesis	e10401302050202	NN	B-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
energy	energy	e50620	NN	B-NP	O
generation	generation	g05060305	NN	I-NP	O
,	,	,000	,	O	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
cell	cell	c040	NN	B-NP	O
death	death	d030	NN	I-NP	B-Disease
,	,	,000	,	O	O
neurotransmitter	neurotransmitter	n0603605250306	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
(	(	(000	(	O	O
FR	FR	f600	NN	B-NP	O
)	)	)000	)	O	O
production	production	p60302305	NN	B-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
FRs	FR	f620	NNS	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
mtDNA	mtDNA	m350	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
phosphorylation	phosphorylation	p02106040305	NN	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
mtDNA	mtDNA	m350	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
encoded	encode	e520303	VBN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
increased	increase	i5260203	VBN	B-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
FR	FR	f600	NN	B-NP	O
during	during	d06052	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
provoke	provoke	p601020	VB	I-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
c	c	c000	NN	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
(	(	(000	(	O	O
CCO	CCO	c200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
complex	complex	c051402	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
chain	chain	c050	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

DNA	DNA	d500	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
low	low	l000	JJ	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
kb	kb	k100	NN	I-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
deletion	deletion	d040305	NN	I-NP	O
but	but	b030	CC	B-PP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
frequency	frequency	f6020520	NN	B-NP	O
or	or	o600	CC	I-NP	O
quantity	quantity	q053030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
and	and	a530	CC	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
find	find	f053	VB	I-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
distribution	distribution	d0236010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
mtDNA	mtDNA	m350	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
encoded	encode	e520303	VBN	B-NP	O
subunit	subunit	s010503	NN	I-NP	O
of	of	o100	IN	B-PP	O
CCO	CCO	c200	NN	B-NP	O
(	(	(000	(	O	O
CCO	CCO	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CCO	CCO	c200	NN	B-NP	O
-	-	-000	HYPH	O	O
I	I	i000	PRP	B-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
nuclear	nuclear	n02406	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
encoded	encode	e520303	VBN	I-NP	O
subunits	subunit	s0105032	NNS	I-NP	O
(	(	(000	(	O	O
CCO	CCO	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
IV	IV	i100	CD	I-NP	O
and	and	a530	CC	I-NP	O
SDH	SDH	s300	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
fp	fp	f100	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
in	in	i500	IN	B-PP	O
CCO	CCO	c200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
histochemistry	histochemistry	h023020502360	NN	B-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
evidences	evidence	e10305202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
published	publish	p0140203	VBN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
suggest	suggest	s02023	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
FRs	FR	f620	NNS	I-NP	O
,	,	,000	,	O	O
generated	generate	g05060303	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
,	,	,000	,	O	O
determined	determine	d030650503	VBN	B-VP	O
important	important	i51063053	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
CCO	CCO	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
CCO	CCO	c200	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
nitrendipine	nitrendipine	n03605301050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
nephrosclerosis	nephrosclerosis	n0106024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
renovascular	renovascular	r0501020406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
nitrendipine	nitrendipine	n03605301050	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
morphology	morphology	m06104020	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nonclipped	nonclipped	n05240103	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
clip	clip	c401	NN	I-NP	O
renovascular	renovascular	r0501020406	JJ	I-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
clipping	clip	c401052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
renal	renal	r0504	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
,	,	,000	,	O	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
178	178	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
untreated	untreated	u5360303	JJ	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	I-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
nitrendipine	nitrendipine	n03605301050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	I-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Sham	Sham	s050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
operated	operate	o1060303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
normotensive	normotensive	n06503052010	JJ	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
128	128	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	O
hemodynamics	hemodynamic	h0503050502	NNS	I-NP	O
(	(	(000	(	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
determination	determination	d03065050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
size	size	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
sclerosis	sclerosis	s24060202	NN	I-NP	O
.	.	.000	.	O	O

Enalapril	Enalapril	e50401604	NNP	B-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
nitrendipine	nitrendipine	n03605301050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
different	different	d0106053	JJ	B-ADJP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
studied	study	s30303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
albumin	albumin	a410505	NN	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
and	and	a530	CC	O	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
after	after	a1306	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nitrendipine	nitrendipine	n03605301050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
albuminuria	albuminuria	a410505060	NN	I-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
163	163	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
55	55	0000	CD	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
hr	hr	h600	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	B-NP	B-Disease
index	index	i5302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nitrendipine	nitrendipine	n03605301050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
38	38	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
versus	versus	v06202	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
size	size	s020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nitrendipine	nitrendipine	n03605301050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
17	17	0000	CD	B-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
mm2	mm2	0000	NN	B-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
mm2	mm2	0000	NN	B-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
17	17	0000	CD	B-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
mm2	mm2	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Ketoconazole	Ketoconazole	k03020502040	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	IN	B-PP	I-Disease
pointes	pointe	p05302	NNS	B-NP	I-Disease
without	without	w0303	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
-	-	-000	HYPH	O	O
prolonging	prolong	p604052052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	O
.	.	.000	.	O	O

Ketoconazole	Ketoconazole	k03020502040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
proarrhythmic	proarrhythmic	p606030502	JJ	B-ADJP	O
without	without	w0303	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
-	-	-000	HYPH	O	O
prolonging	prolong	p604052052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
markedly	markedly	m0620340	RB	I-NP	O
prolonged	prolong	p60405203	VBN	I-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
interval	interval	i5306104	NN	I-NP	I-Disease
and	and	a530	CC	O	O
torsades	torsade	t0620302	NNS	B-NP	B-Disease
de	de	d000	FW	I-NP	I-Disease
pointes	pointes	p05302	FW	I-NP	I-Disease
(	(	(000	(	O	O
TdP	TdP	t310	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
taking	take	t02052	VBG	B-VP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
fungal	fungal	f05204	JJ	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
QT	QT	q300	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
upon	upon	u105	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Genetic	Genetic	g050302	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
find	find	f053	VB	I-VP	O
any	any	a500	DT	B-NP	O
mutation	mutation	m030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
genes	gene	g0502	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
encode	encode	e52030	VBP	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
IKr	IKr	i260	NN	I-NP	O
channel	channel	c0504	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
postulate	postulate	p02304030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
by	by	b000	IN	B-PP	O
virtue	virtue	v0630	NN	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
direct	direct	d06023	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
action	action	a2305	NN	I-NP	O
on	on	o500	IN	B-PP	O
IKr	IKr	i260	NN	B-NP	O
,	,	,000	,	O	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
may	may	m000	MD	B-VP	O
prolong	prolong	p604052	VB	I-VP	O
QT	QT	q300	NN	B-NP	O
interval	interval	i5306104	NN	I-NP	O
and	and	a530	CC	O	O
induce	induce	i53020	VB	B-VP	O
TdP	TdP	t310	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
calls	call	c042	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
attention	attention	a305305	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
acquired	acquire	a20603	VBN	B-NP	O
long	long	l052	JJ	I-NP	B-Disease
QT	QT	q300	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
oral	oral	o604	JJ	B-NP	O
methylphenidate	methylphenidate	m030410503030	NN	I-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
adult	adult	a3043	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Methylphenidate	Methylphenidate	m030410503030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
structurally	structurally	s3602306040	RB	B-ADJP	O
and	and	a530	CC	I-ADJP	O
functionally	functionally	f052305040	RB	I-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
documented	document	d020505303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
rare	rare	r060	JJ	B-NP	O
cases	case	c0202	NNS	I-NP	O
ischaemic	ischaemic	i20502	JJ	B-NP	B-Disease
stroke	stroke	s36020	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
63	63	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
female	female	f05040	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
suffered	suffer	s010603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
ischaemic	ischaemic	i20502	JJ	I-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
consider	consider	c0520306	VBP	B-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
likely	likely	l02040	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
ischaemic	ischaemic	i20502	JJ	I-NP	B-Disease
strokes	stroke	s360202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
work	work	w062	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
mediated	mediate	m030303	VBN	I-NP	O
vasculitis	vasculitis	v02040302	NN	I-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
though	though	t020	IN	B-SBAR	O
very	very	v060	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
,	,	,000	,	O	O
represents	represent	r016020532	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
more	more	m060	JJR	I-NP	O
reason	reason	r0205	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
very	very	v060	RB	B-ADJP	O
restrictive	restrictive	r0236023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

MDMA	MDMA	m350	NN	B-NP	B-Chemical
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
process	process	p60202	NN	B-NP	O
-	-	-000	HYPH	O	O
specific	specific	s1020102	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
executive	executive	e20203010	NN	I-NP	O
impairments	impairment	i510650532	NNS	I-NP	O
coupled	couple	c01403	VBN	B-VP	O
with	with	w030	IN	B-PP	O
impaired	impair	i510603	VBN	B-NP	B-Disease
social	social	s0204	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
emotional	emotional	e5030504	JJ	I-NP	I-Disease
judgement	judgement	j03205053	NN	I-NP	I-Disease
processes	process	p6020202	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
working	work	w062052	VBG	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylenedioxymethamphetamine	methylenedioxymethamphetamine	m030405030205030510305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
ecstasy	ecstasy	e23020	JJ	B-ADJP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
on	on	o500	IN	B-PP	O
three	three	t060	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
executive	executive	e20203010	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
(	(	(000	(	O	O
set	set	s030	VBN	B-VP	O
shifting	shifting	s013052	NN	B-NP	O
,	,	,000	,	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
updating	update	u1303052	VBG	B-VP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
"	"	"000	``	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
"	"	"000	''	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
social	social	s0204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
judgement	judgement	j03205053	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

Fifteen	Fifteen	f01305	CD	B-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
user	user	u206	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Brixton	Brixton	b602305	NNP	I-NP	O
Spatial	Spatial	s10304	NNP	I-NP	O
Anticipation	Anticipation	a5302010305	NNP	I-NP	O
task	task	t020	NN	I-NP	O
(	(	(000	(	O	O
set	set	s030	NN	B-NP	O
shifting	shifting	s013052	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Backward	Backward	b02063	NNP	B-NP	O
Digit	Digit	d0203	NNP	I-NP	O
Span	Span	s105	NNP	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
(	(	(000	(	O	O
memory	memory	m05060	NN	B-NP	O
updating	update	u1303052	VBG	B-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Return	Return	r03065	NN	B-NP	O
(	(	(000	(	O	O
inhibition	inhibition	i5010305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
intelligence	intelligence	i5304020520	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
Tromso	Tromso	t60520	NNP	I-NP	O
Social	Social	s0204	NNP	I-NP	O
Intelligence	Intelligence	i5304020520	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Dysexecutive	Dysexecutive	d02020203010	NN	I-NP	O
Questionnaire	Questionnaire	q02305060	NN	I-NP	O
(	(	(000	(	O	O
DEX	DEX	d020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
polydrug	polydrug	p0403602	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
MDMA	MDMA	m350	NN	B-NP	B-Chemical
polydrug	polydrug	p0403602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
impairments	impairment	i510650532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
set	set	s030	NN	B-NP	O
shifting	shifting	s013052	NN	I-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
updating	update	u1303052	VBG	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
social	social	s0204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
emotional	emotional	e5030504	JJ	I-NP	O
judgement	judgement	j03205053	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
two	two	t000	CD	I-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
other	other	o306	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
lend	lend	l053	VBP	B-VP	O
further	further	f06306	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
proposal	proposal	p6010204	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
cognitive	cognitive	c02503010	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
prefrontal	prefrontal	p601605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
impaired	impair	i510603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
recreational	recreational	r026030504	JJ	B-NP	O
ecstasy	ecstasy	e23020	JJ	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
amsacrine	amsacrine	a52026050	NN	I-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
CI	CI	c000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
921	921	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
NSC	NSC	n200	NN	B-NP	B-Chemical
343499	343499	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
non	non	n050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
small	small	s504	JJ	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

CI	CI	c000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
921	921	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
NSC	NSC	n200	NNP	B-NP	B-Chemical
343499	343499	0000	CD	I-NP	I-Chemical
;	;	;000	:	O	O
9	9	9000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
[	[	[000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxy	methoxy	m03020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
(	(	(000	(	O	I-Chemical
methylsulphonyl	methylsulphonyl	m030420410504	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
amino	amino	a5050	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
phenyl	phenyl	p0504	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
amino	amino	a5050	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
,	,	,000	,	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dimethyl	dimethyl	d050304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acridinecarboxamide	acridinecarboxamide	a260305020610205030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
topoisomerase	topoisomerase	t01020506020	NN	I-NP	O
II	II	i000	CD	I-NP	O
poison	poison	p0205	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
antitumour	antitumour	a53030506	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
to	to	t000	TO	B-PP	O
16	16	0000	CD	B-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
non	non	n050	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
small	small	s504	JJ	B-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lung	lung	l052	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
(	(	(000	(	O	O
NSCLC	NSCLC	n242	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
9	9	9000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
relapse	relapse	r040120	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
/	/	/000	SYM	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
648	648	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
divided	divide	d010303	VBN	B-VP	O
over	over	o106	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
repeated	repeat	r010303	VBD	B-VP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
I	I	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
(	(	(000	(	O	O
WHO	WHO	w000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
61	61	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
histology	histology	h02304020	NN	I-NP	O
comprised	comprise	c05160203	VBD	B-VP	O
squamous	squamous	s20502	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adenocarcinoma	adenocarcinoma	a3050206205050	NN	B-NP	B-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mixed	mix	m0203	VBN	B-NP	O
histology	histology	h02304020	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
bronchio	bronchio	b60520	AFX	O	B-Disease
-	-	-000	HYPH	O	I-Disease
alveolar	alveolar	a410406	JJ	B-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
large	large	l0620	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
undifferentiated	undifferentiated	u5301060530303	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Neutropenia	Neutropenia	n03601050	NNP	B-NP	B-Disease
grade	grade	g6030	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
infections	infection	i51023052	NNS	B-NP	B-Disease
with	with	w030	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
grand	grand	g6053	JJ	B-NP	O
mal	mal	m040	JJ	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
66	66	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
courses	course	c06202	NNS	I-NP	O
and	and	a530	CC	O	O
phlebitis	phlebitis	p04010302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
arm	arm	a650	NN	I-NP	O
in	in	i500	IN	B-PP	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
squamous	squamous	s20502	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
lasting	last	l023052	VBG	B-VP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
tumour	tumour	t0506	NN	I-NP	B-Disease
types	type	t0102	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Pharmacokinetics	Pharmacokinetic	p0650202050302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
when	when	w050	WRB	B-ADVP	O
administered	administer	a35050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
HCl	HCl	h240	NN	I-NP	I-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
work	work	w062	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
P450	P450	0000	NN	I-NP	O
isoenzyme	isoenzyme	i2052050	NN	I-NP	O
(	(	(000	(	O	O
CYP	CYP	c010	NN	B-NP	O
)	)	)000	)	O	O
2D6	2D6	0000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
CYP2D6	CYP2D6	0000	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
probe	probe	p6010	NN	I-NP	O
substrate	substrate	s01236030	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Seventeen	Seventeen	s0105305	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
genotyped	genotype	g05030103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
CYP2D6	CYP2D6	0000	NN	B-NP	O
extensive	extensive	e23052010	JJ	I-NP	O
metabolizers	metabolizer	m03010402062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
label	label	l0104	NN	I-NP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	NN	B-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
occasions	occasion	o202052	NNS	I-NP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
alone	alone	a4050	RB	I-ADVP	O
and	and	a530	CC	I-ADVP	O
once	once	o520	RB	I-ADVP	O
after	after	a1306	IN	B-SBAR	O
multiple	multiple	m0430140	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
90	90	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
predose	predose	p603020	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
72	72	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
postdose	postdose	p023020	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Fourteen	Fourteen	f06305	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
both	both	b030	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
arms	arm	a652	NNS	I-NP	O
.	.	.000	.	O	O

Relative	Relative	r0403010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
AUC	AUC	a020	NN	I-NP	O
and	and	a530	CC	O	O
C	C	c000	NN	B-NP	O
(	(	(000	(	O	O
max	max	m020	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	O	O
fold	fold	f043	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
coadministered	coadministere	c035050230603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
z	z	z000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
longer	long	l05206	JJR	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
coadministered	coadministere	c035050230603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
43	43	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
hs	h	h200	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
max	max	m020	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Fewer	Few	f060	JJR	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
than	than	t050	IN	B-PP	O
when	when	w050	WRB	B-ADVP	O
receiving	receive	r0201052	VBG	B-VP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
versus	versus	v06202	IN	I-NP	O
86	86	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
(	(	(000	(	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
cinacalcet	cinacalcet	c050204203	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
CYP2D6	CYP2D6	0000	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
during	during	d06052	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cinacalcet	cinacalcet	c050204203	NN	B-NP	B-Chemical
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
narrow	narrow	n060	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
and	and	a530	CC	O	O
are	be	a600	VBP	B-VP	O
metabolized	metabolize	m0301040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CYP2D6	CYP2D6	0000	NN	B-NP	O
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
:	:	:000	:	O	O
acute	acute	a2030	JJ	B-NP	O
unintentional	unintentional	u50530530504	JJ	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Intoxications	Intoxication	i53020203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
are	be	a600	VBP	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
an	an	a500	DT	B-NP	O
interesting	interesting	i5306023052	JJ	I-NP	O
case	case	c020	NN	I-NP	O
investigating	investigate	i510230203052	VBG	B-VP	O
a	a	a000	DT	O	O
(	(	(000	(	O	O
near	near	n060	IN	O	O
)	)	)000	)	O	O
fatal	fatal	f0304	JJ	B-NP	O
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
son	son	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
84	84	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	NN	I-NP	O
discovered	discover	d02010603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
newspaper	newspaper	n0210106	NN	I-NP	O
report	report	r01063	NN	I-NP	O
stating	state	s303052	VBG	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
success	success	s0202	NN	I-NP	O
with	with	w030	IN	B-PP	O
plant	plant	p4053	NN	B-NP	O
extracts	extract	e2360232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mode	mode	m030	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
said	say	s030	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
'	'	'000	``	I-NP	O
carbamylcholin	carbamylcholin	c061050420405	NN	I-NP	B-Chemical
'	'	'000	''	O	O
;	;	;000	:	O	O
that	that	t030	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
bought	buy	b0203	VBD	B-VP	O
25	25	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
pure	pure	p060	JJ	B-NP	O
substance	substance	s01230520	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pharmacy	pharmacy	p065020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
father	father	f0306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
400	400	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

Carbachol	Carbachol	c0610204	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
of	of	o100	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
admission	admission	a350205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
HPLC	HPLC	h142	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
mass	mass	m020	NN	I-NP	O
spectrometry	spectrometry	s10236050360	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Minutes	Minute	m050302	NNS	B-NP	O
after	after	a1306	IN	B-SBAR	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
sweating	sweating	s03052	NN	I-NP	O
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
finally	finally	f05040	RB	B-VP	O
collapsed	collapse	c0401203	VBD	I-VP	O
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
,	,	,000	,	O	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
and	and	a530	CC	O	O
asystole	asystole	a2023040	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	I-NP	O
resuscitation	resuscitation	r0202030305	NN	I-NP	O
and	and	a530	CC	O	O
immediate	immediate	i503030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
furosemide	furosemide	f060205030	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
successful	successful	s0202104	JJ	B-ADJP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
admission	admission	a350205	NN	I-NP	O
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intubated	intubated	i53010303	JJ	I-NP	O
,	,	,000	,	I-NP	O
bradyarrhythmic	bradyarrhythmic	b60306030502	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
100	100	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
65	65	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
hyperhidrosis	hyperhidrosis	h01060360202	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypersalivation	hypersalivation	h0106204010305	NN	B-NP	B-Disease
,	,	,000	,	O	O
bronchorrhoea	bronchorrhoea	b6052060	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
miosis	miosis	m0202	NN	I-NP	B-Disease
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
atrio	atrio	a360	AFX	B-ADJP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
dissociation	dissociation	d02020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
extubated	extubate	e23010303	VBN	I-VP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
dyspnoea	dyspnoea	d02150	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
bronchospasm	bronchospasm	b6052021025	NN	I-NP	B-Disease
necessitated	necessitate	n0202030303	VBD	B-VP	O
reintubation	reintubation	r053010305	NN	B-NP	O
.	.	.000	.	O	O

Respiratory	Respiratory	r0210603060	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
further	further	f06306	RBR	I-VP	O
worsened	worsen	w0620503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Proteus	Proteus	p60302	NNP	B-NP	B-Disease
mirabilis	mirabilis	m06010402	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
bronchoconstriction	bronchoconstriction	b6052020523602305	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
again	again	a205	RB	I-VP	O
extubated	extubate	e23010303	VBN	I-VP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
ward	ward	w063	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
day	day	d000	NN	I-NP	O
he	he	h000	PRP	B-NP	O
died	die	d030	VBD	B-VP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
and	and	a530	CC	I-NP	O
second	second	s02053	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
contained	contain	c0530503	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
corresponding	correspond	c06021053052	VBG	I-NP	O
urine	urine	u6050	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
amounted	amounte	a505303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
374	374	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
554	554	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
started	start	s306303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
media	medium	m030	NNS	I-NP	O
report	report	r01063	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
popular	popular	p010406	JJ	I-NP	O
newspaper	newspaper	n0210106	NN	I-NP	O
,	,	,000	,	O	O
initiated	initiate	i5030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
published	publish	p0140203	VBN	B-VP	O
,	,	,000	,	O	O
peer	peer	p060	NN	B-NP	O
-	-	-000	HYPH	O	O
reviewed	review	r0103	VBN	B-VP	O
research	research	r020620	NN	B-NP	O
on	on	o500	IN	B-PP	O
herbals	herbal	h061042	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
involved	involve	i5104103	VBN	B-VP	O
human	human	h0505	JJ	B-NP	O
failure	failure	f04060	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
medical	medical	m030204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
analytical	analytical	a504030204	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
analysed	analyse	a5040203	VBN	I-NP	O
carbachol	carbachol	c0610204	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
supposed	suppose	s010203	VBN	I-NP	O
serum	serum	s0605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
factor	factor	f02306	NN	I-NP	O
of	of	o100	IN	B-PP	O
130	130	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
260	260	0000	CD	B-NP	O
.	.	.000	.	O	O

Especially	Especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
old	old	o430	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
intensivists	intensivist	i53052010232	NNS	B-NP	O
should	should	s043	MD	B-VP	O
consider	consider	c0520306	VB	I-VP	O
intoxications	intoxication	i53020203052	NNS	B-NP	O
(	(	(000	(	O	O
with	with	w030	IN	B-PP	O
cholinergics	cholinergic	c040506202	NNS	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pharmacological	Pharmacological	p0650204020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
Daucus	Daucus	d0202	NN	B-NP	O
carota	carota	c06030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
aimed	aim	a0503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
investigating	investigate	i510230203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Daucus	Daucus	d0202	NN	B-NP	O
carota	carota	c06030	NN	I-NP	O
seeds	seed	s032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
brain	brain	b605	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ethanolic	ethanolic	e3050402	JJ	I-NP	O
extract	extract	e236023	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	I-Chemical
Daucus	Daucus	d0202	NN	B-NP	I-Chemical
carota	carota	c06030	NN	I-NP	I-Chemical
seeds	seed	s032	NNS	I-NP	I-Chemical
(	(	(000	(	O	O
DCE	DCE	d200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
200	200	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
400	400	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
successive	successive	s0202010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
different	different	d0106053	JJ	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
young	young	y052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
aged	aged	a203	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Elevated	Elevate	e4010303	VBN	B-VP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
and	and	a530	CC	O	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
apparatus	apparatus	a1060302	NN	I-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
exteroceptive	exteroceptive	e230602013010	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
testing	testing	t023052	NN	B-NP	O
memory	memory	m05060	NN	I-NP	O
.	.	.000	.	O	O

Diazepam	Diazepam	d020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	O
,	,	,000	,	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
ageing	ageing	a2052	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
interoceptive	interoceptive	i530602013010	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

DCE	DCE	d200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
,	,	,000	,	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
young	young	y052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
aged	aged	a203	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DCE	DCE	d200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
and	and	a530	CC	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
elevated	elevate	e4010303	VBN	B-VP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-NP	O
improvements	improvement	i51601050532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
apparatus	apparatus	a1060302	NN	I-NP	O
and	and	a530	CC	O	O
aged	aged	a203	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
DCE	DCE	d200	NN	B-NP	B-Chemical
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Daucus	Daucus	d0202	NN	B-NP	B-Chemical
carota	carota	c06030	NN	I-NP	I-Chemical
extract	extract	e236023	NN	I-NP	I-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
,	,	,000	,	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
aged	aged	a203	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
cholinesterase	cholinesterase	c040502306020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
DCE	DCE	d200	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-ADJP	O
and	and	a530	CC	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
aged	aged	a203	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
remarkable	remarkable	r050620140	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
as	as	a200	RB	B-ADVP	O
well	well	w040	RB	I-ADVP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
23	23	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-ADJP	O
and	and	a530	CC	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
aged	aged	a203	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
DCE	DCE	d200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
DCE	DCE	d200	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
prove	prove	p6010	VB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
remedy	remedy	r05030	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
on	on	o500	IN	B-PP	O
account	account	a2053	NN	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
multifarious	multifarious	m043010602	JJ	I-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
,	,	,000	,	O	O
memory	memory	m05060	NN	B-NP	O
improving	improve	i51601052	VBG	B-VP	O
property	property	p6010630	NN	B-NP	O
,	,	,000	,	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
lowering	lower	l06052	VBG	B-VP	O
property	property	p6010630	NN	B-NP	O
and	and	a530	CC	I-NP	O
anticholinesterase	anticholinesterase	a5302040502306020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Valproic	Valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
induced	induce	i530203	VBN	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
-	-	-000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
19	19	0000	CD	I-NP	O
new	new	n000	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Germany	Germany	g065050	NNP	B-NP	O
from	from	f605	IN	B-PP	O
1994	1994	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2003	2003	0000	CD	B-NP	O
-	-	-000	HYPH	O	O
-	-	-000	:	O	O
a	a	a000	DT	B-NP	O
side	side	s030	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Valproic	Valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
broad	broad	b603	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
tolerated	tolerate	t04060303	VBN	B-VP	O
.	.	.000	.	O	O

Rare	Rare	r060	NN	B-NP	O
serious	serious	s0602	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
haemorrhagic	haemorrhagic	h05060202	JJ	B-NP	O
pancreatitis	pancreatitis	p0526030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
bone	bone	b050	NN	B-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
,	,	,000	,	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
VPA	VPA	v100	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
consciousness	consciousness	c05202502	NN	I-NP	I-Disease
,	,	,000	,	O	O
sometimes	sometimes	s05030502	RB	B-NP	O
marked	marked	m06203	JJ	I-NP	O
EEG	EEG	e020	NN	I-NP	O
background	background	b026053	NN	I-NP	O
slowing	slow	s4052	VBG	B-VP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
hyperammonemia	hyperammonemia	h01060505050	NN	B-NP	B-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
no	no	n000	DT	B-NP	O
proof	proof	p601	NN	I-NP	O
of	of	o100	IN	B-PP	O
causative	causative	c0203010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
assumed	assume	a20503	VBN	I-NP	O
causal	causal	c0204	JJ	I-NP	O
relation	relation	r040305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
19	19	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Germany	Germany	g065050	NNP	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
years	year	y062	NNS	I-NP	O
1994	1994	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
2003	2003	0000	CD	B-NP	O
,	,	,000	,	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
published	publish	p0140203	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
,	,	,000	,	I-NP	O
severity	severity	s0106030	NN	I-NP	O
and	and	a530	CC	I-NP	O
preventability	preventability	p6010530104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
haemorrhages	haemorrhage	h05060202	NNS	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
living	live	l01052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
county	county	c0530	NN	I-NP	O
of	of	o100	IN	B-PP	O
Osterg	Osterg	o23062	NNP	B-NP	O
tland	tland	t4053	NNP	I-NP	O
,	,	,000	,	O	O
Sweden	Sweden	s0305	NNP	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosed	diagnose	d0250203	VBN	I-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
three	three	t060	CD	B-NP	O
hospitals	hospital	h02103042	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
2000	2000	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2002	2002	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Medical	Medical	m030204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
drug	drug	d602	NN	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
possibly	possibly	p020140	RB	B-NP	O
avoidable	avoidable	a1030140	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Among	Among	a5052	IN	B-PP	O
593	593	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
59	59	0000	CD	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
imply	imply	i5140	VBP	B-VP	O
an	an	a500	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
100	100	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
59	59	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fatal	fatal	f0304	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
136	136	0000	CD	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
haemorrhage	haemorrhage	h0506020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
complication	complication	c0514020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
being	be	b052	VBG	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
haemorrhages	haemorrhage	h05060202	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
fatality	fatality	f0304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Almost	Almost	a45023	RB	B-NP	O
half	half	h041	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
haemorrhages	haemorrhage	h05060202	NNS	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
greater	great	g60306	JJR	B-NP	O
caution	caution	c0305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taken	take	t0205	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
interact	interact	i5306023	VB	I-VP	O
with	with	w030	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Antipsychotic	Antipsychotic	a53012020302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
thioperamide	thioperamide	t010605030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
H3	H3	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Experimental	Experimental	e21060505304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
points	point	p0532	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
histaminergic	histaminergic	h023050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
H	H	h000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
ligands	ligand	l020532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	I-VP	O
climbing	climb	c4051052	VBG	B-VP	O
behavior	behavior	b0106	NN	B-NP	O
and	and	a530	CC	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Catalepsy	Catalepsy	c03040120	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
studying	study	s303052	VBG	B-VP	O
climbing	climb	c4051052	VBG	I-VP	O
behavior	behavior	b0106	NN	B-NP	O
and	and	a530	CC	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

(	(	(000	(	O	B-Chemical
R	R	r000	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
methylhistamine	methylhistamine	m030402305050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
RAMH	RAMH	r050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
thioperamide	thioperamide	t010605030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
THP	THP	t010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
THP	THP	t010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
15	15	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
RAMH	RAMH	r050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
such	such	s020	PDT	B-NP	O
an	an	a500	DT	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
THP	THP	t010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RAMH	RAMH	r050	NN	B-NP	B-Chemical
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
distance	distance	d0230520	NN	B-NP	O
traveled	travel	t6010403	VBN	B-VP	O
and	and	a530	CC	O	O
average	average	a106020	JJ	B-NP	O
speed	speed	s103	NN	I-NP	O
but	but	b030	CC	O	O
THP	THP	t010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
per	per	p060	FW	B-NP	O
se	se	s000	FW	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
,	,	,000	,	O	O
THP	THP	t010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBD	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
distance	distance	d0230520	NN	B-NP	O
traveled	travel	t6010403	VBN	B-VP	O
and	and	a530	CC	O	O
average	average	a106020	JJ	B-NP	O
speed	speed	s103	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
RAMH	RAMH	r050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
could	could	c043	MD	B-VP	O
partially	partially	p063040	RB	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
such	such	s020	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
THP	THP	t010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Climbing	Climb	c4051052	VBG	B-VP	O
behavior	behavior	b0106	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
THP	THP	t010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Such	Such	s020	PDT	B-NP	O
an	an	a500	DT	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
reversed	reverse	r0106203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
RAMH	RAMH	r050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

THP	THP	t010	NN	B-NP	B-Chemical
exhibited	exhibit	e2010303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
by	by	b000	IN	B-PP	O
potentiating	potentiate	p0305303052	VBG	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
,	,	,000	,	O	O
reducing	reduce	r0302052	VBG	B-VP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
reducing	reduce	r0302052	VBG	B-VP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
climbing	climbing	c4051052	NN	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
THP	THP	t010	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
RAMH	RAMH	r050	NN	B-NP	B-Chemical
indicating	indicate	i530203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
H	H	h000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Findings	Finding	f053052	NNS	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
H	H	h000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
improving	improve	i51601052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Cauda	Cauda	c030	NNP	B-NP	B-Disease
equina	equina	e2050	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Conventional	Conventional	c0510530504	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
methods	method	m03032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lumbusacral	lumbusacral	l0510202604	JJ	B-NP	O
radiculopathy	radiculopathy	r03020401030	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
physical	physical	p020204	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
epidural	epidural	e1030604	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
spinal	spinal	s10504	JJ	B-NP	O
manipulative	manipulative	m05010403010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Cauda	Cauda	c030	NNP	B-NP	B-Disease
equina	equina	e2050	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
cauda	cauda	c030	NN	B-NP	B-Disease
equina	equina	e2050	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
possibly	possibly	p020140	RB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
triamcinolone	triamcinolone	t60520504050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

CLINICAL	CLINICAL	c4050204	JJ	B-NP	O
FEATURES	FEATURES	f030602	NNS	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	B-Disease
back	back	b020	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
right	right	r0203	JJ	B-NP	I-Disease
leg	leg	l020	NN	I-NP	I-Disease
pain	pain	p050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
scheduled	schedule	s2030403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

INTERVENTION	INTERVENTION	i5306105305	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OUTCOME	OUTCOME	o032050	NN	I-NP	O
:	:	:000	:	O	O
An	An	a500	DT	B-NP	O
18	18	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
gauge	gauge	g020	NN	I-NP	O
Touhy	Touhy	t000	NN	I-NP	O
needle	needle	n0340	NN	I-NP	O
was	be	w020	VBD	B-VP	O
inserted	insert	i5206303	VBN	I-VP	O
until	until	u5304	IN	B-PP	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
resistance	resistance	r020230520	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
L4	L4	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Spread	Spread	s1603	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrast	contrast	c0536023	NN	I-NP	O
medium	medium	m0305	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
epidural	epidural	e1030604	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
radiographic	radiographic	r030260102	JJ	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
verifying	verify	v0601052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
epidural	epidural	e1030604	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
,	,	,000	,	O	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
triamcinolone	triamcinolone	t60520504050	NN	I-NP	B-Chemical
diacetate	diacetate	d0203030	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
radicular	radicular	r03020406	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
perineal	perineal	p060504	JJ	B-NP	O
numbness	numbness	n051502	NN	I-NP	B-Disease
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	B-Disease
extremity	extremity	e23605030	NN	I-NP	I-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
sensation	sensation	s0520305	NN	B-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saddle	saddle	s0340	JJ	I-NP	O
area	area	a600	NN	I-NP	O
and	and	a530	CC	O	O
medial	medial	m0304	JJ	B-NP	O
aspect	aspect	a21023	NN	I-NP	O
of	of	o100	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
right	right	r0203	JJ	I-NP	O
leg	leg	l020	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
perception	perception	p06201305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pinprick	pinprick	p051602	NN	B-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Deep	Deep	d010	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
tendon	tendon	t05305	NN	I-NP	O
reflexes	reflex	r0140202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
leg	leg	l020	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
urinate	urinate	u605030	VB	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
slightly	slightly	s4020340	RB	B-ADVP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
return	return	r03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
feeling	feeling	f04052	NN	B-NP	O
Foley	Foley	f040	NNP	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
resolved	resolve	r0204103	VBN	I-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
8	8	8000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Complications	Complication	c05140203052	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	O	O
continued	continued	c0530503	JJ	B-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
for	for	f060	IN	B-PP	O
neurologic	neurologic	n06040202	JJ	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
513	513	0000	CD	B-NP	O
naturally	naturally	n0306040	RB	I-NP	O
postmenopausal	postmenopausal	p023505010204	JJ	I-NP	O
women	woman	w0505	NNS	I-NP	O
aged	age	a203	VBN	B-VP	O
54	54	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
67	67	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
reported	report	r0106303	VBN	I-VP	O
intramuscularly	intramuscularly	i5360502040640	RB	B-NP	O
administered	administer	a35050230603	VBN	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
and	and	a530	CC	I-NP	I-Chemical
testosterone	testosterone	t02302306050	NN	I-NP	I-Chemical
esters	ester	e23062	NNS	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
aortic	aortic	a06302	JJ	B-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Aortic	Aortic	a06302	JJ	B-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
radiographic	radiographic	r030260102	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcified	calcify	c0420103	VBN	B-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
aorta	aorta	a0630	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
reflect	reflect	r014023	VB	I-VP	O
intima	intima	i53050	NN	B-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Hormone	Hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
never	never	n0106	JJ	B-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Intramuscular	Intramuscular	i53605020406	JJ	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
use	use	u200	NN	I-NP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
or	or	o600	CC	I-NP	O
longer	longer	l05206	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
25	25	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
half	half	h041	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
severe	severe	s01060	VBP	B-VP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
use	use	u200	NN	I-NP	O
severe	severe	s01060	JJ	I-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
adjusted	adjust	a3202303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
years	year	y062	NNS	B-NP	O
since	since	s0520	IN	B-PP	O
menopause	menopause	m0501020	NN	B-NP	O
,	,	,000	,	O	O
smoking	smoking	s502052	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
body	body	b030	NN	B-NP	O
mass	mass	m020	NN	I-NP	O
index	index	i5302	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
for	for	f060	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
for	for	f060	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
use	use	u200	NN	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
may	may	m000	MD	B-VP	O
adversely	adversely	a31062040	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
postmenopausal	postmenopausal	p023505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
androgen	androgen	a5360205	NN	B-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
women	woman	w0505	NNS	I-NP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
harmless	harmless	h065402	JJ	B-ADJP	O
.	.	.000	.	O	O

Optimising	Optimise	o130502052	VBG	B-VP	O
stroke	stroke	s36020	JJ	B-NP	B-Disease
prevention	prevention	p60105305	NN	I-NP	O
in	in	i500	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
valvular	valvular	v0410406	JJ	I-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Atrial	Atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
substantial	substantial	s012305304	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
.	.	.000	.	O	O

Pooled	Pool	p0403	VBN	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
trials	trial	t6042	NNS	B-NP	O
comparing	compare	c05106052	VBG	B-VP	O
antithrombotic	antithrombotic	a5303060510302	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
62	62	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
by	by	b000	IN	B-PP	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Overall	Overall	o10604	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
strokes	stroke	s360202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Ximelagatran	Ximelagatran	x05040203605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
direct	direct	d06023	JJ	I-NP	O
thrombin	thrombin	t0605105	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
as	as	a200	RB	B-ADJP	O
efficient	efficient	e102053	JJ	I-ADJP	O
as	as	a200	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
K	K	k000	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
embolic	embolic	e510402	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
recently	recently	r0205340	RB	I-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ACTIVE	ACTIVE	a23010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
W	W	w000	NN	I-NP	O
(	(	(000	(	O	O
Atrial	Atrial	a3604	JJ	B-NP	B-Disease
Fibrillation	Fibrillation	f016040305	NN	I-NP	I-Disease
Clopidogrel	Clopidogrel	c4010302604	NN	I-NP	B-Chemical
Trial	Trial	t604	NN	I-NP	O
with	with	w030	IN	B-PP	O
Irbesartan	Irbesartan	i610206305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
Prevention	Prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Vascular	Vascular	v020406	JJ	B-NP	O
Events	Event	e10532	NNS	I-NP	O
)	)	)000	)	O	O
study	study	s3030	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
clopidogrel	clopidogrel	c4010302604	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
af	af	a100	IN	B-PP	O
embolic	embolic	e510402	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Idraparinux	Idraparinux	i3601060502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
Factor	Factor	f02306	NN	I-NP	O
Xa	Xa	x000	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
being	be	b052	VBG	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Angiotensin	Angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
and	and	a530	CC	O	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	O	O
blocking	block	b402052	VBG	B-VP	O
drugs	drug	d602	NNS	B-NP	O
hold	hold	h043	VBP	B-VP	O
promise	promise	p605020	NN	B-NP	O
in	in	i500	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
through	through	t06020	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
remodelling	remodelling	r050304052	NN	I-NP	I-Disease
.	.	.000	.	O	O

Preliminary	Preliminary	p6040505060	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
statins	statin	s303052	NNS	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
recurrence	recurrence	r02060520	NN	B-NP	O
after	after	a1306	IN	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
cardioversion	cardioversion	c0630106205	NN	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
exclusion	exclusion	e240205	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
appendage	appendage	a1053020	NN	I-NP	O
are	be	a600	VBP	B-VP	O
under	under	u5306	IN	B-PP	O
investigation	investigation	i51023020305	NN	B-NP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Anti	Anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
oxidant	oxidant	o203053	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atorvastatin	atorvastatin	a30610230305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Dex	Dex	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NO	NO	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
deficiency	deficiency	d01020520	NN	B-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBN	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
O2	O2	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
)	)	)000	)	O	O
production	production	p60302305	NN	B-NP	O
.	.	.000	.	O	O

Atorvastatin	Atorvastatin	a30610230305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Ato	Ato	a300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
possesses	possess	p020202	VBZ	B-VP	O
pleiotropic	pleiotropic	p40360102	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
improve	improve	i516010	VB	I-VP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
availability	availability	a1040104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
NO	NO	n000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
O2	O2	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
production	production	p60302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
forms	form	f0652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
o	o	o000	NN	B-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
Ato	Ato	a300	NNP	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
eNOS	eNOS	e502	NN	B-NP	O
)	)	)000	)	O	O
downregulation	downregulation	d05602040305	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
O2	O2	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-ADJP	I-Chemical
in	in	i500	IN	B-PP	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
(	(	(000	(	O	O
SD	SD	s300	NNP	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
thereby	thereby	t06010	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
SD	SD	s300	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
30	30	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
Ato	Ato	a300	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
in	in	i500	IN	B-PP	O
drinking	drinking	d6052052	NN	B-NP	O
water	water	w0306	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
tap	tap	t010	NN	B-NP	O
water	water	w0306	NN	I-NP	O
for	for	f060	IN	B-PP	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
saline	saline	s04050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Ato	Ato	a300	NNP	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
and	and	a530	CC	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
continued	continue	c0530503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
11	11	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
on	on	o500	IN	B-PP	O
alternate	alternate	a43065030	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
cuff	cuff	c010	NN	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Endothelial	Endothelial	e53030404	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasorelaxation	vasorelaxation	v020604020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
phenylephrine	phenylephrine	p05040106050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

Vascular	Vascular	v020406	JJ	B-NP	O
eNOS	eNOS	e502	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
semi	semi	s050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
reverse	reverse	r010620	JJ	I-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
polymerase	polymerase	p040506020	NN	I-NP	O
chain	chain	c050	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
SBP	SBP	s100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
109	109	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
133	133	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	O	O
Day	Day	d000	NN	B-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Ato	Ato	a300	NNP	I-NP	B-Chemical
+	+	+000	CC	I-NP	O
Dex	Dex	d020	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
SBP	SBP	s100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
113	113	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
119	119	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
on	on	o500	IN	B-PP	O
Days	Day	d020	NNS	B-NP	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
SBP	SBP	s100	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Endothelial	Endothelial	e53030404	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
relaxation	relaxation	r04020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
eNOS	eNOS	e502	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Dex	Dex	d020	NNP	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
Ato	Ato	a300	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Dex	Dex	d020	NN	I-NP	B-Chemical
only	only	o540	RB	B-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
and	and	a530	CC	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Aortic	Aortic	a06302	JJ	B-NP	O
superoxide	superoxide	s010602030	NN	I-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Dex	Dex	d020	NNP	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
Ato	Ato	a300	NNP	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
Ato	Ato	a300	NNP	B-NP	B-Chemical
improved	improve	i5160103	VBD	B-VP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
production	production	p60302305	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
SBP	SBP	s100	NN	I-NP	O
in	in	i500	IN	B-PP	O
Dex	Dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
SD	SD	s300	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
citrate	citrate	c036030	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
volunteer	volunteer	v0405306	NN	B-NP	O
apheresis	apheresis	a1060202	NN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
donation	donation	d050305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
citrate	citrate	c036030	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
volunteer	volunteer	v0405306	NN	B-NP	O
donor	donor	d0506	NN	I-NP	O
apheresis	apheresis	a1060202	NN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
collection	collection	c0402305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
donor	donor	d0506	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	JJ	I-NP	O
,	,	,000	,	I-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
apheresis	apheresis	a1060202	NN	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
donor	donor	d0506	NN	I-NP	O
.	.	.000	.	O	O

Past	Past	p023	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
remarkable	remarkable	r050620140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
hyperlipidemia	hyperlipidemia	h010640103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
depression	depression	d0160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Reported	Report	r0106303	VBN	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
bumetanide	bumetanide	b050305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
paroxetine	paroxetine	p060203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
donor	donor	d0506	NN	I-NP	O
noted	note	n0303	VBD	B-VP	O
tingling	tingle	t0524052	VBG	I-VP	O
around	around	a6053	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouth	mouth	m030	NN	I-NP	O
,	,	,000	,	O	O
hands	hand	h0532	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
feet	foot	f030	NNS	B-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
very	very	v060	RB	B-ADVP	O
rapidly	rapidly	r010340	RB	I-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
facial	facial	f0204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
extremity	extremity	e23605030	NN	I-NP	O
tetany	tetany	t03050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Empirical	Empirical	e51060204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
gluconate	gluconate	g40205030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
muscle	muscle	m0240	NN	B-NP	B-Disease
contractions	contraction	c0536023052	NNS	I-NP	I-Disease
slowly	slowly	s4040	RB	B-ADVP	O
subsided	subside	s0120303	VBD	B-VP	O
over	over	o106	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
10	10	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
15	15	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
events	event	e10532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chelation	chelation	c040305	NN	I-NP	O
by	by	b000	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
hypocalcemia	hypocalcemia	h0102042050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Upon	Upon	u105	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
bumetanide	bumetanide	b050305030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
loop	loop	l010	NN	I-NP	B-Chemical
diuretic	diuretic	d060302	JJ	I-NP	I-Chemical
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
significant	significant	s0250102053	JJ	B-NP	O
hypocalcemia	hypocalcemia	h0102042050	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
careful	careful	c060104	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
for	for	f060	IN	B-PP	O
medications	medication	m030203052	NNS	B-NP	O
and	and	a530	CC	O	O
underlying	underlie	u53064052	VBG	B-VP	O
conditions	condition	c05303052	NNS	B-NP	O
predisposing	predispose	p60302102052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
hypocalcemia	hypocalcemia	h0102042050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
help	help	h041	VB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
severe	severe	s01060	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
citrate	citrate	c036030	VB	I-VP	B-Chemical
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
donors	donor	d05062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
identify	identify	i3053010	VB	I-VP	O
cases	case	c0202	NNS	B-NP	O
requiring	require	r0206052	VBG	B-VP	O
heightened	heighten	h02030503	VBN	B-NP	O
vigilance	vigilance	v02040520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
maintaining	maintain	m05305052	VBG	B-VP	O
preparedness	preparedness	p6010603502	NN	B-NP	O
for	for	f060	IN	B-PP	O
managing	manage	m0502052	VBG	B-VP	O
rare	rare	r060	JJ	B-NP	O
but	but	b030	CC	I-NP	O
serious	serious	s0602	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
volunteer	volunteer	v0405306	NN	B-NP	O
apheresis	apheresis	a1060202	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
donors	donor	d05062	NNS	I-NP	O
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
immunosuppressant	immunosuppressant	i5050201602053	NN	I-NP	O
with	with	w030	IN	B-PP	O
potent	potent	p03053	JJ	B-NP	O
antiproliferative	antiproliferative	a5301604010603010	JJ	I-NP	O
actions	action	a23052	NNS	I-NP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
the	the	t000	DT	B-NP	O
raptor	raptor	r01306	NN	I-NP	O
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
mammalian	mammalian	m050405	JJ	B-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
protein	protein	p60305	NN	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NNP	B-NP	B-Chemical
represents	represent	r016020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
advance	advance	a310520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
allograft	allograft	a4026013	NN	I-NP	O
rejection	rejection	r0202305	NN	I-NP	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	O
allograft	allograft	a4026013	NN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	B-NP	B-Disease
,	,	,000	,	O	O
autoimmunity	autoimmunity	a030505030	NN	B-NP	B-Disease
,	,	,000	,	O	O
cystic	cystic	c02302	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
investigation	investigation	i51023020305	NN	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
share	share	s060	VB	I-VP	O
the	the	t000	DT	B-NP	O
vasomotor	vasomotor	v02050306	NN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
exhibited	exhibit	e2010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
designated	designate	d020250303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
'	'	'000	``	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	O
'	'	'000	''	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
under	under	u5306	IN	B-PP	O
some	some	s050	DT	B-NP	O
circumstances	circumstance	c062052305202	NNS	I-NP	O
,	,	,000	,	O	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-VP	O
existing	exist	e2023052	VBG	B-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
multifactorial	multifactorial	m043010230604	JJ	B-ADJP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
directly	directly	d0602340	RB	B-ADVP	O
causes	cause	c0202	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
/	/	/000	SYM	B-NP	O
injury	injury	i52060	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
evidence	evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	B-ADJP	O
inconclusive	inconclusive	i52052402010	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
in	in	i500	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
graft	graft	g6013	NN	I-NP	O
function	function	f052305	NN	I-NP	O
)	)	)000	)	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
survival	survival	s0610104	NN	I-NP	O
/	/	/000	SYM	I-NP	O
repair	repair	r0106	NN	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
occur	occur	o206	VBP	B-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
minimised	minimise	m05050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
knowledge	knowledge	k5040320	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
populations	population	p010403052	NNS	I-NP	O
,	,	,000	,	O	O
close	close	c4020	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
or	or	o600	CC	O	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
if	if	i100	IN	B-SBAR	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
and	and	a530	CC	O	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
if	if	i100	IN	B-SBAR	O
needed	need	n0303	VBN	B-VP	O
.	.	.000	.	O	O

Further	Further	f06306	RB	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
allograft	allograft	a4026013	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
de	de	d000	FW	B-NP	O
novo	novo	n010	FW	I-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
will	will	w040	MD	B-VP	O
refine	refine	r01050	VB	I-VP	O
these	these	t020	DT	B-NP	O
issues	issue	i202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
future	future	f03060	NN	I-NP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
SRL	SRL	s640	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
,	,	,000	,	I-NP	O
potent	potent	p03053	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

More	More	m060	RBR	B-ADVP	O
recently	recently	r0205340	RB	I-ADVP	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
remained	remain	r050503	VBN	I-VP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
or	or	o600	CC	I-VP	O
displayed	display	d021403	VBD	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
conversion	conversion	c05106205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
cohort	cohort	c063	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
allograft	allograft	a4026013	NN	I-NP	I-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
(	(	(000	(	O	O
CAN	CAN	c050	NN	B-NP	B-Disease
)	)	)000	)	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
neoplasia	neoplasia	n014020	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
Kaposi	Kaposi	k01020	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
,	,	,000	,	O	O
Four	Four	f060	CD	B-NP	O
skin	skin	s205	NN	I-NP	B-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
One	One	o500	CD	B-NP	O
intestinal	intestinal	i530230504	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
One	One	o500	CD	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carsinom	carsinom	c0620505	NN	I-NP	I-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
BK	BK	b200	NN	B-NP	O
virus	virus	v0602	NN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

SRL	SRL	s640	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
78	78	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
42	42	0000	CD	B-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	O	O
163	163	0000	CD	O	O
)	)	)000	)	O	O
months	month	m05302	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
on	on	o500	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
20	20	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	O	O
43	43	0000	CD	O	O
)	)	)000	)	O	O
months	month	m05302	NNS	B-NP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
445	445	0000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
g	g	g000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
8	8	8000	CD	I-NP	O
(	(	(000	(	O	O
32	32	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
afterwards	afterwards	a13060632	RB	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
proteinuria	proteinuria	p60305060	NNS	I-NP	B-Disease
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
it	it	i300	PRP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
68	68	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
it	it	i300	PRP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
100	100	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

Biopsies	Biopsy	b01202	NNS	B-NP	O
performed	perform	p06106503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
new	new	n000	JJ	B-NP	O
pathological	pathological	p0304020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
:	:	:000	:	O	O
One	One	o500	CD	B-NP	O
membranoproliferative	membranoproliferative	m05160501604010603010	JJ	I-NP	B-Disease
glomerulopathy	glomerulopathy	g405060401030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
nephritis	nephritis	n01060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
persistently	persistently	p06202305340	RB	B-NP	O
good	good	g030	JJ	I-NP	O
graft	graft	g6013	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
98	98	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
before	before	b01060	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
53	53	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
at	at	a300	IN	B-PP	O
last	last	l023	JJ	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
14	14	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
grafts	graft	g60132	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
displayed	display	d021403	VBD	B-VP	O
CAN	CAN	c050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
Kaposi	Kaposi	k01020	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
sarcoma	sarcoma	s062050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
26	26	0000	CD	O	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
g	g	g000	NN	B-NP	O
/	/	/000	SYM	B-VP	O
d	d	d000	NN	B-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
(	(	(000	NN	I-NP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
)	)	)000	)	O	O
g	g	g000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
before	before	b01060	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
21	21	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
and	and	a530	CC	O	O
thereafter	thereafter	t0601306	RB	B-ADVP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
93	93	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	B-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Heavy	Heavy	h010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
rescue	rescue	r020	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
conversion	conversion	c05106205	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
advanced	advanced	a3105203	JJ	B-NP	O
CAN	CAN	c050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
de	de	d000	FW	B-NP	O
novo	novo	n010	FW	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
under	under	u5306	IN	B-PP	O
SRL	SRL	s640	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
requires	require	r020602	VBZ	B-VP	O
further	far	f06306	JJR	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
by	by	b000	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
renal	renal	r0504	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
mesenchymal	mesenchymal	m020520504	JJ	I-NP	I-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
International	International	i53065030504	NNP	I-NP	O
Society	Society	s02030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Pediatric	Pediatric	p0303602	NNP	B-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
74	74	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
mesenchymal	mesenchymal	m020520504	JJ	I-NP	I-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
received	receive	r020103	VBN	I-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
(	(	(000	(	O	O
International	International	i53065030504	NNP	B-NP	O
Society	Society	s02030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Pediatric	Pediatric	p0303602	NNP	B-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Malignant	Malignant	m04025053	NNP	I-NP	B-Disease
Mesenchymal	Mesenchymal	m020520504	NNP	I-NP	I-Disease
Tumor	Tumor	t0506	NNP	I-NP	I-Disease
Study	Study	s3030	NNP	I-NP	O
84	84	0000	CD	I-NP	O
[	[	[000	(	B-NP	O
SIOP	SIOP	s010	NN	I-NP	O
MMT	MMT	m530	NN	I-NP	O
84	84	0000	CD	I-NP	O
]	]	]000	)	O	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
36	36	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
60	60	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
six	six	s020	CD	B-NP	O
or	or	o600	CC	I-NP	O
10	10	0000	CD	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
vincristine	vincristine	v0526023050	NN	B-NP	I-Chemical
,	,	,000	,	O	I-Chemical
and	and	a530	CC	O	I-Chemical
dactinomycin	dactinomycin	d02305050205	NN	B-NP	I-Chemical
[	[	[000	(	O	O
IVA	IVA	i100	NN	B-NP	B-Chemical
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Ages	Age	a202	NNS	B-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
58	58	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
males	male	m0402	NNS	B-NP	O
and	and	a530	CC	O	O
42	42	0000	CD	B-NP	O
females	female	f050402	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
primary	primary	p605060	JJ	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
site	site	s030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
head	head	h030	NN	I-NP	O
and	and	a530	CC	I-NP	O
neck	neck	n020	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
measuring	measure	m0206052	VBG	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
electrolytes	electrolyte	e40236040302	NNS	I-NP	O
,	,	,000	,	O	O
glucosuria	glucosuria	g40202060	NN	B-NP	B-Disease
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
,	,	,000	,	O	O
aminoaciduria	aminoaciduria	a5050203060	NN	B-NP	B-Disease
,	,	,000	,	O	O
urinary	urinary	u605060	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
,	,	,000	,	O	O
osmolarity	osmolarity	o250406030	NN	B-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
phosphate	phosphate	p021030	NN	B-NP	B-Chemical
tubular	tubular	t010406	JJ	I-NP	O
reabsorption	reabsorption	r012061305	NN	I-NP	O
,	,	,000	,	O	O
beta	beta	b030	NN	B-NP	O
2	2	2000	CD	I-NP	O
microglobulinuria	microglobulinuria	m026024010405060	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
lysozymuria	lysozymuria	l020205060	NN	B-NP	O
.	.	.000	.	O	O

Fifty	Fifty	f0130	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
subsets	subset	s012032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
:	:	:000	:	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
included	include	i5240303	VBD	B-VP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
major	major	m0206	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
TDFS	TDFS	t312	NN	B-NP	B-Disease
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
elevated	elevate	e4010303	VBN	B-NP	O
beta	beta	b030	SYM	I-NP	O
2	2	2000	CD	I-NP	O
microglobulinuria	microglobulinuria	m026024010405060	NNS	I-NP	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
phosphate	phosphate	p021030	NN	I-NP	B-Chemical
reabsorption	reabsorption	r012061305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
seven	seven	s0105	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
beta	beta	b030	SYM	B-NP	O
2	2	2000	CD	I-NP	O
microglobulinuria	microglobulinuria	m026024010405060	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
younger	young	y05206	JJR	I-NP	O
age	age	a200	NN	I-NP	O
(	(	(000	(	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
2	2	2000	CD	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
predominance	predominance	p60305050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
vesicoprostatic	vesicoprostatic	v02020160230302	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
low	low	l000	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
TDFS	TDFS	t312	NN	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ifosfamide	ifosfamide	i102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
mesenchymal	mesenchymal	m020520504	JJ	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

Progressive	Progressive	p602602010	JJ	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
statin	statin	s30305	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Statins	Statin	s303052	NNS	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
a	a	a000	DT	B-NP	O
necrotizing	necrotize	n0260302052	VBG	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hyperCKaemia	hyperCKaemia	h01062050	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

What	What	w030	WP	B-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	I-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
whereby	whereby	w06010	WRB	B-ADVP	O
statins	statin	s303052	NNS	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
a	a	a000	DT	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
persists	persist	p0620232	VBZ	B-VP	O
or	or	o600	CC	O	O
may	may	m000	MD	B-VP	O
progress	progress	p602602	VB	I-VP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
in	in	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
such	such	s020	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
had	have	h030	VBD	B-VP	O
myofibre	myofibre	m010160	NN	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
but	but	b030	CC	O	O
only	only	o540	RB	B-NP	O
3	3	3000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
diffuse	diffuse	d01020	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
multifocal	multifocal	m043010204	JJ	I-ADJP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
necrotic	necrotic	n0260302	JJ	I-NP	B-Disease
fibres	fibre	f01602	NNS	I-NP	O
.	.	.000	.	O	O

Progressive	Progressive	p602602010	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
commencement	commencement	c0505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
statins	statin	s303052	NNS	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
initiate	initiate	i503030	VB	I-VP	O
an	an	a500	DT	B-NP	O
immune	immune	i5050	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
mediated	mediate	m030303	VBN	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
persists	persist	p0620232	VBZ	B-VP	O
after	after	a1306	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
responds	respond	r0210532	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
uncertain	uncertain	u5206305	JJ	B-ADJP	O
but	but	b030	CC	O	O
may	may	m000	MD	B-VP	O
involve	involve	i510410	VB	I-VP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
statins	statin	s303052	NNS	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
endoplasmic	endoplasmic	e5301402502	JJ	I-NP	O
reticulum	reticulum	r03020405	NN	I-NP	O
stress	stress	s3602	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
with	with	w030	IN	B-PP	O
associated	associate	a2020303	VBN	B-VP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MHC	MHC	m020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
antigen	antigen	a530205	NN	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
by	by	b000	IN	B-PP	O
muscle	muscle	m0240	NN	B-NP	O
fibres	fibre	f01602	NNS	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
chromosome	chromosome	c060502050	NN	B-NP	O
substitution	substitution	s0123030305	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
loci	locus	l020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
varies	vary	v0602	VBZ	B-VP	O
among	among	a5052	IN	B-PP	O
inbred	inbred	i51603	JJ	B-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

Chromosome	Chromosome	c060502050	NN	B-NP	O
substitution	substitution	s0123030305	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
(	(	(000	(	O	O
CSS	CSS	c200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
chromosome	chromosome	c060502050	NN	I-NP	O
from	from	f605	IN	B-PP	O
one	one	o500	CD	B-NP	O
inbred	inbred	i51603	JJ	I-NP	O
strain	strain	s3605	NN	I-NP	O
(	(	(000	(	O	O
donor	donor	d0506	NN	B-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
onto	onto	o530	IN	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
strain	strain	s3605	NN	I-NP	O
(	(	(000	(	O	O
host	host	h023	NN	B-NP	O
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
backcrossing	backcrossing	b02602052	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
identify	identify	i3053010	VB	I-VP	O
quantitative	quantitative	q0530303010	JJ	B-NP	O
trait	trait	t603	NN	I-NP	O
loci	locus	l020	NNS	I-NP	O
(	(	(000	(	O	O
QTLs	QTL	q342	NNS	B-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	I-VP	O
seizure	seizure	s02060	VB	I-VP	B-Disease
susceptibility	susceptibility	s020130104030	NN	B-NP	O
.	.	.000	.	O	O

QTLs	QTL	q342	NNS	B-NP	O
for	for	f060	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
CSS	CSS	c200	NN	B-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
localize	localize	l0204020	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
genes	gene	g0502	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
QTLs	QTL	q342	NNS	B-NP	O
identified	identify	i30530103	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
B6	B6	0000	NN	I-NP	O
(	(	(000	(	O	O
host	host	h023	NN	B-NP	O
)	)	)000	)	O	O
x	x	x000	NN	B-NP	O
A	A	a000	NN	I-NP	O
/	/	/000	SYM	O	O
J	J	j000	NN	B-NP	O
(	(	(000	(	O	O
donor	donor	d0506	NN	B-NP	O
)	)	)000	)	O	O
CSS	CSS	c200	NN	B-NP	O
panel	panel	p0504	NN	I-NP	O
to	to	t000	TO	B-VP	O
localize	localize	l0204020	VB	I-VP	O
genes	gene	g0502	NNS	B-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
fifty	fifty	f0130	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
adult	adult	a3043	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
CSS	CSS	c200	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
58	58	0000	CD	B-NP	O
B6	B6	0000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
39	39	0000	CD	B-NP	O
A	A	a000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
J	J	j000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
susceptibility	susceptibility	s020130104030	NN	B-NP	O
to	to	t000	TO	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Highest	Highest	h02023	JJ	B-NP	O
stage	stage	s3020	NN	I-NP	O
reached	reach	r0203	VBD	B-VP	O
and	and	a530	CC	O	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
each	each	e020	DT	B-NP	O
stage	stage	s3020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

B6	B6	0000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
resistant	resistant	r02023053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
slower	slow	s406	JJR	B-ADJP	O
to	to	t000	TO	B-VP	O
reach	reach	r020	VB	I-VP	O
stages	stage	s30202	NNS	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
A	A	a000	NN	B-NP	O
/	/	/000	SYM	I-NP	O
J	J	j000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CSS	CSS	c200	NN	I-NP	O
for	for	f060	IN	B-PP	O
Chromosomes	Chromosome	c0605020502	NNS	B-NP	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
18	18	0000	CD	I-NP	O
progressed	progress	p60260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
severe	severe	s01060	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
,	,	,000	,	O	O
diverging	diverge	d01062052	VBG	B-VP	O
dramatically	dramatically	d6050302040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
B6	B6	0000	NN	I-NP	O
phenotype	phenotype	p0503010	NN	I-NP	O
.	.	.000	.	O	O

Latencies	Latency	l0305202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
stages	stage	s30202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
shorter	short	s06306	JJR	I-ADJP	O
for	for	f060	IN	B-PP	O
CSS10	CSS10	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
CSS18	CSS18	0000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

CSS	CSS	c200	NN	B-NP	O
mapping	mapping	m01052	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
susceptibility	susceptibility	s020130104030	NN	I-NP	O
loci	locus	l020	NNS	I-NP	O
on	on	o500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
Chromosomes	Chromosome	c0605020502	NNS	I-NP	O
10	10	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
18	18	0000	CD	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
approach	approach	a16020	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
framework	framework	f605062	NN	I-NP	O
for	for	f060	IN	B-PP	O
identifying	identify	i305301052	VBG	B-VP	O
potentially	potentially	p03053040	RB	B-NP	O
novel	novel	n0104	JJ	I-NP	O
homologous	homologous	h05040202	JJ	I-NP	O
candidate	candidate	c05303030	NN	I-NP	O
genes	gene	g0502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vitro	vitro	v0360	FW	I-NP	O
characterization	characterization	c0602306020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
parasympathetic	parasympathetic	p0602051030302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
detrusor	detrusor	d0360206	NN	B-NP	O
function	function	f052305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
impaired	impaired	i510603	JJ	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	B-NP	O
and	and	a530	CC	O	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
muscarinic	muscarinic	m02060502	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
altered	alter	a430603	VBN	B-VP	O
.	.	.000	.	O	O

Whether	Whether	w0306	RB	B-ADVP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
the	the	t000	DT	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
transmission	transmission	t605250205	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
presently	presently	p60205340	RB	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

Responses	Response	r02105202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
strip	strip	s3601	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
pretreated	pretreate	p60360303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
electrical	electrical	e402360204	JJ	B-NP	O
field	field	f043	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
agonists	agonist	a2050232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
and	and	a530	CC	I-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
muscarinic	muscarinic	m02060502	JJ	B-NP	O
,	,	,000	,	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
purinergic	purinergic	p060506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

Generally	Generally	g0506040	RB	B-ADVP	O
,	,	,000	,	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
contractions	contraction	c0536023052	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
responses	response	r02105202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
low	low	l000	JJ	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
Hz	Hz	h200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
inflamed	inflamed	i5140503	JJ	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
types	type	t0102	NNS	I-NP	O
,	,	,000	,	O	O
purinoceptor	purinoceptor	p06050201306	NN	B-NP	O
desensitization	desensitization	d0205203020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
beta	beta	b030	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
methylene	methylene	m0304050	NN	B-NP	I-Chemical
adenosine	adenosine	a30502050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
triphosphate	triphosphate	t601021030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
beta	beta	b030	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
meATP	meATP	m031	NN	B-NP	I-Chemical
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
low	low	l000	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
Hz	Hz	h200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
diphenylacetoxy	diphenylacetoxy	d0105040203020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
methylpiperidine	methylpiperidine	m03041010603050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DAMP	DAMP	d051	NN	I-NP	I-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
'	'	'000	``	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
selective	selective	s04023010	JJ	B-ADJP	O
'	'	'000	''	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
methoctramine	methoctramine	m03023605050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
'	'	'000	``	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
selective	selective	s04023010	JJ	B-ADJP	O
'	'	'000	''	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pirenzepine	pirenzepine	p0605201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
'	'	'000	``	O	O
M	M	m000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
selective	selective	s04023010	JJ	B-ADJP	O
'	'	'000	''	O	O
)	)	)000	)	O	O
antagonized	antagonize	a5302050203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
-	-	-000	HYPH	O	O
evoked	evoke	e10203	VBN	B-VP	O
contractile	contractile	c0536023040	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
more	more	m060	RBR	B-ADVP	O
potently	potently	p0305340	RB	I-ADVP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
phasic	phasic	p0202	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
.	.	.000	.	O	O

4	4	4000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DAMP	DAMP	d051	NN	I-NP	I-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
contractions	contraction	c0536023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
more	more	m060	RBR	B-ADVP	O
potently	potently	p0305340	RB	I-ADVP	O
than	than	t050	IN	B-PP	O
methoctramine	methoctramine	m03023605050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
pirenzepine	pirenzepine	p0605201050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
inflamed	inflamed	i5140503	JJ	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
phasic	phasic	p0202	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrical	electrical	e402360204	JJ	I-NP	O
field	field	f043	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
evoked	evoke	e10203	VBN	B-NP	O
contraction	contraction	c053602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pirenzepine	pirenzepine	p0605201050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DAMP	DAMP	d051	NN	I-NP	I-Chemical
antagonism	antagonism	a530205025	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
much	much	m020	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
efficient	efficient	e102053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
methoctramine	methoctramine	m03023605050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
-	-	-000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
instead	instead	i52303	RB	B-PP	O
of	of	o100	IN	I-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
-	-	-000	SYM	I-NP	O
-	-	-000	HYPH	O	O
the	the	t000	DT	B-NP	O
tonic	tonic	t0502	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
contractions	contraction	c0536023052	NNS	B-NP	O
to	to	t000	TO	B-PP	O
carbachol	carbachol	c0610204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
in	in	i500	IN	B-PP	O
inflamed	inflamed	i5140503	JJ	B-ADJP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
strips	strip	s36012	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
isoprenaline	isoprenaline	i20160504050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
relaxations	relaxation	r040203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
inflamed	inflamed	i5140503	JJ	B-NP	O
strips	strip	s36012	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
cystitis	cystitis	c0230302	NN	B-NP	B-Disease
substantial	substantial	s012305304	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
efferent	efferent	e106053	JJ	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
occur	occur	o206	VBP	B-VP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
postjunctional	postjunctional	p023205230504	JJ	B-ADJP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
relaxations	relaxation	r040203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
,	,	,000	,	O	O
effects	effect	e10232	NNS	B-NP	O
by	by	b000	IN	B-PP	O
prejunctional	prejunctional	p60205230504	JJ	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

Direct	Direct	d06023	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
hyperpolarization	hyperpolarization	h010610406020305	NN	I-NP	O
-	-	-000	HYPH	O	O
activated	activate	a23010303	VBN	B-VP	O
cyclic	cyclic	c02402	JJ	B-NP	B-Chemical
nucleotide	nucleotide	n02403030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
gated	gate	g0303	VBN	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
channels	channel	c05042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
represents	represent	r016020532	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Activation	Activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
presynaptic	presynaptic	p6020501302	JJ	B-NP	O
alpha2	alpha2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
widely	widely	w03040	RB	I-NP	O
accepted	accept	a201303	VBN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antisympathetic	antisympathetic	a5302051030302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
target	target	t06203	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
elicits	elicit	e402032	VBZ	B-VP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
independent	independent	i5301053053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
alpha2	alpha2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptors	adrenoceptor	a360502013062	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
mice	mouse	m020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
deletion	deletion	d040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
3	3	3000	CD	I-NP	O
alpha2	alpha2	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
adrenoceptor	adrenoceptor	a36050201306	NN	B-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
(	(	(000	(	O	O
alpha2ABC	alpha2ABC	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Alpha2ABC	Alpha2ABC	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADJP	O
unresponsive	unresponsive	u56021052010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
hypnotic	hypnotic	h0150302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
lowered	lower	l0603	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
alpha2ABC	alpha2ABC	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
150	150	0000	CD	I-NP	O
bpm	bpm	b150	NN	I-NP	O
.	.	.000	.	O	O

Clonidine	Clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
alpha2ABC	alpha2ABC	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
bradycardic	bradycardic	b6030206302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-VP	O
beating	beat	b03052	VBG	I-VP	O
right	right	r0203	JJ	B-NP	O
atria	atria	a360	NN	I-NP	O
from	from	f605	IN	B-PP	O
alpha2ABC	alpha2ABC	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
and	and	a530	CC	O	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Clonidine	Clonidine	c40503050	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
native	native	n03010	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
current	current	c06053	NN	I-NP	O
(	(	(000	(	O	O
I	I	i000	NN	B-NP	O
(	(	(000	(	O	O
f	f	f000	NN	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	O
node	node	n030	NN	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
I	I	i000	NN	I-NP	O
(	(	(000	(	O	O
f	f	f000	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
generating	generate	g050603052	VBG	B-NP	O
hyperpolarization	hyperpolarization	h010610406020305	NN	I-NP	O
-	-	-000	HYPH	O	O
activated	activate	a23010303	VBN	B-VP	O
cyclic	cyclic	c02402	JJ	B-NP	B-Chemical
nucleotide	nucleotide	n02403030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
gated	gate	g0303	VBN	I-VP	O
(	(	(000	(	O	O
HCN	HCN	h250	NN	B-NP	O
)	)	)000	)	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	O	O
HCN4	HCN4	0000	NN	B-NP	O
channels	channel	c05042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
transfected	transfecte	t6052102303	VBN	B-NP	O
HEK293	HEK293	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blocking	block	b402052	VBG	B-VP	O
I	I	i000	NN	B-NP	O
(	(	(000	(	O	O
f	f	f000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
slope	slope	s4010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
depolarization	depolarization	d010406020305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
pacemaker	pacemaker	p02050206	NN	B-NP	O
potentials	potential	p03053042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
sinoatrial	sinoatrial	s0503604	JJ	B-NP	O
node	node	n030	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
from	from	f605	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
and	and	a530	CC	I-NP	O
alpha2ABC	alpha2ABC	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Direct	Direct	d06023	JJ	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
HCN	HCN	h250	NN	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
channels	channel	c05042	NNS	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
bradycardic	bradycardic	b6030206302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
gene	gene	g050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
thus	thus	t020	RB	O	O
,	,	,000	,	O	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
represent	represent	r01602053	VBP	B-VP	O
novel	novel	n0104	JJ	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
future	future	f03060	JJ	B-NP	O
HCN	HCN	h250	NN	I-NP	O
channel	channel	c0504	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Granulomatous	Granulomatous	g60504050302	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
combination	combination	c051050305	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	I-Chemical
amoxicillin	amoxicillin	a502020405	NN	B-NP	I-Chemical
and	and	a530	CC	O	I-Chemical
clavulanic	clavulanic	c401040502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
amoxicillin	amoxicillin	a502020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
clavulanic	clavulanic	c401040502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
histologic	histologic	h023040202	JJ	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
granulomas	granuloma	g605040502	NNS	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
lesion	lesion	l0205	NN	B-NP	O
broadens	broaden	b603052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-VP	O
represented	represent	r0160205303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
benign	benign	b05025	JJ	I-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
granulomas	granuloma	g605040502	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
favor	favor	f0106	VBP	B-VP	O
an	an	a500	DT	B-NP	O
immunoallergic	immunoallergic	i5050406202	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
penicillin	penicillin	p05020405	NN	B-NP	B-Chemical
derivatives	derivative	d0601030102	NNS	I-NP	O
and	and	a530	CC	O	O
amoxicillin	amoxicillin	a502020405	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
induce	induce	i53020	VB	I-VP	O
such	such	s020	JJ	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
amoxicillin	amoxicillin	a502020405	NN	I-NP	B-Chemical
component	component	c05105053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
potentiating	potentiating	p0305303052	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clavulanic	clavulanic	c401040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
role	role	r040	NN	I-NP	O
.	.	.000	.	O	O

Dobutamine	Dobutamine	d010305050	NN	B-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
indicator	indicator	i53020306	NN	I-NP	O
of	of	o100	IN	B-PP	O
diminished	diminish	d05050203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
anticancer	anticancer	a530205206	JJ	I-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
echocardiographic	echocardiographic	e2020630260102	JJ	I-NP	O
screening	screening	s2605052	NN	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
cohort	cohort	c063	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
to	to	t000	TO	B-VP	O
differentiate	differentiate	d0106053030	VB	I-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
survivors	survivor	s06101062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
from	from	f605	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Echocardiographic	Echocardiographic	e2020630260102	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
16	16	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
before	before	b01060	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
27	27	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
532	532	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
196	196	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
echocardiographic	echocardiographic	e2020630260102	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
12	12	0000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
matched	match	m03203	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Graded	Grade	g60303	VBN	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
min	min	m050	NN	B-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Echocardiographic	Echocardiographic	e2020630260102	JJ	B-NP	O
Doppler	Doppler	d01406	NNP	I-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
at	at	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Dobutamine	Dobutamine	d010305050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
min	min	m050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
six	six	s020	CD	B-NP	O
studies	study	s30302	NNS	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
important	important	i51063053	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
values	value	v0402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
end	end	e530	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
dimension	dimension	d0505205	NN	I-NP	O
and	and	a530	CC	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
thickening	thicken	t0205052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	I-VP	O
clearly	clearly	c40640	RB	I-VP	O
delineated	delineate	d04050303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

End	End	e530	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
dimension	dimension	d0505205	NN	I-NP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
for	for	f060	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

End	End	e530	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
dimension	dimension	d0505205	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
min	min	m050	NN	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
14	14	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
for	for	f060	IN	B-PP	O
control	control	c053604	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Influence	Influence	i5140520	NN	B-NP	O
of	of	o100	IN	B-PP	O
smoking	smoking	s502052	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
cochlea	cochlea	c02040	NN	B-NP	O
.	.	.000	.	O	O

Does	Do	d020	VBZ	O	O
smoking	smoking	s502052	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
affect	affect	a1023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
amplitudes	amplitude	a514030302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
otoacoustic	otoacoustic	o30202302	JJ	I-NP	O
emissions	emission	e502052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
newborns	newborn	n010652	NNS	B-NP	O
?	?	?000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
Maternal	Maternal	m0306504	JJ	B-NP	O
tobacco	tobacco	t01020	NN	I-NP	O
smoking	smoking	s502052	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
negative	negative	n0203010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
fetal	fetal	f0304	JJ	B-NP	O
growth	growth	g6030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
smoking	smoking	s502052	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
developing	develop	d010401052	VBG	I-NP	O
cochlea	cochlea	c02040	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
smoking	smoking	s502052	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
positively	positively	p020301040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
smoking	smoking	s502052	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
otoacoustic	otoacoustic	o30202302	JJ	I-NP	O
emissions	emission	e502052	NNS	I-NP	O
(	(	(000	(	O	O
TEOAEs	TEOAE	t020	NNS	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
neonatal	neonatal	n050304	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
for	for	f060	IN	B-PP	O
hearing	hear	h06052	VBG	B-VP	B-Disease
impairment	impairment	i51065053	NN	B-NP	I-Disease
and	and	a530	CC	O	O
involved	involve	i5104103	VBD	B-VP	O
both	both	b030	DT	B-NP	O
ears	ear	e062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
newborns	newborn	n010652	NNS	I-NP	O
.	.	.000	.	O	O

Newborns	Newborn	n010652	NNS	B-NP	O
whose	whose	w020	WP$	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
reported	report	r0106303	VBD	B-VP	O
smoking	smoking	s502052	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
200	200	0000	CD	B-NP	O
ears	ear	e062	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
newborns	newborn	n010652	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
200	200	0000	CD	B-NP	O
ears	ear	e062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whose	whose	w020	WP$	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
non	non	n050	AFX	B-ADJP	O
-	-	-000	HYPH	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
.	.	.000	.	O	O

Exposure	Exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
tobacco	tobacco	t01020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
low	low	l000	JJ	B-ADJP	O
(	(	(000	(	O	O
<	<	<000	SYM	O	O
5	5	5000	CD	B-NP	O
cigarettes	cigarette	c02060302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
88	88	0000	CD	B-NP	O
ears	ear	e062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
moderate	moderate	m0306030	JJ	B-ADJP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
<	<	<000	SYM	O	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
cigarettes	cigarette	c02060302	NNS	B-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
<	<	<000	SYM	O	O
10	10	0000	CD	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
76	76	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
high	high	h020	JJ	B-ADJP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
cigarettes	cigarette	c02060302	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
36	36	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
exposed	expose	e210203	VBN	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
,	,	,000	,	O	O
TEOAEs	TEOAE	t020	NNS	B-NP	O
mean	mean	m050	VBP	B-VP	O
response	response	r0210520	NN	B-NP	O
(	(	(000	(	O	O
across	across	a2602	IN	B-PP	O
frequency	frequency	f6020520	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
mean	mean	m050	JJ	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
at	at	a300	IN	B-PP	O
4000Hz	4000Hz	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
exposed	expose	e210203	VBN	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
.	.	.000	.	O	O

Comparisons	Comparison	c0510602052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
exposed	expose	e210203	VBN	B-NP	O
newborns	newborn	n010652	NNS	I-NP	O
'	'	'000	POS	B-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
comparing	compare	c05106052	VBG	B-VP	O
each	each	e020	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
TEOAEs	TEOAE	t020	NNS	B-NP	I-Disease
amplitudes	amplitude	a514030302	NNS	I-NP	I-Disease
at	at	a300	IN	B-PP	O
4000Hz	4000Hz	0000	NNP	B-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
TEOAEs	TEOAE	t020	NNS	I-NP	O
responses	response	r02105202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
highly	highly	h02040	RB	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
newborns	newborn	n010652	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
utero	utero	u3060	NN	B-NP	O
,	,	,000	,	O	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
tobacco	tobacco	t01020	NN	B-NP	O
smoking	smoking	s502052	NN	I-NP	B-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
impact	impact	i51023	NN	I-NP	O
on	on	o500	IN	B-PP	O
outer	outer	o0306	JJ	B-NP	O
hair	hair	h060	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
equally	equally	e2040	RB	B-ADJP	O
true	true	t600	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
newborns	newborn	n010652	NNS	I-NP	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
establish	establish	e23014020	VB	I-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
maternal	maternal	m0306504	JJ	B-NP	O
smoking	smoking	s502052	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
neonate	neonate	n05030	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
hearing	hearing	h06052	NN	I-NP	O
acuity	acuity	a2030	NN	I-NP	O
.	.	.000	.	O	O

Simvastatin	Simvastatin	s0510230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
leg	leg	l020	NN	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myonecrosis	myonecrosis	m050260202	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
hypothyroidism	hypothyroidism	h01030603025	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
54	54	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
hypothyroid	hypothyroid	h01030603	NN	I-NP	B-Disease
male	male	m040	JJ	B-NP	O
taking	take	t02052	VBG	I-NP	O
thyroxine	thyroxine	t0602050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
leg	leg	l020	NN	I-NP	O
compartment	compartment	c0510635053	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myonecrosis	myonecrosis	m050260202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Urgent	Urgent	u62053	JJ	B-NP	O
fasciotomies	fasciotomy	f02030502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
made	make	m030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
uneventful	uneventful	u501053104	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
seen	see	s050	VBN	I-VP	O
more	more	m060	RBR	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
worldwide	worldwide	w0643030	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
approval	approval	a160104	NN	I-NP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
arteriopathic	arteriopathic	a6306010302	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Neuroinflammation	Neuroinflammation	n060514050305	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
neonatal	neonatal	n050304	JJ	B-NP	O
terbutaline	terbutaline	t0610304050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
:	:	:000	:	O	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Autism	Autism	a03025	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
neurodevelopmental	neurodevelopmental	n0603010401505304	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
presenting	present	p602053052	VBG	B-VP	O
before	before	b01060	IN	B-PP	O
3	3	3000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
with	with	w030	IN	B-PP	O
deficits	deficit	d0102032	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
communication	communication	c0505020305	NN	B-NP	I-Disease
and	and	a530	CC	O	I-Disease
social	social	s0204	JJ	B-NP	I-Disease
skills	skill	s2042	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
repetitive	repetitive	r010303010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
influences	influence	i51405202	NNS	I-NP	O
,	,	,000	,	O	O
recent	recent	r02053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
or	or	o600	CC	I-NP	O
chemical	chemical	c050204	NN	I-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Terbutaline	Terbutaline	t0610304050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
beta2	beta2	0000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
arrest	arrest	a6023	VB	I-VP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
labor	labor	l0106	NN	I-NP	I-Disease
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
concordance	concordance	c0520630520	NN	I-NP	O
for	for	f060	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
dizygotic	dizygotic	d02020302	JJ	B-NP	O
twins	twin	t052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
and	and	a530	CC	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
developing	develop	d010401052	VBG	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Newborn	Newborn	n01065	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
daily	daily	d040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
postnatal	postnatal	p02350304	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
PN	PN	p500	NN	B-NP	O
)	)	)000	)	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	O	O
PN	PN	p500	NN	B-NP	O
11	11	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
14	14	0000	CD	I-NP	O
and	and	a530	CC	O	O
examined	examine	e2050503	VBD	B-VP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
PN	PN	p500	NN	B-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
PN	PN	p500	NN	B-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
robust	robust	r01023	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
PN	PN	p500	NN	B-NP	O
30	30	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
and	and	a530	CC	I-NP	O
cerebrocortical	cerebrocortical	c06016020630204	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
PN	PN	p500	NN	B-NP	O
11	11	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
behavioral	behavioral	b010604	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
PN	PN	p500	NN	B-NP	O
2	2	2000	CD	I-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
showed	show	s030	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-NP	O
patterns	pattern	p030652	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyper	hyper	h0106	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
novelty	novelty	n010430	NN	B-NP	O
and	and	a530	CC	O	O
aversive	aversive	a1062010	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
assessed	assess	a20203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
open	open	o105	JJ	I-NP	O
field	field	f043	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acoustic	acoustic	a202302	JJ	I-NP	O
startle	startle	s306340	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
beta2	beta2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
overstimulation	overstimulation	o1062305040305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
critical	critical	c6030204	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
innate	innate	i5030	JJ	B-NP	O
neuroinflammatory	neuroinflammatory	n0605140503060	JJ	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
and	and	a530	CC	O	O
behavioral	behavioral	b010604	JJ	B-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
,	,	,000	,	O	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
described	describe	d0260103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
autism	autism	a03025	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
understanding	understand	u530623053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
neuropathological	neuropathological	n06010304020204	JJ	I-NP	O
processes	process	p6020202	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
autism	autism	a03025	NN	B-NP	B-Disease
spectrum	spectrum	s1023605	NN	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Upregulation	Upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P	P	p000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
glycoprotein	glycoprotein	g4020160305	NN	I-NP	O
in	in	i500	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
TR	TR	t600	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
resembles	resemble	r02051402	VBZ	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-VP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
efflux	efflux	e1402	NN	I-NP	O
transporter	transporter	t6052106306	NN	I-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
multidrug	multidrug	m04303602	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
2	2	2000	CD	I-NP	O
(	(	(000	(	O	O
MRP2	MRP2	0000	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
efflux	efflux	e1402	NN	I-NP	O
transporter	transporter	t6052106306	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
expressed	express	e2160203	VBN	I-VP	O
predominantly	predominantly	p603050505340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
domain	domain	d0505	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatocytes	hepatocyte	h0103020302	NNS	B-NP	O
but	but	b030	CC	O	O
seems	seem	s052	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
expressed	express	e2160203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
apical	apical	a10204	JJ	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
form	form	f065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
(	(	(000	(	O	O
BBB	BBB	b100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MRP2	MRP2	0000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
absent	absent	a12053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
transport	transport	t60521063	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
(	(	(000	(	O	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
Wistar	Wistar	w02306	NNP	B-NP	O
rat	rat	r030	NN	I-NP	O
mutant	mutant	m03053	NN	I-NP	O
,	,	,000	,	O	O
so	so	s000	IN	B-SBAR	O
that	that	t030	IN	I-SBAR	O
this	this	t020	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
strain	strain	s3605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
very	very	v060	RB	B-ADJP	O
helpful	helpful	h04104	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
defining	define	d0105052	VBG	B-VP	O
substrates	substrate	s012360302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
by	by	b000	IN	B-PP	O
comparing	compare	c05106052	VBG	B-VP	O
tissue	tissue	t020	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
or	or	o600	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
transport	transport	t60521063	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
competent	competent	c05103053	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
strategy	strategy	s3603020	NN	I-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
access	access	a202	NN	I-NP	O
of	of	o100	IN	B-PP	O
antiepileptic	antiepileptic	a53010401302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
AEDs	AED	a032	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
recently	recently	r0205340	RB	B-ADVP	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
substrate	substrate	s01236030	NN	I-NP	O
for	for	f060	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
drawback	drawback	d60102	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
genetically	genetically	g050302040	RB	B-NP	O
deficient	deficient	d0102053	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
compensatory	compensatory	c05105203060	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
upregulation	upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
transporters	transporter	t60521063062	NNS	I-NP	O
can	can	c050	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
prompted	prompt	p6051303	VBD	B-VP	O
us	us	u200	PRP	B-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
P	P	p000	NN	B-NP	O
-	-	-000	HYPH	O	O
glycoprotein	glycoprotein	g4020160305	NN	B-NP	O
(	(	(000	(	O	O
Pgp	Pgp	p210	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
efflux	efflux	e1402	NN	I-NP	O
transporter	transporter	t6052106306	NN	I-NP	O
in	in	i500	IN	B-PP	O
many	many	m050	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
nonmutant	nonmutant	n0503053	JJ	O	O
(	(	(000	(	O	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
)	)	)000	)	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
Pgp	Pgp	p210	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
sections	section	s023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
,	,	,000	,	I-NP	O
highly	highly	h02040	RB	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
monoclonal	monoclonal	m050240504	JJ	I-NP	O
MRP2	MRP2	0000	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
monoclonal	monoclonal	m050240504	JJ	I-NP	O
Pgp	Pgp	p210	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
C219	C219	0000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Immunofluorescence	Immunofluorescence	i50501406020520	NN	B-NP	O
staining	staining	s305052	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
MRP2	MRP2	0000	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
label	label	l0104	VB	I-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
microvessels	microvessel	m0260102042	NNS	B-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
such	such	s020	JJ	B-NP	O
labeling	labeling	l0104052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
absent	absent	a12053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	O	O
regulation	regulation	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Pgp	Pgp	p210	NN	B-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
such	such	s020	JJ	I-NP	O
obvious	obvious	o102	JJ	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pgp	Pgp	p210	NN	B-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
sections	section	s023052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
comparable	comparable	c051060140	JJ	I-NP	O
overexpression	overexpression	o10602160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pgp	Pgp	p210	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Experiments	Experiment	e2106050532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pgp	Pgp	p210	NN	I-NP	O
substrate	substrate	s01236030	NN	I-NP	O
phenobarbital	phenobarbital	p05010610304	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
Pgp	Pgp	p210	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
tariquidar	tariquidar	t06020306	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
substantiated	substantiate	s01230530303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Pgp	Pgp	p210	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
functional	functional	f05230504	JJ	B-ADJP	O
and	and	a530	CC	O	O
compensates	compensate	c0510520302	NNS	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
Pgp	Pgp	p210	NN	B-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
compensation	compensation	c0510520305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MRP2	MRP2	0000	NN	B-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
such	such	s020	PDT	B-NP	O
a	a	a000	DT	I-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
occurs	occur	o2062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
injury	injury	i52060	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
brain	brain	b605	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
substantiate	substantiate	s0123053030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
concept	concept	c052013	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
MRP2	MRP2	0000	NN	B-NP	O
performs	perform	p0610652	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
TR	TR	t600	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
an	an	a500	DT	B-NP	O
interesting	interesting	i5306023052	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
consequences	consequence	c0520205202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
overexpression	overexpression	o10602160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
Pgp	Pgp	p210	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NN	I-NP	O
on	on	o500	IN	B-PP	O
access	access	a202	NN	B-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
of	of	o100	IN	B-PP	O
inducing	induce	i5302052	VBG	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
Pgp	Pgp	p210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
enhancing	enhance	e5052052	VBG	B-VP	O
events	event	e10532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
.	.	.000	.	O	O

Role	Role	r040	NN	B-NP	O
of	of	o100	IN	B-PP	O
xanthine	xanthine	x053050	NN	B-NP	B-Chemical
oxidase	oxidase	o203020	NN	I-NP	O
in	in	i500	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

1	1	1000	LS	B-LST	O
.	.	.000	.	O	O

Glucocorticoid	Glucocorticoid	g402020630203	NN	B-NP	O
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
GC	GC	g200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
HT	HT	h300	NN	I-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
redox	redox	r0302	NN	I-NP	O
imbalance	imbalance	i51040520	NN	I-NP	O
.	.	.000	.	O	O

2	2	2000	LS	B-LST	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
xanthine	xanthine	x053050	NN	B-NP	B-Chemical
oxidase	oxidase	o203020	NN	I-NP	O
(	(	(000	(	O	O
XO	XO	x000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
production	production	p60302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	O
species	specie	s10202	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
dex	dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
HT	HT	h300	NN	I-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

3	3	3000	LS	B-LST	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
male	male	m040	JJ	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
divided	divide	d010303	VBN	I-VP	O
randomly	randomly	r0530540	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
four	four	f060	CD	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
:	:	:000	:	O	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
dex	dex	d020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
allopurinol	allopurinol	a401060504	NN	B-NP	B-Chemical
plus	plus	p402	CC	O	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
allopurinol	allopurinol	a401060504	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
dex	dex	d020	NN	I-NP	B-Chemical
.	.	.000	.	O	O

4	4	4000	LS	B-LST	O
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
bodyweights	bodyweight	b0302032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
each	each	e020	DT	B-NP	O
alternate	alternate	a43065030	JJ	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Thymus	Thymus	t0502	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
serum	serum	s0605	NN	B-NP	O
urate	urate	u6030	NN	I-NP	B-Chemical
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
XO	XO	x000	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

5	5	5000	LS	B-LST	O
.	.	.000	.	O	O

Dex	Dex	d020	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	B-Disease
SBP	SBP	s100	NN	B-NP	I-Disease
(	(	(000	(	O	O
110	110	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
126	126	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	B-Disease
thymus	thymus	t0502	NN	B-NP	I-Disease
(	(	(000	(	O	I-Disease
P	P	p000	NN	B-NP	I-Disease
<	<	<000	SYM	B-ADJP	I-Disease
0	0	0000	CD	B-NP	I-Disease
.	.	.000	.	I-NP	I-Disease
001	001	0000	CD	I-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
bodyweights	bodyweight	b0302032	NNS	B-NP	I-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
"	"	"000	''	O	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Allopurinol	Allopurinol	a401060504	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
serum	serum	s0605	NN	B-NP	O
urate	urate	u6030	NN	I-NP	B-Chemical
from	from	f605	IN	B-PP	O
76	76	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
30	30	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
and	and	a530	CC	B-PP	O
from	from	f605	IN	B-PP	O
84	84	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
28	28	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
in	in	i500	IN	B-PP	O
dex	dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	O	O
)	)	)000	)	O	O
groups	group	g6012	NNS	B-NP	O
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
.	.	.000	.	O	O

Allopurinol	Allopurinol	a401060504	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
dex	dex	d020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
HT	HT	h300	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
previous	previous	p60102	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
allopurinol	allopurinol	a401060504	NN	B-NP	B-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
adrenocorticotrophic	adrenocorticotrophic	a360502063020360102	JJ	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
induced	induce	i530203	VBD	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
XO	XO	x000	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
determinant	determinant	d0306505053	NN	I-NP	O
of	of	o100	IN	B-PP	O
GC	GC	g200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
HT	HT	h300	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
emetic	emetic	e50302	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
routine	routine	r03050	JJ	B-NP	O
cataract	cataract	c0306023	NN	I-NP	B-Disease
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
St	St	s300	NN	B-NP	O
.	.	.000	.	O	O

Luke	Luke	l020	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
,	,	,000	,	O	O
Gwardamangia	Gwardamangia	g063050520	NNP	B-NP	O
,	,	,000	,	O	O
Malta	Malta	m0430	NNP	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
armed	armed	a6503	JJ	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
comprised	comprise	c05160203	VBD	B-VP	O
40	40	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
uneventful	uneventful	u501053104	JJ	B-NP	O
sutureless	sutureless	s03060402	JJ	I-NP	O
phacoemulsification	phacoemulsification	p020504201020305	NN	I-NP	O
under	under	u5306	IN	B-PP	O
sub	sub	s010	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
local	local	l0204	JJ	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
plain	plain	p405	JJ	B-NP	O
lignocaine	lignocaine	l02502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
,	,	,000	,	O	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
space	space	s1020	NN	I-NP	O
and	and	a530	CC	I-NP	O
Group	Group	g601	NN	I-NP	O
B	B	b000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
injected	inject	i5202303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
.	.	.000	.	O	O

Postoperatively	Postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	I-Disease
vomiting	vomiting	v0503052	NN	B-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
chi	chi	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
square	square	s2060	NN	I-NP	O
test	test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
statistical	statistical	s3030230204	JJ	I-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
results	result	r020432	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Sixty	Sixty	s0230	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
emetic	emetic	e50302	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
headache	headache	h03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Tenon	Tenon	t0505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
space	space	s1020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	I-Disease
vomiting	vomiting	v0503052	NN	B-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
headache	headache	h03020	NN	B-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
self	self	s041	AFX	B-ADJP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
.	.	.000	.	O	O

Assessment	Assessment	a2025053	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Electrocardiography	Electrocardiography	e4023602063026010	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
low	low	l000	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
detecting	detect	d03023052	VBG	B-VP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
added	add	a303	VBN	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
value	value	v040	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
index	index	i5302	NN	I-NP	O
(	(	(000	(	O	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	B-NP	O
dtejc	dtejc	d302	NN	I-NP	O
)	)	)000	)	O	O
measurement	measurement	m020605053	NN	B-NP	O
,	,	,000	,	O	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
brachial	brachial	b60204	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	I-VP	O
standard	standard	s3053063	VB	I-VP	O
12	12	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
lead	lead	l030	NN	I-NP	O
ECG	ECG	e200	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
detecting	detect	d03023052	VBG	B-VP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
Tc99m	Tc99m	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Sestamibi	Sestamibi	s02305010	NN	I-NP	I-Chemical
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
photon	photon	p0305	NN	I-NP	O
emission	emission	e50205	NN	I-NP	O
computed	compute	c0510303	VBD	B-VP	O
tomography	tomography	t05026010	NN	B-NP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
gold	gold	g043	JJ	I-NP	O
standard	standard	s3053063	NN	I-NP	O
of	of	o100	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
group	group	g601	NN	I-NP	O
comprised	comprise	c05160203	VBD	B-VP	O
40	40	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
Sestamibi	Sestamibi	s02305010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
/	/	/000	SYM	I-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
stress	stress	s3602	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Simultaneous	Simultaneous	s050430502	JJ	B-NP	O
measurements	measurement	m0206050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ECG	ECG	e200	NN	B-NP	O
and	and	a530	CC	O	O
brachial	brachial	b60204	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
dP	dP	d100	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dtejc	dtejc	d302	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
each	each	e020	DT	B-NP	O
dobutamine	dobutamine	d010305050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
40	40	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
compatible	compatible	c051030140	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
ischemia	ischemia	i2050	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
SPECT	SPECT	s1023	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	B-NP	O
dtejc	dtejc	d302	NN	I-NP	O
during	during	d06052	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
dobutamine	dobutamine	d010305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
severely	severely	s0106040	RB	B-ADJP	O
impaired	impaired	i510603	JJ	I-ADJP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
dtejc	dtejc	d302	NN	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
results	result	r020432	NNS	I-NP	O
,	,	,000	,	O	O
giving	give	g01052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
ECG	ECG	e200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
enhanced	enhance	e505203	VBN	I-NP	O
value	value	v040	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
ECG	ECG	e200	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
dramatically	dramatically	d6050302040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
79	79	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
positive	positive	p0203010	JJ	B-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
68	68	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
value	value	v040	NN	I-NP	O
from	from	f605	IN	B-PP	O
54	54	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
78	78	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
specificity	specificity	s1020102030	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
If	If	i100	IN	B-SBAR	O
ECG	ECG	e200	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
specificity	specificity	s1020102030	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
with	with	w030	IN	B-PP	O
dP	dP	d100	NN	B-NP	O
/	/	/000	SYM	I-NP	O
dtejc	dtejc	d302	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
cost	cost	c023	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
savings	saving	s01052	NNS	I-NP	O
alternative	alternative	a4306503010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
or	or	o600	CC	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
exercise	exercise	e2062020	VB	I-VP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
:	:	:000	:	O	O
clinical	clinical	c4050204	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
and	and	a530	CC	O	O
pathogenetic	pathogenetic	p0302050302	JJ	B-NP	O
considerations	consideration	c052030603052	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
published	publish	p0140203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
several	several	s010604	JJ	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
preexisting	preexisting	p602023052	JJ	B-NP	O
,	,	,000	,	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
narrowing	narrowing	n06052	NN	I-NP	O
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
demand	demand	d05053	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
rate	rate	r030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	I-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
spasm	spasm	s1025	NN	B-NP	B-Disease
,	,	,000	,	O	O
thrombus	thrombus	t0605102	NN	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
spasm	spasm	s1025	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
largely	largely	l062040	RB	B-ADJP	O
circumstantial	circumstantial	c062052305304	JJ	I-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
locus	locus	l0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
speculative	speculative	s1020403010	JJ	B-ADJP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
certain	certain	c06305	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
spasm	spasm	s1025	NN	B-NP	B-Disease
involves	involve	i5104102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
epicardial	epicardial	e10206304	JJ	I-NP	O
,	,	,000	,	I-NP	O
medium	medium	m0305	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
size	size	s020	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
intramural	intramural	i536050604	JJ	B-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
.	.	.000	.	O	O

Diffuse	Diffuse	d01020	NN	B-NP	O
intramural	intramural	i536050604	JJ	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
reports	report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
segmental	segmental	s02505304	JJ	B-NP	O
,	,	,000	,	I-NP	O
discrete	discrete	d026030	JJ	I-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
opposite	opposite	o102030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	I-NP	O
in	in	i500	IN	B-PP	O
segments	segment	s0250532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
noninnervated	noninnervated	n05050610303	JJ	B-ADJP	O
)	)	)000	)	O	O
human	human	h0505	JJ	B-NP	O
umbilical	umbilical	u51040204	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
innervation	innervation	i50610305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
explain	explain	e21405	VB	I-VP	O
the	the	t000	DT	B-NP	O
discrepant	discrepant	d02601053	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
,	,	,000	,	I-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

Proteomic	Proteomic	p6030502	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
(	(	(000	(	O	O
LID	LID	l030	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
arise	arise	a6020	VBP	B-VP	O
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
transcriptome	transcriptome	t60526013050	NN	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
LID	LID	l030	NNP	B-NP	B-Disease
[	[	[000	(	O	O
Neurobiol	Neurobiol	n060104	NNP	B-NP	O
.	.	.000	.	I-NP	O
Dis	Dis	d020	NNP	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
17	17	0000	CD	B-NP	O
(	(	(000	(	O	O
2004	2004	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
219	219	0000	CD	B-NP	O
]	]	]000	)	O	O
but	but	b030	CC	O	O
information	information	i510650305	NN	B-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
proteome	proteome	p603050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	I-VP	O
lacking	lack	l02052	VBG	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
samples	sample	s051402	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
unilaterally	unilaterally	u5040306040	RB	I-NP	O
6	6	6000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
bromocriptine	bromocriptine	b605026013050	NN	I-NP	B-Chemical
using	use	u2052	VBG	B-VP	O
two	two	t000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
dimensional	dimensional	d050520504	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
gel	gel	g040	NN	I-NP	O
electrophoresis	electrophoresis	e4023601060202	NN	I-NP	O
and	and	a530	CC	O	O
mass	mass	m020	NN	B-NP	O
spectrometry	spectrometry	s10236050360	NN	I-NP	O
(	(	(000	(	O	O
MS	MS	m200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
DOPA	DOPA	d010	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
LID	LID	l030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
2000	2000	0000	CD	I-NP	O
spots	spot	s1032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
statistical	statistical	s3030230204	JJ	B-NP	O
difference	difference	d01060520	NN	I-NP	O
,	,	,000	,	O	O
67	67	0000	CD	B-NP	O
spots	spot	s1032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
abundance	abundance	a10530520	NN	B-NP	O
and	and	a530	CC	O	O
identified	identify	i30530103	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
matrix	matrix	m03602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
assisted	assist	a202303	VBN	I-NP	O
laser	laser	l0206	NN	I-NP	O
desorption	desorption	d02061305	NN	I-NP	O
/	/	/000	SYM	B-VP	O
ionization	ionization	i05020305	NN	B-NP	O
time	time	t050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
of	of	o100	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
flight	flight	f40203	NN	I-NP	O
MS	MS	m200	NN	I-NP	O
,	,	,000	,	O	O
atmospheric	atmospheric	a350210602	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
assisted	assist	a202303	VBN	B-NP	O
laser	laser	l0206	NN	I-NP	O
desorption	desorption	d02061305	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ionization	ionization	i05020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
HPLC	HPLC	h142	NN	I-NP	O
coupled	couple	c01403	VBN	B-VP	O
tandem	tandem	t05305	JJ	B-NP	O
MS	MS	m200	NN	I-NP	O
(	(	(000	(	O	O
LC	LC	l200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
MS	MS	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
MS	MS	m200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Out	Out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
67	67	0000	CD	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
,	,	,000	,	O	O
LID	LID	l030	NNP	B-NP	B-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
changed	change	c05203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
five	five	f010	CD	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
:	:	:000	:	O	O
alphabeta	alphabeta	a4101030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
crystalin	crystalin	c60230405	NN	I-NP	O
,	,	,000	,	O	O
gamma	gamma	g050	SYM	O	O
-	-	-000	HYPH	O	O
enolase	enolase	e504020	NN	B-NP	O
,	,	,000	,	O	O
guanidoacetate	guanidoacetate	g05030203030	NN	B-NP	O
methyltransferase	methyltransferase	m030436052106020	NN	I-NP	O
,	,	,000	,	O	O
vinculin	vinculin	v0520405	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
proteasome	proteasome	p60302050	NN	B-NP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
subunit	subunit	s010503	NN	I-NP	O
.	.	.000	.	O	O

Complementary	Complementary	c051405053060	JJ	B-NP	O
techniques	technique	t02050202	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
western	western	w023065	JJ	B-NP	O
immunoblotting	immunoblotting	i50501403052	NN	I-NP	O
and	and	a530	CC	I-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
validity	validity	v0403030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
proteomic	proteomic	p6030502	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
new	new	n000	JJ	B-NP	O
insights	insight	i5202032	NNS	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
protein	protein	p60305	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
LID	LID	l030	NNP	B-NP	B-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
Angiography	Angiography	a52026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
Renally	Renally	r05040	RB	B-NP	O
Impaired	Impaired	i510603	JJ	I-NP	O
Patients	Patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
CARE	CARE	c060	NN	B-NP	O
)	)	)000	)	O	O
study	study	s3030	NN	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
No	No	n000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
comparisons	comparison	c0510602052	NNS	I-NP	O
exist	exist	e2023	VBP	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
medium	medium	m0305	NN	I-NP	I-Chemical
iopamidol	iopamidol	i01050304	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
iso	iso	i200	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
contrast	contrast	c0536023	NN	I-NP	B-Chemical
medium	medium	m0305	NN	I-NP	I-Chemical
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
RESULTS	RESULTS	r020432	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
iopamidol	iopamidol	i01050304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
estimated	estimate	e23050303	VBN	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
59	59	0000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
or	or	o600	CC	O	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
SCr	SCr	s260	NN	B-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
and	and	a530	CC	O	O
estimated	estimate	e23050303	VBN	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
medications	medication	m030203052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
postdose	postdose	p023020	JJ	I-NP	O
SCr	SCr	s260	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
over	over	o106	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Secondary	Secondary	s02053060	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
a	a	a000	DT	B-NP	O
postdose	postdose	p023020	JJ	I-NP	O
SCr	SCr	s260	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
>	>	>000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
postdose	postdose	p023020	JJ	I-NP	O
estimated	estimate	e23050303	VBN	I-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
peak	peak	p020	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
SCr	SCr	s260	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
414	414	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
contrast	contrast	c0536023	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
acetylcysteine	acetylcysteine	a203042023050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
SCr	SCr	s260	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
estimated	estimate	e23050303	VBN	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
filtration	filtration	f04360305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
comparable	comparable	c051060140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

SCr	SCr	s260	NN	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
of	of	o100	IN	B-PP	O
204	204	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
iopamidol	iopamidol	i01050304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
14	14	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
210	210	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
rates	rate	r0302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
SCr	SCr	s260	NN	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
44	44	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
SCr	SCr	s260	NN	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
were	be	w060	VBD	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
of	of	o100	IN	B-PP	O
78	78	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
iopamidol	iopamidol	i01050304	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
92	92	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
iodixanol	iodixanol	i03020504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
11	11	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
SCr	SCr	s260	NN	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
37	37	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
SCr	SCr	s260	NN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
iopamidol	iopamidol	i01050304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
07	07	0000	CD	B-NP	O
versus	versus	v06202	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-PP	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
;	;	;000	:	O	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
diabetes	diabete	d010302	NNS	B-NP	B-Disease
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
07	07	0000	CD	B-NP	O
versus	versus	v06202	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
16	16	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
versus	versus	v06202	CC	I-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
micromol	micromol	m0260504	NN	I-NP	O
/	/	/000	SYM	B-PP	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
end	end	e530	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
statistically	statistically	s30302302040	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
intraarterial	intraarterial	i5360630604	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
iopamidol	iopamidol	i01050304	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
iodixanol	iodixanol	i03020504	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Any	Any	a500	DT	B-NP	O
true	true	t600	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
small	small	s504	JJ	B-ADJP	O
and	and	a530	CC	O	O
not	not	n030	RB	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
clinically	clinically	c40502040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
compound	compound	c051053	NN	I-NP	O
,	,	,000	,	O	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
attenuates	attenuate	a3050302	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
shows	show	s020	VBZ	B-VP	O
neuroprotective	neuroprotective	n0601603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
neuroprotection	neuroprotection	n060160302305	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
newly	newly	n040	RB	B-ADVP	O
synthesized	synthesize	s053020203	VBD	B-VP	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
esterification	esterification	e230601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
maltol	maltol	m04304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
p	p	p000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumaric	coumaric	c050602	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
could	could	c043	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
decline	decline	d024050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
injected	inject	i5202303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
amyloid	amyloid	a50403	JJ	B-NP	B-Chemical
beta	beta	b030	SYM	I-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
42	42	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
infused	infuse	i510203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Maltolyl	Maltolyl	m0430404	JJ	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
coumarate	coumarate	c0506030	NN	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
attenuate	attenuate	a305030	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
passive	passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
amyloid	amyloid	a50403	JJ	I-NP	B-Chemical
beta	beta	b030	NN	I-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
42	42	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
infused	infuse	i510203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
neuroprotective	neuroprotective	n0601603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
using	use	u2052	VBG	B-VP	O
SH	SH	s000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
SY5Y	SY5Y	0000	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Cells	Cell	c042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
pretreated	pretreate	p60360303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
before	before	b01060	IN	B-SBAR	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
amyloid	amyloid	a50403	JJ	B-NP	B-Chemical
beta	beta	b030	NN	I-NP	I-Chemical
peptide	peptide	p013030	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
1	1	1000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
42	42	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
,	,	,000	,	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
H2O2	H2O2	0000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
coumarate	coumarate	c0506030	NN	B-NP	I-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
apoptotic	apoptotic	a10130302	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
death	death	d030	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
reactive	reactive	r023010	JJ	I-NP	O
oxygen	oxygen	o20205	NN	I-NP	O
species	specie	s10202	NNS	I-NP	O
,	,	,000	,	O	O
cytochrome	cytochrome	c030206050	NN	B-NP	O
c	c	c000	NN	I-NP	O
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
caspase	caspase	c021020	NN	B-NP	O
3	3	3000	CD	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Taking	Take	t02052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
results	result	r020432	NNS	I-NP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
maltolyl	maltolyl	m0430404	NN	B-NP	B-Chemical
p	p	p000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
coumarate	coumarate	c0506030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
candidate	candidate	c05303030	NN	I-NP	O
against	against	a20523	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
wide	wide	w030	JJ	B-NP	O
spread	spread	s1603	NN	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
progressive	progressive	p602602010	JJ	B-NP	O
decline	decline	d024050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
cognitive	cognitive	c02503010	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Attenuation	Attenuation	a3050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
by	by	b000	IN	B-PP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

Immunological	Immunological	i50504020204	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	B-Disease
terminal	terminal	t0650504	JJ	I-NP	I-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
roles	role	r0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pro	pro	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
in	in	i500	IN	B-PP	O
modulating	modulate	m030403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Lipopolysaccharide	Lipopolysaccharide	l010104020206030	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
body	body	b030	NN	I-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
or	or	o600	CC	I-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
elicited	elicit	e4020303	VBN	B-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
three	three	t060	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
mitigated	mitigate	m03020303	VBD	B-VP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
striatal	striatal	s360304	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	d03602010504020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
depletions	depletion	d01403052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
potent	potent	p03053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
two	two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
or	or	o600	CC	I-PP	O
after	after	a1306	IN	I-PP	O
the	the	t000	DT	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
dosing	dosing	d02052	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
striatal	striatal	s360304	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	d03602010504020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
depletions	depletion	d01403052	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unaltered	unaltered	u50430603	JJ	B-ADJP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
attenuated	attenuate	a3050303	VBD	B-VP	O
local	local	l0204	JJ	B-NP	O
methamphetamine	methamphetamine	m030510305050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
produced	produce	p6030203	VBN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	d03602010504020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
depletions	depletion	d01403052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
interrupted	interrupted	i530601303	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
distribution	distribution	d0236010305	NN	I-NP	O
or	or	o600	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
concluded	conclude	c05240303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
time	time	t050	NN	I-NP	O
window	window	w0530	NN	I-NP	O
for	for	f060	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
lipopolysaccharide	lipopolysaccharide	l010104020206030	NN	I-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
exerting	exert	e2063052	VBG	B-VP	O
effective	effective	e1023010	JJ	B-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nigrostriatal	nigrostriatal	n02602360304	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocarditis	myocarditis	m020630302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
commencement	commencement	c0505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
highlighting	highlight	h02040203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
,	,	,000	,	O	O
course	course	c0620	NN	B-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
urgent	urgent	u62053	JJ	I-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
raise	raise	r020	VB	I-VP	O
awareness	awareness	a060502	NN	B-NP	O
about	about	a103	IN	B-PP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	NN	I-NP	O
with	with	w030	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
sudden	sudden	s0305	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
commencement	commencement	c0505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
intensive	intensive	i53052010	JJ	B-NP	O
medical	medical	m030204	JJ	I-NP	O
support	support	s01063	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
around	around	a6053	RB	B-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inpatient	inpatient	i5103053	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
contributing	contribute	c05360103052	VBG	I-NP	O
factors	factor	f023062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
unaccustomed	unaccustomed	u5020230503	JJ	B-NP	O
physical	physical	p020204	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Myocarditis	Myocarditis	m020630302	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
increasingly	increasingly	i5260205240	RB	I-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
fatal	fatal	f0304	JJ	B-ADJP	O
if	if	i100	IN	B-SBAR	O
not	not	n030	RB	O	O
recognized	recognize	r020250203	VBN	B-VP	O
and	and	a530	CC	I-VP	O
treated	treat	t60303	VBN	I-VP	O
early	early	e0640	RB	B-ADVP	O
.	.	.000	.	O	O

Considering	Consider	c0520306052	VBG	B-VP	O
that	that	t030	DT	B-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
gold	gold	g043	JJ	I-NP	O
standard	standard	s3053063	NN	I-NP	O
in	in	i500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
resistant	resistant	r02023053	JJ	B-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
urgent	urgent	u62053	JJ	I-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
raise	raise	r020	VB	I-VP	O
awareness	awareness	a060502	NN	B-NP	O
among	among	a5052	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
paramedical	paramedical	p0605030204	JJ	I-NP	O
staff	staff	s301	NN	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
care	care	c060	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	B-ADVP	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
recommendations	recommendation	r020505303052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
regulations	regulation	r020403052	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
atazanavir	atazanavir	a302050106	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
atazanavir	atazanavir	a302050106	NN	B-NP	B-Chemical
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
72	72	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
underlying	underlie	u53064052	VBG	B-VP	O
human	human	h0505	JJ	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
,	,	,000	,	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hyperlipidemia	hyperlipidemia	h010640103050	NN	B-NP	B-Disease
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
fatigue	fatigue	f03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dark	dark	d062	JJ	B-NP	O
orange	orange	o60520	JJ	I-NP	O
urine	urine	u6050	NN	I-NP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
bedtime	bedtime	b03050	NN	B-NP	O
(	(	(000	(	O	O
initiated	initiate	i5030303	VBN	B-VP	O
27	27	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
earlier	earlier	e06406	RBR	B-ADVP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
(	(	(000	(	O	O
initiated	initiate	i5030303	VBN	B-VP	O
19	19	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
earlier	earlier	e06406	RBR	B-ADVP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
atazanavir	atazanavir	a302050106	NN	I-NP	B-Chemical
daily	daily	d040	JJ	I-NP	O
(	(	(000	(	O	O
initiated	initiate	i5030303	VBN	B-VP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
66	66	0000	CD	B-NP	O
,	,	,000	,	O	O
680	680	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
,	,	,000	,	O	O
93	93	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
blood	blood	b403	NN	I-NP	B-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
1579	1579	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
738	738	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
alanine	alanine	a405050	NN	I-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
.	.	.000	.	O	O

Simvastatin	Simvastatin	s0510230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
human	human	h0505	JJ	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
medications	medication	m030203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	B-NP	O
temporarily	temporarily	t0510606040	RB	I-NP	O
discontinued	discontinue	d020530503	VBN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
forced	force	f06203	VBN	B-NP	O
alkaline	alkaline	a4204050	NN	I-NP	O
diuresis	diuresis	d060202	NN	I-NP	O
and	and	a530	CC	O	O
started	start	s306303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
dialysis	dialysis	d040202	NN	B-NP	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
days	day	d020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
creatine	creatine	c603050	NN	I-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
had	have	h030	VBD	B-VP	O
dropped	drop	d60103	VBN	I-VP	O
to	to	t000	TO	B-PP	O
1695	1695	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
and	and	a530	CC	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discharged	discharge	d0206203	VBN	I-VP	O
and	and	a530	CC	O	O
continued	continue	c0530503	VBN	B-NP	O
outpatient	outpatient	o03103053	NN	I-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
until	until	u5304	IN	B-PP	O
his	his	h020	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
inhibit	inhibit	i50103	VBP	B-VP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
.	.	.000	.	O	O

Simvastatin	Simvastatin	s0510230305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
metabolized	metabolize	m0301040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
atazanavir	atazanavir	a302050106	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
statins	statin	s303052	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
consideration	consideration	c05203060305	NN	I-NP	O
for	for	f060	IN	B-PP	O
assessing	assess	a202052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
requiring	require	r0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
concurrent	concurrent	c05206053	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
statins	statin	s303052	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
CYP3A4	CYP3A4	0000	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
,	,	,000	,	O	O
pravastatin	pravastatin	p6010230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
fluvastatin	fluvastatin	f4010230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
rosuvastatin	rosuvastatin	r02010230305	NN	B-NP	B-Chemical
carry	carry	c060	VBP	B-VP	O
the	the	t000	DT	B-NP	O
lowest	low	l023	JJS	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
;	;	;000	:	O	O
atorvastatin	atorvastatin	a30610230305	NN	B-NP	B-Chemical
carries	carry	c0602	VBZ	B-VP	O
moderate	moderate	m0306030	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
lovastatin	lovastatin	l010230305	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
risk	risk	r020	NN	I-NP	O
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
CYP3A4	CYP3A4	0000	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Interaction	Interaction	i530602305	NN	B-NP	O
between	between	b0305	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
levofloxacin	levofloxacin	l01014020205	NN	I-NP	B-Chemical
:	:	:000	:	O	O
case	case	c020	NN	B-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

Warfarin	Warfarin	w0610605	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
oral	oral	o604	JJ	I-NP	O
anticoagulant	anticoagulant	a53020204053	NN	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
many	many	m050	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Levofloxacin	Levofloxacin	l01014020205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
fluoroquinolone	fluoroquinolone	f406020504050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
commonly	commonly	c050540	RB	I-NP	O
prescribed	prescribe	p60260103	VBN	I-NP	O
antibiotics	antibiotic	a53010302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
practice	practice	p6023020	NN	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
Gram	Gram	g605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
,	,	,000	,	I-NP	O
Gram	Gram	g605	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
negative	negative	n0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
atypical	atypical	a3010204	JJ	B-NP	O
bacteria	bacteria	b023060	NNS	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
small	small	s504	JJ	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
revealed	reveal	r010403	VBN	I-VP	O
any	any	a500	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
drug	drug	d602	NN	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
levofloxacin	levofloxacin	l01014020205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
several	several	s010604	JJ	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
the	the	t000	DT	B-NP	O
anticoagulation	anticoagulation	a530202040305	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
3	3	3000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
bleeding	bleed	b403052	VBG	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
levofloxacin	levofloxacin	l01014020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
and	and	a530	CC	I-NP	O
use	use	u200	NN	I-NP	O
caution	caution	c0305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
levofloxacin	levofloxacin	l01014020205	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mutations	Mutation	m0303052	NNS	B-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
in	in	i500	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
na	na	n000	NN	I-NP	B-Chemical
ve	ve	v000	NN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
HBV	HBV	h100	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
infected	infected	i5102303	JJ	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	I-PP	O
without	without	w0303	IN	I-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
:	:	:000	:	O	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
antiretroviral	antiretroviral	a5306036010604	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
HIV	HIV	h010	NN	I-NP	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	O	I-Disease
infected	infect	i5102303	VBN	B-VP	I-Disease
South	South	s030	JJ	B-NP	O
African	African	a160205	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
exploratory	exploratory	e2140603060	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
strains	strain	s36052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
na	na	n000	NN	I-NP	B-Chemical
ve	ve	v000	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	O
carriers	carrier	c06062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
human	human	h0505	JJ	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
HIV	HIV	h010	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
South	South	s030	JJ	B-NP	O
African	African	a160205	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
na	na	n000	NN	I-NP	B-Chemical
ve	ve	v000	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
infected	infected	i5102303	JJ	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
:	:	:000	:	O	O
15	15	0000	CD	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
mono	mono	m050	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
HIV	HIV	h010	NN	I-NP	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
further	further	f06306	JJ	B-ADJP	O
sub	sub	s010	AFX	O	O
-	-	-000	HYPH	O	O
divided	divide	d010303	VBN	B-VP	O
into	into	i530	IN	B-PP	O
13	13	0000	CD	B-NP	O
occult	occult	o2043	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	O
(	(	(000	(	O	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
negative	negative	n0203010	JJ	B-ADJP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
overt	overt	o1063	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	O
(	(	(000	(	O	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
positive	positive	p0203010	JJ	O	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
,	,	,000	,	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBs	HB	h120	NNS	I-NP	O
,	,	,000	,	O	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
HBc	HBc	h120	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	O	O
HIV	HIV	h010	NN	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
routine	routine	r03050	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
Axsym	Axsym	a205	NN	B-NP	O
assays	assay	a202	NNS	I-NP	O
(	(	(000	(	O	O
Abbott	Abbott	a103	NNP	B-NP	O
Laboratories	Laboratories	l0106030602	NNP	I-NP	O
,	,	,000	,	O	O
North	North	n0630	NNP	B-NP	O
Chicago	Chicago	c02020	NNP	I-NP	O
,	,	,000	,	O	O
IL	IL	i400	NNP	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
PCR	PCR	p260	NN	B-NP	O
amplified	amplify	a5140103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
reverse	reverse	r010620	JJ	I-NP	O
transcriptase	transcriptase	t60526013020	NN	I-NP	O
(	(	(000	(	O	O
RT	RT	r300	NN	B-NP	O
)	)	)000	)	O	O
primers	primer	p605062	NNS	B-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
sequencing	sequencing	s02052052	NN	I-NP	O
across	across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
tyrosine	tyrosine	t0602050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
methionine	methionine	m0305050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
YMDD	YMDD	y530	NN	B-NP	O
)	)	)000	)	O	O
motif	motif	m0301	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
catalytic	catalytic	c03040302	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
C	C	c000	NN	I-NP	O
domain	domain	d0505	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
HBV	HBV	h100	NN	I-NP	O
RT	RT	r300	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
.	.	.000	.	O	O

HBV	HBV	h100	NN	B-NP	O
viral	viral	v0604	JJ	I-NP	O
load	load	l030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
Amplicor	Amplicor	a5140206	NNP	B-NP	O
HBV	HBV	h100	NNP	I-NP	O
Monitor	Monitor	m050306	NNP	I-NP	O
test	test	t023	NN	I-NP	O
v2	v2	0000	NN	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	O	O
(	(	(000	(	O	O
Roche	Roche	r020	NNP	B-NP	O
Diagnostics	Diagnostics	d02502302	NNP	I-NP	O
,	,	,000	,	O	O
Penzberg	Penzberg	p0521062	NNP	B-NP	O
,	,	,000	,	O	O
Germany	Germany	g065050	NNP	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

HBV	HBV	h100	NN	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
resistant	resistant	r02023053	JJ	B-NP	O
strains	strain	s36052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
mono	mono	m050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
infected	infect	i5102303	VBN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
HIV	HIV	h010	NN	I-NP	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
best	good	b023	JJS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
constitutes	constitute	c0523030302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
resistant	resistant	r02023053	JJ	B-NP	O
strains	strain	s36052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
na	na	n000	NN	I-NP	B-Chemical
ve	ve	v000	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
HIV	HIV	h010	NN	I-NP	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
HBV	HBV	h100	NN	I-NP	O
viral	viral	v0604	JJ	I-NP	O
loads	load	l032	NNS	I-NP	O
for	for	f060	IN	B-PP	O
mono	mono	m050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
infected	infect	i5102303	VBN	B-VP	O
and	and	a530	CC	O	O
co	co	c000	AFX	O	O
-	-	-000	HYPH	B-NP	O
infected	infect	i5102303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
32	32	0000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
82	82	0000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
<	<	<000	SYM	B-NP	O
200	200	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
40	40	0000	CD	I-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
copies	copy	c0102	NNS	B-NP	O
/	/	/000	SYM	B-VP	O
ml	ml	m400	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
remains	remain	r05052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
seen	see	s050	VBN	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
such	such	s020	JJ	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
could	could	c043	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
widespread	widespread	w03021603	JJ	B-NP	O
emergence	emergence	e50620520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
highly	highly	h02040	RB	B-NP	O
active	active	a23010	JJ	I-NP	O
antiretroviral	antiretroviral	a5306036010604	JJ	I-NP	O
(	(	(000	(	O	O
ARV	ARV	a610	NN	B-NP	O
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
(	(	(000	(	O	O
HAART	HAART	h063	NN	B-NP	O
)	)	)000	)	O	O
regimens	regimen	r0205052	NNS	B-NP	O
become	become	b02050	VBP	B-VP	O
widely	widely	w03040	RB	I-VP	O
applied	apply	a1403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
South	South	s030	NNP	B-NP	O
Africa	Africa	a16020	NNP	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
potential	potential	p0305304	JJ	B-NP	O
implications	implication	i5140203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
HIV	HIV	h010	NN	I-NP	I-Disease
co	co	c000	AFX	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Rabbit	Rabbit	r0103	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
antidepressant	antidepressant	a530301602053	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
scan	scan	s205	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rabbit	rabbit	r0103	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
neuroleptic	neuroleptic	n060401302	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
imipramine	imipramine	i501605050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
representing	represent	r01602053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	B-Disease
basal	basal	b0204	JJ	B-NP	I-Disease
ganglia	ganglia	g05240	NN	I-NP	I-Disease
perfusion	perfusion	p0610205	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
return	return	r03065	NN	I-NP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
rabbit	rabbit	r0103	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
resolved	resolve	r0204103	VBN	B-VP	O
.	.	.000	.	O	O

Estrogen	Estrogen	e2360205	NN	B-NP	O
prevents	prevent	p6010532	VBZ	B-VP	O
cholesteryl	cholesteryl	c040230604	NN	B-NP	B-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
macrophages	macrophage	m026010202	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
HIV	HIV	h010	NN	I-NP	O
protease	protease	p603020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
ritonavir	ritonavir	r03050106	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Individuals	Individual	i530103042	NNS	B-NP	O
with	with	w030	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	O
can	can	c050	MD	B-VP	O
now	now	n000	RB	I-VP	O
live	live	l010	VB	I-VP	O
long	long	l052	JJ	B-NP	O
lives	life	l0102	NNS	I-NP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
that	that	t030	WDT	B-NP	O
often	often	o1305	RB	B-ADVP	O
includes	include	i5240302	VBZ	B-VP	O
protease	protease	p603020	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
develop	develop	d010401	VBP	B-VP	O
negative	negative	n0203010	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
premature	premature	p60503060	JJ	B-NP	B-Disease
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
previously	previously	p6010240	RB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	B-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
peripheral	peripheral	p06010604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
monocytes	monocyte	m05020302	NNS	I-NP	O
isolated	isolate	i2040303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
females	female	f050402	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
cholesteryl	cholesteryl	c040230604	NN	I-NP	B-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
female	female	f05040	JJ	B-NP	O
hormones	hormone	h0650502	NNS	I-NP	O
influence	influence	i5140520	VBP	B-VP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
metabolism	metabolism	m030104025	NN	I-NP	O
in	in	i500	IN	B-PP	O
macrophages	macrophage	m026010202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
HIV	HIV	h010	NN	I-NP	O
protease	protease	p603020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
ritonavir	ritonavir	r03050106	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
utilized	utilize	u3040203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
monocyte	monocyte	m0502030	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
line	line	l050	NN	I-NP	O
,	,	,000	,	O	O
THP	THP	t010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
address	address	a3602	VB	I-VP	O
this	this	t020	DT	B-NP	O
question	question	q02305	NN	I-NP	O
.	.	.000	.	O	O

Briefly	Briefly	b60140	RB	B-ADVP	O
,	,	,000	,	O	O
cells	cell	c042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
differentiated	differentiate	d01060530303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
72	72	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
with	with	w030	IN	B-PP	O
100	100	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
PMA	PMA	p500	NN	I-NP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
a	a	a000	DT	B-NP	O
macrophage	macrophage	m02601020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
phenotype	phenotype	p0503010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
17beta	17beta	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
estradiol	estradiol	e2360304	NN	B-NP	I-Chemical
(	(	(000	(	O	O
E2	E2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
progesterone	progesterone	p60202306050	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
vehicle	vehicle	v0240	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Cells	Cell	c042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
30	30	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	O	O
ml	ml	m400	NN	B-NP	O
ritonavir	ritonavir	r03050106	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	I-PP	O
presence	presence	p6020520	NN	I-PP	O
of	of	o100	IN	I-PP	O
aggregated	aggregated	a26020303	JJ	B-NP	O
LDL	LDL	l340	NN	I-NP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
.	.	.000	.	O	O

Cell	Cell	c040	NN	B-NP	O
extracts	extract	e2360232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
harvested	harvest	h06102303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
lipid	lipid	l0103	NN	B-NP	O
or	or	o600	CC	O	O
total	total	t0304	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
was	be	w020	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
.	.	.000	.	O	O

E2	E2	0000	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cholesteryl	cholesteryl	c040230604	NN	B-NP	B-Chemical
esters	ester	e23062	NNS	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
macrophages	macrophage	m026010202	NNS	B-NP	O
following	follow	f04052	VBG	B-PP	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Ritonavir	Ritonavir	r03050106	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
scavenger	scavenger	s20105206	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
,	,	,000	,	O	O
CD36	CD36	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
,	,	,000	,	O	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
uptake	uptake	u13020	NN	I-NP	O
of	of	o100	IN	B-PP	O
LDL	LDL	l340	NN	B-NP	O
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
selectively	selectively	s0402301040	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PPARgamma	PPARgamma	p1062050	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CD36	CD36	0000	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
E2	E2	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
these	these	t020	DT	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

E2	E2	0000	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
suppress	suppress	s01602	VBP	B-VP	O
CD36	CD36	0000	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
fluorescent	fluorescent	f40602053	JJ	B-NP	O
immunocytochemistry	immunocytochemistry	i5050203020502360	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
E2	E2	0000	NN	B-NP	B-Chemical
modifies	modify	m030102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
CD36	CD36	0000	NN	B-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
monocyte	monocyte	m0502030	NN	B-NP	O
-	-	-000	HYPH	O	O
derived	derive	d060103	VBN	B-VP	O
macrophages	macrophage	m026010202	NNS	B-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
cholesteryl	cholesteryl	c040230604	NN	I-NP	B-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
ritonavir	ritonavir	r03050106	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Antibiotic	Antibiotic	a53010302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
widespread	widespread	w03021603	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antimicrobial	antimicrobial	a53050260104	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
frequently	frequently	f60205340	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
among	among	a5052	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
idiosyncratic	idiosyncratic	i30205260302	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
serious	serious	s0602	JJ	I-NP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
height	height	h0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
175	175	0000	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
and	and	a530	CC	I-NP	O
weight	weight	w0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
72	72	0000	CD	B-NP	O
kg	kg	k200	NN	I-NP	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
Marmara	Marmara	m065060	NNP	B-NP	O
University	University	u501062030	NNP	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
Emergency	Emergency	e50620520	NNP	I-NP	O
Department	Department	d010635053	NNP	I-NP	O
,	,	,000	,	O	O
Istanbul	Istanbul	i2305104	NNP	B-NP	O
,	,	,000	,	O	O
Turkey	Turkey	t0620	NNP	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
'	'	'000	POS	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
,	,	,000	,	O	O
malaise	malaise	m04020	NN	B-NP	O
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
400	400	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	B-NP	O
PO	PO	p000	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
an	an	a500	DT	B-NP	O
upper	upper	u106	JJ	I-NP	B-Disease
respiratory	respiratory	r0210603060	JJ	I-NP	I-Disease
tract	tract	t6023	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
.	.	.000	.	O	O

Admission	Admission	a350205	NN	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
as	as	a200	IN	B-SBAR	O
follows	follow	f0402	VBZ	B-VP	O
:	:	:000	:	O	O
alanine	alanine	a405050	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
,	,	,000	,	O	O
67	67	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
reference	reference	r01060520	NN	B-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
37	37	0000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
,	,	,000	,	O	O
98	98	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
alkaline	alkaline	a4204050	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
,	,	,000	,	O	O
513	513	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
270	270	0000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
gamma	gamma	g050	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
glutamyltransferase	glutamyltransferase	g403050436052106020	NN	I-NP	O
,	,	,000	,	O	O
32	32	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
49	49	0000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
amylase	amylase	a504020	NN	B-NP	O
,	,	,000	,	O	O
46	46	0000	CD	B-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
220	220	0000	CD	I-NP	O
U	U	u000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
total	total	t0304	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
,	,	,000	,	O	O
20	20	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
direct	direct	d06023	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
,	,	,000	,	O	O
14	14	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
albumin	albumin	a410505	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
toxin	toxin	t0205	NN	I-NP	O
,	,	,000	,	O	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
other	other	o306	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
suffered	suffer	s010603	VBN	I-VP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
unknown	unknown	u52505	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
,	,	,000	,	O	O
"	"	"000	''	O	O
that	that	t030	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
usage	usage	u2020	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
incidents	incident	i52030532	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
Telithromycin	Telithromycin	t040306050205	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ketolide	ketolide	k0304030	NN	I-NP	O
antibacterials	antibacterial	a530102306042	NNS	I-NP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
US	US	u200	NNP	B-NP	O
Food	Food	f030	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Drug	Drug	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
approval	approval	a160104	NN	I-NP	O
for	for	f060	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
infrequent	infrequent	i51602053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
usually	usually	u2040	RB	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
severe	severe	s01060	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Naranjo	Naranjo	n060520	NNP	I-NP	O
adverse	adverse	a310620	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
probability	probability	p6010104030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
,	,	,000	,	O	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pathological	pathological	p0304020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
toxic	toxic	t0202	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Recurrence	Recurrence	r02060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
attack	attack	a302	NN	I-NP	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
incident	incident	i5203053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
communicated	communicate	c0505020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
attending	attend	a3053052	VBG	I-NP	O
physician	physician	p020205	NN	I-NP	O
who	who	w000	WP	B-NP	O
prescribed	prescribe	p60260103	VBD	B-VP	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
time	time	t050	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
probably	probably	p6010140	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
telithromycin	telithromycin	t040306050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
on	on	o500	IN	B-PP	O
bruising	bruising	b602052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
duration	duration	d060305	NN	I-NP	O
on	on	o500	IN	B-PP	O
bruising	bruise	b602052	VBG	B-NP	B-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
bruising	bruising	b602052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
widely	widely	w03040	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
and	and	a530	CC	I-VP	O
described	describe	d0260103	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
duration	duration	d060305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bruising	bruising	b602052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
little	little	l0340	JJ	B-ADJP	O
documented	document	d020505303	VBN	B-VP	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
within	within	w0305	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
subject	subject	s012023	NN	I-NP	O
,	,	,000	,	O	O
quasi	quasi	q020	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
experimental	experimental	e21060505304	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
whom	whom	w050	WP	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Heparin	Heparin	h010605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
over	over	o106	IN	B-PP	O
10	10	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
site	site	s030	NN	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
site	site	s030	NN	I-NP	O
.	.	.000	.	O	O

Injections	Injection	i52023052	NNS	B-NP	O
areas	area	a602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bruising	bruise	b602052	VBG	B-VP	B-Disease
at	at	a300	IN	B-PP	O
48	48	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
72	72	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
each	each	e020	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Dimensions	Dimension	d05052052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bruising	bruising	b602052	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
applied	apply	a1403	VBD	B-VP	O
areas	area	a602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
transparent	transparent	t6052106053	JJ	B-NP	O
millimetric	millimetric	m040503602	JJ	I-NP	O
measuring	measuring	m0206052	NN	I-NP	O
paper	paper	p0106	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analog	analog	a50402	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
VAS	VAS	v020	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
stop	stop	s301	NN	I-NP	O
-	-	-000	HYPH	O	O
watch	watch	w0320	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
time	time	t050	VB	I-VP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
chi	chi	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
square	square	s2060	JJ	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
Mann	Mann	m050	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Whitney	Whitney	w0350	NNP	I-NP	O
U	U	u000	NNP	I-NP	O
,	,	,000	,	O	O
Wilcoxon	Wilcoxon	w0420205	NNP	B-NP	O
signed	sign	s02503	VBD	B-VP	O
ranks	rank	r052	NNS	B-NP	O
tests	test	t0232	NNS	I-NP	O
and	and	a530	CC	O	O
correlation	correlation	c06040305	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bruising	bruise	b602052	VBG	B-VP	B-Disease
occurrence	occurrence	o2060520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
64	64	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
duration	duration	d060305	NN	I-NP	O
and	and	a530	CC	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
bruising	bruising	b602052	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
smaller	small	s50406	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
period	period	p0603	NN	I-NP	O
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
than	than	t050	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
injection	injection	i5202305	NN	B-NP	O
duration	duration	d060305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
bruising	bruise	b602052	VBG	B-NP	B-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
repeated	repeat	r010303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
larger	large	l06206	JJR	I-NP	O
sample	sample	s05140	NN	I-NP	O
.	.	.000	.	O	O

RELEVANCE	RELEVANCE	r04010520	NN	B-NP	O
TO	TO	t000	TO	B-PP	O
CLINICAL	CLINICAL	c4050204	NN	B-NP	O
PRACTICE	PRACTICE	p6023020	NN	I-NP	O
:	:	:000	:	O	O
When	When	w050	WRB	B-ADVP	O
administering	administer	a350502306052	VBG	B-VP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
extend	extend	e23053	VB	I-VP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
alcohol	alcohol	a4204	NN	I-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
ingesting	ingest	i52023052	VBG	B-VP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	I-VP	O
debated	debate	d010303	VBN	I-VP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
REPORT	REPORT	r01063	NN	I-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
2	2	2000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
regular	regular	r020406	JJ	B-NP	O
consumers	consumer	c05205062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
liver	liver	l0106	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
and	and	a530	CC	O	O
stopping	stop	s301052	VBG	B-VP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
4	4	4000	CD	B-NP	O
g	g	g000	NN	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	.	O	O
regular	regular	r020406	JJ	B-NP	O
consumption	consumption	c052051305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
liver	liver	l0106	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
possible	possible	p020140	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
ingested	ingest	i5202303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
propose	propose	p601020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
exceed	exceed	e203	VB	I-VP	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
closely	closely	c402040	RB	B-ADVP	O
while	while	w040	IN	B-SBAR	O
being	be	b052	VBG	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Associations	Association	a20203052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
or	or	o600	CC	O	O
related	relate	r040303	VBN	B-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
health	health	h0430	NN	I-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
abilities	ability	a1040302	NNS	I-NP	O
and	and	a530	CC	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
randomised	randomise	r053050203	VBN	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
associations	association	a20203052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
or	or	o600	CC	O	O
related	relate	r040303	VBN	B-NP	O
drugs	drug	d602	NNS	I-NP	O
(	(	(000	(	O	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
RDs	RD	r320	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
health	health	h0430	NN	B-NP	O
,	,	,000	,	O	O
functional	functional	f05230504	JJ	B-NP	O
abilities	ability	a1040302	NNS	I-NP	O
and	and	a530	CC	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	B-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
aged	aged	a203	JJ	B-ADJP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
65	65	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
admitted	admit	a350303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
wards	ward	w0632	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

164	164	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	JJ	B-NP	O
age	age	a200	NN	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
standard	standard	s3053063	JJ	B-NP	O
deviation	deviation	d010305	NN	I-NP	O
[	[	[000	(	O	O
SD	SD	s300	NN	B-NP	O
]	]	]000	)	O	O
81	81	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
,	,	,000	,	O	O
nearly	nearly	n0640	RB	B-NP	O
half	half	h041	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
78	78	0000	CD	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	O	O
RDs	RD	r320	NNS	B-NP	O
before	before	b01060	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
remainder	remainder	r0505306	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
86	86	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
non	non	n050	AFX	B-ADJP	O
-	-	-000	HYPH	B-NP	O
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

Cognitive	Cognitive	c02503010	JJ	B-NP	O
ability	ability	a104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Mini	Mini	m050	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Mental	Mental	m05304	NNP	I-NP	O
State	State	s3030	NNP	I-NP	O
Examination	Examination	e205050305	NNP	I-NP	O
(	(	(000	(	O	O
MMSE	MMSE	m520	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
scoring	score	s206052	VBG	B-VP	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
MMSE	MMSE	m520	NN	I-NP	O
sum	sum	s050	NN	I-NP	O
points	point	p0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
interviewed	interview	i5306103	VBN	I-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
79	79	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
questioned	question	q0230503	VBD	B-VP	O
regarding	regard	r02063052	VBG	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
abilities	ability	a1040302	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
week	week	w020	NN	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
admission	admission	a350205	NN	B-NP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	B-VP	O
RDs	RD	r320	NNS	B-NP	O
before	before	b01060	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
,	,	,000	,	O	O
current	current	c06053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
and	and	a530	CC	O	O
discharge	discharge	d020620	NN	B-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

Health	Health	h0430	NNP	B-NP	O
,	,	,000	,	O	O
physical	physical	p020204	JJ	B-NP	O
abilities	ability	a1040302	NNS	I-NP	O
and	and	a530	CC	O	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
BZD	BZD	b230	NN	B-NP	O
/	/	/000	SYM	I-NP	O
RD	RD	r300	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
users	user	u2062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
adjustments	adjustment	a3202350532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
for	for	f060	IN	B-PP	O
confounding	confound	c051053052	VBG	B-VP	O
variables	variable	v0601402	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
residual	residual	r020304	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oxazepam	oxazepam	o2020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
temazepam	temazepam	t05020105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
zopiclone	zopiclone	z01024050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
BZD	BZD	b230	NN	B-NP	O
/	/	/000	SYM	I-NP	O
RD	RD	r300	NN	I-NP	O
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
31	31	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
or	or	o600	CC	I-NP	O
three	three	t060	CD	I-NP	O
BZDs	BZD	b232	NNS	I-NP	B-Chemical
/	/	/000	SYM	I-NP	O
RDs	RD	r320	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
concomitantly	concomitantly	c052050305340	RB	I-VP	O
taken	take	t0205	VBN	I-VP	O
by	by	b000	IN	B-PP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
users	user	u2062	NNS	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
sex	sex	s020	NN	I-NP	O
and	and	a530	CC	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
with	with	w030	IN	B-PP	O
effects	effect	e10232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
diagnosed	diagnose	d0250203	VBN	B-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
as	as	a200	IN	B-PP	O
confounders	confounder	c051053062	NNS	B-NP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
RDs	RD	r320	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
MMSE	MMSE	m520	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
RDs	RD	r320	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dizziness	dizziness	d020502	NN	B-NP	B-Disease
,	,	,000	,	O	O
inability	inability	i50104030	NN	B-NP	B-Disease
to	to	t000	TO	B-VP	I-Disease
sleep	sleep	s401	VB	I-VP	I-Disease
after	after	a1306	IN	B-PP	O
awaking	awake	a02052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
night	night	n0203	NN	B-NP	O
and	and	a530	CC	I-NP	O
tiredness	tiredness	t0603502	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mornings	morning	m065052	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
week	week	w020	NN	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
admission	admission	a350205	NN	B-NP	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
stronger	strong	s3605206	JJR	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
measured	measure	m020603	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
beginning	beginning	b0205052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
stay	stay	s300	NN	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
BZDs	BZD	b232	NNS	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
RDs	RD	r320	NNS	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
walk	walk	w042	VB	I-VP	O
and	and	a530	CC	O	O
shorter	short	s06306	JJR	B-NP	O
night	night	n0203	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
time	time	t050	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
week	week	w020	NN	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
admission	admission	a350205	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
residual	residual	r020304	JJ	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
temazepam	temazepam	t05020105	NN	B-NP	B-Chemical
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
MMSE	MMSE	m520	NN	I-NP	O
sum	sum	s050	NN	I-NP	O
score	score	s2060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
adjustment	adjustment	a320235053	NN	B-NP	O
for	for	f060	IN	B-PP	O
confounding	confound	c051053052	VBG	B-VP	O
variables	variable	v0601402	NNS	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
BZD	BZD	b230	NN	I-NP	O
/	/	/000	SYM	B-NP	O
RD	RD	r300	NN	I-NP	O
were	be	w060	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
hospitalised	hospitalise	h02103040203	VBD	B-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
acute	acute	a2030	JJ	B-NP	O
illnesses	illness	i450202	NNS	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
daytime	daytime	d03050	NN	B-NP	O
and	and	a530	CC	I-NP	O
night	night	n0203	NN	I-NP	O
-	-	-000	HYPH	O	O
time	time	t050	NN	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
poorer	poor	p0606	JJR	B-NP	O
health	health	h0430	NN	I-NP	O
and	and	a530	CC	O	O
potentially	potentially	p03053040	RB	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
vocal	vocal	v0204	JJ	I-NP	B-Disease
fold	fold	f043	JJ	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
disulfiram	disulfiram	d020410605	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
disulfiram	disulfiram	d020410605	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
rare	rare	r060	JJ	I-ADJP	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
it	it	i300	PRP	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
vocal	vocal	v0204	JJ	B-NP	B-Disease
fold	fold	f043	JJ	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
49	49	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
transferred	transfer	t605210603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
department	department	d010635053	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
quadriparesis	quadriparesis	q03601060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
lancinating	lancinate	l0520503052	VBG	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
,	,	,000	,	O	O
sensory	sensory	s052060	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
paresthesia	paresthesia	p06023020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
distal	distal	d02304	JJ	I-NP	O
limbs	limb	l0512	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
previously	previously	p6010240	RB	B-ADVP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
130	130	0000	CD	B-NP	O
tablets	tablet	t014032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ALCOHOL	ALCOHOL	a4204	NNP	B-NP	B-Chemical
STOP	STOP	s301	NNP	I-NP	O
TAB	TAB	t010	NNP	I-NP	O
,	,	,000	,	O	O
Shin	Shin	s050	NNP	B-NP	O
-	-	-000	HYPH	B-NP	O
Poong	Poong	p052	NNP	I-NP	O
Pharm	Pharm	p065	NNP	I-NP	O
.	.	.000	.	I-NP	O
Co	Co	c000	NNP	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
Ansan	Ansan	a5205	NNP	B-NP	O
,	,	,000	,	O	O
Korea	Korea	k060	NNP	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
suicide	suicide	s02030	NN	I-NP	O
attempt	attempt	a30513	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
an	an	a500	DT	B-NP	O
alcoholic	alcoholic	a420402	JJ	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
ingestion	ingestion	i5202305	NN	B-NP	O
,	,	,000	,	O	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
confused	confused	c0510203	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
ataxia	ataxia	a3020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
giddiness	giddiness	g030502	NN	I-NP	B-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
noticed	notice	n030203	VBD	B-VP	O
hoarseness	hoarseness	h0620502	NN	B-NP	B-Disease
and	and	a530	CC	O	O
distally	distally	d023040	RB	B-VP	O
accentuated	accentuate	a20530303	VBN	I-VP	O
motor	motor	m0306	NN	B-NP	O
and	and	a530	CC	O	O
sensory	sensory	s052060	JJ	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
recovered	recover	r02010603	VBN	I-VP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
axonal	axonal	a20504	JJ	I-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Laryngeal	Laryngeal	l0605204	JJ	B-NP	O
electromyography	electromyography	e4023605026010	NN	I-NP	O
(	(	(000	(	O	O
thyroarytenoid	thyroarytenoid	t0606030503	NN	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
ample	ample	a5140	JJ	B-NP	O
denervation	denervation	d050610305	NN	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
.	.	.000	.	O	O

Laryngoscopy	Laryngoscopy	l0605202010	NNP	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
asymmetric	asymmetric	a20503602	JJ	B-NP	O
vocal	vocal	v0204	JJ	I-NP	O
fold	fold	f043	JJ	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
phonation	phonation	p050305	NN	B-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
vocal	vocal	v0204	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
and	and	a530	CC	I-NP	O
weakness	weakness	w02502	NN	I-NP	O
began	begin	b0205	VBD	B-VP	O
to	to	t000	TO	I-VP	O
improve	improve	i516010	VB	I-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
about	about	a103	IN	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
transfer	transfer	t6052106	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
palsy	palsy	p0420	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrent	recurrent	r0206053	JJ	I-NP	O
laryngeal	laryngeal	l0605204	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
and	and	a530	CC	O	O
superimposed	superimpose	s01060510203	VBN	B-VP	O
severe	severe	s01060	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	O
sensorimotor	sensorimotor	s05206050306	NN	I-NP	O
axonal	axonal	a20504	JJ	I-NP	O
polyneuropathy	polyneuropathy	p04050601030	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
disulfiram	disulfiram	d020410605	NN	I-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

Encephalopathy	Encephalopathy	e52010401030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
levetiracetam	levetiracetam	l010306020305	NN	B-NP	B-Chemical
added	add	a303	VBN	B-VP	O
to	to	t000	TO	I-VP	O
valproate	valproate	v0416030	VB	I-VP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
levetiracetam	levetiracetam	l010306020305	NN	I-NP	B-Chemical
(	(	(000	(	O	O
LEV	LEV	l010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
LEV	LEV	l010	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3000	3000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
added	add	a303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
2000	2000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Frequency	Frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
tonic	tonic	t0502	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
clonic	clonic	c40502	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
one	one	o500	CD	B-NP	O
per	per	p060	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
per	per	p060	IN	B-PP	O
month	month	m0530	NN	B-NP	O
.	.	.000	.	O	O

Neuropsychological	Neuropsychological	n060120204020204	JJ	B-NP	O
testing	testing	t023052	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
word	word	w063	NN	I-NP	I-Disease
fluency	fluency	f40520	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
psychomotor	psychomotor	p202050306	NN	B-NP	I-Disease
speed	speed	s103	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
working	work	w062052	VBG	B-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
interictal	interictal	i530602304	JJ	I-NP	O
electroencephalogram	electroencephalogram	e40236052010402605	NN	I-NP	O
(	(	(000	(	O	O
EEG	EEG	e020	NN	B-NP	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
slowing	slow	s4052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
per	per	p060	IN	B-PP	O
second	second	s02053	JJ	B-NP	O
theta	theta	t030	NN	I-NP	O
rhythms	rhythm	r03052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
discharges	discharge	d0206202	NNS	I-NP	O
.	.	.000	.	O	O

OUTCOME	OUTCOME	o032050	NN	B-NP	O
:	:	:000	:	O	O
Following	Follow	f04052	VBG	B-VP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
LEV	LEV	l010	NN	B-NP	B-Chemical
,	,	,000	,	O	O
EEG	EEG	e020	NN	B-NP	O
and	and	a530	CC	O	O
neuropsychological	neuropsychological	n060120204020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
improved	improve	i5160103	VBN	B-VP	O
and	and	a530	CC	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
frequency	frequency	f6020520	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
.	.	.000	.	O	O

Norepinephrine	Norepinephrine	n0601050106050	NN	B-NP	B-Chemical
signaling	signaling	s02504052	NN	I-NP	O
through	through	t06020	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
critical	critical	c6030204	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
abused	abused	a10203	JJ	I-NP	O
psychostimulant	psychostimulant	p2020230504053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
both	both	b030	CC	O	O
rewarding	rewarding	r063052	JJ	B-NP	O
and	and	a530	CC	I-NP	O
aversive	aversive	a1062010	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
rewarding	rewarding	r063052	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
studied	study	s30303	VBN	I-VP	O
extensively	extensively	e2305201040	RB	B-ADVP	O
,	,	,000	,	O	O
less	less	l020	JJR	B-NP	O
attention	attention	a305305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
paid	pay	p030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
unpleasant	unpleasant	u51402053	JJ	I-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
states	state	s30302	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
hydroxylase	hydroxylase	h0360204020	NN	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
(	(	(000	(	O	O
Dbh	Dbh	d100	NN	B-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
lack	lack	l020	VBP	B-VP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NE	NE	n000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
(	(	(000	(	O	O
EPM	EPM	e150	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
noradrenergic	noradrenergic	n060360506202	JJ	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
dependently	dependently	d0105305340	RB	I-VP	O
increased	increase	i5260203	VBN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
Dbh	Dbh	d100	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
open	open	o105	JJ	B-NP	O
arm	arm	a650	NN	I-NP	O
exploration	exploration	e214060305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Dbh	Dbh	d100	NN	I-NP	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
mice	mouse	m020	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
normal	normal	n06504	JJ	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
performance	performance	p0610650520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
EPM	EPM	e150	NN	I-NP	O
but	but	b030	CC	O	O
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADJP	O
resistant	resistant	r02023053	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
anxiogenic	anxiogenic	a52020502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Dbh	Dbh	d100	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
mice	mouse	m020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
hydroxylase	hydroxylase	h0360204020	NN	B-NP	O
(	(	(000	(	O	O
DBH	DBH	d100	NN	B-NP	O
)	)	)000	)	O	O
inhibitor	inhibitor	i5010306	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
specific	specific	s1020102	JJ	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
blocked	block	b40203	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
like	like	l020	JJ	B-NP	O
behavior	behavior	b0106	NN	I-NP	O
in	in	i500	IN	B-PP	O
Dbh	Dbh	d100	NN	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
wild	wild	w043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
C57BL6	C57BL6	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
J	J	j000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
alpha	alpha	a410	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
antagonist	antagonist	a530205023	NN	B-NP	O
yohimbine	yohimbine	y051050	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
noradrenergic	noradrenergic	n060360506202	JJ	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
via	via	v000	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
required	require	r020603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Hypothalamic	Hypothalamic	h0103040502	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
messenger	messenger	m0205206	NN	I-NP	O
ribonucleic	ribonucleic	r010502402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
prolactin	prolactin	p60402305	NN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hyperprolactinemic	hyperprolactinemic	h01061604023050502	JJ	B-NP	B-Disease
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pulsatile	pulsatile	p04203040	JJ	B-NP	O
luteinizing	luteinizing	l030502052	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Hyperprolactinemia	Hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
fertility	fertility	f06304030	NN	B-NP	O
and	and	a530	CC	I-NP	O
libido	libido	l01030	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
central	central	c053604	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
actions	action	a23052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
poorly	poorly	p0640	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
first	first	f0623	RB	B-ADVP	O
tested	test	t02303	VBD	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
inhibited	inhibit	i5010303	VBD	B-VP	O
two	two	t000	CD	B-NP	O
neuroendocrine	neuroendocrine	n06053026050	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
fertility	fertility	f06304030	NN	I-NP	O
:	:	:000	:	O	O
pulsatile	pulsatile	p04203040	JJ	B-NP	O
LH	LH	l000	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
estrogen	estrogen	e2360205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
LH	LH	l000	NN	I-NP	O
surge	surge	s0620	NN	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
sulpiride	sulpiride	s04106030	NN	I-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
LH	LH	l000	NN	I-NP	O
pulse	pulse	p0420	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
in	in	i500	IN	B-PP	O
ovariectomized	ovariectomize	o106023050203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
low	low	l000	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Sulpiride	Sulpiride	s04106030	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
LH	LH	l000	NN	I-NP	O
surge	surge	s0620	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
GnRH	GnRH	g560	NN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
activated	activate	a23010303	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
surge	surge	s0620	NN	I-NP	O
.	.	.000	.	O	O

Estradiol	Estradiol	e2360304	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
influence	influence	i5140520	VB	I-VP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
components	component	c051050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
increases	increase	i5260202	VBZ	B-VP	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
R	R	r000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
sensitivity	sensitivity	s0520301030	NN	B-NP	O
to	to	t000	TO	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
next	next	n023	RB	B-ADVP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
greatly	greatly	g60340	RB	B-ADVP	O
augments	augment	a0250532	VBZ	B-VP	O
prolactin	prolactin	p60402305	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
STAT5	STAT5	0000	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Lastly	Lastly	l02340	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
measured	measure	m020603	VBD	B-VP	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
and	and	a530	CC	I-NP	O
suppressor	suppressor	s0160206	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytokine	cytokine	c0302050	NN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
(	(	(000	(	O	O
SOCS	SOCS	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
CIS	CIS	c020	NN	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
reflect	reflect	r014023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
)	)	)000	)	O	O
mRNAs	mRNA	m6502	NNS	B-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
estradiol	estradiol	e2360304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Sulpiride	Sulpiride	s04106030	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
only	only	o540	RB	B-NP	O
SOCS	SOCS	s020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
medial	medial	m0304	JJ	I-NP	O
preoptic	preoptic	p601302	JJ	I-NP	O
area	area	a600	NN	I-NP	O
,	,	,000	,	O	O
where	where	w060	WRB	B-ADVP	O
GnRH	GnRH	g560	NN	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
regulated	regulate	r02040303	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arcuate	arcuate	a62030	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
and	and	a530	CC	O	O
choroid	choroid	c0603	JJ	B-NP	O
plexus	plexus	p40202	NN	I-NP	O
,	,	,000	,	O	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
,	,	,000	,	O	O
SOCS	SOCS	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
CIS	CIS	c020	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
.	.	.000	.	O	O

Estradiol	Estradiol	e2360304	NN	B-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
SOCS	SOCS	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
CIS	CIS	c020	NN	I-NP	O
.	.	.000	.	O	O

Interestingly	Interestingly	i530602305240	RB	B-ADVP	O
,	,	,000	,	O	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
,	,	,000	,	O	O
SOCS	SOCS	s020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
CIS	CIS	c020	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
independently	independently	i530105305340	RB	B-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
GnRH	GnRH	g560	NN	B-NP	O
pulse	pulse	p0420	NN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
steroid	steroid	s30603	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
provide	provide	p601030	VBP	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
estradiol	estradiol	e2360304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
region	region	r0205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
regulation	regulation	r02040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
and	and	a530	CC	O	O
signaling	signaling	s02504052	NN	B-NP	O
responses	response	r02105202	NNS	I-NP	O
by	by	b000	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
.	.	.000	.	O	O

Clonidine	Clonidine	c40503050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
attention	attention	a305305	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
/	/	/000	SYM	I-NP	I-Disease
hyperactivity	hyperactivity	h010602301030	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
:	:	:000	:	O	O
II	II	i000	CD	B-NP	O
.	.	.000	.	O	O

ECG	ECG	e200	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
used	use	u203	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
with	with	w030	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
attention	attention	a305305	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
/	/	/000	SYM	O	I-Disease
hyperactivity	hyperactivity	h010602301030	NN	B-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
ADHD	ADHD	a303	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
16	16	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
122	122	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ADHD	ADHD	a303	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
31	31	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
29	29	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
32	32	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
30	30	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Doses	Dose	d0202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
flexibly	flexibly	f4020140	RB	I-VP	O
titrated	titrate	t0360303	VBN	I-VP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
both	both	b030	DT	B-NP	O
with	with	w030	IN	B-PP	O
divided	divide	d010303	VBN	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
regarding	regard	r02063052	VBG	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
and	and	a530	CC	I-NP	O
changes	change	c05202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
to	to	t000	TO	B-PP	O
week	week	w020	NN	B-NP	O
16	16	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
electrocardiograms	electrocardiogram	e4023602063026052	NNS	B-NP	O
and	and	a530	CC	O	O
vital	vital	v0304	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
incidents	incident	i52030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
not	not	n030	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
electrocardiogram	electrocardiogram	e402360206302605	NN	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
suggestions	suggestion	s02023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
interactions	interaction	i5306023052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
methylphenidate	methylphenidate	m030410503030	NN	I-NP	B-Chemical
regarding	regard	r02063052	VBG	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

Moderate	Moderate	m0306030	JJ	B-NP	O
or	or	o600	CC	I-NP	O
severe	severe	s01060	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
on	on	o500	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
79	79	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
49	49	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
.	.	.000	.	O	O
0006	0006	0000	CD	B-NP	O
)	)	)000	)	O	O
but	but	b030	CC	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
.	.	.000	.	O	O

Drowsiness	Drowsiness	d6020502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
generally	generally	g0506040	RB	B-VP	O
resolved	resolve	r0204103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Clonidine	Clonidine	c40503050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
used	use	u203	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
with	with	w030	IN	B-PP	O
methylphenidate	methylphenidate	m030410503030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
appears	appear	a1062	VBZ	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-ADJP	O
tolerated	tolerate	t04060303	VBN	I-ADJP	O
in	in	i500	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
ADHD	ADHD	a303	NN	I-NP	B-Disease
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
for	for	f060	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
advise	advise	a31020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
likelihood	likelihood	l020403	NN	I-NP	O
of	of	o100	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
drowsiness	drowsiness	d6020502	NN	I-NP	B-Disease
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
Fanconi	Fanconi	f052050	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
:	:	:000	:	O	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
cytopathy	cytopathy	c0301030	NN	I-NP	I-Disease
?	?	?000	.	O	O

Advances	Advance	a3105202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
field	field	f043	NN	I-NP	O
of	of	o100	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
provide	provide	p601030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
better	good	b0306	JJR	I-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
and	and	a530	CC	O	O
allow	allow	a400	VB	B-VP	O
more	more	m060	RBR	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
growth	growth	g6030	NN	B-NP	O
and	and	a530	CC	I-NP	O
development	development	d0104015053	NN	I-NP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
combinations	combination	c0510503052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
require	require	r02060	VBP	B-VP	O
consideration	consideration	c05203060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
old	old	o430	JJ	I-NP	O
girl	girl	g064	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
orthotopic	orthotopic	o63030102	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
Wilson	Wilson	w04205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tacrolimus	Tacrolimus	t026040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
MMF	MMF	m510	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
as	as	a200	IN	B-PP	O
immunosuppressant	immunosuppressant	i5050201602053	NN	B-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
de	de	d000	FW	B-NP	O
nova	nova	n010	FW	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
her	her	h060	PRP	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
yr	yr	y600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
she	she	s000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
Fanconi	Fanconi	f052050	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypophosphatemia	hypophosphatemia	h010102103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
glycosuria	glycosuria	g40202060	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
aminoaciduria	aminoaciduria	a5050203060	NN	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
late	late	l030	JJ	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
acidosis	acidosis	a2030202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
acidosis	acidosis	a2030202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
electrolyte	electrolyte	e4023604030	NN	B-NP	O
imbalance	imbalance	i51040520	NN	I-NP	O
got	get	g030	VBD	B-VP	O
worse	worse	w0620	JJR	B-ADJP	O
.	.	.000	.	O	O

Proximal	Proximal	p6020504	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
weakness	weakness	w02502	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
her	her	h060	PRP	B-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

Fanconi	Fanconi	f052050	NNP	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
myopathy	myopathy	m01030	NN	B-NP	B-Disease
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
depletion	depletion	d0140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
mtDNA	mtDNA	m350	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
tubular	tubular	t010406	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
resulted	result	r0204303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
triggered	trigger	t6020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
augmented	augment	a02505303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Higher	High	h0206	JJR	B-NP	O
optical	optical	o130204	JJ	I-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
predicts	predict	p6030232	VBZ	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
correlate	correlate	c0604030	VB	I-VP	O
optical	optical	o130204	JJ	B-NP	O
density	density	d052030	NN	I-NP	O
and	and	a530	CC	I-NP	O
percent	percent	p062053	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
two	two	t000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
step	step	s301	NN	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
antigen	antigen	a530205	NN	B-NP	O
assay	assay	a200	NN	I-NP	O
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
assay	assay	a200	NN	I-NP	O
utilizes	utilize	u3040202	VBZ	B-VP	O
reaction	reaction	r02305	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
heparin	heparin	h010605	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
count	count	c053	NN	I-NP	O
or	or	o600	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
150	150	0000	CD	I-NP	O
x	x	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
two	two	t000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
step	step	s301	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
[	[	[000	(	O	O
optical	optical	o130204	JJ	B-NP	O
density	density	d052030	NN	I-NP	O
(	(	(000	(	O	O
OD	OD	o300	NN	B-NP	O
)	)	)000	)	O	O
>	>	>000	SYM	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	O	O
>	>	>000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
]	]	]000	)	O	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
of	of	o100	IN	B-PP	O
94	94	0000	CD	B-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
;	;	;000	:	O	O
54	54	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
94	94	0000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
-	-	-000	HYPH	B-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
30	30	0000	CD	I-NP	O
d	d	d000	NN	I-NP	O
;	;	;000	:	O	O
thus	thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
48	48	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
OD	OD	o300	NN	B-NP	O
between	between	b0305	IN	B-PP	O
HIT	HIT	h030	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
OD	OD	o300	NN	B-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
48	48	0000	CD	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
89	89	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
isolated	isolate	i2040303	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
later	later	l0306	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
within	within	w0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
d	d	d000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
84	84	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
64	64	0000	CD	I-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
HIT	HIT	h030	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
develop	develop	d010401	VB	I-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
96	96	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
75	75	0000	CD	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
011	011	0000	CD	I-NP	O
and	and	a530	CC	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
008	008	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Receiver	Receiver	r020106	NNP	I-NP	O
Operative	Operative	o10603010	NNP	I-NP	O
Characteristic	Characteristic	c060230602302	NNP	I-NP	O
Curve	Curve	c0610	NNP	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
OD	OD	o300	NN	B-NP	O
>	>	>000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
27	27	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
-	-	-000	HYPH	I-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
chance	chance	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
30	30	0000	CD	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
percent	percent	p062053	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

Multivariate	Multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
risk	risk	r020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
OD	OD	o300	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Higher	High	h0206	JJR	B-NP	O
OD	OD	o300	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
thrombosis	thrombosis	t060510202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
isolated	isolate	i2040303	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
HIT	HIT	h030	NN	I-NP	B-Disease
;	;	;000	:	O	O
percent	percent	p062053	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
predictive	predictive	p603023010	JJ	B-ADJP	O
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
limited	limit	l050303	VBN	I-VP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
agent	agent	a2053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
relapsed	relapsed	r0401203	JJ	B-NP	O
or	or	o600	CC	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
indolent	indolent	i5304053	JJ	I-NP	O
non	non	n050	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hodgkin	Hodgkin	h03205	NN	I-NP	I-Disease
lymphomas	lymphoma	l0510502	NNS	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Cancer	Cancer	c05206	NNP	I-NP	B-Disease
and	and	a530	CC	I-NP	O
Leukemia	Leukemia	l02050	NNP	I-NP	B-Disease
Group	Group	g601	NNP	I-NP	O
B	B	b000	NNP	I-NP	O
.	.	.000	.	O	O

Thalidomide	Thalidomide	t040305030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
with	with	w030	IN	B-PP	O
demonstrated	demonstrate	d05052360303	VBN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	B-Disease
myeloma	myeloma	m04050	NN	I-NP	I-Disease
,	,	,000	,	O	O
mantle	mantle	m05340	NN	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
lymphoplasmacytic	lymphoplasmacytic	l051014025020302	JJ	B-NP	B-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
believed	believe	b040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumour	tumour	t0506	NN	I-NP	B-Disease
milieu	milieu	m040	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
downregulation	downregulation	d05602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
and	and	a530	CC	O	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
cytokines	cytokine	c03020502	NNS	I-NP	O
.	.	.000	.	O	O

Between	Between	b0305	IN	B-PP	O
July	July	j040	NNP	B-NP	O
2001	2001	0000	CD	I-NP	O
and	and	a530	CC	O	O
April	April	a1604	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
indolent	indolent	i5304053	JJ	I-NP	O
lymphomas	lymphoma	l0510502	NNS	I-NP	B-Disease
received	receive	r020103	VBD	B-VP	O
thalidomide	thalidomide	t040305030	IN	B-NP	B-Chemical
200	200	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
escalation	escalation	e2040305	NN	B-NP	O
by	by	b000	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
tolerated	tolerate	t04060303	VBN	B-VP	O
,	,	,000	,	O	O
up	up	u100	IN	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
800	800	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
prior	prior	p606	JJ	B-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
-	-	-000	:	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
progressed	progress	p60260203	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Grade	Grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
,	,	,000	,	O	O
fatigue	fatigue	f03020	NN	B-NP	B-Disease
,	,	,000	,	O	O
somnolence	somnolence	s05040520	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
mood	mood	m030	NN	I-NP	I-Disease
,	,	,000	,	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
dyspnea	dyspnea	d02150	NN	I-NP	B-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
concern	concern	c052065	NN	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
thromboembolic	thromboembolic	t060510510402	JJ	I-NP	B-Disease
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
to	to	t000	TO	B-PP	O
single	single	s05240	JJ	B-NP	O
agent	agent	a2053	NN	I-NP	O
thalidomide	thalidomide	t040305030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
indolent	indolent	i5304053	JJ	B-NP	O
lymphomas	lymphoma	l0510502	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
contrast	contrast	c0536023	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
activity	activity	a2301030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
generation	generation	g05060305	NN	I-NP	O
immunomodulatory	immunomodulatory	i50505030403060	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
lenalidomide	lenalidomide	l05040305030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Sex	Sex	s020	NN	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
antihyperalgesia	antihyperalgesia	a530106042020	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
capsaicin	capsaicin	c0120205	NN	I-NP	B-Chemical
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
:	:	:000	:	O	O
comparisons	comparison	c0510602052	NNS	B-NP	O
to	to	t000	TO	B-PP	O
two	two	t000	CD	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
enhance	enhance	e50520	VBP	B-VP	O
the	the	t000	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
in	in	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
than	than	t050	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
extend	extend	e23053	VB	I-VP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
distinguished	distinguish	d0230520203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nociceptive	nociceptive	n0202013010	JJ	I-NP	O
fibers	fiber	f01062	NNS	I-NP	O
activated	activate	a23010303	VBN	B-VP	O
,	,	,000	,	O	O
neurochemical	neurochemical	n0602050204	JJ	B-NP	O
substrates	substrate	s012360302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nociceptive	nociceptive	n0202013010	JJ	I-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
end	end	e530	NN	I-NP	O
,	,	,000	,	O	O
persistent	persistent	p062023053	JJ	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
of	of	o100	IN	B-PP	O
gonadally	gonadally	g0503040	RB	B-NP	O
intact	intact	i53023	JJ	I-NP	O
F344	F344	0000	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
following	follow	f04052	VBG	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
tail	tail	t040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
immersed	immerse	i506203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
mildly	mildly	m04340	RB	I-NP	O
noxious	noxious	n0202	JJ	I-NP	O
thermal	thermal	t06504	JJ	I-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
tail	tail	t040	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
latencies	latency	l0305202	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
,	,	,000	,	O	O
tests	test	t0232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hotplate	hotplate	h0314030	NN	I-NP	O
and	and	a530	CC	I-NP	O
warm	warm	w065	JJ	I-NP	O
water	water	w0306	NN	I-NP	O
tail	tail	t040	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
dextromethorphan	dextromethorphan	d0236050306105	NN	I-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
time	time	t050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

Across	Across	a2602	IN	B-PP	O
the	the	t000	DT	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
times	time	t0502	NNS	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
,	,	,000	,	O	O
enhancement	enhancement	e505205053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
.	.	.000	.	O	O

Enhancement	Enhancement	e505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
antinociception	antinociception	a5305020201305	NN	I-NP	O
by	by	b000	IN	B-PP	O
dextromethorphan	dextromethorphan	d0236050306105	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
males	male	m0402	NNS	I-NP	O
and	and	a530	CC	I-NP	O
females	female	f050402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
being	be	b052	VBG	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
sexually	sexually	s02040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
dimorphic	dimorphic	d0506102	JJ	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
antagonists	antagonist	a5302050232	NNS	I-NP	O
and	and	a530	CC	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
persistent	persistent	p062023053	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
that	that	t030	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
distinguished	distinguish	d0230520203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
models	model	m03042	NNS	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
switch	switch	s0320	NN	B-NP	O
to	to	t000	TO	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
immunosuppression	immunosuppression	i505020160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Calcineurin	Calcineurin	c042050605	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
can	can	c050	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
(	(	(000	(	O	O
IS	IS	i200	NN	B-NP	O
)	)	)000	)	O	O
drug	drug	d602	NN	B-NP	O
sirolmus	sirolmus	s0604502	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Srl	Srl	s640	NN	B-NP	B-Chemical
)	)	)000	)	O	O
lacks	lack	l020	VBZ	B-VP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Srl	Srl	s640	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Srl	Srl	s640	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
switched	switch	s03203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
cyclosporine	cyclosporine	c02402106050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
Srl	Srl	s640	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
based	base	b0203	VBN	B-NP	O
IS	IS	i200	NN	I-NP	O
.	.	.000	.	O	O

Concomitant	Concomitant	c0520503053	JJ	B-NP	O
IS	IS	i200	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
mycophenolate	mycophenolate	m02010504030	NN	B-NP	B-Chemical
mofetil	mofetil	m010304	NN	I-NP	I-Chemical
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	HYPH	B-ADVP	O
steroids	steroid	s306032	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
13	13	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
0	0	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
preswitch	preswitch	p6020320	NN	B-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
23	23	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	I-NP	O
88	88	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
24	24	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
postswitch	postswitch	p02320320	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0024	0024	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
switch	switch	s0320	NN	I-NP	O
,	,	,000	,	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
22	22	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
postswitch	postswitch	p02320320	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
006	006	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

ACE	ACE	a200	NN	B-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
releasing	release	r0402052	VBG	B-VP	I-Chemical
blocker	blocker	b40206	NN	B-NP	I-Chemical
(	(	(000	(	O	O
ARB	ARB	a610	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
development	development	d0104015053	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
42	42	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
64	64	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
grade	grade	g6030	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
showed	show	s030	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
(	(	(000	(	O	O
median	median	m0305	NN	B-NP	O
39	39	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
29	29	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
125	125	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
switch	switch	s0320	NN	B-NP	O
to	to	t000	TO	B-PP	O
Srl	Srl	s640	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Srl	Srl	s640	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ACEi	ACEi	a200	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
ARB	ARB	a610	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
monitored	monitor	m05030603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ginsenoside	Ginsenoside	g0520502030	NN	B-NP	B-Chemical
Rg1	Rg1	0000	NN	I-NP	I-Chemical
restores	restore	r0230602	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Rg1	Rg1	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
ginsenoside	ginsenoside	g0520502030	NN	I-NP	B-Chemical
extracted	extract	e23602303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
Panax	Panax	p0502	NN	B-NP	O
ginseng	ginseng	g052052	NN	I-NP	O
,	,	,000	,	O	O
could	could	c043	MD	B-VP	O
ameliorate	ameliorate	a50406030	VB	I-VP	O
spatial	spatial	s10304	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
learning	learn	l065052	VBG	B-VP	B-Disease
impairment	impairment	i51065053	NN	B-NP	I-Disease
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
subcutaneously	subcutaneously	s01203050240	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
twice	twice	t020	RB	B-NP	O
a	a	a000	DT	I-NP	O
day	day	d000	NN	I-NP	O
at	at	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	I-VP	O
injected	inject	i5202303	VBN	I-VP	O
2	2	2000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
once	once	o520	RB	O	O
a	a	a000	DT	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Spatial	Spatial	s10304	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Morris	Morris	m0602	NNP	I-NP	O
water	water	w0306	NN	I-NP	O
maze	maze	m020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
Morphine	Morphine	m061050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
Rg1	Rg1	0000	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
escape	escape	e2010	NN	B-NP	O
latency	latency	l030520	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
spent	spend	s1053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
platform	platform	p4031065	NN	B-NP	O
quadrant	quadrant	q036053	NN	I-NP	O
and	and	a530	CC	O	O
entering	enter	e5306052	VBG	B-VP	O
frequency	frequency	f6020520	NN	B-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
implantation	implantation	i5140530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
electrodes	electrode	e402360302	NNS	B-NP	O
and	and	a530	CC	O	O
electrophysiological	electrophysiological	e40236010204020204	JJ	B-NP	O
recording	recording	r02063052	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
(	(	(000	(	O	O
LTP	LTP	l310	NN	B-NP	O
)	)	)000	)	O	O
impaired	impair	i510603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
freely	freely	f6040	RB	B-VP	O
moving	move	m01052	VBG	I-VP	O
and	and	a530	CC	O	O
anaesthetised	anaesthetise	a5023030203	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
recording	recording	r02063052	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
LTP	LTP	l310	NN	I-NP	O
in	in	i500	IN	B-PP	O
slices	slice	s40202	NNS	B-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
changed	change	c05203	VBD	B-VP	O
LTP	LTP	l310	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
slices	slice	s40202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
or	or	o600	CC	O	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
Rg1	Rg1	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
aspartate	aspartate	a21063030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
MK801	MK801	0000	NN	I-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
Rg1	Rg1	0000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
spatial	spatial	s10304	JJ	I-NP	O
learning	learning	l065052	NN	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
impaired	impair	i510603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chonic	chonic	c0502	JJ	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
restore	restore	r023060	VB	B-VP	O
the	the	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
inhibited	inhibit	i5010303	VBN	B-NP	O
LTP	LTP	l310	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
.	.	.000	.	O	O

Synthesis	Synthesis	s0530202	NN	B-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pyrimidinyl	pyrimidinyl	p0605030504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenoxyacetamides	phenoxyacetamide	p05020203050302	NNS	I-NP	I-Chemical
as	as	a200	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
A2A	A2A	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pyrimidinyl	pyrimidinyl	p0605030504	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phenoxyacetamide	phenoxyacetamide	p0502020305030	NN	I-NP	I-Chemical
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
2A	2A	2000	NN	B-NP	O
)	)	)000	)	O	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

SAR	SAR	s060	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
compound	compound	c051053	NN	B-NP	O
14	14	0000	CD	I-NP	O
with	with	w030	IN	B-PP	O
excellent	excellent	e204053	JJ	B-NP	O
potency	potency	p030520	NN	I-NP	O
(	(	(000	(	O	O
K	K	k000	NN	B-NP	O
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
selectivity	selectivity	s0402301030	NN	B-NP	O
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
/	/	/000	SYM	B-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
2A	2A	2000	NN	B-NP	O
)	)	)000	)	O	O
>	>	>000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
efficacy	efficacy	e102020	NN	B-NP	O
(	(	(000	(	O	O
MED	MED	m030	NN	B-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
D1	D1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
D2	D2	0000	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mediating	mediate	m0303052	VBG	B-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
repeated	repeat	r010303	VBN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
or	or	o600	CC	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
environment	environment	e510605053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
observe	observe	o120610	VB	I-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
habituation	habituation	h01030305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
environment	environment	e510605053	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
mediating	mediate	m0303052	VBG	B-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
examining	examine	e20505052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
D1	D1	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
D2	D2	0000	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
activity	activity	a2301030	NN	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Locomotor	Locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
photocell	photocell	p030204	NN	B-NP	O
cages	cage	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
locomotor	locomotor	l02050306	NN	B-NP	I-Disease
activity	activity	a2301030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
habituated	habituate	h01030303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
environment	environment	e510605053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
weak	weak	w020	JJ	I-NP	O
and	and	a530	CC	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
stimulant	stimulant	s30504053	NN	I-NP	O
action	action	a2305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
unfamiliar	unfamiliar	u51050406	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
environment	environment	e510605053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stimulant	stimulant	s30504053	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
mecamylamine	mecamylamine	m02050405050	NN	I-NP	B-Chemical
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
by	by	b000	IN	I-PP	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
hexamethonium	hexamethonium	h0205030505	NN	I-NP	B-Chemical
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
probably	probably	p6010140	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nicotinic	nicotinic	n02030502	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
D1	D1	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
SCH	SCH	s200	NN	I-NP	B-Chemical
23390	23390	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
D2	D2	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
raclopride	raclopride	r024016030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
D1	D1	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
D2	D2	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
fluphenazine	fluphenazine	f4010502050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
D2	D2	0000	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
PHNO	PHNO	p050	NN	I-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
D1	D1	0000	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
SKF	SKF	s210	NN	I-NP	B-Chemical
38393	38393	0000	CD	I-NP	I-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
acute	acute	a2030	JJ	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
induces	induce	i530202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
habituated	habituate	h01030303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
environment	environment	e510605053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-VP	O
located	locate	l020303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-VP	O
requires	require	r020602	VBZ	I-VP	O
the	the	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
D1	D1	0000	NN	B-NP	O
and	and	a530	CC	O	O
D2	D2	0000	NN	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clomiphene	clomiphene	c40501050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ovulation	ovulation	o1040305	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clomiphene	clomiphene	c40501050	NN	B-NP	B-Chemical
citrate	citrate	c036030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CC	CC	c200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
:	:	:000	:	O	O
Case	Case	c020	NN	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

SETTING	SETTING	s03052	NN	B-NP	O
:	:	:000	:	O	O
Ophthalmology	Ophthalmology	o10304504020	NN	B-NP	O
clinic	clinic	c40502	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
academic	academic	a2030502	JJ	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

PATIENT	PATIENT	p03053	NN	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
36	36	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
referred	refer	r010603	VBN	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
infertility	infertility	i5106304030	NN	I-NP	B-Disease
clinic	clinic	c40502	NN	I-NP	O
for	for	f060	IN	B-PP	O
blurred	blurred	b40603	JJ	B-NP	B-Disease
vision	vision	v0205	NN	I-NP	I-Disease
.	.	.000	.	O	O

INTERVENTION	INTERVENTION	i5306105305	NN	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
Ophthalmic	Ophthalmic	o10304502	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NN	B-NP	O
OUTCOME	OUTCOME	o032050	NN	I-NP	O
MEASURE	MEASURE	m02060	NN	I-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
Central	Central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
ovulation	ovulation	o1040305	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
with	with	w030	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULT	RESULT	r02043	NN	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
36	36	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
central	central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
search	search	s0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
thromboembolic	thromboembolic	t060510510402	JJ	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
include	include	i524030	VB	I-VP	O
this	this	t020	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
mild	mild	m043	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vein	vein	v050	NN	I-NP	I-Disease
occlusion	occlusion	o240205	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Extra	Extra	e2360	NNP	B-NP	O
caution	caution	c0305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
treating	treat	t603052	VBG	B-VP	O
infertility	infertility	i5106304030	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
CC	CC	c200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
well	well	w040	RB	I-VP	O
informed	inform	i5106503	VBN	I-VP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
before	before	b01060	IN	B-PP	O
commencement	commencement	c0505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
bronchodilating	bronchodilating	b6052030403052	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
obstructive	obstructive	o1236023010	JJ	I-NP	I-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
bronchodilator	bronchodilator	b605203040306	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
aerosol	aerosol	a060204	NN	I-NP	O
(	(	(000	(	O	O
36	36	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
short	short	s063	JJ	B-ADJP	O
-	-	-000	HYPH	B-NP	O
acting	act	a23052	VBG	I-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
tablets	tablet	t014032	NNS	I-NP	O
(	(	(000	(	O	O
dose	dose	d020	NN	B-NP	O
titrated	titrate	t0360303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
serum	serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
crossover	crossover	c6020106	NN	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
,	,	,000	,	I-NP	O
chronic	chronic	c060502	JJ	I-NP	B-Disease
obstructive	obstructive	o1236023010	JJ	I-NP	I-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
peak	peak	p020	JJ	I-NP	O
forced	force	f06203	VBN	I-NP	O
expiratory	expiratory	e210603060	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
second	second	s02053	JJ	I-NP	O
(	(	(000	(	O	O
FEV1	FEV1	0000	NN	B-NP	O
)	)	)000	)	O	O
increases	increase	i5260202	VBZ	B-VP	O
over	over	o106	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
attaining	attain	a305052	VBG	B-VP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
15	15	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
FEV1	FEV1	0000	NN	I-NP	O
(	(	(000	(	O	O
responders	responder	r021053062	NNS	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
FEV1	FEV1	0000	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
observation	observation	o120610305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
were	be	w060	VBD	B-VP	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
for	for	f060	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
,	,	,000	,	O	O
those	those	t020	DT	B-NP	O
experienced	experience	e210605203	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
did	do	d030	VBD	B-VP	O
involve	involve	i510410	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
gastrointestinal	gastrointestinal	g02360530230504	JJ	I-NP	I-Disease
systems	system	s023052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ipratropium	ipratropium	i160360105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
potent	potent	p03053	JJ	I-NP	O
bronchodilator	bronchodilator	b605203040306	NN	I-NP	O
than	than	t050	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
theophylline	theophylline	t0104050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
airflow	airflow	a06140	NN	I-NP	I-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
fractalkine	fractalkine	f6023042050	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
signaling	signaling	s02504052	NN	I-NP	O
.	.	.000	.	O	O

Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
METH	METH	m030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
damages	damage	d050202	NNS	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
DA	DA	d000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
nerve	nerve	n0610	NN	B-NP	O
endings	ending	e53052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
process	process	p60202	NN	I-NP	O
that	that	t030	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
linked	link	l05203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
pathways	pathway	p0302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
mediate	mediate	m03030	VBP	B-VP	O
this	this	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
yet	yet	y030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
delineated	delineate	d04050303	VBN	I-VP	O
.	.	.000	.	O	O

Cardona	Cardona	c063050	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
.	.	.000	.	O	O

[	[	[000	(	O	O
Nat	Nat	n030	NNP	B-NP	O
.	.	.000	.	I-NP	O
Neurosci	Neurosci	n06020	NNP	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
(	(	(000	(	O	O
2006	2006	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
917	917	0000	CD	B-NP	O
]	]	]000	)	O	O
recently	recently	r0205340	RB	B-ADVP	O
identified	identify	i30530103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
microglial	microglial	m02602404	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
fractalkine	fractalkine	f6023042050	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
(	(	(000	(	O	O
CX3CR1	CX3CR1	0000	NN	B-NP	O
)	)	)000	)	O	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
mediator	mediator	m030306	NN	I-NP	O
of	of	o100	IN	B-PP	O
MPTP	MPTP	m131	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurodegeneration	neurodegeneration	n06030205060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
DA	DA	d000	NN	B-NP	B-Chemical
neurons	neuron	n06052	NNS	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
MPTP	MPTP	m131	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
highly	highly	h02040	RB	B-ADJP	O
selective	selective	s04023010	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
DA	DA	d000	NN	I-NP	B-Chemical
neuronal	neuronal	n060504	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
hypothesized	hypothesize	h0103020203	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
CX3CR1	CX3CR1	0000	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Mice	Mouse	m020	NNS	B-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
the	the	t000	DT	B-NP	O
CX3CR1	CX3CR1	0000	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
deleted	delete	d040303	VBN	I-VP	O
and	and	a530	CC	O	O
replaced	replace	r0140203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
cDNA	cDNA	c350	NN	I-NP	O
encoding	encoding	e5203052	NN	I-NP	O
enhanced	enhance	e505203	VBD	B-VP	O
green	green	g605	JJ	B-NP	O
fluorescent	fluorescent	f40602053	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
eGFP	eGFP	e210	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
examined	examine	e2050503	VBN	B-VP	O
for	for	f060	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

METH	METH	m030	NN	B-NP	B-Chemical
depleted	deplete	d0140303	VBD	B-VP	O
DA	DA	d000	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
caused	cause	c0203	VBD	B-VP	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
body	body	b030	NN	B-NP	O
temperature	temperature	t0510603060	NN	I-NP	O
in	in	i500	IN	B-PP	O
CX3CR1	CX3CR1	0000	NN	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
and	and	a530	CC	O	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
CX3CR1	CX3CR1	0000	NN	B-NP	O
knockout	knockout	k50203	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
gender	gender	g05306	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
extend	extend	e23053	VB	I-VP	O
beyond	beyond	b053	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Striatal	Striatal	s360304	JJ	B-NP	O
microglia	microglia	m0260240	NNS	I-NP	O
expressing	express	e21602052	VBG	B-VP	O
eGFP	eGFP	e210	NN	B-NP	O
constitutively	constitutively	c0523030301040	RB	B-VP	O
show	show	s000	VBP	I-VP	O
morphological	morphological	m06104020204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
activation	activation	a23010305	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
restricted	restricted	r023602303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
and	and	a530	CC	O	O
contrasted	contrast	c053602303	VBN	B-VP	O
sharply	sharply	s06140	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
unresponsive	unresponsive	u56021052010	JJ	B-NP	O
eGFP	eGFP	e210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
microglia	microglia	m0260240	NN	I-NP	O
in	in	i500	IN	B-PP	O
surrounding	surround	s06053052	VBG	B-VP	O
brain	brain	b605	NN	B-NP	O
areas	area	a602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
damaged	damage	d050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
from	from	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
that	that	t030	IN	B-NP	O
CX3CR1	CX3CR1	0000	NN	B-NP	O
signaling	signaling	s02504052	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
modulate	modulate	m0304030	VB	I-VP	O
METH	METH	m030	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
or	or	o600	CC	O	O
microglial	microglial	m02602404	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
striatal	striatal	s360304	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
resident	resident	r0203053	JJ	I-NP	O
microglia	microglia	m0260240	NNS	I-NP	O
respond	respond	r021053	VBP	B-VP	O
to	to	t000	TO	B-PP	O
METH	METH	m030	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
cascade	cascade	c02030	NN	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-VP	O
return	return	r03065	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
surveying	survey	s061052	VBG	I-NP	O
state	state	s3030	NN	I-NP	O
without	without	w0303	IN	B-PP	O
undergoing	undergo	u53062052	VBG	B-VP	O
apoptosis	apoptosis	a10130202	NN	B-NP	O
or	or	o600	CC	I-NP	O
migration	migration	m0260305	NN	I-NP	O
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nystagmus	nystagmus	n02302502	NN	I-NP	B-Disease
correlates	correlate	c06040302	VBZ	B-VP	O
with	with	w030	IN	B-PP	O
midpontine	midpontine	m031053050	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathomechanism	pathomechanism	p03050205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nystagmus	nystagmus	n02302502	NN	I-NP	B-Disease
(	(	(000	(	O	O
NIN	NIN	n050	NN	B-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
delineate	delineate	d0405030	VB	I-VP	O
brain	brain	b605	NN	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
NIN	NIN	n050	NN	B-NP	B-Disease
generation	generation	g05060305	NN	I-NP	O
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
inhaled	inhale	i50403	VBD	B-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
darkness	darkness	d062502	NN	B-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
fMRI	fMRI	f560	NN	B-NP	O
)	)	)000	)	O	O
experiment	experiment	e210605053	NN	B-NP	O
;	;	;000	:	O	O
eye	eye	e000	NN	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
registered	register	r020230603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
video	video	v030	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
oculography	oculography	o204026010	NN	I-NP	O
.	.	.000	.	O	O

NIN	NIN	n050	NN	B-NP	B-Disease
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
(	(	(000	(	O	O
BOLD	BOLD	b043	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
midpontine	midpontine	m031053050	JJ	I-NP	O
site	site	s030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
posterior	posterior	p0230606	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
pontis	pontis	p05302	NN	I-NP	O
.	.	.000	.	O	O

NIN	NIN	n050	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
midpontine	midpontine	m031053050	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
may	may	m000	MD	B-VP	O
correspond	correspond	c06021053	VB	I-VP	O
to	to	t000	TO	B-PP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dorsomedial	dorsomedial	d062050304	JJ	I-NP	O
pontine	pontine	p053050	NN	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
reticularis	reticularis	r0302040602	NN	I-NP	O
tegmenti	tegmenti	t0250530	NN	I-NP	O
pontis	pontis	p05302	NN	I-NP	O
,	,	,000	,	O	O
structures	structure	s360230602	NNS	B-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
participate	participate	p0630201030	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
multidirectional	multidirectional	m04303060230504	JJ	B-NP	O
saccades	saccade	s020302	NNS	I-NP	O
and	and	a530	CC	O	O
smooth	smooth	s5030	JJ	B-NP	O
pursuit	pursuit	p06203	NN	I-NP	O
eye	eye	e000	NN	I-NP	O
movements	movement	m01050532	NNS	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
propylpentanoyl	propylpentanoyl	p6010410530504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
urea	urea	u600	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
neurotransmitters	neurotransmitter	n06036052503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
neurotransmitters	neurotransmitter	n06036052503062	NNS	I-NP	O
(	(	(000	(	O	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
glycine	glycine	g402050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
GABA	GABA	g010	NN	B-NP	B-Chemical
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
propylpentanoyl	propylpentanoyl	p6010410530504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
urea	urea	u600	NN	B-NP	I-Chemical
(	(	(000	(	O	O
VPU	VPU	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
parent	parent	p06053	NN	I-NP	O
compound	compound	c051053	NN	I-NP	O
,	,	,000	,	O	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

VPU	VPU	v100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
potent	potent	p03053	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
exhibiting	exhibit	e20103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
ED	ED	e300	VBN	B-VP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
49	49	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
in	in	i500	IN	B-PP	O
protecting	protect	p603023052	VBG	B-VP	O
rats	rat	r032	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
whereas	whereas	w0602	IN	B-PP	O
the	the	t000	DT	B-NP	O
corresponding	corresponding	c06021053052	JJ	I-NP	O
value	value	v040	NN	I-NP	O
for	for	f060	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
322	322	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-NP	O
vivo	vivo	v010	FW	I-NP	O
microdialysis	microdialysis	m02603040202	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
increment	increment	i52605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
whereas	whereas	w0602	IN	B-PP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
glycine	glycine	g402050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
VPU	VPU	v100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
VPA	VPA	v100	NN	B-NP	B-Chemical
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
600	600	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
completely	completely	c051403040	RB	B-ADVP	O
abolished	abolish	a1040203	VBD	B-VP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
evoked	evoke	e10203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
extracellular	extracellular	e23602040406	JJ	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
GABA	GABA	g010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
but	but	b030	CC	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	B-PP	O
a	a	a000	DT	B-NP	O
drastic	drastic	d602302	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
VPU	VPU	v100	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
VPA	VPA	v100	NN	I-NP	B-Chemical
could	could	c043	MD	B-VP	O
protect	protect	p603023	VB	I-VP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
neurotransmitters	neurotransmitter	n06036052503062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
comparatively	comparatively	c051060301040	RB	B-ADJP	O
minor	minor	m0506	JJ	I-ADJP	O
and	and	a530	CC	O	O
offset	offset	o1203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
VPA	VPA	v100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
VPU	VPU	v100	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
drastically	drastically	d602302040	RB	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
aspartate	aspartate	a21063030	NN	I-NP	B-Chemical
should	should	s043	MD	B-VP	O
account	account	a2053	VB	I-VP	O
,	,	,000	,	O	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
partly	partly	p06340	RB	B-ADVP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
anticonvulsant	anticonvulsant	a5302051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
other	other	o306	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
being	be	b052	VBG	B-VP	O
reported	report	r0106303	VBN	I-VP	O
herein	herein	h0605	RB	B-ADVP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
further	further	f06306	RBR	B-ADJP	O
investigated	investigate	i51023020303	VBN	I-ADJP	O
.	.	.000	.	O	O

Protective	Protective	p603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	I-Disease
ulcers	ulcer	u42062	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
concerning	concern	c052065052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
pathogenesis	pathogenesis	p0302050202	NN	B-NP	O
of	of	o100	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
mucosal	mucosal	m020204	JJ	B-NP	O
ulceration	ulceration	u42060305	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
lacking	lack	l02052	VBG	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
back	back	b020	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
,	,	,000	,	O	O
mast	mast	m023	NN	B-NP	O
cell	cell	c040	NN	I-NP	O
histamine	histamine	h02305050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	O
peroxide	peroxide	p0602030	NN	I-NP	O
(	(	(000	(	O	O
LPO	LPO	l100	NN	B-NP	O
)	)	)000	)	O	O
generation	generation	g05060305	NN	B-NP	O
and	and	a530	CC	O	O
mucosal	mucosal	m020204	JJ	B-NP	O
microvascular	microvascular	m02601020406	JJ	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
in	in	i500	IN	B-PP	O
modulating	modulate	m030403052	VBG	B-VP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
ulcer	ulcer	u4206	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
coadministration	coadministration	c0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Additionally	Additionally	a30305040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
ulcer	ulcer	u4206	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
challenged	challenge	c0405203	VBN	I-VP	O
intragastrically	intragastrically	i53602023602040	RB	B-ADJP	O
once	once	o520	RB	I-ADJP	O
daily	daily	d040	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
9	9	9000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
corn	corn	c065	NN	B-NP	O
oil	oil	o040	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
atherosclerosis	atherosclerosis	a306024060202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
corn	corn	c065	NN	B-NP	O
oil	oil	o040	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
rat	rat	r030	NN	B-NP	O
stomachs	stomach	s3050202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
irrigated	irrigate	i6020303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
h	h	h000	NN	I-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
simulated	simulate	s05040303	VBN	B-VP	O
gastric	gastric	g023602	JJ	B-NP	O
juice	juice	j020	NN	I-NP	O
or	or	o600	CC	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
.	.	.000	.	O	O

Gastric	Gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
back	back	b020	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
,	,	,000	,	O	O
mucosal	mucosal	m020204	JJ	B-NP	O
LPO	LPO	l100	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
,	,	,000	,	O	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
microvascular	microvascular	m02601020406	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
,	,	,000	,	O	O
luminal	luminal	l050504	JJ	B-NP	B-Chemical
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	I-NP	O
ulcer	ulcer	u4206	NN	I-NP	B-Disease
areas	area	a602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

Elevated	Elevated	e4010303	JJ	B-NP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	I-NP	B-Disease
parameters	parameter	p060503062	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
density	density	d052030	NN	I-NP	O
lipoprotein	lipoprotein	l010160305	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
gastric	gastric	g023602	JJ	I-NP	O
ulcers	ulcer	u42062	NNS	I-NP	B-Disease
accompanied	accompany	a20510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
ulcerogenic	ulcerogenic	u4206020502	JJ	I-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
back	back	b020	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
,	,	,000	,	O	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
,	,	,000	,	O	O
LPO	LPO	l100	NN	B-NP	O
generation	generation	g05060305	NN	I-NP	O
and	and	a530	CC	O	O
luminal	luminal	l050504	JJ	B-NP	B-Chemical
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
content	content	c053053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
ulcer	ulcer	u4206	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
atherosclerotic	atherosclerotic	a306024060302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
ulcer	ulcer	u4206	NN	I-NP	B-Disease
and	and	a530	CC	O	O
various	various	v0602	JJ	B-NP	O
ulcerogenic	ulcerogenic	u4206020502	JJ	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
dose	dose	d020	NN	B-NP	O
-	-	-000	HYPH	O	O
dependently	dependently	d0105305340	RB	B-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
intragastric	intragastric	i53602023602	JJ	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Atherosclerosis	Atherosclerosis	a306024060202	NN	B-NP	B-Disease
could	could	c043	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
gastric	gastric	g023602	JJ	B-NP	B-Disease
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	I-Disease
ulcer	ulcer	u4206	NN	I-NP	B-Disease
via	via	v000	IN	B-PP	O
aggravation	aggravation	a26010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
gastric	gastric	g023602	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
back	back	b020	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
,	,	,000	,	O	O
LPO	LPO	l100	NN	B-NP	O
generation	generation	g05060305	NN	I-NP	O
,	,	,000	,	O	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
release	release	r04020	NN	I-NP	O
and	and	a530	CC	O	O
microvascular	microvascular	m02601020406	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
B	B	b000	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBSAG	HBSAG	h1202	NN	B-NP	B-Chemical
)	)	)000	)	O	O
seropositive	seropositive	s06010203010	JJ	B-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
worldwide	worldwide	w0643030	RB	B-ADVP	O
.	.	.000	.	O	O

Cancer	Cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
carriers	carrier	c06062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
complication	complication	c0514020305	NN	I-NP	I-Disease
rate	rate	r030	NN	I-NP	O
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
cytotoxic	cytotoxic	c03030202	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
(	(	(000	(	O	O
CT	CT	c300	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
has	have	h020	VBZ	B-VP	O
mainly	mainly	m0540	RB	I-VP	O
been	be	b050	VBN	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
HBV	HBV	h100	NN	B-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
solid	solid	s0403	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hematological	hematological	h050304020204	JJ	I-NP	B-Disease
malignancies	malignancy	m0402505202	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
HBV	HBV	h100	NN	I-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
prior	prior	p606	RB	B-ADVP	O
and	and	a530	CC	O	O
during	during	d06052	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
historical	historical	h023060204	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
who	who	w000	WP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
receive	receive	r02010	VB	I-VP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objectives	objective	o120230102	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
diminishing	diminish	d050502052	VBG	B-VP	O
morbidity	morbidity	m06103030	NN	B-NP	O
and	and	a530	CC	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
during	during	d06052	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
lamivudin	lamivudin	l05010305	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
historical	historical	h023060204	JJ	I-NP	O
controls	control	c0536042	NNS	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
CT	CT	c300	NN	B-NP	O
without	without	w0303	IN	B-PP	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
for	for	f060	IN	I-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
established	establish	e230140203	VBN	I-VP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
severe	severe	s01060	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
006	006	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
ALT	ALT	a430	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
higher	high	h0206	JJR	I-NP	O
mean	mean	m050	JJ	I-NP	O
alanine	alanine	a405050	NN	I-NP	B-Chemical
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
(	(	(000	(	O	O
ALT	ALT	a430	NN	B-NP	O
)	)	)000	)	O	O
values	value	v0402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
;	;	;000	:	O	O
154	154	0000	CD	B-NP	O
:	:	:000	:	O	O
64	64	0000	CD	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
32	32	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
decreases	decrease	d0260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
and	and	a530	CC	O	O
overall	overall	o10604	JJ	B-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
in	in	i500	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
nucleoside	nucleoside	n02402030	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
nucleotide	nucleotide	n02403030	NN	I-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
for	for	f060	IN	B-PP	O
antiviral	antiviral	a53010604	JJ	B-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
during	during	d06052	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
completion	completion	c05140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
CT	CT	c300	NN	B-NP	O
.	.	.000	.	O	O

Recovery	Recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
brachial	brachial	b60204	JJ	I-NP	B-Disease
neuritis	neuritis	n060302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
to	to	t000	TO	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipient	recipient	r0201053	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

TAC	TAC	t020	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
for	for	f060	IN	B-PP	O
solid	solid	s0403	JJ	B-NP	O
organ	organ	o6205	NN	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
pediatrics	pediatric	p0303602	NNS	B-NP	O
.	.	.000	.	O	O

Neurotoxicity	Neurotoxicity	n06030202030	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
serious	serious	s0602	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
,	,	,000	,	O	O
headaches	headache	h030202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
eight	eight	e0203	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
a	a	a000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
half	half	h041	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
old	old	o430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipient	recipient	r0201053	NN	I-NP	O
with	with	w030	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
BN	BN	b500	NN	I-NP	O
.	.	.000	.	O	O

MRI	MRI	m600	NN	B-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
hyperintense	hyperintense	h01060530520	JJ	B-NP	O
T2	T2	0000	NN	I-NP	O
signals	signal	s025042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cervical	cervical	c0610204	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
and	and	a530	CC	O	O
right	right	r0203	JJ	B-NP	O
brachial	brachial	b60204	JJ	I-NP	O
plexus	plexus	p40202	NN	I-NP	O
roots	root	r032	NNS	I-NP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
myelitis	myelitis	m040302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
right	right	r0203	JJ	B-NP	O
brachial	brachial	b60204	JJ	I-NP	B-Disease
plexitis	plexitis	p4020302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Symptoms	Symptom	s0513052	NNS	B-NP	O
persisted	persist	p06202303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
three	three	t060	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
despite	despite	d021030	IN	B-PP	O
TAC	TAC	t020	NN	B-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
IVIG	IVIG	i102	NN	B-NP	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
pulse	pulse	p0420	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
and	and	a530	CC	O	O
eventually	eventually	e1053040	RB	B-ADVP	O
full	full	f040	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
TAC	TAC	t020	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
completely	completely	c051403040	RB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
successfully	successfully	s02021040	RB	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
everolimus	everolimus	e106040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Omitting	Omit	o503052	VBG	B-VP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
nausea	nausea	n020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
day	day	d000	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
AND	AND	a530	CC	I-NP	O
OBJECTIVE	OBJECTIVE	o12023010	NN	I-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
advantages	advantage	a310530202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
and	and	a530	CC	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
occurs	occur	o2062	VBZ	B-VP	O
frequently	frequently	f60205340	RB	B-ADVP	O
.	.	.000	.	O	O

Fentanyl	Fentanyl	f0530504	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
supplement	supplement	s01405053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
analgesia	analgesia	a5042020	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
in	in	i500	IN	B-PP	O
216	216	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
day	day	d000	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
either	either	e0306	CC	O	O
receive	receive	r02010	VB	B-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	B-VP	O
receive	receive	r02010	VB	I-VP	O
1	1	1000	CD	B-NP	O
1	1	1000	CD	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Omission	Omission	o50205	NN	B-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
vomiting	vomit	v0503052	VBG	B-VP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
discharge	discharge	d020620	VB	I-VP	O
from	from	f605	IN	B-PP	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
with	with	w030	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
013	013	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Antiemetic	Antiemetic	a53050302	JJ	B-NP	O
requirements	requirement	r0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0012	0012	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Dexamethasone	Dexamethasone	d02050302050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
or	or	o600	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
.	.	.000	.	O	O

Combining	Combine	c05105052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
fentanyl	fentanyl	f0530504	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
benefits	benefit	b0501032	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
opioids	opioid	o1032	NNS	B-NP	O
,	,	,000	,	O	O
reducing	reduce	r0302052	VBG	B-VP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
discharge	discharge	d020620	VB	I-VP	O
from	from	f605	IN	B-PP	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
049	049	0000	CD	B-NP	O
and	and	a530	CC	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
035	035	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
nausea	nausea	n020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
27	27	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
034	034	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
and	and	a530	CC	O	O
analgesic	analgesic	a50420202	JJ	B-NP	O
requirements	requirement	r0206050532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
omission	omission	o50205	NN	I-NP	O
of	of	o100	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fentanyl	Fentanyl	f0530504	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
minor	minor	m0506	JJ	B-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	O
movement	movement	m0105053	NN	I-NP	O
but	but	b030	CC	O	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
sevoflurane	sevoflurane	s0101406050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
sparing	spar	s106052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
,	,	,000	,	O	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
As	As	a200	IN	B-SBAR	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
exacerbated	exacerbated	e2020610303	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	B-Disease
nausea	nausea	n020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
vomiting	vomiting	v0503052	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
an	an	a500	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
adverse	adverse	a310620	JJ	B-NP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
unnecessary	unnecessary	u50202060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
possibly	possibly	p020140	RB	I-NP	O
detrimental	detrimental	d0360505304	JJ	I-NP	O
supplement	supplement	s01405053	NN	I-NP	O
to	to	t000	TO	B-PP	O
sevoflurane	sevoflurane	s0101406050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
day	day	d000	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Valvular	Valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Course	Course	c0620	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
modifications	modification	m03010203052	NNS	I-NP	O
.	.	.000	.	O	O

Valvular	Valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
vary	vary	v060	VBP	B-VP	O
from	from	f605	IN	B-PP	O
study	study	s3030	NN	B-NP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
course	course	c0620	NN	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
systematically	systematically	s023050302040	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

OBJECTIVES	OBJECTIVES	o120230102	NNS	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
abnormality	abnormality	a1506504030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
possible	possible	p020140	JJ	I-NP	O
reversibility	reversibility	r010620104030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
PD	PD	p300	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Amiens	Amiens	a5052	NNP	I-NP	O
area	area	a600	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
invited	invite	i510303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
attend	attend	a3053	VB	I-VP	O
a	a	a000	DT	B-NP	O
cardiologic	cardiologic	c063040202	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
transthoracic	transthoracic	t60523060202	JJ	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
PD	PD	p300	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
participated	participate	p06302010303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
(	(	(000	(	O	O
median	median	m0305	JJ	B-NP	O
interval	interval	i5306104	NN	I-NP	O
:	:	:000	:	O	O
13	13	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Controls	Control	c0536042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	B-ADJP	O
and	and	a530	CC	O	O
sex	sex	s020	NN	B-NP	O
-	-	-000	HYPH	O	O
matched	match	m03203	VBN	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
referred	refer	r010603	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cardiology	cardiology	c06304020	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Compared	Compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
aortic	aortic	a06302	JJ	B-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
IC	IC	i200	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
mitral	mitral	m03604	JJ	B-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
(	(	(000	(	O	O
OR	OR	o600	NN	B-NP	O
:	:	:000	:	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
IC	IC	i200	NN	I-NP	O
:	:	:000	:	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
53	53	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
tricuspid	tricuspid	t60202103	NN	B-NP	O
:	:	:000	:	O	O
NS	NS	n200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
affected	affect	a102303	VBN	B-NP	O
valves	valve	v04102	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	JJ	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
sum	sum	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
regurgitation	regurgitation	r02062030305	NN	B-NP	O
grades	grade	g60302	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
09	09	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
008	008	0000	CD	I-NP	O
and	and	a530	CC	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
006	006	0000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pergolide	pergolide	p06204030	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Severity	Severity	s0106030	NN	B-NP	O
of	of	o100	IN	B-PP	O
regurgitation	regurgitation	r02062030305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
restrictive	restrictive	r0236023010	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
,	,	,000	,	O	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
/	/	/000	SYM	O	O
30	30	0000	CD	B-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
including	include	i52403052	VBG	B-PP	O
two	two	t000	CD	B-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pergolide	Pergolide	p06204030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
valvular	valvular	v0410406	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
regurgitation	regurgitation	r02062030305	NN	I-NP	O
grade	grade	g6030	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
transthoracic	transthoracic	t60523060202	JJ	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
nearly	nearly	n0640	RB	B-NP	O
normal	normal	n06504	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
restrictive	restrictive	r0236023010	JJ	B-NP	O
valve	valve	v0410	NN	I-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
pergolide	pergolide	p06204030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
reveals	reveal	r01042	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
usual	usual	u204	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
converted	convert	c05106303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
ergot	ergot	e6203	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
agonists	agonist	a2050232	NNS	I-NP	O
.	.	.000	.	O	O

Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
autophagic	autophagic	a03010202	JJ	I-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	O
death	death	d030	NN	I-NP	B-Disease
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
pathogenic	pathogenic	p03020502	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
very	very	v060	RB	B-ADJP	O
complicated	complicate	c0514020303	VBN	I-ADJP	O
and	and	a530	CC	O	O
still	still	s304	RB	B-ADJP	O
unclear	unclear	u52406	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
autophagy	autophagy	a0301020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
so	so	s000	IN	B-SBAR	O
that	that	t030	IN	I-SBAR	O
we	we	w000	PRP	B-NP	O
can	can	c050	MD	B-VP	O
develop	develop	d010401	VB	I-VP	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
for	for	f060	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methyladenine	methyladenine	m03040305050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
3MA	3MA	3500	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
on	on	o500	IN	B-PP	O
autophagy	autophagy	a0301020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Neonatal	Neonatal	n050304	JJ	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
Sprague	Sprague	s16020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rat	rat	r030	NN	I-NP	O
hearts	heart	h0632	NNS	I-NP	O
and	and	a530	CC	O	O
randomly	randomly	r0530540	RB	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
3MA	3MA	3500	NN	I-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
then	then	t050	RB	B-ADVP	O
examined	examine	e2050503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
morphology	morphology	m06104020	NN	I-NP	O
,	,	,000	,	O	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
beclin	beclin	b02405	NN	B-NP	O
1	1	1000	CD	I-NP	O
gene	gene	g050	NN	I-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
transition	transition	t60520305	NN	I-NP	O
(	(	(000	(	O	O
MPT	MPT	m130	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Na	Na	n000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
K	K	k000	NN	I-NP	B-Chemical
+	+	+000	SYM	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
assessed	assess	a20203	VBD	B-VP	O
cell	cell	c040	NN	B-NP	O
viability	viability	v0104030	NN	I-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
membrane	membrane	m0516050	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
counted	count	c05303	VBD	B-VP	O
autophagic	autophagic	a03010202	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
cultured	culture	c0430603	VBN	B-NP	O
cardiomyocytes	cardiomyocyte	c06305020302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
autophagy	autophagy	a0301020	NN	B-NP	O
associated	associated	a2020303	JJ	I-NP	O
gene	gene	g050	NN	I-NP	O
,	,	,000	,	O	O
beclin	beclin	b02405	NN	B-NP	O
1	1	1000	CD	I-NP	O
using	use	u2052	VBG	B-VP	O
RT	RT	r300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
PCR	PCR	p260	NN	I-NP	O
and	and	a530	CC	I-NP	O
Western	Western	w023065	NN	I-NP	O
blotting	blotting	b403052	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
3MA	3MA	3500	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
injury	injury	i52060	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
autophagic	autophagic	a03010202	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3MA	3MA	3500	NN	B-NP	B-Chemical
strongly	strongly	s3605240	RB	B-ADVP	O
downregulated	downregulate	d05602040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
beclin	beclin	b02405	NN	B-NP	O
1	1	1000	CD	I-NP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	I-VP	O
failing	fail	f04052	VBG	B-VP	O
heart	heart	h063	NN	B-NP	O
and	and	a530	CC	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
autophagic	autophagic	a03010202	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Autophagic	Autophagic	a03010202	JJ	B-NP	O
cardiomyocyte	cardiomyocyte	c0630502030	NN	I-NP	O
death	death	d030	NN	I-NP	B-Disease
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
the	the	t000	DT	B-NP	O
autophagy	autophagy	a0301020	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

mToR	mToR	m306	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
:	:	:000	:	O	O
mechanisms	mechanism	m02050252	NNS	B-NP	O
,	,	,000	,	O	O
significance	significance	s02501020520	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
management	management	m050205053	NN	B-NP	O
.	.	.000	.	O	O

Massive	Massive	m02010	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
from	from	f605	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
to	to	t000	TO	B-PP	O
mammalian	mammalian	m050405	JJ	B-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapamycin	rapamycin	r01050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mToR	mToR	m306	NN	B-NP	O
)	)	)000	)	O	O
inhibitors	inhibitor	i50103062	NNS	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
sirolimus	sirolimus	s06040502	NN	I-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
allograft	allograft	a4026013	NN	I-NP	I-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
predictive	predictive	p603023010	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
of	of	o100	IN	B-PP	O
poor	poor	p060	JJ	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
,	,	,000	,	O	O
many	many	m050	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
focused	focus	f020203	VBN	B-VP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	JJ	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Whether	Whether	w0306	IN	B-SBAR	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
consequence	consequence	c052020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
unsolved	unsolved	u5204103	JJ	B-ADJP	O
until	until	u5304	IN	B-SBAR	O
high	high	h020	JJ	B-NP	O
range	range	r0520	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
islet	islet	i2403	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
sirolimus	sirolimus	s06040502	FW	B-NP	B-Chemical
de	de	d000	FW	I-NP	O
novo	novo	n010	FW	I-NP	O
.	.	.000	.	O	O

Podocyte	Podocyte	p0302030	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
mToR	mToR	m306	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
pathways	pathway	p0302	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
remain	remain	r0505	VBP	B-VP	O
hypothetic	hypothetic	h01030302	JJ	B-ADJP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
discuss	discuss	d0202	VBP	B-VP	O
herein	herein	h0605	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
mToR	mToR	m306	NN	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Neuropsychiatric	Neuropsychiatric	n060120203602	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
mefloquine	mefloquine	m01402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mefloquine	mefloquine	m01402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Reactions	Reaction	r023052	NNS	B-NP	O
consisted	consist	c05202303	VBD	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
psychoses	psychos	p2020202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
neurosis	neurosis	n060202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
major	major	m0206	JJ	B-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
sleep	sleep	s401	NN	B-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
wake	wake	w020	NN	I-NP	I-Disease
rhythm	rhythm	r0305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
both	both	b030	CC	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
intake	intake	i53020	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
graded	grade	g60303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Germany	Germany	g065050	NNP	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
mefloquine	mefloquine	m01402050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
suffers	suffer	s01062	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
such	such	s020	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
calculation	calculation	c042040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
215	215	0000	CD	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
users	user	u2062	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
reactions	reaction	r023052	NNS	B-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
000	000	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
making	make	m02052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
mefloquine	mefloquine	m01402050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
60	60	0000	CD	B-ADJP	O
times	time	t0502	NNS	I-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
after	after	a1306	IN	B-PP	O
prophylaxis	prophylaxis	p601040202	NN	B-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
certain	certain	c06305	JJ	B-NP	O
limitations	limitation	l050303052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
malaria	malaria	m04060	NN	B-NP	B-Disease
prophylaxis	prophylaxis	p601040202	NN	I-NP	O
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mefloquine	mefloquine	m01402050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

Prenatal	Prenatal	p6050304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
alters	alter	a43062	VBZ	B-VP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
and	and	a530	CC	O	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
.	.	.000	.	O	O

Epidemiological	Epidemiological	e1030504020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prenatal	prenatal	p6050304	JJ	B-NP	O
nutritional	nutritional	n036030504	JJ	I-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	I-VP	O
use	use	u200	VB	I-VP	O
an	an	a500	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
to	to	t000	TO	B-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prenatal	prenatal	p6050304	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
deprivation	deprivation	d016010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
behaviors	behavior	b01062	NNS	B-NP	O
and	and	a530	CC	O	O
receptor	receptor	r0201306	NN	B-NP	O
binding	binding	b053052	NN	I-NP	O
with	with	w030	IN	B-PP	O
relevance	relevance	r04010520	NN	B-NP	O
to	to	t000	TO	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
prenatally	prenatally	p60503040	RB	B-NP	O
protein	protein	p60305	NN	I-NP	O
deprived	deprive	d0160103	VBN	B-VP	O
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	O
)	)	)000	)	O	O
female	female	f05040	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
stereotypic	stereotypic	s306030102	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
apomorphine	apomorphine	a105061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
puberty	puberty	p010630	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
catalepsy	catalepsy	c03040120	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotion	locomotion	l02050305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
PD	PD	p300	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
PD	PD	p300	NN	B-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

PD	PD	p300	NN	B-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
binding	binding	b053052	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
striatum	striatum	s360305	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
behavior	behavior	b0106	NN	B-NP	O
or	or	o600	CC	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
binding	binding	b053052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	O
males	male	m0402	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
exception	exception	e201305	NN	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-VP	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
H	H	h000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
801	801	0000	CD	B-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
cortex	cortex	c06302	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
prenatal	prenatal	p6050304	JJ	B-NP	O
nutritional	nutritional	n036030504	JJ	I-NP	B-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
enhances	enhance	e505202	VBZ	B-VP	O
risk	risk	r020	NN	B-NP	O
for	for	f060	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
have	have	h010	VB	I-VP	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
developmental	developmental	d010401505304	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
differential	differential	d010605304	JJ	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
drugs	drug	d602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
abuse	abuse	a1020	NN	B-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Papaverine	Papaverine	p010106050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
vasodilator	vasodilator	v0203040306	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
manage	manage	m05020	VB	I-VP	O
vasospasm	vasospasm	v02021025	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
neurosurgical	neurosurgical	n06020620204	JJ	I-NP	O
operations	operation	o10603052	NNS	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
cranial	cranial	c60504	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
previous	previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
and	and	a530	CC	O	O
provides	provide	p6010302	VBZ	B-VP	O
neurophysiological	neurophysiological	n06010204020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
70	70	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
microvascular	microvascular	m02601020406	JJ	I-NP	O
decompression	decompression	d0205160205	NN	I-NP	O
operations	operation	o10603052	NNS	I-NP	O
and	and	a530	CC	O	O
studied	study	s30303	VBN	B-VP	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
topical	topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
vasospasm	vasospasm	v02021025	NN	B-NP	B-Disease
.	.	.000	.	O	O

Topical	Topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
to	to	t000	TO	B-VP	O
manage	manage	m05020	VB	I-VP	O
vasospasm	vasospasm	v02021025	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
timing	timing	t05052	NN	I-NP	O
of	of	o100	IN	B-PP	O
papaverine	papaverine	p010106050	NN	B-NP	B-Chemical
application	application	a14020305	NN	I-NP	O
and	and	a530	CC	O	O
ongoing	ongoing	o52052	JJ	B-NP	O
operative	operative	o10603010	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
relative	relative	r0403010	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
neurophysiological	neurophysiological	n06010204020204	JJ	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
.	.	.000	.	O	O

Brainstem	Brainstem	b6052305	NN	B-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
evoked	evoked	e10203	JJ	I-NP	O
potentials	potential	p03053042	NNS	I-NP	O
(	(	(000	(	O	O
BAEPs	BAEP	b012	NNS	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
routinely	routinely	r0305040	RB	I-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
monitor	monitor	m050306	VB	I-VP	O
cochlear	cochlear	c020406	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
function	function	f052305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
these	these	t020	DT	B-NP	O
operations	operation	o10603052	NNS	I-NP	O
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
BAEP	BAEP	b010	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
waveform	waveform	w0101065	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
between	between	b0305	IN	B-PP	O
papaverine	papaverine	p010106050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
BAEP	BAEP	b010	NN	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
5	5	5000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
BAEP	BAEP	b010	NN	B-NP	O
waves	wave	w0102	VBZ	B-VP	O
II	II	i000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
III	III	i000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
V	V	v000	NN	I-NP	O
completely	completely	c051403040	RB	B-ADVP	O
disappeared	disappear	d02010603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
25	25	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
papaverine	papaverine	p010106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
10	10	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
BAEP	BAEP	b010	NN	B-NP	O
waveforms	waveform	w01010652	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
10	10	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
later	later	l0306	JJ	B-NP	O
waves	wave	w0102	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
profound	profound	p601053	JJ	I-NP	O
sensorineural	sensorineural	s05206050604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
BAEP	BAEP	b010	NN	B-NP	O
waveforms	waveform	w01010652	NNS	I-NP	O
to	to	t000	TO	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
baseline	baseline	b0204050	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
39	39	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Topical	Topical	t010204	JJ	B-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasospasm	vasospasm	v02021025	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
in	in	i500	IN	B-PP	O
neurophysiological	neurophysiological	n06010204020204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ascending	ascend	a2053052	VBG	I-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
BAEP	BAEP	b010	NN	B-NP	O
waveforms	waveform	w01010652	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
consistent	consistent	c052023053	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
proximal	proximal	p6020504	JJ	I-NP	I-Disease
eighth	eighth	e02030	JJ	I-NP	I-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
.	.	.000	.	O	O

Recommendations	Recommendation	r020505303052	NNS	B-NP	O
to	to	t000	TO	B-VP	O
avoid	avoid	a103	VB	I-VP	O
potential	potential	p0305304	JJ	B-NP	O
cranial	cranial	c60504	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
from	from	f605	IN	B-PP	O
papaverine	papaverine	p010106050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
provided	provide	p6010303	VBN	I-VP	O
.	.	.000	.	O	O

Simvastatin	Simvastatin	s0510230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ezetimibe	ezetimibe	e20305010	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
necessitating	necessitate	n02020303052	VBG	B-VP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

Abstract	Abstract	a1236023	NN	B-NP	O
Serum	Serum	s0605	NN	I-NP	O
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
known	know	k505	VBN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hydroxy	hydroxy	h036020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
methylglutaryl	methylglutaryl	m030424030604	NN	I-NP	O
coenzyme	coenzyme	c052050	NN	I-NP	O
A	A	a000	NN	I-NP	O
reductase	reductase	r03023020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
statin	statin	s30305	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
hepatotoxic	hepatotoxic	h0103030202	JJ	B-NP	B-Disease
events	event	e10532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
widely	widely	w03040	RB	I-VP	O
published	publish	p0140203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ezetimibe	ezetimibe	e20305010	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ezetimibe	ezetimibe	e20305010	NN	I-NP	I-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
70	70	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Hispanic	Hispanic	h0210502	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
necessitating	necessitate	n02020303052	VBG	B-VP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
conversion	conversion	c05106205	NN	B-NP	O
from	from	f605	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
to	to	t000	TO	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	I-Chemical
mg	mg	m200	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
ezetimibe	ezetimibe	e20305010	NN	B-NP	I-Chemical
40	40	0000	CD	I-NP	I-Chemical
mg	mg	m200	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
lipid	lipid	l0103	NN	I-NP	O
panel	panel	p0504	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
before	before	b01060	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
conversion	conversion	c05106205	NN	I-NP	O
without	without	w0303	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
routine	routine	r03050	JJ	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
work	work	w062	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
10	10	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
conversion	conversion	c05106205	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Simvastatinezetimibe	Simvastatinezetimibe	s0510230305020305010	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
escitalopram	escitalopram	e2030401605	NN	I-NP	B-Chemical
(	(	(000	(	O	O
which	which	w020	WDT	B-NP	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
taking	take	t02052	VBG	I-VP	O
for	for	f060	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
repeat	repeat	r0103	NN	I-NP	O
work	work	w062	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
revealed	reveal	r010403	VBD	B-VP	O
further	further	f06306	JJ	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
aminotransferase	aminotransferase	a505036052106020	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
severe	severe	s01060	JJ	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
uneventful	uneventful	u501053104	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
by	by	b000	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
day	day	d000	NN	I-NP	O
23	23	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
her	her	h060	PRP	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Ezetimibe	Ezetimibe	e20305010	NNP	B-NP	B-Chemical
undergoes	undergo	u5306202	VBZ	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
glucuronidation	glucuronidation	g4020605030305	NN	I-NP	O
by	by	b000	IN	B-PP	O
uridine	uridine	u603050	NN	B-NP	B-Chemical
diphosphate	diphosphate	d01021030	NN	I-NP	I-Chemical
glucoronosyltransferases	glucoronosyltransferas	g40206050204360521060202	NNS	I-NP	O
(	(	(000	(	O	O
UGT	UGT	u230	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intestine	intestine	i53023050	NN	I-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
the	the	t000	DT	B-NP	O
glucuronidation	glucuronidation	g4020605030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
hydroxy	hydroxy	h036020	NN	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ezetimibe	ezetimibe	e20305010	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
postulate	postulate	p02304030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
simvastatinezetimibe	simvastatinezetimibe	s0510230305020305010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
by	by	b000	IN	B-PP	O
ezetimibe	ezetimibe	e20305010	NN	B-NP	B-Chemical
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
UGT	UGT	u230	NN	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

Clinicians	Clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ezetimibe	ezetimibe	e20305010	NN	I-NP	I-Chemical
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
elderly	elderly	e430640	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
carefully	carefully	c0601040	RB	I-VP	O
monitor	monitor	m050306	VB	I-VP	O
serum	serum	s0605	NN	B-NP	O
aminotransferase	aminotransferase	a505036052106020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
starting	start	s3063052	VBG	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
and	and	a530	CC	O	O
titrating	titrate	t03603052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
.	.	.000	.	O	O

Massive	Massive	m02010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
bisphosphonate	bisphosphonate	b02102105030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
alendronate	alendronate	a4053605030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
segmental	segmental	s02505304	JJ	I-NP	I-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
61	61	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
focal	focal	f0204	JJ	B-NP	B-Disease
segmental	segmental	s02505304	JJ	I-NP	I-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
initially	initially	i503040	RB	I-VP	O
responding	respond	r021053052	VBG	I-VP	O
well	well	w040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
steroid	steroid	s30603	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	O	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
g	g	g000	NN	I-NP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
bisphosphonate	bisphosphonate	b02102105030	NN	I-NP	B-Chemical
(	(	(000	(	O	O
alendronate	alendronate	a4053605030	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
)	)	)000	)	O	O
administration	administration	a350502360305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
g	g	g000	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
discontinuing	discontinue	d0205305052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
alendronate	alendronate	a4053605030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
six	six	s020	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
LDL	LDL	l340	NN	B-NP	O
apheresis	apheresis	a1060202	NN	I-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
and	and	a530	CC	I-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
protein	protein	p60305	NN	I-NP	O
disappearing	disappear	d020106052	VBG	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
40	40	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
intravenous	intravenous	i536010502	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
oral	oral	o604	JJ	B-NP	O
bisphosphonates	bisphosphonate	b021021050302	NNS	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
aggravate	aggravate	a2601030	VB	I-VP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
glucocorticoid	glucocorticoid	g402020630203	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
inducible	inducible	i53020140	JJ	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
1	1	1000	CD	I-NP	O
in	in	i500	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
epithelial	epithelial	e1030404	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
(	(	(000	(	O	O
ENaC	ENaC	e502	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	B-Disease
retention	retention	r0305305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
sensitive	sensitive	s05203010	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
glucocorticoid	glucocorticoid	g402020630203	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
inducible	inducible	i53020140	JJ	I-NP	O
kinase	kinase	k05020	NN	I-NP	O
SGK1	SGK1	0000	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
participate	participate	p0630201030	VB	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ENaC	ENaC	e502	NN	B-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
mediate	mediate	m03030	VB	I-VP	O
renal	renal	r0504	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
mineralocorticoid	mineralocorticoid	m050604020630203	NN	B-NP	O
and	and	a530	CC	I-NP	O
salt	salt	s043	NN	I-NP	O
excess	excess	e202	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
SGK1	SGK1	0000	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	B-Disease
retention	retention	r0305305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
end	end	e530	NN	I-NP	O
,	,	,000	,	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
g	g	g000	NN	I-NP	O
body	body	b030	NN	I-NP	O
wt	wt	w300	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
gene	gene	g050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
targeted	target	t0620303	VBN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
lacking	lack	l02052	VBG	B-VP	O
SGK1	SGK1	0000	NN	B-NP	O
(	(	(000	(	O	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
wild	wild	w043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
littermates	littermate	l030650302	NNS	I-NP	O
(	(	(000	(	O	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Doxorubicin	Doxorubicin	d0206010205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
heavy	heavy	h010	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	I-NP	O
crea	crea	c600	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
44	44	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
44	44	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
ascites	ascite	a20302	NNS	B-NP	B-Disease
,	,	,000	,	O	O
lipidemia	lipidemia	l0103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
hypoalbuminemia	hypoalbuminemia	h010410505050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
genotypes	genotype	g05030102	NNS	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
mice	mouse	m020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
genotypes	genotype	g05030102	NNS	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
SGK1	SGK1	0000	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
excretion	excretion	e260305	NN	I-NP	O
reached	reach	r0203	VBD	B-VP	O
signficantly	signficantly	s02510205340	RB	B-NP	O
lower	low	l060	JJR	I-NP	O
values	value	v0402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	I-NP	O
crea	crea	c600	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
mumol	mumol	m0504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mg	mg	m200	NN	I-NP	O
crea	crea	c600	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
higher	high	h0206	JJR	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
+	+	+000	SYM	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
g	g	g000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
faster	fast	f02306	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
uremia	uremia	u6050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
median	median	m0305	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
40	40	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
sgk1	sgk1	0000	NN	B-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
gene	gene	g050	NN	B-NP	O
-	-	-000	HYPH	O	O
targeted	target	t0620303	VBN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
lacking	lack	l02052	VBG	B-VP	O
SGK1	SGK1	0000	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
blunted	blunted	b405303	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	B-Disease
retention	retention	r0305305	NN	I-NP	I-Disease
,	,	,000	,	O	O
yet	yet	y030	RB	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
protected	protect	p60302303	VBN	I-VP	O
against	against	a20523	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
nephrotic	nephrotic	n01060302	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
haemolytic	haemolytic	h05040302	JJ	B-NP	B-Disease
anaemia	anaemia	a5050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
with	with	w030	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
.	.	.000	.	O	O

Haematological	Haematological	h050304020204	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
are	be	a600	VBP	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
man	man	m050	NN	I-NP	O
reported	report	r0106303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
jaundice	jaundice	j053020	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
suspect	suspect	s021023	NN	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	B-Disease
tract	tract	t6023	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
evaluations	evaluation	e10403052	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
haemolysis	haemolysis	h05040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
petechiae	petechiae	p03020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
purpura	purpura	p061060	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
thorax	thorax	t0602	NN	B-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
limbs	limb	l0512	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
supportive	supportive	s01063010	JJ	I-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
,	,	,000	,	O	O
laboratory	laboratory	l010603060	NN	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
worsened	worsen	w0620503	VBD	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
died	die	d030	VBD	B-VP	O
17	17	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
accurate	accurate	a206030	JJ	I-NP	O
autopsy	autopsy	a030120	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
most	most	m023	JJS	B-NP	O
organs	organ	o62052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
diffuse	diffuse	d01020	JJ	B-NP	O
petechial	petechial	p030204	JJ	I-NP	O
haemorrhages	haemorrhage	h05060202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
thrombi	thrombi	t060510	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
microangiopathies	microangiopathy	m026052010302	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
arterial	arterial	a630604	JJ	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
any	any	a500	DT	B-NP	O
bacterial	bacterial	b0230604	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
ciprofloxacin	ciprofloxacin	c016014020205	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
precipitate	precipitate	p6020103030	VB	I-VP	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
haemolytic	haemolytic	h05040302	JJ	B-NP	B-Disease
anaemia	anaemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
phases	phase	p0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
apparent	apparent	a106053	JJ	B-NP	O
previous	previous	p60102	JJ	I-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
.	.	.000	.	O	O

Alpha	Alpha	a410	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
lipoic	lipoic	l0102	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
prevents	prevent	p6010532	VBZ	B-VP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigates	investigate	i51023020302	VBZ	B-VP	O
if	if	i100	IN	B-SBAR	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
lipoic	lipoic	l0102	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
neuroprotective	neuroprotective	n0601603023010	JJ	B-ADJP	O
against	against	a20523	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	B-Disease
neurodegenerative	neurodegenerative	n060302050603010	JJ	I-NP	I-Disease
cascade	cascade	c02030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
if	if	i100	IN	B-SBAR	O
neuroprotective	neuroprotective	n0601603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
lipoic	lipoic	l0102	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
depend	depend	d01053	VBP	B-VP	O
on	on	o500	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
protection	protection	p60302305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
induced	induced	i530203	JJ	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
closely	closely	c402040	RB	B-ADVP	O
mimic	mimic	m0502	VBP	B-VP	O
the	the	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vivo	vivo	v010	FW	I-NP	O
condition	condition	c0530305	NN	I-NP	O
by	by	b000	IN	B-PP	O
exposing	expose	e2102052	VBG	B-VP	O
primary	primary	p605060	JJ	B-NP	O
cultures	culture	c0430602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dorsal	dorsal	d06204	JJ	B-NP	O
root	root	r030	NN	I-NP	O
ganglion	ganglion	g052405	NN	I-NP	O
(	(	(000	(	O	O
DRG	DRG	d620	NN	B-NP	O
)	)	)000	)	O	O
sensory	sensory	s052060	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
and	and	a530	CC	O	O
highly	highly	h02040	RB	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
approach	approach	a16020	NN	I-NP	O
allowed	allow	a403	VBD	B-VP	O
investigating	investigate	i510230203052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
lipoic	lipoic	l0102	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
apoptosis	apoptosis	a10130202	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
morphology	morphology	m06104020	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitochondria	mitochondrion	m030205360	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
and	and	a530	CC	O	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
lipoic	lipoic	l0102	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
cause	cause	c020	VBP	B-VP	O
early	early	e0640	JJ	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
loss	loss	l020	NN	B-NP	O
of	of	o100	IN	B-PP	O
membrane	membrane	m0516050	NN	B-NP	O
potential	potential	p0305304	NN	I-NP	O
and	and	a530	CC	O	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
autophagic	autophagic	a03010202	JJ	B-NP	O
vacuoles	vacuole	v020402	NNS	I-NP	O
in	in	i500	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
.	.	.000	.	O	O

Alpha	Alpha	a410	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
lipoic	lipoic	l0102	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
exerts	exert	e20632	VBZ	B-VP	O
neuroprotective	neuroprotective	n0601603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
induced	induce	i530203	VBD	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
sensory	sensory	s052060	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
:	:	:000	:	O	O
it	it	i300	PRP	B-NP	O
rescues	rescue	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
induces	induce	i530202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
frataxin	frataxin	f6030205	NN	B-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
essential	essential	e205304	JJ	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
with	with	w030	IN	B-PP	O
anti	anti	a530	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
oxidant	oxidant	o203053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
chaperone	chaperone	c0106050	NN	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
common	common	c0505	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
both	both	b030	CC	B-PP	O
in	in	i500	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Alpha	Alpha	a410	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
lipoic	lipoic	l0102	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
protects	protect	p6030232	VBZ	B-VP	O
sensory	sensory	s052060	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
through	through	t06020	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
oxidant	oxidant	o203053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
regulatory	regulatory	r020403060	JJ	I-NP	O
functions	function	f0523052	NNS	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
inducing	induce	i5302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
frataxin	frataxin	f6030205	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
alpha	alpha	a410	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	I-Chemical
lipoic	lipoic	l0102	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
might	might	m0203	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
encourage	encourage	e5206020	VB	B-VP	O
further	further	f06306	JJ	B-NP	O
confirmatory	confirmatory	c05106503060	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
trials	trial	t6042	NNS	I-NP	O
.	.	.000	.	O	O

Toxicity	Toxicity	t0202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rhesus	rhesus	r0202	NN	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminoquinoline	aminoquinoline	a505020504050	NN	I-NP	I-Chemical
8	8	8000	CD	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
[	[	[000	(	O	I-Chemical
(	(	(000	(	O	I-Chemical
4	4	4000	CD	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
amino	amino	a5050	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
l	l	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylbutyl	methylbutyl	m030410304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
amino	amino	a5050	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
l	l	l000	NN	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hexyloxy	hexyloxy	h0204020	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
6	6	6000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxy	methoxy	m03020	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methylquinoline	methylquinoline	m030420504050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Many	Many	m050	JJ	B-NP	O
substances	substance	s012305202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
form	form	f065	VBP	B-VP	O
methemoglobin	methemoglobin	m03050240105	NN	B-NP	O
(	(	(000	(	O	O
MHb	MHb	m010	NN	B-NP	O
)	)	)000	)	O	O
effectively	effectively	e102301040	RB	B-VP	O
counter	counter	c05306	VBP	I-VP	O
cyanide	cyanide	c05030	NN	B-NP	O
(	(	(000	(	O	O
CN	CN	c500	NN	B-NP	O
)	)	)000	)	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
MHb	MHb	m010	NN	B-NP	O
formers	former	f065062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
generally	generally	g0506040	RB	I-VP	O
applied	apply	a1403	VBN	I-VP	O
as	as	a200	IN	B-PP	O
treatments	treatment	t60350532	NNS	B-NP	O
for	for	f060	IN	B-PP	O
CN	CN	c500	NN	B-NP	O
poisoning	poisoning	p0205052	NN	I-NP	B-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
stable	stable	s30140	JJ	I-NP	O
,	,	,000	,	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
MHb	MHb	m010	NN	I-NP	O
former	former	f06506	JJ	B-ADJP	O
could	could	c043	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
CN	CN	c500	NN	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
rationale	rationale	r0305040	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
8	8	8000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminoquinoline	aminoquinoline	a505020504050	NN	I-NP	I-Chemical
WR242511	WR242511	0000	NN	I-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
lasting	last	l023052	VBG	B-VP	O
MHb	MHb	m010	NN	B-NP	O
former	former	f06506	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
rodents	rodent	r030532	NNS	B-NP	O
and	and	a530	CC	O	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rhesus	rhesus	r0202	NN	I-NP	O
monkey	monkey	m0520	NN	I-NP	O
for	for	f060	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
development	development	d0104015053	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
CN	CN	c500	NN	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
(	(	(000	(	O	O
IV	IV	i100	CD	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
female	female	f05040	JJ	I-NP	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
male	male	m040	JJ	I-NP	O
rhesus	rhesus	r0202	NN	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
male	male	m040	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
orally	orally	o6040	RB	B-ADVP	O
(	(	(000	(	O	O
PO	PO	p000	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

Health	Health	h0430	NNP	B-NP	O
status	status	s30302	NN	I-NP	O
and	and	a530	CC	I-NP	O
MHb	MHb	m010	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
selected	select	s0402303	VBN	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
produced	produce	p6030203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
methemoglobinemia	methemoglobinemia	m03050240105050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
studies	study	s30302	NNS	I-NP	O
conducted	conduct	c05302303	VBN	B-VP	O
elsewhere	elsewhere	e42060	RB	B-ADVP	O
,	,	,000	,	O	O
produced	produce	p6030203	VBD	B-VP	O
very	very	v060	RB	B-NP	O
little	little	l0340	JJ	I-NP	O
MHb	MHb	m010	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
<	<	<000	SYM	O	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rhesus	rhesus	r0202	NN	I-NP	O
monkey	monkey	m0520	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
transient	transient	t6052053	JJ	B-NP	O
hemoglobinuria	hemoglobinuria	h050240105060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
60	60	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
postinjection	postinjection	p02305202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
lethalities	lethality	l03040302	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
(	(	(000	(	O	O
one	one	o500	CD	B-NP	O
IV	IV	i100	CD	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
PO	PO	p000	NN	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Myoglobinuria	Myoglobinuria	m0240105060	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Histopathology	Histopathology	h023010304020	NN	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
died	die	d030	VBD	B-VP	O
revealed	reveal	r010403	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
severity	severity	s0106030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
orally	orally	o6040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
animal	animal	a50504	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
direct	direct	d06023	JJ	B-ADJP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
indirect	indirect	i5306023	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
WR242511	WR242511	0000	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
pursued	pursue	p06203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
CN	CN	c500	NN	B-NP	O
poisoning	poison	p0205052	VBG	B-VP	B-Disease
unless	unless	u5402	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
CN	CN	c500	NN	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
compound	compound	c051053	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
successfully	successfully	s02021040	RB	I-VP	O
dissociated	dissociate	d02020303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
producing	produce	p60302052	VBG	B-VP	O
undesirable	undesirable	u5302060140	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Repetitive	Repetitive	r010303010	JJ	B-NP	O
transcranial	transcranial	t605260504	JJ	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
for	for	f060	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	I-VP	O
,	,	,000	,	O	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blinded	blind	b405303	VBN	B-VP	O
,	,	,000	,	O	O
crossover	crossover	c6020106	NN	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
assessed	assess	a20203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	B-NP	O
real	real	r040	JJ	I-NP	O
"	"	"000	''	I-NP	O
repetitive	repetitive	r010303010	JJ	I-NP	O
transcranial	transcranial	t605260504	JJ	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
(	(	(000	(	O	O
rTMS	rTMS	r352	NN	B-NP	O
)	)	)000	)	O	O
versus	versus	v06202	IN	B-PP	O
"	"	"000	``	B-NP	O
sham	sham	s050	NN	I-NP	O
"	"	"000	''	I-NP	O
rTMS	rTMS	r352	NN	I-NP	O
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
peak	peak	p020	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
and	and	a530	CC	O	O
prominent	prominent	p60505053	JJ	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
had	have	h030	VBD	B-VP	O
rTMS	rTMS	r352	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
800	800	0000	CD	B-NP	O
pulses	pulse	p04202	NNS	I-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
Hz	Hz	h200	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
)	)	)000	)	O	O
delivered	deliver	d04010603	VBN	B-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
motor	motor	m0306	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
twice	twice	t020	RB	B-ADVP	O
,	,	,000	,	O	O
once	once	o520	RB	B-ADVP	O
real	real	r040	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
and	and	a530	CC	O	O
once	once	o520	RB	B-ADVP	O
sham	sham	s050	NN	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
;	;	;000	:	O	O
evaluations	evaluation	e10403052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

Direct	Direct	d06023	JJ	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
between	between	b0305	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
and	and	a530	CC	O	O
real	real	r040	JJ	B-NP	O
rTMS	rTMS	r352	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
clinician	clinician	c4050205	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
assessed	assess	a20203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
baseline	baseline	b0204050	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
small	small	s504	JJ	B-NP	O
but	but	b030	CC	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
real	real	r040	JJ	B-NP	O
rTMS	rTMS	r352	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
dystonia	dystonia	d023050	NN	B-NP	B-Disease
subscore	subscore	s012060	NN	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
diaries	diary	d0602	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
subjective	subjective	s012023010	JJ	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
scores	score	s20602	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intervention	intervention	i5306105305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
intervention	intervention	i5306105305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
real	real	r040	JJ	I-NP	O
rTMS	rTMS	r352	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
rTMS	rTMS	r352	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	I-NP	O
PD	PD	p300	NN	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
the	the	t000	DT	B-NP	O
existence	existence	e20230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
residual	residual	r020304	JJ	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
aftereffects	aftereffect	a1306010232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
consecutive	consecutive	c0520203010	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
applications	application	a140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
rTMS	rTMS	r352	NN	I-NP	O
on	on	o500	IN	B-PP	O
dyskinesias	dyskinesia	d02050202	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
further	further	f06306	RBR	B-ADJP	O
exploited	exploit	e2140303	VBN	I-ADJP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
uses	use	u202	NNS	I-NP	O
.	.	.000	.	O	O

Intracavernous	Intracavernous	i536020106502	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
minimally	minimally	m0505040	RB	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
priapism	priapism	p601025	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
emergency	emergency	e50620520	NN	I-NP	O
department	department	d010635053	NN	I-NP	O
.	.	.000	.	O	O

Priapism	Priapism	p601025	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
erection	erection	e602305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
penis	penis	p0502	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	O
arousal	arousal	a60204	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
45	45	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
admitted	admit	a350303	VBN	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
user	user	u206	NN	I-NP	O
,	,	,000	,	O	O
presented	present	p60205303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Emergency	Emergency	e50620520	NNP	I-NP	O
Department	Department	d010635053	NNP	I-NP	O
(	(	(000	(	O	O
ED	ED	e300	VBN	B-VP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
occasions	occasion	o202052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
priapism	priapism	p601025	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
options	option	o13052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ED	ED	e300	NNP	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
exemplified	exemplify	e205140103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
four	four	f060	CD	B-NP	O
individual	individual	i53010304	JJ	I-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimally	minimally	m0505040	RB	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracorporal	intracorporal	i536020610604	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
instillation	instillation	i523040305	NN	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Prophylactic	Prophylactic	p6010402302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
rheumatologic	rheumatologic	r0503040202	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
objective	objective	o12023010	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	I-VP	O
report	report	r01063	VB	I-VP	O
our	our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
virus	virus	v0602	NN	I-NP	I-Chemical
surface	surface	s061020	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HBs	HB	h120	NNS	B-NP	B-Chemical
Ag	Ag	a200	NN	I-NP	I-Chemical
)	)	)000	)	O	O
positive	positive	p0203010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatologic	rheumatologic	r0503040202	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
June	June	j050	NNP	B-NP	O
2004	2004	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
October	October	o230106	NNP	B-NP	O
2006	2006	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
11	11	0000	CD	I-NP	O
HBs	HB	h120	NNS	I-NP	B-Chemical
Ag	Ag	a200	NN	I-NP	I-Chemical
positive	positive	p0203010	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatologic	rheumatologic	r0503040202	JJ	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
on	on	o500	IN	B-PP	O
both	both	b030	CC	B-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
lamivudine	lamivudine	l050103050	NN	I-NP	B-Chemical
therapies	therapy	t060102	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	I-VP	O
assessed	assess	a20203	VBN	I-VP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
serologic	serologic	s06040202	JJ	B-NP	O
markers	marker	m062062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	B-PRT	O
up	up	u100	RP	B-PRT	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
file	file	f040	NN	I-NP	O
records	record	r020632	NNS	I-NP	O
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
six	six	s020	CD	B-NP	O
male	male	m040	JJ	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
median	median	m0305	JJ	B-NP	O
age	age	a200	NN	I-NP	O
47	47	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
73	73	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
median	median	m0305	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
50	50	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
9	9	9000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
178	178	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
median	median	m0305	JJ	B-VP	O
follow	follow	f040	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
27	27	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
enrolled	enrol	e560403	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
started	start	s306303	VBN	I-VP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
fourth	fourth	f0630	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
:	:	:000	:	O	O
ALT	ALT	a430	NN	B-NP	O
:	:	:000	:	O	O
122	122	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
,	,	,000	,	O	O
AST	AST	a230	NN	B-NP	O
:	:	:000	:	O	O
111	111	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
,	,	,000	,	O	O
tenth	tenth	t0530	NN	B-NP	O
patient	patient	p03053	NN	I-NP	O
:	:	:000	:	O	O
ALT	ALT	a430	NN	B-NP	O
:	:	:000	:	O	O
294	294	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
,	,	,000	,	O	O
AST	AST	a230	NN	B-NP	O
:	:	:000	:	O	O
274	274	0000	CD	B-NP	O
IU	IU	i000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
minimal	minimal	m050504	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Shortly	Shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
their	their	t060	PRP$	B-NP	O
tests	test	t0232	NNS	I-NP	O
normalized	normalize	n065040203	VBN	B-VP	O
and	and	a530	CC	O	O
during	during	d06052	IN	B-VP	O
follow	follow	f040	VB	I-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
none	none	n050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
HBV	HBV	h100	NN	I-NP	O
DNA	DNA	d500	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
normalized	normalize	n065040203	VBN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
others	other	o3062	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
HBV	HBV	h100	NN	B-NP	O
DNA	DNA	d500	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
sings	sing	s052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
HBV	HBV	h100	NN	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

Lamivudine	Lamivudine	l050103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Prophylactic	Prophylactic	p6010402302	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
required	require	r020603	VBD	B-VP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
,	,	,000	,	O	O
well	well	w040	RB	B-ADJP	O
tolerated	tolerate	t04060303	VBN	I-ADJP	O
and	and	a530	CC	O	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
HBV	HBV	h100	NN	B-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
green	green	g605	JJ	B-NP	B-Chemical
tea	tea	t000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
combination	combination	c051050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
aimed	aim	a0503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
combined	combine	c0510503	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
green	green	g605	JJ	B-NP	B-Chemical
tea	tea	t000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
and	and	a530	CC	O	O
membrane	membrane	m0516050	NN	B-NP	O
bound	bind	b053	VBD	B-VP	O
ATPases	ATPas	a310202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ISO	ISO	i200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Adult	Adult	a3043	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
albino	albino	a41050	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
s	s	s000	NNS	B-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	O	O
significant	significant	s0250102053	JJ	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
whereas	whereas	w0602	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	O	O
significant	significant	s0250102053	JJ	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
,	,	,000	,	O	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
K	K	k000	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
and	and	a530	CC	I-NP	O
Mg	Mg	m200	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
green	green	g605	JJ	B-NP	B-Chemical
tea	tea	t000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
together	together	t020306	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
challenged	challenge	c0405203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
day	day	d000	NN	I-NP	O
29th	29th	0000	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
30th	30th	0000	JJ	I-ADJP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
,	,	,000	,	O	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
,	,	,000	,	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
2	2	2000	CD	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
endogenous	endogenous	e53020502	JJ	B-NP	O
antioxidants	antioxidant	a5302030532	NNS	I-NP	O
,	,	,000	,	O	O
Na	Na	n000	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
K	K	k000	NN	B-NP	B-Chemical
+	+	+000	SYM	I-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
and	and	a530	CC	I-NP	O
Mg	Mg	m200	NN	I-NP	B-Chemical
+	+	+000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
ATPase	ATPase	a31020	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
treated	treated	t60303	JJ	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
green	green	g605	JJ	B-NP	B-Chemical
tea	tea	t000	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
alone	alone	a4050	RB	B-NP	O
treated	treat	t60303	VBN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
green	green	g605	JJ	B-NP	B-Chemical
tea	tea	t000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
E	E	e000	NN	I-NP	I-Chemical
during	during	d06052	IN	B-PP	O
ISO	ISO	i200	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Irreversible	Irreversible	i6010620140	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
interstitium	interstitium	i5306230305	NN	I-NP	O
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
F344	F344	0000	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
(	(	(000	(	O	O
RPN	RPN	r150	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
ability	ability	a104030	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
Fischer	Fischer	f0206	NNP	I-NP	O
344	344	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
structure	structure	s36023060	NN	I-NP	O
and	and	a530	CC	O	O
concentrating	concentrate	c052053603052	VBG	B-NP	O
ability	ability	a104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
18	18	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
no	no	n000	DT	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
repair	repair	r0106	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
damaged	damage	d050203	VBN	I-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
proliferation	proliferation	p60401060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
remaining	remain	r0505052	VBG	B-NP	O
undamaged	undamaged	u53050203	JJ	I-NP	O
type	type	t010	NN	I-NP	O
1	1	1000	CD	I-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
ability	ability	a104030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
length	length	l05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
resulting	result	r02043052	VBG	I-NP	O
inner	inner	i506	JJ	I-NP	O
medullary	medullary	m0304060	JJ	I-NP	O
structural	structural	s360230604	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
analgesic	analgesic	a50420202	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
urinary	urinary	u605060	JJ	B-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
ability	ability	a104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
after	after	a1306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
maximum	maximum	m020505	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
ability	ability	a104030	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
recover	recover	r020106	VB	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prolonged	prolonged	p60405203	JJ	B-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
Fischer	Fischer	f0206	NNP	B-NP	O
344	344	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
causes	cause	c0202	VBZ	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
matrix	matrix	m03602	NN	I-NP	O
and	and	a530	CC	I-NP	O
type	type	t010	NN	I-NP	O
1	1	1000	CD	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
RPN	RPN	r150	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
concentrating	concentrate	c052053603052	VBG	I-NP	O
defect	defect	d01023	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
only	only	o540	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
inner	inner	i506	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
in	in	i500	IN	B-PP	O
Dahl	Dahl	d040	NN	B-NP	O
salt	salt	s043	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
more	more	m060	JJR	B-NP	O
salt	salt	s043	NN	I-NP	B-Chemical
sensitive	sensitive	s05203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
men	man	m050	NNS	B-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
premenopausal	premenopausal	p60505010204	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
Dahl	Dahl	d040	NN	B-NP	O
salt	salt	s043	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
(	(	(000	(	O	O
DS	DS	d200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
high	high	h020	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
salt	salt	s043	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HS	HS	h200	NN	B-NP	O
)	)	)000	)	O	O
diet	diet	d030	NN	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
BP	BP	b100	NN	B-NP	O
more	more	m060	JJR	I-NP	O
in	in	i500	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
than	than	t050	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
HS	HS	h200	NN	B-NP	O
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
,	,	,000	,	O	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ANG	ANG	a520	NN	B-NP	O
II	II	i000	CD	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
sexual	sexual	s0204	JJ	I-NP	O
dimorphism	dimorphism	d05061025	NN	I-NP	O
in	in	i500	IN	B-PP	O
HS	HS	h200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
also	also	a420	RB	B-ADVP	O
causes	cause	c0202	VBZ	B-VP	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
BP	BP	b100	NN	B-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	B-Chemical
(	(	(000	(	O	O
LS	LS	l200	NN	B-NP	O
)	)	)000	)	O	O
diet	diet	d030	NN	B-NP	O
,	,	,000	,	O	O
male	male	m040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
had	have	h030	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
than	than	t050	IN	B-PP	O
females	female	f050402	NNS	B-NP	O
.	.	.000	.	O	O

HS	HS	h200	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	O
cortical	cortical	c0630204	JJ	I-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
and	and	a530	CC	I-NP	O
protein	protein	p60305	NN	I-NP	O
only	only	o540	RB	B-PP	O
in	in	i500	IN	I-PP	O
male	male	m040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
castration	castration	c02360305	NN	B-NP	O
.	.	.000	.	O	O

Ovariectomy	Ovariectomy	o106023050	NN	B-NP	O
of	of	o100	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
intrarenal	intrarenal	i536060504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
on	on	o500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

Radiotelemetric	Radiotelemetric	r0303040503602	JJ	B-NP	O
BP	BP	b100	NN	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
males	male	m0402	NNS	B-NP	O
and	and	a530	CC	O	O
castrated	castrate	c02360303	VBN	B-VP	O
rats	rat	r032	NNS	B-NP	O
on	on	o500	IN	B-PP	O
LS	LS	l200	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

HS	HS	h200	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
wk	wk	w200	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
BP	BP	b100	NN	B-NP	O
,	,	,000	,	O	O
protein	protein	p60305	NN	B-NP	O
and	and	a530	CC	O	O
albumin	albumin	a410505	NN	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
attenuated	attenuate	a3050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
castration	castration	c02360305	NN	B-NP	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
replacement	replacement	r0140205053	NN	I-NP	O
in	in	i500	IN	B-PP	O
castrated	castrate	c02360303	VBN	B-NP	O
DS	DS	d200	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
BP	BP	b100	NN	B-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
upregulation	upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
angiotensinogen	angiotensinogen	a5203052050205	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
HS	HS	h200	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
DS	DS	d200	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
on	on	o500	IN	B-PP	O
HS	HS	h200	NN	B-NP	O
diet	diet	d030	NN	I-NP	O
possibly	possibly	p020140	RB	B-ADVP	O
through	through	t06020	IN	B-PP	O
upregulation	upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
intrarenal	intrarenal	i536060504	JJ	I-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Explicit	Explicit	e2140203	JJ	B-NP	O
episodic	episodic	e1020302	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
for	for	f060	IN	B-PP	O
sensory	sensory	s052060	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
discriminative	discriminative	d026050503010	JJ	I-NP	O
components	component	c051050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
:	:	:000	:	O	O
immediate	immediate	i503030	JJ	B-NP	O
and	and	a530	CC	I-NP	O
delayed	delay	d0403	VBN	I-NP	O
ratings	rating	r03052	NNS	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
memory	memory	m05060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
future	future	f03060	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
sensitivity	sensitivity	s0520301030	NN	I-NP	O
and	and	a530	CC	O	O
thus	thus	t020	RB	B-ADVP	O
contribute	contribute	c053601030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
conditions	condition	c05303052	NNS	I-NP	O
.	.	.000	.	O	O

Systematic	Systematic	s023050302	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
human	human	h0505	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
to	to	t000	TO	B-VP	O
remember	remember	r0505106	VB	I-VP	O
sensory	sensory	s052060	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
sparse	sparse	s10620	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
address	address	a3602	VB	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
memory	memory	m05060	NN	I-NP	O
,	,	,000	,	O	O
nine	nine	n050	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
,	,	,000	,	O	O
separated	separate	s01060303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
breaks	break	b602	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
each	each	e020	DT	B-NP	O
given	give	g0105	VBN	B-VP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
balanced	balanced	b0405203	JJ	I-NP	O
design	design	d02025	NN	I-NP	O
across	across	a2602	IN	B-PP	O
three	three	t060	CD	B-NP	O
sessions	session	s02052	NNS	I-NP	O
at	at	a300	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NN	B-NP	B-Disease
rating	rating	r03052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
computerized	computerized	c05103060203	JJ	I-NP	O
visual	visual	v0204	JJ	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
100	100	0000	CD	I-NP	O
)	)	)000	)	O	O
digitized	digitize	d02030203	VBN	B-VP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
s	s	s000	NN	I-NP	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
online	online	o54050	NN	B-NP	O
or	or	o600	CC	O	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
or	or	o600	CC	O	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
also	also	a420	RB	B-ADVP	O
recalled	recall	r020403	VBD	B-VP	O
their	their	t060	PRP$	B-NP	O
pains	pain	p052	NNS	I-NP	B-Disease
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Capsaicin	Capsaicin	c0120205	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
reliably	reliably	r040140	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
flare	flare	f4060	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
within	within	w0305	IN	B-PP	O
or	or	o600	CC	I-PP	O
across	across	a2602	IN	I-PP	O
sessions	session	s02052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
burning	burn	b065052	VBG	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
decayed	decay	d0203	VBD	B-VP	O
exponentially	exponentially	e2105053040	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reliably	reliably	r040140	RB	I-VP	O
discriminate	discriminate	d0260505030	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
magnitude	magnitude	m02503030	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
across	across	a2602	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
(	(	(000	(	O	O
both	both	b030	CC	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
whether	whether	w0306	IN	B-SBAR	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
ratings	rating	r03052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
requested	request	r0202303	VBN	I-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
or	or	o600	CC	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Pain	Pain	p050	NNP	B-NP	B-Disease
recall	recall	r0204	VBP	B-VP	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
similarly	similarly	s05040640	RB	B-ADJP	O
precise	precise	p602020	JJ	I-ADJP	O
(	(	(000	(	O	O
magnitude	magnitude	m02503030	NN	B-NP	O
:	:	:000	:	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
:	:	:000	SYM	B-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Correlation	Correlation	c06040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
rating	rating	r03052	NN	B-NP	O
recall	recall	r0204	NN	I-NP	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
best	well	b023	RBS	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
time	time	t050	NN	I-NP	O
ratings	rating	r03052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
requested	request	r0202303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
late	late	l030	RB	B-NP	O
as	as	a200	IN	I-NP	O
one	one	o500	CD	B-NP	O
day	day	d000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
(	(	(000	(	O	O
R	R	r000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
79	79	0000	CD	I-NP	O
)	)	)000	)	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
rating	rating	r03052	NN	B-NP	O
retrievals	retrieval	r03601042	NNS	I-NP	O
utilized	utilize	u3040203	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
traces	trace	t60202	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
reliable	reliable	r040140	JJ	I-NP	O
memory	memory	m05060	NN	I-NP	O
for	for	f060	IN	B-PP	O
magnitude	magnitude	m02503030	NN	B-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimentally	experimentally	e210605053040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
further	further	f06306	RB	B-ADVP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
consolidation	consolidation	c05204030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
interim	interim	i530605	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
take	take	t020	VB	I-VP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
one	one	o500	CD	I-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
long	long	l052	JJ	I-NP	O
lasting	lasting	l023052	JJ	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
co	co	c000	AFX	O	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
trimoxazole	trimoxazole	t6050202040	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
Pneumocystis	Pneumocystis	p5050202302	NN	B-NP	B-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
infected	infect	i5102303	VBN	B-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
-	-	-000	SYM	O	O
-	-	-000	HYPH	O	O
a	a	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Pneumocystis	Pneumocystis	p5050202302	NN	B-NP	B-Disease
pneumonia	pneumonia	p505050	NN	I-NP	I-Disease
(	(	(000	(	O	O
PCP	PCP	p210	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
opportunistic	opportunistic	o10630502302	JJ	I-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
individuals	individual	i530103042	NNS	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
generally	generally	g0506040	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
co	co	c000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trimoxazole	trimoxazole	t6050202040	NN	I-NP	I-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
limited	limit	l050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severely	severely	s0106040	RB	B-NP	O
immunocompromised	immunocompromise	i505020516050203	VBN	I-NP	O
HIV	HIV	h010	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
intrahepatic	intrahepatic	i536010302	JJ	I-NP	B-Disease
cholestasis	cholestasis	c040230202	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
mimicking	mimic	m0502052	VBG	B-VP	O
liver	liver	l0106	NN	B-NP	B-Disease
abscess	abscess	a1202	NN	I-NP	I-Disease
formation	formation	f0650305	NN	I-NP	O
on	on	o500	IN	B-PP	O
radiologic	radiologic	r03040202	JJ	B-NP	O
exams	exam	e2052	NNS	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
co	co	c000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trimoxazole	trimoxazole	t6050202040	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
PCP	PCP	p210	NN	B-NP	B-Disease
.	.	.000	.	O	O

Whereas	Whereas	w0602	IN	B-SBAR	O
patient	patient	p03053	NN	B-NP	O
1	1	1000	CD	I-NP	O
showed	show	s030	VBD	B-VP	O
lesions	lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
1	1	1000	CD	I-NP	O
cm	cm	c500	NN	I-NP	O
readily	readily	r03040	RB	B-ADJP	O
detectable	detectable	d030230140	JJ	I-ADJP	O
on	on	o500	IN	B-PP	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
under	under	u5306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
co	co	c000	AFX	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trimoxazole	trimoxazole	t6050202040	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
therapy	therapy	t06010	NN	B-NP	O
of	of	o100	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
2	2	2000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
switched	switch	s03203	VBN	I-VP	O
early	early	e0640	RB	B-ADVP	O
.	.	.000	.	O	O

Bradykinin	Bradykinin	b603020505	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
and	and	a530	CC	O	O
nitric	nitric	n03602	JJ	B-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
streptozotocin	streptozotocin	s3601302030205	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	JJ	I-NP	I-Disease
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
irreversible	irreversible	i6010620140	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
constitutive	constitutive	c05230303010	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
NOArg	NOArg	n062	NN	B-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
NIL	NIL	n040	NN	B-NP	O
;	;	;000	:	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
NI	NI	n000	NN	I-NP	O
;	;	;000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
B2	B2	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
B1	B1	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
:	:	:000	:	O	O
D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
Arg	Arg	a620	NN	I-NP	O
-	-	-000	HYPH	O	O
[	[	[000	(	O	O
Hyp3	Hyp3	0000	NN	B-NP	O
,	,	,000	,	O	O
Thi5	Thi5	0000	NN	B-NP	O
,	,	,000	,	O	O
D	D	d000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
Tic7	Tic7	0000	NN	I-NP	O
,	,	,000	,	O	O
Oic8	Oic8	0000	NN	B-NP	O
]	]	]000	)	O	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
(	(	(000	(	O	O
HOE	HOE	h000	NN	B-NP	B-Chemical
140	140	0000	CD	I-NP	I-Chemical
;	;	;000	:	O	O
70	70	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
des	de	d020	VBZ	B-VP	B-Chemical
Arg10	Arg10	0000	NNP	B-NP	I-Chemical
HOE	HOE	h000	NNP	I-NP	I-Chemical
140	140	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
nmol	nmol	n504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
ip	ip	i100	NN	I-NP	O
)	)	)000	)	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
model	model	m0304	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
(	(	(000	(	O	I-Disease
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	I-Disease
-	-	-000	HYPH	B-VP	I-Disease
induced	induce	i530203	VBN	I-VP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
toxic	toxic	t0202	JJ	B-NP	I-Disease
(	(	(000	(	O	I-Disease
vincristine	vincristine	v0526023050	NN	B-NP	I-Disease
-	-	-000	HYPH	B-VP	I-Disease
induced	induce	i530203	VBN	I-VP	I-Disease
)	)	)000	)	O	I-Disease
neuropathy	neuropathy	n0601030	NN	B-NP	I-Disease
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
thresholds	threshold	t06020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	O	O
the	the	t000	DT	B-NP	O
modification	modification	m0301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
classic	classic	c40202	JJ	I-NP	O
paw	paw	p000	NN	I-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
test	test	t023	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
Randall	Randall	r05304	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Selitto	Selitto	s04030	NNP	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
confirm	confirm	c051065	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
inhibition	inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
and	and	a530	CC	O	O
inducible	inducible	i53020140	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
neuronal	neuronal	n060504	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
reduces	reduce	r030202	VBZ	B-VP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pretreatment	Pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
NOArg	NOArg	n062	NN	I-NP	O
and	and	a530	CC	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	O	O
NIL	NIL	n040	NN	B-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
NI	NI	n000	NN	I-NP	O
,	,	,000	,	O	O
significantly	significantly	s025010205340	RB	B-VP	O
increases	increase	i5260202	VBZ	I-VP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
both	both	b030	DT	O	O
HOE	HOE	h000	NN	B-NP	B-Chemical
140	140	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
des	de	d020	VBZ	B-VP	B-Chemical
Arg10	Arg10	0000	NNP	B-NP	I-Chemical
HOE	HOE	h000	NNP	I-NP	I-Chemical
140	140	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	DT	B-NP	O
products	product	p6030232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
inducible	inducible	i53020140	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
and	and	a530	CC	O	O
neuronal	neuronal	n060504	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hyperalgesia	hyperalgesia	h0106042020	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
NOArg	NOArg	n062	NN	I-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
NI	NI	n000	NN	I-NP	O
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
L	L	l000	NN	B-NP	O
-	-	-000	HYPH	O	O
NIL	NIL	n040	NN	B-NP	O
intensify	intensify	i53052010	VBP	B-VP	O
antihyperalgesic	antihyperalgesic	a5301060420202	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
HOE	HOE	h000	NN	B-NP	B-Chemical
140	140	0000	CD	I-NP	I-Chemical
or	or	o600	CC	O	O
des	des	d020	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Arg10HOE	Arg10HOE	0000	NN	B-NP	I-Chemical
140	140	0000	CD	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Results	Result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
B1	B1	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
B2	B2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
engaged	engage	e520203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
transmission	transmission	t605250205	NN	B-NP	O
of	of	o100	IN	B-PP	O
nociceptive	nociceptive	n0202013010	JJ	B-NP	O
stimuli	stimulus	s305040	NNS	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
toxic	toxic	t0202	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
,	,	,000	,	O	O
inducible	inducible	i53020140	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
participates	participate	p06302010302	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
pronociceptive	pronociceptive	p6050202013010	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
in	in	i500	IN	B-PP	O
vincristine	vincristine	v0526023050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
bradykinin	bradykinin	b603020505	NN	I-NP	B-Chemical
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
activate	activate	a2301030	VB	I-VP	O
neuronal	neuronal	n060504	JJ	B-NP	O
NO	NO	n000	NN	I-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
pathway	pathway	p030	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
small	small	s504	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
and	and	a530	CC	O	O
NO	NO	n000	NN	B-NP	B-Chemical
synthase	synthase	s053020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
alleviation	alleviation	a4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
even	even	e105	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
care	care	c060	NN	I-NP	O
.	.	.000	.	O	O

Confusion	Confusion	c0510205	NN	B-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
rather	rather	r0306	RB	I-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
French	French	f60520	JJ	I-NP	O
Pharmacovigilance	Pharmacovigilance	p065020102040520	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
.	.	.000	.	O	O

INTRODUCTION	INTRODUCTION	i5360302305	NN	B-NP	O
:	:	:000	:	O	O
Confusion	Confusion	c0510205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
frequently	frequently	f60205340	RB	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
published	publish	p0140203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
systematic	systematic	s023050302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
sample	sample	s05140	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
published	publish	p0140203	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
the	the	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Using	Use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
French	French	f60520	JJ	I-NP	O
Pharmacovigilance	Pharmacovigilance	p065020102040520	NN	I-NP	O
database	database	d0301020	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
selected	select	s0402303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
reported	report	r0106303	VBD	B-VP	O
since	since	s0520	IN	B-PP	O
1985	1985	0000	CD	B-NP	O
with	with	w030	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
272	272	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
:	:	:000	:	O	O
153	153	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
and	and	a530	CC	O	O
119	119	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
.	.	.000	.	O	O

Confusion	Confusion	c0510205	NN	B-NP	B-Disease
mostly	mostly	m02340	RB	B-ADVP	O
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
first	first	f0623	JJ	I-NP	O
weeks	week	w020	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
exposure	exposure	e2102060	NN	I-NP	O
(	(	(000	(	O	O
39	39	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
"	"	"000	``	B-ADJP	O
serious	serious	s0602	JJ	I-ADJP	O
"	"	"000	''	O	O
for	for	f060	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
2	2	2000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
62	62	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
favourable	favourable	f01060140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
82	82	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
aged	aged	a203	JJ	B-ADJP	O
between	between	b0305	IN	B-PP	O
61	61	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
80	80	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
work	work	w062	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
confusion	confusion	c0510205	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
valproic	valproic	v041602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
,	,	,000	,	I-NP	O
rather	rather	r0306	RB	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
but	but	b030	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
two	two	t000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Reversible	Reversible	r010620140	JJ	B-NP	O
inferior	inferior	i510606	JJ	I-NP	B-Disease
colliculus	colliculus	c04020402	NN	I-NP	I-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
:	:	:000	:	O	O
magnetic	magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
findings	finding	f053052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
diffusion	diffusion	d010205	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
and	and	a530	CC	O	O
fluid	fluid	f403	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
inversion	inversion	i5106205	NN	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
present	present	p602053	VB	I-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
inferior	inferior	i510606	JJ	I-NP	B-Disease
colliculus	colliculus	c04020402	NN	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
focus	focus	f0202	VB	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
imaging	imaging	i502052	NN	B-NP	O
(	(	(000	(	O	O
DWI	DWI	d000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
fluid	fluid	f403	NN	B-NP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
inversion	inversion	i5106205	NN	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
(	(	(000	(	O	O
FLAIR	FLAIR	f406	NN	B-NP	O
)	)	)000	)	O	O
imaging	imaging	i502052	NN	B-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
From	From	f605	IN	B-PP	O
November	November	n0105106	NNP	B-NP	O
2005	2005	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
September	September	s01305106	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
induced	induce	i530203	VBN	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
(	(	(000	(	O	O
age	age	a200	NN	B-NP	O
range	range	r0520	NN	I-NP	O
;	;	;000	:	O	O
43	43	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
78	78	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
total	total	t0304	JJ	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
,	,	,000	,	O	O
45	45	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
120	120	0000	CD	I-NP	O
g	g	g000	NN	I-NP	O
;	;	;000	:	O	O
duration	duration	d060305	NN	B-NP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
the	the	t000	DT	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
organs	organ	o62052	NNS	I-NP	O
.	.	.000	.	O	O

Initial	Initial	i50304	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
MRI	MRI	m600	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospitalization	hospitalization	h0210304020305	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
DWI	DWI	d000	NN	B-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
apparent	apparent	a106053	JJ	B-NP	O
diffusion	diffusion	d010205	NN	I-NP	O
coefficient	coefficient	c0102053	NN	I-NP	O
(	(	(000	(	O	O
ADC	ADC	a320	NN	B-NP	O
)	)	)000	)	O	O
map	map	m010	NN	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
FLAIR	FLAIR	f406	NN	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
/	/	/000	SYM	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
T2	T2	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-NP	O
image	image	i5020	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Follow	Follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
MRIs	MRI	m602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
third	third	t063	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
14th	14th	0000	JJ	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Findings	Finding	f053052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
and	and	a530	CC	O	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
MRIs	MRI	m602	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
retrospectively	retrospectively	r03602102301040	RB	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
2	2	2000	CD	B-NP	O
neuroradiologists	neuroradiologist	n06060304020232	NNS	I-NP	O
by	by	b000	IN	B-PP	O
consensus	consensus	c05205202	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
analyze	analyze	a504020	VB	I-VP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
signal	signal	s02504	NN	I-NP	O
intensities	intensity	i530520302	NNS	I-NP	O
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
locations	location	l0203052	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
signal	signal	s02504	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
on	on	o500	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
images	image	i50202	NNS	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Initial	Initial	i50304	JJ	B-NP	O
MRIs	MRI	m602	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
signal	signal	s02504	NN	I-NP	O
intensities	intensity	i530520302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
DWI	DWI	d000	NN	B-NP	O
and	and	a530	CC	I-NP	O
FLAIR	FLAIR	f406	NN	I-NP	O
(	(	(000	(	O	O
or	or	o600	CC	O	O
T2	T2	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-NP	O
image	image	i5020	NN	I-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
inferior	inferior	i510606	JJ	B-NP	O
colliculus	colliculus	c04020402	NN	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
corpus	corpus	c06102	NN	B-NP	O
callosum	callosum	c040205	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
pons	pon	p052	NNS	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
medulla	medulla	m03040	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	O	O
8	8	8000	CD	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bilateral	bilateral	b04030604	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	O	O
8	8	8000	CD	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
signal	signal	s02504	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
DWI	DWI	d000	NN	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
show	show	s000	VB	I-VP	O
low	low	l000	JJ	B-NP	O
signal	signal	s02504	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
on	on	o500	IN	B-PP	O
ADC	ADC	a320	NN	B-NP	O
map	map	m010	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
signal	signal	s02504	NN	I-NP	O
intensity	intensity	i53052030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
at	at	a300	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
on	on	o500	IN	B-PP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
DWI	DWI	d000	NN	B-NP	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
ADC	ADC	a320	NN	B-NP	O
map	map	m010	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
dentate	dentate	d053030	NN	B-NP	O
,	,	,000	,	O	O
inferior	inferior	i510606	JJ	B-NP	O
colliculus	colliculus	c04020402	NN	I-NP	O
,	,	,000	,	O	O
pons	pon	p052	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
medullas	medulla	m030402	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
resolved	resolve	r0204103	VBN	I-VP	O
completely	completely	c051403040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
MRIs	MRI	m602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
,	,	,000	,	O	O
corpus	corpu	c06102	VBZ	B-VP	O
callosal	callosal	c040204	JJ	B-NP	B-Disease
lesion	lesion	l0205	NN	I-NP	I-Disease
persisted	persist	p06202303	VBD	B-VP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Reversible	Reversible	r010620140	JJ	B-NP	O
inferior	inferior	i510606	JJ	I-NP	B-Disease
colliculus	colliculus	c04020402	NN	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
characteristic	characteristic	c060230602302	NN	I-NP	O
for	for	f060	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
,	,	,000	,	O	O
next	next	n023	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
dentate	dentate	d053030	NN	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
.	.	.000	.	O	O

Clinically	Clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Sirolimus	Sirolimus	s06040502	NNP	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
latest	late	l03023	JJS	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
used	use	u203	VBN	B-VP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
rejection	rejection	r0202305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
less	less	l020	JJR	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
calcineurin	calcineurin	c042050605	NN	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
CNI	CNI	c500	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
there	there	t060	EX	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
little	little	l0340	JJ	B-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
linked	link	l05203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
encountered	encounter	e520530603	VBN	I-VP	O
several	several	s010604	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
commencement	commencement	c0505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
implicated	implicate	i514020303	VBD	B-VP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
likely	likely	l02040	JJ	I-NP	O
etiology	etiology	e304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
laboratory	laboratory	l010603060	JJ	I-NP	O
information	information	i510650305	NN	I-NP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
all	all	a400	DT	B-NP	O
119	119	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
transplanted	transplant	t60521405303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
Washington	Washington	w02052305	NNP	I-NP	O
Hospital	Hospital	h0210304	NNP	I-NP	O
Center	Center	c05306	NNP	I-NP	O
between	between	b0305	IN	B-PP	O
1999	1999	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
2003	2003	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
sirolimus	sirolimus	s06040502	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
immunosuppressant	immunosuppressant	i5050201602053	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
morning	morning	m065052	NN	B-NP	O
urine	urine	u6050	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
by	by	b000	IN	B-PP	O
turbidometric	turbidometric	t061030503602	JJ	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
or	or	o600	CC	O	O
random	random	r05305	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
protein	protein	p60305	NN	I-NP	O
:	:	:000	:	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
ratios	ratio	r0302	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
estimate	estimate	e2305030	NN	I-NP	O
of	of	o100	IN	B-PP	O
grams	gram	g6052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Laboratory	Laboratory	l010603060	NN	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
and	and	a530	CC	O	O
following	follow	f04052	VBG	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	O	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
24	24	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
during	during	d06052	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
course	course	c0620	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
either	either	e0306	CC	O	O
obvious	obvious	o102	JJ	B-NP	O
or	or	o600	CC	I-NP	O
insufficient	insufficient	i520102053	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
conclusive	conclusive	c052402010	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
28	28	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
striking	striking	s3602052	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
range	range	r0520	NN	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
correlated	correlate	c06040303	VBD	B-VP	O
most	most	m023	RBS	B-ADVP	O
strongly	strongly	s3605240	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
demographic	demographic	d050260102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
resolution	resolution	r02040305	NN	B-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Sirolimus	Sirolimus	s06040502	NN	B-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
or	or	o600	CC	I-VP	O
aggravates	aggravate	a26010302	VBZ	I-VP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
unpredictable	unpredictable	u516030230140	JJ	I-NP	O
subset	subset	s01203	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
allograft	allograft	a4026013	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
may	may	m000	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
resolve	resolve	r020410	VB	I-VP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
sirolimus	sirolimus	s06040502	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
.	.	.000	.	O	O

Components	Component	c051050532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
lemon	lemon	l0505	NN	B-NP	O
essential	essential	e205304	JJ	I-NP	O
oil	oil	o040	NN	I-NP	O
attenuate	attenuate	a305030	NN	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
dementia	dementia	d050530	NN	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
s	s	s000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
limonene	limonene	l0505050	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
s	s	s000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
perillyl	perillyl	p060404	NN	I-NP	I-Chemical
alcohol	alcohol	a4204	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
PA	PA	p000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
open	open	o105	JJ	I-NP	O
field	field	f043	NN	I-NP	O
habituation	habituation	h01030305	NN	I-NP	O
test	test	t023	NN	I-NP	O
(	(	(000	(	O	O
OFH	OFH	o100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
lemon	lemon	l0505	JJ	I-NP	O
essential	essential	e205304	JJ	I-NP	O
oils	oil	o042	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
strong	strong	s36052	JJ	B-NP	O
ability	ability	a104030	NN	I-NP	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impaired	impair	i510603	VBN	B-VP	I-Disease
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
s	s	s000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
perillyl	perillyl	p060404	NN	I-NP	I-Chemical
alcohol	alcohol	a4204	NN	I-NP	I-Chemical
relieved	relieve	r040103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
deficit	deficit	d010203	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
associative	associative	a20203010	JJ	B-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
PA	PA	p000	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
improve	improve	i516010	VB	I-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
associative	associative	a20203010	JJ	B-NP	O
memory	memory	m05060	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
OFH	OFH	o100	NN	B-NP	O
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
day	day	d000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
/	/	/000	SYM	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
/	/	/000	SYM	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
s	s	s000	AFX	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
limonene	limonene	l0505050	NN	B-NP	I-Chemical
or	or	o600	CC	O	O
s	s	s000	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
perillyl	perillyl	p060404	NN	I-NP	I-Chemical
alcohol	alcohol	a4204	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Simultaneously	Simultaneously	s05043050240	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
lemon	lemon	l0505	NN	I-NP	O
essential	essential	e205304	JJ	I-NP	O
oil	oil	o040	NN	I-NP	O
components	component	c051050532	NNS	I-NP	O
could	could	c043	MD	B-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Ellman	Ellman	e4505	NNP	I-NP	O
method	method	m0303	NN	I-NP	O
.	.	.000	.	O	O

Attentional	Attentional	a30530504	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
perceived	perceive	p0620103	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Perceived	Perceive	p0620103	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
modulated	modulate	m03040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
attention	attention	a305305	NN	B-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
how	how	h000	WRB	B-ADVP	O
pain	pain	p050	JJ	B-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
ratings	rating	r03052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
attention	attention	a305305	NN	B-NP	O
in	in	i500	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
we	we	w000	PRP	B-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
perceived	perceive	p0620103	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
intensity	intensity	i53052030	NN	I-NP	O
in	in	i500	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
attention	attention	a305305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
distracted	distract	d023602303	VBN	I-VP	O
away	away	a000	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
painful	painful	p05104	JJ	I-NP	O
pinprick	pinprick	p051602	NN	I-NP	O
stimulus	stimulus	s3050402	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
task	task	t020	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
of	of	o100	IN	B-PP	O
attentional	attentional	a30530504	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
,	,	,000	,	I-NP	O
control	control	c053604	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
no	no	n000	DT	B-NP	O
interaction	interaction	i530602305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
attentional	attentional	a30530504	JJ	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
capsaicin	capsaicin	c0120205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
hyperalgesia	hyperalgesia	h0106042020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
attention	attention	a305305	NN	I-NP	O
might	might	m0203	MD	B-VP	O
affect	affect	a1023	VB	I-VP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
through	through	t06020	IN	B-PP	O
independent	independent	i5301053053	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Cardioprotective	Cardioprotective	c06301603023010	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
salvianolic	salvianolic	s041050402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
salvianolic	salvianolic	s041050402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Hemodynamic	Hemodynamic	h0503050502	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
and	and	a530	CC	O	O
lead	lead	l030	VBP	B-VP	O
II	II	i000	CD	B-NP	O
electrocardiograph	electrocardiograph	e4023602063026010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
and	and	a530	CC	O	O
recorded	record	r0206303	VBN	B-VP	O
continuously	continuously	c053050240	RB	B-ADVP	O
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	O
marker	marker	m06206	NN	I-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
and	and	a530	CC	O	O
antioxidative	antioxidative	a53020303010	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

Assay	Assay	a200	NN	B-NP	O
for	for	f060	IN	B-PP	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

Isoproterenol	Isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lactate	lactate	l023030	NN	B-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
,	,	,000	,	O	O
aspartate	aspartate	a21063030	NN	B-NP	B-Chemical
transaminase	transaminase	t60520505020	NN	I-NP	O
,	,	,000	,	O	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
and	and	a530	CC	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
significant	significant	s0250102053	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
activities	activity	a23010302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
superoxide	superoxide	s010602030	NN	B-NP	B-Chemical
dismutase	dismutase	d02503020	NN	I-NP	O
,	,	,000	,	O	O
catalase	catalase	c0304020	NN	B-NP	O
and	and	a530	CC	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
peroxidase	peroxidase	p060203020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
declines	decline	d0240502	NNS	B-NP	O
in	in	i500	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
maximum	maximum	m020505	NN	B-NP	O
and	and	a530	CC	I-NP	O
minimum	minimum	m050505	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
developed	develop	d01040103	VBN	B-NP	O
left	left	l013	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
left	left	l013	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
end	end	e530	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
ST	ST	s300	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
mitochondrial	mitochondrial	m0302053604	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
decreased	decrease	d0260203	VBN	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
and	and	a530	CC	I-NP	O
ADP	ADP	a310	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
O	O	o000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
salvianolic	salvianolic	s041050402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
attenuated	attenuate	a3050303	VBD	B-VP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
improved	improve	i5160103	VBN	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
protective	protective	p603023010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
salvianolic	salvianolic	s041050402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
against	against	a20523	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
further	further	f06306	RBR	I-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
salvianolic	salvianolic	s041050402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
A	A	a000	NN	I-NP	I-Chemical
possessing	possess	p0202052	VBG	B-VP	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
against	against	a20523	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Toxic	Toxic	t0202	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
limiting	limit	l0503052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
with	with	w030	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PAC	PAC	p020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
closely	closely	c402040	RB	I-NP	O
related	related	r040303	JJ	I-NP	O
amino	amino	a5050	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
glutamine	glutamine	g40305050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
claimed	claim	c40503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
ameliorate	ameliorate	a50406030	VB	I-VP	O
PAC	PAC	p020	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
aimed	aim	a0503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
for	for	f060	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
PAC	PAC	p020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blinded	blind	b405303	VBN	B-VP	O
clinical	clinical	c4050204	JJ	B-ADJP	O
and	and	a530	CC	O	O
electro	electro	e402360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
ovarian	ovarian	o10605	JJ	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
analysis	analysis	a5040202	NN	B-NP	O
following	follow	f04052	VBG	B-PP	O
six	six	s020	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
PAC	PAC	p020	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
regimen	regimen	r020505	NN	B-NP	O
:	:	:000	:	O	O
23	23	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
supplemented	supplement	s0140505303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
all	all	a400	DT	O	O
along	along	a4052	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
G	G	g000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
P	P	p000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
,	,	,000	,	O	O
questionnaires	questionnaire	q023050602	NNS	B-NP	O
and	and	a530	CC	O	O
sensory	sensory	s052060	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
motor	motor	m0306	NN	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
or	or	o600	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
although	although	a43020	IN	B-SBAR	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	O
presented	present	p60205303	VBN	B-VP	O
mostly	mostly	m02340	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
scores	score	s20602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
severity	severity	s0106030	NN	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
G	G	g000	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
reached	reach	r0203	VBD	B-VP	O
statistical	statistical	s3030230204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
only	only	o540	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
regard	regard	r02063	NN	B-NP	O
to	to	t000	TO	B-PP	O
reported	report	r0106303	VBN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
sensation	sensation	s0520305	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
011	011	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
electro	electro	e402360	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
similarity	similarity	s050406030	NN	B-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
(	(	(000	(	O	O
G	G	g000	NN	B-NP	O
:	:	:000	:	O	O
7	7	7000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
23	23	0000	CD	I-NP	O
=	=	=000	SYM	B-VP	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
:	:	:000	:	O	O
6	6	6000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
=	=	=000	SYM	I-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
pilot	pilot	p0403	NN	I-NP	O
study	study	s3030	NN	I-NP	O
leads	lead	l032	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
conclusion	conclusion	c05240205	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
glutamate	glutamate	g40305030	NN	B-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
chosen	choose	c0205	VBN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
fails	fail	f042	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
PAC	PAC	p020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
ocular	ocular	o20406	JJ	B-NP	B-Disease
myasthenia	myasthenia	m023050	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
63	63	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
experienced	experienced	e210605203	JJ	I-NP	O
sudden	sudden	s0305	JJ	I-NP	O
diplopia	diplopia	d014010	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
9	9	9000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
(	(	(000	(	O	I-Chemical
IFN	IFN	i150	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2b	2b	2100	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
(	(	(000	(	O	O
CHC	CHC	c020	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Ophthalmologic	Ophthalmologic	o103045040202	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
ptosis	ptosis	p30202	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
right	right	r0203	JJ	I-NP	I-Disease
upper	upper	u106	JJ	I-NP	I-Disease
lid	lid	l030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
restricted	restricted	r023602303	JJ	B-NP	B-Disease
right	right	r0203	JJ	I-NP	I-Disease
eye	eye	e000	NN	I-NP	I-Disease
movement	movement	m0105053	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
other	other	o306	JJ	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
repetitive	repetitive	r010303010	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
test	test	t023	NN	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
abnormality	abnormality	a1506504030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
titer	titer	t0306	NN	I-NP	O
and	and	a530	CC	O	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
acetylcholinesterase	acetylcholinesterase	a203042040502306020	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thyroid	thyroid	t0603	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
ophthalmological	ophthalmological	o10304504020204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
IFN	IFN	i150	NN	I-NP	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2b	2b	2100	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
myasthenia	myasthenia	m023050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
IFN	IFN	i150	NN	I-NP	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2b	2b	2100	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
CHC	CHC	c020	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-VP	O
rarely	rarely	r06040	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
;	;	;000	:	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
eye	eye	e000	NN	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
IFN	IFN	i150	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Learning	Learning	l065052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
neural	neural	n0604	JJ	I-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
face	face	f020	NN	I-NP	O
-	-	-000	HYPH	O	O
learning	learn	l065052	VBG	B-VP	O
task	task	t020	NN	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
consistently	consistently	c05202305340	RB	I-VP	O
shown	show	s050	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
display	display	d02140	VBP	B-VP	O
impairments	impairment	i510650532	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
performance	performance	p0610650520	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
working	work	w062052	VBG	B-VP	O
memory	memory	m05060	NN	B-NP	O
processing	processing	p60202052	NN	I-NP	O
in	in	i500	IN	B-PP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
neural	neural	n0604	JJ	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
cortical	cortical	c0630204	JJ	B-NP	O
regions	region	r02052	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
magnetic	magnetic	m0250302	JJ	I-NP	O
resonance	resonance	r02050520	NN	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
(	(	(000	(	O	O
fMRI	fMRI	f560	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
functional	functional	f05230504	JJ	B-NP	O
imaging	imaging	i502052	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
face	face	f020	NN	I-NP	O
-	-	-000	HYPH	O	O
learning	learn	l065052	VBG	B-VP	O
task	task	t020	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
neural	neural	n0604	JJ	B-NP	O
correlates	correlate	c06040302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
encoding	encode	e5203052	VBG	B-VP	O
and	and	a530	CC	I-VP	O
recalling	recall	r0204052	VBG	I-VP	O
face	face	f020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
name	name	n050	NN	I-NP	O
associations	association	a20203052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
recreational	recreational	r026030504	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
users	user	u2062	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
ecstasy	ecstasy	e23020	JJ	B-ADJP	B-Chemical
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
address	address	a3602	VB	I-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
confounding	confounding	c051053052	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cannabis	cannabis	c050102	NN	I-NP	B-Chemical
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ecstasy	ecstasy	e23020	NN	I-NP	B-Chemical
using	use	u2052	VBG	B-VP	O
group	group	g601	NN	B-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
14	14	0000	CD	B-NP	O
previously	previously	p6010240	RB	I-NP	O
tested	test	t02303	VBN	I-NP	O
cannabis	cannabis	c050102	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
(	(	(000	(	O	O
Nestor	Nestor	n02306	NN	B-NP	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
Roberts	Roberts	r010632	NNP	B-NP	O
,	,	,000	,	O	O
G	G	g000	NNP	B-NP	O
.	.	.000	NNP	I-NP	O
,	,	,000	,	O	O
Garavan	Garavan	g060105	NNP	B-NP	O
,	,	,000	,	O	O
H	H	h000	NNP	B-NP	O
.	.	.000	VBD	B-VP	O
,	,	,000	,	O	O
Hester	Hester	h02306	NNP	B-NP	O
,	,	,000	,	O	O
R	R	r000	NNP	B-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
2008	2008	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
Deficits	Deficit	d0102032	NNPS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
:	:	:000	:	O	O
parahippocampal	parahippocampal	p06010205104	JJ	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
frontocortical	frontocortical	f6053020630204	JJ	B-NP	O
hypoactivity	hypoactivity	h0102301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
cannabis	cannabis	c050102	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O
Neuroimage	Neuroimage	n0605020	NNP	B-NP	O
40	40	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1328	1328	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
1339	1339	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Ecstasy	Ecstasy	e23020	JJ	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
performed	perform	p06106503	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
worse	worse	w0620	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
learning	learning	l065052	NN	B-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
and	and	a530	CC	O	O
cannabis	cannabis	c050102	NN	B-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
conjunction	conjunction	c052052305	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
encode	encode	e52030	NN	I-NP	O
and	and	a530	CC	I-NP	O
recall	recall	r0204	NN	I-NP	O
phases	phase	p0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
task	task	t020	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
bilateral	bilateral	b04030604	JJ	B-NP	O
frontal	frontal	f605304	JJ	I-NP	O
regions	region	r02052	NNS	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
temporal	temporal	t0510604	JJ	B-NP	O
,	,	,000	,	I-NP	O
right	right	r0203	JJ	I-NP	O
parietal	parietal	p060304	JJ	I-NP	O
,	,	,000	,	I-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
bilateral	bilateral	b04030604	JJ	B-NP	O
occipital	occipital	o2010304	NN	I-NP	O
brain	brain	b605	NN	I-NP	O
regions	region	r02052	NNS	I-NP	O
.	.	.000	.	O	O

Ecstasy	Ecstasy	e23020	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
hypoactivity	hypoactivity	h0102301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
dorsal	dorsal	d06204	JJ	I-NP	O
anterior	anterior	a530606	JJ	I-NP	O
cingulated	cingulate	c052040303	VBN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
(	(	(000	(	O	O
ACC	ACC	a200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
posterior	posterior	p0230606	JJ	B-NP	O
cingulated	cingulate	c052040303	VBN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	CC	O	O
ecstasy	ecstasy	e23020	JJ	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cannabis	cannabis	c050102	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
brain	brain	b605	NN	I-NP	O
activation	activation	a23010305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
medial	medial	m0304	JJ	I-NP	O
frontal	frontal	f605304	JJ	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
parahippocampal	parahippocampal	p06010205104	JJ	B-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
,	,	,000	,	O	O
left	leave	l013	VBD	B-VP	O
dorsal	dorsal	d06204	JJ	B-NP	O
cingulate	cingulate	c05204030	NN	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
left	leave	l013	VBD	B-VP	O
caudate	caudate	c03030	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
elucidated	elucidate	e402030303	VBD	B-VP	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
deficits	deficit	d0102032	NNS	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
some	some	s050	DT	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cannabis	cannabis	c050102	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
ecstasy	ecstasy	e23020	AFX	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
vulnerability	vulnerability	v045060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isocortical	isocortical	i2020630204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
allocortical	allocortical	a4020630204	JJ	I-NP	O
regions	region	r02052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ecstasy	ecstasy	e23020	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Disulfiram	Disulfiram	d020410605	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
hydrogen	hydrogen	h0360205	NN	B-NP	B-Chemical
cyanamide	cyanamide	c0505030	NN	I-NP	I-Chemical
professional	professional	p601020504	JJ	I-NP	O
skin	skin	s205	NN	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
:	:	:000	:	O	O
two	two	t000	CD	B-NP	O
case	case	c020	NN	I-NP	O
reports	report	r010632	NNS	I-NP	O
in	in	i500	IN	B-PP	O
France	France	f60520	NNP	B-NP	O
.	.	.000	.	O	O

Hydrogen	Hydrogen	h0360205	NN	B-NP	B-Chemical
cyanamide	cyanamide	c0505030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
plant	plant	p4053	NN	I-NP	O
growth	growth	g6030	NN	I-NP	O
regulator	regulator	r02040306	NN	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
agriculture	agriculture	a2602043060	NN	B-NP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
bud	bud	b030	NN	B-NP	O
break	break	b602	NN	I-NP	O
in	in	i500	IN	B-PP	O
fruit	fruit	f603	NN	B-NP	O
trees	tree	t602	NNS	I-NP	O
.	.	.000	.	O	O

Contact	Contact	c053023	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
percutaneous	percutaneous	p062030502	JJ	B-NP	O
absorption	absorption	a12061305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
substance	substance	s01230520	NN	I-NP	O
that	that	t030	WDT	B-NP	O
inhibits	inhibit	i501032	VBZ	B-VP	O
aldehyde	aldehyde	a43030	NN	B-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
acetaldehyde	acetaldehyde	a203043030	NN	B-NP	B-Chemical
syndrome	syndrome	s0536050	NN	I-NP	O
in	in	i500	IN	B-PP	O
case	case	c020	NN	B-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
disulfiram	disulfiram	d020410605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
occupational	occupational	o201030504	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
hydrogen	hydrogen	h0360205	NN	B-NP	B-Chemical
cyanamide	cyanamide	c0505030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
involved	involve	i5104103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
59	59	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
used	use	u203	VBD	B-VP	O
Dormex	Dormex	d06502	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
contains	contain	c053052	VBZ	B-VP	O
hydrogen	hydrogen	h0360205	NN	B-NP	B-Chemical
cyanamide	cyanamide	c0505030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
consuming	consume	c05205052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
meal	meal	m040	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
malaise	malaise	m04020	NN	B-NP	O
with	with	w030	IN	B-PP	O
flushing	flushing	f402052	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
face	face	f020	NN	I-NP	I-Disease
,	,	,000	,	O	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
dyspnea	dyspnea	d02150	NN	B-NP	B-Disease
.	.	.000	.	O	O

Manifestations	Manifestation	m050102303052	NNS	B-NP	O
regressed	regress	r0260203	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
under	under	u5306	IN	B-PP	O
surveillance	surveillance	s061040520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
case	case	c020	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
55	55	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
farmer	farmer	f06506	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
cutaneous	cutaneous	c030502	JJ	B-NP	O
contact	contact	c053023	NN	I-NP	O
with	with	w030	IN	B-PP	O
Dormex	Dormex	d06502	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
,	,	,000	,	O	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
disulfiram	disulfiram	d020410605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
with	with	w030	IN	B-PP	O
flushing	flushing	f402052	NN	B-NP	B-Disease
,	,	,000	,	O	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
arterial	arterial	a630604	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
consuming	consume	c05205052	VBG	B-VP	O
three	three	t060	CD	B-NP	O
glasses	glass	g40202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
wine	wine	w050	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
surveillance	surveillance	s061040520	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
confirm	confirm	c051065	VBP	B-VP	O
the	the	t000	DT	B-NP	O
necessity	necessity	n0202030	NN	I-NP	O
of	of	o100	IN	B-PP	O
avoiding	avoid	a103052	VBG	B-VP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
recommended	recommend	r020505303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
instructions	instruction	i5236023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
Dormex	Dormex	d06502	NNP	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
cutaneous	cutaneous	c030502	JJ	B-NP	O
contact	contact	c053023	NN	I-NP	O
during	during	d06052	IN	B-PP	O
use	use	u200	NN	B-NP	O
.	.	.000	.	O	O

Sulpiride	Sulpiride	s04106030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tardive	tardive	t063010	NN	I-NP	B-Disease
dystonia	dystonia	d023050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sulpiride	Sulpiride	s04106030	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
D2	D2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
with	with	w030	IN	B-PP	O
antipsychotic	antipsychotic	a53012020302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
antidepressant	antidepressant	a530301602053	JJ	I-NP	B-Chemical
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
initially	initially	i503040	RB	B-VP	O
thought	think	t0203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tardive	tardive	t063010	NN	I-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
parkinsonism	parkinsonism	p06205205025	NN	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
persistent	persistent	p062023053	JJ	B-NP	O
segmental	segmental	s02505304	JJ	I-NP	O
dystonia	dystonia	d023050	NN	I-NP	B-Disease
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
find	find	f053	VB	I-VP	O
any	any	a500	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sulpiride	sulpiride	s04106030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tardive	tardive	t063010	NN	I-NP	B-Disease
dystonia	dystonia	d023050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Comparative	Comparative	c0510603010	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
middle	middle	m0340	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
aged	aged	a203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
older	old	o4306	JJR	I-NP	O
adults	adult	a30432	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
measured	measure	m020603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
objective	objective	o12023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
neurocognitive	neurocognitive	n060202503010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
,	,	,000	,	O	O
older	old	o4306	JJR	B-ADJP	O
(	(	(000	(	O	O
>	>	>000	JJR	B-NP	O
65	65	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
middle	middle	m0340	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
aged	aged	a203	JJ	B-ADJP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
to	to	t000	TO	O	O
55	55	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
adults	adult	a30432	NNS	B-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
suffering	suffer	s0106052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
or	or	o600	CC	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
one	one	o500	CD	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
2	2	2000	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
blind	blind	b4053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
medication	medication	m03020305	NN	B-NP	O
condition	condition	c0530305	NN	I-NP	O
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
peaked	peak	p0203	VBD	B-VP	O
between	between	b0305	IN	B-PP	O
60	60	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
90	90	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
postdose	postdose	p023020	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
pupil	pupil	p0104	NN	B-NP	O
size	size	s020	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
indication	indication	i53020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
physiological	physiological	p0204020204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
peaked	peak	p0203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
90	90	0000	CD	I-NP	O
to	to	t000	TO	I-NP	O
120	120	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
postdose	postdose	p023020	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Significant	Significant	s0250102053	JJ	B-NP	O
declines	decline	d0240502	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
simple	simple	s05140	JJ	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
sustained	sustained	s0230503	JJ	I-NP	I-Disease
attention	attention	a305305	NN	I-NP	I-Disease
,	,	,000	,	O	I-Disease
working	work	w062052	VBG	B-VP	I-Disease
memory	memory	m05060	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
verbal	verbal	v06104	JJ	B-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
postdose	postdose	p023020	NN	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
for	for	f060	IN	B-PP	O
both	both	b030	DT	B-NP	O
age	age	a200	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
trend	trend	t6053	NN	I-NP	O
toward	toward	t063	IN	B-PP	O
return	return	r03065	NN	B-NP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
by	by	b000	IN	B-PP	O
5	5	5000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
postdose	postdose	p023020	VBP	B-VP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
almost	almost	a45023	RB	B-NP	O
all	all	a400	DT	I-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
by	by	b000	IN	B-PP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
interaction	interaction	i530602305	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
age	age	a200	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
for	for	f060	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
older	old	o4306	JJR	I-NP	O
adults	adult	a30432	NNS	I-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
suffering	suffer	s0106052	VBG	I-VP	O
from	from	f605	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
neurocognitive	neurocognitive	n060202503010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
release	release	r04020	NN	I-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
for	for	f060	IN	B-PP	O
middle	middle	m0340	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
aged	aged	a203	JJ	I-NP	O
adults	adult	a30432	NNS	I-NP	O
.	.	.000	.	O	O

PERSPECTIVE	PERSPECTIVE	p0621023010	NN	B-NP	O
:	:	:000	:	O	O
Study	Study	s3030	NN	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
,	,	,000	,	O	O
neurocognitive	neurocognitive	n060202503010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
physical	physical	p020204	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
oxycodone	oxycodone	o20203050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
middle	middle	m0340	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
aged	aged	a203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
older	old	o4306	JJR	I-NP	O
adults	adult	a30432	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
clinicians	clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
avoid	avoid	a103	VB	I-VP	O
prescribing	prescribe	p602601052	VBG	I-VP	O
oral	oral	o604	JJ	B-NP	O
opioids	opioid	o1032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
older	old	o4306	JJR	B-NP	O
adults	adult	a30432	NNS	I-NP	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
belief	belief	b0401	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
older	old	o4306	JJR	B-NP	O
adults	adult	a30432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
at	at	a300	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
younger	young	y05206	JJR	B-NP	O
adults	adult	a30432	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
SSR103800	SSR103800	0000	NN	I-NP	B-Chemical
displays	display	d021402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
transgenic	transgenic	t60520502	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Schizophrenia	Schizophrenia	s2020106050	NNP	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
initially	initially	i503040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
dysfunction	dysfunction	d021052305	NN	B-NP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
antagonists	antagonist	a5302050232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
N	N	n000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
aspartate	aspartate	a21063030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
)	)	)000	)	O	O
receptor	receptor	r0201306	NN	B-NP	O
produce	produce	p603020	VBP	B-VP	O
schizophrenic	schizophrenic	s20201060502	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
has	have	h020	VBZ	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
idea	idea	i300	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
dysfunctioning	dysfunctioning	d021052305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
via	via	v000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
growing	grow	g6052	VBG	I-NP	O
interest	interest	i5306023	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
enhance	enhance	e50520	VBP	B-VP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glutamatergic	glutamatergic	g403050306202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
modulation	modulation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
them	them	t050	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
glycine	glycine	g402050	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
GlyT1	GlyT1	0000	NN	B-NP	O
)	)	)000	)	O	O
inhibitors	inhibitor	i50103062	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
indirectly	indirectly	i530602340	RB	B-ADVP	O
enhance	enhance	e50520	VBP	B-VP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
function	function	f052305	NN	I-NP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
glycine	glycine	g402050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
)	)	)000	)	O	O
levels	level	l01042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
synapse	synapse	s050120	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
investigating	investigate	i510230203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
focus	focus	f0202	NN	I-NP	O
on	on	o500	IN	B-PP	O
models	model	m03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
,	,	,000	,	O	O
involving	involve	i51041052	VBG	B-VP	O
either	either	e0306	CC	O	O
drug	drug	d602	NN	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
(	(	(000	(	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	I-NP	O
amphetamine	amphetamine	a510305050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
MK	MK	m200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
transgenic	transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
ie	ie	i000	FW	B-NP	O
,	,	,000	,	O	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
Nr1	Nr1	0000	NN	I-NP	O
(	(	(000	(	O	O
neo	neo	n000	AFX	O	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
DAT	DAT	d030	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
blocked	block	b40203	VBD	B-VP	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
NMDA	NMDA	n530	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
801	801	0000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
partially	partially	p063040	RB	B-VP	O
reversed	reverse	r0106203	VBD	I-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
NMDA	NMDA	n530	NN	B-NP	B-Chemical
Nr1	Nr1	0000	NN	I-NP	O
(	(	(000	(	O	O
neo	neo	n000	AFX	O	O
-	-	-000	HYPH	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
naturally	naturally	n0306040	RB	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
transporter	transporter	t6052106306	NN	I-NP	O
(	(	(000	(	O	O
DAT	DAT	d030	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
knockout	knockout	k50203	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Importantly	Importantly	i5106305340	RB	B-ADVP	O
,	,	,000	,	O	O
both	both	b030	DT	O	O
classical	classical	c4020204	JJ	O	O
(	(	(000	(	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
atypical	atypical	a3010204	JJ	B-NP	O
(	(	(000	(	O	O
olanzapine	olanzapine	o405201050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
aripiprazole	aripiprazole	a60101602040	NN	B-NP	B-Chemical
)	)	)000	)	O	O
antipsychotics	antipsychotic	a53012020302	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
these	these	t020	DT	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hyperactivity	hyperactivity	h010602301030	NN	B-NP	B-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
unlike	unlike	u54020	IN	B-PP	O
these	these	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
,	,	,000	,	O	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
(	(	(000	(	O	O
retention	retention	r0305305	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bar	bar	b060	NN	I-NP	O
test	test	t023	NN	I-NP	O
)	)	)000	)	O	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O

Together	Together	t020306	RB	B-ADVP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
GlyT1	GlyT1	0000	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
SSR103800	SSR103800	0000	NN	B-NP	B-Chemical
,	,	,000	,	O	O
produces	produce	p6030202	VBZ	B-VP	O
antipsychotic	antipsychotic	a53012020302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
like	like	l020	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
differ	differ	d0106	VBP	B-VP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
compounds	compound	c0510532	NNS	B-NP	O
primarily	primarily	p60506040	RB	B-VP	O
targeting	target	t06203052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
effect	effect	e1023	NN	I-NP	O
potential	potential	p0305304	NN	I-NP	O
as	as	a200	IN	B-PP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Pyrrolidine	Pyrrolidine	p060403050	NN	B-NP	B-Chemical
dithiocarbamate	dithiocarbamate	d030206105030	NN	I-NP	I-Chemical
protects	protect	p6030232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
piriform	piriform	p0601065	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Pyrrolidine	Pyrrolidine	p060403050	NN	B-NP	B-Chemical
dithiocarbamate	dithiocarbamate	d030206105030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PDTC	PDTC	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
dual	dual	d040	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
antioxidant	antioxidant	a530203053	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
transcription	transcription	t6052601305	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
kappa	kappa	k010	NN	I-NP	O
-	-	-000	HYPH	O	O
beta	beta	b030	SYM	B-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
,	,	,000	,	O	O
production	production	p60302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
sub	sub	s010	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
regions	region	r02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
surrounding	surround	s06053052	VBG	I-NP	O
cortices	cortex	c0630202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
PDTC	PDTC	p320	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
-	-	-000	HYPH	B-VP	O
associated	associate	a2020303	VBN	B-NP	O
cell	cell	c040	NN	I-NP	O
loss	loss	l020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
and	and	a530	CC	I-NP	O
piriform	piriform	p0601065	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
fractionated	fractionate	f6023050303	VBD	B-VP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	O	O
following	follow	f04052	VBG	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
to	to	t000	TO	B-PP	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	B-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
(	(	(000	(	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
exert	exert	e2063	VB	I-VP	O
major	major	m0206	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
caused	cause	c0203	VBD	B-VP	O
pronounced	pronounced	p60505203	JJ	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
piriform	piriform	p0601065	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
comprising	comprise	c051602052	VBG	B-VP	O
both	both	b030	CC	O	O
pyramidal	pyramidal	p06050304	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
and	and	a530	CC	I-NP	O
interneurons	interneuron	i5306506052	NNS	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
almost	almost	a45023	RB	B-VP	O
completely	completely	c051403040	RB	I-VP	O
protected	protect	p60302303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
piriform	piriform	p0601065	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
neuronal	neuronal	n060504	JJ	B-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
hilar	hilar	h0406	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
rats	rat	r032	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
NF	NF	n100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
and	and	a530	CC	O	O
antioxidant	antioxidant	a530203053	JJ	B-NP	O
PDTC	PDTC	p320	NN	I-NP	B-Chemical
protected	protect	p60302303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
piriform	piriform	p0601065	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
hilar	hilar	h0406	JJ	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
generation	generation	g05060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
reactive	reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
and	and	a530	CC	O	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
kappaB	kappaB	k0101	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
central	central	c053604	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
neuronal	neuronal	n060504	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
hilus	hilus	h0402	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
future	future	f03060	JJ	B-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
exactly	exactly	e202340	RB	I-VP	O
analyze	analyze	a504020	VB	I-VP	O
the	the	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
PDTC	PDTC	p320	NN	B-NP	B-Chemical
exerted	exert	e206303	VBD	B-VP	O
its	its	i320	PRP$	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
piriform	piriform	p0601065	NN	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Anaesthetists	Anaesthetist	a5023030232	NNS	B-NP	O
'	'	'000	POS	B-NP	O
nightmare	nightmare	n02035060	NN	I-NP	O
:	:	:000	:	O	O
masseter	masseter	m020306	NN	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
undiagnosed	undiagnosed	u530250203	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myotonia	myotonia	m03050	NN	B-NP	B-Disease
congenita	congenita	c05205030	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
an	an	a500	DT	B-NP	O
undiagnosed	undiagnosed	u530250203	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myotonia	myotonia	m03050	NN	B-NP	B-Disease
congenita	congenita	c05205030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
primigravida	primigravida	p60502601030	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
life	life	l010	NN	B-NP	O
threatening	threatening	t060305052	JJ	I-NP	O
masseter	masseter	m020306	NN	I-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
suxamethonium	suxamethonium	s0205030505	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
nor	nor	n060	CC	O	O
the	the	t000	DT	B-NP	O
anaesthetist	anaesthetist	a502303023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
before	before	b01060	IN	B-PP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Twin	Twin	t050	CD	B-NP	O
preterm	preterm	p603065	JJ	I-NP	O
neonates	neonate	n050302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lopinavir	lopinavir	l01050106	NN	B-NP	B-Chemical
/	/	/000	SYM	O	I-Chemical
ritonavir	ritonavir	r03050106	NN	B-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
twin	twin	t050	JJ	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
born	bear	b065	VBN	I-VP	O
prematurely	prematurely	p6050306040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
32	32	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
mother	mother	m0306	NN	I-NP	O
with	with	w030	IN	B-PP	O
human	human	h0505	JJ	B-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
twins	twin	t052	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
heart	heart	h063	NN	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
and	and	a530	CC	O	O
dilated	dilated	d040303	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lopinavir	lopinavir	l01050106	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
ritonavir	ritonavir	r03050106	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
boosted	boost	b02303	VBN	I-NP	O
protease	protease	p603020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
twin	twin	t050	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
mild	mild	m043	JJ	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recommend	recommend	r0205053	VBP	B-VP	O
caution	caution	c0305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
lopinavir	lopinavir	l01050106	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
ritonavir	ritonavir	r03050106	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
neonatal	neonatal	n050304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
drugs	drug	d602	NNS	B-NP	O
disappear	disappear	d020106	VBP	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
:	:	:000	:	O	O
elimination	elimination	e405050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
by	by	b000	IN	B-PP	O
hemodiafiltration	hemodiafiltration	h05030104360305	NN	B-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
,	,	,000	,	O	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
acute	acute	a2030	JJ	B-NP	O
right	right	r0203	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
requiring	require	r0206052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
venovenous	venovenous	v05010502	JJ	I-NP	O
hemodiafiltration	hemodiafiltration	h05030104360305	NN	I-NP	O
(	(	(000	(	O	O
CVVHDF	CVVHDF	c1031	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Increasing	Increase	i52602052	VBG	B-VP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
sedatives	sedative	s03030102	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
muscle	muscle	m0240	NN	B-NP	O
relaxants	relaxant	r04020532	NNS	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
bolus	bolus	b0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
injected	inject	i5202303	VBN	B-VP	O
through	through	t06020	IN	B-PP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
provoked	provoke	p6010203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
crisis	crisis	c60202	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
interference	interference	i53061060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
dialysis	dialysis	d040202	NN	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
catheters	catheter	c0303062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
changed	change	c05203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
hemodynamics	hemodynamic	h0503050502	NNS	B-NP	O
stabilized	stabilize	s301040203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
catecholamine	catecholamine	c03020405050	NN	I-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
IV	IV	i100	CD	B-NP	O
drugs	drug	d602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
inadequate	inadequate	i50302030	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
CVVHDF	CVVHDF	c1031	NN	B-NP	O
,	,	,000	,	O	O
interference	interference	i53061060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
adjacent	adjacent	a3202053	JJ	B-NP	O
catheters	catheter	c0303062	NNS	I-NP	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
elimination	elimination	e405050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
by	by	b000	IN	B-PP	O
CVVHDF	CVVHDF	c1031	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

Less	Less	l020	RBR	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
lower	low	l060	JJR	B-NP	O
urine	urine	u6050	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
maintained	maintain	m0530503	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
once	once	o520	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
per	per	p060	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	B-NP	O
schedule	schedule	s203040	NN	I-NP	O
have	have	h010	VBP	B-VP	O
lower	low	l060	JJR	B-NP	O
urine	urine	u6050	NN	I-NP	O
volumes	volume	v040502	NNS	I-NP	O
than	than	t050	IN	B-SBAR	O
do	do	d000	VBP	O	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
85	85	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
clinic	clinic	c40502	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
different	different	d0106053	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
schedules	schedule	s2030402	NNS	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
for	for	f060	IN	B-PP	O
measurement	measurement	m020605053	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
level	level	l0104	NN	I-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
,	,	,000	,	O	O
urine	urine	u6050	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
maximum	maximum	m020505	JJ	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Multiple	Multiple	m0430140	JJ	B-NP	O
daily	daily	d040	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
higher	high	h0206	JJR	B-NP	O
urine	urine	u6050	NN	I-NP	O
volumes	volume	v040502	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
schedule	schedule	s203040	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
daily	daily	d040	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
maximum	maximum	m020505	JJ	B-NP	O
osmolality	osmolality	o250404030	NN	I-NP	O
or	or	o600	CC	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Urine	Urine	u6050	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
extrarenal	extrarenal	e236060504	JJ	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
to	to	t000	TO	B-PP	O
renal	renal	r0504	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Antibacterial	Antibacterial	a53010230604	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
use	use	u200	NN	I-NP	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
and	and	a530	CC	O	O
risk	risk	r020	NN	B-NP	O
of	of	o100	IN	B-PP	O
birth	birth	b0630	NN	B-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
:	:	:000	:	O	O
National	National	n030504	NNP	B-NP	O
Birth	Birth	b0630	NNP	I-NP	B-Disease
Defects	Defect	d010232	NNPS	I-NP	I-Disease
Prevention	Prevention	p60105305	NNP	I-NP	O
Study	Study	s3030	NNP	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
antibacterial	antibacterial	a53010230604	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
and	and	a530	CC	O	O
selected	select	s0402303	VBN	B-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
.	.	.000	.	O	O

DESIGN	DESIGN	d02025	NN	B-NP	O
,	,	,000	,	O	O
SETTING	SETTING	s03052	NN	B-NP	O
,	,	,000	,	O	O
AND	AND	a530	CC	O	O
PARTICIPANTS	PARTICIPANTS	p06302010532	NNS	B-NP	O
:	:	:000	:	O	O
Population	Population	p01040305	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
,	,	,000	,	I-NP	O
multisite	multisite	m04302030	JJ	I-NP	O
,	,	,000	,	I-NP	O
case	case	c020	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
control	control	c053604	NN	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
pregnancies	pregnancy	p602505202	NNS	B-NP	O
affected	affect	a102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
30	30	0000	CD	I-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
major	major	m0206	JJ	I-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
identified	identify	i30530103	VBN	B-VP	O
via	via	v000	IN	B-PP	O
birth	birth	b0630	NN	B-NP	B-Disease
defect	defect	d01023	NN	I-NP	I-Disease
surveillance	surveillance	s061040520	NN	I-NP	O
programs	program	p6026052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
states	state	s30302	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
13	13	0000	CD	B-NP	O
155	155	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
control	control	c053604	NN	B-NP	O
women	woman	w0505	NNS	I-NP	O
randomly	randomly	r0530540	RB	B-VP	O
selected	select	s0402303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
geographical	geographical	g026010204	JJ	I-NP	O
regions	region	r02052	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4941	4941	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NN	B-NP	O
EXPOSURE	EXPOSURE	e2102060	NN	I-NP	O
:	:	:000	:	O	O
Reported	Report	r0106303	VBN	B-VP	O
maternal	maternal	m0306504	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antibacterials	antibacterial	a530102306042	NNS	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
before	before	b01060	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
trimester	trimester	t60502306	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

MAIN	MAIN	m050	NNP	B-NP	O
OUTCOME	OUTCOME	o032050	NNP	I-NP	O
MEASURE	MEASURE	m02060	NNP	I-NP	O
:	:	:000	:	O	O
Odds	Odd	o320	NNS	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
(	(	(000	(	O	O
ORs	OR	o620	NNS	B-NP	O
)	)	)000	)	O	O
measuring	measure	m0206052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
antibacterial	antibacterial	a53010230604	JJ	B-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
selected	select	s0402303	VBN	B-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
adjusted	adjust	a3202303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
confounders	confounder	c051053062	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antibacterials	antibacterial	a530102306042	NNS	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
,	,	,000	,	O	O
peaking	peak	p02052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

Sulfonamides	Sulfonamide	s04105050302	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
anencephaly	anencephaly	a505201040	RB	O	B-Disease
(	(	(000	(	O	O
adjusted	adjust	a3202303	VBN	B-NP	O
OR	OR	o600	NN	I-NP	O
[	[	[000	(	O	O
AOR	AOR	a060	NN	B-NP	O
]	]	]000	)	O	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
8	8	8000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hypoplastic	hypoplastic	h0101402302	JJ	B-NP	B-Disease
left	left	l013	JJ	I-NP	I-Disease
heart	heart	h063	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
coarctation	coarctation	c06230305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
aorta	aorta	a0630	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
choanal	choanal	c0504	JJ	B-NP	B-Disease
atresia	atresia	a36020	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
23	23	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
transverse	transverse	t605210620	JJ	B-NP	B-Disease
limb	limb	l051	NN	I-NP	I-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
diaphragmatic	diaphragmatic	d01060250302	JJ	B-NP	B-Disease
hernia	hernia	h0650	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nitrofurantoins	Nitrofurantoin	n0360106053052	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
anophthalmia	anophthalmia	a501030450	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
microphthalmos	microphthalmo	m026010304502	NNS	I-NP	B-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hypoplastic	hypoplastic	h0101402302	JJ	B-NP	B-Disease
left	left	l013	JJ	I-NP	I-Disease
heart	heart	h063	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cleft	cleft	c4013	NN	B-NP	B-Disease
lip	lip	l010	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
cleft	cleft	c4013	NN	B-NP	B-Disease
palate	palate	p04030	NN	I-NP	I-Disease
(	(	(000	(	O	O
AOR	AOR	a060	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
antibacterial	antibacterial	a53010230604	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
showed	show	s030	VBD	B-VP	O
associations	association	a20203052	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
erythromycins	erythromycin	e603060502052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
defects	defect	d010232	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
penicillins	penicillin	p050204052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
defect	defect	d01023	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cephalosporins	cephalosporin	c010402106052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
defect	defect	d01023	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
quinolones	quinolone	q05040502	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
defect	defect	d01023	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Reassuringly	Reassuringly	r020605240	RB	B-ADVP	O
,	,	,000	,	O	O
penicillins	penicillin	p050204052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
erythromycins	erythromycin	e603060502052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
cephalosporins	cephalosporin	c010402106052	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
used	use	u203	VBN	B-VP	O
commonly	commonly	c050540	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
many	many	m050	JJ	B-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Sulfonamides	Sulfonamide	s04105050302	NNS	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nitrofurantoins	nitrofurantoin	n0360106053052	NNS	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
birth	birth	b0630	NN	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
additional	additional	a3030504	JJ	B-NP	O
scrutiny	scrutiny	s2603050	NN	I-NP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
escape	escape	e2010	NN	I-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
G145R	G145R	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
P120T	P120T	0000	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
replication	replication	r014020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
virus	virus	v0602	NN	I-NP	I-Chemical
e	e	e000	NN	I-NP	I-Chemical
antigen	antigen	a530205	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
positive	positive	p0203010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
negative	negative	n0203010	JJ	I-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

Immune	Immune	i5050	JJ	B-NP	O
escape	escape	e2010	NN	I-NP	O
variants	variant	v060532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
B	B	b000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HBV	HBV	h100	NN	B-NP	O
)	)	)000	)	O	O
represent	represent	r01602053	VBP	B-VP	O
an	an	a500	DT	B-NP	O
emerging	emerge	e5062052	VBG	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
vaccine	vaccine	v02050	NN	B-NP	O
escape	escape	e2010	NN	I-NP	O
,	,	,000	,	O	O
HBV	HBV	h100	NN	B-NP	O
reactivation	reactivation	r023010305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
failure	failure	f04060	NN	B-NP	O
of	of	o100	IN	B-PP	O
diagnostic	diagnostic	d02502302	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
preferential	preferential	p6010605304	JJ	I-NP	O
selection	selection	s0402305	NN	I-NP	O
of	of	o100	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
escape	escape	e2010	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
distinct	distinct	d0230523	JJ	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
leukocyte	leukocyte	l0202030	NN	I-NP	O
compartments	compartment	c05106350532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
infected	infected	i5102303	JJ	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
therefore	therefore	t0601060	RB	B-ADVP	O
systematically	systematically	s023050302040	RB	B-ADVP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
prevalent	prevalent	p60104053	JJ	I-NP	O
immune	immune	i5050	JJ	I-NP	O
escape	escape	e2010	NN	I-NP	O
variants	variant	v060532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
sG145R	sG145R	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
sP120T	sP120T	0000	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
viral	viral	v0604	JJ	I-NP	O
replication	replication	r014020305	NN	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	O	O
antiviral	antiviral	a53010604	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
resistance	resistance	r020230520	NN	B-NP	O
to	to	t000	TO	B-PP	O
lamivudine	lamivudine	l050103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
LAM	LAM	l050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
negativity	negativity	n020301030	NN	I-NP	O
.	.	.000	.	O	O

Replication	Replication	r014020305	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
competent	competent	c05103053	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
sG145R	sG145R	0000	NN	B-NP	O
or	or	o600	CC	O	O
sP120T	sP120T	0000	NN	B-NP	O
and	and	a530	CC	O	O
LAM	LAM	l050	NN	B-NP	B-Chemical
resistance	resistance	r020230520	NN	I-NP	O
(	(	(000	(	O	O
rtM204I	rtM204I	0000	NN	B-NP	O
or	or	o600	CC	O	O
rtL180M	rtL180M	0000	NN	B-NP	O
/	/	/000	SYM	B-NP	O
rtM204V	rtM204V	0000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
generated	generate	g05060303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
an	an	a500	DT	B-NP	O
HBeAg	HBeAg	h102	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
HBeAg	HBeAg	h102	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
background	background	b026053	NN	I-NP	O
with	with	w030	IN	B-PP	O
precore	precore	p602060	NN	B-NP	O
(	(	(000	(	O	O
PC	PC	p200	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
basal	basal	b0204	JJ	B-NP	O
core	core	c060	NN	I-NP	O
promoter	promoter	p6050306	NN	I-NP	O
(	(	(000	(	O	O
BCP	BCP	b210	NN	B-NP	O
)	)	)000	)	O	O
mutants	mutant	m030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
sG145R	sG145R	0000	NN	I-NP	O
mutation	mutation	m030305	NN	I-NP	O
strongly	strongly	s3605240	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
fully	fully	f040	RB	I-VP	O
restore	restore	r023060	VB	I-VP	O
the	the	t000	DT	B-NP	O
impaired	impaired	i510603	JJ	I-NP	O
replication	replication	r014020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LAM	LAM	l050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
HBV	HBV	h100	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PC	PC	p200	NN	B-NP	O
or	or	o600	CC	I-NP	O
BCP	BCP	b210	NN	I-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
further	further	f06306	RBR	B-ADVP	O
enhanced	enhance	e505203	VBD	B-VP	O
viral	viral	v0604	JJ	B-NP	O
replication	replication	r014020305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
sP120T	sP120T	0000	NN	I-NP	O
substitution	substitution	s0123030305	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
impaired	impair	i510603	VBD	B-VP	O
HBsAg	HBsAg	h1202	NN	B-NP	B-Chemical
secretion	secretion	s0260305	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
enhance	enhance	e50520	VB	I-VP	O
the	the	t000	DT	B-NP	O
replication	replication	r014020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
LAM	LAM	l050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
resistant	resistant	r02023053	JJ	I-NP	O
clones	clone	c40502	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
HBeAg	HBeAg	h102	NN	B-NP	B-Chemical
negativity	negativity	n020301030	NN	I-NP	O
(	(	(000	(	O	O
PC	PC	p200	NN	B-NP	O
/	/	/000	SYM	O	O
BCP	BCP	b210	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
sP120T	sP120T	0000	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
LAM	LAM	l050	NN	B-NP	B-Chemical
resistance	resistance	r020230520	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
replication	replication	r014020305	NN	B-NP	O
to	to	t000	TO	B-PP	O
levels	level	l01042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
wild	wild	w043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
HBV	HBV	h100	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
clones	clone	c40502	NNS	I-NP	O
with	with	w030	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
immune	immune	i5050	JJ	I-NP	O
escape	escape	e2010	NN	I-NP	O
and	and	a530	CC	I-NP	O
LAM	LAM	l050	NN	I-NP	B-Chemical
resistance	resistance	r020230520	NN	I-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
nucleotide	nucleotide	n02403030	NN	I-NP	B-Chemical
analogues	analogue	a5040202	NNS	I-NP	O
adefovir	adefovir	a3010106	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
tenofovir	tenofovir	t05010106	NN	I-NP	B-Chemical
remained	remain	r050503	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
suppressing	suppress	s01602052	VBG	B-VP	O
viral	viral	v0604	JJ	B-NP	O
replication	replication	r014020305	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
reveal	reveal	r0104	VBP	B-VP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
immune	immune	i5050	JJ	B-NP	O
escape	escape	e2010	NN	I-NP	O
variants	variant	v060532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
replication	replication	r014020305	NN	I-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	O
susceptibility	susceptibility	s020130104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
complex	complex	c051402	JJ	B-NP	O
HBV	HBV	h100	NN	I-NP	O
mutants	mutant	m030532	NNS	I-NP	O
,	,	,000	,	O	O
supporting	support	s01063052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
of	of	o100	IN	B-PP	O
close	close	c4020	JJ	B-NP	O
surveillance	surveillance	s061040520	NN	I-NP	O
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
selection	selection	s0402305	NN	I-NP	O
of	of	o100	IN	B-PP	O
distinct	distinct	d0230523	JJ	B-NP	O
mutational	mutational	m03030504	JJ	I-NP	O
patterns	pattern	p030652	NNS	I-NP	O
.	.	.000	.	O	O

Hemolytic	Hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Omeprazole	Omeprazole	o501602040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
designed	design	d0202503	VBN	B-VP	O
to	to	t000	TO	I-VP	O
block	block	b402	VB	I-VP	O
the	the	t000	DT	B-NP	O
final	final	f0504	JJ	I-NP	O
step	step	s301	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acid	acid	a203	NN	I-NP	O
secretory	secretory	s02603060	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
parietal	parietal	p060304	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
extremely	extremely	e23605040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
peptic	peptic	p01302	JJ	B-NP	B-Disease
ulcer	ulcer	u4206	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
reflux	reflux	r01402	NN	B-NP	B-Disease
esophagitis	esophagitis	e201020302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Zollinger	Zollinger	z0405206	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Ellison	Ellison	e40205	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
clinical	clinical	c4050204	JJ	B-NP	O
experience	experience	e21060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
limited	limited	l050303	JJ	B-ADJP	O
,	,	,000	,	O	O
many	many	m050	JJ	B-NP	O
controlled	controlled	c05360403	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
established	establish	e230140203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
:	:	:000	:	O	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
weakness	weakness	w02502	NN	B-NP	O
,	,	,000	,	O	O
lethargy	lethargy	l030620	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
shortness	shortness	s063502	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
breath	breath	b6030	NN	B-NP	I-Disease
2	2	2000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
hematocrit	hematocrit	h050302603	NN	I-NP	O
had	have	h030	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
44	44	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
direct	direct	d06023	JJ	I-NP	O
Coombs	Coomb	c0512	NNS	I-NP	O
antiglobulin	antiglobulin	a53024010405	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
elevated	elevate	e4010303	VBN	I-NP	O
indirect	indirect	i5306023	JJ	I-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
discontinued	discontinue	d020530503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
omeprazole	omeprazole	o501602040	NN	I-NP	B-Chemical
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
and	and	a530	CC	I-NP	O
hematocrit	hematocrit	h050302603	NN	I-NP	O
gradually	gradually	g603040	RB	B-ADVP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
omeprazole	omeprazole	o501602040	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
uncertain	uncertain	u5206305	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
physicians	physician	p0202052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
alerted	alert	a406303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Phenylephrine	Phenylephrine	p05040106050	NN	B-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	B-Disease
frontal	frontal	f605304	JJ	B-NP	I-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
oxygenation	oxygenation	o202050305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Vasopressor	Vasopressor	v020160206	NN	B-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
correct	correct	c06023	VB	I-VP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
ephedrine	ephedrine	e1036050	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
frontal	frontal	f605304	JJ	B-NP	O
lobe	lobe	l010	NN	I-NP	O
oxygenation	oxygenation	o202050305	NN	I-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Following	Follow	f04052	VBG	B-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
by	by	b000	IN	B-PP	O
fentanyl	fentanyl	f0530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
iv	iv	i100	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
restore	restore	r023060	VB	I-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
MAP	MAP	m010	NN	B-NP	O
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
volume	volume	v04050	NN	I-NP	O
(	(	(000	(	O	O
SV	SV	s100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
(	(	(000	(	O	O
CO	CO	c000	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
frontal	frontal	f605304	JJ	B-NP	O
lobe	lobe	l010	NN	I-NP	O
oxygenation	oxygenation	o202050305	NN	I-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
registered	register	r020230603	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	B-Disease
decrease	decrease	d026020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	I-Disease
MAP	MAP	m010	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
HR	HR	h600	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
SV	SV	s100	NN	B-NP	I-Disease
,	,	,000	,	O	I-Disease
and	and	a530	CC	O	I-Disease
CO	CO	c000	NN	B-NP	I-Disease
concomitant	concomitant	c0520503053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
MAP	MAP	m010	NN	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
(	(	(000	(	O	O
51	51	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
12	12	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
81	81	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
14	14	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
from	from	f605	IN	B-PP	O
70	70	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
60	60	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
followed	follow	f0403	VBN	B-VP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
CO	CO	c000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
l	l	l000	NN	I-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
MAP	MAP	m010	NN	B-NP	O
(	(	(000	(	O	O
53	53	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
9	9	9000	CD	B-NP	O
to	to	t000	TO	B-PP	O
79	79	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
restored	restore	r0230603	VBD	B-VP	O
CO	CO	c000	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
l	l	l000	NN	I-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
preserved	preserve	p60206103	VBN	B-VP	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
utilization	utilization	u304020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
correct	correct	c06023	VB	I-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
impact	impact	i51023	NN	I-NP	O
on	on	o500	IN	B-PP	O
S	S	s000	NN	B-NP	O
(	(	(000	(	O	O
c	c	c000	NN	B-NP	O
)	)	)000	)	O	O
O	O	o000	NN	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
while	while	w040	IN	B-SBAR	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
maintains	maintain	m053052	VBZ	B-VP	O
frontal	frontal	f605304	JJ	B-NP	O
lobe	lobe	l010	NN	I-NP	O
oxygenation	oxygenation	o202050305	NN	I-NP	O
potentially	potentially	p03053040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CO	CO	c000	NN	B-NP	O
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Direct	Direct	d06023	JJ	B-NP	O
thrombin	thrombin	t0605105	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
DTIs	DTI	d302	NNS	B-NP	O
)	)	)000	)	O	O
provide	provide	p601030	VBP	B-VP	O
an	an	a500	DT	B-NP	O
alternative	alternative	a4306503010	JJ	I-NP	O
method	method	m0303	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
(	(	(000	(	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
or	or	o600	CC	O	O
HIT	HIT	h030	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
(	(	(000	(	O	O
HITT	HITT	h030	NN	B-NP	B-Disease
)	)	)000	)	O	O
undergoing	undergo	u53062052	VBG	B-VP	O
cardiopulmonary	cardiopulmonary	c0630104505060	JJ	B-NP	O
bypass	bypass	b0102	NN	I-NP	O
(	(	(000	(	O	O
CPB	CPB	c100	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
65	65	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
critically	critically	c60302040	RB	I-NP	B-Disease
ill	ill	i400	JJ	I-NP	I-Disease
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
HITT	HITT	h030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
on	on	o500	IN	B-PP	O
bypass	bypass	b0102	NN	B-NP	O
during	during	d06052	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
transplantation	transplantation	t6052140530305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
required	require	r020603	VBD	B-VP	O
massive	massive	m02010	JJ	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
support	support	s01063	NN	I-NP	O
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
red	red	r030	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
42	42	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fresh	fresh	f6020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
frozen	frozen	f60205	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cryoprecipitate	cryoprecipitate	c6016020103030	NN	B-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
units	unit	u5032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
platelets	platelet	p40304032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
three	three	t060	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
recombinant	recombinant	r0205105053	JJ	B-NP	O
Factor	Factor	f02306	NN	I-NP	O
VIIa	VIIa	v000	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
intraoperative	intraoperative	i536010603010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
postoperative	postoperative	p023010603010	JJ	I-NP	I-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
.	.	.000	.	O	O

STUDY	STUDY	s3030	NN	B-NP	O
DESIGN	DESIGN	d02025	NN	I-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Plasma	Plasma	p40250	NN	B-NP	O
samples	sample	s051402	NNS	I-NP	O
from	from	f605	IN	B-PP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
CPB	CPB	c100	NN	B-NP	O
were	be	w060	VBD	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
argatroban	argatroban	a620360105	JJ	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
modified	modify	m030103	VBN	I-NP	O
ecarin	ecarin	e20605	NN	I-NP	O
clotting	clotting	c403052	NN	I-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
ECT	ECT	e230	NN	B-NP	O
)	)	)000	)	O	O
assay	assay	a200	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Unexpectedly	Unexpectedly	u50210230340	RB	B-NP	O
high	high	h020	JJ	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
argatroban	argatroban	a620360105	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
samples	sample	s051402	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
32	32	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
half	half	h041	NN	I-NP	O
life	life	l010	NN	I-NP	O
(	(	(000	(	O	O
t	t	t000	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	O	O
2	2	2000	CD	O	O
)	)	)000	)	O	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
514	514	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
(	(	(000	(	O	O
published	publish	p0140203	VBN	B-NP	O
elimination	elimination	e405050305	NN	I-NP	O
t	t	t000	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
39	39	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
51	51	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
[	[	[000	(	O	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
181	181	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
]	]	]000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Correlation	Correlation	c06040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
versus	versus	v06202	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
coagulation	coagulation	c02040305	NN	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
course	course	c0620	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
prolonged	prolonged	p60405203	JJ	B-NP	O
elevated	elevated	e4010303	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
argatroban	argatroban	a620360105	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
extended	extend	e2305303	VBD	B-VP	O
coagulopathy	coagulopathy	c020401030	NN	B-NP	B-Disease
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
DTIs	DTI	d302	NNS	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
reversal	reversal	r0106204	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
surgical	surgical	s0620204	JJ	B-NP	O
teams	team	t052	NNS	I-NP	O
and	and	a530	CC	O	O
transfusion	transfusion	t605210205	NN	B-NP	O
services	service	s0610202	NNS	I-NP	O
should	should	s043	MD	B-VP	O
remain	remain	r0505	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
transfusion	transfusion	t605210205	NN	I-NP	O
events	event	e10532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
anticoagulation	anticoagulation	a530202040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
to	to	t000	TO	B-VP	O
measure	measure	m02060	VB	I-VP	O
plasma	plasma	p40250	NN	B-NP	O
argatroban	argatroban	a620360105	JJ	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
context	context	c053023	NN	I-NP	O
of	of	o100	IN	B-PP	O
CPB	CPB	c100	NN	B-NP	O
and	and	a530	CC	O	O
extended	extended	e2305303	JJ	B-NP	O
coagulopathy	coagulopathy	c020401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
adjunctive	adjunctive	a320523010	JJ	I-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	B-Chemical
serotonin	serotonin	s06030505	NN	I-NP	I-Chemical
reuptake	reuptake	r013020	NN	I-NP	I-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
and	and	a530	CC	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adjunctive	adjunctive	a320523010	JJ	B-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
sustained	sustain	s0230503	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
release	release	r04020	NN	I-NP	O
(	(	(000	(	O	O
SR	SR	s600	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
sexual	sexual	s0204	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
SD	SD	s300	NN	B-NP	B-Disease
)	)	)000	)	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	B-Chemical
serotonin	serotonin	s06030505	NN	I-NP	I-Chemical
reuptake	reuptake	r013020	NN	I-NP	I-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SSRI	SSRI	s260	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
SD	SD	s300	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
SSRIs	SSRI	s2602	NNS	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
yet	yet	y030	RB	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
sample	sample	s05140	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
234	234	0000	CD	B-NP	O
euthymic	euthymic	e030502	JJ	I-NP	O
men	man	m050	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
some	some	s050	DT	B-NP	O
type	type	t010	NN	I-NP	O
of	of	o100	IN	B-PP	O
SSRI	SSRI	s260	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
men	man	m050	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
SR	SR	s600	NN	I-NP	O
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
,	,	,000	,	O	O
117	117	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	B-ADVP	O
,	,	,000	,	O	O
117	117	0000	CD	B-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Clinical	Clinical	c4050204	JJ	I-NP	O
Global	Global	g40104	NNP	I-NP	O
Impression	Impression	i5160205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
Sexual	Sexual	s0204	JJ	I-NP	O
Function	Function	f052305	NN	I-NP	O
(	(	(000	(	O	O
CGI	CGI	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
SF	SF	s100	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
measure	measure	m02060	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
International	International	i53065030504	NNP	I-NP	O
Index	Index	i5302	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Erectile	Erectile	e6023040	NNP	B-NP	O
Function	Function	f052305	NNP	I-NP	O
(	(	(000	(	O	O
IIEF	IIEF	i010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
Arizona	Arizona	a602050	NNP	B-NP	O
Sexual	Sexual	s0204	NNP	I-NP	O
Experience	Experience	e21060520	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
ASEX	ASEX	a202	NNP	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
Erectile	Erectile	e6023040	JJ	B-NP	B-Disease
Dysfunction	Dysfunction	d021052305	NN	I-NP	I-Disease
Inventory	Inventory	i51053060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Treatment	Treatment	t6035053	NN	B-NP	O
Satisfaction	Satisfaction	s0302102305	NN	I-NP	O
(	(	(000	(	O	O
EDITS	EDITS	e3032	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
secondary	secondary	s02053060	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
measures	measure	m020602	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
biweekly	biweekly	b0240	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
study	study	s3030	NN	B-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
After	After	a1306	IN	B-NP	O
12	12	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
(	(	(000	(	O	O
sd	sd	s300	JJ	B-ADJP	O
)	)	)000	)	O	O
scores	score	s20602	NNS	B-NP	O
for	for	f060	IN	B-PP	O
CGI	CGI	c200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
SF	SF	s100	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
better	well	b0306	RBR	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
SR	SR	s600	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
(	(	(000	NN	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
(	(	(000	NN	I-NP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Men	Men	m050	NN	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
IIEF	IIEF	i010	NN	I-NP	O
score	score	s2060	NN	I-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
003	003	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
five	five	f010	CD	I-NP	O
different	different	d0106053	JJ	I-NP	O
domains	domain	d05052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
IIEF	IIEF	i010	NN	I-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
ASEX	ASEX	a202	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
better	well	b0306	RBR	O	O
,	,	,000	,	O	O
among	among	a5052	IN	B-PP	O
men	man	m050	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
vs	vs	v200	IN	B-PP	O
21	21	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	O	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
002	002	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
EDITS	EDITS	e3032	NNS	I-NP	O
scores	score	s20602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
(	(	(000	NN	I-NP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
bupropion	bupropion	b0160105	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
36	36	0000	CD	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
(	(	(000	NN	I-NP	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ASEX	ASEX	a202	NN	I-NP	O
score	score	s2060	NN	I-NP	O
and	and	a530	CC	I-NP	O
CGI	CGI	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
SF	SF	s100	NN	I-NP	O
score	score	s2060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
003	003	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
linear	linear	l0506	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
CGI	CGI	c200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
SF	SF	s100	NN	I-NP	O
score	score	s2060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
SD	SD	s300	NN	B-NP	B-Disease
,	,	,000	,	O	O
type	type	t010	NN	B-NP	O
of	of	o100	IN	B-PP	O
SSRI	SSRI	s260	NN	B-NP	B-Chemical
used	use	u203	VBN	B-VP	O
and	and	a530	CC	O	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Bupropion	Bupropion	b0160105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
male	male	m040	JJ	B-NP	O
SD	SD	s300	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
SSRIs	SSRI	s2602	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
empirical	empirical	e51060204	JJ	B-NP	O
support	support	s01063	NN	I-NP	O
for	for	f060	IN	B-PP	O
conducting	conduct	c053023052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupropion	bupropion	b0160105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Prevention	Prevention	p60105305	NN	B-NP	O
of	of	o100	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
reorganization	reorganization	r06205020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
functions	function	f0523052	NNS	I-NP	O
by	by	b000	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
mononuclear	mononuclear	m050502406	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
BMCs	BMC	b520	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
epilepsy	epilepsy	e1040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pilocarpine	pilocarpine	p0402061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

BMCs	BMC	b520	NNS	B-NP	O
obtained	obtain	o130503	VBN	B-VP	O
from	from	f605	IN	B-PP	O
green	green	g605	JJ	B-NP	O
fluorescent	fluorescent	f40602053	JJ	I-NP	O
protein	protein	p60305	NN	I-NP	O
(	(	(000	(	O	O
GFP	GFP	g100	NN	B-NP	O
)	)	)000	)	O	O
transgenic	transgenic	t60520502	JJ	B-NP	O
mice	mouse	m020	NNS	I-NP	O
or	or	o600	CC	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
transplanted	transplant	t60521405303	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
status	status	s30302	NN	B-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
(	(	(000	(	O	O
SE	SE	s000	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	B-Disease
recurrent	recurrent	r0206053	JJ	I-NP	I-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
(	(	(000	(	O	O
SRS	SRS	s620	NNS	B-NP	B-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
Racine	Racine	r02050	NN	B-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
severity	severity	s0106030	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saline	saline	s04050	NN	I-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
SRS	SRS	s620	NN	B-NP	B-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BMC	BMC	b520	NN	I-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
term	term	t065	NN	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BMC	BMC	b520	NN	I-NP	O
source	source	s0620	NN	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
(	(	(000	(	O	O
120	120	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
transplantation	transplantation	t6052140530305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
25	25	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
BMC	BMC	b520	NN	B-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-VP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
animals	animal	a505042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
BMCs	BMC	b520	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
hippocampal	hippocampal	h010205104	JJ	B-NP	O
Schaeffer	Schaeffer	s20106	NNP	I-NP	O
collateral	collateral	c04030604	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
CA1	CA1	0000	NN	I-NP	O
synapses	synapsis	s0501202	NNS	I-NP	O
,	,	,000	,	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
preserved	preserve	p60206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
BMC	BMC	b520	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
transplanted	transplant	t60521405303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
donor	donor	d0506	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
derived	derive	d060103	VBN	B-NP	O
GFP	GFP	g100	NN	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
cells	cell	c042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
rarely	rarely	r06040	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brains	brain	b6052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
transplanted	transplant	t60521405303	VBN	B-NP	O
epileptic	epileptic	e10401302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
BMCs	BMC	b520	NNS	B-NP	O
can	can	c050	MD	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
reduce	reduce	r03020	VB	B-VP	O
neuronal	neuronal	n060504	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
influence	influence	i5140520	VB	B-VP	O
the	the	t000	DT	B-NP	O
reorganization	reorganization	r06205020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampal	hippocampal	h010205104	JJ	I-NP	O
neuronal	neuronal	n060504	JJ	I-NP	O
network	network	n03062	NN	I-NP	O
.	.	.000	.	O	O

Normalizing	Normalize	n0650402052	VBG	B-VP	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
modafinil	modafinil	m03010504	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
morning	morning	m065052	NN	B-NP	O
-	-	-000	HYPH	O	O
dosed	dose	d0203	VBN	B-NP	O
modafinil	modafinil	m03010504	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	O
and	and	a530	CC	I-NP	O
daytime	daytime	d03050	NN	I-NP	B-Disease
sleepiness	sleepiness	s4010502	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
modafinil	modafinil	m03010504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
400	400	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
every	every	e1060	DT	B-NP	O
morning	morning	m065052	NN	I-NP	O
at	at	a300	IN	B-PP	O
7	7	7000	CD	B-NP	O
:	:	:000	:	O	O
30	30	0000	CD	B-NP	O
a	a	a000	DT	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
for	for	f060	IN	B-PP	O
16	16	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inpatient	inpatient	i5103053	NN	I-NP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Participants	Participant	p06302010532	NNS	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
polysomnographic	polysomnographic	p0402050260102	JJ	B-NP	O
sleep	sleep	s401	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
14	14	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
16	16	0000	CD	I-NP	O
(	(	(000	(	O	O
first	first	f0623	JJ	B-ADVP	O
,	,	,000	,	O	O
second	second	s02053	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
third	third	t063	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
abstinence	abstinence	a123050520	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Multiple	Multiple	m0430140	JJ	I-NP	O
Sleep	Sleep	s401	NN	I-NP	O
Latency	Latency	l030520	NN	I-NP	O
Test	Test	t023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
11	11	0000	CD	B-NP	O
:	:	:000	:	O	O
30	30	0000	CD	B-NP	O
a	a	a000	DT	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
:	:	:000	:	O	O
00	00	0000	CD	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
4	4	4000	CD	B-NP	O
:	:	:000	:	O	O
30	30	0000	CD	B-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
sleep	sleep	s401	JJ	B-NP	O
architecture	architecture	a6203023060	NN	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
comparison	comparison	c051060205	NN	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
night	night	n0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
polysomnography	polysomnography	p040205026010	NN	I-NP	O
that	that	t030	WDT	B-NP	O
followed	follow	f0403	VBD	B-VP	O
1	1	1000	CD	B-NP	O
night	night	n0203	NN	I-NP	O
of	of	o100	IN	B-PP	O
accommodation	accommodation	a205030305	NN	B-NP	O
polysomnography	polysomnography	p040205026010	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Progressive	Progressive	p602602010	JJ	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
from	from	f605	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
worsening	worsen	w06205052	VBG	B-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
measured	measure	m020603	VBN	I-NP	O
polysomnographic	polysomnographic	p0402050260102	JJ	I-NP	O
sleep	sleep	s401	NN	I-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
modafinil	modafinil	m03010504	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
nighttime	nighttime	n0203050	RB	I-VP	O
sleep	sleep	s401	VB	I-VP	O
latency	latency	l030520	NN	B-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
slow	slow	s400	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
wave	wave	w010	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
time	time	t050	NN	I-NP	O
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
modafinil	modafinil	m03010504	NN	B-NP	B-Chemical
interacted	interact	i530602303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
abstinence	abstinence	a123050520	NN	I-NP	O
week	week	w020	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
longer	long	l05206	JJR	B-NP	O
total	total	t0304	JJ	I-NP	O
sleep	sleep	s401	NN	I-NP	O
time	time	t050	NN	I-NP	O
and	and	a530	CC	O	O
shorter	short	s06306	JJR	B-NP	O
REM	REM	r050	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
latency	latency	l030520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
third	third	t063	JJ	I-NP	O
week	week	w020	NN	I-NP	O
of	of	o100	IN	B-PP	O
abstinence	abstinence	a123050520	NN	B-NP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
slow	slow	s400	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
wave	wave	w010	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
total	total	t0304	JJ	B-NP	O
sleep	sleep	s401	NN	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sleep	sleep	s401	VB	B-VP	O
latency	latency	l030520	NN	B-NP	O
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
normalizing	normalize	n0650402052	VBG	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
modafinil	modafinil	m03010504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
participants	participant	p06302010532	NNS	I-NP	O
.	.	.000	.	O	O

Modafinil	Modafinil	m03010504	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
daytime	daytime	d03050	NN	I-NP	O
sleep	sleep	s401	NN	I-NP	O
latency	latency	l030520	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Multiple	Multiple	m0430140	NNP	I-NP	O
Sleep	Sleep	s401	NNP	I-NP	O
Latency	Latency	l030520	NNP	I-NP	O
Test	Test	t023	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
nearly	nearly	n0640	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
subjective	subjective	s012023010	JJ	B-NP	O
daytime	daytime	d03050	NN	I-NP	B-Disease
sleepiness	sleepiness	s4010502	NN	I-NP	I-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Morning	Morning	m065052	NN	B-NP	O
-	-	-000	HYPH	O	O
dosed	dose	d0203	VBN	B-NP	O
modafinil	modafinil	m03010504	NN	I-NP	B-Chemical
promotes	promote	p6050302	VBZ	B-VP	O
nocturnal	nocturnal	n02306504	JJ	B-NP	O
sleep	sleep	s401	NN	I-NP	O
,	,	,000	,	O	O
normalizes	normalize	n065040202	VBZ	B-VP	O
sleep	sleep	s401	NN	B-NP	O
architecture	architecture	a6203023060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
daytime	daytime	d03050	NN	B-NP	B-Disease
sleepiness	sleepiness	s4010502	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
abstinent	abstinent	a12305053	JJ	B-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
users	user	u2062	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
relevant	relevant	r0401053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
dependence	dependence	d010530520	NN	I-NP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
of	of	o100	IN	B-PP	O
transesophageal	transesophageal	t605202010204	JJ	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
:	:	:000	:	O	O
study	study	s3030	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
multidisciplinary	multidisciplinary	m043030201405060	JJ	I-NP	O
hospital	hospital	h0210304	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
TEE	TEE	t000	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
semi	semi	s050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
invasive	invasive	i5102010	JJ	I-NP	O
tool	tool	t040	NN	I-NP	O
broadly	broadly	b60340	RB	B-VP	O
used	use	u203	VBN	I-VP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
utilization	utilization	u304020305	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
sedatives	sedative	s03030102	NNS	B-NP	O
drugs	drug	d602	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
to	to	t000	TO	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
safety	safety	s01030	NN	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
to	to	t000	TO	B-VP	O
analyze	analyze	a504020	VB	I-VP	O
aspects	aspect	a210232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
TEE	TEE	t000	NN	B-NP	O
safety	safety	s01030	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
Midazolan	Midazolan	m03020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MZ	MZ	m200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
Flumazenil	Flumazenil	f405020504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FL	FL	f400	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
event	event	e1053	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
prospective	prospective	p6021023010	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
137	137	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
TEE	TEE	t000	NN	B-NP	O
with	with	w030	IN	B-PP	O
MZ	MZ	m200	NN	B-NP	B-Chemical
associated	associate	a2020303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
moderate	moderate	m0306030	JJ	B-NP	O
sedation	sedation	s030305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
following	following	f04052	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
:	:	:000	:	O	O
complications	complication	c05140203052	NNS	B-NP	O
related	relate	r040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
topical	topical	t010204	JJ	I-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
MZ	MZ	m200	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
and	and	a530	CC	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

Uni	Uni	u500	NNP	B-NP	O
-	-	-000	:	O	O
and	and	a530	CC	O	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
:	:	:000	:	O	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
sex	sex	s020	NN	B-NP	O
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
,	,	,000	,	O	O
myocardiopathy	myocardiopathy	m0206301030	NN	B-NP	B-Disease
(	(	(000	(	O	O
MP	MP	m100	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
mitral	mitral	m03604	JJ	B-NP	B-Disease
regurgitation	regurgitation	r02062030305	NN	I-NP	I-Disease
(	(	(000	(	O	O
MR	MR	m600	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
MZ	MZ	m200	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
65	65	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
16	16	0000	CD	B-NP	O
yrs	yr	y620	NNS	I-NP	O
;	;	;000	:	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
males	male	m0402	NNS	I-NP	O
)	)	)000	)	O	O
finished	finish	f050203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
examination	examination	e205050305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MZ	MZ	m200	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
FL	FL	f400	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
28	28	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
examination	examination	e205050305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
ejection	ejection	e202305	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
(	(	(000	(	O	O
EF	EF	e100	NN	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
and	and	a530	CC	O	O
60	60	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Mild	Mild	m043	JJ	B-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
(	(	(000	(	O	O
SO2	SO2	0000	NN	B-NP	O
<	<	<000	SYM	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
presented	present	p60205303	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
hypoxia	hypoxia	h01020	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
upper	upper	u106	JJ	B-NP	O
airway	airway	a060	NN	I-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
probe	probe	p6010	NN	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
hypoxia	hypoxia	h01020	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
MZ	MZ	m200	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
SAP	SAP	s010	NN	B-NP	O
<	<	<000	SYM	B-NP	O
90mmHg	90mmHg	0000	NN	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
multivariate	multivariate	m0430106030	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
severe	severe	s01060	JJ	B-NP	O
MR	MR	m600	NN	I-NP	B-Disease
,	,	,000	,	O	O
MP	MP	m100	NN	B-NP	B-Disease
(	(	(000	(	O	O
EF	EF	e100	NN	B-NP	O
<	<	<000	SYM	O	O
45	45	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MZ	MZ	m200	NN	B-NP	B-Chemical
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
5mg	5mg	5200	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
EF	EF	e100	NN	I-NP	O
was	be	w020	VBD	B-VP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
with	with	w030	IN	B-PP	O
MP	MP	m100	NN	B-NP	B-Disease
and	and	a530	CC	O	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
MR	MR	m600	NN	I-NP	B-Disease
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
factor	factor	f02306	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
TEE	TEE	t000	NN	B-NP	O
with	with	w030	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
presents	present	p6020532	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
and	and	a530	CC	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
interrupt	interrupt	i5306013	VB	I-VP	O
the	the	t000	DT	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylergonovine	methylergonovine	m03040620501050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intracoronary	intracoronary	i536020605060	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylergonovine	methylergonovine	m03040620501050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
22	22	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
atypical	atypical	a3010204	JJ	B-NP	O
chest	chest	c023	NN	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
others	other	o3062	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
angina	angina	a52050	NN	B-NP	B-Disease
pectoris	pectoris	p0230602	NN	I-NP	I-Disease
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Methylergonovine	Methylergonovine	m03040620501050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
continuously	continuously	c053050240	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	O	O
min	min	m050	NN	B-NP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
50	50	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
,	,	,000	,	O	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
spasm	spasm	s1025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
provoked	provoke	p6010203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
28	28	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
13	13	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SD	SD	s300	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
neither	neither	n0306	CC	O	O
ischemic	ischemic	i20502	JJ	B-NP	O
ST	ST	s300	NN	I-NP	O
change	change	c0520	NN	I-NP	O
nor	nor	n060	CC	O	O
localized	localized	l02040203	JJ	B-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
basal	basal	b0204	JJ	I-NP	O
tone	tone	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasoconstriction	vasoconstriction	v02020523602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
spasm	spasm	s1025	NN	B-NP	B-Disease
provocation	provocation	p601020305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
use	use	u200	VBP	B-VP	O
an	an	a500	DT	B-NP	O
intracoronary	intracoronary	i536020605060	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
relatively	relatively	r040301040	RB	I-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
methylergonovine	methylergonovine	m03040620501050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
vasoreactivity	vasoreactivity	v020602301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
meth	meth	m030	NN	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
"	"	"000	''	O	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

AIM	AIM	a050	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
documentation	documentation	d02050530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
to	to	t000	TO	B-VP	O
make	make	m020	VB	I-VP	O
clinicians	clinician	c40502052	NNS	B-NP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
meth	meth	m030	NN	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
"	"	"000	''	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Methamphetamine	Methamphetamine	m030510305050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
very	very	v060	RB	I-NP	O
addictive	addictive	a3023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
powerful	powerful	p06104	JJ	I-NP	O
stimulant	stimulant	s30504053	NN	I-NP	O
that	that	t030	WDT	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
wakefulness	wakefulness	w020104502	NN	B-NP	O
and	and	a530	CC	O	O
physical	physical	p020204	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
other	other	o306	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
dysrhythmias	dysrhythmia	d026030502	NNS	I-NP	I-Disease
,	,	,000	,	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
hallucinations	hallucination	h04020503052	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
violent	violent	v04053	JJ	B-NP	B-Disease
behavior	behavior	b0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dental	Dental	d05304	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
abusing	abuse	a102052	VBG	B-VP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
present	present	p602053	VB	I-VP	O
with	with	w030	IN	B-PP	O
poor	poor	p060	JJ	B-NP	O
oral	oral	o604	JJ	I-NP	O
hygiene	hygiene	h02050	NN	I-NP	O
,	,	,000	,	O	O
xerostomia	xerostomia	x06023050	NN	B-NP	B-Disease
,	,	,000	,	O	O
rampant	rampant	r051053	JJ	B-NP	O
caries	cary	c0602	NNS	I-NP	B-Disease
(	(	(000	(	O	O
"	"	"000	``	O	O
meth	meth	m030	NN	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
"	"	"000	''	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
excessive	excessive	e202010	JJ	B-NP	O
tooth	tooth	t030	NN	I-NP	B-Disease
wear	wear	w060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
rehabilitation	rehabilitation	r0104030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
challenging	challenging	c04052052	JJ	B-ADJP	O
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
DESCRIPTION	DESCRIPTION	d02601305	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Caucasian	Caucasian	c020205	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
dental	dental	d05304	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
,	,	,000	,	O	O
bad	bad	b030	JJ	B-NP	B-Disease
breath	breath	b6030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
self	self	s041	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
reported	report	r0106303	VBN	B-NP	O
poor	poor	p060	JJ	I-NP	O
esthetics	esthetic	e230302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
comprehensive	comprehensive	c0516052010	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
her	her	h060	PRP$	B-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
panoramic	panoramic	p05060502	JJ	B-NP	O
radiograph	radiograph	r03026010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intraoral	intraoral	i5360604	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
19	19	0000	CD	B-NP	O
carious	carious	c0602	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
very	very	v060	RB	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
adult	adult	a3043	NN	I-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
reported	report	r0106303	VBD	B-VP	O
her	her	h060	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
methamphetamine	methamphetamine	m030510305050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
experienced	experience	e210605203	VBN	I-VP	O
any	any	a500	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
carious	carious	c0602	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	I-Disease
before	before	b01060	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
started	start	s306303	VBD	B-VP	O
using	use	u2052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

SUMMARY	SUMMARY	s05060	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
medical	medical	m030204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
dental	dental	d05304	JJ	I-NP	O
histories	history	h0230602	NNS	I-NP	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
radiographic	radiographic	r030260102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
"	"	"000	``	O	O
meth	meth	m030	NN	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
.	.	.000	.	O	O
"	"	"000	''	O	O
Although	Although	a43020	IN	B-SBAR	O
three	three	t060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
dental	dental	d05304	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
modalities	modality	m03040302	NNS	I-NP	O
(	(	(000	(	O	O
either	either	e0306	CC	O	O
conventional	conventional	c0510530504	JJ	O	O
or	or	o600	CC	O	O
implant	implant	i514053	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
supported	support	s0106303	VBN	I-VP	O
)	)	)000	)	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
offered	offer	o10603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
since	since	s0520	IN	B-PP	O
August	August	a02023	NNP	B-NP	O
2007	2007	0000	CD	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
yet	yet	y030	RB	I-VP	O
to	to	t000	TO	I-VP	O
initiate	initiate	i503030	VB	I-VP	O
any	any	a500	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

CLINICAL	CLINICAL	c4050204	JJ	B-NP	O
SIGNIFICANCE	SIGNIFICANCE	s02501020520	NN	I-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
showing	show	s052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
meth	meth	m030	NN	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
presented	present	p60205303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
help	help	h041	VB	I-VP	O
dental	dental	d05304	JJ	B-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
recognize	recognize	r02025020	VBP	B-VP	O
and	and	a530	CC	I-VP	O
manage	manage	m05020	VBP	I-VP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
abusing	abuse	a102052	VBG	I-VP	O
methamphetamines	methamphetamine	m0305103050502	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Dental	Dental	d05304	JJ	B-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
skeptical	skeptical	s20130204	JJ	B-ADJP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
reliability	reliability	r040104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
appointment	appointment	a10535053	NN	B-NP	O
keeping	keeping	k01052	NN	I-NP	O
by	by	b000	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
frequently	frequently	f60205340	RB	B-ADVP	O
miss	miss	m020	VBP	B-VP	O
their	their	t060	PRP$	B-NP	O
appointments	appointment	a105350532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
reasonable	reasonable	r02050140	JJ	B-NP	O
justification	justification	j02301020305	NN	I-NP	O
.	.	.000	.	O	O

Antituberculosis	Antituberculosis	a530301062040202	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
:	:	:000	:	O	O
magnitude	magnitude	m02503030	NN	B-NP	O
,	,	,000	,	O	O
profile	profile	p601040	NN	B-NP	O
,	,	,000	,	O	O
prognosis	prognosis	p60250202	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
predictors	predictor	p603023062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
outcome	outcome	o032050	NN	B-NP	O
.	.	.000	.	O	O

Antituberculosis	Antituberculosis	a530301062040202	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
ATT	ATT	a300	NN	B-NP	O
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
liver	liver	l0106	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
(	(	(000	(	O	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
commonest	common	c0505023	JJS	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
South	South	s030	NNP	B-NP	O
Asia	Asia	a200	NNP	I-NP	O
.	.	.000	.	O	O

Prospective	Prospective	p6021023010	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
lacking	lack	l02052	VBG	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
,	,	,000	,	O	O
clinical	clinical	c4050204	JJ	B-NP	O
course	course	c0620	NN	I-NP	O
,	,	,000	,	O	O
outcome	outcome	o032050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
prognostic	prognostic	p602502302	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
1986	1986	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
January	January	j05060	NNP	B-NP	O
2009	2009	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
1223	1223	0000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
:	:	:000	:	O	O
ATT	ATT	a300	NN	B-NP	O
alone	alone	a4050	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
70	70	0000	CD	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Another	Another	a50306	DT	B-NP	O
15	15	0000	CD	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
ATT	ATT	a300	NN	B-NP	O
and	and	a530	CC	O	O
simultaneous	simultaneous	s050430502	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
virus	virus	v0602	NN	I-NP	I-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
44	44	0000	CD	B-NP	O
(	(	(000	(	O	O
62	62	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
ATT	ATT	a300	NN	B-NP	O
was	be	w020	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
empirically	empirically	e510602040	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
definitive	definitive	d010503010	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
tuberculosis	tuberculosis	t01062040202	NN	B-NP	B-Disease
.	.	.000	.	O	O

ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	O	O
ALF	ALF	a410	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
younger	young	y05206	JJR	B-ADJP	O
(	(	(000	(	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
87	87	0000	CD	I-NP	O
[	[	[000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
]	]	]000	)	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
49	49	0000	CD	B-NP	O
(	(	(000	(	O	O
70	70	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
women	woman	w0505	NNS	B-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
had	have	h030	VBD	B-VP	O
hyperacute	hyperacute	h010602030	JJ	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
icterus	icterus	i230602	NN	I-NP	B-Disease
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
interval	interval	i5306104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
)	)	)000	)	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ATT	ATT	a300	NN	B-NP	O
before	before	b01060	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
30	30	0000	CD	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
350	350	0000	CD	I-NP	O
)	)	)000	)	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
,	,	,000	,	O	O
advanced	advance	a3105203	VBD	B-VP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
51	51	0000	CD	B-NP	O
(	(	(000	(	O	O
76	76	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
29	29	0000	CD	B-NP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Gastrointestinal	Gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
bleed	bleed	b403	NN	I-NP	I-Disease
,	,	,000	,	O	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
infection	infection	i5102305	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
five	five	f010	CD	B-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
26	26	0000	CD	B-NP	O
(	(	(000	(	O	O
37	37	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
seven	seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
E	E	e000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	O
(	(	(000	(	O	O
HEV	HEV	h010	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
A	A	a000	NN	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
E	E	e000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
,	,	,000	,	O	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	O	O
ALF	ALF	a410	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
nearly	nearly	n0640	RB	B-NP	O
similar	similar	s050406	JJ	I-NP	O
presentations	presentation	p60205303052	NNS	I-NP	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
older	old	o4306	JJR	B-NP	O
age	age	a200	NN	I-NP	O
and	and	a530	CC	O	O
less	less	l020	JJR	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
enzymes	enzyme	e520502	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ALF	ALF	a410	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
high	high	h020	JJ	B-ADJP	O
(	(	(000	(	O	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
47	47	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
only	only	o540	RB	B-NP	O
23	23	0000	CD	I-NP	O
(	(	(000	(	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
recovered	recover	r02010603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
multivariate	multivariate	m0430106030	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
factors	factor	f023062	NNS	I-NP	O
independently	independently	i530105305340	RB	B-ADVP	O
predicted	predict	p60302303	VBD	B-VP	O
mortality	mortality	m06304030	NN	B-NP	O
:	:	:000	:	O	O
serum	serum	s0605	NN	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dL	dL	d400	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
prothrombin	prothrombin	p6030605105	NN	B-NP	O
time	time	t050	NN	I-NP	O
(	(	(000	(	O	O
PT	PT	p300	NN	B-NP	O
)	)	)000	)	O	O
prolongation	prolongation	p6040520305	NN	B-NP	O
(	(	(000	(	O	O
>	>	>000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
26	26	0000	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
grade	grade	g6030	NN	B-NP	O
III	III	i000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
IV	IV	i100	CD	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
ATT	ATT	a300	NN	B-NP	O
-	-	-000	HYPH	O	O
ALF	ALF	a410	NN	B-NP	B-Disease
constituted	constitute	c0523030303	VBN	B-VP	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
ALF	ALF	a410	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
center	center	c05306	NN	I-NP	O
and	and	a530	CC	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
so	so	s000	RB	B-ADJP	O
high	high	h020	JJ	I-ADJP	O
,	,	,000	,	O	O
determining	determine	d0306505052	VBG	B-VP	O
which	which	w020	WDT	B-NP	O
factors	factor	f023062	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
predictors	predictor	p603023062	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
less	less	l020	RBR	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
consumed	consume	c0520503	VBN	I-VP	O
ATT	ATT	a300	NNP	B-NP	O
empirically	empirically	e510602040	RB	B-ADVP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
.	.	.000	.	O	O

Design	Design	d02025	NN	B-NP	O
and	and	a530	CC	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
HYPREN	HYPREN	h01605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
trial	trial	t604	NN	I-NP	O
:	:	:000	:	O	O
safety	safety	s01030	NN	B-NP	O
of	of	o100	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	I-Chemical
enzyme	enzyme	e52050	NN	B-NP	I-Chemical
(	(	(000	(	O	I-Chemical
ACE	ACE	a200	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
inhibitors	inhibitor	i50103062	NNS	B-NP	I-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
adjunctive	adjunctive	a320523010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
congestive	congestive	c052023010	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
occasionally	occasionally	o20205040	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ACE	ACE	a200	NN	I-NP	B-Chemical
inhibitor	inhibitor	i5010306	NN	I-NP	I-Chemical
enalapril	enalapril	e50401604	VBP	B-VP	B-Chemical
a	a	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	NN	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
controlled	control	c05360403	VBN	B-NP	O
trial	trial	t604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
symptomatic	symptomatic	s0513050302	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Trial	Trial	t604	JJ	B-NP	O
medication	medication	m03020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
prazosin	prazosin	p6020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
1210	1210	0000	CD	B-NP	O
inpatients	inpatient	i51030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
New	New	n000	NNP	B-NP	O
York	York	y062	NNP	I-NP	O
Heart	Heart	h063	NNP	I-NP	O
Association	Association	a2020305	NNP	I-NP	O
(	(	(000	(	O	O
NYHA	NYHA	n000	NNP	B-NP	O
)	)	)000	)	O	O
functional	functional	f05230504	JJ	B-NP	O
class	class	c402	NN	I-NP	O
II	II	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
III	III	i000	CD	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
experienced	experience	e210605203	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
statistically	statistically	s30302302040	RB	B-NP	O
significantly	significantly	s025010205340	RB	I-NP	O
less	less	l020	RBR	I-NP	O
symptomatic	symptomatic	s0513050302	JJ	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
therefore	therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
unreasonable	unreasonable	u5602050140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
restrict	restrict	r0236023	VB	I-VP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
inpatients	inpatient	i51030532	NNS	B-NP	O
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
institution	institution	i523030305	NN	I-NP	O
.	.	.000	.	O	O

Central	Central	c053604	JJ	B-NP	B-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
CNS	CNS	c520	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
complications	complication	c05140203052	NNS	B-NP	I-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
childhood	childhood	c04303	NN	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
(	(	(000	(	O	O
ALL	ALL	a400	NN	B-NP	B-Disease
)	)	)000	)	O	O
remain	remain	r0505	VBP	B-VP	O
a	a	a000	DT	B-NP	O
challenging	challenging	c04052052	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
problem	problem	p601405	NN	I-NP	O
.	.	.000	.	O	O

Outcome	Outcome	o032050	DT	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
with	with	w030	IN	B-PP	O
more	more	m060	RBR	B-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
analyzed	analyze	a5040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
ALL	ALL	a400	NN	B-NP	B-Disease
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
institution	institution	i523030305	NN	I-NP	O
,	,	,000	,	O	O
focusing	focus	f0202052	VBG	B-VP	O
on	on	o500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
,	,	,000	,	I-NP	O
radiological	radiological	r0304020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
electrophysiological	electrophysiological	e40236010204020204	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Exclusion	Exclusion	e240205	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
CNS	CNS	c520	NN	B-NP	O
leukemic	leukemic	l020502	JJ	I-NP	B-Disease
infiltration	infiltration	i5104360305	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
,	,	,000	,	O	O
therapy	therapy	t06010	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
late	late	l030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
neurocognitive	neurocognitive	n060202503010	JJ	I-NP	B-Disease
defects	defect	d010232	NNS	I-NP	I-Disease
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
9	9	9000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
retrospectively	retrospectively	r03602102301040	RB	B-ADVP	O
collected	collect	c0402303	VBD	B-VP	O
27	27	0000	CD	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
as	as	a200	RB	B-NP	O
many	many	m050	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
from	from	f605	IN	B-PP	O
253	253	0000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
enrolled	enrol	e560403	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ALL	ALL	a400	NN	I-NP	B-Disease
front	front	f6053	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
line	line	l050	NN	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
.	.	.000	.	O	O

CNS	CNS	c520	NN	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
posterior	posterior	p0230606	JJ	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
temporal	temporal	t0510604	JJ	B-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
epilepsy	epilepsy	e1040120	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
syndrome	syndrome	s0536050	NN	B-NP	O
of	of	o100	IN	B-PP	O
inappropriate	inappropriate	i5016016030	JJ	B-NP	B-Disease
antidiuretic	antidiuretic	a5303060302	JJ	I-NP	I-Disease
hormone	hormone	h065050	NN	I-NP	I-Disease
secretion	secretion	s0260305	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
unclassified	unclassified	u524020103	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
CNS	CNS	c520	NN	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
ALL	ALL	a400	NN	B-NP	B-Disease
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
require	require	r02060	VB	B-VP	O
rapid	rapid	r0103	JJ	B-NP	O
detection	detection	d0302305	NN	I-NP	O
and	and	a530	CC	O	O
prompt	prompt	p60513	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
to	to	t000	TO	B-VP	O
limit	limit	l0503	VB	I-VP	O
permanent	permanent	p06505053	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Cocaine	Cocaine	c02050	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
learning	learning	l065052	NN	I-NP	I-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
:	:	:000	:	O	O
involvement	involvement	i5104105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
nuclear	nuclear	n02406	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
kappa	kappa	k010	NN	I-NP	O
B	B	b000	NN	I-NP	O
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
prevention	prevention	p60105305	NN	B-NP	O
by	by	b000	IN	B-PP	O
topiramate	topiramate	t010605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Different	Different	d0106053	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
including	include	i52403052	VBG	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
induced	induce	i530203	VBN	B-VP	O
-	-	-000	HYPH	B-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
poorly	poorly	p0640	RB	B-ADJP	O
understood	understand	u53062303	VBN	I-ADJP	O
.	.	.000	.	O	O

Nuclear	Nuclear	n02406	JJ	B-NP	O
factor	factor	f02306	NN	I-NP	O
kappa	kappa	k010	NN	I-NP	O
B	B	b000	NN	I-NP	O
(	(	(000	(	O	O
NFkappaB	NFkappaB	n120101	NN	B-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
sensor	sensor	s05206	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	O	O
participates	participate	p06302010302	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
addiction	addiction	a302305	NN	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-NP	O
NFkappaB	NFkappaB	n120101	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
,	,	,000	,	O	O
neuronal	neuronal	n060504	JJ	B-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
nNOS	nNOS	n502	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
,	,	,000	,	O	O
spatial	spatial	s10304	JJ	B-NP	O
learning	learning	l065052	NN	I-NP	O
and	and	a530	CC	I-NP	O
memory	memory	m05060	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
topiramate	topiramate	t010605030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
proposed	propose	p6010203	VBN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Disease
addiction	addiction	a302305	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

NFkappaB	NFkappaB	n120101	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frontal	frontal	f605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
GSH	GSH	g200	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
peroxidase	peroxidase	p060203020	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
nNOS	nNOS	n502	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hippocampus	hippocampus	h010205102	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

Memory	Memory	m05060	NN	B-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
of	of	o100	IN	B-PP	O
experiences	experience	e210605202	NNS	B-NP	O
acquired	acquire	a20603	VBN	B-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-ADJP	O
and	and	a530	CC	O	O
negatively	negatively	n020301040	RB	B-VP	O
correlated	correlate	c06040303	VBD	I-VP	O
with	with	w030	IN	B-PP	O
NFkappaB	NFkappaB	n120101	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frontal	frontal	f605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
learning	learn	l065052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
tasks	task	t020	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
and	and	a530	CC	O	O
correlated	correlate	c06040303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
of	of	o100	IN	B-PP	O
nNOS	nNOS	n502	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
peroxidase	peroxidase	p060203020	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
mechanistic	mechanistic	m020502302	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
nitrosative	nitrosative	n0360203010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
and	and	a530	CC	I-NP	O
NFkappaB	NFkappaB	n120101	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Topiramate	Topiramate	t010605030	NN	B-NP	B-Chemical
prevented	prevent	p60105303	VBD	B-VP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
novel	novel	n0104	JJ	B-NP	O
neuroprotective	neuroprotective	n0601603023010	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Efficacy	Efficacy	e102020	NN	B-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
trial	trial	t604	NN	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
exacerbation	exacerbation	e2020610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Asenapine	Asenapine	a20501050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
approved	approve	a160103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Food	Food	f030	NNP	I-NP	O
and	and	a530	CC	I-NP	O
Drugs	Drugs	d602	NNP	I-NP	O
Administration	Administration	a350502360305	NNP	I-NP	O
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
for	for	f060	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
schizophrenia	schizophrenia	s2020106050	NN	B-NP	B-Disease
or	or	o600	CC	B-PP	O
of	of	o100	IN	B-PP	O
manic	manic	m0502	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	O
mixed	mixed	m0203	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
I	I	i000	NN	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
features	feature	f030602	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
458	458	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
schizophrenia	schizophrenia	s2020106050	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
fixed	fix	f0203	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	O	O
(	(	(000	(	O	O
BID	BID	b030	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
,	,	,000	,	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
(	(	(000	(	O	O
to	to	t000	TO	B-VP	O
verify	verify	v06010	VB	I-VP	O
assay	assay	a200	NN	B-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
last	last	l023	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
carried	carry	c0603	VBD	B-VP	O
forward	forward	f06063	JJ	B-ADJP	O
(	(	(000	(	O	O
LOCF	LOCF	l021	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
Positive	Positive	p0203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
Negative	Negative	n0203010	JJ	I-NP	O
Syndrome	Syndrome	s0536050	NN	I-NP	O
Scale	Scale	s2040	NN	I-NP	O
total	total	t0304	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
to	to	t000	TO	B-VP	O
endpoint	endpoint	e531053	VB	I-VP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
16	16	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
;	;	;000	:	O	O
both	both	b030	CC	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
using	use	u2052	VBG	B-VP	O
mixed	mix	m0203	VBN	B-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
measures	measure	m020602	NNS	I-NP	O
(	(	(000	(	O	O
MMRM	MMRM	m565	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
changes	change	c05202	NNS	B-NP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
42	42	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
21	21	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
-	-	-000	SYM	B-NP	O
19	19	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
20	20	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
14	14	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
;	;	;000	:	O	O
all	all	a400	DT	B-NP	O
P	P	p000	NN	I-NP	O
<	<	<000	JJR	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Positive	Positive	p0203010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
Negative	Negative	n0203010	JJ	I-NP	O
Syndrome	Syndrome	s0536050	NN	I-NP	O
Scale	Scale	s2040	NN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
subscale	subscale	s012040	NN	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
with	with	w030	IN	B-PP	O
LOCF	LOCF	l021	NN	B-NP	O
and	and	a530	CC	I-NP	O
MMRM	MMRM	m565	NN	I-NP	O
;	;	;000	:	O	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
superior	superior	s010606	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
placebo	placebo	p402010	VB	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
subscale	subscale	s012040	NN	I-NP	O
with	with	w030	IN	B-PP	O
MMRM	MMRM	m565	NN	B-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
general	general	g050604	JJ	I-NP	O
psychopathology	psychopathology	p202010304020	NN	I-NP	O
subscale	subscale	s012040	NN	I-NP	O
with	with	w030	IN	B-PP	O
LOCF	LOCF	l021	NN	B-NP	O
and	and	a530	CC	I-NP	O
MMRM	MMRM	m565	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
(	(	(000	(	O	O
AEs	AE	a020	NNS	B-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
44	44	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
52	52	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
57	57	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
asenapine	asenapine	a20501050	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
reported	report	r0106303	VBN	B-VP	O
as	as	a200	IN	B-SBAR	O
AEs	AE	a020	NNS	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
34	34	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
asenapine	asenapine	a20501050	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
5	5	5000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
BID	BID	b030	NN	I-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Across	Across	a2602	IN	B-PP	O
all	all	a400	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
more	more	m060	JJR	I-NP	O
than	than	t050	IN	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
had	have	h030	VBD	B-VP	O
clinically	clinically	c40502040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
change	change	c0520	NN	I-NP	O
.	.	.000	.	O	O

Post	Post	p023	JJ	B-NP	O
hoc	hoc	h020	NN	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
efficacy	efficacy	e102020	NN	B-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
asenapine	asenapine	a20501050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
;	;	;000	:	O	O
greater	great	g60306	JJR	B-NP	O
contrasts	contrast	c05360232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
AEs	AE	a020	NNS	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Salvage	Salvage	s041020	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
nelarabine	nelarabine	n040601050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
relapsed	relapse	r0401203	VBN	B-NP	O
/	/	/000	SYM	I-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
paediatric	paediatric	p0303602	JJ	I-NP	O
T	T	t000	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukaemia	leukaemia	l02050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
d	d	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
nelarabine	nelarabine	n040601050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AraG	AraG	a602	NN	B-NP	B-Chemical
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	O
d	d	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VP	VP	v100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CPM	CPM	c150	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
prophylactic	prophylactic	p6010402302	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
salvage	salvage	s041020	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
or	or	o600	CC	I-NP	O
relapsed	relapse	r0401203	VBN	I-NP	O
T	T	t000	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
leukaemia	leukaemia	l02050	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
AraG	AraG	a602	NN	I-NP	B-Chemical
included	include	i5240303	VBD	B-VP	O
Grade	Grade	g6030	NN	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
sensory	sensory	s052060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
motor	motor	m0306	NN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
musculoskeletal	musculoskeletal	m020402040304	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Haematological	Haematological	h050304020204	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
than	than	t050	IN	B-PP	O
AraG	AraG	a602	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
median	median	m0305	JJ	B-NP	O
time	time	t050	NN	I-NP	O
to	to	t000	TO	B-PP	O
neutrophil	neutrophil	n0360104	NN	B-NP	O
and	and	a530	CC	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
salvage	salvage	s041020	NN	I-NP	O
therapies	therapy	t060102	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
seven	seven	s0105	CD	I-NP	O
went	go	w053	VBD	B-VP	O
into	into	i530	IN	B-PP	O
complete	complete	c0514030	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
two	two	t000	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AraG	AraG	a602	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
VP	VP	v100	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
CPM	CPM	c150	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
AraG	AraG	a602	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
salvage	salvage	s041020	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
synchrony	synchrony	s05206050	NN	B-NP	O
with	with	w030	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
closely	closely	c402040	RB	I-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
whole	whole	w040	JJ	B-NP	O
body	body	b030	NN	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

Thermal	Thermal	t06504	JJ	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
normal	normal	n06504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
whole	whole	w040	JJ	B-NP	O
body	body	b030	NN	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
F344	F344	0000	NN	I-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Antitumor	Antitumor	a53030506	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
growth	growth	g6030	NN	I-NP	O
delay	delay	d040	NN	I-NP	O
assay	assay	a200	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
normal	normal	n06504	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
leukopenia	leukopenia	l0201050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
)	)	)000	)	O	O
and	and	a530	CC	O	O
late	late	l030	JJ	B-NP	O
normal	normal	n06504	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
(	(	(000	(	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
e	e	e000	NN	I-NP	O
.	.	.000	.	O	O
,	,	,000	,	O	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
injury	injury	i52060	NN	I-NP	I-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
/	/	/000	SYM	I-NP	O
physiological	physiological	p0204020204	JJ	I-NP	O
assays	assay	a202	NNS	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
morphological	morphological	m06104020204	JJ	B-NP	O
techniques	technique	t02050202	NNS	I-NP	O
.	.	.000	.	O	O

Whole	Whole	w040	JJ	B-NP	O
body	body	b030	NN	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
(	(	(000	(	O	O
120	120	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
41	41	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
C	C	c000	NN	I-NP	O
)	)	)000	)	O	O
enhanced	enhance	e505203	VBD	B-VP	O
both	both	b030	CC	O	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
toxic	toxic	t0202	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
thermal	thermal	t06504	JJ	I-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
antitumor	antitumor	a53030506	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	O	O

Thermal	Thermal	t06504	JJ	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
ratios	ratio	r0302	NNS	I-NP	O
estimated	estimate	e23050303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
"	"	"000	``	B-NP	O
acute	acute	a2030	JJ	I-NP	O
"	"	"000	''	I-NP	O
hematological	hematological	h050304020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
those	those	t020	DT	B-NP	O
estimated	estimate	e23050303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
"	"	"000	``	O	O
late	late	l030	JJ	B-NP	O
"	"	"000	''	I-NP	O
damage	damage	d05020	NN	I-NP	O
(	(	(000	(	O	O
based	base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
morphological	morphological	m06104020204	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
)	)	)000	)	O	O
varied	vary	v0603	VBD	B-VP	O
between	between	b0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
whole	whole	w040	JJ	B-NP	O
body	body	b030	NN	I-NP	O
hyperthermia	hyperthermia	h010630650	NN	I-NP	B-Disease
enhances	enhance	e505202	VBZ	B-VP	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-NP	O
antitumor	antitumor	a53030506	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
gain	gain	g050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
modality	modality	m0304030	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
eroded	erode	e60303	VBN	I-VP	O
.	.	.000	.	O	O

Permeability	Permeability	p0650104030	NN	B-NP	O
,	,	,000	,	O	O
ultrastructural	ultrastructural	u43602360230604	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
distribution	distribution	d0236010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
novel	novel	n0104	JJ	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
in	in	i500	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
/	/	/000	SYM	I-NP	O
AIMS	AIMS	a052	NNS	I-NP	O
:	:	:000	:	O	O
It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-ADJP	O
what	what	w030	WP	B-NP	O
happens	happen	h01052	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerulus	glomerulus	g405060402	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
starts	start	s30632	VBZ	B-VP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	O
)	)	)000	)	O	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
early	early	e0640	RB	B-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
relation	relation	r040305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
podocyte	podocyte	p0302030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
molecules	molecule	m04020402	NNS	I-NP	O
nephrin	nephrin	n010605	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
actinin	actinin	a230505	NN	I-NP	O
,	,	,000	,	O	O
dendrin	dendrin	d053605	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
plekhh2	plekhh2	0000	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
two	two	t000	CD	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
only	only	o540	RB	B-VP	O
recently	recently	r0205340	RB	I-VP	O
discovered	discover	d02010603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
podocytes	podocyte	p03020302	NNS	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Using	Use	u2052	VBG	B-VP	O
immune	immune	i5050	JJ	B-NP	O
stainings	staining	s305052	NNS	I-NP	O
,	,	,000	,	O	O
semiquantitative	semiquantitative	s05020530303010	JJ	B-NP	O
measurement	measurement	m020605053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
electron	electron	e4023605	NN	I-NP	O
microscope	microscope	m02602010	NN	I-NP	O
.	.	.000	.	O	O

Permeability	Permeability	p0650104030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
isolated	isolate	i2040303	VBN	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
perfusion	perfusion	p0610205	NN	I-NP	O
with	with	w030	IN	B-PP	O
tracers	tracer	t602062	NNS	B-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ACE	ACE	a200	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
By	By	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
some	some	s050	DT	B-NP	O
patchy	patchy	p0320	JJ	I-NP	O
foot	foot	f030	NN	I-NP	O
process	process	p60202	NN	I-NP	O
effacement	effacement	e10205053	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
,	,	,000	,	O	O
appeared	appear	a10603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrin	nephrin	n010605	NN	B-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
diseased	diseased	d020203	JJ	I-NP	O
and	and	a530	CC	I-NP	O
normal	normal	n06504	JJ	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
few	few	f000	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
limited	limit	l050303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
diseased	diseased	d020203	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
foot	foot	f030	NN	B-NP	O
process	process	p60202	NN	I-NP	O
effacement	effacement	e10205053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
complete	complete	c0514030	JJ	B-ADJP	O
and	and	a530	CC	O	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
parallel	parallel	p060404	NN	B-NP	O
with	with	w030	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
size	size	s020	NN	B-NP	O
barrier	barrier	b0606	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Nephrin	Nephrin	n010605	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
further	further	f06306	RBR	B-ADVP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
dendrin	dendrin	d053605	NN	B-NP	O
and	and	a530	CC	I-NP	O
plekhh2	plekhh2	0000	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
but	but	b030	CC	O	O
a	a	a000	DT	O	O
-	-	-000	:	O	O
actinin	actinin	a230505	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

ACE	ACE	a200	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
PAN	PAN	p050	NN	B-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
already	already	a46030	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
pathology	pathology	p0304020	NN	I-NP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
mild	mild	m043	JJ	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
altered	alter	a430603	VBN	B-NP	O
nephrin	nephrin	n010605	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
,	,	,000	,	O	O
supporting	support	s01063052	VBG	B-VP	O
its	its	i320	PRP$	B-NP	O
pivotal	pivotal	p010304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
podocyte	podocyte	p0302030	NN	B-NP	O
morphology	morphology	m06104020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
dendrin	dendrin	d053605	NN	I-NP	O
and	and	a530	CC	I-NP	O
plekhh2	plekhh2	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
both	both	b030	DT	O	O
reduced	reduce	r030203	VBN	B-VP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
roles	role	r0402	NNS	B-NP	O
in	in	i500	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
a	a	a000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
actinin	actinin	a230505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
,	,	,000	,	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
symptom	symptom	s051305	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
obsessive	obsessive	o1202010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Current	Current	c06053	JJ	B-NP	O
animal	animal	a50504	NN	I-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
obsessive	obsessive	o1202010	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
OCD	OCD	o230	NN	B-NP	B-Disease
)	)	)000	)	O	O
typically	typically	t0102040	RB	B-ADVP	O
involve	involve	i510410	VBP	B-VP	O
acute	acute	a2030	JJ	B-NP	O
,	,	,000	,	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
symptom	symptom	s051305	NN	I-NP	O
provocation	provocation	p601020305	NN	I-NP	O
or	or	o600	CC	O	O
a	a	a000	DT	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
stereotypies	stereotypy	s306030102	NNS	B-NP	O
or	or	o600	CC	O	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
models	model	m03042	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
multiple	multiple	m0430140	JJ	B-NP	O
OCD	OCD	o230	NNP	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Neonatal	Neonatal	n050304	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
tricyclic	tricyclic	t60202402	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
clomipramine	clomipramine	c40501605050	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
between	between	b0305	IN	B-PP	O
days	day	d020	NNS	B-NP	O
9	9	9000	CD	B-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
twice	twice	t020	RB	I-NP	O
daily	daily	d040	RB	I-NP	O
and	and	a530	CC	O	O
behaviorally	behaviorally	b0106040	RB	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
adulthood	adulthood	a304303	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Clomipramine	Clomipramine	c40501605050	NN	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
in	in	i500	IN	B-PP	O
immature	immature	i503060	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
include	include	i524030	VBP	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
anxiety	anxiety	a52030	NN	B-NP	B-Disease
(	(	(000	(	O	O
elevated	elevate	e4010303	VBN	B-VP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
and	and	a530	CC	I-NP	O
marble	marble	m06140	NN	I-NP	O
burying	burying	b06052	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
behavioral	behavioral	b010604	JJ	B-NP	B-Disease
inflexibility	inflexibility	i514020104030	NN	I-NP	I-Disease
(	(	(000	(	O	O
perseveration	perseveration	p06201060305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
alternation	alternation	a430650305	NN	I-NP	O
task	task	t020	NN	I-NP	O
and	and	a530	CC	O	O
impaired	impaired	i510603	JJ	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
learning	learning	l065052	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
working	work	w062052	VBG	B-VP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
(	(	(000	(	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
g	g	g000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
win	win	w050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
shift	shift	s013	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
hoarding	hoard	h063052	VBG	B-VP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
corticostriatal	corticostriatal	c0630202360304	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dopamine	Dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
2C	2C	2000	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
1A	1A	1000	NN	I-NP	O
,	,	,000	,	O	O
receptors	receptor	r02013062	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
orbital	orbital	o610304	JJ	I-NP	O
frontal	frontal	f605304	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
demonstration	demonstration	d05052360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
OCD	OCD	o230	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
behaviors	behavior	b01062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
regions	region	r02052	NNS	I-NP	O
previously	previously	p6010240	RB	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
as	as	a200	IN	B-PP	O
relevant	relevant	r0401053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
OCD	OCD	o230	NNP	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
OCD	OCD	o230	NN	B-NP	B-Disease
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
drug	drug	d602	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
a	a	a000	DT	B-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
can	can	c050	MD	B-VP	O
program	program	p602605	VB	I-VP	O
disease	disease	d02020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
like	like	l020	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
permanently	permanently	p0650505340	RB	B-ADVP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
have	have	h010	VB	I-VP	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
current	current	c06053	JJ	B-NP	O
and	and	a530	CC	I-NP	O
future	future	f03060	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
psychiatric	psychiatric	p20203602	JJ	I-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Elevation	Elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ADAM10	ADAM10	0000	NN	B-NP	O
,	,	,000	,	O	O
ADAM17	ADAM17	0000	NN	B-NP	O
,	,	,000	,	O	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
MMP	MMP	m510	NN	I-NP	O
-	-	-000	HYPH	O	O
9	9	9000	CD	B-NP	O
expression	expression	e2160205	NN	I-NP	O
with	with	w030	IN	B-PP	O
media	medium	m030	NNS	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
features	feature	f030602	VBZ	B-VP	O
CaCl2	CaCl2	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
thoracic	thoracic	t060202	JJ	I-NP	B-Disease
aortic	aortic	a06302	JJ	I-NP	I-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
establish	establish	e23014020	VB	I-VP	O
a	a	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
thoracic	thoracic	t060202	JJ	B-NP	B-Disease
aortic	aortic	a06302	JJ	I-NP	I-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
(	(	(000	(	O	O
TAA	TAA	t000	NN	B-NP	B-Disease
)	)	)000	)	O	O
by	by	b000	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
arterial	arterial	a630604	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
explore	explore	e214060	VB	I-VP	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
disintegrin	disintegrin	d0205302605	NN	I-NP	O
and	and	a530	CC	I-NP	O
metalloproteinase	metalloproteinase	m03040160305020	NN	I-NP	O
(	(	(000	(	O	O
ADAM	ADAM	a305	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
matrix	matrix	m03602	NN	B-NP	O
metalloproteinases	metalloproteinas	m030401603050202	NNS	I-NP	O
(	(	(000	(	O	O
MMPs	MMP	m512	NNS	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
(	(	(000	(	O	O
TIMPs	TIMP	t0512	NNS	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
TAA	TAA	t000	NN	B-NP	B-Disease
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Thoracic	Thoracic	t060202	JJ	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
of	of	o100	IN	B-PP	O
male	male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5M	5M	5000	NN	B-NP	O
CaCl	CaCl	c024	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
or	or	o600	CC	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
NaCl	NaCl	n024	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
12weeks	12week	0000	NNS	B-NP	O
,	,	,000	,	O	O
animals	animal	a505042	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
euthanized	euthanize	e03050203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
,	,	,000	,	O	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	O	O
untreated	untreated	u5360303	JJ	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
NaCl	NaCl	n024	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
treated	treat	t60303	VBN	B-NP	O
aortic	aortic	a06302	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
assessments	assessment	a20250532	NNS	I-NP	O
.	.	.000	.	O	O

MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
TIMP	TIMP	t051	NN	I-NP	O
and	and	a530	CC	I-NP	O
ADAM	ADAM	a305	NN	I-NP	O
mRNAs	mRNA	m6502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
semi	semi	s050	AFX	O	O
-	-	-000	HYPH	O	O
quantitatively	quantitatively	q053030301040	RB	B-VP	O
analyzed	analyze	a5040203	VBN	I-VP	O
and	and	a530	CC	O	O
protein	protein	p60305	NN	B-NP	O
expressions	expression	e21602052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Despite	Despite	d021030	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
external	external	e2306504	JJ	I-NP	O
diameters	diameter	d0503062	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
,	,	,000	,	O	O
non	non	n050	AFX	O	O
-	-	-000	HYPH	O	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	B-VP	O
and	and	a530	CC	O	O
NaCl	NaCl	n024	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
,	,	,000	,	O	O
aneurymal	aneurymal	a5060504	JJ	B-NP	O
alteration	alteration	a43060305	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
media	medium	m030	NNS	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
with	with	w030	IN	B-PP	O
regional	regional	r020504	JJ	B-NP	O
disruption	disruption	d02601305	NN	I-NP	O
,	,	,000	,	O	O
fragmentation	fragmentation	f60250530305	NN	B-NP	O
of	of	o100	IN	B-PP	O
elastic	elastic	e402302	JJ	B-NP	O
fiber	fiber	f0106	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
collagen	collagen	c040205	NN	B-NP	O
deposition	deposition	d01020305	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
ADAM	ADAM	a305	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
ADAM	ADAM	a305	NN	I-NP	O
-	-	-000	HYPH	O	O
17	17	0000	CD	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	JJR	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
trends	trend	t60532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
elevation	elevation	e4010305	NN	B-NP	O
in	in	i500	IN	B-PP	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
NaCl	NaCl	n024	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

Immunohistochemistry	Immunohistochemistry	i505023020502360	NN	B-NP	O
displayed	display	d021403	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
expressions	expression	e21602052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
ADAM	ADAM	a305	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
ADAM	ADAM	a305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
all	all	a400	DT	B-NP	O
p	p	p000	NN	I-NP	O
<	<	<000	JJR	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
intima	intima	i53050	NNS	B-NP	O
and	and	a530	CC	I-NP	O
media	medium	m030	NNS	I-NP	O
for	for	f060	IN	B-PP	O
CaCl	CaCl	c024	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

TIMP	TIMP	t051	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
and	and	a530	CC	I-NP	O
tissue	tissue	t020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
obviously	obviously	o10240	RB	B-ADVP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
aortic	aortic	a06302	JJ	I-NP	O
segments	segment	s0250532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
establishes	establish	e230140202	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
TAA	TAA	t000	NN	I-NP	B-Disease
model	model	m0304	NN	I-NP	O
by	by	b000	IN	B-PP	O
periarterial	periarterial	p060630604	JJ	B-NP	O
CaCl	CaCl	c024	NN	I-NP	B-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
exposure	exposure	e2102060	NN	B-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
expression	expression	e2160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
MMP	MMP	m510	NN	B-NP	O
-	-	-000	HYPH	O	O
9	9	9000	CD	B-NP	O
,	,	,000	,	O	O
ADAM10	ADAM10	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
ADAM17	ADAM17	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
remodeling	remodeling	r050304052	NN	I-NP	O
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
causes	cause	c0202	VBZ	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
pseudocholinesterase	pseudocholinesterase	p20302040502306020	NN	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
gets	get	g032	VBZ	B-VP	O
deactivated	deactivate	d023010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
organophosphorus	organophosphorus	o6205010210602	NN	B-NP	B-Chemical
(	(	(000	(	O	I-Chemical
OP	OP	o100	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
poisons	poison	p02052	NNS	B-NP	I-Chemical
.	.	.000	.	O	O

Here	Here	h060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
incident	incident	i5203053	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
severely	severely	s0106040	RB	I-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
ECT	ECT	e230	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
ensued	ensue	e5203	VBD	B-VP	O
because	because	b02020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
information	information	i510650305	NN	I-NP	O
about	about	a103	IN	B-PP	O
suicidal	suicidal	s020304	JJ	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
by	by	b000	IN	B-PP	O
OP	OP	o100	NN	B-NP	B-Chemical
compound	compound	c051053	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
concealed	conceal	c0520403	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
treating	treat	t603052	VBG	I-NP	O
team	team	t050	NN	I-NP	O
.	.	.000	.	O	O

Curcumin	Curcumin	c0620505	NN	B-NP	B-Chemical
ameliorates	ameliorate	a504060302	VBZ	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	I-NP	O
phenobarbitone	phenobarbitone	p050106103050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
well	well	w040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	B-VP	O
cause	cause	c020	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
on	on	o500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
free	free	f600	JJ	B-NP	O
radical	radical	r030204	NN	I-NP	O
generation	generation	g05060305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
antiepileptic	antiepileptic	a53010401302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Curcumin	Curcumin	c0620505	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
antioxidant	antioxidant	a530203053	JJ	B-ADJP	O
,	,	,000	,	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	O	O
inflammatory	inflammatory	i5140503060	JJ	B-ADJP	O
and	and	a530	CC	O	O
neuro	neuro	n060	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
protective	protective	p603023010	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
curcumin	curcumin	c0620505	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
on	on	o500	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
curcumin	curcumin	c0620505	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

Vehicle	Vehicle	v0240	NN	B-NP	O
/	/	/000	SYM	I-NP	O
drugs	drug	d602	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
daily	daily	d040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
21days	21day	0000	NNS	B-NP	O
to	to	t000	TO	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Passive	Passive	p02010	JJ	B-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
and	and	a530	CC	O	O
elevated	elevate	e4010303	VBN	B-VP	O
plus	plus	p402	CC	O	O
maze	maze	m020	NN	B-NP	O
test	test	t023	NN	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
phenobarbitone	phenobarbitone	p050106103050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
whole	whole	w040	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
malondialdehyde	malondialdehyde	m04053043030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
reduced	reduce	r030203	VBN	B-NP	O
glutathione	glutathione	g40303050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
21days	21day	0000	NNS	B-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
impairment	impairment	i51065053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
learning	learning	l065052	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
.	.	.000	.	O	O

Concomitant	Concomitant	c0520503053	JJ	B-NP	O
curcumin	curcumin	c0620505	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
prevented	prevent	p60105303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
oxidative	oxidative	o20303010	JJ	I-NP	O
stress	stress	s3602	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
these	these	t020	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Curcumin	Curcumin	c0620505	NN	B-NP	B-Chemical
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
administration	administration	a350502360305	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
any	any	a500	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
alteration	alteration	a43060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
phenobarbitone	phenobarbitone	p050106103050	NN	I-NP	B-Chemical
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
curcumin	curcumin	c0620505	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
mitigating	mitigate	m030203052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
cognitive	cognitive	c02503010	JJ	B-NP	I-Disease
functions	function	f0523052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
oxidative	oxidative	o20303010	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
without	without	w0303	IN	B-PP	O
significantly	significantly	s025010205340	RB	B-VP	O
altering	alter	a4306052	VBG	I-VP	O
their	their	t060	PRP$	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
curcumin	curcumin	c0620505	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
safe	safe	s010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
adjuvant	adjuvant	a3201053	JJ	I-NP	O
to	to	t000	TO	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Can	Can	c050	MD	O	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
be	be	b000	VB	B-VP	O
a	a	a000	DT	B-NP	O
target	target	t06203	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
associated	associated	a2020303	JJ	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
?	?	?000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
/	/	/000	SYM	I-NP	O
AIMS	AIMS	a052	NNS	I-NP	O
:	:	:000	:	O	O
Recently	Recently	r0205340	RB	B-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
sunitinib	sunitinib	s05030501	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
sorafenib	sorafenib	s06010501	NN	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
,	,	,000	,	O	O
haptoglobin	haptoglobin	h0130240105	NN	B-NP	O
and	and	a530	CC	O	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
soluble	soluble	s040140	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
are	be	a600	VBP	B-VP	O
modifiable	modifiable	m03010140	JJ	B-ADJP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
help	help	h041	VB	I-VP	O
in	in	i500	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
strategies	strategy	s36030202	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Fourteen	Fourteen	f06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
chronically	chronically	c060502040	RB	B-VP	B-Disease
infected	infect	i5102303	VBN	I-VP	I-Disease
with	with	w030	IN	B-PP	I-Disease
hepatitis	hepatitis	h01030302	NN	B-NP	I-Disease
C	C	c000	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
alpha	alpha	a410	NN	I-NP	I-Chemical
2a	2a	2000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Serum	Serum	s0605	NN	B-NP	O
hemoglobin	hemoglobin	h050240105	NN	I-NP	O
,	,	,000	,	O	O
haptoglobin	haptoglobin	h0130240105	NN	B-NP	O
and	and	a530	CC	I-NP	O
angiogenesis	angiogenesis	a5202050202	NN	I-NP	O
markers	marker	m062062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vascular	vascular	v020406	JJ	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
and	and	a530	CC	I-NP	O
angiopoetin	angiopoetin	a52010305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
2	2	2000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
haptoglobin	haptoglobin	h0130240105	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Hemoglobin	Hemoglobin	h050240105	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
but	but	b030	CC	O	O
insignificantly	insignificantly	i52025010205340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
pegylated	pegylate	p02040303	VBN	B-NP	B-Chemical
interferon	interferon	i530610605	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
soluble	soluble	s040140	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
or	or	o600	CC	I-NP	O
haptoglobin	haptoglobin	h0130240105	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
investigating	investigate	i510230203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
link	link	l052	NN	I-NP	O
between	between	b0305	IN	B-PP	O
angiogenesis	angiogenesis	a5202050202	NN	B-NP	O
soluble	soluble	s040140	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
and	and	a530	CC	I-NP	O
ribavirin	ribavirin	r01010605	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
C	C	c000	NN	I-NP	I-Disease
and	and	a530	CC	O	O
we	we	w000	PRP	B-NP	O
could	could	c043	MD	B-VP	O
not	not	n030	RB	I-VP	O
find	find	f053	VB	I-VP	O
any	any	a500	DT	B-NP	O
relation	relation	r040305	NN	I-NP	O
.	.	.000	.	O	O

Future	Future	f03060	JJ	B-NP	O
research	research	r020620	NN	I-NP	O
with	with	w030	IN	B-PP	O
larger	large	l06206	JJR	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
needed	need	n0303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
find	find	f053	VB	I-VP	O
out	out	o030	RP	B-PRT	O
modifiable	modifiable	m03010140	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
will	will	w040	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
using	use	u2052	VBG	B-VP	O
buffered	buffer	b010603	VBN	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
before	before	b01060	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
reports	report	r010632	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
pain	pain	p050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
acidic	acidic	a20302	JJ	I-NP	O
pH	pH	p000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
solution	solution	s040305	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
buffering	buffering	b0106052	NN	I-NP	O
solution	solution	s040305	NN	I-NP	O
to	to	t000	TO	B-VP	O
adjust	adjust	a32023	VB	I-VP	O
the	the	t000	DT	B-NP	O
pH	pH	p000	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
physiologic	physiologic	p02040202	JJ	I-NP	O
range	range	r0520	NN	I-NP	O
would	would	w043	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
blinded	blind	b405303	VBN	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
asked	ask	a203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
quantify	quantify	q053010	VB	I-VP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
standard	standard	s3053063	JJ	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
femoral	femoral	f050604	JJ	I-NP	O
area	area	a600	NN	I-NP	O
and	and	a530	CC	O	O
buffered	buffer	b010603	VBN	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
opposite	opposite	o102030	JJ	I-NP	O
femoral	femoral	f050604	JJ	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
buffered	buffer	b010603	VBN	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
score	score	s2060	NN	I-NP	O
for	for	f060	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pH	pH	p000	NN	I-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
of	of	o100	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
accomplished	accomplish	a205140203	VBN	I-VP	O
easily	easily	e02040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
before	before	b01060	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
and	and	a530	CC	O	O
results	result	r020432	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
occurring	occur	o206052	VBG	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
infiltration	infiltration	i5104360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tissues	tissue	t0202	NNS	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
glyceryl	glyceryl	g4020604	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
phosphorylcholine	phosphorylcholine	p0210604204050	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
to	to	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
glycerylphosphorylcholine	glycerylphosphorylcholine	g402060410210604204050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
GFC	GFC	g120	NN	B-NP	I-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
young	young	y052	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
four	four	f060	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
ten	ten	t050	CD	I-NP	O
day	day	d000	NN	I-NP	O
pretreatment	pretreatment	p6036035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
alpha	alpha	a410	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
GFC	GFC	g120	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
.	.	.000	.	O	O
o	o	o000	NN	B-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
eleventh	eleventh	e4010530	JJ	I-NP	O
day	day	d000	NN	I-NP	O
either	either	e0306	CC	O	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-ADVP	O
and	and	a530	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
attention	attention	a305305	NN	B-NP	O
and	and	a530	CC	O	O
mnemonic	mnemonic	m5050502	JJ	B-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
impairment	impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
attention	attention	a305305	NN	B-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
memory	memory	m05060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
of	of	o100	IN	B-PP	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
review	review	r010	NN	I-NP	O
.	.	.000	.	O	O

IMPORTANCE	IMPORTANCE	i510630520	NN	B-NP	O
OF	OF	o100	IN	B-PP	O
THE	THE	t000	DT	B-NP	O
FIELD	FIELD	f043	NN	I-NP	O
:	:	:000	:	O	O
Fluoropyrimidines	Fluoropyrimidine	f406010605030502	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
mainstay	mainstay	m05230	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
solid	solid	s0403	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
colorectal	colorectal	c040602304	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
breast	breast	b6023	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
head	head	h030	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
>	>	>000	JJR	B-NP	O
40	40	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

AREAS	AREAS	a602	NNP	B-NP	O
COVERED	COVERED	c010603	NNP	I-NP	O
IN	IN	i500	NNP	I-NP	O
THIS	THIS	t020	NNP	I-NP	O
REVIEW	REVIEW	r010	NNP	I-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
reviews	review	r0102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
special	special	s10204	JJ	I-NP	O
emphasis	emphasis	e510202	NN	I-NP	O
on	on	o500	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
safety	safety	s01030	NN	I-NP	O
.	.	.000	.	O	O

WHAT	WHAT	w030	WDT	B-NP	O
THE	THE	t000	DT	B-NP	O
READER	READER	r0306	NN	I-NP	O
WILL	WILL	w040	NN	I-NP	O
GAIN	GAIN	g050	NN	I-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
reader	reader	r0306	NN	I-NP	O
will	will	w040	MD	B-VP	O
gain	gain	g050	VB	I-VP	O
better	good	b0306	JJR	B-NP	O
insight	insight	i520203	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
special	special	s10204	JJ	B-NP	O
populations	population	p010403052	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advanced	a3105203	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
explore	explore	e214060	VBP	B-VP	O
different	different	d0106053	JJ	B-NP	O
dosing	dosing	d02052	NN	I-NP	O
and	and	a530	CC	O	O
schedules	schedule	s2030402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

TAKE	TAKE	t020	NN	B-NP	O
HOME	HOME	h050	NN	I-NP	O
MESSAGE	MESSAGE	m02020	NN	I-NP	O
:	:	:000	:	O	O
Capecitabine	Capecitabine	c01020301050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
prodrug	prodrug	p603602	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
fulfill	fulfill	f04104	VB	I-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
convenient	convenient	c05105053	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
provide	provide	p601030	VBP	B-VP	O
an	an	a500	DT	B-NP	O
improved	improve	i5160103	VBN	I-NP	O
safety	safety	s01030	NN	I-NP	O
/	/	/000	SYM	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
shown	show	s050	VBN	I-VP	O
promising	promising	p60502052	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
colorectal	colorectal	c040602304	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
breast	breast	b6023	NN	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
pancreaticobiliary	pancreaticobiliary	p052603020104060	JJ	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
gastric	gastric	g023602	JJ	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
head	head	h030	NN	B-NP	I-Disease
and	and	a530	CC	O	I-Disease
neck	neck	n020	NN	B-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
commonly	commonly	c050540	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
capecitabine	capecitabine	c01020301050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
diarrhea	diarrhea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
vomiting	vomiting	v0503052	NN	B-NP	B-Disease
,	,	,000	,	O	O
stomatitis	stomatitis	s305030302	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
hand	hand	h053	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
foot	foot	f030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Capecitabine	Capecitabine	c01020301050	NNP	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
established	establish	e230140203	VBN	I-NP	O
safety	safety	s01030	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
and	and	a530	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
safely	safely	s01040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advanced	a3105203	JJ	B-NP	O
age	age	a200	NN	I-NP	O
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
filling	fill	f04052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
bench	bench	b0520	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
bedside	bedside	b032030	NN	I-NP	O
gap	gap	g010	NN	I-NP	O
.	.	.000	.	O	O

Levodopa	Levodopa	l0103010	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
precursor	precursor	p60206206	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
complicated	complicate	c0514020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
highly	highly	h02040	RB	B-VP	O
disabling	disable	d02014052	VBG	I-VP	O
fluctuations	fluctuation	f402303052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
preclinical	preclinical	p6024050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
pulsatile	pulsatile	p04203040	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
striatal	striatal	s360304	JJ	B-NP	O
postsynaptic	postsynaptic	p02320501302	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
key	key	k000	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
levodopa	levodopa	l0103010	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
,	,	,000	,	O	O
their	their	t060	PRP$	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unclear	unclear	u52406	JJ	B-ADJP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
evidence	evidence	e1030520	NN	B-NP	O
from	from	f605	IN	B-PP	O
animal	animal	a50504	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
provided	provide	p6010303	VBN	I-VP	O
important	important	i51063053	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
to	to	t000	TO	B-VP	O
understand	understand	u530623053	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
and	and	a530	CC	O	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
underlying	underlie	u53064052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
dyskinetic	dyskinetic	d02050302	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Recent	Recent	r02053	JJ	B-NP	O
preclinical	preclinical	p6024050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
from	from	f605	IN	B-PP	O
promising	promising	p60502052	JJ	B-NP	O
lines	line	l0502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
research	research	r020620	NN	B-NP	O
focus	focus	f0202	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
presynaptic	presynaptic	p6020501302	JJ	B-NP	O
versus	versus	v06202	IN	B-PP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
,	,	,000	,	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
,	,	,000	,	O	O
ionotropic	ionotropic	i050360102	JJ	B-NP	O
and	and	a530	CC	I-NP	O
metabotropic	metabotropic	m03010360102	JJ	I-NP	O
glutamate	glutamate	g40305030	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
neurotransmitter	neurotransmitter	n0603605250306	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
pallidal	pallidal	p040304	JJ	B-NP	O
neurotensin	neurotensin	n060305205	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
catalepsy	catalepsy	c03040120	NN	I-NP	I-Disease
:	:	:000	:	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
plays	play	p402	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
movement	movement	m0105053	NN	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
receives	receive	r020102	VBZ	B-VP	O
neurotensinergic	neurotensinergic	n06030520506202	JJ	B-NP	O
innervation	innervation	i50610305	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
systemic	systemic	s0230502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
neurotensin	neurotensin	n060305205	NN	I-NP	B-Chemical
analog	analog	a50402	NN	I-NP	O
could	could	c043	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pallidal	pallidal	p040304	JJ	B-NP	O
neurotensin	neurotensin	n060305205	NN	I-NP	B-Chemical
on	on	o500	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Behavioral	Behavioral	b010604	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
and	and	a530	CC	O	O
electrophysiological	electrophysiological	e40236010204020204	JJ	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Bilateral	Bilateral	b04030604	JJ	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neurotensin	neurotensin	n060305205	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
globus	globus	g40102	NN	I-NP	O
pallidus	pallidus	p040302	NN	I-NP	O
reversed	reverse	r0106203	VBD	B-VP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
catalepsy	catalepsy	c03040120	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Electrophysiological	Electrophysiological	e40236010204020204	JJ	B-NP	O
recordings	recording	r02063052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
microinjection	microinjection	m02605202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
neurotensin	neurotensin	n060305205	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
excitation	excitation	e2030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pallidal	pallidal	p040304	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
neurotensin	neurotensin	n060305205	NN	I-NP	B-Chemical
type	type	t010	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	I-Chemical
SR48692	SR48692	0000	NN	I-NP	B-Chemical
blocked	block	b40203	VBD	B-VP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
behavioral	behavioral	b010604	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
electrophysiological	electrophysiological	e40236010204020204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
neurotensin	neurotensin	n060305205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Activation	Activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
pallidal	pallidal	p040304	JJ	B-NP	O
neurotensin	neurotensin	n060305205	NN	I-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
neurotensin	neurotensin	n060305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
antiparkinsonian	antiparkinsonian	a53010620520505	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Carmofur	Carmofur	c0650106	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
organic	organic	o620502	JJ	I-NP	B-Disease
mental	mental	m05304	JJ	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Organic	Organic	o620502	JJ	B-NP	B-Disease
mental	mental	m05304	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
29	29	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
female	female	f05040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prognostic	prognostic	p602502302	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
carmofur	carmofur	c0650106	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Symptoms	Symptom	s0513052	NNS	B-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
euphoria	euphoria	e01060	NN	B-NP	O
,	,	,000	,	O	O
emotional	emotional	e5030504	JJ	B-NP	O
lability	lability	l0104030	NN	I-NP	O
and	and	a530	CC	O	O
puerile	puerile	p06040	JJ	B-NP	O
attitude	attitude	a303030	NN	I-NP	O
noted	note	n0303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
organic	organic	o620502	JJ	B-NP	B-Disease
personality	personality	p0620504030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
defined	define	d010503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
DSM	DSM	d250	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
III	III	i000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
R	R	r000	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
frontal	frontal	f605304	JJ	I-NP	B-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
CT	CT	c300	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
periventricular	periventricular	p06010536020406	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
density	density	d052030	NN	I-NP	O
area	area	a600	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
frontal	frontal	f605304	JJ	I-NP	O
white	white	w030	JJ	I-NP	O
matter	matter	m0306	NN	I-NP	O
and	and	a530	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
dilatation	dilatation	d04030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
ventricles	ventricle	v053602402	NNS	I-NP	O
especially	especially	e2102040	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
anterior	anterior	a530606	JJ	I-NP	O
horns	horn	h0652	NNS	I-NP	O
.	.	.000	.	O	O

Consequently	Consequently	c0520205340	RB	B-ADVP	O
,	,	,000	,	O	O
carmofur	carmofur	c0650106	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
leukoencephalopathy	leukoencephalopathy	l02052010401030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
uncommonly	uncommonly	u52050540	RB	I-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
organic	organic	o620502	JJ	B-NP	B-Disease
personality	personality	p0620504030	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
residual	residual	r020304	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
frontal	frontal	f605304	JJ	I-NP	I-Disease
lobe	lobe	l010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Butyrylcholinesterase	Butyrylcholinesterase	b0306042040502306020	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
mutations	mutation	m0303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
apnea	apnea	a150	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
electroconvulsive	electroconvulsive	e4023602051042010	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
ECT	ECT	e230	NN	B-NP	O
)	)	)000	)	O	O
often	often	o1305	RB	B-ADVP	O
receive	receive	r02010	VBP	B-VP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
part	part	p063	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
prolonged	prolong	p60405203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
variants	variant	v060532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
butyrylcholinesterase	butyrylcholinesterase	b0306042040502306020	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
(	(	(000	(	O	O
BChE	BChE	b200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
K	K	k000	NN	I-NP	O
-	-	-000	HYPH	B-ADJP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
variants	variant	v060532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
significance	significance	s02501020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
genetic	genetic	g050302	JJ	B-NP	O
variants	variant	v060532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
butyrylcholinesterase	butyrylcholinesterase	b0306042040502306020	NN	B-NP	O
gene	gene	g050	NN	I-NP	O
(	(	(000	(	O	O
BCHE	BCHE	b200	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
suspected	suspect	s02102303	VBN	I-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
ECT	ECT	e230	NN	B-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
referred	refer	r010603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
Danish	Danish	d05020	NNP	I-NP	O
Cholinesterase	Cholinesterase	c040502306020	NNP	I-NP	O
Research	Research	r020620	NNP	I-NP	O
Unit	Unit	u503	NNP	I-NP	O
after	after	a1306	IN	B-PP	O
ECT	ECT	e230	NN	B-NP	O
during	during	d06052	IN	B-PP	O
38	38	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
determined	determine	d030650503	VBD	B-VP	O
the	the	t000	DT	B-NP	O
BChE	BChE	b200	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
BCHE	BCHE	b200	NN	I-NP	O
genotype	genotype	g0503010	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
molecular	molecular	m04020406	JJ	B-NP	O
genetic	genetic	g050302	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apnea	apnea	a150	NN	B-NP	B-Disease
,	,	,000	,	O	O
time	time	t050	NN	B-NP	O
to	to	t000	TO	B-PP	O
sufficient	sufficient	s0102053	JJ	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
and	and	a530	CC	O	O
whether	whether	w0306	IN	B-SBAR	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apnea	apnea	a150	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
published	publish	p0140203	VBN	B-NP	O
data	datum	d030	NNS	I-NP	O
on	on	o500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
mutations	mutation	m0303052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BCHE	BCHE	b200	NN	I-NP	O
gene	gene	g050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
K	K	k000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
variant	variant	v06053	NN	I-NP	O
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
apnea	apnea	a150	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
min	min	m050	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
distress	distress	d023602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Neuromuscular	Neuromuscular	n0605020406	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
eleven	eleven	e40105	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
succinylcholine	succinylcholine	s020504204050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
mutations	mutation	m0303052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
BCHE	BCHE	b200	NN	B-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
reason	reason	r0205	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
apnea	apnea	a150	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
recommend	recommend	r0205053	VBP	B-VP	O
objective	objective	o12023010	JJ	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
ECT	ECT	e230	NN	I-NP	O
.	.	.000	.	O	O

Perhexiline	Perhexiline	p060204050	NN	B-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
noted	note	n0303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
perhexiline	perhexiline	p060204050	NN	B-NP	B-Chemical
maleate	maleate	m04030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
widely	widely	w03040	RB	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
France	France	f60520	NNP	B-NP	O
(	(	(000	(	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
trials	trial	t6042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
prophylactic	prophylactic	p6010402302	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
angina	angina	a52050	NN	B-NP	B-Disease
pectoris	pectoris	p0230602	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
slowing	slowing	s4052	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
velocity	velocity	v0402030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
electromyographic	electromyographic	e40236050260102	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
imply	imply	i5140	VBP	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
demyelinating	demyelinate	d05040503052	VBG	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
denervation	denervation	d050610305	NN	I-NP	O
signified	signify	s0250103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
only	only	o540	RB	B-NP	O
slight	slight	s40203	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
causing	cause	c02052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
yet	yet	y030	RB	B-VP	O
fully	fully	f040	RB	I-VP	O
known	know	k505	VBN	I-VP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
some	some	s050	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
storage	storage	s306020	NN	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	B-Chemical
'	'	'000	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
0	0	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydropyranyladriamycin	tetrahydropyranyladriamycin	t03603601060504036050205	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
pharmacology	pharmacology	p0650204020	NN	I-NP	O
and	and	a530	CC	I-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Phase	Phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
(	(	(000	(	O	O
IV	IV	i100	CD	O	O
)	)	)000	)	O	O
bolus	bolus	b0402	NN	B-NP	O
4	4	4000	CD	I-NP	B-Chemical
'	'	'000	SYM	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
0	0	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydropyranyladriamycin	tetrahydropyranyladriamycin	t03603601060504036050205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Pirarubicin	Pirarubicin	p0606010205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
55	55	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
good	good	g030	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
with	with	w030	IN	B-PP	O
refractory	refractory	r016023060	JJ	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
had	have	h030	VBD	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
prior	prior	p606	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
good	good	g030	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
prior	prior	p606	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
poor	poor	p060	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
had	have	h030	VBD	B-VP	O
renal	renal	r0504	JJ	B-ADJP	B-Disease
and	and	a530	CC	O	I-Disease
/	/	/000	SYM	B-NP	I-Disease
or	or	o600	CC	O	I-Disease
hepatic	hepatic	h010302	JJ	B-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
167	167	0000	CD	B-NP	O
courses	course	c06202	NNS	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
70	70	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
m2	m2	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

Maximum	Maximum	m020505	JJ	B-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
in	in	i500	IN	B-PP	O
good	good	g030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
70	70	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
poor	poor	p060	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
toxic	toxic	t0202	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
noncumulative	noncumulative	n052050403010	JJ	I-NP	O
granulocytopenia	granulocytopenia	g60504020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Granulocyte	Granulocyte	g6050402030	NN	B-NP	O
nadir	nadir	n0306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
14	14	0000	CD	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
22	22	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Less	Less	l020	RBR	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
included	include	i5240303	VBD	B-VP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
,	,	,000	,	O	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
mild	mild	m043	JJ	B-NP	O
alopecia	alopecia	a401020	NN	I-NP	B-Disease
,	,	,000	,	O	O
phlebitis	phlebitis	p04010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
mucositis	mucositis	m02020302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Myelosuppression	Myelosuppression	m04020160205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
more	more	m060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
21	21	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
Pirarubicin	Pirarubicin	p0606010205	NN	B-NP	B-Chemical
plasma	plasma	p40250	NN	I-NP	O
T	T	t000	NN	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
alpha	alpha	a410	SYM	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	B-NP	O
SE	SE	s000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
85	85	0000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
T	T	t000	NN	B-NP	O
beta	beta	b030	SYM	I-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
of	of	o100	IN	B-PP	O
25	25	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
T	T	t000	NN	B-NP	O
1	1	1000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
gamma	gamma	g050	NN	I-NP	O
of	of	o100	IN	B-PP	O
23	23	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
curve	curve	c0610	NN	I-NP	O
was	be	w020	VBD	B-VP	O
537	537	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
149	149	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
x	x	x000	SYM	I-NP	O
hours	hour	h062	NNS	I-NP	O
,	,	,000	,	O	O
volume	volume	v04050	NN	B-NP	O
of	of	o100	IN	B-PP	O
distribution	distribution	d0236010305	NN	B-NP	O
(	(	(000	(	O	O
Vd	Vd	v300	NN	B-NP	O
)	)	)000	)	O	O
3504	3504	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
644	644	0000	CD	B-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
clearance	clearance	c4060520	NN	I-NP	O
(	(	(000	(	O	O
ClT	ClT	c430	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
204	204	0000	CD	B-NP	O
+	+	+000	SYM	I-NP	O
39	39	0000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
l	l	l000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
hour	hour	h060	NN	I-NP	O
/	/	/000	SYM	I-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

Adriamycinol	Adriamycinol	a3605020504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
adriamycinone	adriamycinone	a36050205050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
tetrahydropyranyladriamycinol	tetrahydropyranyladriamycinol	t0360360106050403605020504	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
detected	detect	d0302303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
doxorubicin	doxorubicin	d0206010205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
.	.	.000	.	O	O

Urinary	Urinary	u605060	JJ	B-NP	O
excretion	excretion	e260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Pirarubicin	Pirarubicin	p0606010205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
24	24	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Activity	Activity	a2301030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mesothelioma	mesothelioma	m020304050	NN	B-NP	B-Disease
,	,	,000	,	O	O
leiomyosarcoma	leiomyosarcoma	l0502062050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
basal	basal	b0204	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
starting	starting	s3063052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
for	for	f060	IN	B-PP	O
Phase	Phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
trials	trial	t6042	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
every	every	e1060	DT	B-NP	O
3	3	3000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Ocular	Ocular	o20406	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
auditory	auditory	a0303060	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
hemodialyzed	hemodialyze	h0503040203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
an	an	a500	DT	B-NP	O
18	18	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
study	study	s3030	NN	B-NP	O
41	41	0000	CD	I-NP	O
hemodialyzed	hemodialyze	h0503040203	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
BW	BW	b000	NN	I-NP	O
/	/	/000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
weekly	weekly	w0240	RB	B-ADVP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
monitored	monitor	m05030603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
detection	detection	d0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
audiovisual	audiovisual	a03010204	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
auditory	auditory	a0303060	JJ	I-NP	I-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
detailed	detail	d030403	VBD	B-VP	O
ophthalmologic	ophthalmologic	o103045040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
audiologic	audiologic	a03040202	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
disclosed	disclose	d0240203	VBD	B-VP	O
abnormalities	abnormality	a15065040302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
more	more	m060	JJR	I-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
of	of	o100	IN	B-PP	O
retinal	retinal	r030504	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
tritan	tritan	t60305	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
dyschromatopsy	dyschromatopsy	d020605030120	NN	I-NP	B-Disease
,	,	,000	,	O	O
sometimes	sometimes	s05030502	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
visual	visual	v0204	JJ	B-NP	I-Disease
acuity	acuity	a2030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
pigmentary	pigmentary	p025053060	JJ	B-NP	B-Disease
retinal	retinal	r030504	JJ	I-NP	I-Disease
deposits	deposit	d0102032	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Auditory	Auditory	a0303060	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
mid	mid	m030	NN	I-NP	O
-	-	-000	HYPH	B-ADVP	O
to	to	t000	TO	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
neurosensorial	neurosensorial	n06020520604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
lesion	lesion	l0205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cochlear	cochlear	c020406	JJ	I-NP	O
type	type	t010	NN	I-NP	O
.	.	.000	.	O	O

Desferrioxamine	Desferrioxamine	d021060205050	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
partial	partial	p06304	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
partial	partial	p06304	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
coincided	coincide	c0520303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
normalization	normalization	n06504020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ferritin	ferritin	f060305	NN	B-NP	O
or	or	o600	CC	I-NP	O
aluminium	aluminium	a4050505	NN	I-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
audiovisual	audiovisual	a03010204	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
an	an	a500	DT	B-NP	O
infrequent	infrequent	i51602053	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemodialyzed	hemodialyze	h0503040203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
desferrioxamine	desferrioxamine	d021060205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Periodical	Periodical	p06030204	JJ	B-NP	O
audiovisual	audiovisual	a03010204	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
hemodialyzed	hemodialyze	h0503040203	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
as	as	a200	RB	B-ADVP	O
early	early	e0640	RB	I-ADVP	O
as	as	a200	IN	B-PP	O
possible	possible	p020140	JJ	B-ADJP	O
.	.	.000	.	O	O

Serial	Serial	s0604	JJ	B-NP	O
epilepsy	epilepsy	e1040120	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
/	/	/000	SYM	O	I-Chemical
carbidopa	carbidopa	c06103010	NN	B-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
similar	similar	s050406	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
:	:	:000	:	O	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
hemodialysis	hemodialysis	h0503040202	NN	B-NP	O
for	for	f060	IN	B-PP	O
many	many	m050	JJ	B-NP	O
years	year	y062	NNS	I-NP	O
but	but	b030	CC	O	O
recently	recently	r0205340	RB	B-VP	O
begun	begin	b0205	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
flux	flux	f402	NN	I-NP	O
dialyzer	dialyzer	d040206	NN	I-NP	O
;	;	;000	:	O	O
both	both	b030	DT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
receiving	receive	r0201052	VBG	I-VP	O
a	a	a000	DT	B-NP	O
carbidopa	carbidopa	c06103010	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	I-Chemical
levodopa	levodopa	l0103010	NN	I-NP	I-Chemical
preparation	preparation	p601060305	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
had	have	h030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
hallucinosis	hallucinosis	h0402050202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
recurrent	recurrent	r0206053	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
refractory	refractory	r016023060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
anticonvulsants	anticonvulsant	a53020510420532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
died	die	d030	VBD	B-VP	O
without	without	w0303	IN	B-PP	O
a	a	a000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dramatic	dramatic	d6050302	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
B6	B6	0000	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Neither	Neither	n0306	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
sufficiently	sufficiently	s010205340	RB	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
enough	enough	e5020	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
explain	explain	e21405	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
.	.	.000	.	O	O

Randomized	Randomize	r053050203	VBN	B-VP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
Duchenne	Duchenne	d02050	NNP	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
growth	growth	g6030	NN	B-NP	O
hormone	hormone	h065050	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
weakness	weakness	w02502	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
Duchenne	Duchenne	d02050	NNP	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conducted	conduct	c05302303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
12	12	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
controlled	control	c05360403	VBD	B-VP	O
trial	trial	t604	NN	B-NP	O
of	of	o100	IN	B-PP	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
putative	putative	p0303010	JJ	I-NP	O
growth	growth	g6030	NN	I-NP	O
hormone	hormone	h065050	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
83	83	0000	CD	B-NP	O
boys	boy	b020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Duchenne	Duchenne	d02050	JJ	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Muscle	Muscle	m0240	NN	B-NP	O
strength	strength	s3605230	NN	I-NP	O
,	,	,000	,	O	O
contractures	contracture	c05360230602	NNS	B-NP	O
,	,	,000	,	O	O
functional	functional	f05230504	JJ	B-NP	O
ability	ability	a104030	NN	I-NP	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
power	power	p060	NN	I-NP	O
of	of	o100	IN	B-PP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
90	90	0000	CD	I-NP	O
to	to	t000	TO	B-VP	O
detect	detect	d03023	VB	I-VP	O
a	a	a000	DT	B-NP	O
slowing	slowing	s4052	NN	I-NP	O
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
expected	expect	e2102303	VBN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
weakness	weakness	w02502	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
.	.	.000	.	O	O

Mazindol	Mazindol	m0205304	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
benefit	benefit	b050103	VB	I-VP	O
strength	strength	s3605230	NN	B-NP	O
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
point	point	p053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
included	include	i5240303	VBD	B-VP	O
decreased	decrease	d0260203	VBN	B-NP	B-Disease
appetite	appetite	a103030	NN	I-NP	I-Disease
(	(	(000	(	O	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
dry	dry	d600	JJ	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
behavioral	behavioral	b010604	JJ	B-NP	O
change	change	c0520	NN	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
dosage	dosage	d02020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
GH	GH	g000	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
indirectly	indirectly	i530602340	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
comparing	compare	c05106052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
postabsorptive	postabsorptive	p0230120613010	JJ	I-NP	O
IGF	IGF	i210	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
I	I	i000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
following	follow	f04052	VBG	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
12	12	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mazindol	mazindol	m0205304	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
mazindol	mazindol	m0205304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
gained	gain	g0503	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	I-NP	O
height	height	h0203	NN	I-NP	O
than	than	t050	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
IGF	IGF	i210	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Mazindol	Mazindol	m0205304	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
not	not	n030	RB	O	O
slow	slow	s400	VB	B-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
weakness	weakness	w02502	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
Duchenne	Duchenne	d02050	NNP	B-NP	B-Disease
dystrophy	dystrophy	d0236010	NN	I-NP	I-Disease
.	.	.000	.	O	O

Facilitation	Facilitation	f0204030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
by	by	b000	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
state	state	s3030	NN	I-NP	O
dependency	dependency	d010530520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
step	step	s301	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
through	through	t06020	IN	B-PP	O
type	type	t010	NN	B-NP	O
passive	passive	p02010	JJ	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
learning	learn	l065052	VBG	B-VP	O
test	test	t023	NN	B-NP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

Amnesia	Amnesia	a5020	NN	B-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cycloheximide	cycloheximide	c0240205030	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
(	(	(000	(	O	O
pre	pre	p600	AFX	O	O
-	-	-000	HYPH	O	O
test	test	t023	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
facilitated	facilitate	f0204030303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
memory	memory	m05060	NN	I-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
training	training	t605052	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Similarly	Similarly	s05040640	RB	B-ADVP	O
,	,	,000	,	O	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
partially	partially	p063040	RB	B-ADVP	O
reversed	reverse	r0106203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADVP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
cycloheximide	cycloheximide	c0240205030	NN	I-NP	B-Chemical
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
cycloheximide	cycloheximide	c0240205030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
facilitation	facilitation	f0204030305	NN	I-NP	O
of	of	o100	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
retrieval	retrieval	r0360104	NN	I-NP	O
by	by	b000	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
test	test	t023	NN	I-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
a	a	a000	DT	B-NP	O
state	state	s3030	NN	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
reverses	reverse	r0106202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
unanesthetized	unanesthetized	u505023030203	JJ	B-NP	O
,	,	,000	,	I-NP	O
spontaneously	spontaneously	s1053050240	RB	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
or	or	o600	CC	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nalozone	nalozone	n0402050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
partially	partially	p063040	RB	I-VP	O
reversed	reverse	r0106203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Naloxone	Naloxone	n0402050	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
either	either	e0306	CC	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
or	or	o600	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
membranes	membrane	m05160502	NNS	I-NP	O
from	from	f605	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
stereoselective	stereoselective	s3060204023010	JJ	B-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
naloxone	naloxone	n0402050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
4	4	4000	CD	O	O
)	)	)000	)	O	O
M	M	m000	NN	B-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
suppressible	suppressible	s016020140	JJ	I-NP	O
binding	binding	b053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dihydroergocryptine	dihydroergocryptine	d036062026013050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
nM	nM	n500	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
spontaneously	spontaneously	s1053050240	RB	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoceptor	adrenoceptor	a36050201306	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
involve	involve	i510410	VBP	B-VP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
opiate	opiate	o1030	JJ	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
naloxone	naloxone	n0402050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
clonidine	clonidine	c40503050	NN	I-NP	B-Chemical
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
interact	interact	i5306023	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
site	site	s030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
functional	functional	f05230504	JJ	I-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
endogenous	endogenous	e53020502	JJ	I-NP	O
opiate	opiate	o1030	NN	I-NP	O
by	by	b000	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
alpha	alpha	a410	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
methyldopa	methyldopa	m03043010	NN	B-NP	I-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
opiate	opiate	o1030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
tone	tone	t050	NN	I-NP	O
.	.	.000	.	O	O

Neurotoxicity	Neurotoxicity	n06030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
halogenated	halogenate	h0402050303	VBN	B-NP	B-Chemical
hydroxyquinolines	hydroxyquinoline	h036020205040502	NNS	I-NP	I-Chemical
:	:	:000	:	O	O
clinical	clinical	c4050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
reported	report	r0106303	VBN	B-VP	O
outside	outside	o032030	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
220	220	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
halogenated	halogenate	h0402050303	VBN	B-NP	B-Chemical
hydroxyquinolines	hydroxyquinoline	h036020205040502	NNS	I-NP	I-Chemical
reported	report	r0106303	VBN	B-VP	O
from	from	f605	IN	B-PP	O
outside	outside	o032030	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
80	80	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
insufficient	insufficient	i520102053	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
adequate	adequate	a302030	JJ	B-NP	O
comment	comment	c05053	NN	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
29	29	0000	CD	B-NP	O
a	a	a000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
clioquinol	clioquinol	c4020504	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
remainder	remainder	r0505306	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
clioquinol	clioquinol	c4020504	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
probable	probable	p6010140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
42	42	0000	CD	B-NP	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
69	69	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
usually	usually	u2040	RB	B-ADVP	O
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clioquinol	clioquinol	c4020504	NN	B-NP	B-Chemical
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
,	,	,000	,	O	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
further	further	f06306	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
isolated	isolate	i2040303	VBN	I-VP	O
optic	optic	o1302	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
most	most	m023	RBS	I-VP	O
frequently	frequently	f60205340	RB	I-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
,	,	,000	,	O	O
many	many	m050	DT	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
clioquinol	clioquinol	c4020504	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
acrodermatitis	acrodermatitis	a2603065030302	NN	B-NP	B-Disease
enteropathica	enteropathica	e53060103020	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
myelopathy	myelopathy	m0401030	JJ	B-NP	B-Disease
,	,	,000	,	I-NP	O
visual	visual	v0204	JJ	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
.	.	.000	.	O	O

Isolated	Isolate	i2040303	VBN	B-NP	O
myelopathy	myelopathy	m0401030	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
or	or	o600	CC	O	O
these	these	t020	DT	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
occurring	occur	o206052	VBG	B-VP	O
together	together	t020306	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
infrequent	infrequent	i51602053	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
(	(	(000	(	O	O
except	except	e2013	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
subacute	subacute	s0102030	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
partial	partial	p06304	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

Older	Old	o4306	JJR	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
display	display	d02140	VB	I-VP	O
more	more	m060	RBR	B-NP	O
side	side	s030	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
full	full	f040	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
of	of	o100	IN	B-PP	O
subacute	subacute	s0102030	JJ	B-NP	O
myelo	myelo	m040	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
optic	optic	o1302	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
they	they	t000	PRP	B-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
taken	take	t0205	VBN	I-VP	O
greater	great	g60306	JJR	B-NP	O
quantities	quantity	q0530302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Prazosin	Prazosin	p6020205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
stress	stress	s3602	NN	I-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
genuine	genuine	g05050	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

Prazosin	Prazosin	p6020205	NN	B-NP	B-Chemical
exerts	exert	e20632	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
through	through	t06020	IN	B-PP	O
vasodilatation	vasodilatation	v020304030305	NN	B-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
selective	selective	s04023010	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocker	blocker	b40206	NN	B-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
exerts	exert	e20632	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
relaxant	relaxant	r0402053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
neck	neck	n020	NN	I-NP	O
and	and	a530	CC	I-NP	O
urethra	urethra	u603060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
course	course	c0620	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
and	and	a530	CC	I-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
initial	initial	i50304	JJ	B-NP	O
urodynamic	urodynamic	u603050502	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
on	on	o500	IN	B-PP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
incontinence	incontinence	i52053050520	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
continence	continence	c053050520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
maximum	maximum	m020505	JJ	B-NP	O
urethral	urethral	u6030604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
maximum	maximum	m020505	JJ	B-NP	O
urethral	urethral	u6030604	JJ	I-NP	O
closure	closure	c402060	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	O
urethral	urethral	u6030604	JJ	I-NP	O
length	length	l05230	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
present	present	p602053	VBP	B-VP	O
with	with	w030	IN	B-PP	O
stress	stress	s3602	NN	B-NP	B-Disease
incontinence	incontinence	i52053050520	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
prazosin	prazosin	p6020205	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
change	change	c0520	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
before	before	b01060	IN	B-PP	O
considering	consider	c0520306052	VBG	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
incontinence	incontinence	i52053050520	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
resolve	resolve	r020410	VB	I-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
sublingual	sublingual	s01405204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isosorbide	isosorbide	i202061030	NN	B-NP	B-Chemical
dinitrate	dinitrate	d05036030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
78	78	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
old	old	o430	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
healed	heal	h0403	VBN	B-NP	O
septal	septal	s01304	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
suffered	suffer	s010603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
recurrent	recurrent	r0206053	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anterior	anterior	a530606	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isosorbide	isosorbide	i202061030	NN	B-NP	B-Chemical
dinitrate	dinitrate	d05036030	NN	I-NP	I-Chemical
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
sublingually	sublingually	s014052040	RB	B-ADVP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
detailing	detail	d0304052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
discuss	discuss	d0202	VBP	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
paradoxical	paradoxical	p0603020204	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
mediated	mediate	m030303	VBN	B-VP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
downstream	downstream	d0523605	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	B-Disease
arterial	arterial	a630604	JJ	I-NP	I-Disease
stenosis	stenosis	s3050202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
coronary	coronary	c0605060	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
regional	regional	r020504	JJ	B-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
by	by	b000	IN	B-PP	O
extradural	extradural	e236030604	JJ	B-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
apnoea	apnoea	a150	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
73	73	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
extradural	extradural	e236030604	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
192	192	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
24	24	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
period	period	p0603	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
upper	upper	u106	JJ	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

Monitoring	Monitoring	m050306052	NNP	B-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
airflow	airflow	a06140	NN	B-NP	O
detection	detection	d0302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
carbon	carbon	c06105	NN	I-NP	B-Chemical
dioxide	dioxide	d02030	NN	I-NP	I-Chemical
analyser	analyser	a5040206	NN	I-NP	O
,	,	,000	,	O	O
chest	chest	c023	NN	B-NP	O
wall	wall	w040	NN	I-NP	O
movement	movement	m0105053	NN	I-NP	O
detected	detect	d0302303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pneumatic	pneumatic	p5050302	JJ	B-NP	O
capsules	capsule	c0120402	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
continuous	continuous	c0530502	JJ	B-NP	O
electrocardiograph	electrocardiograph	e4023602063026010	NN	I-NP	O
recorded	record	r0206303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
Holter	Holter	h04306	NNP	I-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
monitor	monitor	m050306	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
obstructive	obstructive	o1236023010	JJ	O	B-Disease
(	(	(000	(	O	I-Disease
P	P	p000	NN	B-NP	I-Disease
less	less	l020	JJR	B-NP	I-Disease
than	than	t050	IN	I-NP	I-Disease
0	0	0000	CD	I-NP	I-Disease
.	.	.000	.	I-NP	I-Disease
05	05	0000	CD	I-NP	I-Disease
)	)	)000	)	O	I-Disease
and	and	a530	CC	O	I-Disease
central	central	c053604	JJ	B-NP	I-Disease
apnoea	apnoea	a150	NN	I-NP	I-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
ectopic	ectopic	e230102	JJ	I-NP	I-Disease
beats	beat	b032	NNS	I-NP	I-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
morphine	morphine	m061050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
threshold	threshold	t0602043	NN	I-NP	O
for	for	f060	IN	B-PP	O
initiating	initiate	i50303052	VBG	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
additive	additive	a303010	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
precipitating	precipitate	p602010303052	VBG	B-VP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
only	only	o540	RB	I-VP	O
recently	recently	r0205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
emphasized	emphasize	e51020203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
threshold	threshold	t0602043	NN	I-NP	O
during	during	d06052	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
acid	acid	a203	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
base	base	b020	NN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
anesthetized	anesthetize	a5023030203	VBN	B-NP	O
open	open	o105	JJ	I-NP	O
chest	chest	c023	NN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
threshold	threshold	t0602043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
by	by	b000	IN	B-PP	O
passing	pass	p02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
gated	gate	g0303	VBN	I-NP	O
train	train	t605	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
constant	constant	c0523053	JJ	I-NP	O
current	current	c06053	JJ	I-NP	O
pulses	pulse	p04202	NNS	I-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
vulnerable	vulnerable	v045060140	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
threshold	threshold	t0602043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
30	30	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
pH	pH	p000	NN	B-NP	O
and	and	a530	CC	I-NP	O
partial	partial	p06304	JJ	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PO2	PO2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
dioxide	dioxide	d02030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CO2	CO2	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
kept	keep	k013	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
limits	limit	l05032	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
hypoventilation	hypoventilation	h0101053040305	NN	B-NP	B-Disease
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
;	;	;000	:	O	O
PC02	PC02	0000	NN	B-NP	O
70	70	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
100	100	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
:	:	:000	:	O	O
P02	P02	0000	NN	B-NP	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
40	40	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
even	even	e105	RB	I-NP	O
greater	great	g60306	JJR	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
threshold	threshold	t0602043	NN	I-NP	O
to	to	t000	TO	B-PP	O
60	60	0000	CD	B-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
although	although	a43020	IN	B-SBAR	O
many	many	m050	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
arrhythmias	arrhythmia	a6030502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
aminophylline	aminophylline	a5050104050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
.	.	.000	.	O	O

Pentoxifylline	Pentoxifylline	p053020104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Trental	Trental	t605304	JJ	B-ADJP	B-Chemical
)	)	)000	)	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
:	:	:000	:	O	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
thallium	thallium	t0405	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
201	201	0000	CD	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
.	.	.000	.	O	O

Dipyridamole	Dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
thallium	thallium	t0405	NN	I-NP	B-Chemical
-	-	-000	SYM	I-NP	O
201	201	0000	CD	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
exercise	exercise	e2062020	VB	I-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
vascular	vascular	v020406	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Many	Many	m050	JJ	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
taking	take	t02052	VBG	I-VP	O
pentoxifylline	pentoxifylline	p053020104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Trental	Trental	t605304	JJ	B-ADVP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
methylxanthine	methylxanthine	m03042053050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
intermittent	intermittent	i5306503053	JJ	B-NP	B-Disease
claudication	claudication	c403020305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Whether	Whether	w0306	IN	B-SBAR	O
pentoxifylline	pentoxifylline	p053020104050	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
like	like	l020	IN	B-PP	O
other	other	o306	JJ	B-NP	O
methylxanthines	methylxanthine	m030420530502	NNS	I-NP	B-Chemical
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
stopped	stop	s30103	VBN	I-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
thallium	thallium	t0405	NN	I-NP	B-Chemical
-	-	-000	SYM	I-NP	O
201	201	0000	CD	I-NP	O
imaging	imaging	i502052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
hyperemic	hyperemic	h01060502	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
open	open	o105	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
chest	chest	c023	NN	I-NP	O
anesthetized	anesthetize	a5023030203	VBN	B-VP	O
dogs	dog	d020	NNS	B-NP	O
after	after	a1306	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
pentoxifylline	pentoxifylline	p053020104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Baseline	Baseline	b0204050	NNP	B-NP	O
circumflex	circumflex	c062051402	NN	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flows	flow	f402	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
among	among	a5052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Dipyridamole	Dipyridamole	d01060305040	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
after	after	a1306	IN	I-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
15	15	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
pentoxifylline	pentoxifylline	p053020104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Neither	Neither	n0306	CC	O	O
dose	dose	d020	NN	B-NP	O
of	of	o100	IN	B-PP	O
pentoxifylline	pentoxifylline	p053020104050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
peak	peak	p020	NN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
after	after	a1306	IN	B-PP	O
theophylline	theophylline	t0104050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
pentoxyifylline	pentoxyifylline	p053020104050	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
hyperemia	hyperemia	h0106050	NN	I-NP	B-Disease
even	even	e105	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

Cause	Cause	c020	NN	B-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Causes	Cause	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
special	special	s10204	JJ	B-NP	O
reference	reference	r01060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
among	among	a5052	IN	B-PP	O
240	240	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
pathologically	pathologically	p03040202040	RB	B-NP	O
verified	verify	v060103	VBN	I-NP	O
Parkinson	Parkinson	p06205205	NNP	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
Annuals	Annual	a5042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Pathological	Pathological	p0304020204	JJ	I-NP	O
Autopsy	Autopsy	a030120	NN	I-NP	O
Cases	Case	c0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
from	from	f605	IN	B-PP	O
1981	1981	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1985	1985	0000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
leading	lead	l03052	VBG	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
pneumonia	pneumonia	p505050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
bronchitis	bronchitis	b60520302	NN	B-NP	B-Disease
(	(	(000	(	O	O
44	44	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
malignant	malignant	m04025053	JJ	B-NP	O
neoplasms	neoplasm	n0140252	NNS	I-NP	B-Disease
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	B-Disease
diseases	disease	d020202	NNS	I-NP	I-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
septicaemia	septicaemia	s01302050	NN	B-NP	B-Disease
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
11th	11th	0000	JJ	I-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
,	,	,000	,	O	O
accounting	account	a2053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
only	only	o540	RB	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
deaths	death	d0302	NNS	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
5th	5th	5300	JJ	I-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
Japanese	Japanese	j0105020	JJ	I-NP	O
general	general	g050604	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
1985	1985	0000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
reflect	reflect	r014023	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
mechanism	mechanism	m0205025	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
parkinsonian	parkinsonian	p0620520505	JJ	I-NP	B-Disease
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
intramuscular	intramuscular	i53605020406	JJ	I-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Midazolam	Midazolam	m03020405	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
dental	dental	d05304	JJ	B-NP	O
or	or	o600	CC	I-NP	O
endoscopic	endoscopic	e53020102	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
generally	generally	g0506040	RB	B-ADVP	O
consisted	consist	c05202303	VBN	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
given	give	g0105	VBN	B-VP	O
intramuscularly	intramuscularly	i5360502040640	RB	B-ADVP	O
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
cause	cause	c020	VB	I-VP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	I-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
published	publish	p0140203	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiorespiratory	cardiorespiratory	c063060210603060	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Information	Information	i510650305	NN	B-NP	O
regarding	regard	r02063052	VBG	B-VP	O
midazolam	midazolam	m03020405	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
provide	provide	p601030	VB	I-VP	O
recommendation	recommendation	r02050530305	NN	B-NP	O
for	for	f060	IN	B-PP	O
safe	safe	s010	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Myasthenia	Myasthenia	m023050	NNP	B-NP	B-Disease
gravis	gravi	g60102	VBZ	B-VP	I-Disease
presenting	present	p602053052	VBG	I-VP	O
as	as	a200	IN	B-PP	O
weakness	weakness	w02502	NN	B-NP	O
after	after	a1306	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
became	become	b02050	VBD	B-VP	O
virtually	virtually	v063040	RB	B-ADJP	O
quadriplegic	quadriplegic	q0360140202	JJ	I-ADJP	B-Disease
after	after	a1306	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
preeclampsia	preeclampsia	p602405120	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
well	well	w040	RB	B-ADJP	O
tolerated	tolerate	t04060303	VBN	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
magnesium	magnesium	m0250205	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
and	and	a530	CC	O	O
she	she	s000	PRP	B-NP	O
recovered	recover	r02010603	VBD	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
she	she	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
weak	weak	w020	JJ	B-ADJP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
Hz	Hz	h200	NN	I-NP	O
repetitive	repetitive	r010303010	JJ	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrement	decrement	d02605053	NN	I-NP	O
without	without	w0303	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
facilitation	facilitation	f0204030305	NN	I-NP	O
at	at	a300	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
or	or	o600	CC	B-PP	O
after	after	a1306	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
postsynaptic	postsynaptic	p02320501302	JJ	B-NP	B-Disease
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	I-Disease
blockade	blockade	b402030	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
her	her	h060	PRP$	B-NP	O
strength	strength	s3605230	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
,	,	,000	,	O	O
repetitive	repetitive	r010303010	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
single	single	s05240	JJ	B-NP	O
fiber	fiber	f0106	NN	I-NP	O
EMG	EMG	e520	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
jitter	jitter	j0306	NN	I-NP	O
and	and	a530	CC	I-NP	O
blocking	blocking	b402052	NN	I-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antibody	antibody	a5301030	NN	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADJP	O
elevated	elevated	e4010303	JJ	I-ADJP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
paralysis	paralysis	p06040202	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
described	describe	d0260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
known	know	k505	VBN	B-NP	O
myasthenia	myasthenia	m023050	NN	I-NP	B-Disease
gravis	gravis	g60102	NN	I-NP	I-Disease
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
or	or	o600	CC	I-NP	O
only	only	o540	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
unusually	unusually	u502040	RB	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
neuromuscular	neuromuscular	n0605020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
magnesium	magnesium	m0250205	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
having	have	h01052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
disorder	disorder	d0206306	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	I-Disease
transmission	transmission	t605250205	NN	I-NP	I-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
by	by	b000	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatocarcinogenicity	hepatocarcinogenicity	h01030206205020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
test	test	t023	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
inclusion	inclusion	i5240205	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
would	would	w043	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
hepatocarcinogenicity	hepatocarcinogenicity	h01030206205020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
old	old	o430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
Fischer	Fischer	f0206	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
344	344	0000	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
fed	feed	f030	VBN	I-VP	O
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
25	25	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
semipurified	semipurifie	s0501060103	VBD	B-VP	O
choline	choline	c04050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
or	or	o600	CC	I-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
supplemented	supplement	s0140505303	VBN	I-NP	O
diets	diet	d032	NNS	I-NP	O
,	,	,000	,	O	O
containing	contain	c05305052	VBG	B-VP	O
or	or	o600	CC	O	O
not	not	n030	RB	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
06	06	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
phenobarbital	phenobarbital	p05010610304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
preneoplastic	preneoplastic	p60501402302	JJ	I-NP	O
nodules	nodule	n030402	NNS	I-NP	O
or	or	o600	CC	O	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
fed	feed	f030	VBN	B-VP	O
the	the	t000	DT	B-NP	O
plain	plain	p405	JJ	I-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
supplemented	supplement	s0140505303	VBN	B-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
preneoplastic	preneoplastic	p60501402302	JJ	I-NP	O
nodule	nodule	n03040	NN	I-NP	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
fed	feed	f030	VBN	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
preneoplastic	preneoplastic	p60501402302	JJ	B-NP	O
nodules	nodule	n030402	NNS	I-NP	O
and	and	a530	CC	B-PP	O
of	of	o100	IN	B-PP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
fed	feed	f030	VBN	B-VP	O
the	the	t000	DT	B-NP	O
plain	plain	p405	JJ	I-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
17	17	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
fed	feed	f030	VBN	B-VP	O
the	the	t000	DT	B-NP	O
phenobarbital	phenobarbital	p05010610304	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
containing	contain	c05305052	VBG	B-VP	O
choline	choline	c04050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
evinced	evince	e105203	VBD	B-VP	O
no	no	n000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatocarcinogenicity	hepatocarcinogenicity	h01030206205020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
choline	choline	c04050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
devoid	devoid	d0103	JJ	I-NP	O
diet	diet	d030	NN	I-NP	O
by	by	b000	IN	B-PP	O
phenobarbital	phenobarbital	p05010610304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Sporadic	Sporadic	s1060302	JJ	B-NP	O
neoplastic	neoplastic	n01402302	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
organs	organ	o62052	NNS	B-NP	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
irrespective	irrespective	i6021023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
fed	feed	f030	VBN	B-VP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
two	two	t000	CD	B-NP	O
paradoxical	paradoxical	p0603020204	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	O	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
ribosomal	ribosomal	r01020504	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
biosyntheses	biosynthes	b020530202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	B-Disease
enlargement	enlargement	e5406205053	NN	I-NP	I-Disease
and	and	a530	CC	O	O
muscle	muscle	m0240	NN	B-NP	B-Disease
wastage	wastage	w023020	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
RNA	RNA	r500	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
biosynthesis	biosynthesis	b020530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribosomal	ribosomal	r01020504	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
while	while	w040	IN	B-SBAR	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
RNA	RNA	r500	NN	I-NP	O
content	content	c053053	NN	I-NP	O
and	and	a530	CC	O	O
ribosomal	ribosomal	r01020504	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
biosynthesis	biosynthesis	b020530202	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
gastrocnemius	gastrocnemius	g02360250502	NN	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
acted	act	a2303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
tissue	tissue	t020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
to	to	t000	TO	B-VP	O
enhance	enhance	e50520	VB	I-VP	O
ribosomal	ribosomal	r01020504	JJ	B-NP	O
RNA	RNA	r500	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	O	O
depress	depress	d01602	VBP	B-VP	O
such	such	s020	JJ	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
view	view	v000	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
contention	contention	c05305305	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
and	and	a530	CC	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
are	be	a600	VBP	B-VP	O
independent	independent	i5301053053	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prednisolone	prednisolone	p60350204050	JJ	B-NP	B-Chemical
action	action	a2305	NN	I-NP	O
.	.	.000	.	O	O

Differential	Differential	d010605304	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	h020204060202402050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
pharmacologically	pharmacologically	p06502040202040	RB	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Gamma	Gamma	g050	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hexachlorocyclohexane	hexachlorocyclohexane	h020204060202402050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
HCH	HCH	h200	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
ingredient	ingredient	i52603053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
insecticide	insecticide	i5202302030	NN	I-NP	O
lindane	lindane	l053050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
decrease	decrease	d026020	VB	I-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
to	to	t000	TO	B-PP	O
pentylenetrazol	pentylenetrazol	p05304050360204	NN	B-NP	O
(	(	(000	(	O	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
3	3	3000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCH	HCH	h200	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
conversely	conversely	c051062040	RB	B-VP	O
increase	increase	i526020	VBP	I-VP	O
threshold	threshold	t0602043	NN	B-NP	O
to	to	t000	TO	B-PP	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCH	HCH	h200	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Vohland	Vohland	v04053	NNP	B-NP	O
et	et	e300	FW	I-NP	O
al	al	a400	FW	I-NP	O
.	.	.000	.	I-NP	O
1981	1981	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
inducing	induce	i5302052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
intraperitoneal	intraperitoneal	i5360106030504	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
HCH	HCH	h200	NN	B-NP	I-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
HCH	HCH	h200	NN	B-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
-	-	-000	HYPH	O	O
inducing	induce	i5302052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
,	,	,000	,	O	O
regardless	regardless	r02063402	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCH	HCH	h200	NN	I-NP	I-Chemical
a	a	a000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
picrotoxin	picrotoxin	p026030205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
PTX	PTX	p320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
mercaptopropionic	mercaptopropionic	m062013016010502	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
MPA	MPA	m100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
bicuculline	bicuculline	b020204050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
BCC	BCC	b200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
methyl	methyl	m0304	NN	B-NP	B-Chemical
6	6	6000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
7	7	7000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dimethoxy	dimethoxy	d0503020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
ethyl	ethyl	e304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
B	B	b000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
carboline	carboline	c06104050	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
carboxylate	carboxylate	c0610204030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
DMCM	DMCM	d525	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
strychnine	strychnine	s360205050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
STR	STR	s360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
control	control	c053604	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
,	,	,000	,	O	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HCH	HCH	h200	NN	I-NP	I-Chemical
,	,	,000	,	I-NP	O
pentylenetetrazol	pentylenetetrazol	p0530405030360204	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
picrotoxin	picrotoxin	p026030205	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
3H	3H	3000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
TBOB	TBOB	t101	NN	I-NP	I-Chemical
binding	binding	b053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
whole	whole	w040	JJ	I-NP	O
brain	brain	b605	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
IC50	IC50	0000	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
,	,	,000	,	I-NP	O
404	404	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

MPA	MPA	m100	NN	B-NP	B-Chemical
,	,	,000	,	O	O
BCC	BCC	b200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
DMCM	DMCM	d525	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
STR	STR	s360	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3H	3H	3000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
TBOB	TBOB	t101	NN	I-NP	I-Chemical
(	(	(000	(	O	O
t	t	t000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
butyl	butyl	b0304	NN	I-NP	I-Chemical
bicyclo	bicyclo	b020240	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
orthobenzoate	orthobenzoate	o6301052030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
binding	binding	b053052	NN	B-NP	O
at	at	a300	IN	B-PP	O
concentrations	concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
micron	micron	m02605	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pharmacological	pharmacological	p0650204020204	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
tolerance	tolerance	t04060520	NN	B-NP	O
may	may	m000	MD	B-VP	O
occur	occur	o206	VB	I-VP	O
to	to	t000	TO	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PTZ	PTZ	p320	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
PTX	PTX	p320	NN	I-NP	B-Chemical
24	24	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
gamma	gamma	g050	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
HCH	HCH	h200	NN	I-NP	I-Chemical
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
only	only	o540	RB	B-NP	O
these	these	t020	DT	I-NP	O
two	two	t000	CD	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
-	-	-000	HYPH	B-VP	O
inducing	induce	i5302052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
in	in	i500	FW	I-NP	O
vitro	vitro	v0360	FW	I-NP	O
data	datum	d030	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
activity	activity	a2301030	NN	I-NP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
gamma	gamma	g050	SYM	O	B-Chemical
-	-	-000	HYPH	O	I-Chemical
HCH	HCH	h200	NN	B-NP	I-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
GABA	GABA	g010	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
A	A	a000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
linked	link	l05203	VBN	B-NP	O
chloride	chloride	c0406030	NN	I-NP	O
channel	channel	c0504	NN	I-NP	O
.	.	.000	.	O	O

Tolerance	Tolerance	t04060520	NN	B-NP	O
and	and	a530	CC	I-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Argentine	Argentine	a62053050	JJ	B-NP	B-Disease
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	I-Disease
fever	fever	f0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tolerance	Tolerance	t04060520	NN	B-NP	O
and	and	a530	CC	I-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Argentine	Argentine	a62053050	JJ	B-NP	B-Disease
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	I-Disease
fever	fever	f0106	NN	I-NP	I-Disease
(	(	(000	(	O	O
AHF	AHF	a010	NN	B-NP	B-Disease
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
8	8	8000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
evolution	evolution	e1040305	NN	B-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
neutralization	neutralization	n03604020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
viremia	viremia	v06050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
drop	drop	d601	NN	I-NP	O
of	of	o100	IN	B-PP	O
endogenous	endogenous	e53020502	JJ	B-NP	O
interferon	interferon	i530610605	NN	I-NP	O
titers	titer	t03062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
delayed	delay	d0403	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antiviral	antiviral	a53010604	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AHF	AHF	a010	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
secondary	secondary	s02053060	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
easily	easily	e02040	RB	I-VP	O
managed	manage	m050203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
ribavirin	ribavirin	r01010605	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AHF	AHF	a010	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Is	Be	i200	VBZ	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
scabies	scaby	s20102	NNS	B-NP	B-Disease
hazardous	hazardous	h0206302	JJ	B-ADJP	O
?	?	?000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
scabies	scaby	s20102	NNS	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
usually	usually	u2040	RB	I-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
;	;	;000	:	O	O
most	most	m023	RBS	B-NP	O
consider	consider	c0520306	JJ	I-NP	O
lindane	lindane	l053050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
gamma	gamma	g050	NN	B-NP	B-Chemical
benzene	benzene	b052050	NN	I-NP	I-Chemical
hexachloride	hexachloride	h02020406030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
.	.	.000	.	O	O

Lindane	Lindane	l053050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	B-ADVP	O
widely	widely	w03040	RB	B-VP	O
used	use	u203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
agricultural	agricultural	a26020430604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
industrial	industrial	i53023604	JJ	I-NP	O
pesticide	pesticide	p02302030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
insecticide	insecticide	i5202302030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
well	well	w040	RB	I-VP	O
understood	understand	u53062303	VBN	I-VP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
accumulating	accumulate	a2050403052	VBG	I-VP	O
that	that	t030	DT	B-NP	O
lindane	lindane	l053050	NN	I-NP	B-Chemical
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
toxic	toxic	t0202	JJ	B-ADJP	B-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
central	central	c053604	JJ	I-NP	I-Disease
nervous	nervous	n06102	JJ	I-NP	I-Disease
system	system	s02305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
aplastic	aplastic	a1402302	JJ	B-NP	B-Disease
anaemia	anaemia	a5050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Preparations	Preparation	p6010603052	NNS	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
lindane	lindane	l053050	NN	B-NP	B-Chemical
continue	continue	c053050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
sold	sell	s043	VBN	I-VP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
counter	counter	c05306	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
represent	represent	r01602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
hazard	hazard	h02063	NN	I-NP	O
to	to	t000	TO	B-PP	O
poorly	poorly	p0640	RB	B-NP	O
informed	inform	i5106503	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
review	review	r010	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
general	general	g050604	JJ	B-NP	O
practitioners	practitioner	p60230305062	NNS	I-NP	O
should	should	s043	MD	B-VP	O
prescribe	prescribe	p6026010	VB	I-VP	O
scabicides	scabicide	s201020302	NNS	B-NP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
caution	caution	c0305	NN	I-NP	O
for	for	f060	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
at	at	a300	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
risk	risk	r020	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
give	give	g010	VB	B-VP	O
adequate	adequate	a302030	JJ	B-NP	O
warnings	warning	w065052	NNS	I-NP	O
regarding	regard	r02063052	VBG	B-VP	O
potential	potential	p0305304	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Mouse	Mouse	m020	NN	B-NP	O
strain	strain	s3605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
motility	motility	m0304030	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
biogenic	biogenic	b020502	JJ	I-NP	O
amines	amine	a50502	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
injected	inject	i5202303	VBN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
increments	increment	i526050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
each	each	e020	DT	B-NP	O
over	over	o106	IN	I-NP	O
30	30	0000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
motility	motility	m0304030	NN	I-NP	O
and	and	a530	CC	O	O
whole	whole	w040	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
selected	select	s0402303	VBN	B-NP	O
biogenic	biogenic	b020502	JJ	I-NP	O
amines	amine	a50502	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
major	major	m0206	JJ	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
strains	strain	s36052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
the	the	t000	DT	B-NP	O
albino	albino	a41050	JJ	I-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
ICR	ICR	i260	NN	I-NP	O
and	and	a530	CC	I-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
C	C	c000	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
black	black	b402	JJ	I-NP	O
C57BL	C57BL	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
brown	brown	b605	VBN	I-NP	O
CDF	CDF	c310	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
I	I	i000	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
.	.	.000	.	O	O

Amantadine	Amantadine	a505303050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
biphasic	biphasic	b010202	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
motility	motility	m0304030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
depressed	depress	d0160203	VBD	B-VP	B-Disease
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-VP	O
C	C	c000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
amantadine	amantadine	a505303050	NN	I-NP	B-Chemical
treatments	treatment	t60350532	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
enhancement	enhancement	e505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
motility	motility	m0304030	NN	B-NP	O
from	from	f605	IN	B-PP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
control	control	c053604	NN	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
strains	strain	s36052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-VP	O
C	C	c000	NN	B-NP	O
mice	mouse	m020	NNS	I-NP	O
being	be	b052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
least	least	l023	JJS	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
controls	control	c0536042	NNS	B-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
,	,	,000	,	O	O
except	except	e2013	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
ICR	ICR	i260	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
an	an	a500	DT	B-NP	O
overnight	overnight	o10650203	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
free	free	f600	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
amantadine	amantadine	a505303050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Readministration	Readministration	r0350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
overnight	overnight	o10650203	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
motility	motility	m0304030	NN	B-NP	O
from	from	f605	IN	B-PP	O
respective	respective	r021023010	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
control	control	c053604	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
strains	strain	s36052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
exception	exception	e201305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
C	C	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
suppression	suppression	s0160205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
motility	motility	m0304030	NN	B-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
whole	whole	w040	JJ	B-NP	O
brain	brain	b605	NN	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
but	but	b030	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
amounts	amount	a50532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dihydroxyphenylacetic	dihydroxyphenylacetic	d03602010504020302	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
C	C	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
saline	saline	s04050	NN	B-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Conversely	Conversely	c051062040	RB	B-ADVP	O
,	,	,000	,	O	O
brain	brain	b605	NN	B-NP	O
normetanephrine	normetanephrine	n06503050106050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
control	control	c053604	NN	I-NP	O
by	by	b000	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
C	C	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
strain	strain	s3605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
motility	motility	m0304030	NN	B-NP	O
and	and	a530	CC	O	O
indicate	indicate	i5302030	VBP	B-VP	O
a	a	a000	DT	B-NP	O
differential	differential	d010605304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	I-NP	O
C	C	c000	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
strain	strain	s3605	NN	I-NP	O
and	and	a530	CC	O	O
could	could	c043	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
strain	strain	s3605	NN	I-NP	O
of	of	o100	IN	B-PP	O
choice	choice	c020	NN	B-NP	O
for	for	f060	IN	B-PP	O
evaluating	evaluate	e10403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
biogenic	biogenic	b020502	JJ	I-NP	O
amines	amine	a50502	NNS	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
BALB	BALB	b041	NN	B-NP	O
/	/	/000	SYM	I-NP	O
C	C	c000	NN	I-NP	O
mouse	mouse	m020	NN	I-NP	O
strain	strain	s3605	NN	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
probable	probable	p6010140	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
of	of	o100	IN	B-PP	O
catecholamine	catecholamine	c03020405050	NN	B-NP	B-Chemical
turnover	turnover	t0650106	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
metabolism	metabolism	m030104025	NN	B-NP	O
by	by	b000	IN	B-PP	O
monoamine	monoamine	m0505050	NN	B-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
resulting	result	r02043052	VBG	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
O	O	o000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
methylation	methylation	m03040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
account	account	a2053	VB	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
amantadine	amantadine	a505303050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
BALB	BALB	b041	NN	I-NP	O
/	/	/000	SYM	B-NP	O
C	C	c000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
.	.	.000	.	O	O

Chloroacetaldehyde	Chloroacetaldehyde	c04060203043030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
to	to	t000	TO	B-PP	O
urotoxicity	urotoxicity	u6030202030	NN	B-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
ifosfamide	ifosfamide	i102105030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
/	/	/000	SYM	B-NP	O
short	short	s063	JJ	I-NP	O
communication	communication	c0505020305	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
chloroacetaldehyde	chloroacetaldehyde	c04060203043030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CAA	CAA	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
metabolite	metabolite	m030104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxazaphosphorine	oxazaphosphorine	o2020102106050	NN	B-NP	O
cytostatics	cytostatic	c030230302	NNS	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
carried	carry	c0603	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
CAA	CAA	c000	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
CAA	CAA	c000	NN	B-NP	B-Chemical
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
administration	administration	a350502360305	NN	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
bladder	bladder	b40306	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
instilled	instill	i5230403	VBN	B-VP	O
directly	directly	d0602340	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
,	,	,000	,	O	O
CAA	CAA	c000	NN	B-NP	B-Chemical
exerts	exert	e20632	VBZ	B-VP	O
urotoxic	urotoxic	u6030202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
susceptible	susceptible	s020130140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
detoxification	detoxification	d030201020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
mesna	mesna	m0250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Source	Source	s0620	NN	B-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
primitive	primitive	p60503010	JJ	B-NP	O
dysfunction	dysfunction	d021052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
site	site	s030	NN	I-NP	O
?	?	?000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
common	common	c0505	JJ	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
one	one	o500	CD	I-NP	O
sided	sided	s0303	JJ	I-NP	O
frontotemporal	frontotemporal	f6053030510604	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
ointment	ointment	o0535053	NN	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	JJ	B-NP	O
onset	onset	o5203	NN	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
attacks	attack	a302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
out	out	o030	IN	I-NP	O
of	of	o100	IN	I-NP	O
10	10	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
versus	versus	v06202	IN	B-PP	O
no	no	n000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-NP	O
20	20	0000	CD	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
attack	attack	a302	NN	I-NP	O
with	with	w030	IN	B-PP	O
frontotemporal	frontotemporal	f6053030510604	JJ	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
induction	induction	i5302305	NN	I-NP	O
test	test	t023	NN	I-NP	O
at	at	a300	IN	B-PP	O
other	other	o306	JJ	B-NP	O
body	body	b030	NN	I-NP	O
areas	area	a602	NNS	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
-	-	-000	HYPH	O	O
inducing	induce	i5302052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
seems	seem	s052	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
depend	depend	d01053	VB	I-VP	O
on	on	o500	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
habitual	habitual	h010304	JJ	I-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
frontotemporal	frontotemporal	f6053030510604	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
crucial	crucial	c60204	JJ	B-NP	O
importance	importance	i510630520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
migraine	migraine	m026050	NN	I-NP	B-Disease
crisis	crisis	c60202	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
origin	origin	o60205	NN	I-NP	O
of	of	o100	IN	B-PP	O
migraine	migraine	m026050	NN	B-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

Hypersensitivity	Hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
presenting	present	p602053052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
leukemoid	leukemoid	l020503	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
,	,	,000	,	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
,	,	,000	,	O	O
erythroderma	erythroderma	e60306030650	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
erythroderma	erythroderma	e60306030650	NN	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
leukemoid	leukemoid	l020503	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
,	,	,000	,	O	O
eosinophilia	eosinophilia	e020501040	NN	B-NP	B-Disease
,	,	,000	,	O	O
hyponatremia	hyponatremia	h0105036050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
an	an	a500	DT	I-NP	O
unusual	unusual	u50204	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Fluoxetine	Fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
:	:	:000	:	O	O
clinical	clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
theoretical	theoretical	t06030204	JJ	I-NP	O
implications	implication	i5140203052	NNS	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
obsessive	obsessive	o1202010	JJ	B-NP	B-Disease
compulsive	compulsive	c051042010	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
or	or	o600	CC	O	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
akathisia	akathisia	a203020	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
typical	typical	t010204	JJ	I-NP	O
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
restlessness	restlessness	r023402502	NN	B-NP	O
,	,	,000	,	O	O
constant	constant	c0523053	JJ	B-NP	O
pacing	pacing	p02052	NN	I-NP	O
,	,	,000	,	O	O
purposeless	purposeless	p061020402	JJ	B-NP	O
movements	movement	m01050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
feet	foot	f030	NNS	I-NP	O
and	and	a530	CC	I-NP	O
legs	leg	l020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
marked	marked	m06203	JJ	B-NP	O
anxiety	anxiety	a52030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
indistinguishable	indistinguishable	i53023052020140	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
neuroleptic	neuroleptic	n060401302	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
identical	identical	i30530204	JJ	B-ADJP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
somewhat	somewhat	s0503	RB	B-ADJP	O
milder	mild	m04306	JJR	I-ADJP	O
.	.	.000	.	O	O

Akathisia	Akathisia	a203020	NNP	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
generally	generally	g0506040	RB	B-VP	O
responded	respond	r02105303	VBD	I-VP	O
well	well	w040	RB	I-VP	O
to	to	t000	TO	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
,	,	,000	,	O	O
dose	dose	d020	NN	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
authors	author	a03062	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
serotonergically	serotonergically	s06030506202040	RB	B-NP	O
mediated	mediate	m030303	VBN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurotransmission	neurotransmission	n0603605250205	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
akathisia	akathisia	a203020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
"	"	"000	``	I-NP	O
jitteriness	jitteriness	j03060502	NN	I-NP	O
"	"	"000	''	O	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
identical	identical	i30530204	JJ	B-ADJP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
converting	convert	c051063052	VBG	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
(	(	(000	(	O	O
CEI	CEI	c000	NN	B-NP	O
)	)	)000	)	O	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Munich	Munich	m05020	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
established	establish	e230140203	VBN	B-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
month	month	m0530	NN	I-NP	O
later	later	l0306	RB	B-VP	O
divided	divide	d010303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
four	four	f060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
matched	match	m03203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
remained	remain	r050503	VBD	B-VP	O
untreated	untreated	u5360303	JJ	B-ADJP	O
while	while	w040	IN	B-SBAR	O
groups	group	g6012	NNS	B-NP	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
received	receive	r020103	VBD	B-VP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
micropuncture	micropuncture	m026010523060	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
10	10	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
101	101	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
124	124	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
group	group	g601	NN	B-NP	O
2	2	2000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
glomerular	glomerular	g405060406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
54	54	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
61	61	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
(	(	(000	(	O	O
617	617	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
50	50	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
570	570	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
47	47	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
GFR	GFR	g160	NN	B-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
03	03	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
04	04	0000	CD	I-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
04	04	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
11	11	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Groups	Group	g6012	NNS	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
four	four	f060	CD	B-NP	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
enalapril	enalapril	e50401604	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
progression	progression	p60260205	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
enalapril	enalapril	e50401604	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
reduced	reduce	r030203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
without	without	w0303	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O

Untreated	Untreated	u5360303	JJ	B-NP	O
group	group	g601	NN	I-NP	O
3	3	3000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
08	08	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
27	27	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
07	07	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Enalapril	Enalapril	e50401604	NNP	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
blunted	blunt	b405303	VBD	B-VP	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
prevent	prevent	p601053	VB	I-VP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
86	86	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
15	15	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
4	4	4000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
69	69	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
13	13	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
P	P	p000	NN	I-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
vs	vs	v200	CC	O	O
.	.	.000	.	O	O
group	group	g601	NN	B-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
GFR	GFR	g160	NN	B-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	B-Disease
sclerosis	sclerosis	s24060202	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
treated	treat	t60303	VBN	I-NP	O
and	and	a530	CC	I-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Clotiazepam	Clotiazepam	c403020105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	B-Disease
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
clotiazepam	clotiazepam	c403020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
thienodiazepine	thienodiazepine	t05030201050	NN	I-NP	B-Chemical
derivative	derivative	d060103010	NN	I-NP	O
.	.	.000	.	O	O

Clotiazepam	Clotiazepam	c403020105	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prompt	prompt	p60513	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
chemically	chemically	c0502040	RB	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
clotiazepam	clotiazepam	c403020105	NN	B-NP	B-Chemical
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
any	any	a500	DT	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
shows	show	s020	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
clotiazepam	clotiazepam	c403020105	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
cross	cross	c602	JJ	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
between	between	b0305	IN	B-PP	O
clotiazepam	clotiazepam	c403020105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
several	several	s010604	JJ	B-NP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azacytidine	azacytidine	a2020303050	NN	I-NP	I-Chemical
potentiates	potentiate	p030530302	VBZ	B-VP	O
initiation	initiation	i5030305	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	I-Disease
by	by	b000	IN	B-PP	I-Disease
carcinogens	carcinogen	c0620502052	NNS	B-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
test	test	t023	VB	I-VP	O
the	the	t000	DT	B-NP	O
validity	validity	v0403030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
hypomethylation	hypomethylation	h010503040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
plays	play	p402	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
initiation	initiation	i5030305	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
carcinogenic	carcinogenic	c06205020502	JJ	B-NP	I-Disease
process	process	p60202	NN	I-NP	I-Disease
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azacytidine	azacytidine	a2020303050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AzC	AzC	a200	NN	I-NP	I-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
methylation	methylation	m03040305	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
repair	repair	r0106	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
carcinogens	carcinogen	c0620502052	NNS	I-NP	O
,	,	,000	,	O	O
benzo	benzo	b0520	NN	B-NP	B-Chemical
[	[	[000	(	O	I-Chemical
a	a	a000	DT	O	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pyrene	pyrene	p06050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
N	N	n000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
nitrosourea	nitrosourea	n03602060	NN	I-NP	I-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dimethylhydrazine	dimethylhydrazine	d05030403602050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DMH	DMH	d500	NN	I-NP	I-Chemical
)	)	)000	)	O	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
initiated	initiate	i5030303	VBN	I-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assayed	assay	a203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
glutamyltransferase	glutamyltransferase	g403050436052106020	NN	I-NP	O
(	(	(000	(	O	O
gamma	gamma	g050	SYM	B-NP	O
-	-	-000	HYPH	I-NP	O
GT	GT	g300	NN	I-NP	O
)	)	)000	)	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
foci	focus	f020	NNS	I-NP	O
formed	form	f06503	VBN	B-VP	O
following	follow	f04052	VBG	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
selection	selection	s0402305	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
consisting	consist	c052023052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
dietary	dietary	d03060	JJ	B-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
02	02	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acetylaminofluorene	acetylaminofluorene	a20304050501406050	NN	I-NP	I-Chemical
coupled	couple	c01403	VBN	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
necrogenic	necrogenic	n026020502	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
CCl4	CCl4	0000	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
with	with	w030	IN	B-PP	O
all	all	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
carcinogens	carcinogen	c0620502052	NNS	I-NP	O
,	,	,000	,	O	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AzC	AzC	a200	NN	I-NP	I-Chemical
during	during	d06052	IN	B-PP	O
repair	repair	r0106	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
initiated	initiate	i5030303	VBN	B-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
example	example	e205140	NN	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
foci	focus	f020	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
cm2	cm2	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AzC	AzC	a200	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
5	5	5000	CD	I-NP	O
foci	focus	f020	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
cm2	cm2	0000	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carcinogen	carcinogen	c062050205	NN	B-NP	O
only	only	o540	RB	B-ADVP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	B-Chemical
3H	3H	3000	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
azadeoxycytidine	azadeoxycytidine	a20302020303050	NN	I-NP	I-Chemical
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
repair	repair	r0106	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
DMH	DMH	d500	NN	I-NP	I-Chemical
further	further	f06306	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
019	019	0000	CD	B-NP	O
mol	mol	m040	NN	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytosine	cytosine	c0302050	NN	B-NP	B-Chemical
residues	residue	r020302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
were	be	w060	VBD	B-VP	O
substituted	substitute	s0123030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
analogue	analogue	a504020	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
incorporation	incorporation	i52061060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AzC	AzC	a200	NN	I-NP	I-Chemical
occurs	occur	o2062	VBZ	B-VP	O
during	during	d06052	IN	B-PP	O
repair	repair	r0106	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
AzC	AzC	a200	NN	I-NP	I-Chemical
given	give	g0105	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
two	two	t000	CD	I-NP	O
thirds	third	t0632	NNS	I-NP	O
partial	partial	p06304	JJ	I-NP	O
hepatectomy	hepatectomy	h0103023050	NN	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
its	its	i320	PRP$	B-NP	O
incorporation	incorporation	i52061060305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
maximum	maximum	m020505	JJ	B-ADJP	O
,	,	,000	,	O	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
induce	induce	i53020	VB	I-VP	O
any	any	a500	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
GT	GT	g300	NN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
foci	focus	f020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hypomethylation	hypomethylation	h010503040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
.	.	.000	.	O	O

Perhaps	Perhaps	p06012	RB	B-ADVP	O
two	two	t000	CD	B-NP	O
events	event	e10532	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
carcinogen	carcinogen	c062050205	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
involving	involve	i51041052	VBG	I-NP	O
hypomethylation	hypomethylation	h010503040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
DNA	DNA	d500	NN	B-NP	O
.	.	.000	.	O	O

Antihypertensive	Antihypertensive	a5301063052010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	I-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
reappraisal	reappraisal	r0160204	NN	I-NP	O
.	.	.000	.	O	O

Eighty	Eighty	e02030	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
nine	nine	n050	CD	I-NP	O
new	new	n000	JJ	I-NP	O
referral	referral	r010604	JJ	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
out	out	o030	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
46	46	0000	CD	B-NP	O
new	new	n000	JJ	I-NP	O
referral	referral	r010604	JJ	I-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
chronically	chronically	c060502040	RB	B-VP	O
physically	physically	p0202040	RB	I-VP	O
ill	ill	i400	VB	I-VP	O
out	out	o030	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
completed	complete	c05140303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mood	mood	m030	NN	I-NP	O
rating	rating	r03052	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
at	at	a300	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
preponderance	preponderance	p601053060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Hypertensive	Hypertensive	h01063052010	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
histories	history	h0230602	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
accounted	account	a205303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
depressions	depression	d01602052	NNS	B-NP	B-Disease
occurring	occur	o206052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
methyl	methyl	m0304	NN	B-NP	B-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
treated	treat	t60303	VBN	B-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
histories	history	h0230602	NNS	I-NP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	B-Disease
active	active	a23010	JJ	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Diclofenac	Diclofenac	d024010502	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Voltarol	Voltarol	v0430604	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
Geigy	Geigy	g020	NNP	B-NP	O
Pharmaceuticals	Pharmaceuticals	p065020302042	NNP	I-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
steroidal	steroidal	s3060304	JJ	I-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	I-NP	O
derivative	derivative	d060103010	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylacetic	phenylacetic	p0504020302	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
generally	generally	g0506040	RB	B-VP	O
well	well	w040	RB	I-VP	O
-	-	-000	HYPH	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
,	,	,000	,	O	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
liver	liver	l0106	NN	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
recorded	record	r0206303	VBN	I-VP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
less	less	l020	RBR	B-ADVP	O
commonly	commonly	c050540	RB	I-ADVP	O
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
described	describe	d0260103	VBN	B-VP	O
developed	develop	d01040103	VBD	B-VP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
active	active	a23010	JJ	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
diclofenac	diclofenac	d024010502	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
which	which	w020	WDT	B-NP	O
progressed	progress	p60260203	VBD	B-VP	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
finding	finding	f053052	NN	I-NP	O
not	not	n030	RB	O	O
previously	previously	p6010240	RB	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Arterial	Arterial	a630604	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
ketoconazole	ketoconazole	k03020502040	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Cushing	Cushing	c02052	NN	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
basis	basis	b0202	NN	I-NP	O
with	with	w030	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
sustained	sustained	s0230503	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
normal	normal	n06504	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	O	O
urinary	urinary	u605060	JJ	B-NP	O
free	free	f600	JJ	I-NP	O
cortisol	cortisol	c0630204	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
achieved	achieve	a20103	VBN	I-VP	O
following	follow	f04052	VBG	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
yet	yet	y030	RB	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
31	31	0000	CD	I-NP	O
(	(	(000	(	O	O
patient	patient	p03053	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
52	52	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
patient	patient	p03053	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
deoxycorticosterone	deoxycorticosterone	d02020630202306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
deoxycortisol	deoxycortisol	d02020630204	NN	I-NP	I-Chemical
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patient	patient	p03053	NN	B-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	CC	O	O
deoxycorticosterone	deoxycorticosterone	d02020630202306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
11	11	0000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
deoxycortisol	deoxycortisol	d02020630204	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
aldosterone	aldosterone	a4302306050	NN	I-NP	B-Chemical
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
raised	raise	r0203	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
suppression	suppression	s0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
renin	renin	r0505	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
mineralocorticoid	mineralocorticoid	m050604020630203	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
intravascular	intravascular	i53601020406	JJ	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Induction	Induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravascular	intravascular	i53601020406	JJ	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrinolysis	fibrinolysis	f01605040202	NN	B-NP	O
by	by	b000	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
thrombin	thrombin	t0605105	NN	B-NP	O
and	and	a530	CC	O	O
tranexamic	tranexamic	t605020502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AMCA	AMCA	a520	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
gives	give	g0102	VBZ	B-VP	O
rise	rise	r020	NN	B-NP	O
to	to	t000	TO	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
resembling	resemble	r020514052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
occurring	occur	o206052	VBG	B-VP	O
after	after	a1306	IN	B-PP	O
trauma	trauma	t6050	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	O
sepsis	sepsis	s01202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Injection	Injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
(	(	(000	(	O	O
ACE	ACE	a200	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
reduced	reduce	r030203	VBD	B-VP	O
both	both	b030	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
lung	lung	l052	NN	I-NP	O
weights	weight	w02032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
and	and	a530	CC	O	O
PaO2	PaO2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
given	give	g0105	VBN	B-VP	O
this	this	t020	DT	B-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
-	-	-000	HYPH	O	O
blocking	block	b402052	VBG	B-VP	O
agent	agent	a2053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
contents	content	c0530532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
albumin	albumin	a410505	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lungs	lung	l052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
influence	influence	i5140520	VB	I-VP	O
the	the	t000	DT	B-NP	O
extravasation	extravasation	e23601020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
protein	protein	p60305	NN	B-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
as	as	a200	IN	B-SBAR	O
reflected	reflect	r01402303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
urea	urea	u600	NN	I-NP	B-Chemical
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
kidney	kidney	k0350	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrin	fibrin	f01605	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
thrombin	thrombin	t0605105	NN	B-NP	O
and	and	a530	CC	I-NP	O
AMCA	AMCA	a520	NN	I-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lungs	lung	l052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
attributable	attributable	a3601030140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
vasodilatory	vasodilatory	v02030403060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
circulating	circulate	c0620403052	VBG	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
Angiotension	Angiotension	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
prostacyclin	prostacyclin	p60230202405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Captopril	Captopril	c01301604	NNP	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
,	,	,000	,	O	O
reduce	reduce	r03020	VBP	B-VP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
filtration	filtration	f04360305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	B-VP	O
occur	occur	o206	VB	I-VP	O
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
thrombin	thrombin	t0605105	NN	B-NP	O
,	,	,000	,	O	O
thereby	thereby	t06010	RB	B-VP	O
diminishing	diminish	d050502052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
aggregation	aggregation	a26020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
fibrin	fibrin	f01605	NN	B-NP	O
monomers	monomer	m0505062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomeruli	glomerulus	g40506040	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
less	less	l020	JJR	B-NP	O
fibrin	fibrin	f01605	NN	I-NP	O
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
deposited	deposit	d01020303	VBN	I-VP	O
and	and	a530	CC	O	O
thus	thus	t020	RB	O	O
less	less	l020	JJR	B-NP	O
kidney	kidney	k0350	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
will	will	w040	MD	B-VP	O
be	be	b000	VB	I-VP	O
produced	produce	p6030203	VBN	I-VP	O
.	.	.000	.	O	O

Stroke	Stroke	s36020	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
eight	eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
stroke	stroke	s36020	VB	I-VP	B-Disease
and	and	a530	CC	I-VP	O
review	review	r010	VB	I-VP	O
39	39	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
these	these	t020	DT	B-NP	O
47	47	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
age	age	a200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
32	32	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
12	12	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
;	;	;000	:	O	O
76	76	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
34	34	0000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
45	45	0000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
men	man	m050	NNS	B-NP	O
.	.	.000	.	O	O

Stroke	Stroke	s36020	NNP	B-NP	B-Disease
followed	follow	f0403	VBD	B-VP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
by	by	b000	IN	B-PP	O
inhalation	inhalation	i5040305	NN	B-NP	O
,	,	,000	,	O	O
intranasal	intranasal	i536050204	JJ	B-NP	O
,	,	,000	,	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intramuscular	intramuscular	i53605020406	JJ	B-NP	O
routes	route	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Intracranial	Intracranial	i5360260504	JJ	B-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
arteriovenous	arteriovenous	a6306010502	JJ	B-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
17	17	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
32	32	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
angiographically	angiographically	a520260102040	RB	B-ADVP	O
or	or	o600	CC	O	O
at	at	a300	IN	B-PP	O
autopsy	autopsy	a030120	NN	B-NP	O
;	;	;000	:	O	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
22	22	0000	CD	B-NP	O
(	(	(000	(	O	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
(	(	(000	(	B-LST	O
1	1	1000	LS	I-LST	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
stroke	stroke	s36020	NN	B-NP	B-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
2	2	2000	LS	I-LST	O
)	)	)000	)	O	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
occurs	occur	o2062	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
adults	adult	a30432	NNS	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
3	3	3000	LS	I-LST	O
)	)	)000	)	O	O
stroke	stroke	s36020	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
follow	follow	f040	VB	I-VP	O
any	any	a500	DT	B-NP	O
route	route	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
;	;	;000	:	O	O
(	(	(000	(	B-LST	O
4	4	4000	LS	I-LST	O
)	)	)000	)	O	O
stroke	stroke	s36020	VB	B-VP	B-Disease
after	after	a1306	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
intracranial	intracranial	i5360260504	JJ	B-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
arteriovenous	arteriovenous	a6306010502	JJ	B-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
(	(	(000	(	B-LST	O
5	5	5000	LS	I-LST	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
stroke	stroke	s36020	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
intracranial	intracranial	i5360260504	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
exceeds	exceed	e2032	VBZ	B-VP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
nitroprusside	nitroprusside	n03601602030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
scheduled	schedule	s2030403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
orthopedic	orthopedic	o63010302	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
identical	identical	i30530204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
protocol	protocol	p6030204	NN	I-NP	O
and	and	a530	CC	O	O
similar	similar	s050406	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
reductions	reduction	r03023052	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
mean	mean	m050	JJ	B-NP	I-Disease
arterial	arterial	a630604	JJ	I-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
(	(	(000	(	O	O
BP	BP	b100	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
to	to	t000	TO	O	O
55	55	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Nitroprusside	Nitroprusside	n03601602030	NN	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	O	O
)	)	)000	)	O	O
increase	increase	i526020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
heart	heart	h063	NN	B-NP	I-Disease
rate	rate	r030	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
cardiac	cardiac	c06302	JJ	B-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
;	;	;000	:	O	O
rebound	rebound	r01053	NN	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Labetalol	Labetalol	l01030404	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Arterial	Arterial	a630604	JJ	B-NP	O
PO2	PO2	0000	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
offers	offer	o1062	VBZ	B-VP	O
advantages	advantage	a310530202	NNS	B-NP	O
over	over	o106	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
status	status	s30302	NN	I-NP	O
influences	influence	i51405202	VBZ	B-VP	O
chronic	chronic	c060502	JJ	B-NP	O
amphotericin	amphotericin	a5103060205	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
intraperitoneally	intraperitoneally	i53601060305040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
depleted	deplete	d0140303	VBN	I-NP	O
,	,	,000	,	I-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
depleted	deplete	d0140303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
linearly	linearly	l050640	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
time	time	t050	NN	B-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
85	85	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
by	by	b000	IN	B-PP	O
week	week	w020	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
but	but	b030	CC	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
extent	extent	e23053	NN	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
2	2	2000	CD	I-NP	O
and	and	a530	CC	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
depleted	deplete	d0140303	VBN	B-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
patchy	patchy	p0320	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	I-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
tubules	tubule	t010402	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	O
or	or	o600	CC	I-NP	O
salt	salt	s043	NN	I-NP	O
-	-	-000	HYPH	O	O
loaded	load	l0303	VBN	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Concentrations	Concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significantly	significantly	s025010205340	RB	I-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
time	time	t050	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
and	and	a530	CC	I-NP	O
liver	liver	l0106	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	O	O
depleted	deplete	d0140303	VBN	B-NP	O
and	and	a530	CC	I-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
/	/	/000	SYM	B-VP	O
kidney	kidney	k0350	NN	B-NP	O
ratios	ratio	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
21	21	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
in	in	i500	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
depleted	deplete	d0140303	VBN	I-NP	O
,	,	,000	,	I-NP	O
normal	normal	n06504	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
salt	salt	s043	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
salt	salt	s043	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
loaded	load	l0303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
reductions	reduction	r03023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
amphotericin	amphotericin	a5103060205	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
accumulation	accumulation	a205040305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
amphotericin	amphotericin	a5103060205	NN	I-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
administration	administration	a350502360305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
salt	salt	s043	NN	B-NP	O
depletion	depletion	d0140305	NN	I-NP	O
and	and	a530	CC	O	O
attenuated	attenuate	a3050303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
loading	loading	l03052	NN	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
ultra	ultra	u4360	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ACC	ACC	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9089	9089	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
nonselective	nonselective	n05204023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
,	,	,000	,	O	O
ultra	ultra	u4360	AFX	O	O
-	-	-000	HYPH	O	O
short	short	s063	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
acting	act	a23052	VBG	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
intrinsic	intrinsic	i53605202	JJ	I-NP	O
sympathomimetic	sympathomimetic	s0510305050302	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
metabolized	metabolize	m0301040203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
esterases	esteras	e23060202	NNS	I-NP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
elimination	elimination	e405050305	NN	I-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
of	of	o100	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
6	6	6000	CD	I-NP	O
.	.	.000	.	I-NP	O
5	5	5000	CD	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
100	100	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
blocking	block	b402052	VBG	B-VP	O
dose	dose	d020	NN	B-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
seven	seven	s0105	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
blood	blood	b403	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
linearly	linearly	l050640	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	I-NP	O
good	good	g030	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
exists	exist	e20232	VBZ	B-VP	O
between	between	b0305	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
attenuation	attenuation	a3050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
.	.	.000	.	O	O

Electrophysiologic	Electrophysiologic	e402360102040202	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
beta	beta	b030	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
beta	beta	b030	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
reverse	reverse	r010620	VBP	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
(	(	(000	(	O	O
within	within	w0305	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
)	)	)000	)	O	O
following	follow	f04052	VBG	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
its	its	i320	PRP$	B-NP	O
short	short	s063	JJ	I-NP	O
half	half	h041	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
life	life	l010	NN	I-NP	O
.	.	.000	.	O	O

Flestolol	Flestolol	f40230404	NN	B-NP	B-Chemical
effectively	effectively	e102301040	RB	B-ADVP	O
reduced	reduce	r030203	VBD	B-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
supraventricular	supraventricular	s016010536020406	JJ	B-NP	B-Disease
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
unstable	unstable	u5230140	JJ	B-NP	B-Disease
angina	angina	a52050	NN	I-NP	I-Disease
,	,	,000	,	O	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
safe	safe	s010	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
controlling	control	c053604052	VBG	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potent	potent	p03053	JJ	I-NP	O
,	,	,000	,	O	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
tolerated	tolerate	t04060303	VBN	B-VP	O
,	,	,000	,	O	O
ultra	ultra	u4360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
short	short	s063	JJ	B-ADJP	O
-	-	-000	HYPH	O	O
acting	act	a23052	VBG	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
blocking	block	b402052	VBG	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
flestolol	flestolol	f40230404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
care	care	c060	NN	I-NP	O
setting	setting	s03052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
currently	currently	c0605340	RB	I-VP	O
undergoing	undergo	u53062052	VBG	I-VP	O
investigation	investigation	i51023020305	NN	B-NP	O
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
,	,	,000	,	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
morphometric	morphometric	m0610503602	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
prolactinomas	prolactinoma	p604023050502	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
prolactinoma	prolactinoma	p60402305050	NN	B-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
,	,	,000	,	I-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
morphometrical	morphometrical	m061050360204	JJ	I-NP	O
analyses	analysis	a5040202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
applied	apply	a1403	VBN	I-VP	O
to	to	t000	TO	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
prolactinoma	prolactinoma	p60402305050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
1	1	1000	CD	B-NP	O
h	h	h000	NN	I-NP	O
and	and	a530	CC	I-NP	O
6	6	6000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
of	of	o100	IN	B-PP	O
body	body	b030	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
markedly	markedly	m0620340	RB	B-ADVP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
disclosed	disclose	d0240203	VBD	B-VP	O
many	many	m050	JJ	B-NP	O
secretory	secretory	s02603060	JJ	I-NP	O
granules	granule	g6050402	NNS	I-NP	O
,	,	,000	,	O	O
slightly	slightly	s4020340	RB	B-NP	O
distorted	distorted	d02306303	JJ	I-NP	O
rough	rough	r020	JJ	I-NP	O
endoplasmic	endoplasmic	e5301402502	JJ	I-NP	O
reticulum	reticulum	r03020405	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
partially	partially	p063040	RB	B-NP	O
dilated	dilated	d040303	JJ	I-NP	O
Golgi	Golgi	g0420	NNP	I-NP	O
cisternae	cisterna	c0230650	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prolactinoma	prolactinoma	p60402305050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Morphometric	Morphometric	m0610503602	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
secretory	secretory	s02603060	JJ	B-NP	O
granules	granule	g6050402	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	B-NP	O
microtubules	microtubule	m02603010402	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
lowered	lower	l0603	VBN	B-NP	O
serum	serum	s0605	NN	I-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
phase	phase	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
impaired	impaired	i510603	JJ	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
decreasing	decrease	d02602052	VBG	B-NP	O
numbers	number	n051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cytoplasmic	cytoplasmic	c0301402502	JJ	B-NP	O
microtubules	microtubule	m02603010402	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
,	,	,000	,	O	O
serum	serum	s0605	NN	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
still	still	s304	RB	B-ADVP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prolactinoma	prolactinoma	p60402305050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
time	time	t050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
well	well	w040	RB	I-VP	O
granulated	granulate	g605040303	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
vesiculated	vesiculate	v0202040303	VBN	B-NP	O
rough	rough	r020	JJ	I-NP	O
endoplasmic	endoplasmic	e5301402502	JJ	I-NP	O
reticulum	reticulum	r03020405	NN	I-NP	O
and	and	a530	CC	O	O
markedly	markedly	m0620340	RB	B-VP	O
dilated	dilate	d040303	VBD	I-VP	O
Golgi	Golgi	g0420	NNP	B-NP	O
cisternae	cisterna	c0230650	NNS	I-NP	O
.	.	.000	.	O	O

Electron	Electron	e4023605	NN	B-NP	O
microscopical	microscopical	m02602010204	JJ	I-NP	O
immunohistochemistry	immunohistochemistry	i505023020502360	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
positive	positive	p0203010	JJ	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
noted	note	n0303	VBN	B-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
secretory	secretory	s02603060	JJ	I-NP	O
granules	granule	g6050402	NNS	I-NP	O
,	,	,000	,	O	O
Golgi	Golgi	g0420	NNP	B-NP	O
cisternae	cisterna	c0230650	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
endoplasmic	endoplasmic	e5301402502	JJ	B-NP	O
reticulum	reticulum	r03020405	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
untreated	untreated	u5360303	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
prolactinoma	prolactinoma	p60402305050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
secretory	secretory	s02603060	JJ	I-NP	O
granules	granule	g6050402	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
products	product	p6030232	NNS	I-NP	O
for	for	f060	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
6	6	6000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
adenoma	adenoma	a305050	NN	I-NP	B-Disease
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
density	density	d052030	NN	I-NP	O
of	of	o100	IN	B-PP	O
secretory	secretory	s02603060	JJ	B-NP	O
granules	granule	g6050402	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
volume	volume	v04050	NN	I-NP	O
densities	density	d0520302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rough	rough	r020	JJ	B-NP	O
endoplasmic	endoplasmic	e5301402502	JJ	I-NP	O
reticulum	reticulum	r03020405	NN	I-NP	O
and	and	a530	CC	I-NP	O
microtubules	microtubule	m02603010402	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
morphometric	morphometric	m0610503602	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
bromocriptine	bromocriptine	b605026013050	NN	B-NP	B-Chemical
inhibits	inhibit	i501032	VBZ	B-VP	O
protein	protein	p60305	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
bringing	bring	b6052052	VBG	B-VP	O
about	about	a103	IN	B-PP	O
a	a	a000	DT	B-NP	O
disturbance	disturbance	d0230610520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
.	.	.000	.	O	O

Sulfasalazine	Sulfasalazine	s041020402050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lupus	lupus	l0102	NN	I-NP	B-Disease
erythematosus	erythematosus	e60305030202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Pneumonitis	Pneumonitis	p505050302	NN	B-NP	B-Disease
,	,	,000	,	O	O
bilateral	bilateral	b04030604	JJ	B-NP	O
pleural	pleural	p40604	JJ	I-NP	B-Disease
effusions	effusion	e102052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
echocardiographic	echocardiographic	e2020630260102	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
tamponade	tamponade	t05105030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
positive	positive	p0203010	JJ	B-NP	O
autoantibodies	autoantibody	a03053010302	NNS	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
43	43	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
sulfasalazine	sulfasalazine	s041020402050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
ulcerative	ulcerative	u420603010	JJ	I-NP	B-Disease
colitis	colitis	c040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sulfasalazine	sulfasalazine	s041020402050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
six	six	s020	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
,	,	,000	,	O	O
these	these	t020	DT	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
resolved	resolve	r0204103	VBN	B-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
four	four	f060	CD	B-NP	O
to	to	t000	TO	I-NP	O
six	six	s020	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lupus	lupus	l0102	NN	I-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
manifested	manifest	m050102303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
serositis	serositis	s06020302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
parenchymal	parenchymal	p060520504	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
joint	joint	j053	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
who	who	w000	WP	B-NP	O
use	use	u200	VBP	B-VP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sulfasalazine	sulfasalazine	s041020402050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
lupus	lupus	l0102	NN	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
:	:	:000	:	O	O
efficacy	efficacy	e102020	NN	B-NP	O
,	,	,000	,	O	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
effect	effect	e1023	NN	B-NP	O
on	on	o500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
tissue	tissue	t020	NN	I-NP	O
folate	folate	f04030	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

Folate	Folate	f04030	JJ	B-NP	B-Chemical
depletion	depletion	d0140305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
often	often	o1305	RB	I-VP	O
been	be	b050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
problem	problem	p601405	NN	I-NP	O
in	in	i500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
(	(	(000	(	O	O
AED	AED	a030	NN	B-NP	O
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Carbamazepine	Carbamazepine	c061050201050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
used	use	u203	VBN	I-NP	O
AED	AED	a030	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
model	model	m0304	NN	I-NP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
folate	folate	f04030	JJ	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
vehicle	vehicle	v0240	NN	I-NP	O
,	,	,000	,	O	O
propylene	propylene	p60104050	NN	B-NP	B-Chemical
glycol	glycol	g40204	NN	I-NP	I-Chemical
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
itself	itself	i32041	PRP	B-NP	O
in	in	i500	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
exhibit	exhibit	e20103	VB	I-VP	O
protective	protective	p603023010	JJ	B-NP	O
properties	property	p60106302	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
inhibited	inhibit	i5010303	VBD	B-VP	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seizures	Seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hexafluorodiethyl	hexafluorodiethyl	h0201406030304	NN	B-NP	B-Chemical
ether	ether	e306	NN	I-NP	I-Chemical
(	(	(000	(	O	O
HFDE	HFDE	h130	NN	B-NP	B-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
sensitive	sensitive	s05203010	JJ	I-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
protection	protection	p60302305	NN	B-NP	O
by	by	b000	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
electroshock	electroshock	e402360202	NN	I-NP	O
(	(	(000	(	O	O
MES	MES	m020	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
aqueous	aqueous	a202	JJ	I-NP	O
suspension	suspension	s02105205	NN	I-NP	O
every	every	e1060	DT	B-NP	O
8	8	8000	CD	I-NP	O
h	h	h000	NN	I-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
continuously	continuously	c053050240	RB	B-ADJP	O
protective	protective	p603023010	JJ	I-ADJP	O
against	against	a20523	IN	B-PP	O
HFDE	HFDE	h130	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
minimally	minimally	m0505040	RB	B-ADJP	O
toxic	toxic	t0202	JJ	I-ADJP	O
as	as	a200	IN	B-SBAR	O
measured	measure	m020603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
over	over	o106	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
CBZ	CBZ	c120	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
measured	measure	m020603	VBN	B-VP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
below	below	b040	IN	B-PP	O
those	those	t020	DT	B-NP	O
normally	normally	n065040	RB	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
protective	protective	p603023010	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
CBZ	CBZ	c120	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
folate	folate	f04030	JJ	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
indeed	indeed	i5303	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
folate	folate	f04030	JJ	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
after	after	a1306	IN	B-PP	O
6	6	6000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Dipyridamole	Dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Angina	Angina	a52050	NNP	B-NP	B-Disease
and	and	a530	CC	O	O
ischemic	ischemic	i20502	JJ	B-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
awaiting	await	a03052	VBG	B-VP	O
urgent	urgent	u62053	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
revascularization	revascularization	r01020406020305	NN	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
preoperative	preoperative	p6010603010	JJ	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
ischemia	ischemia	i2050	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
occur	occur	o206	VB	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
and	and	a530	CC	I-NP	O
humans	human	h05052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Epicardial	Epicardial	e10206304	JJ	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
collateral	collateral	c04030604	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
"	"	"000	``	I-NP	O
steal	steal	s304	JJ	I-NP	O
"	"	"000	''	I-NP	O
phenomenon	phenomenon	p05050505	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ischemia	ischemia	i2050	NN	I-NP	B-Disease
observed	observe	o1206103	VBN	B-VP	O
.	.	.000	.	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
sympathoadrenal	sympathoadrenal	s051030360504	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
by	by	b000	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
conscious	conscious	c05202	JJ	I-NP	O
,	,	,000	,	I-NP	O
trained	trained	t60503	JJ	I-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
maintained	maintain	m0530503	VBN	B-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
sympathetic	sympathetic	s051030302	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
during	during	d06052	IN	B-PP	O
15	15	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
minute	minute	m05030	JJ	I-NP	O
i	i	i000	NNS	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
atrial	atrial	a3604	JJ	I-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	HYPH	B-NP	O
SEM	SEM	s050	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
randomized	randomize	r053050203	VBN	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
99	99	0000	CD	B-NP	O
+	+	+000	SYM	B-VP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	I-NP	O
95	95	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
93	93	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
79	79	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
tachycardia	tachycardia	t02020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
augmentation	augmentation	a0250530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
release	release	r04020	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
up	up	u100	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
comparable	comparable	c051060140	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hydralazine	hydralazine	h0360402050	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
release	release	r04020	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
control	control	c053604	NN	B-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
declined	decline	d0240503	VBD	B-VP	O
immediately	immediately	i50303040	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
infusions	infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
49	49	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	B-NP	O
and	and	a530	CC	B-PP	O
to	to	t000	TO	B-PP	O
63	63	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
p	p	p000	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
95	95	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
not	not	n030	RB	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
or	or	o600	CC	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Steady	Steady	s3030	JJ	B-NP	O
state	state	s3030	NN	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
were	be	w060	VBD	B-VP	O
39	39	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
infusions	infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
and	and	a530	CC	O	O
284	284	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
24	24	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
1520	1520	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
300	300	0000	CD	B-NP	O
pg	pg	p200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
factor	factor	f02306	NN	I-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Inhibition	Inhibition	i5010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
immunoreactive	immunoreactive	i50506023010	JJ	B-NP	O
corticotropin	corticotropin	c063020360105	NN	I-NP	O
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypophysial	hypophysial	h01010204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
portal	portal	p06304	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
by	by	b000	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
glucocorticoid	glucocorticoid	g402020630203	NN	I-NP	O
feedback	feedback	f03102	NN	I-NP	O
.	.	.000	.	O	O

Nitroprusside	Nitroprusside	n03601602030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
evokes	evoke	e10202	VBZ	B-VP	O
ACTH	ACTH	a230	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
primarily	primarily	p60506040	RB	I-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunoreactive	immunoreactive	i50506023010	JJ	B-NP	O
corticotropin	corticotropin	c063020360105	NN	I-NP	O
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
(	(	(000	(	O	O
irCRF	irCRF	i6261	NN	B-NP	O
)	)	)000	)	O	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypophysial	hypophysial	h01010204	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
portal	portal	p06304	JJ	I-NP	O
circulation	circulation	c062040305	NN	I-NP	O
.	.	.000	.	O	O

Portal	Portal	p06304	JJ	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neither	neither	n0306	CC	O	O
arginine	arginine	a6205050	NN	B-NP	B-Chemical
vasopressin	vasopressin	v020160205	NN	I-NP	I-Chemical
nor	nor	n060	CC	I-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
altered	alter	a430603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
paradigm	paradigm	p0603025	NN	I-NP	O
.	.	.000	.	O	O

Application	Application	a14020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
feedback	feedback	f03102	NN	I-NP	O
signal	signal	s02504	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
h	h	h000	NN	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
urethane	urethane	u603050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
anesthetized	anesthetize	a5023030203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
blockade	blockade	b402030	NN	I-NP	O
of	of	o100	IN	B-PP	O
glucocorticoid	glucocorticoid	g402020630203	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
without	without	w0303	IN	B-PP	O
effect	effect	e1023	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
resting	rest	r023052	VBG	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
of	of	o100	IN	B-PP	O
arginine	arginine	a6205050	NN	B-NP	B-Chemical
vasopressin	vasopressin	v020160205	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
oxytocin	oxytocin	o2030205	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
any	any	a500	DT	B-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
feedback	feedback	f03102	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
tested	test	t02303	VBN	B-VP	O
.	.	.000	.	O	O

Resting	Rest	r023052	VBG	B-VP	O
irCRF	irCRF	i6261	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
40	40	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
.	.	.000	.	O	O

Suppression	Suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
irCRF	irCRF	i6261	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
in	in	i500	IN	B-PP	O
response	response	r0210520	NN	I-PP	O
to	to	t000	TO	I-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
and	and	a530	CC	O	O
occurs	occur	o2062	VBZ	B-VP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
corticosterone	corticosterone	c0630202306050	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
12	12	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
provide	provide	p601030	VBP	B-VP	O
further	further	f06306	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
central	central	c053604	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
feedback	feedback	f03102	NN	I-NP	O
process	process	p60202	NN	I-NP	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
modulation	modulation	m03040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
irCRF	irCRF	i6261	NN	B-NP	O
release	release	r04020	NN	I-NP	O
.	.	.000	.	O	O

Noradrenergic	Noradrenergic	n060360506202	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
delta	delta	d0430	SYM	B-NP	B-Chemical
9	9	9000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrahydrocannabinol	tetrahydrocannabinol	t0360360205010504	NN	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
elucidate	elucidate	e40203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
catecholaminergic	catecholaminergic	c030204050506202	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cataleptogenic	cataleptogenic	c0304013020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
delta	delta	d0430	SYM	B-NP	B-Chemical
9	9	9000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
tetrahydrocannabinol	tetrahydrocannabinol	t0360360205010504	NN	B-NP	I-Chemical
(	(	(000	(	O	O
THC	THC	t020	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxydopamine	hydroxydopamine	h03602030105050	NN	I-NP	I-Chemical
(	(	(000	(	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
locus	locus	l0202	NN	I-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cataleptogenic	cataleptogenic	c0304013020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
THC	THC	t020	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
locus	locus	l0202	NN	I-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cataleptogenic	cataleptogenic	c0304013020502	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
6	6	6000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
OHDA	OHDA	o030	NN	I-NP	I-Chemical
or	or	o600	CC	B-PP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
locus	locus	l0202	NN	I-NP	O
coeruleus	coeruleus	c060402	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
noradrenergic	noradrenergic	n060360506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
THC	THC	t020	NN	B-NP	B-Chemical
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
neurons	neuron	n06052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
catalepsy	catalepsy	c03040120	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Reversibility	Reversibility	r010620104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
use	use	u200	NN	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
renovascular	renovascular	r0501020406	JJ	B-NP	B-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
occluded	occlude	o240303	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
solitary	solitary	s0403060	JJ	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
deterioration	deterioration	d0306060305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
renal	renal	r0504	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
impaired	impaired	i510603	JJ	B-ADJP	O
but	but	b030	CC	I-ADJP	O
stable	stable	s30140	JJ	I-ADJP	O
during	during	d06052	IN	B-PP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
'	'	'000	POS	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
reversibility	reversibility	r010620104030	NN	B-NP	O
in	in	i500	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
even	even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
organic	organic	o620502	JJ	I-NP	O
damage	damage	d05020	NN	I-NP	O
occurs	occur	o2062	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
glomerular	glomerular	g405060406	JJ	B-NP	O
arterioles	arteriole	a63060402	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
ACE	ACE	a200	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
.	.	.000	.	O	O

HMG	HMG	h520	NN	B-NP	O
CoA	CoA	c000	NN	I-NP	O
reductase	reductase	r03023020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
experience	experience	e21060520	NN	I-NP	O
.	.	.000	.	O	O

Lovastatin	Lovastatin	l010230305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
best	good	b023	JJS	I-NP	O
-	-	-000	HYPH	I-NP	O
known	know	k505	VBN	I-NP	O
members	member	m051062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypolipidaemic	hypolipidaemic	h010401030502	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
known	know	k505	VBN	B-VP	O
as	as	a200	IN	B-PP	O
HMG	HMG	h520	NN	B-NP	O
CoA	CoA	c000	NN	I-NP	O
reductase	reductase	r03023020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
experience	experience	e21060520	NN	I-NP	O
with	with	w030	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
includes	include	i5240302	VBZ	B-VP	O
over	over	o106	IN	B-NP	O
5000	5000	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
700	700	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
experience	experience	e21060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
simvastatin	simvastatin	s0510230305	NN	B-NP	B-Chemical
includes	include	i5240302	VBZ	B-VP	O
over	over	o106	IN	B-NP	O
3500	3500	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
350	350	0000	CD	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
18	18	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
.	.	.000	.	O	O

Lovastatin	Lovastatin	l010230305	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
marketed	market	m0620303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
for	for	f060	IN	B-PP	O
over	over	o106	IN	B-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
show	show	s000	VBP	B-VP	O
substantial	substantial	s012305304	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
reductions	reduction	r03023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
total	total	t0304	JJ	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
over	over	o106	IN	B-NP	O
30	30	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
LDL	LDL	l340	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
of	of	o100	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

Modest	Modest	m03023	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
HDL	HDL	h340	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
about	about	a103	IN	B-NP	O
10	10	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
are	be	a600	VBP	B-VP	O
also	also	a420	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
good	good	g030	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
fewer	few	f060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
withdrawn	withdraw	w0303605	VBN	B-VP	O
from	from	f605	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
experiences	experience	e210605202	NNS	I-NP	O
.	.	.000	.	O	O

Ophthalmological	Ophthalmological	o10304504020204	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
over	over	o106	IN	B-NP	O
1100	1100	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
have	have	h010	VBP	B-VP	O
revealed	reveal	r010403	VBN	I-VP	O
no	no	n000	DT	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
short	short	s063	JJ	I-NP	O
term	term	t065	NN	I-NP	O
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
)	)	)000	)	O	O
cataractogenic	cataractogenic	c0306023020502	JJ	B-NP	O
potential	potential	p0305304	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
to	to	t000	TO	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
elevations	elevation	e40103052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
the	the	t000	DT	I-NP	O
upper	upper	u106	JJ	I-NP	O
limit	limit	l0503	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
therapy	therapy	t06010	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
.	.	.000	.	O	O

Minor	Minor	m0506	JJ	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
kinase	kinase	k05020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
about	about	a103	RB	B-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Myopathy	Myopathy	m01030	NN	B-NP	B-Disease
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
myoglobinuria	myoglobinuria	m0240105060	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
rarely	rarely	r06040	RB	I-VP	O
reported	report	r0106303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lovastatin	lovastatin	l010230305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
concomitantly	concomitantly	c052050305340	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
gemfibrozil	gemfibrozil	g0510160204	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
niacin	niacin	n0205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Lovastatin	Lovastatin	l010230305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
simvastatin	simvastatin	s0510230305	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
both	both	b030	DT	O	O
effective	effective	e1023010	JJ	B-ADJP	O
and	and	a530	CC	O	O
well	well	w040	RB	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
tolerated	tolerate	t04060303	VBN	B-NP	O
agents	agent	a20532	NNS	I-NP	O
for	for	f060	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
elevated	elevated	e4010303	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
wider	wide	w0306	JJR	B-NP	O
use	use	u200	NN	I-NP	O
confirms	confirm	c0510652	VBZ	B-VP	O
their	their	t060	PRP$	B-NP	O
safety	safety	s01030	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
will	will	w040	MD	B-VP	O
gain	gain	g050	VB	I-VP	O
increasing	increase	i52602052	VBG	B-NP	O
importance	importance	i510630520	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
approach	approach	a16020	NN	I-NP	O
to	to	t000	TO	B-PP	O
hypercholesterolaemia	hypercholesterolaemia	h01062040230604050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
.	.	.000	.	O	O

Hepatic	Hepatic	h010302	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
Kingdom	Kingdom	k052305	NNP	I-NP	O
.	.	.000	.	O	O

Ketoconazole	Ketoconazole	k03020502040	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
introduced	introduce	i536030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
Kingdom	Kingdom	k052305	NNP	I-NP	O
in	in	i500	IN	B-PP	O
1981	1981	0000	CD	B-NP	O
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
November	November	n0105106	NNP	B-NP	O
1984	1984	0000	CD	I-NP	O
the	the	t000	DT	B-NP	O
Committee	Committee	c05030	NNP	I-NP	O
on	on	o500	IN	B-PP	O
Safety	Safety	s01030	NNP	B-NP	O
of	of	o100	IN	B-PP	O
Medicines	Medicines	m03020502	NNP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
82	82	0000	CD	B-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
possible	possible	p020140	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
five	five	f010	CD	B-NP	O
deaths	death	d0302	NNS	I-NP	B-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
75	75	0000	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
adequately	adequately	a30203040	RB	I-VP	O
followed	follow	f0403	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
16	16	0000	CD	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
three	three	t060	CD	B-NP	O
deaths	death	d0302	NNS	I-NP	B-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
probably	probably	p6010140	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
remainder	remainder	r0505306	NN	I-NP	O
,	,	,000	,	O	O
48	48	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
possibly	possibly	p020140	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
five	five	f010	CD	B-NP	O
were	be	w060	VBD	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
so	so	s000	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
were	be	w060	VBD	B-VP	O
unclassifiable	unclassifiable	u52402010140	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
16	16	0000	CD	I-NP	O
probable	probable	p6010140	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
57	57	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
being	be	b052	VBG	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
61	61	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
well	well	w040	RB	I-NP	O
validated	validate	v04030303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
10	10	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
rest	rest	r023	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mixed	mix	m0203	VBN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
often	often	o1305	RB	B-ADVP	O
showed	show	s030	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
cholestasis	cholestasis	c040230202	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
characteristics	characteristic	c060230602302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
48	48	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
cases	case	c0202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
.	.	.000	.	O	O

Allergic	Allergic	a406202	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
rash	rash	r020	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
eosinophilia	eosinophilia	e020501040	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

Hepatitis	Hepatitis	h01030302	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
usually	usually	u2040	RB	B-ADVP	O
reversible	reversible	r010620140	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
treatment	treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
returning	return	r03065052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
deaths	death	d0302	NNS	I-NP	B-Disease
probably	probably	p6010140	RB	B-ADVP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
continued	continue	c0530503	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
jaundice	jaundice	j053020	NN	B-NP	B-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
at	at	a300	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
for	for	f060	IN	B-PP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
advised	advise	a310203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
long	long	l052	JJ	B-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
ketoconazole	ketoconazole	k03020502040	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
possible	possible	p020140	JJ	B-NP	O
serious	serious	s0602	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Glyburide	Glyburide	g40106030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
common	common	c0505	JJ	B-ADJP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
infrequently	infrequently	i5160205340	RB	I-ADVP	O
with	with	w030	IN	B-PP	O
sulfonylureas	sulfonylurea	s04105040602	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
glyburide	glyburide	g40106030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
generation	generation	g05060305	NN	I-NP	O
sulfonylurea	sulfonylurea	s0410504060	NN	I-NP	B-Chemical
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
two	two	t000	CD	I-NP	O
brief	brief	b601	JJ	I-NP	O
reports	report	r010632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
exist	exist	e2023	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
type	type	t010	NN	B-NP	B-Disease
II	II	i000	CD	I-NP	I-Disease
diabetes	diabete	d010302	NNS	I-NP	I-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
soon	soon	s050	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
glyburide	glyburide	g40106030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
serologic	serologic	s06040202	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
viral	viral	v0604	JJ	B-NP	B-Disease
infection	infection	i5102305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
drug	drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
induced	induce	i530203	VBN	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
quickly	quickly	q0240	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
glyburide	glyburide	g40106030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
have	have	h010	VBP	B-VP	O
remained	remain	r050503	VBN	I-VP	O
well	well	w040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

Glyburide	Glyburide	g40106030	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
illness	illness	i4502	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
some	some	s050	DT	B-NP	O
persons	person	p062052	NNS	I-NP	O
.	.	.000	.	O	O

Intracranial	Intracranial	i5360260504	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
during	during	d06052	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Intracranial	Intracranial	i5360260504	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
ICP	ICP	i210	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
,	,	,000	,	I-NP	O
central	central	c053604	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
(	(	(000	(	O	O
CVP	CVP	c100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
subdural	subdural	s0130604	JJ	B-NP	O
cannulae	cannulae	c05040	NNS	I-NP	O
inserted	insert	i5206303	VBN	B-VP	O
under	under	u5306	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mechanically	mechanically	m020502040	RB	I-VP	O
ventilated	ventilate	v053040303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
achieve	achieve	a2010	VB	I-VP	O
normocarbia	normocarbia	n065020610	NN	B-NP	O
(	(	(000	(	O	O
PCO2	PCO2	0000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
42	42	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
1	1	1000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SE	SE	s000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
instrumentation	instrumentation	i5236050530305	NN	B-NP	O
,	,	,000	,	O	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
(	(	(000	(	O	O
125	125	0000	CD	B-NP	O
mu	mu	m000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-NP	O
iv	iv	i100	NN	I-NP	O
during	during	d06052	IN	B-PP	O
emergence	emergence	e50620520	NN	B-NP	O
from	from	f605	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
five	five	f010	CD	I-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
somatic	somatic	s050302	JJ	B-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
,	,	,000	,	I-NP	O
ICP	ICP	i210	NN	I-NP	O
and	and	a530	CC	I-NP	O
CVP	CVP	c100	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
above	above	a1010	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
(	(	(000	(	O	O
delta	delta	d0430	SYM	B-NP	O
ICP	ICP	i210	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
,	,	,000	,	O	O
delta	delta	d0430	SYM	O	O
CVP	CVP	c100	NN	B-NP	O
5	5	5000	CD	I-NP	O
.	.	.000	.	I-NP	O
9	9	9000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
variables	variable	v0601402	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
when	when	w050	WRB	B-ADVP	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
abolished	abolish	a1040203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
metocurine	metocurine	m030206050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
five	five	f010	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
become	become	b02050	VBN	I-VP	O
rigid	rigid	r0203	JJ	B-NP	O
,	,	,000	,	I-NP	O
ICP	ICP	i210	NN	I-NP	O
and	and	a530	CC	I-NP	O
CVP	CVP	c100	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
following	follow	f04052	VBG	B-PP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
alfentanil	alfentanil	a410530504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
presumably	presumably	p602050140	RB	B-ADVP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
opiates	opiate	o10302	NNS	I-NP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ICP	ICP	i210	NN	B-NP	O
problems	problem	p6014052	NNS	I-NP	O
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
hypertensive	hypertensive	h01063052010	JJ	I-NP	B-Disease
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
angiogram	angiogram	a5202605	NN	I-NP	O
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	O	O
relatively	relatively	r040301040	RB	B-ADJP	O
-	-	-000	HYPH	I-ADJP	O
safe	safe	s010	JJ	B-NP	O
antihypertensive	antihypertensive	a5301063052010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Serious	Serious	s0602	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
and	and	a530	CC	O	O
mainly	mainly	m0540	RB	B-VP	O
have	have	h010	VBP	I-VP	O
been	be	b050	VBN	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
and	and	a530	CC	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
combined	combine	c0510503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-PP	O
blocking	block	b402052	VBG	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
coincided	coincide	c0520303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
introduction	introduction	i5360302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
captopril	captopril	c01301604	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
asymptomatic	asymptomatic	a20513050302	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
involve	involve	i510410	VBP	B-VP	O
a	a	a000	DT	B-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
platelet	platelet	p4030403	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
vascular	vascular	v020406	JJ	B-NP	O
alpha	alpha	a410	NN	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenoreceptor	adrenoreceptor	a3605060201306	NN	I-NP	O
affinity	affinity	a105030	NN	I-NP	O
for	for	f060	IN	B-PP	O
catecholamines	catecholamine	c030204050502	NNS	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Haemolytic	Haemolytic	h05040302	JJ	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uraemic	uraemic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
paper	paper	p0106	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
haemolytic	haemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uraemic	uraemic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
children	child	c043605	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
older	old	o4306	JJR	B-ADJP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
undergone	undergo	u53062050	VBN	I-VP	O
recent	recent	r02053	JJ	B-NP	O
bowel	bowel	b040	NN	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
than	than	t050	IN	B-SBAR	O
are	be	a600	VBP	B-VP	O
other	other	o306	JJ	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
aetiology	aetiology	a0304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
haemolytic	haemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uraemic	uraemic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
established	establish	e230140203	VBN	I-VP	O
firmly	firmly	f06540	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
sensitizing	sensitize	s0520302052	VBG	B-VP	O
tissues	tissue	t0202	NNS	B-NP	O
to	to	t000	TO	B-PP	O
oxidation	oxidation	o2030305	NN	B-NP	O
injury	injury	i52060	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
reported	report	r0106303	VBN	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidation	oxidation	o2030305	NN	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
haemolytic	haemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uraemic	uraemic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
link	link	l052	NN	I-NP	O
between	between	b0305	IN	B-PP	O
metronidazole	metronidazole	m036050302040	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
some	some	s050	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
haemolytic	haemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uraemic	uraemic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
platin	platin	p40305	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Survival	Survival	s0610104	NN	B-NP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
advanced	advance	a3105203	VBN	B-NP	O
head	head	h030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
esophageal	esophageal	e2010204	JJ	B-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
poor	poor	p060	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

Obviously	Obviously	o10240	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
effective	effective	e1023010	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
cis	cis	c020	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
platin	platin	p40305	NN	B-NP	I-Chemical
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2BSA	m2BSA	0000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2BSA	m2BSA	0000	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
during	during	d06052	IN	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
76	76	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
and	and	a530	CC	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
and	and	a530	CC	B-PP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
serial	serial	s0604	JJ	I-NP	O
ECG	ECG	e200	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
,	,	,000	,	O	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
33	33	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
18	18	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
as	as	a200	IN	B-PP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
64	64	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
without	without	w0303	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
T	T	t000	NN	I-NP	O
wave	wave	w010	NN	I-NP	O
changes	change	c05202	NNS	I-NP	O
and	and	a530	CC	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
sudden	sudden	s0305	JJ	B-NP	B-Disease
death	death	d030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
under	under	u5306	IN	B-PP	O
close	close	c4020	JJ	B-NP	O
supervision	supervision	s010610205	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
tachyarrhythmia	tachyarrhythmia	t020603050	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Death	Death	d030	NN	B-NP	B-Disease
from	from	f605	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
in	in	i500	IN	B-PP	O
gestational	gestational	g023030504	JJ	B-NP	B-Disease
trophoblastic	trophoblastic	t60101402302	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Multiple	Multiple	m0430140	JJ	B-NP	O
cytotoxic	cytotoxic	c03030202	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
generally	generally	g0506040	RB	I-NP	O
accepted	accept	a201303	VBN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
stage	stage	s3020	NN	I-NP	O
of	of	o100	IN	B-PP	O
choriocarcinoma	choriocarcinoma	c060206205050	NN	B-NP	B-Disease
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
this	this	t020	DT	B-NP	O
principle	principle	p60520140	NN	I-NP	O
a	a	a000	DT	B-NP	O
27	27	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
old	old	o430	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
,	,	,000	,	O	O
classified	classify	c4020103	VBN	B-VP	O
as	as	a200	IN	B-PP	O
being	be	b052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
risk	risk	r020	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
Goldstein	Goldstein	g0432305	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Berkowitz	Berkowitz	b062032	NNP	I-NP	O
score	score	s2060	NN	I-NP	O
:	:	:000	:	O	O
11	11	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
multiple	multiple	m0430140	JJ	B-NP	O
cytotoxic	cytotoxic	c03030202	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
schema	schema	s2050	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
:	:	:000	:	O	O
Etoposide	Etoposide	e30102030	NN	B-NP	B-Chemical
16	16	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
213	213	0000	CD	I-NP	O
,	,	,000	,	O	O
Methotrexate	Methotrexate	m0303602030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
Actomycin	Actomycin	a23050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
D	D	d000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
Cisplatin	Cisplatin	c02140305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
schedule	schedule	s203040	NN	I-NP	O
,	,	,000	,	O	O
moderate	moderate	m0306030	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Methotrexate	Methotrexate	m0303602030	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
Etoposide	Etoposide	e30102030	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
.	.	.000	.	O	O

Within	Within	w0305	IN	B-PP	O
8	8	8000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
died	die	d030	VBD	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
resembling	resemble	r020514052	VBG	B-VP	O
massive	massive	m02010	JJ	B-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	B-Disease
obstruction	obstruction	o123602305	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
choriocarcinomic	choriocarcinomic	c0602062050502	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
plugs	plug	p402	NNS	I-NP	O
,	,	,000	,	O	O
probably	probably	p6010140	RB	B-ADVP	O
originating	originate	o6020503052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
uterus	uterus	u30602	NN	I-NP	O
.	.	.000	.	O	O

Formation	Formation	f0650305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
plugs	plug	p402	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
extensive	extensive	e23052010	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
walls	wall	w042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
uterine	uterine	u306050	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
exchange	exchange	e20520	NN	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
plugs	plug	p402	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
spaces	space	s10202	NNS	I-NP	O
;	;	;000	:	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
tissue	tissue	t020	NN	I-NP	O
coherence	coherence	c060520	NN	I-NP	O
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
further	further	f06306	RBR	I-VP	O
contributed	contribute	c0536010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
emboli	embolus	e51040	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
close	close	c4020	JJ	I-NP	O
time	time	t050	NN	I-NP	O
association	association	a2020305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
embolism	embolism	e5104025	NN	I-NP	B-Disease
other	other	o306	JJ	I-NP	O
explanations	explanation	e2140503052	NNS	I-NP	O
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
,	,	,000	,	O	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
less	less	l020	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
pelvic	pelvic	p04102	JJ	I-NP	B-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
loads	load	l032	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
,	,	,000	,	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
existing	exist	e2023052	VBG	B-NP	O
classifications	classification	c402010203052	NNS	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
high	high	h020	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
to	to	t000	TO	B-VP	O
die	die	d000	VB	I-VP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
drug	drug	d602	NN	B-NP	O
resistance	resistance	r020230520	NN	I-NP	O
.	.	.000	.	O	O

Notwithstanding	Notwithstanding	n0303023053052	IN	B-PP	O
these	these	t020	DT	B-NP	O
facts	fact	f0232	NNS	I-NP	O
our	our	o060	PRP$	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
benefit	benefit	b050103	VB	I-VP	O
from	from	f605	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
mild	mild	m043	JJ	I-NP	O
initial	initial	i50304	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADJP	O
true	true	t600	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
not	not	n030	RB	B-VP	O
previously	previously	p6010240	RB	I-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Close	Close	c4020	JJ	B-NP	O
observation	observation	o120610305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
both	both	b030	CC	O	O
clinically	clinically	c40502040	RB	B-ADVP	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
hCG	hCG	h200	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
may	may	m000	MD	B-VP	O
indicate	indicate	i5302030	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
and	and	a530	CC	O	O
when	when	w050	WRB	B-ADVP	O
more	more	m060	RBR	B-NP	O
agressive	agressive	a2602010	JJ	I-NP	O
combination	combination	c051050305	NN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
started	start	s306303	VBN	I-VP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Pulmonary	Pulmonary	p04505060	JJ	B-NP	O
shunt	shunt	s053	NN	I-NP	O
and	and	a530	CC	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
CPAP	CPAP	c101	NN	B-NP	O
during	during	d06052	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
airway	airway	a060	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
CPAP	CPAP	c101	NN	B-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
and	and	a530	CC	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
shunt	shunt	s053	NN	I-NP	O
(	(	(000	(	O	O
QS	QS	q200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
dogs	dog	d020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
that	that	t030	WDT	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
CPAP	CPAP	c101	NN	I-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
,	,	,000	,	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
,	,	,000	,	O	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
QS	QS	q200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
CPAP	CPAP	c101	NN	I-NP	O
before	before	b01060	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
arterial	arterial	a630604	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
significantly	significantly	s025010205340	RB	B-VP	O
increased	increase	i5260203	VBD	I-VP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	B-Disease
cardiac	cardiac	c06302	JJ	B-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
QS	QS	q200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
.	.	.000	.	O	O

Nitroprusside	Nitroprusside	n03601602030	NNP	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
arterial	arterial	a630604	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
systemic	systemic	s0230502	JJ	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
and	and	a530	CC	I-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
or	or	o600	CC	I-NP	O
QS	QS	q200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
CPAP	CPAP	c101	NN	I-NP	O
during	during	d06052	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
further	further	f06306	RBR	I-VP	O
alter	alter	a4306	VB	I-VP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
above	above	a1010	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
mentioned	mention	m0530503	VBN	I-NP	O
variables	variable	v0601402	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
CPAP	CPAP	c101	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
QS	QS	q200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
decrease	decrease	d026020	VBP	B-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
by	by	b000	IN	B-PP	O
40	40	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
50	50	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
cent	cent	c053	NN	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
cardiac	cardiac	c06302	JJ	B-NP	O
output	output	o03103	NN	I-NP	O
or	or	o600	CC	I-NP	O
QS	QS	q200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
nitroprusside	nitroprusside	n03601602030	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
low	low	l000	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CPAP	CPAP	c101	NN	B-NP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
markedly	markedly	m0620340	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
dynamics	dynamic	d050502	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
CPAP	CPAP	c101	NN	B-NP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
cm	cm	c500	NN	I-NP	O
H2O	H2O	0000	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
decreasing	decrease	d02602052	VBG	B-VP	O
QS	QS	q200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
QT	QT	q300	NN	I-NP	O
,	,	,000	,	O	O
produce	produce	p603020	VBP	B-VP	O
marked	marked	m06203	JJ	B-NP	O
decreases	decrease	d0260202	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
arterial	arterial	a630604	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
cardiac	cardiac	c06302	JJ	B-NP	I-Disease
output	output	o03103	NN	I-NP	I-Disease
.	.	.000	.	O	O

Systolic	Systolic	s0230402	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
variation	variation	v060305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
during	during	d06052	IN	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
than	than	t050	IN	B-PP	O
during	during	d06052	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
ventilated	ventilate	v053040303	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
variation	variation	v060305	NN	I-NP	O
(	(	(000	(	O	O
SPV	SPV	s100	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
minimal	minimal	m050504	JJ	I-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
systolic	systolic	s0230402	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
SBP	SBP	s100	NN	B-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
breath	breath	b6030	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
ventilated	ventilate	v053040303	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Mean	Mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
50	50	0000	CD	B-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
either	either	e0306	CC	B-PP	O
by	by	b000	IN	B-PP	O
hemorrhage	hemorrhage	h0506020	NN	B-NP	B-Disease
(	(	(000	(	O	O
HEM	HEM	h050	NN	B-NP	B-Disease
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
by	by	b000	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
HEM	HEM	h050	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
lower	low	l060	JJR	B-NP	O
and	and	a530	CC	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
vascular	vascular	v020406	JJ	I-NP	O
resistance	resistance	r020230520	NN	I-NP	O
higher	high	h0206	JJR	B-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
that	that	t030	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
,	,	,000	,	I-NP	O
central	central	c053604	JJ	I-NP	O
venous	venous	v0502	JJ	I-NP	O
,	,	,000	,	I-NP	O
pulmonary	pulmonary	p04505060	JJ	I-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
wedge	wedge	w0320	NN	I-NP	O
pressures	pressure	p6020602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Analysis	Analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
respiratory	respiratory	r0210603060	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
waveform	waveform	w0101065	NN	I-NP	O
enabled	enable	e501403	VBD	B-VP	O
differentiation	differentiation	d01060530305	NN	B-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
SPV	SPV	s100	NN	I-NP	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
15	15	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
7	7	7000	CD	I-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
HEM	HEM	h050	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
delta	delta	d0430	SYM	I-NP	O
down	down	d050	RP	B-PRT	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
decrease	decrease	d026020	NN	B-NP	O
of	of	o100	IN	B-PP	O
SBP	SBP	s100	NN	B-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
breath	breath	b6030	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
20	20	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
8	8	8000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
HEM	HEM	h050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
increases	increase	i5260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
SPV	SPV	s100	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
delta	delta	d0430	SYM	I-NP	O
down	down	d050	RP	B-PRT	O
are	be	a600	VBP	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
state	state	s3030	NN	I-NP	O
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
preload	preload	p60403	NN	B-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
thus	thus	t020	RB	B-ADJP	O
more	more	m060	RBR	I-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
during	during	d06052	IN	B-PP	O
absolute	absolute	a1204030	JJ	B-NP	O
hypovolemia	hypovolemia	h010104050	NN	I-NP	B-Disease
than	than	t050	IN	B-PP	O
during	during	d06052	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Ventricular	Ventricular	v0536020406	JJ	B-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
section	section	s02305	NN	I-NP	O
after	after	a1306	IN	B-PP	O
ritodrine	ritodrine	r03036050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
:	:	:000	:	O	O
interaction	interaction	i530602305	NN	B-NP	O
with	with	w030	IN	B-PP	O
anesthetics	anesthetic	a50230302	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
ritodrine	ritodrine	r03036050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
labor	labor	l0106	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
risk	risk	r020	VB	I-VP	O
interactions	interaction	i5306023052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
residual	residual	r020304	JJ	I-NP	O
betamimetic	betamimetic	b0305050302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ritodrine	ritodrine	r03036050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
anesthetics	anesthetic	a50230302	NNS	B-NP	O
during	during	d06052	IN	B-PP	O
cesarean	cesarean	c020605	JJ	B-NP	O
section	section	s02305	NN	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
even	even	e105	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
ritodrine	ritodrine	r03036050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Preoperative	Preoperative	p6010603010	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
should	should	s043	MD	B-VP	O
focus	focus	f0202	VB	I-VP	O
on	on	o500	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
and	and	a530	CC	O	O
serum	serum	s0605	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

Delaying	Delay	d04052	VBG	B-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
whenever	whenever	w050106	WRB	B-ADJP	O
possible	possible	p020140	JJ	I-ADJP	O
.	.	.000	.	O	O

Careful	Careful	c060104	JJ	B-NP	O
fluid	fluid	f403	NN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
cautious	cautious	c0302	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
titrated	titrate	t0360303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ephedrine	ephedrine	e1036050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
advised	advise	a310203	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
delivery	delivery	d0401060	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
no	no	n000	DT	B-NP	O
contraindication	contraindication	c0536053020305	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
vasopressor	vasopressor	v020160206	NN	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
hypotensive	hypotensive	h0103052010	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
tachycardia	tachycardia	t02020630	NN	B-NP	B-Disease
.	.	.000	.	O	O

Verapamil	Verapamil	v06010504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
entry	entry	e5360	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
.	.	.000	.	O	O

Use	Use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
either	either	e0306	RB	I-VP	O
be	be	b000	VB	I-VP	O
avoided	avoid	a10303	VBN	I-VP	O
or	or	o600	CC	I-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
usually	usually	u2040	RB	B-ADVP	O
reduction	reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
carbamazepine	carbamazepine	c061050201050	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
by	by	b000	IN	B-PP	O
one	one	o500	CD	B-NP	O
half	half	h041	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Paracetamol	Paracetamol	p0602030504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
coma	coma	c050	NN	I-NP	B-Disease
,	,	,000	,	O	O
metabolic	metabolic	m03010402	JJ	B-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
metabolic	metabolic	m03010402	JJ	B-NP	B-Disease
acidosis	acidosis	a2030202	NN	I-NP	I-Disease
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	I-Disease
hepatic	hepatic	h010302	JJ	B-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
diagnostic	diagnostic	d02502302	JJ	I-NP	O
difficulty	difficulty	d01020430	NN	I-NP	O
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
highlighted	highlight	h0204020303	VBN	I-VP	O
.	.	.000	.	O	O

Continuous	Continuous	c0530502	JJ	B-NP	O
arteriovenous	arteriovenous	a6306010502	JJ	I-NP	O
haemofiltration	haemofiltration	h050104360305	NN	I-NP	O
proved	prove	p60103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
valuable	valuable	v040140	JJ	I-NP	O
means	mean	m052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
maintaining	maintain	m05305052	VBG	B-VP	O
fluid	fluid	f403	NN	B-NP	O
and	and	a530	CC	I-NP	O
electrolyte	electrolyte	e4023604030	NN	I-NP	O
balance	balance	b040520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
.	.	.000	.	O	O

Sexual	Sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
arthritis	arthritis	a63060302	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
arthritis	arthritis	a63060302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
among	among	a5052	IN	B-PP	O
169	169	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
,	,	,000	,	I-NP	O
osteoarthritis	osteoarthritis	o23063060302	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
spondyloarthropathy	spondyloarthropathy	s1053040630601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
130	130	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
were	be	w060	VBD	B-VP	O
pair	pair	p060	NN	I-VP	O
-	-	-000	HYPH	O	O
matched	match	m03203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Assessments	Assessment	a20250532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
marital	marital	m060304	JJ	B-NP	O
happiness	happiness	h010502	NN	I-NP	O
and	and	a530	CC	O	O
depressed	depressed	d0160203	JJ	B-NP	B-Disease
mood	mood	m030	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
also	also	a420	RB	I-VP	O
made	make	m030	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
CES	CES	c020	NN	I-NP	O
-	-	-000	HYPH	O	O
D	D	d000	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
Azrin	Azrin	a2605	NNP	I-NP	O
Marital	Marital	m060304	NNP	I-NP	O
Happiness	Happiness	h010502	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
(	(	(000	(	O	O
AMHS	AMHS	a502	NNP	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Sexual	Sexual	s0204	JJ	B-NP	B-Disease
dysfunctions	dysfunction	d0210523052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
common	common	c0505	JJ	B-ADJP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	I-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
reporting	report	r01063052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
dysfunctions	dysfunction	d0210523052	NNS	I-NP	O
.	.	.000	.	O	O

Impotence	Impotence	i51030520	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
male	male	m040	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
co	co	c000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
morbidity	morbidity	m06103030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
taking	taking	t02052	NN	I-NP	O
of	of	o100	IN	B-PP	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Depressed	Depress	d0160203	VBN	B-NP	B-Disease
mood	mood	m030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
common	common	c0505	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
sexual	sexual	s0204	JJ	I-NP	O
difficulties	difficulty	d010204302	NNS	I-NP	O
,	,	,000	,	B-PP	O
but	but	b030	CC	I-PP	O
not	not	n030	RB	B-PP	O
with	with	w030	IN	I-PP	O
impotence	impotence	i51030520	NN	B-NP	B-Disease
.	.	.000	.	O	O

Marital	Marital	m060304	JJ	B-NP	O
unhappiness	unhappiness	u5010502	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
AMHS	AMHS	a502	NN	B-NP	O
scores	score	s20602	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
arthritis	arthritis	a63060302	NN	B-NP	B-Disease
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
sexual	sexual	s0204	JJ	B-NP	O
dissatisfaction	dissatisfaction	d020302102305	NN	I-NP	O
and	and	a530	CC	O	O
being	be	b052	VBG	B-VP	O
female	female	f05040	JJ	B-ADJP	O
.	.	.000	.	O	O

Does	Does	d020	NNP	B-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
cause	cause	c020	VBP	B-VP	O
urothelial	urothelial	u6030404	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
or	or	o600	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
?	?	?000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	O
cancer	cancer	c05206	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
pelvis	pelvis	p04102	NN	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
ureter	ureter	u60306	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
consumption	consumption	c052051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	O	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
paracetamol	paracetamol	p0602030504	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
calculated	calculate	c042040303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
data	datum	d030	NNS	B-NP	O
acquired	acquire	a20603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
questionnaire	questionnaire	q02305060	NN	B-NP	O
from	from	f605	IN	B-PP	O
381	381	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
808	808	0000	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
nearly	nearly	n0640	RB	B-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
consumption	consumption	c052051305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
also	also	a420	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
pelvis	pelvis	p04102	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
for	for	f060	IN	I-PP	O
ureteric	ureteric	u6030602	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
.	.	.000	.	O	O

By	By	b000	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
substantiate	substantiate	s0123053030	VB	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
from	from	f605	IN	B-PP	O
paracetamol	paracetamol	p0602030504	NN	B-NP	B-Chemical
consumption	consumption	c052051305	NN	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
papillary	papillary	p0104060	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
or	or	o600	CC	O	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
although	although	a43020	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
suggestion	suggestion	s0202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
with	with	w030	IN	B-PP	O
cancer	cancer	c05206	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
ureter	ureter	u60306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Dapsone	Dapsone	d012050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
Heinz	Heinz	h052	NN	I-NP	O
body	body	b030	NN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
Cambodian	Cambodian	c0510305	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
E	E	e000	NN	I-NP	O
trait	trait	t603	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
Cambodian	Cambodian	c0510305	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
E	E	e000	NN	I-NP	O
trait	trait	t603	NN	I-NP	O
(	(	(000	(	O	O
AE	AE	a000	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
leprosy	leprosy	l016020	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
Heinz	Heinz	h052	NNP	I-NP	O
body	body	b030	NN	I-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
taking	take	t02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dapsone	dapsone	d012050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
)	)	)000	)	O	O
not	not	n030	RB	B-VP	O
usually	usually	u2040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
hemolysis	hemolysis	h05040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
red	red	r030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
(	(	(000	(	O	O
RBCs	RBC	r120	NNS	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
incubated	incubate	i52010303	VBN	B-VP	O
Heinz	Heinz	h052	NNP	B-NP	O
body	body	b030	NN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
glutathione	glutathione	g40303050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
GSH	GSH	g200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
GSH	GSH	g200	NN	B-NP	B-Chemical
stability	stability	s30104030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pentose	pentose	p053020	NN	I-NP	B-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
shunt	shunt	s053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
dapsone	dapsone	d012050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
exposed	expose	e210203	VBN	B-NP	O
AE	AE	a000	NN	I-NP	O
RBCs	RBC	r120	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
RBCs	RBC	r120	NNS	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
AE	AE	a000	NN	I-NP	O
RBCs	RBC	r120	NNS	I-NP	O
from	from	f605	IN	B-PP	O
an	an	a500	DT	B-NP	O
individual	individual	i53010304	NN	I-NP	O
not	not	n030	RB	B-VP	O
taking	take	t02052	VBG	I-VP	O
dapsone	dapsone	d012050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
incubated	incubate	i52010303	VBN	B-VP	O
Heinz	Heinz	h052	NNP	B-NP	O
body	body	b030	NN	I-NP	O
formation	formation	f0650305	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
GSH	GSH	g200	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
and	and	a530	CC	O	O
GSH	GSH	g200	NN	B-NP	B-Chemical
stability	stability	s30104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pentose	pentose	p053020	NN	I-NP	B-Chemical
phosphate	phosphate	p021030	NN	I-NP	I-Chemical
shunt	shunt	s053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
dapsone	dapsone	d012050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
exposed	expose	e210203	VBN	B-NP	O
AE	AE	a000	NN	I-NP	O
RBCs	RBC	r120	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
RBCs	RBC	r120	NNS	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
AE	AE	a000	NN	B-NP	O
RBCs	RBC	r120	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
oxidant	oxidant	o203053	JJ	B-NP	O
stress	stress	s3602	NN	I-NP	O
both	both	b030	CC	O	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
and	and	a530	CC	O	O
in	in	i500	FW	B-ADVP	O
vivo	vivo	v010	FW	I-ADVP	O
,	,	,000	,	O	O
since	since	s0520	IN	B-SBAR	O
dapsone	dapsone	d012050	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
hemolytic	hemolytic	h05040302	JJ	B-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
at	at	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hematologically	hematologically	h0503040202040	RB	B-NP	O
normal	normal	n06504	JJ	I-NP	O
individuals	individual	i530103042	NNS	I-NP	O
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-PP	O
the	the	t000	DT	B-NP	O
influx	influx	i51402	NN	I-NP	O
of	of	o100	IN	B-PP	O
Southeast	Southeast	s03023	NNP	B-NP	O
Asians	Asian	a2052	NNPS	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
,	,	,000	,	O	O
oxidant	oxidant	o203053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
if	if	i100	IN	B-SBAR	O
an	an	a500	DT	B-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
present	present	p602053	JJ	B-ADJP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
individuals	individual	i530103042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
ethnic	ethnic	e30502	JJ	B-NP	O
backgrounds	background	b0260532	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
E	E	e000	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antianginal	antianginal	a530520504	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
identified	identify	i30530103	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
metabolizer	metabolizer	m0301040206	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
propafenone	propafenone	p6010105050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
sparteine	sparteine	s1063050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
47	47	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
patient	patient	p03053	NN	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
CCU	CCU	c200	NN	I-NP	O
in	in	i500	IN	B-PP	O
shock	shock	s020	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
III	III	i000	CD	B-NP	O
.	.	.000	.	O	O

AV	AV	a100	NN	B-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
,	,	,000	,	O	O
severe	severe	s01060	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
impairment	impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
ventricular	ventricular	v0536020406	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
week	week	w020	NN	I-NP	O
prior	prior	p606	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
admission	admission	a350205	NN	I-VP	O
a	a	a000	DT	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
t	t	t000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
and	and	a530	CC	O	O
then	then	t050	RB	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
admission	admission	a350205	NN	B-NP	O
diltiazem	diltiazem	d0430205	NN	I-NP	B-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
prescribed	prescribe	p60260103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
.	.	.000	.	O	O

Analyses	Analysis	a5040202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
unusually	unusually	u502040	RB	B-NP	O
high	high	h020	JJ	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3000	3000	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
526	526	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
week	week	w020	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
antianginal	antianginal	a530520504	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
,	,	,000	,	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
propafenone	propafenone	p6010105050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
since	since	s0520	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
past	past	p023	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
sparteine	sparteine	s1063050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
probe	probe	p6010	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
debrisoquine	debrisoquine	d0160202050	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
sparteine	sparteine	s1063050	NN	I-NP	B-Chemical
type	type	t010	NN	I-NP	O
polymorphism	polymorphism	p0405061025	NN	I-NP	O
of	of	o100	IN	B-PP	O
oxidative	oxidative	o20303010	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
metabolizer	metabolizer	m0301040206	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
genetic	genetic	g050302	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
belonging	belong	b04052052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
poor	poor	p060	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
metabolizer	metabolizer	m0301040206	NN	I-NP	O
phenotype	phenotype	p0503010	NN	I-NP	O
of	of	o100	IN	B-PP	O
sparteine	sparteine	s1063050	NN	B-NP	B-Chemical
/	/	/000	SYM	B-NP	O
debrisoquine	debrisoquine	d0160202050	NN	I-NP	B-Chemical
polymorphism	polymorphism	p0405061025	NN	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
constitutes	constitute	c0523030302	VBZ	B-VP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
German	German	g06505	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
experience	experience	e21060520	VB	I-VP	O
adverse	adverse	a310620	JJ	B-NP	B-Disease
drug	drug	d602	NN	I-NP	I-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
coadministration	coadministration	c0350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
frequently	frequently	f60205340	RB	I-NP	O
used	use	u203	VBN	I-NP	O
drugs	drug	d602	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
expected	expect	e2102303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
especially	especially	e2102040	RB	B-ADJP	O
harmful	harmful	h065104	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
experiences	experience	e210605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
open	open	o105	JJ	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
sixty	sixty	s0230	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trated	trate	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
bromperidol	bromperidol	b6051060304	NN	B-NP	B-Chemical
first	first	f0623	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
open	open	o105	JJ	B-NP	O
conditions	condition	c05303052	NNS	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
reference	reference	r01060520	NN	I-NP	O
substance	substance	s01230520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
open	open	o105	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
lasted	last	l02303	VBD	B-VP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
administrated	administrate	a350502360303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
initial	initial	i50304	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
;	;	;000	:	O	O
mean	mean	m050	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
:	:	:000	:	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
47	47	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
always	always	a402	RB	I-VP	O
administered	administer	a35050230603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Nineteen	Nineteen	n050305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
finished	finish	f050203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
18	18	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
the	the	t000	DT	B-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
result	result	r02043	NN	I-NP	O
was	be	w020	VBD	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
very	very	v060	RB	B-ADJP	O
good	good	g030	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
good	good	g030	JJ	B-ADJP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
statistical	statistical	s3030230204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
.	.	.000	.	O	O

Nine	Nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
exhibited	exhibit	e2010303	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
moderate	moderate	m0306030	VB	I-VP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
concomitant	concomitant	c0520503053	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
;	;	;000	:	O	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
detailed	detailed	d030403	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
and	and	a530	CC	I-NP	O
evaluations	evaluation	e10403052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
quantitative	quantitative	q0530303010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
qualitative	qualitative	q040303010	JJ	I-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
substances	substance	s012305202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
highly	highly	h02040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychotic	psychotic	p2020302	JJ	B-NP	B-Disease
syndromes	syndrome	s05360502	NNS	I-NP	I-Disease
belonging	belong	b04052052	VBG	B-VP	I-Disease
predominantly	predominantly	p603050505340	RB	B-ADVP	I-Disease
to	to	t000	TO	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
schizophrenia	schizophrenia	s2020106050	NN	I-NP	I-Disease
group	group	g601	NN	I-NP	I-Disease
.	.	.000	.	O	O

Certain	Certain	c06305	JJ	B-NP	O
clues	clue	c402	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
,	,	,000	,	O	O
seem	seem	s050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
indicative	indicative	i530203010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
superiority	superiority	s010606030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bromperidol	bromperidol	b6051060304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
general	general	g050604	JJ	B-NP	O
tolerability	tolerability	t04060104030	NN	I-NP	O
.	.	.000	.	O	O

Prolonged	Prolonged	p60405203	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
troleandomycin	troleandomycin	t604053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
troleandomycin	troleandomycin	t604053050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
anicteric	anicteric	a50230602	JJ	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Jaundice	Jaundice	j053020	NNP	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
troleandomycin	troleandomycin	t604053050205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
hypereosinophilia	hypereosinophilia	h0106020501040	NN	B-NP	B-Disease
.	.	.000	.	O	O

Jaundice	Jaundice	j053020	NNP	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
but	but	b030	CC	O	O
was	be	w020	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
anicteric	anicteric	a50230602	JJ	I-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
marked	mark	m06203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
alkaline	alkaline	a4204050	NN	B-NP	O
phosphatase	phosphatase	p02103020	NN	I-NP	O
and	and	a530	CC	I-NP	O
gammaglutamyltransferase	gammaglutamyltransferase	g0502403050436052106020	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
pruritus	pruritus	p6060302	NN	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
19	19	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
liver	liver	l0106	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-NP	O
27	27	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
prolonged	prolong	p60405203	VBN	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
can	can	c050	MD	B-VP	O
follow	follow	f040	VB	I-VP	O
troleandomycin	troleandomycin	t604053050205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

Serial	Serial	s0604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
auditory	auditory	a0303060	JJ	I-NP	I-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
documented	document	d020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
42	42	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
89	89	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
transfusion	transfusion	t605210205	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
iron	iron	i605	NN	B-NP	B-Chemical
chelation	chelation	c040305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
with	with	w030	IN	B-PP	O
daily	daily	d040	JJ	B-NP	O
subcutaneous	subcutaneous	s012030502	JJ	I-NP	O
deferoxamine	deferoxamine	d01060205050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
affected	affect	a102303	VBN	I-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	B-Disease
audiograms	audiogram	a03026052	NNS	I-NP	I-Disease
with	with	w030	IN	B-PP	I-Disease
deficits	deficit	d0102032	NNS	B-NP	I-Disease
mostly	mostly	m02340	RB	B-ADVP	I-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
high	high	h020	JJ	I-NP	I-Disease
frequency	frequency	f6020520	NN	I-NP	I-Disease
range	range	r0520	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
4	4	4000	CD	B-NP	I-Disease
,	,	,000	,	O	I-Disease
000	000	0000	CD	B-NP	I-Disease
to	to	t000	TO	I-NP	I-Disease
8	8	8000	CD	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
000	000	0000	CD	I-NP	I-Disease
Hz	Hz	h200	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hearing	hearing	h06052	NN	I-NP	O
threshold	threshold	t0602043	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
100	100	0000	CD	I-NP	O
decibels	decibel	d0201042	NNS	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
and	and	a530	CC	O	O
serial	serial	s0604	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
,	,	,000	,	O	O
audiograms	audiogram	a03026052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
reverted	revert	r0106303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
or	or	o600	CC	O	O
near	near	n060	RB	B-ADJP	O
normal	normal	n06504	JJ	I-ADJP	O
within	within	w0305	IN	B-PP	O
two	two	t000	CD	B-NP	O
to	to	t000	TO	I-NP	O
three	three	t060	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
nine	nine	n050	CD	B-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
became	become	b02050	VBD	B-VP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-ADJP	O
.	.	.000	.	O	O

Audiograms	Audiogram	a03026052	NNS	B-NP	O
from	from	f605	IN	B-PP	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
abnormal	abnormal	a1506504	JJ	B-ADJP	O
and	and	a530	CC	O	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
required	require	r020603	VBD	B-VP	O
hearing	hearing	h06052	NN	B-NP	O
aids	aid	a032	NNS	I-NP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
permanent	permanent	p06505053	JJ	B-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Since	Since	s0520	IN	B-PP	O
18	18	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
22	22	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
initially	initially	i503040	RB	I-VP	O
receiving	receive	r0201052	VBG	I-VP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
excess	excess	e202	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
commonly	commonly	c050540	RB	I-NP	O
recommended	recommend	r020505303	VBN	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
,	,	,000	,	O	O
therapy	therapy	t06010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
restarted	restart	r02306303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
usually	usually	u2040	RB	B-ADVP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
or	or	o600	CC	O	O
less	less	l020	JJR	B-NP	O
depending	depend	d01053052	VBG	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	B-Disease
abnormality	abnormality	a1506504030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
exception	exception	e201305	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
.	.	.000	.	O	O

Auditory	Auditory	a0303060	JJ	B-NP	O
deterioration	deterioration	d0306060305	NN	I-NP	O
and	and	a530	CC	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
,	,	,000	,	O	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
serially	serially	s06040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
and	and	a530	CC	O	O
not	not	n030	RB	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
provided	provide	p6010303	VBN	B-PP	O
convincing	convince	c051052052	VBG	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
effect	effect	e1023	NN	I-NP	O
relation	relation	r040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	I-NP	O
ototoxicity	ototoxicity	o3030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
plan	plan	p405	NN	I-NP	O
of	of	o100	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
developed	develop	d01040103	VBN	I-VP	O
that	that	t030	WDT	B-NP	O
allows	allow	a402	VBZ	B-VP	O
effective	effective	e1023010	JJ	B-NP	O
yet	yet	y030	RB	I-NP	O
safe	safe	s010	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
without	without	w0303	IN	B-PP	O
audiogram	audiogram	a0302605	NN	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
mild	mild	m043	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
to	to	t000	TO	B-PP	O
30	30	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
should	should	s043	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reversal	reversal	r0106204	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
within	within	w0305	IN	B-PP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Moderate	Moderate	m0306030	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
require	require	r02060	VBP	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
deferoxamine	deferoxamine	d01060205050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
with	with	w030	IN	B-PP	O
careful	careful	c060104	JJ	B-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
stopped	stop	s30103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
four	four	f060	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
audiogram	audiogram	a0302605	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
improved	improved	i5160103	JJ	I-ADJP	O
,	,	,000	,	O	O
therapy	therapy	t06010	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
restarted	restart	r02306303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
.	.	.000	.	O	O

Serial	Serial	s0604	JJ	B-NP	O
audiograms	audiogram	a03026052	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
six	six	s020	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
without	without	w0303	IN	B-PP	O
problems	problem	p6014052	NNS	B-NP	O
and	and	a530	CC	O	O
more	more	m060	RBR	B-ADVP	O
frequently	frequently	f60205340	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
ferritin	ferritin	f060305	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
auditory	auditory	a0303060	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Lidocaine	Lidocaine	l0302050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
asystole	asystole	a2023040	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intravenous	Intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
50	50	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
67	67	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
profound	profound	p601053	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	O
nodal	nodal	n0304	JJ	I-NP	O
pacemakers	pacemaker	p020502062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
associated	associate	a2020303	VBN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
have	have	h010	VB	I-VP	O
predisposed	predispose	p6030210203	VBN	I-VP	O
him	him	h050	PRP	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmias	bradyarrhythmia	b60306030502	NNS	B-NP	B-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
thus	thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
probably	probably	p6010140	RB	I-NP	O
represented	represent	r0160205303	VBN	I-NP	O
a	a	a000	DT	B-NP	O
true	true	t600	JJ	I-NP	O
idiosyncrasy	idiosyncrasy	i3020526020	NN	I-NP	O
to	to	t000	TO	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Flurbiprofen	Flurbiprofen	f40610160105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
juvenile	juvenile	j0105040	JJ	B-NP	B-Disease
rheumatoid	rheumatoid	r050303	JJ	I-NP	I-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
juvenile	juvenile	j0105040	JJ	B-NP	B-Disease
rheumatoid	rheumatoid	r050303	JJ	I-NP	I-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
flurbiprofen	flurbiprofen	f40610160105	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decreases	decrease	d0260202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
in	in	i500	IN	B-PP	O
6	6	6000	CD	B-NP	O
arthritis	arthritis	a63060302	NN	I-NP	B-Disease
indices	index	i530202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Improvements	Improvement	i51601050532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
tender	tender	t05306	NN	B-NP	B-Disease
joints	joint	j0532	NNS	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
swelling	swelling	s04052	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
tenderness	tenderness	t05306502	NN	I-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
walk	walk	w042	NN	B-NP	O
50	50	0000	CD	B-NP	O
feet	foot	f030	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morning	morning	m065052	NN	B-NP	B-Disease
stiffness	stiffness	s301502	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
circumference	circumference	c062051060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
knee	knee	k500	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequently	frequently	f60205340	RB	I-NP	O
observed	observe	o1206103	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
fecal	fecal	f0204	JJ	B-NP	B-Disease
occult	occult	o2043	JJ	I-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
(	(	(000	(	O	I-Disease
GI	GI	g000	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
bleeding	bleed	b403052	VBG	B-VP	I-Disease
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
prematurely	prematurely	p6050306040	RB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
for	for	f060	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
headache	headache	h03020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
and	and	a530	CC	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
GI	GI	g000	NN	I-NP	O
tract	tract	t6023	NN	I-NP	O
.	.	.000	.	O	O

Hyperkalemia	Hyperkalemia	h0106204050	NN	B-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Hyperkalemia	Hyperkalemia	h0106204050	NN	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
recently	recently	r0205340	RB	I-VP	O
been	be	b050	VBN	I-VP	O
recognized	recognize	r020250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
antiinflammatory	antiinflammatory	a5305140503060	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
(	(	(000	(	O	O
NSAID	NSAID	n203	NN	B-NP	O
)	)	)000	)	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Several	Several	s010604	JJ	B-NP	O
recent	recent	r02053	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
stressed	stress	s360203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
sparing	spar	s106052	VBG	I-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
,	,	,000	,	O	O
owing	owe	o052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
lack	lack	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
interference	interference	i53061060520	NN	B-NP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
prostacyclin	prostacyclin	p60230202405	NN	I-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
ranging	range	r052052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
/	/	/000	SYM	B-NP	O
l	l	l000	NN	I-NP	O
developed	develop	d01040103	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
normal	normal	n06504	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
reached	reach	r0203	VBN	B-VP	O
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
4	4	4000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
stopping	stop	s301052	VBG	B-VP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
known	know	k505	VBN	B-VP	O
to	to	t000	TO	B-VP	O
effect	effect	e1023	VB	I-VP	O
serum	serum	s0605	NN	B-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
given	give	g0105	VBN	I-VP	O
concomitantly	concomitantly	c052050305340	RB	B-ADVP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
suggestive	suggestive	s02023010	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
and	and	a530	CC	I-NP	O
-	-	-000	HYPH	I-NP	O
effect	effect	e1023	NN	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
hyperkalemia	hyperkalemia	h0106204050	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
initial	initial	i50304	JJ	B-NP	O
hopes	hope	h0102	NNS	I-NP	O
that	that	t030	IN	B-SBAR	O
sulindac	sulindac	s0405302	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
NSAID	NSAID	n203	NN	I-NP	O
are	be	a600	VBP	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
not	not	n030	RB	O	O
justified	justified	j0230103	JJ	B-ADJP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
spasm	spasm	s1025	NN	I-NP	B-Disease
relieved	relieve	r040103	VBN	B-VP	O
by	by	b000	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Case	Case	c020	NN	B-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
major	major	m0206	JJ	B-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	O
surgery	surgery	s062060	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
35	35	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
,	,	,000	,	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
pentothal	pentothal	p0530304	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
intravenously	intravenously	i53601050240	RB	I-VP	O
infused	infuse	i510203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
minimize	minimize	m0505020	VB	I-VP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
ischaemia	ischaemia	i2050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intense	Intense	i530520	JJ	B-NP	O
vasospasm	vasospasm	v02021025	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
threatened	threaten	t06030503	VBN	B-NP	O
gangrene	gangrene	g0526050	NN	I-NP	B-Disease
arose	arise	a6020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arm	arm	a650	NN	I-NP	O
used	use	u203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
cranial	cranial	c60504	JJ	I-NP	O
condition	condition	c0530305	NN	I-NP	O
precluded	preclude	p60240303	VBD	B-VP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
usual	usual	u204	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
,	,	,000	,	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
intra	intra	i5360	AFX	O	O
-	-	-000	HYPH	O	O
arterially	arterially	a6306040	RB	B-ADVP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
careful	careful	c060104	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
monitoring	monitoring	m050306052	NN	I-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
counteract	counteract	c05306023	VB	I-VP	O
the	the	t000	DT	B-NP	O
vasospasm	vasospasm	v02021025	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADJP	O
successful	successful	s0202104	JJ	I-ADJP	O
.	.	.000	.	O	O

Regional	Regional	r020504	JJ	B-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antagonism	antagonism	a530205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	B-Chemical
injections	injection	i52023052	NNS	I-NP	O
.	.	.000	.	O	O

Calcitonin	Calcitonin	c042030505	NN	B-NP	B-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
behavioral	behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
these	these	t020	DT	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
food	food	f030	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
and	and	a530	CC	O	O
decreases	decrease	d0260202	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
food	food	f030	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	B-Chemical
into	into	i530	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
hypothalamic	hypothalamic	h0103040502	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
and	and	a530	CC	B-PP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
accumbens	accumbens	a2051052	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
calcitonin	calcitonin	c042030505	NN	I-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
locally	locally	l02040	RB	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
it	it	i300	PRP	B-NP	O
decreases	decrease	d0260202	VBZ	B-VP	O
food	food	f030	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
areas	area	a602	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
calcitonin	calcitonin	c042030505	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
are	be	a600	VBP	B-VP	O
located	located	l020303	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypothalamus	hypothalamus	h0103040502	NN	I-NP	O
and	and	a530	CC	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
accumbens	accumben	a2051052	NNS	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
areas	area	a602	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
calcitonin	calcitonin	c042030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
inhibiting	inhibit	i50103052	VBG	B-VP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cefonicid	cefonicid	c01050203	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cefazedone	cefazedone	c010203050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
cephalosporin	cephalosporin	c01040210605	NN	B-NP	B-Chemical
hematotoxicity	hematotoxicity	h0503030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
.	.	.000	.	O	O

Cephalosporin	Cephalosporin	c01040210605	NN	B-NP	B-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
cause	cause	c020	VBP	B-VP	O
a	a	a000	DT	B-NP	O
variety	variety	v06030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hematologic	hematologic	h0503040202	JJ	B-NP	B-Disease
disturbances	disturbance	d02306105202	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
pathogeneses	pathogenes	p0302050202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
hematopathology	hematopathology	h0503010304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
remain	remain	r0505	VBP	B-VP	O
poorly	poorly	p0640	RB	B-ADJP	O
characterized	characterize	c06023060203	VBN	I-ADJP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
defined	define	d010503	VBN	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
in	in	i500	IN	B-PP	O
which	which	w020	WDT	B-NP	O
these	these	t020	DT	B-NP	O
blood	blood	b403	NN	I-NP	B-Disease
dyscrasias	dyscrasia	d0260202	NNS	I-NP	I-Disease
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
subacute	subacute	s0102030	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cefonicid	cefonicid	c01050203	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
cefazedone	cefazedone	c010203050	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
beagle	beagle	b0240	NN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
anemia	anemia	a5050	NN	B-NP	B-Disease
,	,	,000	,	O	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
nonregenerative	nonregenerative	n05602050603010	JJ	I-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
compromising	compromising	c05160502052	JJ	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cytopenias	cytopenia	c03010502	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
400	400	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
500	500	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
kg	kg	k200	NN	B-NP	O
cefonicid	cefonicid	c01050203	NN	I-NP	B-Chemical
or	or	o600	CC	O	O
540	540	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
840	840	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
cefazedone	cefazedone	c010203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
three	three	t060	CD	I-NP	O
cytopenias	cytopenia	c03010502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADJP	O
reversible	reversible	r010620140	JJ	I-ADJP	O
following	follow	f04052	VBG	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
required	require	r020603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
erythron	erythron	e6030605	NN	I-NP	O
(	(	(000	(	O	O
approximately	approximately	a16020503040	RB	B-NP	O
1	1	1000	CD	I-NP	O
month	month	m0530	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
considerably	considerably	c05203060140	RB	B-ADVP	O
longer	longer	l05206	RBR	I-ADVP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
granulocytes	granulocyte	g60504020302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
platelets	platelet	p40304032	NNS	I-NP	O
(	(	(000	(	O	O
hours	hour	h062	NNS	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Upon	Upon	u105	IN	B-PP	O
rechallenge	rechallenge	r02040520	NN	B-NP	O
with	with	w030	IN	B-PP	O
either	either	e0306	CC	O	O
cephalosporin	cephalosporin	c01040210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
reproduced	reproduce	r016030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
dogs	dog	d020	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
;	;	;000	:	O	O
cefonicid	cefonicid	c01050203	NN	B-NP	B-Chemical
(	(	(000	(	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
cefazedone	cefazedone	c010203050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
substantially	substantially	s0123053040	RB	I-NP	O
reduced	reduce	r030203	VBN	I-NP	O
induction	induction	i5302305	NN	I-NP	O
period	period	p0603	NN	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
(	(	(000	(	O	O
61	61	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
24	24	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
observation	observation	o120610305	NN	I-NP	O
,	,	,000	,	O	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
decline	decline	d024050	NN	B-NP	O
in	in	i500	IN	B-PP	O
red	red	r030	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
mass	mass	m020	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
affected	affect	a102303	VBN	B-NP	O
dogs	dog	d020	NNS	I-NP	O
,	,	,000	,	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
component	component	c05105053	NN	I-NP	O
complicated	complicate	c0514020303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
red	red	r030	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
production	production	p60302305	NN	I-NP	O
problem	problem	p601405	NN	I-NP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
multiple	multiple	m0430140	JJ	B-NP	O
toxicologic	toxicologic	t0202040202	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
contributed	contribute	c0536010303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cytopenia	cytopenia	c0301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cefonicid	cefonicid	c01050203	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
cefazedone	cefazedone	c010203050	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
dogs	dog	d020	NNS	B-NP	O
can	can	c050	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
hematotoxicity	hematotoxicity	h0503030202030	NN	B-NP	B-Disease
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
cephalosporin	cephalosporin	c01040210605	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
blood	blood	b403	NN	I-NP	B-Disease
dyscrasias	dyscrasia	d0260202	NNS	I-NP	I-Disease
described	describe	d0260103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
man	man	m050	NN	B-NP	O
and	and	a530	CC	O	O
thus	thus	t020	RB	B-VP	O
provides	provide	p6010302	VBZ	I-VP	O
a	a	a000	DT	B-NP	O
useful	useful	u20104	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
studying	study	s303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
and	and	a530	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
during	during	d06052	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
for	for	f060	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
aneurysms	aneurysm	a5060252	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
and	and	a530	CC	O	O
cerebral	cerebral	c0601604	JJ	B-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
for	for	f060	IN	B-PP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
subjected	subject	s01202303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
craniotomy	craniotomy	c60503050	NN	B-NP	O
for	for	f060	IN	B-PP	O
clipping	clipping	c401052	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
aneurysm	aneurysm	a506025	NN	I-NP	I-Disease
.	.	.000	.	O	O

Flow	Flow	f400	NN	B-NP	O
and	and	a530	CC	I-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
13	13	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	B-Disease
haemorrhage	haemorrhage	h0506020	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
modification	modification	m0301020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
classical	classical	c4020204	JJ	I-NP	O
Kety	Kety	k030	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Schmidt	Schmidt	s20503	NNP	I-NP	O
technique	technique	t0205020	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
xenon	xenon	x0505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
133	133	0000	CD	B-NP	O
i	i	i000	NNS	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
Anaesthesia	Anaesthesia	a5023020	NNP	I-NP	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
inspired	inspired	i5210603	JJ	I-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
plus	plus	p402	CC	O	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
nitrous	nitrous	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
oxygen	oxygen	o20205	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
during	during	d06052	IN	B-PP	O
which	which	w020	WDT	B-NP	O
CBF	CBF	c100	NN	B-NP	O
and	and	a530	CC	I-NP	O
CMRO2	CMRO2	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
34	34	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	O	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	I-NP	O
32	32	0000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
16	16	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
at	at	a300	IN	B-PP	O
PaCO2	PaCO2	0000	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	I-NP	O
1	1	1000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
1	1	1000	CD	I-NP	O
kPa	kPa	k100	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	HYPH	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Controlled	Controlled	c05360403	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
MAP	MAP	m010	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
55	55	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
maintained	maintain	m0530503	VBD	B-VP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
inspired	inspired	i5210603	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CMRO2	CMRO2	0000	NN	B-NP	O
(	(	(000	(	O	O
to	to	t000	TO	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
73	73	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
16	16	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
CBF	CBF	c100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
clipping	clipping	c401052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aneurysm	aneurysm	a506025	NN	I-NP	B-Disease
the	the	t000	DT	B-NP	O
isoflurane	isoflurane	i201406050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
CBF	CBF	c100	NN	B-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
CMRO2	CMRO2	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
,	,	,000	,	O	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
pre	pre	p600	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
offer	offer	o106	VB	I-VP	O
protection	protection	p60302305	NN	B-NP	O
to	to	t000	TO	B-PP	O
brain	brain	b605	NN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
periods	period	p06032	NNS	B-NP	O
of	of	o100	IN	B-PP	O
induced	induce	i530203	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Triazolam	Triazolam	t6020405	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
brief	brief	b601	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
secondary	secondary	s02053060	JJ	B-NP	O
mania	mania	m050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Large	Large	l0620	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
triazolam	triazolam	t6020405	NN	B-NP	B-Chemical
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
induced	induce	i530203	VBD	B-VP	O
brief	brief	b601	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mania	mania	m050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
elderly	elderly	e430640	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

Features	Feature	f030602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
organic	organic	o620502	JJ	B-NP	B-Disease
mental	mental	m05304	JJ	I-NP	I-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
(	(	(000	(	O	O
delirium	delirium	d040605	NN	B-NP	B-Disease
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
present	present	p602053	JJ	B-ADJP	O
.	.	.000	.	O	O

Manic	Manic	m0502	JJ	B-NP	B-Disease
excitement	excitement	e20305053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
coincident	coincident	c05203053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
of	of	o100	IN	B-PP	O
triazolam	triazolam	t6020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
contribution	contribution	c0536010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
triazolo	triazolo	t602040	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
to	to	t000	TO	B-PP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
affective	affective	a1023010	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
neurotoxic	neurotoxic	n06030202	JJ	B-NP	B-Disease
esterase	esterase	e2306020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
and	and	a530	CC	I-NP	O
mipafox	mipafox	m010102	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
neuropathic	neuropathic	n06010302	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
neurotoxic	neurotoxic	n06030202	JJ	B-NP	B-Disease
esterase	esterase	e2306020	NN	I-NP	O
or	or	o600	CC	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
target	target	t06203	NN	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
(	(	(000	(	O	O
NTE	NTE	n300	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
acutely	acutely	a203040	RB	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
Mipafox	Mipafox	m010102	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
N	N	n000	NN	B-NP	I-Chemical
'	'	'000	SYM	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
diisopropylphosphorodiamidofluoridate	diisopropylphosphorodiamidofluoridate	d0201601041021060305030140603030	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
neurotoxic	neurotoxic	n06030202	JJ	I-NP	B-Disease
organophosphate	organophosphate	o620501021030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Brain	Brain	b605	NN	B-NP	O
and	and	a530	CC	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
NTE	NTE	n300	NN	I-NP	O
activities	activity	a23010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Long	Long	l052	NNP	B-NP	O
-	-	-000	HYPH	I-NP	O
Evans	Evans	e1052	NNP	I-NP	O
male	male	m040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
1	1	1000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
post	post	p023	AFX	O	O
-	-	-000	HYPH	O	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Mipafox	Mipafox	m010102	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
ip	ip	i100	RB	B-ADVP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
histologically	histologically	h023040202040	RB	B-NP	O
scored	score	s20603	VBN	I-NP	O
cervical	cervical	c0610204	JJ	I-NP	O
cord	cord	c063	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
similarly	similarly	s05040640	RB	B-NP	O
dosed	dose	d0203	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
sampled	sample	s051403	VBD	B-VP	O
14	14	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
21	21	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

Those	Those	t020	DT	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
that	that	t030	WDT	B-NP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
NTE	NTE	n300	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cord	cord	c063	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
73	73	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
severe	severe	s01060	JJ	B-ADJP	O
(	(	(000	(	O	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
cervical	cervical	c0610204	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
pathology	pathology	p0304020	NN	I-NP	O
in	in	i500	IN	B-PP	O
85	85	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
dosages	dosage	d020202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
Mipafox	Mipafox	m010102	NNP	B-NP	B-Chemical
(	(	(000	(	O	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
which	which	w020	WDT	B-NP	O
inhibited	inhibit	i5010303	VBD	B-VP	O
mean	mean	m050	JJ	B-NP	O
NTE	NTE	n300	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
brain	brain	b605	NN	I-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
or	or	o600	CC	O	O
equal	equal	e204	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
this	this	t020	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
cord	cord	c063	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
9	9	9000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
critical	critical	c6030204	JJ	I-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
NTE	NTE	n300	NN	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
and	and	a530	CC	O	O
spinal	spinal	s10504	JJ	B-NP	O
cord	cord	c063	NN	I-NP	O
sampled	sample	s051403	VBN	B-VP	O
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
Mipafox	Mipafox	m010102	NNP	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
can	can	c050	MD	B-VP	O
predict	predict	p603023	VB	I-VP	O
neuropathic	neuropathic	n06010302	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
several	several	s010604	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
.	.	.000	.	O	O

Allergic	Allergic	a406202	JJ	B-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
consisting	consist	c052023052	VBG	B-VP	O
of	of	o100	IN	B-PP	O
angioneurotic	angioneurotic	a5205060302	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
oral	oral	o604	JJ	I-NP	I-Disease
cavity	cavity	c01030	NN	I-NP	I-Disease
,	,	,000	,	O	O
cirrhosis	cirrhosis	c060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
impaired	impaired	i510603	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
sixth	sixth	s0230	JJ	I-NP	O
and	and	a530	CC	I-NP	O
seventh	seventh	s010530	JJ	I-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
infusional	infusional	i51020504	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Oral	Oral	o604	JJ	B-NP	O
diphenhydramine	diphenhydramine	d010503605050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
prednisone	prednisone	p603502050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
ineffective	ineffective	i501023010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Discontinuance	Discontinuance	d02053050520	NN	B-NP	O
of	of	o100	IN	B-PP	O
effective	effective	e1023010	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
remission	remission	r050205	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
progression	progression	p60260205	NN	I-NP	O
.	.	.000	.	O	O

Myasthenia	Myasthenia	m023050	NN	B-NP	B-Disease
gravis	gravis	g60102	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
chloroquine	chloroquine	c040602050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
a	a	a000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
reversible	reversible	r010620140	JJ	B-NP	O
and	and	a530	CC	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
myasthenia	myasthenia	m023050	NN	I-NP	B-Disease
gravis	gravis	g60102	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
penicillamine	penicillamine	p05020405050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
chloroquine	chloroquine	c040602050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
detectable	detectable	d030230140	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

On	On	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tolerance	tolerance	t04060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tolerance	tolerance	t04060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
muscular	muscular	m020406	JJ	I-NP	B-Disease
rigidity	rigidity	r0203030	NN	I-NP	I-Disease
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Saline	Saline	s04050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
pretreated	pretreate	p60360303	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
given	give	g0105	VBN	B-VP	O
a	a	a000	DT	B-NP	O
test	test	t023	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
pronounced	pronounced	p60505203	JJ	I-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
recorded	record	r0206303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
tonic	tonic	t0502	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
electromyogram	electromyogram	e402360502605	NN	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
for	for	f060	IN	B-PP	O
11	11	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
with	with	w030	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
withdrawn	withdraw	w0303605	VBN	B-VP	O
for	for	f060	IN	B-PP	O
36	36	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
tolerance	tolerance	t04060520	NN	B-NP	O
:	:	:000	:	O	O
about	about	a103	IN	B-NP	O
half	half	h041	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
test	test	t023	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
akinetic	akinetic	a2050302	JJ	B-ADJP	B-Disease
(	(	(000	(	O	O
A	A	a000	NN	B-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
strong	strong	s36052	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
stereotyped	stereotyped	s306030103	JJ	B-NP	O
(	(	(000	(	O	O
S	S	s000	NN	B-NP	O
)	)	)000	)	O	O
licking	licking	l02052	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
gnawing	gnaw	g5052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
presence	presence	p6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
akinetic	akinetic	a2050302	JJ	B-NP	B-Disease
or	or	o600	CC	I-NP	O
hyperkinetic	hyperkinetic	h01062050302	JJ	I-NP	B-Disease
(	(	(000	(	O	O
K	K	k000	NN	B-NP	O
)	)	)000	)	O	O
behaviour	behaviour	b0106	NN	B-NP	O
(	(	(000	(	O	O
AS	AS	a200	NN	B-NP	O
/	/	/000	SYM	B-NP	O
KS	KS	k200	NN	I-NP	O
group	group	g601	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
considerably	considerably	c05203060140	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
20	20	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
'	'	'000	POS	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
series	series	s0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
block	block	b402	VB	I-VP	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
activation	activation	a23010305	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
estimate	estimate	e2305030	VB	I-VP	O
the	the	t000	DT	B-NP	O
real	real	r040	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
any	any	a500	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
interference	interference	i53061060520	NN	I-NP	O
.	.	.000	.	O	O

Haloperidol	Haloperidol	h0401060304	NN	B-NP	B-Chemical
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
rigidity	rigidity	r0203030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
AS	AS	a200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
KS	KS	k200	NN	I-NP	O
group	group	g601	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
considerably	considerably	c05203060140	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
A	A	a000	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
assumed	assume	a20503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
morphine	morphine	m061050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
antagonized	antagonize	a5302050203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
another	another	a50306	DT	B-NP	O
process	process	p60202	NN	I-NP	O
leading	lead	l03052	VBG	B-VP	O
to	to	t000	TO	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
striatum	striatum	s360305	NN	I-NP	O
.	.	.000	.	O	O

Nevertheless	Nevertheless	n010630402	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
occurs	occur	o2062	VBZ	B-VP	O
some	some	s050	DT	B-NP	O
real	real	r040	JJ	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
alternations	alternation	a4306503052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rigidity	rigidity	r0203030	NN	B-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
dopaminergic	dopaminergic	d01050506202	JJ	B-NP	O
activation	activation	a23010305	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
AS	AS	a200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
KS	KS	k200	NN	I-NP	O
group	group	g601	NN	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
shifts	shift	s0132	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
predominance	predominance	p60305050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
DA	DA	d000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
innervated	innervate	i50610303	VBN	I-NP	O
structures	structure	s360230602	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
massive	massive	m02010	JJ	B-NP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
molindone	molindone	m04053050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Rhabdomyolysis	Rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
lethal	lethal	l0304	JJ	I-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
that	that	t030	IN	B-NP	O
psychiatric	psychiatric	p20203602	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
seem	seem	s050	VBP	B-VP	O
predisposed	predispose	p6030210203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
develop	develop	d010401	VB	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
signs	sign	s0252	NNS	I-NP	O
and	and	a530	CC	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
,	,	,000	,	O	O
typical	typical	t010204	JJ	B-NP	O
laboratory	laboratory	l010603060	NN	I-NP	O
features	feature	f030602	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
complications	complication	c05140203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	B-NP	B-Disease
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
patient	patient	p03053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
illustrate	illustrate	i40236030	VB	I-VP	O
massive	massive	m02010	JJ	B-NP	O
rhabdomyolysis	rhabdomyolysis	r01305040202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
molindone	molindone	m04053050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Physicians	Physician	p0202052	NNS	B-NP	O
who	who	w000	WP	B-NP	O
prescribe	prescribe	p6026010	VBP	B-VP	O
molindone	molindone	m04053050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
reaction	reaction	r02305	NN	I-NP	O
.	.	.000	.	O	O

Compression	Compression	c05160205	NN	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
radial	radial	r0304	JJ	I-NP	I-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
pentazocine	pentazocine	p0530202050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
fibrous	fibrous	f01602	JJ	I-NP	B-Disease
myopathy	myopathy	m01030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Fibrous	Fibrous	f01602	JJ	B-NP	B-Disease
myopathy	myopathy	m01030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
,	,	,000	,	O	O
well	well	w040	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
known	know	k505	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
pentazocine	pentazocine	p0530202050	NN	I-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
compression	compression	c05160205	NN	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
fibrotic	fibrotic	f0160302	JJ	B-NP	O
muscle	muscle	m0240	NN	I-NP	O
affected	affect	a102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
pentazocine	pentazocine	p0530202050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myopathy	myopathy	m01030	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
documented	document	d020505303	VBN	B-NP	O
pentazocine	pentazocine	p0530202050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
fibrous	fibrous	f01602	JJ	I-NP	B-Disease
myopathy	myopathy	m01030	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
triceps	tricep	t602012	NNS	B-NP	O
and	and	a530	CC	O	O
deltoid	deltoid	d04303	JJ	B-NP	O
muscles	muscle	m02402	NNS	I-NP	O
bilaterally	bilaterally	b040306040	RB	B-ADVP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
three	three	t060	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
right	right	r0203	JJ	B-NP	O
wrist	wrist	w6023	NN	I-NP	O
drop	drop	d601	NN	I-NP	O
,	,	,000	,	O	O
electrodiagnostic	electrodiagnostic	e402360302502302	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
partial	partial	p06304	JJ	I-NP	O
lesion	lesion	l0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
radial	radial	r0304	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
distal	distal	d02304	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
branches	branch	b605202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
triceps	tricep	t602012	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
fibrous	fibrous	f01602	JJ	I-NP	B-Disease
myopathy	myopathy	m01030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Surgery	Surgery	s062060	NNP	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
radial	radial	r0304	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
severely	severely	s0106040	RB	I-VP	O
compressed	compress	c05160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
densely	densely	d052040	RB	I-NP	O
fibrotic	fibrotic	f0160302	JJ	I-NP	O
lateral	lateral	l030604	JJ	I-NP	O
head	head	h030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
triceps	tricep	t602012	NNS	I-NP	O
.	.	.000	.	O	O

Decompression	Decompression	d0205160205	NN	B-NP	O
and	and	a530	CC	I-NP	O
neurolysis	neurolysis	n06040202	NN	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
good	good	g030	JJ	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
function	function	f052305	NN	B-NP	O
.	.	.000	.	O	O

Recurrent	Recurrent	r0206053	JJ	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
from	from	f605	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cryptogenic	cryptogenic	c6013020502	JJ	B-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
disseminated	disseminate	d0205050303	VBN	B-NP	O
sporotrichosis	sporotrichosis	s106036020202	NN	I-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
immediately	immediately	i50303040	RB	B-VP	O
following	follow	f04052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
B	B	b000	NN	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
four	four	f060	CD	B-NP	O
separate	separate	s0106030	JJ	I-NP	O
occasions	occasion	o202052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
abruptness	abruptness	a16013502	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
reversibility	reversibility	r010620104030	NN	I-NP	O
within	within	w0305	IN	B-PP	O
days	day	d020	NNS	B-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
component	component	c05105053	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
propose	propose	p601020	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
amphotericin	amphotericin	a5103060205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
setting	setting	s03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
reduced	reduce	r030203	VBN	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
may	may	m000	MD	B-VP	O
activate	activate	a2301030	VB	I-VP	O
tubuloglomerular	tubuloglomerular	t010402405060406	JJ	B-NP	O
feedback	feedback	f03102	NN	I-NP	O
,	,	,000	,	O	O
thereby	thereby	t06010	RB	B-VP	O
contributing	contribute	c05360103052	VBG	I-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cerebral	Cerebral	c0601604	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylpropanolamine	phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Phenylpropanolamine	Phenylpropanolamine	p05041601050405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PPA	PPA	p100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
synthetic	synthetic	s0530302	JJ	I-NP	O
sympathomimetic	sympathomimetic	s0510305050302	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
structurally	structurally	s3602306040	RB	B-ADJP	O
similar	similar	s050406	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
amphetamine	amphetamine	a510305050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
counter	counter	c05306	NN	I-NP	O
in	in	i500	IN	B-PP	O
anorectics	anorectic	a50602302	NNS	B-NP	O
,	,	,000	,	O	O
nasal	nasal	n0204	JJ	B-NP	O
congestants	congestant	c0520230532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cold	cold	c043	JJ	B-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

Its	Its	i320	PRP$	B-NP	O
prolonged	prolonged	p60405203	JJ	I-NP	O
use	use	u200	NN	I-NP	O
or	or	o600	CC	I-NP	O
overuse	overuse	o106020	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
seizures	seizure	s020602	NNS	B-NP	B-Disease
,	,	,000	,	O	O
intracerebral	intracerebral	i536020601604	JJ	B-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
,	,	,000	,	O	O
neuropsychiatric	neuropsychiatric	n060120203602	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
nonhemorrhagic	nonhemorrhagic	n0505060202	JJ	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
who	who	w000	WP	B-NP	O
suffered	suffer	s010603	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
taking	take	t02052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
oral	oral	o604	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
PPA	PPA	p100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Remission	Remission	r050205	NN	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
meningeal	meningeal	m0505204	JJ	B-NP	B-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
meningeal	meningeal	m0505204	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	O
that	that	t030	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
and	and	a530	CC	I-VP	O
maintain	maintain	m05305	VB	I-VP	O
CSF	CSF	c210	NN	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
mol	mol	m040	NN	B-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
concomitant	concomitant	c0520503053	JJ	B-NP	O
intrathecal	intrathecal	i536030204	JJ	I-NP	O
dosing	dosing	d02052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
6	6	6000	CD	B-NP	O
,	,	,000	,	O	O
000	000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
h	h	h000	NN	I-NP	O
for	for	f060	IN	B-PP	O
23	23	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
.	.	.000	.	O	O

Leucovorin	Leucovorin	l02010605	NN	B-NP	B-Chemical
rescue	rescue	r020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
initiated	initiate	i5030303	VBN	I-VP	O
12	12	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
end	end	e530	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
loading	loading	l03052	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
every	every	e1060	DT	B-NP	O
three	three	t060	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
six	six	s020	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
every	every	e1060	DT	B-NP	O
six	six	s020	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
until	until	u5304	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
7	7	7000	CD	O	O
)	)	)000	)	O	O
mol	mol	m040	NN	B-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
steady	steady	s3030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
state	state	s3030	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	I-NP	O
CSF	CSF	c210	NN	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
achieved	achieve	a20103	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	O	O
)	)	)000	)	O	O
mol	mol	m040	NN	B-NP	O
/	/	/000	SYM	B-NP	O
L	L	l000	NN	I-NP	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
X	X	x000	SYM	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	O	O
)	)	)000	)	O	O
mol	mol	m040	NN	B-NP	O
/	/	/000	SYM	B-VP	O
L	L	l000	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
20	20	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
16	16	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
20	20	0000	CD	I-NP	O
(	(	(000	(	O	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
obtained	obtain	o130503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
remission	remission	r050205	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
encountered	encounter	e520530603	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
transient	transient	t6052053	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
transaminase	transaminase	t60520505020	NN	I-NP	O
and	and	a530	CC	I-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
elevations	elevation	e40103052	NNS	I-NP	O
,	,	,000	,	O	O
neutropenia	neutropenia	n03601050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
mucositis	mucositis	m02020302	NN	B-NP	B-Disease
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
focal	focal	f0204	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
and	and	a530	CC	O	O
transient	transient	t6052053	JJ	B-NP	B-Disease
hemiparesis	hemiparesis	h0501060202	NN	I-NP	I-Disease
but	but	b030	CC	O	O
recovered	recover	r02010603	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
methotrexate	methotrexate	m0303602030	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
remission	remission	r050205	NN	B-NP	O
after	after	a1306	IN	B-PP	O
meningeal	meningeal	m0505204	JJ	B-NP	O
relapse	relapse	r040120	NN	I-NP	O
in	in	i500	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
lymphoblastic	lymphoblastic	l05101402302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Interaction	Interaction	i530602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
antineoplastic	antineoplastic	a530501402302	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
synergistic	synergistic	s0506202302	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
T	T	t000	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
lymphocytic	lymphocytic	l051020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
relapse	relapse	r040120	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
eradication	eradication	e603020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
hitherto	hitherto	h030630	NN	B-NP	O
refractory	refractory	r016023060	JJ	I-NP	O
leukemic	leukemic	l020502	JJ	I-NP	B-Disease
infiltration	infiltration	i5104360305	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
marrow	marrow	m060	NN	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
progressive	progressive	p602602010	JJ	B-NP	O
hyperbilirubinemia	hyperbilirubinemia	h0106104060105050	NN	I-NP	B-Disease
,	,	,000	,	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
point	point	p053	NN	B-NP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
of	of	o100	IN	B-PP	O
antineoplastic	antineoplastic	a530501402302	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
but	but	b030	CC	O	O
also	also	a420	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
tissues	tissue	t0202	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
time	time	t050	NN	I-NP	O
that	that	t030	IN	B-ADVP	O
the	the	t000	DT	B-NP	O
pharmacodynamic	pharmacodynamic	p0650203050502	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
confined	confine	c0510503	VBN	I-VP	O
strictly	strictly	s3602340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
suppression	suppression	s0160205	NN	B-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
T	T	t000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
cell	cell	c040	NN	I-NP	O
functions	function	f0523052	NNS	I-NP	O
.	.	.000	.	O	O

Incidence	Incidence	i52030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
neoplasms	neoplasm	n0140252	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
different	different	d0106053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
.	.	.000	.	O	O

Immunosuppressive	Immunosuppressive	i5050201602010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
30	30	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
rheumatoid	rheumatoid	r050303	JJ	I-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
commonly	commonly	c050540	RB	B-VP	O
used	use	u203	VBN	I-VP	O
are	be	a600	VBP	B-VP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
chlorambucil	chlorambucil	c04060510204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
alkylating	alkylate	a420403052	VBG	B-NP	B-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
purine	purine	p06050	NN	B-NP	B-Chemical
analogue	analogue	a504020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
folic	folic	f0402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
analogue	analogue	a504020	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
all	all	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
can	can	c050	MD	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
synovitis	synovitis	s05010302	NN	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
disease	disease	d02020	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
almost	almost	a45023	RB	B-ADVP	O
always	always	a402	RB	I-ADVP	O
recurs	recur	r02062	VBZ	B-VP	O
after	after	a1306	IN	B-SBAR	O
therapy	therapy	t06010	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
,	,	,000	,	O	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
percent	percent	p062053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
are	be	a600	VBP	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
continue	continue	c053050	VB	I-VP	O
a	a	a000	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
takes	take	t0202	VBZ	B-VP	O
three	three	t060	CD	B-NP	O
to	to	t000	TO	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
maximal	maximal	m020504	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
those	those	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
are	be	a600	VBP	B-VP	O
unable	unable	u50140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
continue	continue	c053050	VB	I-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
receive	receive	r02010	VB	B-VP	O
little	little	l0340	JJ	B-NP	O
benefit	benefit	b050103	NN	I-NP	O
from	from	f605	IN	B-PP	O
it	it	i300	PRP	B-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
alkylating	alkylate	a420403052	VBG	B-NP	B-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
have	have	h010	VBP	B-VP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
nonlymphocytic	nonlymphocytic	n054051020302	JJ	I-NP	I-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
alkylating	alkylate	a420403052	VBG	I-NP	B-Chemical
agents	agent	a20532	NNS	I-NP	I-Chemical
and	and	a530	CC	O	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
non	non	n050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hodgkin	Hodgkin	h03205	NN	I-NP	I-Disease
'	'	'000	''	I-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
lymphoma	lymphoma	l051050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cyclophosphamide	Cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
several	several	s010604	JJ	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
most	most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
common	common	c0505	JJ	I-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
increased	increase	i5260203	VBN	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
malignancy	malignancy	m040250520	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
still	still	s304	RB	I-VP	O
being	be	b052	VBG	I-VP	O
collected	collect	c0402303	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
until	until	u5304	IN	B-SBAR	O
further	further	f06306	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunosuppressive	immunosuppressive	i5050201602010	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
alkylating	alkylate	a420403052	VBG	B-VP	B-Chemical
agents	agent	a20532	NNS	B-NP	I-Chemical
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
rheumatoid	rheumatoid	r050303	JJ	B-NP	B-Disease
arthritis	arthritis	a63060302	NN	I-NP	I-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reserved	reserve	r0206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
or	or	o600	CC	O	O
life	life	l010	NN	B-NP	O
-	-	-000	HYPH	O	O
threatening	threaten	t060305052	VBG	B-VP	O
complications	complication	c05140203052	NNS	B-NP	O
.	.	.000	.	O	O

Warfarin	Warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
iliopsoas	iliopsoa	i401202	NNS	I-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
femoral	femoral	f050604	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
28	28	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
on	on	o500	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
warfarin	warfarin	w0610605	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
who	who	w000	WP	B-NP	O
sustained	sustain	s0230503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
minor	minor	m0506	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	B-Disease
tear	tear	t060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
developed	develop	d01040103	VBD	B-VP	O
increasing	increase	i52602052	VBG	I-VP	O
pain	pain	p050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
flexure	flexure	f402060	NN	I-NP	O
contracture	contracture	c0536023060	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
right	right	r0203	JJ	I-NP	O
hip	hip	h010	NN	I-NP	O
.	.	.000	.	O	O

Surgical	Surgical	s0620204	JJ	B-NP	O
exploration	exploration	e214060305	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
an	an	a500	DT	B-NP	O
iliopsoas	iliopsoas	i401202	JJ	I-NP	O
hematoma	hematoma	h0503050	NN	I-NP	B-Disease
and	and	a530	CC	O	O
femoral	femoral	f050604	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	B-Disease
entrapment	entrapment	e536015053	NN	I-NP	I-Disease
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
femoral	femoral	f050604	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
and	and	a530	CC	O	O
partial	partial	p06304	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
quadriceps	quadricep	q03602012	NNS	B-NP	I-Disease
functions	function	f0523052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Anticoagulant	Anticoagulant	a53020204053	NN	B-NP	O
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
femoral	femoral	f050604	JJ	I-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
palsy	palsy	p0420	NN	I-NP	I-Disease
represents	represent	r016020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
warfarin	warfarin	w0610605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
characterized	characterize	c06023060203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
inguinal	inguinal	i520504	JJ	I-NP	O
region	region	r0205	NN	I-NP	O
,	,	,000	,	O	O
varying	vary	v06052	VBG	B-VP	O
degrees	degree	d02602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	B-Disease
and	and	a530	CC	O	I-Disease
sensory	sensory	s052060	JJ	B-NP	I-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
flexure	flexure	f402060	NN	B-NP	O
contracture	contracture	c0536023060	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
involved	involve	i5104103	VBN	I-NP	O
extremity	extremity	e23605030	NN	I-NP	O
.	.	.000	.	O	O

Pneumonitis	Pneumonitis	p505050302	NN	B-NP	O
with	with	w030	IN	B-PP	O
pleural	pleural	p40604	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
pericardial	pericardial	p060206304	JJ	I-NP	I-Disease
effusion	effusion	e10205	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
during	during	d06052	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
sinuatrial	sinuatrial	s0503604	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
implanted	implant	i51405303	VBN	B-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
maximum	maximum	m020505	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
1000	1000	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
maintenance	maintenance	m053050520	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
800	800	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
control	control	c053604	NN	B-NP	O
of	of	o100	IN	B-PP	O
supraventricular	supraventricular	s016010536020406	JJ	B-NP	B-Disease
tachyarrhythmias	tachyarrhythmia	t0206030502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
pneumonitis	pneumonitis	p505050302	NN	B-NP	B-Disease
,	,	,000	,	O	O
pleural	pleural	p40604	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
pericardial	pericardial	p060206304	JJ	I-NP	I-Disease
effusions	effusion	e102052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
predominantly	predominantly	p603050505340	RB	I-NP	O
proximal	proximal	p6020504	JJ	I-NP	B-Disease
motor	motor	m0306	NN	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Immediate	Immediate	i503030	JJ	B-NP	O
but	but	b030	CC	I-NP	O
gradual	gradual	g60304	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
prednisolone	prednisolone	p60350204050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Review	Review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
and	and	a530	CC	I-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-PP	O
early	early	e0640	JJ	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
pneumonitis	pneumonitis	p505050302	NN	I-NP	B-Disease
,	,	,000	,	O	O
immediate	immediate	i503030	JJ	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
prompt	prompt	p60513	NN	B-NP	O
but	but	b030	CC	O	O
continued	continue	c0530503	VBD	B-VP	O
steroid	steroid	s30603	JJ	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
to	to	t000	TO	B-VP	O
ensure	ensure	e52060	VB	I-VP	O
full	full	f040	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
observed	observe	o1206103	VBD	B-VP	O
sinoatrial	sinoatrial	s0503604	JJ	B-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
,	,	,000	,	O	O
Wolff	Wolff	w041	NNP	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
White	White	w030	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
supraventricular	supraventricular	s016010536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
disappearance	disappearance	d0201060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sinoatrial	sinoatrial	s0503604	JJ	I-NP	B-Disease
block	block	b402	NN	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
persistence	persistence	p0620230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
asymptomatic	asymptomatic	a20513050302	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
bradycardia	bradycardia	b603020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Desipramine	Desipramine	d0201605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
"	"	"000	``	B-NP	O
subtherapeutic	subtherapeutic	s01306010302	JJ	I-NP	O
"	"	"000	''	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
Desipramine	Desipramine	d0201605050	NN	I-NP	B-Chemical
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
delirium	delirium	d040605	NN	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
her	her	h060	PRP$	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
"	"	"000	``	I-NP	O
subtherapeutic	subtherapeutic	s01306010302	JJ	I-NP	O
"	"	"000	''	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

Delirium	Delirium	d040605	NNP	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
tricyclic	tricyclic	t60202402	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
,	,	,000	,	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
tricyclics	tricyclic	t60202402	NNS	B-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
anticholinergic	anticholinergic	a5302040506202	JJ	I-NP	O
potency	potency	p030520	NN	I-NP	O
.	.	.000	.	O	O

Therapeutic	Therapeutic	t06010302	JJ	B-NP	O
ranges	range	r05202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
antidepressants	antidepressant	a5303016020532	NNS	B-NP	B-Chemical
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
derived	derive	d060103	VBN	I-VP	O
from	from	f605	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
adult	adult	a3043	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
appropriate	appropriate	a16016030	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
specifically	specifically	s1020102040	RB	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
now	now	n000	RB	I-VP	O
required	require	r020603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
establish	establish	e23014020	VB	I-VP	O
safer	safe	s0106	JJR	B-NP	O
and	and	a530	CC	I-NP	O
more	more	m060	RBR	I-NP	O
appropriate	appropriate	a16016030	JJ	I-NP	O
guidelines	guideline	g03040502	NNS	I-NP	O
for	for	f060	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Indomethacin	Indomethacin	i5305030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
:	:	:000	:	O	O
recurrence	recurrence	r02060520	NN	B-NP	O
on	on	o500	IN	B-PP	O
rechallenge	rechallenge	r02040520	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
oliguric	oliguric	o4020602	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
hyperkalemia	hyperkalemia	h0106204050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
cirrhosis	cirrhosis	c060202	NN	B-NP	B-Disease
,	,	,000	,	O	O
ascites	ascite	a20302	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cor	cor	c060	NN	B-NP	B-Disease
pulmonale	pulmonale	p04505040	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Prompt	Prompt	p60513	JJ	B-NP	O
restoration	restoration	r023060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
drug	drug	d602	NN	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
indomethacin	indomethacin	i5305030205	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
recurrence	recurrence	r02060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
oliguria	oliguria	o402060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
case	case	c020	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
endogenous	endogenous	e53020502	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
prostaglandins	prostaglandin	p6023024053052	NNS	I-NP	B-Chemical
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
circulating	circulate	c0620403052	VBG	B-VP	O
plasma	plasma	p40250	NN	B-NP	O
volume	volume	v04050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
diminished	diminish	d05050203	VBN	I-VP	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
nonsteroidal	nonsteroidal	n0523060304	JJ	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
interfere	interfere	i53061060	VBP	B-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
and	and	a530	CC	O	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
in	in	i500	IN	B-PP	O
such	such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Patterns	Pattern	p030652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
related	relate	r040303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
1967	1967	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1977	1977	0000	CD	I-NP	O
.	.	.000	.	O	O

Illness	Illness	i4502	NN	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	B-NP	O
-	-	-000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
commencement	commencement	c0505205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
3	3	3000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
having	have	h01052	VBG	B-VP	O
received	receive	r020103	VBN	I-VP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
for	for	f060	IN	B-PP	O
13	13	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
and	and	a530	CC	O	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
experiencing	experience	e2106052052	VBG	B-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
.	.	.000	.	O	O

Jaundice	Jaundice	j053020	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
tender	tender	t05306	NN	B-NP	O
hepatomegaly	hepatomegaly	h01030502040	NN	I-NP	B-Disease
,	,	,000	,	O	O
usually	usually	u2040	RB	B-VP	O
preceded	precede	p6020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
malaise	malaise	m04020	NN	B-NP	O
,	,	,000	,	I-NP	O
anorexia	anorexia	a506020	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
nausea	nausea	n020	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
vomiting	vomiting	v0503052	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
upper	upper	u106	JJ	B-NP	O
abdominal	abdominal	a13050504	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
invariable	invariable	i51060140	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Biochemical	Biochemical	b02050204	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
and	and	a530	CC	O	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
histopathological	histopathological	h023010304020204	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
spectrum	spectrum	s1023605	NN	I-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
fatty	fatty	f030	JJ	B-NP	B-Disease
change	change	c0520	NN	I-NP	I-Disease
and	and	a530	CC	O	O
focal	focal	f0204	JJ	B-NP	O
hepatocellular	hepatocellular	h010302040406	JJ	I-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
massive	massive	m02010	JJ	B-NP	B-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
acute	acute	a2030	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
or	or	o600	CC	O	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
active	active	a23010	JJ	I-NP	I-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
on	on	o500	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
to	to	t000	TO	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
in	in	i500	IN	B-PP	O
11	11	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
died	die	d030	VBD	B-VP	O
,	,	,000	,	O	O
having	have	h01052	VBG	B-VP	O
presented	present	p60205303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
another	another	a50306	DT	B-NP	O
,	,	,000	,	O	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
taking	take	t02052	VBG	I-VP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
7	7	7000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
slower	slow	s406	JJR	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
biochemical	biochemical	b02050204	JJ	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
several	several	s010604	JJ	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
patient	patient	p03053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
series	series	s0602	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
fulminant	fulminant	f04505053	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
accidentally	accidentally	a203053040	RB	I-VP	O
recommenced	recommence	r020505203	VBN	I-VP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
prior	prior	p606	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
others	other	o3062	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
causal	causal	c0204	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
methyldopa	methyldopa	m03043010	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
proved	prove	p60103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
observed	observe	o1206103	VBN	B-NP	O
fasciculations	fasciculation	f02020403052	NNS	I-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
response	response	r0210520	NN	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Sch	Sch	s200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
i	i	i000	NNS	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
to	to	t000	TO	B-PP	O
36	36	0000	CD	B-NP	O
adult	adult	a3043	JJ	I-NP	O
males	male	m0402	NNS	I-NP	O
at	at	a300	IN	B-PP	O
six	six	s020	CD	B-NP	O
rates	rate	r0302	NNS	I-NP	O
:	:	:000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
s	s	s000	SYM	B-NP	O
-	-	-000	SYM	B-ADJP	O
1	1	1000	CD	B-NP	O
to	to	t000	TO	I-NP	O
20	20	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
s	s	s000	AFX	O	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
either	either	e0306	CC	O	O
when	when	w050	WRB	B-ADVP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
muscular	muscular	m020406	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
tetanic	tetanic	t030502	JJ	B-NP	B-Disease
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ulnar	ulnar	u4506	JJ	I-NP	O
nerve	nerve	n0610	NN	I-NP	O
or	or	o600	CC	O	O
when	when	w050	WRB	B-ADVP	O
Sch	Sch	s200	NNP	B-NP	B-Chemical
120	120	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
exceeded	exceed	e20303	VBN	I-VP	O
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Fasciculations	Fasciculation	f02020403052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
areas	area	a602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
body	body	b030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
scored	score	s20603	VBN	I-VP	O
from	from	f605	IN	B-PP	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
and	and	a530	CC	O	O
summated	summate	s050303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
fasciculation	fasciculation	f0202040305	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
times	time	t0502	NNS	I-NP	O
to	to	t000	TO	B-PP	O
first	first	f0623	JJ	B-NP	O
fasciculation	fasciculation	f0202040305	NN	I-NP	B-Disease
,	,	,000	,	O	O
twitch	twitch	t0320	NN	B-NP	B-Disease
suppression	suppression	s0160205	NN	I-NP	O
and	and	a530	CC	O	O
tetanus	tetanus	t030502	NN	B-NP	B-Disease
suppression	suppression	s0160205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
inversely	inversely	i51062040	RB	I-VP	O
related	relate	r040303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
.	.	.000	.	O	O

Fasciculations	Fasciculation	f02020403052	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
six	six	s020	CD	I-NP	O
areas	area	a602	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
fasciculation	fasciculation	f0202040305	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
related	relate	r040303	VBN	I-VP	O
directly	directly	d0602340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
fasciculation	fasciculation	f0202040305	NN	I-NP	B-Disease
scores	score	s20602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
bolus	bolus	b0402	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
s	s	s000	AFX	O	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
s	s	s000	AFX	O	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	B-ADJP	O
significantly	significantly	s025010205340	RB	I-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
psoriasis	psoriasis	p2060202	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Azathioprine	Azathioprine	a203016050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
benefited	benefit	b05010303	VBD	B-VP	O
19	19	0000	CD	B-NP	O
(	(	(000	(	O	O
66	66	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
psoriasis	psoriasis	p2060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Haematological	Haematological	h050304020204	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
troublesome	troublesome	t601402050	JJ	B-ADJP	O
and	and	a530	CC	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
biochemical	biochemical	b02050204	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
remained	remain	r050503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

Minimal	Minimal	m050504	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
and	and	a530	CC	O	O
portal	portal	p06304	JJ	B-NP	O
fibrosis	fibrosis	f0160202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
in	in	i500	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
.	.	.000	.	O	O

Liver	Liver	l0106	NN	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
at	at	a300	IN	B-PP	O
regular	regular	r020406	JJ	B-NP	O
intervals	interval	i53061042	NNS	I-NP	O
if	if	i100	IN	B-SBAR	O
azathioprine	azathioprine	a203016050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
continued	continue	c0530503	VBN	I-VP	O
so	so	s000	RB	B-SBAR	O
that	that	t030	IN	I-SBAR	O
structural	structural	s360230604	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
detected	detect	d0302303	VBN	I-VP	O
at	at	a300	IN	B-PP	O
an	an	a500	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
stage	stage	s3020	NN	I-NP	O
.	.	.000	.	O	O

Angiosarcoma	Angiosarcoma	a5202062050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
diethylstilbestrol	diethylstilbestrol	d030423041023604	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Angiosarcoma	Angiosarcoma	a5202062050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
76	76	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
differentiated	differentiate	d01060530303	VBN	I-NP	O
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
diethylstilbestrol	diethylstilbestrol	d030423041023604	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
13	13	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Angiosarcoma	Angiosarcoma	a5202062050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
present	present	p602053	JJ	B-ADJP	O
within	within	w0305	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	O
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
intraarterial	intraarterial	i5360630604	JJ	I-NP	B-Disease
lesions	lesion	l02052	NNS	I-NP	I-Disease
might	might	m0203	MD	B-VP	O
represent	represent	r01602053	VB	I-VP	O
independent	independent	i5301053053	JJ	B-NP	O
primary	primary	p605060	JJ	I-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
considered	consider	c052030603	VBN	I-VP	O
.	.	.000	.	O	O

Galanthamine	Galanthamine	g0405305050	NN	B-NP	B-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
longer	longer	l05206	RBR	I-NP	O
acting	act	a23052	VBG	I-NP	O
anticholinesterase	anticholinesterase	a5302040502306020	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Hyoscine	Hyoscine	h02050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Galanthamine	Galanthamine	g0405305050	NN	B-NP	B-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
anticholinesterase	anticholinesterase	a5302040502306020	NN	I-NP	O
drug	drug	d602	NN	I-NP	O
capable	capable	c010140	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
penetrating	penetrate	p0503603052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
central	central	c053604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
hyoscine	hyoscine	h02050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
overdosage	overdosage	o106302020	NN	B-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
longer	longer	l05206	RB	I-VP	O
acting	act	a23052	VBG	I-VP	O
than	than	t050	IN	B-PP	O
physostigmine	physostigmine	p02023025050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
to	to	t000	TO	B-VP	O
reverse	reverse	r010620	VB	I-VP	O
the	the	t000	DT	B-NP	O
non	non	n050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
depolarizing	depolarize	d01040602052	VBG	B-VP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	O
block	block	b402	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
studies	study	s30302	NNS	B-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
combating	combat	c05103052	VBG	B-VP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
following	follow	f04052	VBG	B-PP	O
oral	oral	o604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
flunitrazepam	flunitrazepam	f405036020105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
volunteers	volunteer	v04053062	NNS	B-NP	O
.	.	.000	.	O	O

Flunitrazepam	Flunitrazepam	f405036020105	NNP	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
,	,	,000	,	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
oral	oral	o604	JJ	I-NP	O
or	or	o600	CC	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	I-NP	O
routes	route	r0302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
groups	group	g6012	NNS	B-NP	O
of	of	o100	IN	B-PP	O
volunteers	volunteer	v04053062	NNS	B-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
effects	effect	e10232	NNS	I-NP	O
compared	compare	c0510603	VBN	B-VP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
were	be	w060	VBD	B-VP	O
estimated	estimate	e23050303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
gas	gas	g020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
liquid	liquid	l0203	NN	I-NP	O
chromatography	chromatography	c060503026010	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
smaller	small	s50406	JJR	I-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
striking	striking	s3602052	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
sedation	sedation	s030305	NN	B-NP	O
which	which	w020	WDT	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
producing	produce	p60302052	VBG	B-VP	O
deep	deep	d010	JJ	B-NP	O
sleep	sleep	s401	NN	I-NP	O
although	although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
could	could	c043	MD	B-VP	O
still	still	s304	RB	I-VP	O
be	be	b000	VB	I-VP	O
aroused	arouse	a60203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
m	m	m000	NN	B-NP	O
.	.	.000	.	O	O
administration	administration	a350502360305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
apparent	apparent	a106053	JJ	B-ADJP	O
earlier	earlier	e06406	RBR	B-ADVP	O
and	and	a530	CC	O	O
sometimes	sometimes	s05030502	RB	B-VP	O
lasted	last	l02303	VBN	I-VP	O
longer	long	l05206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
following	follow	f04052	VBG	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

Dizziness	Dizziness	d020502	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
marked	marked	m06203	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
pain	pain	p050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
m	m	m000	NN	B-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
flunitrazepam	flunitrazepam	f405036020105	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
more	more	m060	RBR	I-ADVP	O
often	often	o1305	RB	I-ADVP	O
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
isotonic	isotonic	i2030502	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
varied	vary	v0603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
dose	dose	d020	NN	B-NP	O
and	and	a530	CC	I-NP	O
route	route	r030	NN	I-NP	O
and	and	a530	CC	O	O
corresponded	correspond	c0602105303	VBD	B-VP	O
qualitatively	qualitatively	q04030301040	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
subjective	subjective	s012023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
still	still	s304	RB	B-ADVP	O
present	present	p602053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
measurable	measurable	m02060140	JJ	B-NP	O
quantities	quantity	q0530302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
even	even	e105	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
smallest	small	s504023	JJS	I-NP	O
dose	dose	d020	NN	I-NP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
teratogenicity	teratogenicity	t0603020502030	NN	I-NP	O
of	of	o100	IN	B-PP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
infants	infant	i510532	NNS	I-NP	O
,	,	,000	,	O	O
born	bear	b065	VBN	B-VP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
with	with	w030	IN	B-PP	O
inflammatory	inflammatory	i5140503060	JJ	B-NP	B-Disease
bowel	bowel	b040	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
throughout	throughout	t060203	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
major	major	m0206	JJ	B-NP	O
congenital	congenital	c052050304	JJ	I-NP	B-Disease
anomalies	anomaly	a5050402	NNS	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
singleton	singleton	s05240305	JJ	I-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mother	mother	m0306	NN	I-NP	O
had	have	h030	VBD	B-VP	O
ulcerative	ulcerative	u420603010	JJ	B-NP	B-Disease
colitis	colitis	c040302	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
male	male	m040	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
coarctation	coarctation	c06230305	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
aorta	aorta	a0630	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
septal	septal	s01304	JJ	I-NP	I-Disease
defect	defect	d01023	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
twin	twin	t050	NN	I-NP	O
pregnancy	pregnancy	p60250520	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
mother	mother	m0306	NN	I-NP	O
had	have	h030	VBD	B-VP	O
Crohn	Crohn	c605	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
twin	twin	t050	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
female	female	f05040	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
left	left	l013	JJ	I-NP	O
Potter	Potter	p0306	NN	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
type	type	t010	NN	I-NP	I-Disease
IIa	IIa	i000	NN	I-NP	I-Disease
polycystic	polycystic	p040202302	JJ	I-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
rudimentary	rudimentary	r0305053060	JJ	I-NP	B-Disease
left	left	l013	JJ	I-NP	I-Disease
uterine	uterine	u306050	JJ	I-NP	I-Disease
cornu	cornu	c0650	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
twin	twin	t050	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
male	male	m040	NN	I-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
some	some	s050	DT	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Potter	Potter	p0306	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
facies	facy	f0202	NNS	I-NP	I-Disease
,	,	,000	,	O	O
hypoplastic	hypoplastic	h0101402302	JJ	B-NP	B-Disease
lungs	lung	l052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
absent	absent	a12053	JJ	B-NP	B-Disease
kidneys	kidney	k03502	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	I-Disease
ureters	ureter	u603062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
talipes	talipe	t040102	NNS	B-NP	B-Disease
equinovarus	equinovarus	e205010602	NN	I-NP	I-Disease
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
reports	report	r010632	NNS	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
contrary	contrary	c0536060	NN	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
sulphasalazine	sulphasalazine	s041020402050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
teratogenic	teratogenic	t0603020502	JJ	B-ADJP	O
.	.	.000	.	O	O

Thrombotic	Thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
antineoplastic	antineoplastic	a530501402302	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
developed	develop	d01040103	VBD	B-VP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
(	(	(000	(	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
insufficiency	insufficiency	i5201020520	NN	I-NP	I-Disease
,	,	,000	,	O	O
microangiopathic	microangiopathic	m026052010302	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
usually	usually	u2040	RB	B-ADVP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	B-NP	B-Disease
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
bleomycin	bleomycin	b4050205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
vinca	vinca	v0520	NN	I-NP	B-Chemical
alkaloid	alkaloid	a420403	NN	I-NP	I-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
thrombotic	thrombotic	t060510302	JJ	B-NP	B-Disease
thrombocytopenic	thrombocytopenic	t060510203010502	JJ	I-NP	I-Disease
purpura	purpura	p061060	NN	I-NP	I-Disease
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
the	the	t000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
an	an	a500	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
forme	forme	f0650	NN	I-NP	O
fruste	fruste	f60230	NN	I-NP	O
of	of	o100	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
.	.	.000	.	O	O

Histologic	Histologic	h023040202	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
tissue	tissue	t020	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
evidence	evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
intravascular	intravascular	i53601020406	JJ	B-NP	B-Disease
coagulation	coagulation	c02040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
primarily	primarily	p60506040	RB	B-ADVP	O
affecting	affect	a1023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
arteries	artery	a630602	NNS	I-NP	O
,	,	,000	,	O	O
arterioles	arteriole	a63060402	NNS	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
glomeruli	glomerulus	g40506040	NNS	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
each	each	e020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
-	-	-000	HYPH	B-PP	O
free	free	f600	JJ	B-ADJP	O
or	or	o600	CC	O	O
had	have	h030	VBD	B-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
small	small	s504	JJ	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
thrombotic	thrombotic	t060510302	JJ	I-NP	B-Disease
microangiopathy	microangiopathy	m02605201030	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
have	have	h010	VB	I-VP	O
been	be	b050	VBN	I-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
.	.	.000	.	O	O

Diagnosis	Diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
fatal	fatal	f0304	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
delayed	delay	d0403	VBN	I-VP	O
or	or	o600	CC	I-VP	O
missed	miss	m0203	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
renal	renal	r0504	JJ	B-NP	O
tissue	tissue	t020	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
peripheral	peripheral	p06010604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
smear	smear	s506	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
examined	examine	e2050503	VBN	I-VP	O
,	,	,000	,	O	O
because	because	b02020	IN	B-SBAR	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
ascribed	ascribe	a260103	VBN	I-VP	O
to	to	t000	TO	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
anemia	anemia	a5050	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
thrombocytopenia	thrombocytopenia	t06051020301050	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bone	bone	b050	NN	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

International	International	i53065030504	JJ	B-NP	O
mexiletine	mexiletine	m020403050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
coronary	coronary	c0605060	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
:	:	:000	:	O	O
I	I	i000	LS	B-LST	O
.	.	.000	.	O	O

Report	Report	r01063	NN	B-NP	O
on	on	o500	IN	B-PP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
other	other	o306	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Impact	Impact	i51023	NNP	B-NP	O
Research	Research	r020620	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sustained	sustained	s0230503	JJ	I-NP	O
release	release	r04020	NN	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
mexiletine	mexiletine	m020403050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Mexitil	Mexitil	m020304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
Perlongets	Perlonget	p064052032	NNPS	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
in	in	i500	IN	B-PP	O
630	630	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
recent	recent	r02053	JJ	B-NP	O
documented	document	d020505303	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
variable	variable	v060140	JJ	I-NP	O
was	be	w020	VBD	B-VP	O
based	base	b0203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
reading	reading	r03052	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
ambulatory	ambulatory	a510403060	JJ	I-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
defined	define	d010503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
single	single	s05240	JJ	I-NP	O
premature	premature	p60503060	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
any	any	a500	DT	B-NP	O
two	two	t000	CD	I-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
30	30	0000	CD	I-NP	O
minute	minute	m05030	NN	I-NP	O
blocks	block	b402	NNS	I-NP	O
or	or	o600	CC	O	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
runs	run	r052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
premature	premature	p60503060	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
complexes	complex	c05140202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
entire	entire	e53060	JJ	I-NP	O
24	24	0000	CD	I-NP	O
hour	hour	h060	NN	I-NP	O
electrocardiographic	electrocardiographic	e40236020630260102	JJ	I-NP	O
recording	recording	r02063052	NN	I-NP	O
.	.	.000	.	O	O

Large	Large	l0620	JJ	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
,	,	,000	,	O	O
regarded	regard	r0206303	VBN	B-VP	O
as	as	a200	IN	B-PP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
,	,	,000	,	O	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
mexiletine	mexiletine	m020403050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
that	that	t030	DT	B-NP	O
end	end	e530	NN	I-NP	O
point	point	p053	NN	I-NP	O
at	at	a300	IN	B-PP	O
months	month	m05302	NNS	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	B-NP	O
trends	trend	t60532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
month	month	m0530	NN	B-NP	O
12	12	0000	CD	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
even	even	e105	RB	B-SBAR	O
though	though	t020	IN	I-SBAR	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
mexiletine	mexiletine	m020403050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
generally	generally	g0506040	RB	B-ADJP	O
lower	low	l060	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
observed	observe	o1206103	VBN	B-VP	O
in	in	i500	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
the	the	t000	DT	B-NP	O
regular	regular	r020406	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
deaths	death	d0302	NNS	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mexiletine	mexiletine	m020403050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
difference	difference	d01060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
coronary	coronary	c0605060	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Previously	Previously	p6010240	RB	B-NP	O
recognized	recognize	r020250203	VBN	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
and	and	a530	CC	O	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
problems	problem	p6014052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mexiletine	mexiletine	m020403050	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
during	during	d06052	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
after	after	a1306	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
X	X	x000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
ray	ray	r000	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
including	include	i52403052	VBG	B-PP	O
241	241	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
placebo	placebo	p402010	NN	B-NP	O
126	126	0000	CD	I-NP	O
,	,	,000	,	O	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
115	115	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
was	be	w020	VBD	B-VP	O
12	12	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
but	but	b030	CC	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
from	from	f605	IN	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
timolol	timolol	t050404	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
compensatory	compensatory	c05105203060	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
end	end	e530	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
diastolic	diastolic	d0230402	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
borderline	borderline	b063064050	JJ	I-NP	O
heart	heart	h063	NN	I-NP	O
size	size	s020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cardiomegaly	cardiomegaly	c0630502040	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
re	re	r000	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
size	size	s020	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
placebo	placebo	p402010	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
remained	remain	r050503	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
timolol	timolol	t050404	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
dairy	dairy	d060	NN	B-NP	O
cows	cow	c020	NNS	I-NP	O
.	.	.000	.	O	O

Large	Large	l0620	JJ	B-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
x	x	x000	CC	I-NP	O
10	10	0000	CD	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
IU	IU	i000	NN	B-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
hypercalcemia	hypercalcemia	h01062042050	NN	I-NP	B-Disease
,	,	,000	,	O	O
hyperphosphatemia	hyperphosphatemia	h0106102103050	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
large	large	l0620	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
metabolites	metabolite	m0301040302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
of	of	o100	IN	B-PP	O
nonlactating	nonlactating	n05402303052	JJ	B-NP	O
nonpregnant	nonpregnant	n0516025053	JJ	I-NP	O
and	and	a530	CC	I-NP	O
pregnant	pregnant	p6025053	JJ	I-NP	O
Jersey	Jersey	j0620	NNP	I-NP	O
cows	cow	c020	NNS	I-NP	O
.	.	.000	.	O	O

Calcium	Calcium	c04205	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
1	1	1000	CD	I-NP	O
day	day	d000	NN	I-NP	O
postpartum	postpartum	p023106305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
cows	cow	c020	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
about	about	a103	IN	B-NP	O
32	32	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
prepartum	prepartum	p60106305	NN	I-NP	O
(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
cows	cow	c020	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cows	cow	c020	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
showed	show	s030	VBD	B-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
peripartal	peripartal	p060106304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
22	22	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
cows	cow	c020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
milk	milk	m042	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
this	this	t020	DT	B-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

Signs	Sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
nonlactating	nonlactating	n05402303052	JJ	B-NP	O
nonpregnant	nonpregnant	n0516025053	JJ	I-NP	O
cows	cow	c020	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
pregnant	pregnant	p6025053	JJ	B-NP	O
cows	cow	c020	NNS	I-NP	O
commonly	commonly	c050540	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
17	17	0000	CD	B-NP	O
cows	cow	c020	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
widespread	widespread	w03021603	JJ	B-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
calcification	calcification	c04201020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cows	cow	c020	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
extreme	extreme	e236050	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
Jersey	Jersey	j0620	NNP	I-NP	O
cows	cow	c020	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
margin	margin	m06205	NN	I-NP	O
of	of	o100	IN	B-PP	O
safety	safety	s01030	NN	B-NP	O
between	between	b0305	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
that	that	t030	WDT	B-NP	O
prevent	prevent	p601053	VBP	B-VP	O
milk	milk	m042	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
doses	dose	d0202	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
induce	induce	i53020	VBP	B-VP	O
milk	milk	m042	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
concluded	conclude	c05240303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
D3	D3	0000	NN	I-NP	I-Chemical
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
practically	practically	p602302040	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
milk	milk	m042	NN	B-NP	B-Disease
fever	fever	f0106	NN	I-NP	I-Disease
when	when	w050	WRB	B-ADVP	O
injected	inject	i5202303	VBN	B-VP	O
several	several	s010604	JJ	B-NP	O
weeks	week	w020	NNS	I-NP	O
prepartum	prepartum	p60106305	NN	I-NP	O
.	.	.000	.	O	O

Diseases	Disease	d020202	NNS	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
peripheral	peripheral	p06010604	JJ	B-NP	I-Disease
nerves	nerve	n06102	NNS	I-NP	I-Disease
as	as	a200	IN	B-SBAR	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Nigerian	Nigerian	n020605	JJ	I-NP	O
African	African	a160205	NNP	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
anatomical	anatomical	a503050204	JJ	I-NP	O
and	and	a530	CC	I-NP	O
aetiological	aetiological	a0304020204	JJ	I-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
nerve	nerve	n0610	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
excluding	exclude	e2403052	VBG	B-PP	O
its	its	i320	PRP$	B-NP	O
primary	primary	p605060	JJ	I-NP	O
benign	benign	b05025	JJ	I-NP	O
and	and	a530	CC	I-NP	O
malignant	malignant	m04025053	JJ	I-NP	O
disorders	disorder	d02063062	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
358	358	0000	CD	B-NP	O
Nigerians	Nigerian	n0206052	NNPS	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
male	male	m040	JJ	I-NP	O
preponderance	preponderance	p601053060520	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
peak	peak	p020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
decade	decade	d02030	NN	I-NP	O
.	.	.000	.	O	O

Sensori	Sensori	s052060	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
motor	motor	m0306	NN	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
commonest	common	c0505023	JJS	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Guillain	Guillain	g0405	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Barr	Barr	b060	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
commonest	common	c0505023	JJS	I-NP	O
identifiable	identifiable	i3053010140	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
accounting	account	a2053052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
half	half	h041	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
motor	motor	m0306	NN	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
nutritional	nutritional	n036030504	JJ	B-NP	B-Disease
deficiency	deficiency	d01020520	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	O
thiamine	thiamine	t05050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
riboflavin	riboflavin	r010140105	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
presented	present	p60205303	VBN	B-VP	O
mainly	mainly	m0540	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
sensory	sensory	s052060	JJ	B-ADJP	O
and	and	a530	CC	O	O
sensori	sensori	s052060	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
motor	motor	m0306	NN	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Diabetes	Diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Isoniazid	Isoniazid	i2050203	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
frequent	frequent	f602053	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Migraine	Migraine	m026050	NN	B-NP	B-Disease
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
an	an	a500	DT	B-NP	O
uncommon	uncommon	u520505	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cranial	cranial	c60504	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
although	although	a43020	IN	B-SBAR	O
malignancies	malignancy	m0402505202	NNS	B-NP	B-Disease
arising	arise	a602052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
reticuloendothelial	reticuloendothelial	r030204053030404	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
or	or	o600	CC	O	O
related	relate	r040303	VBN	B-NP	O
structures	structure	s360230602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
head	head	h030	NN	I-NP	O
and	and	a530	CC	I-NP	O
neck	neck	n020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
frequent	frequent	f602053	JJ	I-ADJP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
26	26	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
aetiology	aetiology	a0304020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuropathy	neuropathy	n0601030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
undetermined	undetermined	u53030650503	JJ	B-ADJP	O
.	.	.000	.	O	O

Heredofamilial	Heredofamilial	h060301050404	JJ	B-NP	O
and	and	a530	CC	I-NP	O
connective	connective	c05023010	JJ	I-NP	B-Disease
tissue	tissue	t020	NN	I-NP	I-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
.	.	.000	.	O	O

Some	Some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
factors	factor	f023062	NNS	I-NP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
presentation	presentation	p6020530305	NN	I-NP	O
and	and	a530	CC	I-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
neuropathies	neuropathy	n06010302	NNS	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
briefly	briefly	b60140	RB	I-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
allegedly	allegedly	a4020340	RB	B-ADVP	O
consumed	consume	c0520503	VBD	B-VP	O
100	100	0000	CD	B-NP	O
tablets	tablet	t014032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
over	over	o106	IN	I-NP	O
-	-	-000	HYPH	I-NP	O
the	the	t000	DT	B-NP	O
-	-	-000	HYPH	I-NP	O
counter	counter	c05306	NN	I-NP	O
analgesic	analgesic	a50420202	JJ	I-NP	O
containing	contain	c05305052	VBG	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
acetylsalicylate	acetylsalicylate	a203042040204030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
displayed	display	d021403	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
CNS	CNS	c520	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
despite	despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
175	175	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
per	per	p060	IN	B-PP	O
mL	mL	m400	NN	B-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
salicylates	salicylate	s0402040302	NNS	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
augment	augment	a025053	VB	I-VP	O
the	the	t000	DT	B-NP	O
stimulatory	stimulatory	s3050403060	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
,	,	,000	,	O	O
attention	attention	a305305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
focused	focus	f020203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
52	52	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
DBA	DBA	d100	NN	B-NP	O
/	/	/000	SYM	B-NP	O
2J	2J	2000	NN	I-NP	O
mice	mouse	m020	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
:	:	:000	:	O	O
1	1	1000	LS	B-LST	O
)	)	)000	)	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
interval	interval	i5306104	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
to	to	t000	TO	O	O
450	450	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
IP	IP	i100	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
factor	factor	f02306	NN	I-NP	O
of	of	o100	IN	B-PP	O
about	about	a103	IN	B-NP	O
two	two	t000	CD	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
2	2	2000	LS	B-LST	O
)	)	)000	)	O	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
audiogenic	audiogenic	a03020502	JJ	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
produced	produce	p6030203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
to	to	t000	TO	I-NP	O
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
IP	IP	i100	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
sound	sound	s053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
or	or	o600	CC	I-NP	O
25	25	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
caffeine	caffeine	c01050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
50	50	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
300	300	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
modify	modify	m03010	VB	I-VP	O
the	the	t000	DT	B-NP	O
seizures	seizure	s020602	NNS	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
maximal	maximal	m020504	JJ	B-NP	O
electroshock	electroshock	e402360202	NN	I-NP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pentylenetetrezol	pentylenetetrezol	p0530405030360204	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
(	(	(000	(	O	O
tests	test	t0232	NNS	B-NP	O
performed	perform	p06106503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Anticonvulsant	Anticonvulsant	a5302051042053	NNP	I-NP	O
Screening	Screening	s2605052	NNP	I-NP	O
Project	Project	p602023	NNP	I-NP	O
of	of	o100	IN	B-PP	O
NINCDS	NINCDS	n05232	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
150	150	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
mL	mL	m400	NN	I-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
retard	retard	r03063	VB	I-VP	O
the	the	t000	DT	B-NP	O
incorporation	incorporation	i52061060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
radioactive	radioactive	r03023010	JJ	B-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
into	into	i530	IN	B-PP	O
ATP	ATP	a310	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
slices	slice	s40202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
cerebral	cerebral	c0601604	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
by	by	b000	IN	B-PP	O
which	which	w020	WDT	B-NP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
antagonizes	antagonize	a5302050202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
caffeine	caffeine	c01050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
CNS	CNS	c520	NN	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
dothiepin	dothiepin	d030105	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
major	major	m0206	JJ	B-NP	O
depressive	depressive	d01602010	JJ	I-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
parallel	parallel	p060404	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
dothiepin	dothiepin	d030105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amitriptyline	amitriptyline	a503601304050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
33	33	0000	CD	B-NP	O
depressed	depressed	d0160203	JJ	I-NP	B-Disease
outpatients	outpatient	o031030532	NNS	I-NP	O
.	.	.000	.	O	O

Dothiepin	Dothiepin	d030105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
amitriptyline	amitriptyline	a503601304050	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
equally	equally	e2040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
alleviating	alleviate	a40103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
depressive	depressive	d01602010	JJ	B-NP	B-Disease
illness	illness	i4502	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
superior	superior	s010606	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
blurred	blurred	b40603	JJ	B-NP	B-Disease
vision	vision	v0205	NN	I-NP	I-Disease
,	,	,000	,	O	O
dry	dry	d600	JJ	B-NP	B-Disease
mouth	mouth	m030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
drowsiness	drowsiness	d6020502	NN	B-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
with	with	w030	IN	B-PP	O
dothiepin	dothiepin	d030105	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
amitriptyline	amitriptyline	a503601304050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Dothiepin	Dothiepin	d030105	NNP	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
produced	produce	p6030203	VBD	B-VP	O
fewer	few	f060	JJR	B-NP	O
CNS	CNS	c520	NN	I-NP	O
and	and	a530	CC	I-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
important	important	i51063053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
laboratory	laboratory	l010603060	NN	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

Dothiepin	Dothiepin	d030105	NNP	B-NP	B-Chemical
thus	thus	t020	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
drug	drug	d602	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fewer	few	f060	JJR	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
than	than	t050	IN	B-PP	O
amitriptyline	amitriptyline	a503601304050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
depressed	depressed	d0160203	JJ	B-NP	B-Disease
outpatients	outpatient	o031030532	NNS	I-NP	O
.	.	.000	.	O	O

Behavioral	Behavioral	b010604	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
agoraphobia	agoraphobia	a20601010	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
single	single	s05240	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
(	(	(000	(	O	O
single	single	s05240	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
80	80	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
240	240	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
psychological	psychological	p20204020204	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
agoraphobia	agoraphobia	a20601010	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	O	O
randomized	randomize	r053050203	VBN	B-VP	O
and	and	a530	CC	O	O
crossover	crossover	c6020106	NN	B-NP	O
design	design	d02025	NN	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
impaired	impair	i510603	VBD	B-VP	B-Disease
immediate	immediate	i503030	JJ	B-NP	I-Disease
free	free	f600	JJ	I-NP	I-Disease
recall	recall	r0204	NN	I-NP	I-Disease
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
for	for	f060	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Delayed	Delay	d0403	VBN	B-NP	B-Disease
free	free	f600	JJ	I-NP	I-Disease
recall	recall	r0204	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	I-Disease
also	also	a420	RB	B-ADVP	I-Disease
impaired	impaired	i510603	JJ	B-ADJP	I-Disease
but	but	b030	CC	O	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
tapped	tap	t0103	VBD	B-VP	O
faster	faster	f02306	RBR	B-ADVP	O
after	after	a1306	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
they	they	t000	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	I-VP	O
sedated	sedate	s030303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
diazepam	diazepam	d020105	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
2	2	2000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
tested	test	t02303	VBN	B-VP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
8	8	8000	CD	I-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
medication	medication	m03020305	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
any	any	a500	DT	B-NP	O
decrement	decrement	d02605053	NN	I-NP	O
of	of	o100	IN	B-PP	O
performance	performance	p0610650520	NN	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
previously	previously	p6010240	RB	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
healthy	healthy	h0430	JJ	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
.	.	.000	.	O	O

Accumulation	Accumulation	a205040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
drugs	drug	d602	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reflected	reflect	r01402303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
behavioral	behavioral	b010604	JJ	I-NP	B-Disease
impairment	impairment	i51065053	NN	I-NP	I-Disease
.	.	.000	.	O	O

Comparison	Comparison	c051060205	NN	B-NP	O
of	of	o100	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	O	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prevention	prevention	p60105305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effectiveness	effectiveness	e1023010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
10	10	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
20	20	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
immediately	immediately	i50303040	RB	B-ADVP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
arrhythmia	arrhythmia	a603050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
repeated	repeated	r010303	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
was	be	w020	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
comparison	comparison	c051060205	NN	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
significantly	significantly	s025010205340	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Bradycardia	Bradycardia	b603020630	NNP	B-NP	B-Disease
(	(	(000	(	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
to	to	t000	TO	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
beat	beat	b030	NN	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
larger	large	l06206	JJR	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	CC	B-NP	O
active	active	a23010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
either	either	e0306	CC	O	O
glycopyrrolate	glycopyrrolate	g402010604030	NN	B-NP	B-Chemical
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	O	O
atropine	atropine	a3601050	NN	B-NP	B-Chemical
20	20	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
should	should	s043	MD	B-VP	O
immediately	immediately	i50303040	RB	I-VP	O
precede	precede	p602030	VB	I-VP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
,	,	,000	,	O	O
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
repeated	repeat	r010303	VBN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
anticipated	anticipate	a5302010303	VBN	I-VP	O
.	.	.000	.	O	O

Veno	Veno	v050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
occlusive	occlusive	o2402010	JJ	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
dacarbazine	dacarbazine	d0206102050	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
(	(	(000	(	O	O
DTIC	DTIC	d302	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
melanoma	melanoma	m0405050	NN	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
veno	veno	v050	AFX	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
occlusive	occlusive	o2402010	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
fatal	fatal	f0304	JJ	B-NP	O
outcome	outcome	o032050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
dacarbazine	dacarbazine	d0206102050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DTIC	DTIC	d302	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
for	for	f060	IN	B-PP	O
melanoma	melanoma	m0405050	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
fulminant	fulminant	f04505053	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
course	course	c0620	NN	I-NP	O
from	from	f605	IN	B-PP	O
start	start	s3063	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
until	until	u5304	IN	B-PP	O
death	death	d030	NN	B-NP	B-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
autopsy	autopsy	a030120	NN	B-NP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
was	be	w020	VBD	B-VP	O
enlarged	enlarge	e5406203	VBN	I-VP	O
and	and	a530	CC	O	O
firm	firm	f065	NN	B-NP	O
with	with	w030	IN	B-PP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	B-Disease
congestion	congestion	c05202305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Small	Small	s504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
and	and	a530	CC	I-NP	O
medium	medium	m0305	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
sized	size	s0203	VBN	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
veins	vein	v052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
.	.	.000	.	O	O

Eosinophilic	Eosinophilic	e0205010402	JJ	B-NP	O
infiltrations	infiltration	i51043603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
around	around	a6053	IN	B-PP	O
the	the	t000	DT	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

Published	Publish	p0140203	VBN	B-NP	O
cases	case	c0202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
and	and	a530	CC	O	O
pertinent	pertinent	p06305053	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
discussed	discuss	d020203	VBN	B-VP	O
.	.	.000	.	O	O

Maternal	Maternal	m0306504	JJ	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
neonatal	neonatal	n050304	JJ	B-NP	O
Ebstein	Ebstein	e12305	NN	I-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
anomaly	anomaly	a505040	RB	B-ADVP	I-Disease
:	:	:000	:	O	O
evaluation	evaluation	e1040305	NN	B-NP	O
with	with	w030	IN	B-PP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
.	.	.000	.	O	O

Cross	Cross	c602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
two	two	t000	CD	B-NP	O
neonates	neonate	n050302	NNS	I-NP	O
whose	whose	w020	WP$	B-NP	O
mothers	mother	m03062	NNS	I-NP	O
ingested	ingest	i5202303	VBD	B-VP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
infant	infant	i51053	NN	I-NP	O
,	,	,000	,	O	O
Ebstein	Ebstein	e12305	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
anomaly	anomaly	a505040	RB	B-ADVP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tricuspid	tricuspid	t60202103	JJ	I-NP	O
valve	valve	v0410	NN	I-NP	O
was	be	w020	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
infant	infant	i51053	NN	I-NP	O
cross	cross	c602	AFX	O	O
-	-	-000	HYPH	O	O
sectional	sectional	s0230504	JJ	B-NP	O
echocardiography	echocardiography	e202063026010	NN	I-NP	O
provided	provide	p6010303	VBD	B-VP	O
reassurance	reassurance	r02060520	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
infant	infant	i51053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
Ebstein	Ebstein	e12305	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NNS	I-NP	I-Disease
anomaly	anomaly	a505040	RB	B-ADVP	I-Disease
.	.	.000	.	O	O

Cross	Cross	c602	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
sectional	sectional	s0230504	JJ	I-NP	O
echocardiographic	echocardiographic	e2020630260102	JJ	I-NP	O
screening	screening	s2605052	NN	I-NP	O
of	of	o100	IN	B-PP	O
newborns	newborn	n010652	NNS	B-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
during	during	d06052	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
can	can	c050	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
highly	highly	h02040	RB	B-NP	O
accurate	accurate	a206030	JJ	I-NP	O
,	,	,000	,	I-NP	O
noninvasive	noninvasive	n0505102010	JJ	I-NP	O
assessment	assessment	a2025053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
or	or	o600	CC	I-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
training	training	t605052	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
aging	age	a2052	VBG	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
exercise	exercise	e2062020	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
isoproterenol	isoproterenol	i201603060504	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
female	female	f05040	JJ	B-NP	O
albino	albino	a41050	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
40	40	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
60	60	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
80	80	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
trained	train	t60503	VBN	I-VP	O
to	to	t000	TO	I-VP	O
swim	swim	s050	VB	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
infarcts	infarct	i5106232	NNS	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
confirmed	confirm	c05106503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
histological	histological	h02304020204	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
.	.	.000	.	O	O

Elevations	Elevation	e40103052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
GOT	GOT	g030	NN	I-NP	O
and	and	a530	CC	I-NP	O
GPT	GPT	g130	NN	I-NP	O
were	be	w060	VBD	B-VP	O
maximum	maximum	m020505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sedentary	sedentary	s03053060	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
isoproterenols	isoproterenol	i2016030605042	NNS	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
minimum	minimum	m050505	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
exercise	exercise	e2062020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
depletions	depletion	d01403052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	O
GOT	GOT	g030	NN	I-NP	O
and	and	a530	CC	I-NP	O
GPT	GPT	g130	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
age	age	a200	NN	B-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
responses	response	r02105202	NNS	I-NP	O
exhibited	exhibit	e2010303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
young	young	y052	JJ	I-NP	O
and	and	a530	CC	I-NP	O
old	old	o430	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Studies	Study	s30302	NNS	B-NP	O
dealing	deal	d04052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
informative	informative	i5106503010	JJ	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
dealt	dealt	d043	NN	B-NP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
polyethylene	polyethylene	p040304050	NN	B-NP	B-Chemical
glycol	glycol	g40204	NN	I-NP	I-Chemical
400	400	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
widely	widely	w03040	RB	I-NP	O
used	use	u203	VBN	I-NP	O
organic	organic	o620502	JJ	I-NP	O
solvent	solvent	s041053	NN	I-NP	O
,	,	,000	,	O	O
polyethylene	polyethylene	p040304050	NN	B-NP	B-Chemical
glycol	glycol	g40204	NN	I-NP	I-Chemical
400	400	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
PEG	PEG	p020	NN	B-NP	B-Chemical
400	400	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
or	or	o600	CC	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ADR	ADR	a360	NN	B-NP	B-Chemical
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
.	.	.000	.	O	O

PEG	PEG	p020	NN	B-NP	B-Chemical
400	400	0000	CD	I-NP	I-Chemical
impressively	impressively	i5160201040	RB	B-ADVP	O
decreased	decrease	d0260203	VBD	B-VP	O
both	both	b030	CC	O	O
acute	acute	a2030	JJ	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
and	and	a530	CC	O	O
chronic	chronic	c060502	JJ	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
lethality	lethality	l0304030	NN	I-NP	O
.	.	.000	.	O	O

Light	Light	l0203	NN	B-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
protection	protection	p60302305	NN	I-NP	O
against	against	a20523	IN	B-PP	O
ADR	ADR	a360	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
morphological	morphological	m06104020204	JJ	I-NP	I-Disease
alterations	alteration	a430603052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
diminish	diminish	d0505020	VB	I-VP	O
the	the	t000	DT	B-NP	O
ADR	ADR	a360	NN	I-NP	B-Chemical
antitumor	antitumor	a53030506	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
L1210	L1210	0000	NN	B-NP	B-Disease
leukemia	leukemia	l02050	NN	I-NP	I-Disease
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
Ehrlich	Ehrlich	e064020	NNP	B-NP	B-Disease
ascites	ascite	a20302	NNS	I-NP	I-Disease
tumor	tumor	t0506	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sublingual	Sublingual	s01405204	JJ	B-NP	O
absorption	absorption	a12061305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
quaternary	quaternary	q03065060	JJ	I-NP	B-Chemical
ammonium	ammonium	a50505	NN	I-NP	I-Chemical
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
UM	UM	u500	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
272	272	0000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

UM	UM	u500	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
272	272	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
N	N	n000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dimethylpropranolol	dimethylpropranolol	d05030416016050404	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
quaternary	quaternary	q03065060	JJ	I-NP	O
antiarrhythmic	antiarrhythmic	a5306030502	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
sublingually	sublingually	s014052040	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
dogs	dog	d020	NNS	B-NP	O
with	with	w030	IN	B-PP	O
ouabain	ouabain	o0105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardias	tachycardia	t020206302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
anti	anti	a530	AFX	O	O
-	-	-000	HYPH	B-NP	O
arrhythmic	arrhythmic	a6030502	JJ	I-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
bioavailability	bioavailability	b01040104030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
oral	oral	o604	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Sublingual	Sublingual	s01405204	JJ	B-NP	O
UM	UM	u500	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
272	272	0000	CD	I-NP	I-Chemical
converted	convert	c05106303	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
sinus	sinus	s0502	NN	B-NP	O
rhythm	rhythm	r0305	NN	I-NP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
5	5	5000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
area	area	a600	NN	I-NP	O
under	under	u5306	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
time	time	t050	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
at	at	a300	IN	B-PP	O
90	90	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
4	4	4000	CD	B-NP	O
-	-	-000	HYPH	B-ADJP	O
12	12	0000	CD	I-ADJP	O
times	time	t0502	NNS	I-ADJP	O
greater	great	g60306	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
for	for	f060	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
existence	existence	e20230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
absorption	absorption	a12061305	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
process	process	p60202	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
intestine	intestine	i53023050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
providing	provide	p60103052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
alternate	alternate	a43065030	JJ	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
for	for	f060	IN	B-PP	O
quaternary	quaternary	q03065060	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Early	Early	e0640	RB	B-NP	O
adjuvant	adjuvant	a3201053	JJ	I-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
superficial	superficial	s010610204	JJ	B-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
multicenter	multicenter	m0430205306	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
110	110	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
superficial	superficial	s010610204	JJ	B-NP	O
transitional	transitional	t6052030504	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
50	50	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravesically	intravesically	i536010202040	RB	B-ADVP	O
within	within	w0305	IN	B-PP	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
transurethral	transurethral	t605206030604	JJ	B-NP	O
resection	resection	r0202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
TA	TA	t000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
T1	T1	0000	NN	I-NP	O
(	(	(000	(	O	O
O	O	o000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
bladder	bladder	b40306	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Instillation	Instillation	i523040305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
twice	twice	t020	RB	B-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
week	week	w020	NN	I-NP	O
,	,	,000	,	O	O
then	then	t050	RB	B-ADVP	O
weekly	weekly	w0240	RB	I-ADVP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
month	month	m0530	NN	I-NP	O
and	and	a530	CC	O	O
afterwards	afterwards	a13060632	RB	B-ADJP	O
monthly	monthly	m053040	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
110	110	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
29	29	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
local	local	l0204	JJ	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
24	24	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
chemical	chemical	c050204	NN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
severe	severe	s01060	JJ	B-ADJP	O
enough	enough	e5020	RB	I-ADJP	O
for	for	f060	IN	B-SBAR	O
them	them	t050	PRP	B-NP	O
to	to	t000	TO	B-VP	O
drop	drop	d601	VB	I-VP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Recurrence	Recurrence	r02060520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
82	82	0000	CD	B-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
72	72	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
32	32	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
82	82	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
primary	primary	p605060	JJ	B-ADJP	O
and	and	a530	CC	O	O
59	59	0000	CD	B-NP	O
recurrent	recurrent	r0206053	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
82	82	0000	CD	I-NP	O
evaluable	evaluable	e1040140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
50	50	0000	CD	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
any	any	a500	DT	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
after	after	a1306	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
(	(	(000	(	O	O
61	61	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
32	32	0000	CD	B-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
recurrences	recurrence	r020605202	NNS	I-NP	O
(	(	(000	(	O	O
39	39	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
recurrences	recurrence	r020605202	NNS	I-NP	O
,	,	,000	,	O	O
27	27	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
T1	T1	0000	NN	B-NP	O
tumors	tumor	t05062	NNS	I-NP	B-Disease
while	while	w040	IN	B-SBAR	O
five	five	f010	CD	B-NP	O
progressed	progress	p60260203	VBD	B-VP	O
to	to	t000	TO	B-PP	O
more	more	m060	RBR	B-ADVP	O
highly	highly	h02040	RB	I-ADVP	O
invasive	invasive	i5102010	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
free	free	f600	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
recurrence	recurrence	r02060520	NN	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
80	80	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
-	-	-000	HYPH	B-ADJP	O
free	free	f600	JJ	I-ADJP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	B-ADJP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developing	develop	d010401052	VBG	B-VP	O
one	one	o500	CD	B-NP	O
or	or	o600	CC	I-NP	O
more	more	m060	JJR	I-NP	O
recurrences	recurrence	r020605202	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
only	only	o540	RB	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
presented	present	p60205303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
once	once	o520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
instillations	instillation	i5230403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
obvious	obvious	o102	JJ	B-ADJP	O
and	and	a530	CC	O	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
itself	itself	i32041	PRP	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
and	and	a530	CC	I-NP	O
repeated	repeated	r010303	JJ	I-NP	O
instillations	instillation	i5230403052	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
TUR	TUR	t060	NN	B-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
.	.	.000	.	O	O

D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
angiopathy	angiopathy	a5201030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
D	D	d000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
penicillamine	penicillamine	p05020405050	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
on	on	o500	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
to	to	t000	TO	B-PP	O
albumin	albumin	a410505	NN	B-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
ultrastructure	ultrastructure	u4360236023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vessel	vessel	v0204	NN	I-NP	O
.	.	.000	.	O	O

Male	Male	m040	JJ	B-NP	O
Sprague	Sprague	s16020	NNP	I-NP	O
-	-	-000	HYPH	I-NP	O
Dawley	Dawley	d040	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
penicillamine	penicillamine	p05020405050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
)	)	)000	)	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
10	10	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
42	42	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

Pair	Pair	p060	NN	B-NP	O
fed	feed	f030	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
served	serve	s06103	VBD	B-VP	O
as	as	a200	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Changes	Change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
morphology	morphology	m06104020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
light	light	l0203	NN	B-NP	O
-	-	-000	HYPH	O	O
and	and	a530	CC	O	O
transmission	transmission	t605250205	NN	B-NP	O
-	-	-000	HYPH	O	O
electron	electron	e4023605	NN	B-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
(	(	(000	(	O	O
TEM	TEM	t050	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
penetration	penetration	p050360305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
the	the	t000	DT	B-NP	O
aortic	aortic	a06302	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
of	of	o100	IN	B-PP	O
albumin	albumin	a410505	NN	B-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
10	10	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
24	24	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
48	48	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
v	v	v000	NN	B-NP	O
.	.	.000	.	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
131I	131I	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
(	(	(000	(	O	O
131I	131I	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
HSA	HSA	h200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

TEM	TEM	t050	NN	B-NP	O
revealed	reveal	r010403	VBD	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
elastolysis	elastolysis	e4023040202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
crosslink	crosslink	c6024052	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
excess	excess	e202	JJ	B-NP	O
deposition	deposition	d01020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
collagen	collagen	c040205	NN	B-NP	O
and	and	a530	CC	I-NP	O
glycoaminoglycans	glycoaminoglycan	g402050502402052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subendothelial	subendothelial	s01053030404	JJ	I-NP	O
and	and	a530	CC	I-NP	O
medial	medial	m0304	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
aortic	aortic	a06302	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
prominent	prominent	p60505053	JJ	B-NP	O
basal	basal	b0204	JJ	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
substance	substance	s01230520	NN	I-NP	O
around	around	a6053	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
smooth	smooth	s5030	JJ	I-NP	O
muscle	muscle	m0240	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
/	/	/000	SYM	B-NP	O
serum	serum	s0605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ratio	ratio	r030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
radioactive	radioactive	r03023010	JJ	I-NP	O
build	build	b043	VB	B-VP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
24	24	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
48	48	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
131I	131I	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
HSA	HSA	h200	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
42	42	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
impeded	impeded	i510303	JJ	I-NP	O
transmural	transmural	t605250604	JJ	I-NP	O
transport	transport	t60521063	NN	I-NP	O
of	of	o100	IN	B-PP	O
tracer	tracer	t60206	NN	B-NP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
steric	steric	s30602	JJ	I-NP	O
exclusion	exclusion	e240205	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
abundant	abundant	a1053053	JJ	B-NP	O
hyaluronate	hyaluronate	h040605030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
ultrastructure	ultrastructure	u4360236023060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
131I	131I	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
HSA	HSA	h200	NN	I-NP	O
radioactivity	radioactivity	r0302301030	NN	I-NP	O
or	or	o600	CC	I-NP	O
aorta	aorta	a0630	NN	I-NP	O
/	/	/000	SYM	B-NP	O
serum	serum	s0605	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ratio	ratio	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
10	10	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
tracer	tracer	t60206	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
to	to	t000	TO	B-PP	O
albumin	albumin	a410505	NN	B-NP	O
remained	remain	r050503	VBD	B-VP	O
unaffected	unaffected	u50102303	JJ	B-ADJP	O
by	by	b000	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
D	D	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
pen	pen	p050	NN	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
induce	induce	i53020	VB	I-VP	O
a	a	a000	DT	B-NP	O
fibroproliferative	fibroproliferative	f01601604010603010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
,	,	,000	,	O	O
possibly	possibly	p020140	RB	B-ADVP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
inhibitory	inhibitory	i50103060	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cross	cross	c602	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
linking	link	l052052	VBG	I-NP	O
of	of	o100	IN	B-PP	O
collagen	collagen	c040205	NN	B-NP	O
and	and	a530	CC	I-NP	O
elastin	elastin	e402305	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitro	nitro	n0360	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
furyl	furyl	f0604	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thiazolyl	thiazolyl	t020404	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
formamide	formamide	f06505030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
epithelial	epithelial	e1030404	JJ	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
and	and	a530	CC	I-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
co	co	c000	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
N	N	n000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
5	5	5000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitro	nitro	n0360	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
furyl	furyl	f0604	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
thiazolyl	thiazolyl	t020404	NN	I-NP	I-Chemical
]	]	]000	)	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
formamide	formamide	f06505030	NN	B-NP	I-Chemical
(	(	(000	(	O	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bladder	bladder	b40306	NN	I-NP	B-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
concomitant	concomitant	c0520503053	JJ	I-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
forestomach	forestomach	f0602305020	NN	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
autoradiographic	autoradiographic	a0306030260102	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
male	male	m040	JJ	B-NP	O
F	F	f000	NN	I-NP	O
-	-	-000	HYPH	O	O
344	344	0000	CD	B-NP	O
rats	rat	r032	NNS	I-NP	O
fed	feed	f030	VBN	B-VP	O
diet	diet	d030	NN	B-NP	O
containing	contain	c05305052	VBG	B-VP	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
and	and	a530	CC	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
.	.	.000	.	O	O

FANFT	FANFT	f0513	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
suppressed	suppress	s0160203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
co	co	c000	AFX	O	O
-	-	-000	HYPH	O	O
administration	administration	a350502360305	NN	B-NP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
after	after	a1306	IN	I-PP	O
12	12	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
,	,	,000	,	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
FANFT	FANFT	f0513	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
labeling	label	l0104052	VBG	B-VP	O
index	index	i5302	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
consistent	consistent	c052023053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
carcinogenicity	carcinogenicity	c06205020502030	NN	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
different	different	d0106053	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
carcinogenesis	carcinogenesis	c0620502050202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
and	and	a530	CC	I-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
FANFT	FANFT	f0513	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
forestomach	forestomach	f0602305020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
an	an	a500	DT	B-NP	O
irritant	irritant	i603053	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
cell	cell	c040	NN	I-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
adaptation	adaptation	a30130305	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tardive	tardive	t063010	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Abnormal	Abnormal	a1506504	JJ	B-NP	B-Disease
involuntary	involuntary	i5104053060	JJ	I-NP	I-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouth	mouth	m030	NN	I-NP	O
,	,	,000	,	I-NP	O
tongue	tongue	t0520	NN	I-NP	O
,	,	,000	,	I-NP	O
neck	neck	n020	NN	I-NP	O
and	and	a530	CC	I-NP	O
abdomen	abdomen	a130505	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
64	64	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
male	male	m040	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
after	after	a1306	IN	B-SBAR	O
he	he	h000	PRP	B-NP	O
took	take	t020	VBD	B-VP	O
metoclopramide	metoclopramide	m0302401605030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
gastrointestinal	gastrointestinal	g02360530230504	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
about	about	a103	IN	B-NP	O
260	260	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
exacerbated	exacerbate	e2020610303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
metoclopramide	metoclopramide	m0302401605030	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
gradually	gradually	g603040	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
considerable	considerable	c05203060140	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
.	.	.000	.	O	O

Attention	Attention	a305305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
induction	induction	i5302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
tardive	tardive	t063010	JJ	I-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
called	call	c0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

Intra	Intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
gliomas	glioma	g40502	NNS	I-NP	I-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
the	the	t000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	O	I-Chemical
3	3	3000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
bis	bis	b020	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroethyl	chloroethyl	c04060304	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
nitrosourea	nitrosourea	n03602060	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
intra	intra	i5360	AFX	O	O
-	-	-000	HYPH	O	O
arterial	arterial	a630604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
should	should	s043	MD	B-VP	O
provide	provide	p601030	VB	I-VP	O
a	a	a000	DT	B-NP	O
substantial	substantial	s012305304	JJ	I-NP	O
advantage	advantage	a31053020	NN	I-NP	O
over	over	o106	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
malignant	malignant	m04025053	JJ	B-NP	B-Disease
gliomas	glioma	g40502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
every	every	e1060	DT	B-NP	O
6	6	6000	CD	I-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
by	by	b000	IN	B-PP	O
transfemoral	transfemoral	t60521050604	JJ	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
internal	internal	i5306504	JJ	I-NP	O
carotid	carotid	c060303	NN	I-NP	O
or	or	o600	CC	O	O
vertebral	vertebral	v06301604	JJ	B-NP	O
artery	artery	a63060	NN	I-NP	O
or	or	o600	CC	B-PP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
fully	fully	f040	RB	I-NP	O
implantable	implantable	i5140530140	JJ	I-NP	O
intracarotid	intracarotid	i53602060303	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
delivery	delivery	d0401060	NN	I-NP	O
system	system	s02305	NN	I-NP	O
,	,	,000	,	O	O
beginning	begin	b0205052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
sq	sq	s200	NN	I-NP	O
m	m	m000	NN	I-NP	O
body	body	b030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
area	area	a600	NN	I-NP	O
.	.	.000	.	O	O

Twelve	Twelve	t0410	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Grade	Grade	g6030	NN	B-NP	O
III	III	i000	CD	I-NP	O
or	or	o600	CC	I-NP	O
IV	IV	i100	CD	I-NP	O
astrocytomas	astrocytoma	a23602030502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
partial	partial	p06304	JJ	B-NP	O
resection	resection	r0202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
radiation	radiation	r030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
two	two	t000	CD	B-NP	O
to	to	t000	TO	I-NP	O
seven	seven	s0105	CD	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
,	,	,000	,	O	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
tumor	tumor	t0506	NN	B-NP	B-Disease
size	size	s020	NN	I-NP	O
and	and	a530	CC	O	O
surrounding	surround	s06053052	VBG	B-VP	O
edema	edema	e3050	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
-	-	-000	HYPH	O	O
enhanced	enhance	e505203	VBN	B-VP	O
computerized	computerize	c05103060203	VBN	B-NP	O
tomography	tomography	t05026010	NN	I-NP	O
scans	scan	s2052	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
nine	nine	n050	CD	I-NP	O
responders	responder	r021053062	NNS	I-NP	O
,	,	,000	,	O	O
median	median	m0305	JJ	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
operation	operation	o1060305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
25	25	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
12	12	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
91	91	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
survival	survival	s0610104	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
12	12	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
54	54	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
21	21	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
156	156	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
18	18	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
survival	survival	s0610104	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
Grade	Grade	g6030	NN	I-NP	O
I	I	i000	CD	I-NP	O
to	to	t000	TO	I-NP	O
IV	IV	i100	CD	I-NP	O
astrocytomas	astrocytoma	a23602030502	NNS	I-NP	B-Disease
,	,	,000	,	O	O
whose	whose	w020	WP$	B-NP	O
resection	resection	r0202305	NN	I-NP	O
and	and	a530	CC	I-NP	O
irradiation	irradiation	i6030305	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
had	have	h030	VBD	B-VP	O
failed	fail	f0403	VBN	I-VP	O
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
two	two	t000	CD	B-NP	O
to	to	t000	TO	I-NP	O
eight	eight	e0203	CD	I-NP	O
courses	course	c06202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
BCNU	BCNU	b250	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Seventeen	Seventeen	s0105305	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
or	or	o600	CC	O	O
were	be	w060	VBD	B-VP	O
stable	stable	s30140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	NN	I-NP	O
of	of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
6	6	6000	CD	I-NP	O
to	to	t000	TO	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
66	66	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
catheterization	catheterization	c030306020305	NN	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
safe	safe	s010	JJ	B-ADJP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
no	no	n000	DT	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
111	111	0000	CD	B-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
BCNU	BCNU	b250	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
delayed	delay	d0403	VBN	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
loss	loss	l020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
vision	vision	v0205	NN	B-NP	I-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
retinal	retinal	r030504	JJ	I-NP	B-Disease
vasculitis	vasculitis	v02040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
decreased	decrease	d0260203	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ethanol	ethanol	e30504	NN	I-NP	B-Chemical
diluent	diluent	d04053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lowered	lower	l0603	VBN	I-VP	O
.	.	.000	.	O	O

Provocation	Provocation	p601020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
postural	postural	p0230604	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
autonomic	autonomic	a03050502	JJ	I-NP	I-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
?	?	?000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
subjects	subject	s0120232	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
and	and	a530	CC	I-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
after	after	a1306	IN	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
normal	normal	n06504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
subjects	subject	s0120232	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
a	a	a000	DT	B-NP	O
lesser	less	l0206	JJR	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
greater	great	g60306	JJR	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
systolic	systolic	s0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
subjects	subject	s0120232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
therefore	therefore	t0601060	RB	I-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
caution	caution	c0305	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
exercised	exercise	e20620203	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
prescribing	prescribe	p602601052	VBG	B-VP	O
vasodilator	vasodilator	v0203040306	NN	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
autonomic	autonomic	a03050502	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Blood	Blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
intrarenal	intrarenal	i536060504	JJ	I-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
in	in	i500	IN	B-PP	O
conscious	conscious	c05202	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
solution	solution	s040305	NN	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
,	,	,000	,	I-NP	O
12	12	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
36	36	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
h	h	h000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
was	be	w020	VBD	B-VP	O
infused	infuse	i510203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
five	five	f010	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
days	day	d020	NNS	I-NP	O
,	,	,000	,	O	O
either	either	e0306	CC	O	O
intrarenally	intrarenally	i5360605040	RB	B-ADVP	O
(	(	(000	(	O	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
technique	technique	t0205020	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
removed	remove	r050103	VBN	B-VP	O
.	.	.000	.	O	O

Intrarenal	Intrarenal	i536060504	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
at	at	a300	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
which	which	w020	WDT	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
do	do	d000	VB	I-VP	O
so	so	s000	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
infused	infuse	i510203	VBN	B-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
.	.	.000	.	O	O

Intrarenal	Intrarenal	i536060504	JJ	B-ADJP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
higher	high	h0206	JJR	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
shift	shift	s013	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
curve	curve	c0610	NN	I-NP	O
towards	towards	t0632	IN	B-PP	O
lower	low	l060	JJR	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
after	after	a1306	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
intrarenal	intrarenal	i536060504	JJ	I-NP	O
noradrenaline	noradrenaline	n060360504050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
higher	high	h0206	JJR	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
circulating	circulate	c0620403052	VBG	B-VP	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
triggering	triggering	t60206052	NN	B-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
additional	additional	a3030504	JJ	I-NP	O
intrarenal	intrarenal	i536060504	JJ	I-NP	O
pressor	pressor	p60206	NN	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
.	.	.000	.	O	O

Characterization	Characterization	c0602306020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
estrogen	estrogen	e2360205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
adenohypophyseal	adenohypophyseal	a30501010204	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Fischer	Fischer	f0206	NNP	I-NP	O
344	344	0000	CD	I-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Pituitary	Pituitary	p0303060	JJ	B-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
F344	F344	0000	NN	B-NP	O
female	female	f05040	JJ	I-NP	O
rats	rat	r032	NNS	I-NP	O
by	by	b000	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
diethylstilbestrol	diethylstilbestrol	d030423041023604	NN	B-NP	B-Chemical
(	(	(000	(	O	O
DES	DES	d020	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
implanted	implant	i51405303	VBN	B-VP	O
subcutaneously	subcutaneously	s01203050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
silastic	silastic	s0402302	JJ	B-NP	O
capsules	capsule	c0120402	NNS	I-NP	O
.	.	.000	.	O	O

Over	Over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
150	150	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
pairs	pair	p062	NNS	B-NP	O
of	of	o100	IN	B-PP	O
control	control	c053604	NN	B-NP	O
and	and	a530	CC	I-NP	O
DES	DES	d020	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
sacrificed	sacrifice	s026010203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
their	their	t060	PRP$	B-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
dissociated	dissociate	d02020303	VBN	B-VP	O
enzymatically	enzymatically	e52050302040	RB	B-ADVP	O
into	into	i530	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
preparations	preparation	p6010603052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cell	cell	c040	NN	I-NP	O
populations	population	p010403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
regarding	regard	r02063052	VBG	B-PP	O
total	total	t0304	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
correlated	correlate	c06040303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
gland	gland	g4053	NN	B-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
intracellular	intracellular	i53602040406	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	O
)	)	)000	)	O	O
content	content	c053053	NN	B-NP	O
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
release	release	r04020	NN	I-NP	O
in	in	i500	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	O
culture	culture	c043060	NN	I-NP	O
,	,	,000	,	O	O
immunocytochemical	immunocytochemical	i505020302050204	JJ	B-NP	O
PRL	PRL	p640	NN	I-NP	O
staining	staining	s305052	NN	I-NP	O
,	,	,000	,	O	O
density	density	d052030	NN	B-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
size	size	s020	NN	B-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
via	via	v000	IN	B-PP	O
separation	separation	s01060305	NN	B-NP	O
on	on	o500	IN	B-PP	O
Ficoll	Ficoll	f0204	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
Hypaque	Hypaque	h01020	NN	I-NP	O
and	and	a530	CC	B-PP	O
by	by	b000	IN	B-PP	O
unit	unit	u503	NN	B-NP	O
gravity	gravity	g601030	NN	I-NP	O
sedimentation	sedimentation	s03050530305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cell	cell	c040	NN	B-NP	O
cycle	cycle	c0240	NN	I-NP	O
analysis	analysis	a5040202	NN	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
acriflavine	acriflavine	a2601401050	NN	B-NP	B-Chemical
DNA	DNA	d500	NN	I-NP	O
staining	staining	s305052	NN	I-NP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
laser	laser	l0206	NN	B-NP	O
flow	flow	f400	NN	I-NP	O
cytometry	cytometry	c03050360	NN	I-NP	O
.	.	.000	.	O	O

Total	Total	t0304	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
yields	yield	y0432	NNS	I-NP	O
from	from	f605	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
pituitaries	pituitary	p03030602	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
control	control	c053604	VBP	B-VP	O
yields	yield	y0432	NNS	B-NP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
to	to	t000	TO	B-PP	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
control	control	c053604	VBP	B-VP	O
values	value	v0402	NNS	B-NP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
150	150	0000	CD	I-NP	O
.	.	.000	.	O	O

Intracellular	Intracellular	i53602040406	JJ	B-NP	O
PRL	PRL	p640	NN	I-NP	O
content	content	c053053	NN	I-NP	O
ranged	range	r05203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
to	to	t000	TO	B-PP	O
9	9	9000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
control	control	c053604	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
PRL	PRL	p640	NN	B-NP	O
release	release	r04020	NN	I-NP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
consistently	consistently	c05202305340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
8	8	8000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

Beyond	Beyond	b053	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
exposure	exposure	e2102060	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
immunochemically	immunochemically	i505020502040	RB	I-NP	O
PRL	PRL	p640	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cells	cell	c042	NNS	B-NP	O
increased	increase	i5260203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
over	over	o106	IN	B-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Increased	Increase	i5260203	VBN	B-NP	O
density	density	d052030	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
size	size	s020	NN	B-NP	O
and	and	a530	CC	I-NP	O
PRL	PRL	p640	NN	I-NP	O
content	content	c053053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
indicated	indicate	i53020303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
PRL	PRL	p640	NN	I-NP	O
cell	cell	c040	NN	I-NP	O
population	population	p01040305	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
types	type	t0102	NNS	I-NP	O
of	of	o100	IN	B-PP	O
separation	separation	s01060305	NN	B-NP	O
protocols	protocol	p60302042	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
these	these	t020	DT	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
DES	DES	d020	NNS	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
among	among	a5052	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
ovariectomized	ovariectomize	o106023050203	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
extend	extend	e23053	VBP	B-VP	O
the	the	t000	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
other	other	o306	JJ	B-NP	O
investigators	investigator	i510230203062	NNS	I-NP	O
,	,	,000	,	O	O
further	further	f06306	RB	B-ADVP	O
establishing	establish	e2301402052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
DES	DES	d020	NNP	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
study	study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
control	control	c053604	NN	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
and	and	a530	CC	I-NP	O
renal	renal	r0504	JJ	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
35	35	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
ages	age	a202	NNS	B-NP	O
20	20	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
86	86	0000	CD	I-NP	O
yr	yr	y600	NN	I-NP	O
)	)	)000	)	O	O
receiving	receive	r0201052	VBG	B-VP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
therapeutically	therapeutically	t06010302040	RB	B-NP	O
two	two	t000	CD	I-NP	O
serum	serum	s0605	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
formed	form	f06503	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interim	interim	i530605	NN	I-NP	O
were	be	w060	VBD	B-VP	O
collected	collect	c0402303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
analysis	analysis	a5040202	NN	B-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
liquid	liquid	l0203	NN	I-NP	O
chromatography	chromatography	c060503026010	NN	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Cimetidine	Cimetidine	c050303050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
extrapolated	extrapolate	e23601040303	VBN	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hr	hr	h600	NN	I-NP	O
serum	serum	s0605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
per	per	p060	IN	B-PP	O
unit	unit	u503	NN	B-NP	O
dose	dose	d020	NN	I-NP	O
,	,	,000	,	O	O
after	after	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
to	to	t000	TO	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
(	(	(000	(	O	O
Rc	Rc	r200	NN	B-NP	O
)	)	)000	)	O	O
averaged	average	a1060203	VBD	B-VP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0	0	0000	CD	I-NP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
net	net	n030	JJ	B-NP	O
tubular	tubular	t010406	JJ	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
for	for	f060	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Rc	Rc	r200	NN	B-NP	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
independent	independent	i5301053053	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
serum	serum	s0605	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
secretion	secretion	s0260305	NN	B-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
saturable	saturable	s03060140	JJ	I-NP	O
process	process	p60202	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
only	only	o540	RB	B-NP	O
one	one	o500	CD	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
dementia	dementia	d050530	NN	B-NP	B-Disease
possibly	possibly	p020140	RB	B-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	B-NP	O
6	6	6000	CD	I-NP	O
hr	hr	h600	NN	I-NP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
or	or	o600	CC	I-NP	I-Disease
kidney	kidney	k0350	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
above	above	a1010	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
25	25	0000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
always	always	a402	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
dementia	dementia	d050530	NN	B-NP	B-Disease
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
amiodarone	amiodarone	a50306050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
presented	present	p60205303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
reversible	reversible	r010620140	JJ	I-NP	O
intra	intra	i5360	AFX	I-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Hisian	Hisian	h0205	JJ	I-NP	I-Disease
block	block	b402	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
under	under	u5306	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
without	without	w0303	IN	B-PP	O
clear	clear	c406	JJ	B-NP	O
intraventricular	intraventricular	i536010536020406	JJ	I-NP	B-Disease
conduction	conduction	c05302305	NN	I-NP	I-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
.	.	.000	.	O	O

His	His	h020	PRP$	B-NP	O
bundle	bundle	b05340	NN	I-NP	O
recordings	recording	r02063052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
an	an	a500	DT	B-NP	O
atrial	atrial	a3604	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
exit	exit	e203	NN	I-NP	O
block	block	b402	NN	I-NP	O
and	and	a530	CC	O	O
greatly	greatly	g60340	RB	B-VP	O
prolonged	prolong	p60405203	VBD	I-VP	O
BH	BH	b000	NN	B-NP	O
and	and	a530	CC	I-NP	O
HV	HV	h100	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
100	100	0000	CD	I-NP	O
msec	msec	m202	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
amiodarone	amiodarone	a50306050	NN	B-NP	B-Chemical
discontinuation	discontinuation	d02053050305	NN	I-NP	O
,	,	,000	,	O	O
His	His	h020	PRP$	B-NP	O
bundle	bundle	b05340	NN	I-NP	O
electrograms	electrogram	e40236026052	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
without	without	w0303	IN	B-PP	O
intra	intra	i5360	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
Hisian	Hisian	h0205	JJ	I-NP	O
or	or	o600	CC	I-NP	O
infra	infra	i5160	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
Hisian	Hisian	h0205	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
.	.	.000	.	O	O

Amiodarone	Amiodarone	a50306050	NN	B-NP	B-Chemical
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
used	use	u203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
during	during	d06052	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
oral	oral	o604	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
clear	clear	c406	JJ	B-NP	O
intraventricular	intraventricular	i536010536020406	JJ	I-NP	O
conduction	conduction	c05302305	NN	I-NP	O
defects	defect	d010232	NNS	I-NP	O
.	.	.000	.	O	O

Development	Development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
clear	clear	c406	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
DES	DES	d020	NNP	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
exposed	expose	e210203	VBN	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
under	under	u5306	IN	B-PP	O
observation	observation	o120610305	NN	B-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
clear	clear	c406	JJ	B-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
vagina	vagina	v02050	NN	I-NP	I-Disease
detected	detect	d0302303	VBN	B-VP	O
at	at	a300	IN	B-PP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
in	in	i500	IN	B-PP	O
young	young	y052	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
utero	utero	u3060	NN	B-NP	O
to	to	t000	TO	B-PP	O
diethylstilbestrol	diethylstilbestrol	d030423041023604	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
23	23	0000	CD	B-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
followed	follow	f0403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
2	2	2000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
before	before	b01060	IN	B-SBAR	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
aged	age	a203	VBN	B-VP	O
22	22	0000	CD	B-NP	O
,	,	,000	,	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
seen	see	s050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
a	a	a000	DT	B-NP	O
regular	regular	r020406	JJ	I-NP	O
basis	basis	b0202	NN	I-NP	O
for	for	f060	IN	B-PP	O
5	5	5000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
instances	instance	i52305202	NNS	I-NP	O
,	,	,000	,	O	O
suspicion	suspicion	s0210205	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
carcinoma	carcinoma	c06205050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
aroused	arouse	a60203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
palpation	palpation	p0410305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
small	small	s504	JJ	I-NP	O
nodule	nodule	n03040	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vaginal	vaginal	v020504	JJ	I-NP	O
fornix	fornix	f06502	NN	I-NP	O
.	.	.000	.	O	O

Hysterosalpingography	Hysterosalpingography	h0230602041052026010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
on	on	o500	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
instance	instance	i5230520	NN	I-NP	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
abnormal	abnormal	a1506504	JJ	I-NP	O
x	x	x000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
ray	ray	r000	NN	I-NP	O
film	film	f045	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reflected	reflect	r01402303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
gross	gross	g602	JJ	I-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
uterine	uterine	u306050	JJ	I-NP	O
cavity	cavity	c01030	NN	I-NP	O
found	find	f053	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
specimen	specimen	s1020505	NN	I-NP	O
.	.	.000	.	O	O

Neurologic	Neurologic	n06040202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
CE	CE	c000	NN	B-NP	I-Chemical
,	,	,000	,	O	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
consequences	consequence	c0520205202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
deliberate	deliberate	d040106030	JJ	B-NP	O
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
large	large	l0620	JJ	B-NP	O
volumes	volume	v040502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
CE	CE	c000	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
animals	animal	a505042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
total	total	t0304	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
as	as	a200	IN	B-PP	O
potential	potential	p0305304	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
causing	cause	c02052	VBG	B-VP	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
65	65	0000	CD	I-NP	O
dogs	dog	d020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
injections	injection	i52023052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	O
space	space	s1020	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
follows	follow	f0402	VBZ	B-VP	O
:	:	:000	:	O	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
8	8	8000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
15	15	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
CE	CE	c000	NN	B-NP	I-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	O	O
)	)	)000	)	O	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
20	20	0000	CD	I-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
CE	CE	c000	NN	B-NP	I-Chemical
seven	seven	s0105	CD	I-NP	O
(	(	(000	(	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
hind	hind	h053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
limb	limb	l051	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
titrated	titrate	t0360303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
pH	pH	p000	NN	I-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
0	0	0000	CD	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
hind	hind	h053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
limb	limb	l051	NN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
15	15	0000	CD	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cords	cord	c0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
2	2	2000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloroprocaine	chloroprocaine	c040601602050	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
CE	CE	c000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
13	13	0000	CD	B-NP	O
showed	show	s030	VBD	B-VP	O
subpial	subpial	s0104	JJ	B-NP	B-Disease
necrosis	necrosis	n0260202	NN	I-NP	I-Disease
;	;	;000	:	O	O
the	the	t000	DT	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
roots	root	r032	NNS	I-NP	O
and	and	a530	CC	O	O
subarachnoid	subarachnoid	s0106020503	JJ	B-NP	O
vessels	vessel	v02042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
cords	cord	c0632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
animals	animal	a505042	NNS	I-NP	O
that	that	t030	WDT	B-NP	O
received	receive	r020103	VBD	B-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
pH	pH	p000	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
normal	normal	n06504	JJ	B-NP	O
saline	saline	s04050	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
show	show	s000	VB	I-VP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
.	.	.000	.	O	O

Procainamide	Procainamide	p6020505030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
polymorphous	polymorphous	p040506102	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polymorphous	polymorphous	p040506102	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
polymorphous	polymorphous	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
appeared	appear	a10603	VBD	B-VP	O
after	after	a1306	IN	B-SBAR	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
400	400	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
sustained	sustained	s0230503	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
three	three	t060	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
orally	orally	o6040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	O
premature	premature	p60503060	JJ	I-NP	B-Disease
ventricular	ventricular	v0536020406	JJ	I-NP	I-Disease
contractions	contraction	c0536023052	NNS	I-NP	I-Disease
or	or	o600	CC	O	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
flutter	flutter	f40306	NN	I-NP	I-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
Q	Q	q000	NN	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
T	T	t000	NN	I-NP	I-Disease
prolongation	prolongation	p6040520305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
recurrent	recurrent	r0206053	JJ	B-NP	O
syncope	syncope	s052010	NN	I-NP	B-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
polymorphous	polymorphous	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
rapidly	rapidly	r010340	RB	I-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
disappearance	disappearance	d0201060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
further	further	f06306	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
degenerated	degenerate	d0205060303	VBD	B-VP	O
into	into	i530	IN	B-PP	O
irreversible	irreversible	i6010620140	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
seventh	seventh	s010530	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
permanent	permanent	p06505053	JJ	I-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
pacemaker	pacemaker	p02050206	NN	I-NP	O
was	be	w020	VBD	B-VP	O
inserted	insert	i5206303	VBN	I-VP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
continuation	continuation	c053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
polymorphous	polymorphous	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
reoccur	reoccur	r0206	VB	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
seven	seven	s0105	CD	I-NP	O
cases	case	c0202	NNS	I-NP	O
demonstrate	demonstrate	d0505236030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
procainamide	procainamide	p6020505030	NN	B-NP	B-Chemical
can	can	c050	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
an	an	a500	DT	B-NP	O
acquired	acquire	a20603	VBN	I-NP	O
prolonged	prolong	p60405203	VBN	I-NP	B-Disease
Q	Q	q000	NN	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
T	T	t000	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
polymorphous	polymorphous	p040506102	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Phenobarbitone	Phenobarbitone	p050106103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
:	:	:000	:	O	O
its	its	i320	PRP$	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
to	to	t000	TO	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
yield	yield	y043	NN	I-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
cirrhosis	cirrhosis	c060202	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
(	(	(000	(	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
shrunken	shrink	s0605205	VBN	I-NP	O
finely	finely	f05040	RB	I-NP	O
nodular	nodular	n030406	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	O
with	with	w030	IN	B-PP	O
micronodular	micronodular	m02605030406	JJ	B-NP	O
histology	histology	h02304020	NN	I-NP	O
,	,	,000	,	O	O
ascites	ascite	a20302	VBZ	B-VP	B-Disease
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
30	30	0000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
plasma	plasma	p40250	NN	B-NP	O
albumin	albumin	a410505	NN	I-NP	O
less	less	l020	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	B-NP	O
,	,	,000	,	O	O
splenomegaly	splenomegaly	s14050502040	NN	B-NP	B-Disease
2	2	2000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
3	3	3000	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
normal	normal	n06504	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
testicular	testicular	t023020406	JJ	B-NP	O
atrophy	atrophy	a36010	NN	I-NP	B-Disease
approximately	approximately	a16020503040	RB	B-NP	O
half	half	h041	DT	I-NP	O
normal	normal	n06504	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
given	give	g0105	VBN	B-VP	O
intragastrically	intragastrically	i53602023602040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
phenobarbitone	phenobarbitone	p050106103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
primed	prim	p60503	VBN	B-NP	O
rat	rat	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
increased	increase	i5260203	VBN	I-VP	O
from	from	f605	IN	B-PP	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
56	56	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
giving	give	g01052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
"	"	"000	``	B-NP	O
calibrating	calibrate	c0401603052	VBG	I-NP	O
"	"	"000	''	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
peak	peak	p020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
phenobarbitone	phenobarbitone	p050106103050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
enlargement	enlargement	e5406205053	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
liver	liver	l0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
this	this	t020	DT	B-NP	O
point	point	p053	NN	I-NP	O
it	it	i300	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
assumed	assume	a20503	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
P450	P450	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
CCl4	CCl4	0000	NN	I-NP	B-Chemical
toxic	toxic	t0202	JJ	I-NP	O
state	state	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
both	both	b030	CC	O	O
maximal	maximal	m020504	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
stable	stable	s30140	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
rat	rat	r030	NN	I-NP	O
size	size	s020	NN	I-NP	O
to	to	t000	TO	B-VP	O
begin	begin	b0205	VB	I-VP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
as	as	a200	IN	B-PP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
size	size	s020	NN	I-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
group	group	g601	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
maximum	maximum	m020505	JJ	I-NP	O
relative	relative	r0403010	JJ	I-NP	O
liver	liver	l0106	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
47	47	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
body	body	b030	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
optimal	optimal	o130504	JJ	I-NP	O
time	time	t050	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
tetrachloride	tetrachloride	t036020406030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
on	on	o500	IN	B-PP	O
phenobarbitone	phenobarbitone	p050106103050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Triamterene	Triamterene	t605306050	NN	B-NP	B-Chemical
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
dyazide	dyazide	d02030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
triamterene	triamterene	t605306050	NN	B-NP	B-Chemical
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
man	man	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
4	4	4000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hydrochlorothiazide	hydrochlorothiazide	h0360204060302030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
triamterene	triamterene	t605306050	NN	I-NP	I-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stone	stone	s3050	NN	I-NP	O
passed	pass	p0203	VBD	B-VP	O
spontaneously	spontaneously	s1053050240	RB	B-ADVP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
contain	contain	c05305	VB	I-VP	O
a	a	a000	DT	B-NP	O
triamterene	triamterene	t605306050	NN	I-NP	B-Chemical
metabolite	metabolite	m030104030	NN	I-NP	O
admixed	admix	a350203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
uric	uric	u602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
salts	salt	s0432	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Factors	Factor	f023062	NNS	B-NP	O
affecting	affect	a1023052	VBG	B-VP	O
triamterene	triamterene	t605306050	NN	B-NP	B-Chemical
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
and	and	a530	CC	O	O
2	2	2000	CD	B-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
cases	case	c0202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

Busulfan	Busulfan	b0204105	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
hemorrhagic	hemorrhagic	h05060202	JJ	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
busulfan	busulfan	b0204105	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hemorrhage	hemorrhage	h0506020	NN	I-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

Spontaneous	Spontaneous	s10530502	JJ	B-NP	O
resolution	resolution	r02040305	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
following	follow	f04052	VBG	I-VP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
similarity	similarity	s050406030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
histologic	histologic	h023040202	JJ	I-NP	O
appearances	appearance	a10605202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
busulfan	busulfan	b0204105	NN	B-NP	B-Chemical
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
and	and	a530	CC	O	O
both	both	b030	CC	O	O
radiation	radiation	r030305	NN	B-NP	O
and	and	a530	CC	I-NP	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
cystitis	cystitis	c0230302	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
world	world	w0643	NN	I-NP	O
literature	literature	l030603060	NN	I-NP	O
reviewed	review	r0103	VBN	B-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
known	known	k505	JJ	I-NP	O
tendency	tendency	t0530520	NN	I-NP	O
of	of	o100	IN	B-PP	O
busulfan	busulfan	b0204105	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
cellular	cellular	c040406	JJ	B-NP	O
atypia	atypia	a3010	NN	I-NP	O
and	and	a530	CC	I-NP	O
carcinoma	carcinoma	c06205050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
other	other	o306	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
,	,	,000	,	O	O
periodic	periodic	p060302	JJ	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
cytology	cytology	c0304020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Variant	Variant	v06053	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
desipramine	desipramine	d0201605050	NN	B-NP	B-Chemical
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Unusual	Unusual	u50204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arrhythmia	arrhythmia	a603050	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
repetitive	repetitive	r010303010	JJ	B-NP	O
group	group	g601	NN	I-NP	O
beating	beating	b03052	NN	I-NP	O
,	,	,000	,	O	O
progressive	progressive	p602602010	JJ	B-NP	O
shortening	shortening	s06305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
R	R	r000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
R	R	r000	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
progressive	progressive	p602602010	JJ	B-NP	O
widening	widening	w0305052	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
QRS	QRS	q620	NN	I-NP	O
complex	complex	c051402	NN	I-NP	O
with	with	w030	IN	B-PP	O
eventual	eventual	e105304	JJ	B-NP	O
failure	failure	f04060	NN	I-NP	O
of	of	o100	IN	B-PP	O
intraventricular	intraventricular	i536010536020406	JJ	B-NP	O
conduction	conduction	c05302305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
direction	direction	d0602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
QRS	QRS	q620	NNP	I-NP	O
axis	axis	a202	NN	I-NP	O
.	.	.000	.	O	O

Recognition	Recognition	r020250305	NN	B-NP	O
of	of	o100	IN	B-PP	O
variant	variant	v06053	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
because	because	b02020	IN	B-SBAR	O
therapy	therapy	t06010	NN	B-NP	O
differs	differ	d01062	VBZ	B-VP	O
from	from	f605	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
classic	classic	c40202	JJ	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	B-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
.	.	.000	.	O	O

Rebound	Rebound	r01053	VB	B-VP	O
hypertensive	hypertensive	h01063052010	JJ	B-ADJP	B-Disease
after	after	a1306	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
prevented	prevent	p60105303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
saralasin	saralasin	s06040205	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
and	and	a530	CC	O	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
nitroprusside	nitroprusside	n03601602030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
MAC	MAC	m020	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
one	one	o500	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
SNP	SNP	s510	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
40	40	0000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
followed	follow	f0403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
30	30	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
identically	identically	i305302040	RB	B-ADVP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
received	receive	r020103	VBD	B-VP	O
an	an	a500	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
saralasin	saralasin	s06040205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
competitive	competitive	c0510303010	JJ	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
of	of	o100	IN	B-PP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
SNP	SNP	s510	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
from	from	f605	IN	B-PP	O
86	86	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
and	and	a530	CC	O	O
83	83	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
48	48	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
61	61	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
the	the	t000	DT	B-NP	O
saralasin	saralasin	s06040205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
SNP	SNP	s510	NN	B-NP	B-Chemical
,	,	,000	,	O	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
rebounded	rebound	r0105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
94	94	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
78	78	0000	CD	B-NP	O
torr	torr	t060	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
saralasin	saralasin	s06040205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
with	with	w030	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
halothane	halothane	h0403050	NN	I-NP	B-Chemical
anesthesia	anesthesia	a5023020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
during	during	d06052	IN	B-PP	O
SNP	SNP	s510	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
post	post	p023	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
rebound	rebound	r01053	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
completely	completely	c051403040	RB	I-VP	O
blocked	block	b40203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
saralasin	saralasin	s06040205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
participation	participation	p06302010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	O	O
-	-	-000	HYPH	B-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
antagonizing	antagonize	a53020502052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
SNP	SNP	s510	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Nearly	Nearly	n0640	RB	B-NP	O
3	3	3000	CD	I-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
million	million	m0405	CD	I-NP	O
people	people	p0140	NNS	I-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
country	country	c05360	NN	I-NP	O
receive	receive	r02010	VBP	B-VP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
annually	annually	a5040	RB	B-ADVP	O
.	.	.000	.	O	O

Gentamicin	Gentamicin	g053050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
continue	continue	c053050	VBP	B-VP	O
to	to	t000	TO	I-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
ototoxicity	ototoxicity	o3030202030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
both	both	b030	CC	B-NP	O
animal	animal	a50504	JJ	I-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
62	62	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
confirmed	confirm	c05106503	VBN	B-NP	O
initial	initial	i50304	JJ	I-NP	O
normal	normal	n06504	JJ	I-NP	O
renal	renal	r0504	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
or	or	o600	CC	O	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
minimum	minimum	m050505	NN	I-NP	O
of	of	o100	IN	B-PP	O
seven	seven	s0105	CD	B-NP	O
days	day	d020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
followed	follow	f0403	VBN	I-VP	O
up	up	u100	RP	B-PRT	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
aminoglycoside	aminoglycoside	a5050240202030	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
,	,	,000	,	O	O
defined	define	d010503	VBN	B-VP	O
as	as	a200	IN	B-PP	O
at	at	a300	IN	B-ADVP	O
least	least	l023	JJS	I-ADVP	O
a	a	a000	DT	B-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
third	third	t063	JJ	I-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
62	62	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
33	33	0000	CD	B-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
tobramycin	tobramycin	t016050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
29	29	0000	CD	B-NP	O
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
gentamicin	gentamicin	g053050205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
three	three	t060	CD	I-NP	O
times	time	t0502	NNS	I-NP	O
as	as	a200	RB	I-NP	O
often	often	o1305	RB	I-NP	O
as	as	a200	IN	I-NP	O
was	be	w020	VBD	B-VP	O
tobramycin	tobramycin	t016050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Metabolic	Metabolic	m03010402	JJ	B-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cardiotoxic	cardiotoxic	c063030202	JJ	I-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mammalian	mammalian	m050405	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
culture	culture	c043060	NN	B-NP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
model	model	m0304	NN	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Adriamycin	Adriamycin	a36050205	NN	B-NP	B-Chemical
inhibited	inhibit	i5010303	VBD	B-VP	O
cell	cell	c040	NN	B-NP	O
growth	growth	g6030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
rhythmic	rhythmic	r030502	JJ	I-NP	O
contractions	contraction	c0536023052	NNS	I-NP	O
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
myocardial	myocardial	m0206304	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
culture	culture	c043060	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
energy	energy	e50620	NN	B-NP	O
metabolism	metabolism	m030104025	NN	I-NP	O
was	be	w020	VBD	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
the	the	t000	DT	B-NP	O
adenylate	adenylate	a30504030	NN	I-NP	O
energy	energy	e50620	NN	I-NP	O
charge	charge	c0620	NN	I-NP	O
and	and	a530	CC	I-NP	O
phosphorylcreatine	phosphorylcreatine	p02106042603050	NN	I-NP	B-Chemical
mole	mole	m040	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
adenylate	adenylate	a30504030	NN	I-NP	O
energy	energy	e50620	NN	I-NP	O
charge	charge	c0620	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
phophorylcreatine	phophorylcreatine	p0106042603050	NN	I-NP	B-Chemical
mole	mole	m040	NN	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
unchanged	unchanged	u5205203	JJ	B-ADJP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
disparity	disparity	d02106030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
creatine	creatine	c603050	NN	B-NP	B-Chemical
phosphokinase	phosphokinase	p0210205020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
adenosine	adenosine	a30502050	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
cultures	culture	c0430602	NNS	I-NP	O
markedly	markedly	m0620340	RB	B-ADVP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
pathway	pathway	p030	NN	I-NP	O
reportedly	reportedly	r010630340	RB	B-VP	O
leading	lead	l03052	VBG	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
compartmentalized	compartmentalize	c0510635053040203	VBN	I-NP	O
ATP	ATP	a310	NN	I-NP	B-Chemical
pool	pool	p040	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
adriamycin	adriamycin	a36050205	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
adenosine	adenosine	a30502050	NN	B-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
adenylate	adenylate	a30504030	NN	I-NP	O
charge	charge	c0620	NN	I-NP	O
and	and	a530	CC	O	O
,	,	,000	,	O	O
concomitant	concomitant	c0520503053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
inrcease	inrcease	i562020	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
'	'	'000	POS	B-NP	O
functional	functional	f05230504	JJ	I-NP	O
integrity	integrity	i53026030	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
terms	term	t0652	NNS	B-NP	O
of	of	o100	IN	B-PP	O
percentage	percentage	p062053020	NN	B-NP	O
of	of	o100	IN	B-PP	O
beating	beat	b03052	VBG	B-VP	O
cells	cell	c042	NNS	B-NP	O
and	and	a530	CC	O	O
rate	rate	r030	NN	B-NP	O
of	of	o100	IN	B-PP	O
contractions	contraction	c0536023052	NNS	B-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
maintained	maintain	m0530503	VBN	I-VP	O
.	.	.000	.	O	O

Age	Age	a200	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
to	to	t000	TO	B-PP	O
neurotoxic	neurotoxic	n06030202	JJ	B-NP	B-Disease
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
streptomycin	streptomycin	s36013050205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Streptomycin	Streptomycin	s36013050205	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
(	(	(000	(	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
s	s	s000	NNS	I-NP	O
.	.	.000	.	B-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
periods	period	p06032	NNS	I-NP	O
into	into	i530	IN	B-PP	O
preweanling	preweanle	p6054052	VBG	B-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
into	into	i530	IN	B-PP	O
weanling	weanle	w054052	VBG	B-VP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Beginning	Begin	b0205052	VBG	B-VP	O
at	at	a300	IN	B-PP	O
8	8	8000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
body	body	b030	NN	B-NP	O
movement	movement	m0105053	NN	I-NP	O
and	and	a530	CC	I-NP	O
hearing	hearing	h06052	NN	I-NP	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	O	O
up	up	u100	RB	B-NP	O
to	to	t000	TO	I-NP	O
17	17	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Abnormal	Abnormal	a1506504	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
and	and	a530	CC	I-NP	O
deafness	deafness	d01502	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
preweaning	preweaning	p605052	JJ	I-NP	O
period	period	p0603	NN	I-NP	O
;	;	;000	:	O	O
within	within	w0305	IN	B-PP	O
this	this	t020	DT	B-NP	O
period	period	p0603	NN	I-NP	O
the	the	t000	DT	B-NP	O
greatest	great	g603023	JJS	I-NP	O
sensitivities	sensitivity	s05203010302	NNS	I-NP	O
for	for	f060	IN	B-PP	O
these	these	t020	DT	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
-	-	-000	:	O	O
17	17	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
5	5	5000	CD	I-NP	O
to	to	t000	TO	I-NP	O
11	11	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
,	,	,000	,	O	O
indicating	indicate	i530203052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
cochlea	cochlea	c02040	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
sensitive	sensitive	s05203010	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
streptomycin	streptomycin	s36013050205	NN	B-NP	B-Chemical
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
(	(	(000	(	O	O
vestibular	vestibular	v023010406	JJ	B-ADJP	O
or	or	o600	CC	I-ADJP	O
central	central	c053604	JJ	I-ADJP	O
)	)	)000	)	O	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
dyskinesias	dyskinesia	d02050202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

Late	Late	l030	RB	B-ADVP	O
,	,	,000	,	O	O
late	late	l030	JJ	B-NP	O
doxorubicin	doxorubicin	d0206010205	NN	I-NP	B-Chemical
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cardiac	Cardiac	c06302	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
limits	limit	l05032	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
adriamycin	adriamycin	a36050205	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
chemotherapeutic	chemotherapeutic	c050306010302	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Cardiomyopathy	Cardiomyopathy	c0630501030	NNP	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
frequent	frequent	f602053	JJ	B-ADJP	O
when	when	w050	WRB	B-ADVP	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
exceeds	exceed	e2032	VBZ	B-VP	O
600	600	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
and	and	a530	CC	O	O
occurs	occur	o2062	VBZ	B-VP	O
within	within	w0305	IN	B-PP	O
one	one	o500	CD	B-NP	O
to	to	t000	TO	I-NP	O
six	six	s020	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	B-Disease
two	two	t000	CD	B-NP	O
and	and	a530	CC	I-NP	O
one	one	o500	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
half	half	h041	NN	I-NP	O
years	year	y062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
receiving	receive	r0201052	VBG	B-VP	O
580	580	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
which	which	w020	WDT	B-NP	O
apparently	apparently	a10605340	RB	B-ADVP	O
represents	represent	r016020532	VBZ	B-VP	O
late	late	l030	JJ	B-NP	O
,	,	,000	,	I-NP	O
late	late	l030	JJ	I-NP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Attenuation	Attenuation	a3050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polydipsia	polydipsia	p04030120	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
,	,	,000	,	I-NP	O
brain	brain	b605	NN	I-NP	O
,	,	,000	,	I-NP	O
kidney	kidney	k0350	NN	I-NP	O
,	,	,000	,	I-NP	O
thyroid	thyroid	t0603	NN	I-NP	O
and	and	a530	CC	I-NP	O
red	red	r030	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
cells	cell	c042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
chronically	chronically	c060502040	RB	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
LiCl	LiCl	l024	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Amiloride	Amiloride	a50406030	NN	B-NP	B-Chemical
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
drinking	drinking	d6052052	NN	I-NP	O
and	and	a530	CC	I-NP	O
urine	urine	u6050	NN	I-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
or	or	o600	CC	I-NP	O
12	12	0000	CD	I-NP	O
h	h	h000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
subacute	subacute	s0102030	JJ	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
)	)	)000	)	O	O
experiment	experiment	e210605053	NN	B-NP	O
.	.	.000	.	O	O

6	6	6000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
content	content	c053053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	B-PP	O
in	in	i500	IN	I-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
organs	organ	o62052	NNS	I-NP	O
studied	study	s30303	VBN	B-VP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
12	12	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
tissues	tissue	t0202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
slight	slight	s40203	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
combined	combined	c0510503	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
marked	marked	m06203	JJ	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
and	and	a530	CC	I-NP	O
tissue	tissue	t020	NN	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
accompanied	accompany	a20510503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
water	water	w0306	NN	B-NP	O
intake	intake	i53020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
attenuation	attenuation	a3050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
induced	induce	i530203	VBN	B-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
like	like	l020	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ratio	ratio	r030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	O
medulla	medulla	m03040	NN	I-NP	O
and	and	a530	CC	O	O
its	its	i320	PRP$	B-NP	O
levels	level	l01042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
and	and	a530	CC	O	O
an	an	a500	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
potassium	potassium	p030205	NN	I-NP	B-Chemical
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
acute	acute	a2030	JJ	B-NP	O
amiloride	amiloride	a50406030	NN	I-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
polydipsia	polydipsia	p04030120	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
might	might	m0203	MD	B-VP	O
relieve	relieve	r04010	VB	I-VP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
but	but	b030	CC	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
amiloride	amiloride	a50406030	NN	B-NP	B-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
would	would	w043	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
elevated	elevated	e4010303	JJ	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
hazardous	hazardous	h0206302	JJ	B-ADJP	O
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
labor	labor	l0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
complications	complication	c05140203052	NNS	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
eight	eight	e0203	CD	B-NP	O
of	of	o100	IN	B-PP	O
160	160	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
terbutaline	terbutaline	t0610304050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	B-Disease
labor	labor	l0106	NN	I-NP	I-Disease
.	.	.000	.	O	O

Associated	Associate	a2020303	VBN	B-NP	O
corticosteroid	corticosteroid	c063020230603	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	I-NP	O
twin	twin	t050	NN	I-NP	O
gestations	gestation	g02303052	NNS	I-NP	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
predisposing	predispose	p60302102052	VBG	I-VP	O
factors	factor	f023062	NNS	B-NP	O
.	.	.000	.	O	O

Potential	Potential	p0305304	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathophysiology	pathophysiology	p03010204020	NN	I-NP	O
are	be	a600	VBP	B-VP	O
briefly	briefly	b60140	RB	I-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Toxic	Toxic	t0202	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
:	:	:000	:	O	O
four	four	f060	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
including	include	i52403052	VBG	B-PP	O
one	one	o500	CD	B-NP	O
with	with	w030	IN	B-PP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
reactivity	reactivity	r02301030	NN	I-NP	O
between	between	b0305	IN	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
benzylthiouracil	benzylthiouracil	b052043060204	NN	I-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
assess	assess	a202	VB	I-VP	O
the	the	t000	DT	B-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	B-Disease
adverse	adverse	a310620	JJ	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	I-Disease
encountered	encounter	e520530603	VBN	B-VP	O
with	with	w030	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Retrospective	Retrospective	r036021023010	JJ	B-NP	O
review	review	r010	NN	I-NP	O
of	of	o100	IN	B-PP	O
medical	medical	m030204	JJ	B-NP	O
records	record	r020632	NNS	I-NP	O
of	of	o100	IN	B-PP	O
236	236	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
hyperthyroidism	hyperthyroidism	h010630603025	NN	B-NP	B-Disease
admitted	admit	a350303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
department	department	d010635053	NN	I-NP	O
(	(	(000	(	O	O
in	in	i500	IN	B-PP	O
-	-	-000	HYPH	B-NP	O
or	or	o600	CC	O	O
out	out	o030	RP	B-PRT	O
-	-	-000	HYPH	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
from	from	f605	IN	B-PP	O
1986	1986	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
1992	1992	0000	CD	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
toxic	toxic	t0202	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
could	could	c043	MD	B-VP	O
reasonably	reasonably	r02050140	RB	I-VP	O
be	be	b000	VB	I-VP	O
attributed	attribute	a36010303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	B-Chemical
omercazole	omercazole	o506202040	NN	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
others	other	o3062	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	O	O
mixed	mixed	m0203	JJ	O	O
(	(	(000	(	O	O
cholestatic	cholestatic	c040230302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	O
cytolytic	cytolytic	c03040302	JJ	I-NP	O
)	)	)000	)	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
two	two	t000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
further	further	f06306	RBR	B-ADVP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
cytolytic	cytolytic	c03040302	JJ	I-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
appeared	appear	a10603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
Benzylthiouracil	Benzylthiouracil	b052043060204	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Basd	Basd	b023	NN	B-NP	B-Chemical
ne	ne	n000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
replaced	replace	r0140203	VBN	I-VP	O
carbimazole	carbimazole	c0610502040	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Biological	Biological	b04020204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hepatitis	hepatitis	h01030302	NN	B-NP	B-Disease
disappeared	disappear	d02010603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
incriminated	incriminate	i52605050303	VBN	I-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
biliary	biliary	b04060	JJ	B-NP	O
,	,	,000	,	I-NP	O
viral	viral	v0604	JJ	I-NP	O
and	and	a530	CC	I-NP	O
immunological	immunological	i50504020204	JJ	I-NP	O
searches	search	s06202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
2	2	2000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
retrospective	retrospective	r036021023010	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
mild	mild	m043	JJ	I-NP	O
or	or	o600	CC	I-NP	O
severe	severe	s01060	JJ	I-NP	O
neutropenia	neutropenia	n03601050	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
Toxic	Toxic	t0202	JJ	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
warrants	warrant	w060532	NNS	B-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-PP	O
for	for	f060	IN	B-PP	O
haematological	haematological	h050304020204	JJ	B-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
pre	pre	p600	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
careful	careful	c060104	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
relevant	relevant	r0401053	JJ	B-NP	O
biological	biological	b04020204	JJ	I-NP	O
markers	marker	m062062	NNS	I-NP	O
.	.	.000	.	O	O

Moreover	Moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
restricted	restrict	r023602303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
antithyroid	antithyroid	a53030603	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

Interactive	Interactive	i5306023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
variations	variation	v0603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
[	[	[000	(	B-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
on	on	o500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
varying	vary	v06052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
extracellular	extracellular	e23602040406	JJ	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
[	[	[000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
and	and	a530	CC	O	O
[	[	[000	(	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
both	both	b030	CC	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
beating	beating	b03052	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
isolated	isolate	i2040303	VBN	I-NP	O
rat	rat	r030	NN	I-NP	O
atria	atria	a360	NN	I-NP	O
.	.	.000	.	O	O

Basal	Basal	b0204	JJ	B-NP	O
frequency	frequency	f6020520	NN	I-NP	O
(	(	(000	(	O	O
BF	BF	b100	NN	B-NP	O
)	)	)000	)	O	O
evaluated	evaluate	e1040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
surface	surface	s061020	NN	B-NP	O
electrogram	electrogram	e4023602605	NN	I-NP	O
was	be	w020	VBD	B-VP	O
223	223	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
beats	beat	b032	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
Krebs	Kreb	k6012	NNS	I-NP	O
-	-	-000	HYPH	B-NP	O
Ringer	Ringer	r05206	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
137	137	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
Na	Na	n000	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
by	by	b000	IN	B-PP	O
16	16	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
[	[	[000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
to	to	t000	TO	B-PP	O
78	78	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
(	(	(000	(	O	O
LNa	LNa	l500	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
[	[	[000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
to	to	t000	TO	B-PP	O
78	78	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
and	and	a530	CC	O	O
[	[	[000	(	B-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
to	to	t000	TO	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
675	675	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
(	(	(000	(	O	O
LNa	LNa	l500	NN	B-NP	O
+	+	+000	SYM	B-NP	O
LCa	LCa	l200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
31	31	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
by	by	b000	IN	B-PP	O
lowering	lower	l06052	VBG	B-VP	O
[	[	[000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
to	to	t000	TO	B-PP	O
78	78	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
plus	plus	p402	CC	O	O
increasing	increase	i52602052	VBG	B-VP	O
[	[	[000	(	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
to	to	t000	TO	B-PP	O
3	3	3000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
(	(	(000	(	O	O
LNa	LNa	l500	NN	B-NP	O
+	+	+000	SYM	O	O
HCa	HCa	h200	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
[	[	[000	(	O	O
Na	Na	n000	NN	O	B-Chemical
]	]	]000	)	O	O
o	o	o000	NN	B-NP	O
,	,	,000	,	O	O
decrease	decrease	d026020	NN	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
675	675	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
increase	increase	i526020	NN	B-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mM	mM	m500	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
[	[	[000	(	O	O
Ca	Ca	c000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
modify	modify	m03010	VB	I-VP	O
BF	BF	b100	NN	B-NP	O
;	;	;000	:	O	O
a	a	a000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ten	ten	t050	CD	B-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
135	135	0000	CD	B-NP	O
mM	mM	m500	NN	I-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
[	[	[000	(	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
effective	effective	e1023010	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
BF	BF	b100	NN	B-NP	O
by	by	b000	IN	B-PP	O
40	40	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
BF	BF	b100	NN	B-NP	O
-	-	-000	HYPH	B-VP	O
dependent	dependent	d01053053	JJ	B-ADJP	O
.	.	.000	.	O	O

Dose	Dose	d020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
LNa	LNa	l500	NN	B-NP	O
,	,	,000	,	O	O
LCa	LCa	l200	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
HCa	HCa	h200	NN	B-NP	O
.	.	.000	.	O	O

Independent	Independent	i5301053053	JJ	B-ADJP	O
but	but	b030	CC	I-ADJP	O
not	not	n030	RB	I-ADJP	O
additive	additive	a303010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
Na	Na	n000	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
by	by	b000	IN	B-PP	O
decreases	decrease	d0260202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
values	value	v0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
[	[	[000	(	B-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
needed	need	n0303	VBN	B-VP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
BF	BF	b100	NN	B-NP	O
by	by	b000	IN	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
IC30	IC30	0000	NN	B-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
order	order	o6306	NN	I-NP	O
of	of	o100	IN	B-PP	O
inhibitory	inhibitory	i50103060	JJ	B-NP	O
potency	potency	p030520	NN	I-NP	O
:	:	:000	:	O	O
LNa	LNa	l500	NN	B-NP	O
>	>	>000	SYM	B-NP	O
LCa	LCa	l200	NN	I-NP	O
>	>	>000	SYM	I-NP	O
HCa	HCa	h200	NN	I-NP	O
>	>	>000	SYM	I-NP	O
N	N	n000	NN	I-NP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
LNa	LNa	l500	NN	B-NP	O
+	+	+000	SYM	B-NP	O
HCa	HCa	h200	NN	I-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
LNa	LNa	l500	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
[	[	[000	(	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
that	that	t030	WDT	B-NP	O
arrested	arrest	a602303	VBD	B-VP	O
atrial	atrial	a3604	JJ	B-NP	O
beating	beating	b03052	NN	I-NP	O
(	(	(000	(	O	O
AC	AC	a200	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
order	order	o6306	NN	I-NP	O
LNa	LNa	l500	NN	I-NP	O
=	=	=000	SYM	B-VP	O
LNa	LNa	l500	NN	B-NP	O
+	+	+000	SYM	B-NP	O
LCa	LCa	l200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
LNa	LNa	l500	NN	B-NP	O
+	+	+000	SYM	B-NP	O
HCa	HCa	h200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
LCa	LCa	l200	NN	B-NP	O
>	>	>000	SYM	B-NP	O
HCa	HCa	h200	NN	I-NP	O
=	=	=000	SYM	B-VP	O
N	N	n000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
rat	rat	r030	NN	B-NP	O
atrial	atrial	a3604	JJ	I-NP	O
spontaneous	spontaneous	s10530502	JJ	I-NP	O
beating	beating	b03052	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
more	more	m060	RBR	B-ADJP	O
dependent	dependent	d01053053	JJ	I-ADJP	O
on	on	o500	IN	B-PP	O
[	[	[000	(	O	O
Na	Na	n000	NN	B-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
than	than	t050	IN	B-PP	O
on	on	o500	IN	B-PP	O
[	[	[000	(	B-NP	O
Ca	Ca	c000	NN	I-NP	B-Chemical
]	]	]000	)	I-NP	O
o	o	o000	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
50	50	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
normal	normal	n06504	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	O
beating	beating	b03052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
at	at	a300	IN	B-PP	O
LNa	LNa	l500	NN	B-NP	O
than	than	t050	IN	B-PP	O
at	at	a300	IN	B-PP	O
LCa	LCa	l200	NNP	B-NP	O
.	.	.000	.	O	O
(	(	(000	(	O	O
ABSTRACT	ABSTRACT	a1236023	NN	B-NP	O
TRUNCATED	TRUNCATED	t60520303	VBN	B-VP	O
AT	AT	a300	IN	B-PP	O
250	250	0000	CD	B-NP	O
WORDS	WORDS	w0632	NNS	I-NP	O
)	)	)000	)	O	O

Pseudo	Pseudo	p2030	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
allergic	allergic	a406202	JJ	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
:	:	:000	:	O	O
diagnosis	diagnosis	d0250202	NN	B-NP	O
and	and	a530	CC	I-NP	O
alternatives	alternative	a43065030102	NNS	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
parenteral	parenteral	p060530604	JJ	B-NP	O
paramethasone	paramethasone	p06050302050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Triniol	Triniol	t60504	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dexamethasone	dexamethasone	d02050302050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Sedionbel	Sedionbel	s0305104	NN	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
minutes	minute	m050302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
they	they	t000	PRP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
urticaria	urticaria	u6302060	NN	B-NP	B-Disease
(	(	(000	(	O	O
patients	patient	p030532	NNS	B-NP	O
1	1	1000	CD	O	O
and	and	a530	CC	O	O
2	2	2000	CD	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
conjunctivitis	conjunctivitis	c0520523010302	NN	B-NP	B-Disease
(	(	(000	(	O	O
patient	patient	p03053	NN	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
immunological	immunological	i50504020204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
involved	involve	i5104103	VBN	B-VP	O
and	and	a530	CC	O	O
whether	whether	w0306	IN	B-SBAR	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
tolerate	tolerate	t0406030	VB	I-VP	O
any	any	a500	DT	B-NP	O
kind	kind	k053	NN	I-NP	O
of	of	o100	IN	B-PP	O
corticoid	corticoid	c0630203	NN	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
examinations	examination	e2050503052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
skin	skin	s205	NN	I-NP	O
,	,	,000	,	O	O
oral	oral	o604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
challenges	challenge	c0405202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
ELISA	ELISA	e4020	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
skin	skin	s205	NN	B-NP	O
and	and	a530	CC	I-NP	O
ELISA	ELISA	e4020	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
paramethasone	paramethasone	p06050302050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
prick	prick	p602	NN	I-NP	O
test	test	t023	NN	I-NP	O
with	with	w030	IN	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
excipients	excipient	e2010532	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
challenge	challenge	c040520	NN	I-NP	O
with	with	w030	IN	B-PP	O
Triniol	Triniol	t60504	NN	B-NP	O
was	be	w020	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
negative	negative	n0203010	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
excipients	excipient	e2010532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
carried	carry	c0603	VBD	B-VP	O
out	out	o030	RP	B-PRT	O
oral	oral	o604	JJ	B-NP	O
and	and	a530	CC	I-NP	O
parenteral	parenteral	p060530604	JJ	I-NP	O
challenges	challenge	c0405202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
corticosteroids	corticosteroid	c0630202306032	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
found	find	f053	VBN	B-VP	O
intolerance	intolerance	i5304060520	NN	B-NP	O
to	to	t000	TO	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
paramethasone	paramethasone	p06050302050	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
pseudoallergic	pseudoallergic	p2030406202	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Corticosteroids	Corticosteroid	c0630202306032	NNS	B-NP	O
different	different	d0106053	JJ	B-ADJP	O
from	from	f605	IN	B-PP	O
paramethasone	paramethasone	p06050302050	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
produced	produce	p6030203	VBD	B-VP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
few	few	f000	JJ	I-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
were	be	w060	VBD	B-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
basic	basic	b0202	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
yet	yet	y030	RB	B-ADVP	O
fully	fully	f040	RB	B-ADJP	O
understood	understand	u53062303	VBN	I-ADJP	O
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
pseudo	pseudo	p2030	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
allergy	allergy	a40620	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
paramethasone	paramethasone	p06050302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Study	Study	s3030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
,	,	,000	,	I-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ZDV	ZDV	z310	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
bone	bone	b050	NN	I-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	I-NP	O
human	human	h0505	JJ	I-NP	B-Disease
immunodeficiency	immunodeficiency	i5050301020520	NN	I-NP	I-Disease
virus	virus	v0602	NN	I-NP	I-Disease
(	(	(000	(	O	I-Disease
HIV	HIV	h010	NN	B-NP	I-Disease
)	)	)000	)	O	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
infected	infect	i5102303	VBN	B-VP	I-Disease
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	B-VP	O
cell	cell	c040	NN	B-NP	O
counts	count	c0532	NNS	I-NP	O
<	<	<000	SYM	O	O
500	500	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
mm3	mm3	0000	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomized	randomize	r053050203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
receive	receive	r02010	VB	I-VP	O
either	either	e0306	CC	O	O
ZDV	ZDV	z310	NN	B-NP	B-Chemical
(	(	(000	(	O	O
500	500	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
alone	alone	a4050	RB	B-ADVP	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
I	I	i000	NN	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
38	38	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	JJ	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
intramascular	intramascular	i53605020406	JJ	B-NP	O
vitamin	vitamin	v030505	NN	I-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
1000	1000	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
monthly	monthly	m053040	JJ	B-ADJP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
37	37	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
excluded	exclude	e240303	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
(	(	(000	(	O	O
noncompliance	noncompliance	n05205140520	NN	B-NP	O
14	14	0000	CD	I-NP	O
,	,	,000	,	O	O
death	death	d030	NN	B-NP	B-Disease
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
thus	thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
60	60	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
31	31	0000	CD	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
29	29	0000	CD	I-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
eligible	eligible	e4020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
analysis	analysis	a5040202	NN	B-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
at	at	a300	IN	B-PP	O
enrollment	enrollment	e56045053	NN	B-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
folate	folate	f04030	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
,	,	,000	,	O	O
hematocrit	hematocrit	h050302603	NN	B-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
corpuscular	corpuscular	c061020406	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
white	white	w030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
cell	cell	c040	NN	I-NP	O
,	,	,000	,	I-NP	O
neutrophil	neutrophil	n0360104	NN	I-NP	O
and	and	a530	CC	I-NP	O
platelet	platelet	p4030403	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
at	at	a300	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
9	9	9000	CD	I-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Severe	Severe	s01060	JJ	B-NP	O
hematologic	hematologic	h0503040202	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
(	(	(000	(	O	O
neutrophil	neutrophil	n0360104	NN	B-NP	O
count	count	c053	NN	I-NP	O
<	<	<000	SYM	B-NP	O
1000	1000	0000	CD	B-NP	O
/	/	/000	SYM	I-NP	O
mm3	mm3	0000	NN	I-NP	O
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
<	<	<000	SYM	O	O
8	8	8000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
dl	dl	d400	NN	I-NP	O
)	)	)000	)	O	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
4	4	4000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
assigned	assign	a202503	VBN	B-VP	O
to	to	t000	TO	B-PP	O
group	group	g601	NN	B-NP	O
I	I	i000	CD	I-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
assigned	assign	a202503	VBN	B-VP	O
to	to	t000	TO	B-PP	O
group	group	g601	NN	B-NP	O
II	II	i000	CD	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
vitamin	vitamin	v030505	NN	B-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
or	or	o600	CC	O	O
folate	folate	f04030	JJ	B-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
development	development	d0104015053	NN	B-NP	O
of	of	o100	IN	B-PP	O
myelosuppression	myelosuppression	m04020160205	NN	B-NP	B-Disease
.	.	.000	.	O	O

Vitamin	Vitamin	v030505	NN	B-NP	B-Chemical
B12	B12	0000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
supplementation	supplementation	s014050530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ZDV	ZDV	z310	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
useful	useful	u20104	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
preventing	prevent	p601053052	VBG	B-VP	O
or	or	o600	CC	I-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
ZDV	ZDV	z310	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
myelotoxicity	myelotoxicity	m04030202030	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
treated	treat	t60303	VBN	I-NP	O
population	population	p01040305	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
in	in	i500	IN	B-PP	O
certain	certain	c06305	JJ	B-NP	O
subgroups	subgroup	s0126012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
excluded	exclude	e240303	VBN	I-VP	O
.	.	.000	.	O	O

Safety	Safety	s01030	NN	B-NP	O
and	and	a530	CC	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	O	O
effects	effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
alprazolam	alprazolam	a416020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Controlled	Control	c05360403	VBN	B-NP	O
study	study	s3030	NN	I-NP	O
in	in	i500	IN	B-PP	O
agoraphobia	agoraphobia	a20601010	NN	B-NP	B-Disease
with	with	w030	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
benzodiazepines	benzodiazepine	b0520302010502	NNS	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
led	lead	l030	VBN	I-VP	O
to	to	t000	TO	B-PP	O
increasing	increase	i52602052	VBG	B-NP	O
recognition	recognition	r020250305	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
unwanted	unwanted	u505303	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
alprazolam	alprazolam	a416020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
in	in	i500	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
agoraphobia	agoraphobia	a20601010	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	O	O
effect	effect	e1023	NN	B-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
London	London	l05305	NNP	B-NP	O
and	and	a530	CC	O	O
Toronto	Toronto	t060530	NNP	B-NP	O
154	154	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
met	meet	m030	VBD	B-VP	O
DSM	DSM	d250	NN	B-NP	O
-	-	-000	HYPH	O	O
III	III	i000	CD	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
for	for	f060	IN	B-PP	O
panic	panic	p0502	NN	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
agoraphobia	agoraphobia	a20601010	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
randomised	randomise	r053050203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
alprazolam	alprazolam	a416020405	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
.	.	.000	.	O	O

Subjects	Subject	s0120232	NNS	B-NP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
group	group	g601	NN	I-NP	O
also	also	a420	RB	B-ADVP	O
received	receive	r020103	VBD	B-VP	O
either	either	e0306	CC	O	O
exposure	exposure	e2102060	NN	B-NP	O
or	or	o600	CC	I-NP	O
relaxation	relaxation	r04020305	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
was	be	w020	VBD	B-VP	O
from	from	f605	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
0	0	0000	CD	B-NP	O
to	to	t000	TO	O	O
8	8	8000	CD	B-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
then	then	t050	RB	I-VP	O
tapered	taper	t010603	VBN	I-VP	O
from	from	f605	IN	B-PP	O
weeks	week	w020	NNS	B-NP	O
8	8	8000	CD	B-NP	O
to	to	t000	TO	B-PP	O
16	16	0000	CD	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Mean	Mean	m050	JJ	B-NP	O
alprazolam	alprazolam	a416020405	NN	I-NP	B-Chemical
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
daily	daily	d040	RB	B-ADVP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
,	,	,000	,	O	O
alprazolam	alprazolam	a416020405	NN	B-NP	B-Chemical
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
more	more	m060	RBR	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
(	(	(000	(	O	O
21	21	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
depression	depression	d0160205	NN	B-NP	B-Disease
,	,	,000	,	I-NP	O
enuresis	enuresis	e5060202	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
disinhibition	disinhibition	d0205010305	NN	I-NP	O
and	and	a530	CC	I-NP	O
aggression	aggression	a260205	NN	I-NP	B-Disease
;	;	;000	:	O	O
and	and	a530	CC	O	O
more	more	m060	JJR	B-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
irritability	irritability	i6030104030	NN	B-NP	B-Disease
,	,	,000	,	O	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
memory	memory	m05060	NN	I-NP	I-Disease
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
ataxia	ataxia	a3020	NN	I-NP	B-Disease
.	.	.000	.	O	O

Side	Side	s030	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
effects	effect	e10232	NNS	I-NP	O
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
diminish	diminish	d0505020	VB	I-VP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
but	but	b030	CC	O	O
remained	remain	r050503	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
week	week	w020	NN	B-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
this	this	t020	DT	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
drop	drop	d601	VB	I-NP	O
-	-	-000	HYPH	B-VP	O
out	out	o030	RP	B-PRT	O
rate	rate	r030	NN	B-NP	O
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Alprazolam	Alprazolam	a416020405	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
side	side	s030	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
but	but	b030	CC	O	O
many	many	m050	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
willing	willing	w04052	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
accept	accept	a2013	VB	I-VP	O
these	these	t020	DT	B-NP	O
.	.	.000	.	O	O

Crescentic	Crescentic	c60205302	JJ	B-NP	O
fibrillary	fibrillary	f01604060	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
rifampin	rifampin	r0105105	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
tuberculosis	tuberculosis	t01062040202	NN	I-NP	I-Disease
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
study	study	s3030	NN	I-NP	O
reveals	reveal	r01042	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapidly	rapidly	r010340	RB	B-NP	O
proliferative	proliferative	p604010603010	JJ	I-NP	O
crescentic	crescentic	c60205302	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
identifiable	identifiable	i3053010140	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
for	for	f060	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
month	month	m0530	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
isoniazid	isoniazid	i2050203	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
tuberculosis	tuberculosis	t01062040202	NN	I-NP	I-Disease
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
discovered	discover	d02010603	VBN	I-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
signs	sign	s0252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
failure	failure	f04060	NN	I-NP	I-Disease
five	five	f010	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
completion	completion	c05140305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
crescents	crescent	c6020532	NNS	B-NP	O
,	,	,000	,	O	O
electron	electron	e4023605	NN	B-NP	O
dense	dense	d0520	JJ	I-NP	O
fibrillar	fibrillar	f0160406	JJ	I-NP	O
deposits	deposit	d0102032	NNS	I-NP	O
and	and	a530	CC	O	O
moderate	moderate	m0306030	JJ	B-NP	O
lymphocytic	lymphocytic	l051020302	JJ	I-NP	O
interstitial	interstitial	i5306230304	JJ	I-NP	O
infiltrate	infiltrate	i510436030	NN	I-NP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
possible	possible	p020140	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
rapidly	rapidly	r010340	RB	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
and	and	a530	CC	O	O
ruled	rule	r0403	VBN	B-VP	O
out	out	o030	RP	B-PRT	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
documents	document	d02050532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
occurrence	occurrence	o2060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
rapidly	rapidly	r010340	RB	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
crescents	crescent	c6020532	NNS	B-NP	O
and	and	a530	CC	O	O
fibrillar	fibrillar	f0160406	JJ	B-NP	O
glomerulonephritis	glomerulonephritis	g40506040501060302	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rifampin	rifampin	r0105105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
61	61	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
incorporating	incorporate	i520610603052	VBG	B-VP	O
cisplatinum	cisplatinum	c0214030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
etoposide	etoposide	e30102030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
250	250	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
an	an	a500	DT	B-NP	O
inoperable	inoperable	i501060140	JJ	I-NP	O
gastric	gastric	g023602	JJ	I-NP	B-Disease
adenocarcinoma	adenocarcinoma	a3050206205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

He	He	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
neurologic	neurologic	n06040202	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
disorientation	disorientation	d02060530305	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
irritability	irritability	i6030104030	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
lapsed	lapse	l01203	VBD	B-VP	O
into	into	i530	IN	B-PP	O
a	a	a000	DT	B-NP	O
deep	deep	d010	JJ	I-NP	O
coma	coma	c050	NN	I-NP	B-Disease
,	,	,000	,	O	O
lasting	last	l023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
40	40	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
day	day	d000	NN	B-NP	O
2	2	2000	CD	I-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
reappeared	reappear	r010603	VBD	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
25	25	0000	CD	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
second	second	s02053	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
then	then	t050	RB	B-ADVP	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
given	give	g0105	VBN	B-VP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
this	this	t020	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
,	,	,000	,	O	O
neurotoxicity	neurotoxicity	n06030202030	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
highly	highly	h02040	RB	I-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
Krebs	Krebs	k6012	NNP	I-NP	O
cycle	cycle	c0240	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
by	by	b000	IN	B-PP	O
fluoroacetate	fluoroacetate	f4060203030	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
fluorocitrate	fluorocitrate	f40602036030	NN	I-NP	B-Chemical
,	,	,000	,	O	O
thiamine	thiamine	t05050	NN	B-NP	B-Chemical
deficiency	deficiency	d01020520	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
dihydrouracil	dihydrouracil	d036060204	NN	B-NP	B-Chemical
dehydrogenase	dehydrogenase	d0360205020	NN	I-NP	O
deficiency	deficiency	d01020520	NN	I-NP	O
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
folinic	folinic	f040502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
infusion	infusion	i510205	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
recently	recently	r0205340	RB	I-VP	O
become	become	b02050	VBN	I-VP	O
a	a	a000	DT	B-NP	O
popular	popular	p010406	JJ	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
cancers	cancer	c052062	NNS	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
oncologists	oncologist	o5204020232	NNS	B-NP	O
and	and	a530	CC	I-NP	O
neurologists	neurologist	n0604020232	NNS	I-NP	O
be	be	b000	VB	B-VP	O
fully	fully	f040	RB	B-ADJP	O
aware	aware	a060	JJ	I-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
oxcarbazepine	oxcarbazepine	o20610201050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neuroleptics	neuroleptic	n060401302	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
.	.	.000	.	O	O

Carbamazepine	Carbamazepine	c061050201050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
switched	switch	s03203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
its	its	i320	PRP$	B-NP	O
10	10	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
keto	keto	k030	NN	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
oxcarbazepine	oxcarbazepine	o20610201050	NN	I-NP	B-Chemical
among	among	a5052	IN	B-PP	O
six	six	s020	CD	B-NP	O
difficult	difficult	d0102043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
to	to	t000	TO	B-PP	O
-	-	-000	HYPH	B-NP	O
treat	treat	t603	NN	I-NP	O
schizophrenic	schizophrenic	s20201060502	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	O
organic	organic	o620502	JJ	I-NP	B-Disease
psychotic	psychotic	p2020302	JJ	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
concomitantly	concomitantly	c052050305340	RB	B-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
chlorpromazine	chlorpromazine	c0406160502050	NN	I-NP	B-Chemical
or	or	o600	CC	I-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
change	change	c0520	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
within	within	w0305	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
50	50	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
200	200	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
any	any	a500	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
deteriotation	deteriotation	d0306030305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
3	3	3000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
6	6	6000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
idea	idea	i300	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
oxcarbazepine	oxcarbazepine	o20610201050	NN	I-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
induce	induce	i53020	VB	I-VP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
microsomal	microsomal	m026020504	JJ	I-NP	O
enzyme	enzyme	e52050	NN	I-NP	O
systems	system	s023052	NNS	I-NP	O
regulating	regulate	r020403052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
inactivation	inactivation	i5023010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
antipsychotic	antipsychotic	a53012020302	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

Time	Time	t050	NN	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Reactive	Reactive	r023010	JJ	B-NP	O
oxygen	oxygen	o20205	NN	I-NP	B-Chemical
species	specie	s10202	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
puromycin	puromycin	p06050205	NN	I-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PAN	PAN	p050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
antioxidants	antioxidant	a5302030532	NNS	B-NP	O
significantly	significantly	s025010205340	RB	B-VP	O
reducing	reduce	r0302052	VBG	I-VP	O
the	the	t000	DT	B-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidney	kidney	k0350	NN	I-NP	O
and	and	a530	CC	I-NP	O
proteinuria	proteinuria	p60305060	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
.	.	.000	.	O	O

Rats	Rat	r032	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
IV	IV	i100	CD	I-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
(	(	(000	(	O	O
PAN	PAN	p050	NNP	B-NP	B-Chemical
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
24	24	0000	CD	B-NP	O
hour	hour	h060	NN	I-NP	O
urine	urine	u6050	NN	I-NP	O
samples	sample	s051402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-VP	O
sacrifice	sacrifice	s02601020	VB	I-VP	O
on	on	o500	IN	B-PP	O
days	day	d020	NNS	B-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	I-NP	O
7	7	7000	CD	I-NP	O
,	,	,000	,	I-NP	O
10	10	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
17	17	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
27	27	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
41	41	0000	CD	I-NP	O
(	(	(000	(	O	O
N	N	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
10	10	0000	CD	I-NP	O
per	per	p060	IN	B-PP	O
group	group	g601	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
removed	remove	r050103	VBN	I-VP	O
,	,	,000	,	O	O
flushed	flush	f40203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
ice	ice	i200	NN	B-NP	O
cold	cold	c043	JJ	I-NP	O
TRIS	TRIS	t602	NN	I-NP	O
buffer	buffer	b0106	NN	I-NP	O
.	.	.000	.	O	O

Kidney	Kidney	k0350	NN	B-NP	O
cortices	cortex	c0630202	NNS	I-NP	O
from	from	f605	IN	B-PP	O
each	each	e020	DT	B-NP	O
animal	animal	a50504	NN	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
prepare	prepare	p601060	VB	I-VP	O
homogenates	homogenate	h0502050302	NNS	B-NP	O
.	.	.000	.	O	O

Tissue	Tissue	t020	NN	B-NP	O
lipid	lipid	l0103	NN	I-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
whole	whole	w040	JJ	B-NP	O
homogenates	homogenate	h0502050302	NNS	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
in	in	i500	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
extracts	extract	e2360232	NNS	I-NP	O
from	from	f605	IN	B-PP	O
homogenates	homogenate	h0502050302	NNS	B-NP	O
as	as	a200	IN	B-PP	O
thiobarbituric	thiobarbituric	t01061030602	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
reactive	reactive	r023010	JJ	I-NP	O
substances	substance	s012305202	NNS	I-NP	O
.	.	.000	.	O	O

Proteinuria	Proteinuria	p60305060	NNP	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
evident	evident	e103053	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
5	5	5000	CD	I-NP	O
,	,	,000	,	O	O
peaked	peak	p0203	VBD	B-VP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
7	7	7000	CD	I-NP	O
and	and	a530	CC	O	O
persisted	persist	p06202303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
day	day	d000	NN	B-NP	O
27	27	0000	CD	I-NP	O
.	.	.000	.	O	O

Lipid	Lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
homogenates	homogenate	h0502050302	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
maximal	maximal	m020504	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
day	day	d000	NN	B-NP	O
3	3	3000	CD	I-NP	O
and	and	a530	CC	O	O
declined	decline	d0240503	VBD	B-VP	O
rapidly	rapidly	r010340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
control	control	c053604	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
day	day	d000	NN	B-NP	O
17	17	0000	CD	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
supports	support	s010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
lipid	lipid	l0103	NN	B-NP	O
peroxidation	peroxidation	p0602030305	NN	I-NP	O
in	in	i500	IN	B-PP	O
mediating	mediate	m0303052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
proteinuric	proteinuric	p603050602	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
PAN	PAN	p050	NN	B-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
.	.	.000	.	O	O

Composition	Composition	c051020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
gall	gall	g040	NN	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
:	:	:000	:	O	O
response	response	r0210520	NN	B-NP	O
to	to	t000	TO	B-PP	O
oral	oral	o604	JJ	B-NP	O
ursodeoxycholic	ursodeoxycholic	u620302020402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Octreotide	Octreotide	o23603030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
acromegaly	acromegaly	a260502040	RB	B-NP	B-Disease
,	,	,000	,	O	O
induces	induce	i530202	VBZ	B-VP	O
gall	gall	g040	NN	B-NP	B-Disease
bladder	bladder	b40306	NN	I-NP	I-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
13	13	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Because	Because	b02020	IN	B-SBAR	O
knowledge	knowledge	k5040320	NN	B-NP	O
of	of	o100	IN	B-PP	O
stone	stone	s3050	NN	B-NP	O
composition	composition	c051020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
essential	essential	e205304	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
studies	study	s30302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
,	,	,000	,	O	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
prevention	prevention	p60105305	NN	B-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
direct	direct	d06023	JJ	B-NP	O
and	and	a530	CC	I-NP	O
indirect	indirect	i5306023	JJ	I-NP	O
methods	method	m03032	NNS	I-NP	O
in	in	i500	IN	B-PP	O
14	14	0000	CD	B-NP	O
octreotide	octreotide	o23603030	NN	I-NP	B-Chemical
treated	treat	t60303	VBN	B-VP	O
acromegalic	acromegalic	a2605020402	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
gall	gall	g040	NN	B-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Chemical	Chemical	c050204	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
of	of	o100	IN	B-PP	O
gall	gall	g040	NN	B-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
retrieved	retrieve	r0360103	VBD	B-VP	O
at	at	a300	IN	B-PP	O
cholecystectomy	cholecystectomy	c0402023023050	NN	B-NP	O
from	from	f605	IN	B-PP	O
two	two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
they	they	t000	PRP	B-NP	O
contained	contain	c0530503	VBD	B-VP	O
71	71	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
87	87	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
weight	weight	w0203	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
12	12	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
localised	localised	l02040203	JJ	B-NP	O
computed	compute	c0510303	VBN	I-NP	O
tomography	tomography	t05026010	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
gall	gall	g040	NN	I-NP	O
bladder	bladder	b40306	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
eight	eight	e0203	CD	B-NP	O
had	have	h030	VBD	B-VP	O
stones	stone	s30502	NNS	B-NP	O
with	with	w030	IN	B-PP	O
maximum	maximum	m020505	JJ	B-NP	O
attenuation	attenuation	a3050305	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
<	<	<000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
Hounsfield	Hounsfield	h0521043	NNP	I-NP	O
units	unit	u5032	NNS	I-NP	O
(	(	(000	(	O	O
values	value	v0402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
<	<	<000	SYM	B-NP	O
100	100	0000	CD	I-NP	O
HU	HU	h000	NN	I-NP	O
predict	predict	p603023	VBP	B-VP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
rich	rich	r020	JJ	I-NP	O
,	,	,000	,	I-NP	O
dissolvable	dissolvable	d020410140	JJ	I-NP	O
stones	stone	s30502	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Gall	Gall	g040	NN	B-NP	O
bladder	bladder	b40306	NN	I-NP	O
bile	bile	b040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
obtained	obtain	o130503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
ultrasound	ultrasound	u43602053	JJ	B-NP	O
guided	guide	g0303	VBN	I-NP	O
,	,	,000	,	I-NP	O
fine	fine	f050	JJ	I-NP	O
needle	needle	n0340	NN	I-NP	O
puncture	puncture	p0523060	NN	I-NP	O
from	from	f605	IN	B-PP	O
six	six	s020	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
six	six	s020	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
supersaturated	supersaturate	s0106203060303	VBN	I-VP	O
bile	bile	b040	NN	B-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
(	(	(000	(	O	O
SEM	SEM	s050	NN	B-NP	O
)	)	)000	)	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
saturation	saturation	s03060305	NN	I-NP	O
index	index	i5302	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	I-NP	O
19	19	0000	CD	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
08	08	0000	CD	O	O
)	)	)000	)	O	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O
01	01	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
53	53	0000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
all	all	a400	DT	B-NP	O
had	have	h030	VBD	B-VP	O
abnormally	abnormally	a15065040	RB	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
cholesterol	cholesterol	c040230604	NN	I-NP	B-Chemical
microcrystal	microcrystal	m02602602304	NN	I-NP	O
nucleation	nucleation	n0240305	NN	I-NP	O
times	time	t0502	NNS	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	B-NP	O
4	4	4000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	B-NP	O
4	4	4000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
whilst	whilst	w0423	IN	B-ADVP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
bile	bile	b040	NN	I-NP	O
contained	contain	c0530503	VBD	B-VP	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
microcrystals	microcrystal	m026026023042	NNS	I-NP	O
immediately	immediately	i50303040	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
sampling	sample	s0514052	VBG	B-VP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
12	12	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
considered	consider	c052030603	VBN	B-VP	O
for	for	f060	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
ursodeoxycholic	ursodeoxycholic	u620302020402	JJ	I-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
(	(	(000	(	O	O
UDCA	UDCA	u320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
blocked	block	b40203	VBN	I-NP	O
cystic	cystic	c02302	JJ	I-NP	O
duct	duct	d023	NN	I-NP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
started	start	s306303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
UDCA	UDCA	u320	NN	B-NP	B-Chemical
while	while	w040	IN	B-SBAR	O
one	one	o500	CD	B-NP	O
was	be	w020	VBD	B-VP	O
lost	lose	l023	VBN	I-VP	O
to	to	t000	TO	I-VP	O
follow	follow	f040	VB	I-VP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
one	one	o500	CD	B-NP	O
year	year	y060	NN	I-NP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
five	five	f010	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
nine	nine	n050	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
either	either	e0306	CC	O	O
partial	partial	p06304	JJ	O	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
3	3	3000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
complete	complete	c0514030	JJ	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
gall	gall	g040	NN	B-NP	B-Disease
stone	stone	s3050	NN	I-NP	I-Disease
dissolution	dissolution	d02040305	NN	I-NP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
their	their	t060	PRP$	B-NP	O
stones	stone	s30502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
cholesterol	cholesterol	c040230604	NN	B-ADJP	B-Chemical
rich	rich	r020	JJ	I-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
corresponds	correspond	c060210532	VBZ	B-VP	O
,	,	,000	,	O	O
by	by	b000	IN	B-PP	O
actuarial	actuarial	a230604	JJ	B-ADJP	O
(	(	(000	(	O	O
life	life	l010	NN	B-NP	O
table	table	t0140	NN	I-NP	O
)	)	)000	)	O	O
analysis	analysis	a5040202	NN	B-NP	O
,	,	,000	,	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
combined	combined	c0510503	JJ	I-NP	O
gall	gall	g040	NN	I-NP	B-Disease
stone	stone	s3050	NN	I-NP	I-Disease
dissolution	dissolution	d02040305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
58	58	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
conclusion	conclusion	c05240205	NN	B-NP	O
,	,	,000	,	O	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
gall	gall	g040	NN	B-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
generally	generally	g0506040	RB	B-ADVP	O
small	small	s504	JJ	B-NP	O
,	,	,000	,	I-NP	O
multiple	multiple	m0430140	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
cholesterol	cholesterol	c040230604	NN	B-NP	B-Chemical
rich	rich	r020	JJ	B-ADJP	O
although	although	a43020	IN	B-SBAR	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
common	common	c0505	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
gall	gall	g040	NN	I-NP	B-Disease
stone	stone	s3050	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
some	some	s050	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
will	will	w040	MD	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
blocked	block	b40203	VBN	I-NP	O
cystic	cystic	c02302	JJ	I-NP	O
duct	duct	d023	NN	I-NP	O
and	and	a530	CC	O	O
some	some	s050	DT	B-NP	O
gall	gall	g040	JJ	I-NP	B-Disease
stones	stone	s30502	NNS	I-NP	I-Disease
containing	contain	c05305052	VBG	B-VP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Erythema	Erythema	e603050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	NN	I-NP	I-Disease
and	and	a530	CC	O	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
13	13	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
boy	boy	b000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
gentamicin	gentamicin	g053050205	NN	I-NP	B-Chemical
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
septicemia	septicemia	s01302050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Medications	Medication	m030203052	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
when	when	w050	WRB	B-ADVP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	JJ	I-NP	I-Disease
and	and	a530	CC	I-NP	O
congestive	congestive	c052023010	JJ	I-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
methylprednisolone	methylprednisolone	m0304160350204050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
gradually	gradually	g603040	RB	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
.	.	.000	.	O	O

Macrophage	Macrophage	m02601020	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
migration	migration	m0260305	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
(	(	(000	(	O	O
MIF	MIF	m010	NN	B-NP	O
)	)	)000	)	O	O
test	test	t023	NN	B-NP	O
with	with	w030	IN	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
After	After	a1306	IN	B-PP	O
most	most	m023	JJS	B-NP	O
infections	infection	i51023052	NNS	I-NP	B-Disease
causing	cause	c02052	VBG	B-VP	O
erythema	erythema	e603050	NN	B-NP	B-Disease
multiforme	multiforme	m043010650	JJ	I-NP	I-Disease
and	and	a530	CC	O	O
myocarditis	myocarditis	m020630302	NN	B-NP	B-Disease
were	be	w060	VBD	B-VP	O
ruled	rule	r0403	VBN	I-VP	O
out	out	o030	RP	B-PRT	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
drug	drug	d602	NN	I-NP	B-Disease
-	-	-000	HYPH	O	I-Disease
induced	induce	i530203	VBN	B-NP	I-Disease
allergic	allergic	a406202	JJ	I-NP	I-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
suspected	suspect	s02102303	VBN	I-VP	O
.	.	.000	.	O	O

Positive	Positive	p0203010	JJ	B-NP	O
MIF	MIF	m010	NN	I-NP	O
test	test	t023	NN	I-NP	O
for	for	f060	IN	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
sensitization	sensitization	s05203020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NN	I-NP	O
lymphocytes	lymphocyte	l051020302	NNS	I-NP	O
to	to	t000	TO	B-PP	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Hypersensitivity	Hypersensitivity	h010620520301030	NN	B-NP	B-Disease
myocarditis	myocarditis	m020630302	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
and	and	a530	CC	I-NP	O
dangerous	dangerous	d0520602	JJ	I-NP	O
manifestation	manifestation	m05010230305	NN	I-NP	O
of	of	o100	IN	B-PP	O
allergy	allergy	a40620	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
penicillins	penicillin	p050204052	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

Clomipramine	Clomipramine	c40501605050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
sleep	sleep	s401	NN	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
impair	impair	i5106	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
-	-	-000	HYPH	O	O
releasing	release	r0402052	VBG	B-VP	O
action	action	a2305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
undertaken	undertake	u530630205	VBN	I-VP	O
to	to	t000	TO	I-VP	O
examine	examine	e205050	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
sleep	sleep	s401	NN	B-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
,	,	,000	,	O	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
clomipramine	clomipramine	c40501605050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
secretory	secretory	s02603060	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
(	(	(000	(	O	O
PRL	PRL	p640	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
supine	supine	s01050	NN	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
under	under	u5306	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
controlled	control	c05360403	VBN	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
night	night	n0203	NN	I-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
sleeping	sleep	s401052	VBG	B-VP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
at	at	a300	IN	B-PP	O
daytime	daytime	d03050	NN	B-NP	O
,	,	,000	,	O	O
when	when	w050	WRB	B-ADVP	O
awake	awake	a020	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
6	6	6000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
subject	subject	s012023	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
clomipramine	clomipramine	c40501605050	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
orally	orally	o6040	RB	B-NP	O
2	2	2000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
before	before	b01060	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
collection	collection	c0402305	NN	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
PRL	PRL	p640	NN	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
analysed	analyse	a5040203	VBN	I-VP	O
at	at	a300	IN	B-PP	O
10	10	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
and	and	a530	CC	O	O
underlying	underlie	u53064052	VBG	B-VP	O
secretory	secretory	s02603060	JJ	B-NP	O
rates	rate	r0302	NNS	I-NP	O
calculated	calculate	c042040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
deconvolution	deconvolution	d02051040305	NN	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
both	both	b030	DT	B-NP	O
experiments	experiment	e2106050532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
intake	intake	i53020	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
,	,	,000	,	O	O
acting	act	a23052	VBG	B-VP	O
preferentially	preferentially	p60106053040	RB	B-ADVP	O
on	on	o500	IN	B-PP	O
tonic	tonic	t0502	JJ	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
as	as	a200	IN	B-PP	O
pulse	pulse	p0420	NN	B-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
and	and	a530	CC	O	O
frequency	frequency	f6020520	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
corresponding	correspond	c06021053052	VBG	B-VP	O
control	control	c053604	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
night	night	n0203	NN	I-NP	O
clomipramine	clomipramine	c40501605050	NN	I-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
altered	alter	a430603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
sleep	sleep	s401	NN	I-NP	O
architecture	architecture	a6203023060	NN	I-NP	O
in	in	i500	IN	B-PP	O
that	that	t030	IN	B-NP	O
it	it	i300	PRP	B-NP	O
suppressed	suppress	s0160203	VBD	B-VP	O
REM	REM	r050	NN	B-NP	O
sleep	sleep	s401	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
sleep	sleep	s401	JJ	I-NP	O
cycles	cycle	c02402	NNS	I-NP	O
and	and	a530	CC	O	O
induced	induce	i530203	VBD	B-VP	O
increased	increase	i5260203	VBN	B-NP	O
wakefulness	wakefulness	w020104502	NN	I-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
PRL	PRL	p640	NN	B-NP	O
secretion	secretion	s0260305	NN	I-NP	O
expressed	express	e2160203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
percentage	percentage	p062053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
night	night	n0203	NN	I-NP	O
and	and	a530	CC	I-NP	O
day	day	d000	NN	I-NP	O
time	time	t050	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
(	(	(000	(	O	O
46	46	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
vs	vs	v200	IN	B-PP	O
34	34	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
sleep	sleep	s401	NN	I-NP	B-Disease
disturbance	disturbance	d0230610520	NN	I-NP	I-Disease
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
interfere	interfere	i53061060	VB	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
action	action	a2305	NN	I-NP	O
per	per	p060	FW	B-ADVP	O
se	se	s000	FW	I-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
REM	REM	r050	NN	B-NP	O
sleep	sleep	s401	NN	I-NP	O
was	be	w020	VBD	B-VP	O
shown	show	s050	VBN	I-VP	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
determining	determine	d0306505052	VBG	I-NP	O
factor	factor	f02306	NN	I-NP	O
either	either	e0306	CC	B-PP	O
for	for	f060	IN	B-PP	O
secretory	secretory	s02603060	JJ	B-NP	O
pulse	pulse	p0420	NN	I-NP	O
amplitude	amplitude	a51403030	NN	I-NP	O
and	and	a530	CC	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
both	both	b030	DT	B-NP	O
,	,	,000	,	O	O
mean	mean	m050	JJ	B-NP	O
nocturnal	nocturnal	n02306504	JJ	I-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
and	and	a530	CC	O	O
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
clomipramine	clomipramine	c40501605050	NN	I-NP	B-Chemical
ingestion	ingestion	i5202305	NN	I-NP	O
.	.	.000	.	O	O

Survey	Survey	s0610	NN	B-NP	O
of	of	o100	IN	B-PP	O
complications	complication	c05140203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
indocyanine	indocyanine	i530205050	NN	B-NP	B-Chemical
green	green	g605	JJ	I-NP	I-Chemical
angiography	angiography	a52026010	NN	I-NP	O
in	in	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
safety	safety	s01030	NN	I-NP	O
of	of	o100	IN	B-PP	O
indocyanine	indocyanine	i530205050	NN	B-NP	B-Chemical
green	green	g605	NN	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
fundus	fundus	f05302	NN	B-NP	O
angiography	angiography	a52026010	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
sent	send	s053	VBD	B-VP	O
a	a	a000	DT	B-NP	O
questionnaire	questionnaire	q02305060	NN	I-NP	O
concerning	concern	c052065052	VBG	B-VP	O
complications	complication	c05140203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
indocyanine	indocyanine	i530205050	NN	B-NP	B-Chemical
green	green	g605	JJ	B-ADJP	I-Chemical
to	to	t000	TO	B-PP	O
32	32	0000	CD	B-NP	O
institutions	institution	i5230303052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
Japan	Japan	j0105	NNP	B-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
selected	select	s0402303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
client	client	c4053	NN	I-NP	O
list	list	l023	NN	I-NP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
Topcon	Topcon	t01205	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
manufactures	manufacture	m05010230602	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
indocyanine	indocyanine	i530205050	NN	I-NP	B-Chemical
green	green	g605	JJ	I-NP	I-Chemical
fundus	fundus	f05302	NN	I-NP	O
camera	camera	c05060	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Ophthalmologists	Ophthalmologist	o10304504020232	NNS	B-NP	O
at	at	a300	IN	B-PP	O
15	15	0000	CD	B-NP	O
institutions	institution	i5230303052	NNS	I-NP	O
responded	respond	r02105303	VBD	B-VP	O
,	,	,000	,	O	O
reporting	report	r01063052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
,	,	,000	,	O	O
774	774	0000	CD	B-NP	O
indocyanine	indocyanine	i530205050	NN	I-NP	B-Chemical
green	green	g605	JJ	I-NP	I-Chemical
angiograms	angiogram	a52026052	NNS	I-NP	O
performed	perform	p06106503	VBN	B-VP	O
on	on	o500	IN	B-PP	O
2	2	2000	CD	B-NP	O
,	,	,000	,	O	O
820	820	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
June	June	j050	NNP	B-NP	O
1984	1984	0000	CD	I-NP	O
and	and	a530	CC	O	O
September	September	s01305106	NNP	B-NP	O
1992	1992	0000	CD	I-NP	O
.	.	.000	.	O	O

Before	Before	b01060	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
,	,	,000	,	O	O
intradermal	intradermal	i5360306504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
indocyanine	indocyanine	i530205050	NN	I-NP	B-Chemical
green	green	g605	JJ	I-NP	I-Chemical
testing	testing	t023052	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
both	both	b030	DT	B-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
13	13	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
15	15	0000	CD	B-NP	O
institutions	institution	i5230303052	NNS	I-NP	O
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
decision	decision	d020205	NN	I-NP	O
was	be	w020	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
not	not	n030	RB	O	O
to	to	t000	TO	B-VP	O
proceed	proceed	p60203	VB	I-VP	O
with	with	w030	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
after	after	a1306	IN	B-PP	O
positive	positive	p0203010	JJ	B-NP	O
preangiographic	preangiographic	p60520260102	JJ	I-NP	O
testing	testing	t023052	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dosage	dosage	d02020	NN	I-NP	O
of	of	o100	IN	B-PP	O
indocyanine	indocyanine	i530205050	NN	B-NP	B-Chemical
green	green	g605	JJ	B-NP	I-Chemical
used	use	u203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
varied	vary	v0603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
25	25	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
75	75	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
depending	depend	d01053052	VBG	B-VP	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
institution	institution	i523030305	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
13	13	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
34	34	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
ten	ten	t050	CD	B-NP	O
of	of	o100	IN	B-PP	O
which	which	w020	WDT	B-NP	O
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
nausea	nausea	n020	NN	B-NP	B-Disease
,	,	,000	,	O	O
exanthema	exanthema	e2053050	NN	B-NP	B-Disease
,	,	,000	,	O	O
urtication	urtication	u63020305	NN	B-NP	B-Disease
,	,	,000	,	O	O
itchiness	itchiness	i320502	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
urgency	urgency	u620520	NN	B-NP	O
to	to	t000	TO	B-VP	O
defecate	defecate	d0102030	VB	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
.	.	.000	.	O	O

Also	Also	a420	RB	B-VP	O
recorded	record	r0206303	VBN	I-VP	O
were	be	w060	VBD	B-VP	O
one	one	o500	CD	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
vein	vein	v050	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
required	require	r020603	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
required	require	r020603	VBD	B-VP	O
treatment	treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
shock	shock	s020	NN	B-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
of	of	o100	IN	B-PP	O
frequency	frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-VP	O
indocyanine	indocyanine	i530205050	VB	I-VP	B-Chemical
green	green	g605	JJ	B-ADJP	I-Chemical
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
reported	report	r0106303	VBN	I-NP	O
frequency	frequency	f6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
such	such	s020	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
fluorescein	fluorescein	f4060205	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
indicated	indicate	i53020303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
indocyanine	indocyanine	i530205050	NN	B-NP	B-Chemical
green	green	g605	NN	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
safe	safe	s010	NN	I-NP	O
as	as	a200	IN	B-PP	O
fluorescein	fluorescein	f4060205	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
use	use	u200	NN	B-NP	O
in	in	i500	IN	B-PP	O
angiography	angiography	a52026010	NN	B-NP	O
.	.	.000	.	O	O

Angioedema	Angioedema	a5203050	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
metoprolol	metoprolol	m030160404	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
72	72	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
with	with	w030	IN	B-PP	O
"	"	"000	``	O	O
flash	flash	f4020	NN	B-NP	O
"	"	"000	''	O	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
,	,	,000	,	O	O
preceded	precede	p6020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
chest	chest	c023	NN	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
,	,	,000	,	O	O
requiring	require	r0206052	VBG	B-VP	O
intubation	intubation	i53010305	NN	B-NP	O
.	.	.000	.	O	O

Her	Her	h060	PRP$	B-NP	O
medical	medical	m030204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
coronary	coronary	c0605060	JJ	B-NP	B-Disease
artery	artery	a63060	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
previous	previous	p60102	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
mellitus	mellitus	m040302	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
angioedema	angioedema	a5203050	NN	B-NP	B-Disease
secondary	secondary	s02053060	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lisinopril	lisinopril	l020501604	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
elicited	elicit	e4020303	VBN	I-VP	O
.	.	.000	.	O	O

Current	Current	c06053	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
include	include	i524030	VB	I-VP	O
angiotensin	angiotensin	a520305205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
or	or	o600	CC	O	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	B-VP	O
blockers	blocker	b402062	NNS	B-NP	O
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
blocking	block	b402052	VBG	B-VP	O
drug	drug	d602	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
day	day	d000	NN	I-NP	O
of	of	o100	IN	B-PP	O
hospitalization	hospitalization	h0210304020305	NN	B-NP	O
(	(	(000	(	O	O
while	while	w040	IN	B-SBAR	O
intubated	intubate	i53010303	VBN	B-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
intravenous	intravenous	i536010502	JJ	B-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
,	,	,000	,	O	O
resulting	result	r02043052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
angioedema	angioedema	a5203050	NN	I-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
after	after	a1306	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
and	and	a530	CC	O	O
diphenhydramine	diphenhydramine	d010503605050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	O
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
developing	develop	d010401052	VBG	I-NP	O
chick	chick	c020	NN	I-NP	O
embryo	embryo	e5160	NN	I-NP	O
.	.	.000	.	O	O

Coniine	Coniine	c05050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
alkaloid	alkaloid	a420403	NN	I-NP	O
from	from	f605	IN	B-PP	O
Conium	Conium	c0505	NN	B-NP	O
maculatum	maculatum	m02040305	NN	I-NP	O
(	(	(000	(	O	O
poison	poison	p0205	NN	B-NP	O
hemlock	hemlock	h05402	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
teratogenic	teratogenic	t0603020502	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
livestock	livestock	l0102302	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
teratogenic	teratogenic	t0603020502	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
arthrogryposis	arthrogryposis	a6306026010202	NN	B-NP	B-Disease
,	,	,000	,	O	O
presumably	presumably	p602050140	RB	B-ADJP	O
due	due	d000	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
failed	fail	f0403	VBN	I-VP	O
to	to	t000	TO	I-VP	O
produce	produce	p603020	VB	I-VP	O
arthrogryposis	arthrogryposis	a6306026010202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
or	or	o600	CC	I-NP	O
mice	mouse	m020	NNS	I-NP	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
only	only	o540	RB	B-ADJP	O
weakly	weakly	w0240	RB	I-ADJP	O
teratogenic	teratogenic	t0603020502	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
rabbits	rabbit	r01032	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
and	and	a530	CC	I-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
developing	develop	d010401052	VBG	I-NP	O
chick	chick	c020	NN	I-NP	O
.	.	.000	.	O	O

Concentrations	Concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
015	015	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
075	075	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
3	3	3000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
1	1	1000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
deformations	deformation	d0106503052	NNS	B-NP	B-Disease
and	and	a530	CC	O	O
lethality	lethality	l0304030	NN	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
caused	cause	c0203	VBD	B-VP	O
some	some	s050	DT	B-NP	O
lethality	lethality	l0304030	NN	I-NP	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
no	no	n000	DT	I-NP	O
effect	effect	e1023	NN	I-NP	O
level	level	l0104	NN	I-NP	O
for	for	f060	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
lethality	lethality	l0304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
deformations	deformation	d0106503052	NNS	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
excessive	excessive	e202010	JJ	B-NP	B-Disease
flexion	flexion	f40205	NN	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
extension	extension	e2305205	NN	I-NP	I-Disease
of	of	o100	IN	B-PP	I-Disease
one	one	o500	CD	B-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
more	more	m060	JJR	I-NP	I-Disease
toes	toe	t020	NNS	I-NP	I-Disease
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
histopathological	histopathological	h023010304020204	JJ	I-NP	O
alterations	alteration	a430603052	NNS	I-NP	O
or	or	o600	CC	I-NP	O
differences	difference	d010605202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
bone	bone	b050	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
limbs	limb	l0512	NNS	I-NP	O
or	or	o600	CC	I-NP	O
toes	toe	t020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
chicks	chick	c020	NNS	I-NP	O
from	from	f605	IN	B-PP	O
any	any	a500	DT	B-NP	O
group	group	g601	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
extensive	extensive	e23052010	JJ	B-NP	O
cranial	cranial	c60504	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
chicks	chick	c020	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
movement	movement	m0105053	NN	B-NP	O
in	in	i500	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
treated	treat	t60303	VBN	B-VP	O
chicks	chick	c020	NNS	B-NP	O
as	as	a200	IN	B-SBAR	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ultrasound	ultrasound	u43602053	NN	B-NP	O
.	.	.000	.	O	O

Control	Control	c053604	NN	B-NP	O
chicks	chick	c020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
motion	motion	m0305	NN	B-NP	O
an	an	a500	DT	B-NP	O
average	average	a106020	NN	I-NP	O
of	of	o100	IN	B-PP	O
33	33	0000	CD	B-NP	O
.	.	.000	.	O	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
chicks	chick	c020	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
only	only	o540	RB	I-VP	O
moving	move	m01052	VBG	I-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
min	min	m050	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
movement	movement	m0105053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
for	for	f060	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
sulfate	sulfate	s041030	NN	I-NP	O
treated	treat	t60303	VBN	B-NP	O
chicks	chick	c020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
summary	summary	s05060	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
chick	chick	c020	NN	I-NP	O
embryo	embryo	e5160	NN	I-NP	O
provides	provide	p6010302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
reliable	reliable	r040140	JJ	I-NP	O
and	and	a530	CC	I-NP	O
simple	simple	s05140	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
animal	animal	a50504	NN	I-NP	O
model	model	m0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
coniine	coniine	c05050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
arthrogryposis	arthrogryposis	a6306026010202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Data	Datum	d030	NNS	B-NP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
support	support	s01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
involving	involve	i51041052	VBG	B-VP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
with	with	w030	IN	B-PP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
decreased	decrease	d0260203	VBN	I-NP	O
fetal	fetal	f0304	JJ	I-NP	O
movement	movement	m0105053	NN	I-NP	O
.	.	.000	.	O	O

Immediate	Immediate	i503030	JJ	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
amoxicillin	amoxicillin	a502020405	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
detailed	detailed	d030403	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
history	history	h023060	NN	I-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
skin	skin	s205	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
RAST	RAST	r023	NN	B-NP	O
(	(	(000	(	O	O
radioallergosorbent	radioallergosorbent	r030406202061053	JJ	B-NP	O
test	test	t023	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
controlled	control	c05360403	VBN	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
establish	establish	e23014020	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
patients	patient	p030532	NNS	B-NP	O
allergic	allergic	a406202	JJ	B-ADJP	B-Disease
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
selective	selective	s04023010	JJ	B-NP	O
immediate	immediate	i503030	JJ	I-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
amoxicillin	amoxicillin	a502020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AX	AX	a200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
were	be	w060	VBD	B-VP	O
cross	cross	c602	AFX	B-ADJP	O
-	-	-000	HYPH	O	O
reacting	react	r023052	VBG	B-VP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
penicillin	penicillin	p05020405	NN	I-NP	B-Chemical
derivatives	derivative	d0601030102	NNS	I-NP	O
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
benzylpenicilloyl	benzylpenicilloyl	b05204105020404	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
poly	poly	p040	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
L	L	l000	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
lysine	lysine	l02050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
BPO	BPO	b100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
PLL	PLL	p400	NN	I-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
benzylpenicilloate	benzylpenicilloate	b052041050204030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
benzylpenicillin	benzylpenicillin	b05204105020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
PG	PG	p200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
ampicillin	ampicillin	a51020405	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AMP	AMP	a510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
AX	AX	a200	NNP	B-NP	B-Chemical
.	.	.000	.	O	O

RAST	RAST	r023	NN	B-NP	O
for	for	f060	IN	B-PP	O
BPO	BPO	b100	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
PLL	PLL	p400	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
AX	AX	a200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
PLL	PLL	p400	NN	I-NP	O
was	be	w020	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
both	both	b030	CC	O	O
skin	skin	s205	NN	B-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
RAST	RAST	r023	NN	B-NP	O
for	for	f060	IN	B-PP	O
BPO	BPO	b100	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
negative	negative	n0203010	JJ	B-NP	O
,	,	,000	,	I-NP	O
single	single	s05240	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
challenge	challenge	c040520	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
to	to	t000	TO	B-VP	O
ensure	ensure	e52060	VB	I-VP	O
tolerance	tolerance	t04060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
sensitivity	sensitivity	s0520301030	NN	I-NP	O
to	to	t000	TO	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
177	177	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
diagnosed	diagnose	d0250203	VBN	I-VP	O
as	as	a200	IN	B-PP	O
allergic	allergic	a406202	JJ	B-ADJP	B-Disease
to	to	t000	TO	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
selected	select	s0402303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
54	54	0000	CD	I-NP	O
(	(	(000	(	O	O
30	30	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
AX	AX	a200	NN	I-NP	B-Chemical
allergy	allergy	a40620	NN	I-NP	B-Disease
with	with	w030	IN	B-PP	O
good	good	g030	JJ	B-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Anaphylaxis	Anaphylaxis	a501040202	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
37	37	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
69	69	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
17	17	0000	CD	I-NP	O
(	(	(000	(	O	O
31	31	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
having	have	h01052	VBG	B-VP	O
urticaria	urticaria	u6302060	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
angioedema	angioedema	a5203050	NN	B-NP	B-Disease
.	.	.000	.	O	O

All	All	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
skin	skin	s205	NN	B-NP	O
test	test	t023	NN	I-NP	O
negative	negative	n0203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
BPO	BPO	b100	NN	B-NP	B-Chemical
;	;	;000	:	O	O
49	49	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
51	51	0000	CD	B-NP	O
(	(	(000	(	O	O
96	96	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
negative	negative	n0203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
MDM	MDM	m350	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
44	44	0000	CD	B-NP	O
of	of	o100	IN	B-PP	O
46	46	0000	CD	B-NP	O
(	(	(000	(	O	O
96	96	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Skin	Skin	s205	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
34	34	0000	CD	B-NP	O
(	(	(000	(	O	O
63	63	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

RAST	RAST	r023	NN	B-NP	O
was	be	w020	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
22	22	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
41	41	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-PP	O
BPO	BPO	b100	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
just	just	j023	RB	B-NP	O
5	5	5000	CD	I-NP	O
(	(	(000	NN	I-NP	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sera	serum	s060	NNS	I-NP	O
with	with	w030	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
RAST	RAST	r023	NN	I-NP	O
for	for	f060	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
positive	positive	p0203010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
BPO	BPO	b100	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Challenge	Challenge	c040520	NN	B-NP	O
tests	test	t0232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
23	23	0000	CD	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
(	(	(000	(	O	O
43	43	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
establish	establish	e23014020	VB	I-VP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
immediate	immediate	i503030	JJ	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
to	to	t000	TO	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
15	15	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
(	(	(000	(	O	O
28	28	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
both	both	b030	CC	O	O
skin	skin	s205	NN	B-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
RAST	RAST	r023	NN	B-NP	O
for	for	f060	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
negative	negative	n0203010	JJ	B-ADJP	O
.	.	.000	.	O	O

PG	PG	p200	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
all	all	a400	DT	B-NP	O
54	54	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
the	the	t000	DT	B-NP	O
largest	large	l062023	JJS	I-NP	O
group	group	g601	NN	I-NP	O
of	of	o100	IN	B-PP	O
AX	AX	a200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
PG	PG	p200	NN	B-NP	B-Chemical
reported	report	r0106303	VBN	B-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
.	.	.000	.	O	O

Diagnosis	Diagnosis	d0250202	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
achieved	achieve	a20103	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
if	if	i100	IN	B-SBAR	O
specific	specific	s1020102	JJ	B-NP	O
AX	AX	a200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
reagents	reagent	r020532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
employed	employ	e51403	VBN	I-VP	O
.	.	.000	.	O	O

Further	Further	f06306	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
necessary	necessary	n0202060	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
exact	exact	e2023	JJ	I-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
problem	problem	p601405	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
of	of	o100	IN	B-PP	O
diagnostic	diagnostic	d02502302	JJ	B-NP	O
methods	method	m03032	NNS	I-NP	O
.	.	.000	.	O	O

Reversal	Reversal	r0106204	NN	B-NP	O
by	by	b000	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
beneficial	beneficial	b05010204	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nitroglycerin	Nitroglycerin	n036024020605	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
reduce	reduce	r03020	VB	I-VP	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevation	elevation	e4010305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
potentiated	potentiate	p030530303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dog	dog	d020	NN	I-NP	O
by	by	b000	IN	B-PP	O
agents	agent	a20532	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
reverse	reverse	r010620	VBP	B-VP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
combined	combine	c0510503	VBN	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
phenylephrine	phenylephrine	p05040106050	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Ten	Ten	t050	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
transmural	transmural	t605250604	JJ	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarctions	infarction	i510623052	NNS	I-NP	I-Disease
received	receive	r020103	VBD	B-VP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
,	,	,000	,	O	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
reduce	reduce	r03020	VB	I-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
from	from	f605	IN	B-PP	O
107	107	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
6	6	6000	CD	B-NP	O
to	to	t000	TO	I-NP	O
85	85	0000	CD	I-NP	O
+	+	+000	SYM	I-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
60	60	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
.	.	.000	.	O	O

Left	Leave	l013	VBN	B-NP	O
ventricular	ventricular	v0536020406	JJ	I-NP	O
filling	filling	f04052	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
from	from	f605	IN	B-PP	O
19	19	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
11	11	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

SigmaST	SigmaST	s025023	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
sum	sum	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
ST	ST	s300	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
segment	segment	s025053	NN	I-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
precordial	precordial	p60206304	JJ	I-NP	O
leads	lead	l032	NNS	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBD	B-VP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
nitroglycerin	nitroglycerin	n036024020605	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Subsequent	Subsequent	s01202053	JJ	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
,	,	,000	,	O	O
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
re	re	r000	VB	I-VP	O
-	-	-000	HYPH	O	O
elevate	elevate	e401030	VB	B-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
to	to	t000	TO	B-PP	O
106	106	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
4	4	4000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
30	30	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
,	,	,000	,	O	O
increased	increase	i5260203	VBN	B-VP	O
left	leave	l013	VBD	B-VP	O
ventricular	ventricular	v0536020406	JJ	B-NP	O
filling	filling	f04052	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
to	to	t000	TO	B-PP	O
17	17	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
increased	increase	i5260203	VBN	B-NP	O
sigmaST	sigmaST	s025023	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
addition	addition	a30305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
nitroglycerin	nitroglycerin	n036024020605	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
beneficial	beneficial	b05010204	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	B-Disease
myocardial	myocardial	m0206304	JJ	I-NP	I-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Acetazolamide	Acetazolamide	a203020405030	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	I-NP	B-Disease
:	:	:000	:	O	O
implications	implication	i5140203052	NNS	B-NP	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
neuromuscular	neuromuscular	n0605020406	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Carbonic	Carbonic	c0610502	JJ	B-NP	O
anhydrase	anhydrase	a5036020	NN	I-NP	O
inhibitors	inhibitor	i50103062	NNS	I-NP	O
can	can	c050	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
nephrolithiasis	nephrolithiasis	n010604030202	NN	B-NP	B-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
carbonic	carbonic	c0610502	JJ	I-NP	O
anhydrase	anhydrase	a5036020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
periodic	periodic	p060302	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
myotonia	myotonia	m03050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
on	on	o500	IN	B-PP	O
acetazolamide	acetazolamide	a203020405030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
renal	renal	r0504	JJ	B-NP	B-Disease
calculi	calculus	c042040	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Extracorporeal	Extracorporeal	e236020610604	JJ	B-NP	O
lithotripsy	lithotripsy	l030360120	NN	I-NP	O
successfully	successfully	s02021040	RB	B-VP	O
removed	remove	r050103	VBD	I-VP	O
a	a	a000	DT	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
calculus	calculus	c0420402	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
and	and	a530	CC	O	O
surgery	surgery	s062060	NN	B-NP	O
removed	remove	r050103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
staghorn	staghorn	s302065	JJ	I-NP	O
calculus	calculus	c0420402	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
another	another	a50306	DT	B-NP	O
,	,	,000	,	O	O
permitting	permit	p06503052	VBG	B-VP	O
continued	continued	c0530503	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Renal	Renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Nephrolithiasis	Nephrolithiasis	n010604030202	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetazolamide	acetazolamide	a203020405030	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
preclude	preclude	p6024030	VB	I-VP	O
its	its	i320	PRP$	B-NP	O
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
on	on	o500	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
tested	test	t02303	VBN	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
(	(	(000	(	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
)	)	)000	)	O	O
6	6	6000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
two	two	t000	CD	B-NP	O
different	different	d0106053	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
e	e	e000	NN	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	NN	I-NP	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
an	an	a500	DT	B-NP	O
equal	equal	e204	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
saline	saline	s04050	NN	B-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
20	20	0000	CD	B-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
15	15	0000	CD	B-NP	O
minutes	minute	m050302	NNS	I-NP	O
later	later	l0306	RB	B-ADVP	O
,	,	,000	,	O	O
all	all	a400	PDT	B-NP	O
the	the	t000	DT	I-NP	O
animals	animal	a505042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	SYM	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
convulsant	convulsant	c051042053	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-PP	O
convulse	convulse	c0510420	NN	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
mortality	mortality	m06304030	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
each	each	e020	DT	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
local	local	l0204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
mortality	mortality	m06304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
different	different	d0106053	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
convulsant	convulsant	c051042053	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
modified	modify	m030103	VBN	I-VP	O
but	but	b030	CC	O	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
latency	latency	l030520	NN	B-NP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
convulsions	convulsion	c051042052	NNS	I-NP	B-Disease
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
less	less	l020	RBR	B-ADJP	O
pronounced	pronounced	p60505203	JJ	I-ADJP	O
with	with	w030	IN	B-PP	O
bepridil	bepridil	b0160304	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Epidural	Epidural	e1030604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
during	during	d06052	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E1	E1	0000	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
trimethaphan	trimethaphan	t605030105	NN	I-NP	B-Chemical
induced	induce	i530203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E1	E1	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
or	or	o600	CC	O	O
trimethaphan	trimethaphan	t605030105	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TMP	TMP	t510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
induced	induce	i530203	VBD	B-VP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
on	on	o500	IN	B-PP	O
epidural	epidural	e1030604	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
flow	flow	f400	NN	I-NP	O
(	(	(000	(	O	O
EBF	EBF	e100	NN	B-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
,	,	,000	,	O	O
EBF	EBF	e100	NN	B-NP	O
was	be	w020	VBD	B-VP	O
measured	measure	m020603	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
heat	heat	h030	NN	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
method	method	m0303	NN	I-NP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
postero	postero	p023060	AFX	B-ADVP	O
-	-	-000	HYPH	B-NP	O
lateral	lateral	l030604	JJ	I-NP	O
interbody	interbody	i53061030	NN	I-NP	O
fusion	fusion	f0205	NN	I-NP	O
under	under	u5306	IN	B-PP	O
isoflurane	isoflurane	i201406050	NN	B-NP	B-Chemical
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
initial	initial	i50304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
microgram	microgram	m02602605	NN	I-NP	O
.	.	.000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
or	or	o600	CC	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
(	(	(000	(	O	O
15	15	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
intravenously	intravenously	i53601050240	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
dural	dural	d0604	JJ	I-NP	O
opening	opening	o105052	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
adjusted	adjust	a3202303	VBN	I-VP	O
to	to	t000	TO	B-VP	O
maintain	maintain	m05305	VB	I-VP	O
the	the	t000	DT	B-NP	O
mean	mean	m050	JJ	I-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
MAP	MAP	m010	NN	B-NP	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
about	about	a103	RB	B-NP	O
60	60	0000	CD	I-NP	O
mmHg	mmHg	m502	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
drug	drug	d602	NN	I-NP	O
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
completion	completion	c05140305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
operative	operative	o10603010	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
starting	start	s3063052	VBG	B-VP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
TMP	TMP	t510	NN	I-NP	B-Chemical
,	,	,000	,	I-NP	O
MAP	MAP	m010	NN	I-NP	O
and	and	a530	CC	I-NP	O
rate	rate	r030	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
product	product	p603023	NN	I-NP	O
(	(	(000	(	O	O
RPP	RPP	r100	NN	B-NP	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
preinfusion	preinfusion	p60510205	NN	B-NP	O
values	value	v0402	NNS	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
remained	remain	r050503	VBD	B-VP	O
constant	constant	c0523053	JJ	B-ADJP	O
until	until	u5304	IN	B-SBAR	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
discontinuation	discontinuation	d02053050305	NN	I-NP	O
.	.	.000	.	O	O

Heart	Heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
HR	HR	h600	NN	B-NP	O
)	)	)000	)	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
in	in	i500	IN	B-PP	O
either	either	e0306	DT	B-NP	O
group	group	g601	NN	I-NP	O
.	.	.000	.	O	O

EBFF	EBFF	e100	NN	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
change	change	c0520	VB	I-VP	O
during	during	d06052	IN	B-PP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
whereas	whereas	w0602	IN	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
TMP	TMP	t510	NN	I-NP	B-Chemical
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
EBF	EBF	e100	NN	B-NP	O
decreased	decrease	d0260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
at	at	a300	IN	B-PP	O
30	30	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
60	60	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
(	(	(000	(	O	O
preinfusion	preinfusion	p60510205	NN	B-NP	O
:	:	:000	:	O	O
45	45	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
13	13	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100g	100g	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O
30	30	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
:	:	:000	:	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	O	O
3	3	3000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
:	:	:000	:	O	O
30	30	0000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-ADVP	O
-	-	-000	SYM	B-NP	O
7	7	7000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
ml	ml	m400	NN	I-NP	O
/	/	/000	SYM	B-NP	O
100	100	0000	CD	B-NP	O
g	g	g000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
min	min	m050	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
preferable	preferable	p601060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
TMP	TMP	t510	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
hypotensive	hypotensive	h0103052010	JJ	B-NP	B-Disease
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
in	in	i500	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
because	because	b02020	IN	B-SBAR	O
TMP	TMP	t510	NN	B-NP	B-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
EBF	EBF	e100	NN	B-NP	O
.	.	.000	.	O	O

Dup	Dup	d010	IN	B-PP	B-Chemical
753	753	0000	CD	B-NP	I-Chemical
prevents	prevent	p6010532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
appearance	appearance	a1060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
nephrotic	nephrotic	n01060302	JJ	B-NP	B-Disease
syndromes	syndrome	s05360502	NNS	I-NP	I-Disease
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
proteinuria	proteinuria	p60305060	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypoalbuminemia	hypoalbuminemia	h010410505050	NN	B-NP	B-Disease
,	,	,000	,	O	O
hypercholesterolemia	hypercholesterolemia	h01062040230604050	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
blood	blood	b403	NN	B-NP	B-Chemical
nitrogen	nitrogen	n0360205	NN	I-NP	I-Chemical
urea	urea	u600	NN	I-NP	I-Chemical
,	,	,000	,	O	O
induced	induce	i530203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
by	by	b000	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
oral	oral	o604	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
Dup	Dup	d010	NN	B-NP	B-Chemical
753	753	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
losartan	losartan	l0206305	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
novel	novel	n0104	JJ	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
II	II	i000	CD	I-NP	I-Chemical
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
,	,	,000	,	O	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
per	per	p060	IN	B-PP	O
day	day	d000	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
a	a	a000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
involvement	involvement	i5104105053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
renin	renin	r0505	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
angiotensin	angiotensin	a520305205	NN	I-NP	B-Chemical
system	system	s02305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
puromycin	puromycin	p06050205	NN	B-NP	B-Chemical
aminonucleoside	aminonucleoside	a5050502402030	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
nephrosis	nephrosis	n01060202	NN	I-NP	B-Disease
.	.	.000	.	O	O

Neuroplasticity	Neuroplasticity	n0601402302030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
adult	adult	a3043	JJ	I-NP	O
primate	primate	p605030	JJ	I-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
cochlear	cochlear	c020406	JJ	B-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Tonotopic	Tonotopic	t05030102	JJ	B-NP	O
organization	organization	o6205020305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
essential	essential	e205304	JJ	I-NP	O
feature	feature	f03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
primary	primary	p605060	JJ	I-NP	O
auditory	auditory	a0303060	JJ	I-NP	O
area	area	a600	NN	I-NP	O
(	(	(000	(	O	O
A1	A1	0000	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
primate	primate	p605030	JJ	B-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
A1	A1	0000	NN	B-NP	O
of	of	o100	IN	B-PP	O
macaque	macaque	m02020	NN	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
,	,	,000	,	O	O
low	low	l000	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
represented	represent	r0160205303	VBN	I-VP	O
rostrolaterally	rostrolaterally	r0236040306040	RB	B-ADVP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
represented	represent	r0160205303	VBN	I-VP	O
caudomedially	caudomedially	c030503040	RB	B-ADVP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
purpose	purpose	p061020	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
changes	change	c05202	NNS	B-NP	O
occur	occur	o206	VBP	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
tonotopic	tonotopic	t05030102	JJ	I-NP	O
organization	organization	o6205020305	NN	I-NP	O
following	follow	f04052	VBG	B-PP	O
cochlear	cochlear	c020406	JJ	B-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Under	Under	u5306	IN	B-PP	O
anesthesia	anesthesia	a5023020	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
superior	superior	s010606	JJ	I-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
gyrus	gyrus	g0602	NN	I-NP	O
of	of	o100	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
macaque	macaque	m02020	NN	I-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
exposed	expose	e210203	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
tonotopic	tonotopic	t05030102	JJ	I-NP	O
organization	organization	o6205020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
A1	A1	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
mapped	map	m0103	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
conventional	conventional	c0510530504	JJ	B-NP	O
microelectrode	microelectrode	m026040236030	NN	I-NP	O
recording	recording	r02063052	NN	I-NP	O
techniques	technique	t02050202	NNS	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
monkeys	monkey	m05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
selectively	selectively	s0402301040	RB	I-VP	O
deafened	deafen	d010503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
high	high	h020	JJ	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
using	use	u2052	VBG	B-VP	O
kanamycin	kanamycin	k05050205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
furosemide	furosemide	f060205030	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
actual	actual	a2304	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
deafened	deafen	d010503	VBN	B-VP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
loss	loss	l020	NN	I-NP	O
of	of	o100	IN	B-PP	O
tone	tone	t050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
burst	burst	b0623	NN	I-NP	O
elicited	elicit	e4020303	VBD	B-VP	O
auditory	auditory	a0303060	JJ	B-NP	O
brainstem	brainstem	b6052305	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
deafening	deafening	d0105052	NN	B-NP	O
,	,	,000	,	O	O
A1	A1	0000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
remapped	remappe	r050103	VBN	I-VP	O
.	.	.000	.	O	O

Postmortem	Postmortem	p023506305	JJ	B-NP	O
cytoarchitectural	cytoarchitectural	c03062030230604	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
identifying	identify	i305301052	VBG	B-VP	O
A1	A1	0000	NN	B-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
electrophysiologic	electrophysiologic	e402360102040202	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
deprived	deprive	d0160103	VBN	I-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
A1	A1	0000	NN	B-NP	O
undergoes	undergo	u5306202	VBZ	B-VP	O
extensive	extensive	e23052010	JJ	B-NP	O
reorganization	reorganization	r06205020305	NN	I-NP	O
and	and	a530	CC	O	O
becomes	become	b020502	VBZ	B-VP	O
responsive	responsive	r021052010	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
intact	intact	i53023	JJ	B-NP	O
cochlear	cochlear	c020406	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
region	region	r0205	NN	I-NP	O
of	of	o100	IN	B-PP	O
cortex	cortex	c06302	NN	B-NP	O
that	that	t030	WDT	B-NP	O
represents	represent	r016020532	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
obviously	obviously	o10240	RB	I-VP	O
affected	affect	a102303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
cochlear	cochlear	c020406	JJ	I-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Sodium	Sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
alleviates	alleviate	a4010302	VBZ	B-VP	O
penile	penile	p05040	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
intracavernous	intracavernous	i536020106502	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
attempt	attempt	a30513	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
penile	penile	p05040	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
intracorporeal	intracorporeal	i536020610604	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
could	could	c043	MD	B-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
acidity	acidity	a203030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
study	study	s3030	NN	I-NP	O
comparing	compare	c05106052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
penile	penile	p05040	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
intracorporeal	intracorporeal	i536020610604	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
or	or	o600	CC	B-PP	O
without	without	w0303	IN	B-PP	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
intracorporeal	intracorporeal	i536020610604	JJ	I-NP	O
medications	medication	m030203052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
total	total	t0304	NN	I-NP	O
of	of	o100	IN	B-PP	O
38	38	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
presented	present	p60205303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
clinic	clinic	c40502	NN	I-NP	O
with	with	w030	IN	B-PP	O
impotence	impotence	i51030520	NN	B-NP	B-Disease
received	receive	r020103	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	O
drugs	drug	d602	NNS	I-NP	O
:	:	:000	:	O	O
6	6	6000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	I-NP	O
papaverine	papaverine	p010106050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
100	100	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O
phentolamine	phentolamine	p0530405050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
10	10	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O
prostaglandin	prostaglandin	p602302405305	NN	B-NP	B-Chemical
E1	E1	0000	NN	I-NP	I-Chemical
with	with	w030	IN	B-PP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
7	7	7000	CD	I-NP	O
.	.	.000	.	O	O
05	05	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
without	without	w0303	IN	B-PP	O
(	(	(000	(	O	O
pH	pH	p000	NN	B-NP	O
4	4	4000	CD	I-NP	O
.	.	.000	.	O	O
17	17	0000	CD	O	O
)	)	)000	)	O	O
the	the	t000	DT	B-NP	O
addition	addition	a30305	NN	I-NP	O
of	of	o100	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
19	19	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
added	add	a303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
11	11	0000	CD	I-NP	O
(	(	(000	(	O	O
58	58	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
penile	penile	p05040	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
due	due	d000	JJ	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
only	only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
19	19	0000	CD	I-NP	O
men	man	m050	NNS	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
bicarbonate	bicarbonate	b0206105030	NN	I-NP	I-Chemical
complained	complain	c05140503	VBN	B-VP	O
of	of	o100	IN	B-PP	O
penile	penile	p05040	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
we	we	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
penile	penile	p05040	JJ	I-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
intracorporeal	intracorporeal	i536020610604	JJ	B-NP	O
injections	injection	i52023052	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
due	due	d000	IN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
acidity	acidity	a203030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
overcome	overcome	o1062050	VBN	I-VP	O
by	by	b000	IN	B-PP	O
elevating	elevate	e40103052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
pH	pH	p000	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
neutral	neutral	n03604	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
didanosine	didanosine	d030502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ddI	ddI	d300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
HIV	HIV	h010	NN	B-NP	B-Disease
antibody	antibody	a5301030	NN	I-NP	I-Disease
-	-	-000	HYPH	B-NP	I-Disease
positive	positive	p0203010	JJ	I-NP	I-Disease
individuals	individual	i530103042	NNS	I-NP	O
intolerant	intolerant	i530406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O

One	One	o500	CD	B-NP	O
hundred	hundred	h053603	CD	I-NP	O
and	and	a530	CC	I-NP	O
fifty	fifty	f0130	CD	I-NP	O
-	-	-000	HYPH	O	O
one	one	o500	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
intolerant	intolerant	i530406053	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
zidovudine	zidovudine	z030103050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
AZT	AZT	a230	NN	B-NP	B-Chemical
)	)	)000	)	O	O
received	receive	r020103	VBD	B-VP	O
didanosine	didanosine	d030502050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
ddI	ddI	d300	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
.	.	.000	.	O	O

Patient	Patient	p03053	NN	B-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
subset	subset	s01203	NN	I-NP	O
count	count	c053	NN	I-NP	O
,	,	,000	,	O	O
HIV	HIV	h010	NN	B-NP	O
p24	p24	0000	NN	I-NP	O
antigen	antigen	a530205	NN	I-NP	O
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

Seventy	Seventy	s010530	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
major	major	m0206	JJ	B-NP	O
opportunistic	opportunistic	o10630502302	JJ	I-NP	B-Disease
infections	infection	i51023052	NNS	I-NP	I-Disease
whilst	whilst	w0423	IN	B-PP	O
on	on	o500	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
AIDS	AIDS	a032	NNP	I-NP	B-Disease
diagnosis	diagnosis	d0250202	NN	I-NP	O
in	in	i500	IN	B-PP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
minor	minor	m0506	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	B-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
subset	subset	s01203	NN	I-NP	O
count	count	c053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
AIDS	AIDS	a032	NN	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
rise	rise	r020	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
earlier	early	e06406	JJR	B-NP	O
stages	stage	s30202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
disease	disease	d02020	NN	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
positive	positive	p0203010	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
p24	p24	0000	NN	B-NP	O
antigen	antigen	a530205	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
commencement	commencement	c0505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
67	67	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
most	most	m023	RBS	B-ADVP	O
likely	likely	l02040	RB	I-ADVP	O
in	in	i500	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
CD4	CD4	0000	NN	B-NP	O
+	+	+000	SYM	I-NP	O
lymphocyte	lymphocyte	l05102030	NN	I-NP	O
subset	subset	s01203	NN	I-NP	O
counts	count	c0532	NNS	I-NP	O
above	above	a1010	IN	B-PP	O
100	100	0000	CD	B-NP	O
mm3	mm3	0000	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
positive	positive	p0203010	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
patients	patient	p030532	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
improvement	improvement	i5160105053	NN	B-NP	O
in	in	i500	IN	B-PP	O
individual	individual	i53010304	JJ	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
and	and	a530	CC	O	O
global	global	g40104	JJ	B-NP	O
score	score	s2060	NN	I-NP	O
of	of	o100	IN	B-PP	O
quality	quality	q04030	NN	B-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
possibly	possibly	p020140	RB	B-ADJP	O
attributable	attributable	a3601030140	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
didanosine	didanosine	d030502050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
common	common	c0505	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
common	common	c0505	JJ	I-NP	O
side	side	s030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effect	effect	e1023	NN	I-NP	O
was	be	w020	VBD	B-VP	O
diarrhoea	diarrhoea	d060	NN	B-NP	B-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
cessation	cessation	c020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
in	in	i500	IN	B-PP	O
19	19	0000	CD	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
.	.	.000	.	O	O

Peripheral	Peripheral	p06010604	JJ	B-NP	B-Disease
neuropathy	neuropathy	n0601030	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
12	12	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
pancreatitis	pancreatitis	p0526030302	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
six	six	s020	CD	B-NP	O
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
raised	raise	r0203	VBN	I-NP	O
serum	serum	s0605	NN	I-NP	O
amylase	amylase	a504020	NN	I-NP	O
without	without	w0303	IN	B-PP	O
abdominal	abdominal	a13050504	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
glucose	glucose	g402020	NN	B-NP	B-Disease
tolerance	tolerance	t04060520	NN	I-NP	I-Disease
curves	curve	c06102	NNS	I-NP	I-Disease
characteristic	characteristic	c060230602302	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
but	but	b030	CC	O	O
these	these	t020	DT	B-NP	O
were	be	w060	VBD	B-VP	O
mild	mild	m043	JJ	B-ADJP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	O	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
on	on	o500	IN	B-PP	O
ceasing	cease	c02052	VBG	B-VP	O
didanosine	didanosine	d030502050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
antibodies	antibody	a53010302	NNS	B-NP	O
to	to	t000	TO	B-PP	O
neurofilament	neurofilament	n06010405053	NN	B-NP	O
proteins	protein	p603052	NNS	I-NP	O
on	on	o500	IN	B-PP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
experimental	experimental	e21060505304	JJ	B-NP	O
focal	focal	f0204	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
.	.	.000	.	O	O

Immunohistochemistry	Immunohistochemistry	i505023020502360	NN	B-NP	O
with	with	w030	IN	B-PP	O
monoclonal	monoclonal	m050240504	JJ	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
against	against	a20523	IN	B-PP	O
neurofilament	neurofilament	n06010405053	NN	B-NP	O
(	(	(000	(	O	O
NF	NF	n100	NN	B-NP	O
)	)	)000	)	O	O
proteins	protein	p603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
middle	middle	m0340	JJ	B-NP	O
and	and	a530	CC	I-NP	O
high	high	h020	JJ	I-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
class	class	c402	NN	I-NP	O
,	,	,000	,	O	O
NF	NF	n100	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
M	M	m000	NN	I-NP	O
and	and	a530	CC	I-NP	O
NF	NF	n100	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
H	H	h000	NN	I-NP	O
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
study	study	s3030	VB	I-VP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
borderzone	borderzone	b063062050	NN	I-NP	O
of	of	o100	IN	B-PP	O
focal	focal	f0204	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

Focal	Focal	f0204	JJ	B-NP	O
injury	injury	i52060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
the	the	t000	DT	B-NP	I-Disease
cortex	cortex	c06302	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
infusion	infusion	i510205	NN	B-NP	O
of	of	o100	IN	B-PP	O
lactate	lactate	l023030	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
acid	acid	a203	NN	B-NP	O
pH	pH	p000	NN	I-NP	O
or	or	o600	CC	B-PP	O
by	by	b000	IN	B-PP	O
stab	stab	s301	NN	B-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
needle	needle	n0340	NN	B-NP	O
insertion	insertion	i5206305	NN	I-NP	O
.	.	.000	.	O	O

Infarcts	Infarct	i5106232	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
substantia	substantia	s01230530	NN	B-NP	I-Disease
nigra	nigra	n0260	NN	I-NP	I-Disease
pars	par	p062	NNS	I-NP	I-Disease
reticulata	reticulata	r030204030	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
evoked	evoke	e10203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
pilocarpine	pilocarpine	p0402061050	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
status	status	s30302	NN	I-NP	B-Disease
epilepticus	epilepticus	e1040130202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Immunohistochemical	Immunohistochemical	i50502302050204	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
for	for	f060	IN	B-PP	O
NFs	NF	n120	NNS	B-NP	O
showed	show	s030	VBD	B-VP	O
characteristic	characteristic	c060230602302	JJ	B-NP	O
terminal	terminal	t0650504	JJ	I-NP	O
clubs	club	c4012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
axons	axon	a2052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
borderzone	borderzone	b063062050	NN	I-NP	O
of	of	o100	IN	B-PP	O
lesions	lesion	l02052	NNS	B-NP	O
.	.	.000	.	O	O

Differences	Difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
labelling	labelling	l0104052	NN	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
with	with	w030	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
antibodies	antibody	a53010302	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
apparently	apparently	a10605340	RB	B-ADVP	O
depended	depend	d0105303	VBD	B-VP	O
on	on	o500	IN	B-PP	O
molecular	molecular	m04020406	JJ	B-NP	O
weight	weight	w0203	NN	I-NP	O
class	class	c402	NN	I-NP	O
of	of	o100	IN	B-PP	O
NFs	NF	n120	NNS	B-NP	O
and	and	a530	CC	O	O
phosphorylation	phosphorylation	p02106040305	NN	B-NP	O
state	state	s3030	NN	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
NFs	NF	n120	NNS	B-NP	O
can	can	c050	MD	B-VP	O
serve	serve	s0610	VB	I-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
marker	marker	m06206	NN	I-NP	O
for	for	f060	IN	B-PP	O
axonal	axonal	a20504	JJ	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
traumatic	traumatic	t6050302	JJ	I-NP	B-Disease
or	or	o600	CC	I-NP	O
ischemic	ischemic	i20502	JJ	I-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

Pharmacokinetic	Pharmacokinetic	p0650202050302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
.	.	.000	.	O	O

15	15	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
mental	mental	m05304	JJ	I-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
order	order	o6306	NN	B-NP	O
that	that	t030	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
syndrome	syndrome	s0536050	NN	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
mental	mental	m05304	JJ	B-NP	O
status	status	s30302	NN	I-NP	O
(	(	(000	(	O	O
M	M	m000	NN	B-NP	O
.	.	.000	.	O	O
S	S	s000	NNP	B-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
renal	renal	r0504	JJ	B-NP	O
and	and	a530	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
36	36	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
M	M	m000	NN	I-NP	O
.	.	.000	.	O	O
S	S	s000	NN	B-NP	O
.	.	.000	.	I-NP	O
change	change	c0520	NN	I-NP	O
on	on	o500	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
6	6	6000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
both	both	b030	CC	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
and	and	a530	CC	O	I-Disease
liver	liver	l0106	NN	B-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
trough	trough	t6020	NN	I-NP	O
-	-	-000	HYPH	O	O
concentrations	concentration	c052053603052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
microgram	microgram	m02602605	NN	I-NP	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	B-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
M	M	m000	NN	B-NP	O
.	.	.000	.	O	O
S	S	s000	NNP	B-NP	O
.	.	.000	.	I-NP	O
changes	change	c05202	NNS	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
as	as	a200	IN	B-PP	O
trough	trough	t6020	NN	B-NP	O
-	-	-000	HYPH	O	O
concentrations	concentration	c052053603052	NNS	B-NP	O
rose	rise	r020	VBD	B-VP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
lumbar	lumbar	l05106	JJ	B-NP	O
puncture	puncture	p0523060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cerebrospinal	cerebrospinal	c060160210504	JJ	I-NP	O
fluid	fluid	f403	NN	I-NP	O
:	:	:000	:	O	O
serum	serum	s0605	NN	B-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
24	24	0000	CD	I-NP	O
:	:	:000	:	O	O
1	1	1000	CD	B-NP	O
and	and	a530	CC	O	O
indicates	indicate	i53020302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
passes	pass	p0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
;	;	;000	:	O	O
it	it	i300	PRP	B-NP	O
also	also	a420	RB	B-ADVP	O
raises	raise	r0202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
M	M	m000	NN	B-NP	O
.	.	.000	.	O	O
S	S	s000	NN	B-NP	O
.	.	.000	.	I-NP	O
changes	change	c05202	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
due	due	d000	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
blockade	blockade	b402030	NN	B-NP	O
of	of	o100	IN	B-PP	O
histamine	histamine	h02305050	NN	B-NP	B-Chemical
H2	H2	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
likely	likely	l02040	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
both	both	b030	CC	O	O
raised	raise	r0203	VBN	B-NP	O
trough	trough	t6020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
and	and	a530	CC	O	O
mental	mental	m05304	JJ	B-NP	O
confusion	confusion	c0510205	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
both	both	b030	CC	O	O
severe	severe	s01060	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
hepatic	hepatic	h010302	JJ	I-NP	I-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
closely	closely	c402040	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
and	and	a530	CC	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
given	give	g0105	VBN	I-VP	O
reduced	reduce	r030203	VBN	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Prospective	Prospective	p6021023010	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
somatostatin	somatostatin	s05030230305	NN	B-NP	O
analog	analog	a50402	NN	I-NP	O
(	(	(000	(	O	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
)	)	)000	)	O	O
on	on	o500	IN	B-PP	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
and	and	a530	CC	O	O
gallstone	gallstone	g0423050	NN	B-NP	B-Disease
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
acromegalic	acromegalic	a2605020402	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
reports	report	r010632	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ultrasonography	ultrasonography	u4360205026010	NN	B-NP	O
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
active	active	a23010	JJ	B-NP	O
acromegaly	acromegaly	a260502040	RB	B-VP	B-Disease
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sc	sc	s200	NN	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
somatostatin	somatostatin	s05030230305	NN	I-NP	O
analog	analog	a50402	NN	I-NP	O
octreotide	octreotide	o23603030	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
dosages	dosage	d020202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
300	300	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1500	1500	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
mean	mean	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
24	24	0000	CD	B-NP	O
.	.	.000	.	O	O
2	2	2000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-VP	O
13	13	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
,	,	,000	,	O	O
17	17	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
sludge	sludge	s40320	NN	B-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
had	have	h030	VBD	B-VP	O
gallstones	gallstone	g04230502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	B-Disease
cholecystitis	cholecystitis	c04020230302	NN	I-NP	I-Disease
requiring	require	r0206052	VBG	B-VP	O
surgery	surgery	s062060	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
7	7	7000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
acutely	acutely	a203040	RB	B-ADVP	O
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
inhibited	inhibit	i5010303	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
100	100	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
injection	injection	i5202305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
followed	follow	f0403	VBN	B-VP	O
for	for	f060	IN	B-PP	O
24	24	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
remained	remain	r050503	VBD	B-VP	O
depressed	depressed	d0160203	JJ	B-ADJP	B-Disease
throughout	throughout	t060203	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
gallstones	gallstone	g04230502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
assessed	assess	a20203	VBN	B-VP	O
had	have	h030	VBD	B-VP	O
return	return	r03065	NN	B-NP	O
of	of	o100	IN	B-PP	O
normal	normal	n06504	JJ	B-NP	O
gallbladder	gallbladder	g04140306	NN	I-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
within	within	w0305	IN	B-PP	O
1	1	1000	CD	B-NP	O
month	month	m0530	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
10	10	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
gallstones	gallstone	g04230502	NNS	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
normalized	normalize	n065040203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
has	have	h020	VBZ	B-VP	O
disappearance	disappearance	d0201060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
stones	stone	s30502	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
3	3	3000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
remained	remain	r050503	VBD	B-VP	O
depressed	depress	d0160203	VBN	I-VP	B-Disease
in	in	i500	IN	B-PP	O
3	3	3000	CD	B-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
of	of	o100	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
had	have	h030	VBD	B-VP	O
stones	stone	s30502	NNS	B-NP	O
present	present	p602053	JJ	B-ADJP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
suppression	suppression	s0160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
contractility	contractility	c053602304030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
successive	successive	s0202010	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
sludge	sludge	s40320	NN	I-NP	O
,	,	,000	,	O	O
gallstones	gallstone	g04230502	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
cholecystitis	cholecystitis	c04020230302	NN	B-NP	B-Disease
during	during	d06052	IN	B-PP	O
octreotide	octreotide	o23603030	NN	B-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
in	in	i500	IN	B-PP	O
Chinese	Chinese	c05020	JJ	B-NP	O
acromegalic	acromegalic	a2605020402	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
therefore	therefore	t0601060	RB	B-ADVP	O
very	very	v060	RB	B-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
follow	follow	f040	VB	I-VP	O
the	the	t000	DT	B-NP	O
changes	change	c05202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
gallbladder	gallbladder	g04140306	NN	B-NP	O
function	function	f052305	NN	I-NP	O
during	during	d06052	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
octreotide	octreotide	o23603030	NN	I-NP	B-Chemical
therapy	therapy	t06010	NN	I-NP	O
of	of	o100	IN	B-PP	O
acromegalic	acromegalic	a2605020402	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Increase	Increase	i526020	NN	B-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

Depression	Depression	d0160205	NN	B-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
major	major	m0206	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
feature	feature	f03060	NN	I-NP	O
of	of	o100	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
fluoxetine	fluoxetine	f40203050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinically	clinically	c40502040	RB	I-NP	O
relevant	relevant	r0401053	JJ	I-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
antagonistic	antagonistic	a53020502302	JJ	I-NP	O
capacity	capacity	c0102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluoxetine	fluoxetine	f40203050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
.	.	.000	.	O	O

Sinus	Sinus	s0502	NN	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
intermittent	intermittent	i5306503053	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
infusions	infusion	i5102052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
infrequently	infrequently	i5160205340	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradyarrhythmias	bradyarrhythmia	b60306030502	NNS	B-NP	B-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
man	man	m050	NN	I-NP	O
with	with	w030	IN	B-PP	O
leukemia	leukemia	l02050	NN	B-NP	B-Disease
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
developed	develop	d01040103	VBD	B-VP	O
recurrent	recurrent	r0206053	JJ	B-NP	O
,	,	,000	,	I-NP	O
brief	brief	b601	JJ	I-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
apparent	apparent	a106053	JJ	B-NP	O
sinus	sinus	s0502	NN	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
while	while	w040	IN	B-SBAR	O
receiving	receive	r0201052	VBG	B-VP	O
continuous	continuous	c0530502	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
50	50	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
hour	hour	h060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
arrhythmias	arrhythmia	a6030502	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
temporally	temporally	t05106040	RB	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
to	to	t000	TO	B-PP	O
cimetidine	cimetidine	c050303050	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
disappeared	disappear	d02010603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
dechallenge	dechallenge	d02040520	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
recur	recur	r0206	VB	I-VP	O
during	during	d06052	IN	B-PP	O
ranitidine	ranitidine	r050303050	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
sinus	sinus	s0502	NN	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
continuous	continuous	c0530502	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
cimetidine	cimetidine	c050303050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Phase	Phase	p020	NN	B-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
vinorelbine	vinorelbine	v0506041050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
squamous	squamous	s20502	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
esophageal	esophageal	e2010204	JJ	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

European	European	e060105	NNP	B-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
for	for	f060	IN	B-PP	O
Research	Research	r020620	NNP	B-NP	O
and	and	a530	CC	I-NP	O
Treatment	Treatment	t6035053	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Cancer	Cancer	c05206	NNP	B-NP	B-Disease
Gastrointestinal	Gastrointestinal	g02360530230504	NNP	I-NP	O
Treat	Treat	t603	NNP	I-NP	O
Cancer	Cancer	c05206	NNP	I-NP	B-Disease
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
toxic	toxic	t0202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
vinorelbine	vinorelbine	v0506041050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
VNB	VNB	v510	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
squamous	squamous	s20502	JJ	I-NP	B-Disease
cell	cell	c040	NN	I-NP	I-Disease
esophageal	esophageal	e2010204	JJ	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

PATIENTS	PATIENTS	p030532	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Forty	Forty	f0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
eligible	eligible	e4020140	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
measurable	measurable	m02060140	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
included	include	i5240303	VBN	I-VP	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
stratified	stratify	s36030103	VBN	I-VP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
previous	previous	p60102	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
and	and	a530	CC	O	O
16	16	0000	CD	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
were	be	w060	VBD	B-VP	O
assessable	assessable	a2020140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

VNB	VNB	v510	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
weekly	weekly	w0240	RB	B-ADVP	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
short	short	s063	JJ	B-NP	O
intravenous	intravenous	i536010502	JJ	I-NP	O
(	(	(000	(	O	O
i	i	i000	JJ	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
infusion	infusion	i510205	NN	B-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Six	Six	s020	CD	B-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
PR	PR	p600	NN	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
confidence	confidence	c051030520	NN	I-NP	O
interval	interval	i5306104	NN	I-NP	O
[	[	[000	(	O	O
CI	CI	c000	NN	B-NP	O
]	]	]000	)	O	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
39	39	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
was	be	w020	VBD	B-VP	O
21	21	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
(	(	(000	(	O	O
range	range	r0520	NN	B-NP	O
,	,	,000	,	O	O
17	17	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
28	28	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
16	16	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
(	(	(000	(	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
prior	prior	p606	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
had	have	h030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
)	)	)000	)	O	O
of	of	o100	IN	B-PP	O
31	31	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
'	'	'000	POS	B-NP	O
duration	duration	d060305	NN	I-NP	O
(	(	(000	(	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
(	(	(000	(	O	O
World	World	w0643	NNP	B-NP	O
Health	Health	h0430	NNP	I-NP	O
Organization	Organization	o6205020305	NNP	I-NP	O
[	[	[000	(	O	O
WHO	WHO	w000	WP	B-NP	O
]	]	]000	)	O	O
criteria	criterion	c603060	NNS	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
15	15	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
PR	PR	p600	NN	B-NP	O
13	13	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
95	95	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
CI	CI	c000	NN	I-NP	O
,	,	,000	,	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
to	to	t000	TO	I-NP	O
29	29	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
intensity	intensity	i53052030	NN	B-NP	O
(	(	(000	(	O	O
DI	DI	d000	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
20	20	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
/	/	/000	SYM	I-NP	O
wk	wk	w200	NN	I-NP	O
.	.	.000	.	O	O

VNB	VNB	v510	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
well	well	w040	RB	I-VP	O
tolerated	tolerate	t04060303	VBN	I-VP	O
and	and	a530	CC	O	O
zero	zero	z060	CD	B-NP	O
instances	instance	i52305202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
WHO	WHO	w000	NN	B-NP	O
grade	grade	g6030	NN	I-NP	O
4	4	4000	CD	I-NP	O
nonhematologic	nonhematologic	n050503040202	JJ	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

At	At	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
grade	grade	g6030	NN	B-NP	O
3	3	3000	CD	I-NP	O
or	or	o600	CC	I-NP	O
4	4	4000	CD	I-NP	O
granulocytopenia	granulocytopenia	g60504020301050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
59	59	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
grade	grade	g6030	NN	I-NP	O
2	2	2000	CD	I-NP	O
or	or	o600	CC	I-NP	O
3	3	3000	CD	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
16	16	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
no	no	n000	DT	B-NP	O
toxic	toxic	t0202	JJ	I-NP	O
deaths	death	d0302	NNS	I-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
rare	rare	r060	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
peripheral	peripheral	p06010604	JJ	B-NP	B-Disease
neurotoxicity	neurotoxicity	n06030202030	NN	I-NP	I-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
minor	minor	m0506	JJ	B-ADJP	O
(	(	(000	(	O	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
grade	grade	g6030	NN	I-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
VNB	VNB	v510	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
active	active	a23010	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
in	in	i500	IN	B-PP	O
metastatic	metastatic	m030230302	JJ	B-NP	O
esophageal	esophageal	e2010204	JJ	I-NP	B-Disease
squamous	squamous	s20502	JJ	I-NP	I-Disease
cell	cell	c040	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

Given	Give	g0105	VBN	B-VP	O
its	its	i320	PRP$	B-NP	O
excellent	excellent	e204053	JJ	I-NP	O
tolerance	tolerance	t04060520	NN	I-NP	O
profile	profile	p601040	NN	I-NP	O
and	and	a530	CC	O	O
low	low	l000	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
,	,	,000	,	O	O
further	further	f06306	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
VNB	VNB	v510	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Evaluation	Evaluation	e1040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
reactions	reaction	r023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
aponidine	aponidine	a10503050	NN	B-NP	B-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	I-Chemical
ophthalmic	ophthalmic	o10304502	JJ	I-NP	O
solution	solution	s040305	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
prospectively	prospectively	p602102301040	RB	B-ADVP	O
evaluated	evaluate	e1040303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
reactions	reaction	r023052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
apraclonidine	apraclonidine	a160240503050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
20	20	0000	CD	B-NP	O
normal	normal	n06504	JJ	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
by	by	b000	IN	B-PP	O
instilling	instill	i52304052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
drop	drop	d601	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
apraclonidine	apraclonidine	a160240503050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
right	right	r0203	JJ	I-NP	O
eyes	eye	e020	NNS	I-NP	O
.	.	.000	.	O	O

Examinations	Examination	e2050503052	NNS	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
pulse	pulse	p0420	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
,	,	,000	,	O	O
conjunctiva	conjunctiva	c0520523010	NN	B-NP	O
and	and	a530	CC	I-NP	O
cornea	cornea	c0650	NN	I-NP	O
,	,	,000	,	O	O
intraocular	intraocular	i536020406	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
(	(	(000	(	O	O
IOP	IOP	i010	NN	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
pupil	pupil	p0104	NN	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
,	,	,000	,	O	O
basal	basal	b0204	JJ	B-NP	O
tear	tear	t060	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
and	and	a530	CC	O	O
margin	margin	m06205	NN	B-NP	O
reflex	reflex	r01402	NN	I-NP	O
distance	distance	d0230520	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	B-NP	O
upper	upper	u106	JJ	I-NP	O
and	and	a530	CC	I-NP	O
lower	low	l060	JJR	I-NP	O
eyelids	eyelid	e04032	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
entry	entry	e5360	NN	B-NP	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
and	and	a530	CC	I-NP	O
7	7	7000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
instillation	instillation	i523040305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
ocular	ocular	o20406	JJ	I-NP	B-Disease
hypotensive	hypotensive	h0103052010	JJ	I-NP	I-Disease
effects	effect	e10232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
apraclonidine	apraclonidine	a160240503050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
treated	treat	t60303	VBN	I-NP	O
eyes	eye	e020	NNS	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
study	study	s3030	NN	I-NP	O
and	and	a530	CC	O	O
also	also	a420	RB	B-ADVP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
for	for	f060	IN	B-PP	O
contralateral	contralateral	c053604030604	JJ	B-NP	O
eyes	eye	e020	NNS	I-NP	O
from	from	f605	IN	B-PP	O
three	three	t060	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
topical	topical	t010204	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
apraclonidine	apraclonidine	a160240503050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Decreases	Decrease	d0260202	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
systolic	systolic	s0230402	JJ	B-NP	I-Disease
blood	blood	b403	NN	I-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
clinically	clinically	c40502040	RB	B-ADVP	O
,	,	,000	,	O	O
significant	significant	s0250102053	JJ	B-ADJP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
diastolic	diastolic	d0230402	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
pulse	pulse	p0420	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
basal	basal	b0204	JJ	B-NP	O
tear	tear	t060	NN	I-NP	O
secretion	secretion	s0260305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

Conjunctival	Conjunctival	c05205230104	JJ	B-NP	B-Disease
blanching	blanching	b4052052	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
mydriasis	mydriasis	m0360202	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
commonly	commonly	c050540	RB	I-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Upper	Upper	u106	IN	B-PP	O
lid	lid	l030	JJ	B-NP	O
retraction	retraction	r03602305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
frequently	frequently	f60205340	RB	I-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

While	While	w040	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
elevations	elevation	e40103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
upper	upper	u106	JJ	I-NP	O
lid	lid	l030	JJ	I-NP	O
margin	margin	m06205	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
subjects	subject	s0120232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
2	2	2000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
and	and	a530	CC	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
noticeable	noticeable	n03020140	JJ	B-NP	O
change	change	c0520	NN	I-NP	O
in	in	i500	IN	B-PP	O
appearance	appearance	a1060520	NN	B-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
subject	subject	s012023	NN	I-NP	O
suffered	suffer	s010603	VBD	B-VP	O
from	from	f605	IN	B-PP	O
mechanical	mechanical	m02050204	JJ	B-NP	O
entropion	entropion	e5360105	NN	I-NP	B-Disease
and	and	a530	CC	O	O
marked	marked	m06203	JJ	B-NP	O
corneal	corneal	c06504	JJ	I-NP	B-Disease
abrasion	abrasion	a160205	NN	I-NP	I-Disease
3	3	3000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
instillation	instillation	i523040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
medication	medication	m03020305	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
may	may	m000	MD	B-VP	O
well	well	w040	RB	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
particularly	particularly	p06302040640	RB	I-NP	O
notable	notable	n030140	JJ	I-NP	O
finding	finding	f053052	NN	I-NP	O
in	in	i500	IN	B-PP	O
Asian	Asian	a205	JJ	B-NP	O
people	people	p0140	NNS	I-NP	O
.	.	.000	.	O	O

Thiopentone	Thiopentone	t01053050	NN	B-NP	B-Chemical
pretreatment	pretreatment	p6036035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
ambulatory	ambulatory	a510403060	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
ambulatory	ambulatory	a510403060	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
trial	trial	t604	NN	I-NP	O
,	,	,000	,	O	O
90	90	0000	CD	B-NP	O
women	woman	w0505	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
treatments	treatment	t60350532	NNS	I-NP	O
prior	prior	p606	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
anaesthesia	anaesthesia	a5023020	NN	B-NP	O
with	with	w030	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
2	2	2000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
normal	normal	n06504	JJ	I-NP	O
saline	saline	s04050	NN	I-NP	O
,	,	,000	,	O	O
Group	Group	g601	NNP	B-NP	O
L	L	l000	NNP	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
,	,	,000	,	O	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
40	40	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Group	Group	g601	NNP	B-NP	O
T	T	t000	NNP	I-NP	O
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
thiopentone	thiopentone	t01053050	NN	I-NP	B-Chemical
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
50	50	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Venous	Venous	v0502	JJ	B-NP	O
discomfort	discomfort	d02051063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
visual	visual	v0204	JJ	I-NP	O
analogue	analogue	a504020	NN	I-NP	O
scale	scale	s2040	NN	I-NP	O
(	(	(000	(	O	O
VAS	VAS	v020	NN	B-NP	O
)	)	)000	)	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
15	15	0000	CD	I-NP	O
sec	sec	s020	NN	I-NP	O
after	after	a1306	IN	B-PP	O
commencing	commence	c05052052	VBG	B-VP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
pump	pump	p051	NN	I-NP	O
(	(	(000	(	O	O
rate	rate	r030	NN	B-NP	O
1000	1000	0000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
.	.	.000	.	O	O
kg	kg	k200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
min	min	m050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Loss	Loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
consciousness	consciousness	c05202502	NN	B-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
in	in	i500	IN	B-PP	O
60	60	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
90	90	0000	CD	I-NP	O
sec	sec	s020	NN	I-NP	O
.	.	.000	.	O	O

Visual	Visual	v0204	JJ	B-NP	O
analogue	analogue	a504020	NN	I-NP	O
scores	score	s20602	NNS	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
SD	SD	s300	NN	I-NP	O
)	)	)000	)	O	O
during	during	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
were	be	w060	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Groups	Group	g6012	NNS	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
3	3	3000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
T	T	t000	NN	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
2	2	2000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
7	7	7000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	I-NP	O
-	-	-000	SYM	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
3	3	3000	CD	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0031	0031	0000	CD	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
venous	venous	v0502	JJ	B-NP	O
discomfort	discomfort	d02051063	NN	I-NP	O
was	be	w020	VBD	B-VP	O
lower	low	l060	JJR	B-ADJP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
L	L	l000	NN	I-NP	O
(	(	(000	(	O	O
76	76	0000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
100	100	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
not	not	n030	RB	B-ADJP	O
different	different	d0106053	JJ	I-ADJP	O
from	from	f605	IN	B-PP	O
Group	Group	g601	NN	B-NP	O
T	T	t000	NN	I-NP	O
(	(	(000	(	O	O
90	90	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
VAS	VAS	v020	NNP	I-NP	O
scores	score	s20602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
recall	recall	r0204	NN	B-NP	O
of	of	o100	IN	B-PP	O
pain	pain	p050	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
room	room	r050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
correlated	correlate	c06040303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
VAS	VAS	v020	NNP	I-NP	O
scores	score	s20602	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
(	(	(000	(	O	O
r	r	r000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
7045	7045	0000	CD	B-NP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Recovery	Recovery	r0201060	NN	B-NP	O
room	room	r050	NN	I-NP	O
discharge	discharge	d020620	NN	I-NP	O
times	time	t0502	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
:	:	:000	:	O	O
C	C	c000	NN	B-NP	O
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
4	4	4000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
L	L	l000	NN	B-NP	O
73	73	0000	CD	I-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	B-VP	O
-	-	-000	SYM	B-NP	O
21	21	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
6	6	6000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
;	;	;000	:	O	O
T	T	t000	NN	B-NP	O
(	(	(000	(	O	O
77	77	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	B-NP	O
18	18	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
9	9	9000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Assessing	Assess	a202052	VBG	B-VP	O
their	their	t060	PRP$	B-NP	O
overall	overall	o10604	JJ	I-NP	O
satisfaction	satisfaction	s0302102305	NN	I-NP	O
,	,	,000	,	O	O
89	89	0000	CD	B-NP	O
.	.	.000	.	O	O
7	7	7000	CD	B-NP	O
%	%	%000	NN	I-NP	O
would	would	w043	MD	B-VP	O
choose	choose	c020	VB	I-VP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
again	again	a205	RB	B-ADVP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
reduces	reduce	r030202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
propofol	propofol	p6010104	NN	B-NP	B-Chemical
injection	injection	i5202305	NN	I-NP	O
pain	pain	p050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
ambulatory	ambulatory	a510403060	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
whereas	whereas	w0602	IN	B-PP	O
thiopentone	thiopentone	t01053050	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
reduces	reduce	r030202	VBZ	B-VP	O
its	its	i320	PRP$	B-NP	O
severity	severity	s0106030	NN	I-NP	O
.	.	.000	.	O	O

Persistent	Persistent	p062023053	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
atracurium	atracurium	a36020605	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
.	.	.000	.	O	O

Neuromuscular	Neuromuscular	n0605020406	JJ	B-NP	O
blocking	block	b402052	VBG	I-NP	O
agents	agent	a20532	NNS	I-NP	O
(	(	(000	(	O	O
NMBAs	NMBA	n5102	NNS	B-NP	O
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	I-VP	O
used	use	u203	VBN	I-VP	O
for	for	f060	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
requiring	require	r0206052	VBG	B-VP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
mechanical	mechanical	m02050204	JJ	I-NP	O
ventilation	ventilation	v053040305	NN	I-NP	O
.	.	.000	.	O	O

Reports	Report	r010632	NNS	B-NP	O
of	of	o100	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
discontinuance	discontinuance	d02053050520	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
most	most	m023	RBS	I-VP	O
often	often	o1305	RB	I-VP	O
involved	involve	i5104103	VBN	B-NP	O
aminosteroid	aminosteroid	a5050230603	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
based	base	b0203	VBN	I-NP	O
NMBAs	NMBA	n5102	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
vecuronium	vecuronium	v02060505	NN	B-NP	B-Chemical
bromide	bromide	b605030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
especially	especially	e2102040	RB	B-ADVP	O
when	when	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
conjunction	conjunction	c052052305	NN	B-NP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
.	.	.000	.	O	O

Atracurium	Atracurium	a36020605	NNP	B-NP	B-Chemical
besylate	besylate	b0204030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	I-NP	O
benzylisoquinolinium	benzylisoquinolinium	b05204020205040505	NN	I-NP	B-Chemical
NMBA	NMBA	n510	NN	I-NP	O
that	that	t030	WDT	B-NP	O
is	be	i200	VBZ	B-VP	O
eliminated	eliminate	e405050303	VBN	I-VP	O
independently	independently	i530105305340	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
or	or	o600	CC	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
,	,	,000	,	O	O
has	have	h020	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
persistent	persistent	p062023053	JJ	B-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
only	only	o540	RB	O	O
when	when	w050	WRB	B-ADVP	O
used	use	u203	VBN	B-VP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
atracurium	atracurium	a36020605	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
paralysis	paralysis	p06040202	NN	I-NP	B-Disease
persisting	persist	p062023052	VBG	B-VP	O
for	for	f060	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
50	50	0000	CD	I-NP	O
hours	hour	h062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
II	II	i000	CD	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
plus	plus	p402	CC	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
first	first	f0623	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
for	for	f060	IN	B-PP	O
head	head	h030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
cancers	cancer	c052062	NNS	I-NP	I-Disease
:	:	:000	:	O	O
preliminary	preliminary	p6040505060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

Improved	Improve	i5160103	VBN	B-NP	O
outcomes	outcome	o0320502	NNS	I-NP	O
among	among	a5052	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
head	head	h030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
carcinomas	carcinoma	c062050502	NNS	I-NP	I-Disease
require	require	r02060	VBP	B-VP	O
investigations	investigation	i510230203052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
new	new	n000	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
for	for	f060	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Preliminary	Preliminary	p6040505060	JJ	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
an	an	a500	DT	B-NP	O
Eastern	Eastern	e023065	NNP	I-NP	O
Cooperative	Cooperative	c010603010	NNP	I-NP	O
Oncology	Oncology	o5204020	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
single	single	s05240	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
agent	agent	a2053	NN	I-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
(	(	(000	(	O	O
Taxol	Taxol	t0204	NN	B-NP	B-Chemical
;	;	;000	:	O	O
Bristol	Bristol	b602304	NNP	B-NP	O
-	-	-000	:	O	O
Myers	Myers	m062	NNP	B-NP	O
Squibb	Squibb	s201	NNP	I-NP	O
Company	Company	c051050	NNP	I-NP	O
,	,	,000	,	O	O
Princeton	Princeton	p60520305	NNP	B-NP	O
,	,	,000	,	O	O
NJ	NJ	n200	NNP	B-NP	O
)	)	)000	)	O	O
reported	report	r0106303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
37	37	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
head	head	h030	NN	B-NP	B-Disease
and	and	a530	CC	O	I-Disease
neck	neck	n020	NN	B-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
paclitaxel	paclitaxel	p024030204	NN	I-NP	B-Chemical
/	/	/000	SYM	B-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
combination	combination	c051050305	NN	I-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
successfully	successfully	s02021040	RB	B-ADVP	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
median	median	m0305	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
duration	duration	d060305	NN	I-NP	O
in	in	i500	IN	B-PP	O
ovarian	ovarian	o10605	JJ	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
initiated	initiate	i5030303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
phase	phase	p020	NN	I-NP	O
I	I	i000	CD	I-NP	O
/	/	/000	SYM	I-NP	O
II	II	i000	CD	I-NP	O
trial	trial	t604	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
escalating	escalate	e20403052	VBG	B-VP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
fixed	fix	f0203	VBN	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
granulocyte	granulocyte	g6050402030	NN	B-NP	O
colony	colony	c04050	NN	I-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
support	support	s01063	NN	I-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
untreated	untreated	u5360303	JJ	B-NP	O
locally	locally	l02040	RB	I-NP	O
advanced	advanced	a3105203	JJ	I-NP	O
inoperable	inoperable	i501060140	JJ	I-NP	O
head	head	h030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
carcinoma	carcinoma	c06205050	NN	I-NP	I-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-PP	O
date	date	d030	NN	B-NP	O
,	,	,000	,	O	O
23	23	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
age	age	a200	NN	I-NP	O
of	of	o100	IN	B-PP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
good	good	g030	JJ	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
status	status	s30302	NN	I-NP	O
have	have	h010	VBP	B-VP	O
entered	enter	e530603	VBN	I-VP	O
the	the	t000	DT	B-NP	O
trial	trial	t604	NN	I-NP	O
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	O
tumor	tumor	t0506	NN	I-NP	B-Disease
sites	site	s0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
oropharynx	oropharynx	o60106052	NN	B-NP	O
,	,	,000	,	O	O
10	10	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
;	;	;000	:	O	O
hypopharynx	hypopharynx	h010106052	NN	B-NP	O
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
;	;	;000	:	O	O
larynx	larynx	l06052	NN	B-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
;	;	;000	:	O	O
oral	oral	o604	JJ	B-NP	O
cavity	cavity	c01030	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
;	;	;000	:	O	O
unknown	unknown	u52505	JJ	B-NP	O
primary	primary	p605060	JJ	I-NP	O
,	,	,000	,	O	O
two	two	t000	CD	B-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
nasal	nasal	n0204	JJ	B-NP	O
cavity	cavity	c01030	NN	I-NP	O
and	and	a530	CC	I-NP	O
parotid	parotid	p060303	NN	I-NP	O
gland	gland	g4053	NN	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
each	each	e020	DT	B-NP	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
20	20	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
,	,	,000	,	O	O
four	four	f060	CD	B-NP	O
had	have	h030	VBD	B-VP	O
stage	stage	s3020	NN	B-NP	O
III	III	i000	CD	B-NP	O
and	and	a530	CC	I-NP	O
16	16	0000	CD	I-NP	O
had	have	h030	VBD	B-VP	O
stage	stage	s3020	NN	B-NP	O
IV	IV	i100	CD	I-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
,	,	,000	,	O	O
given	give	g0105	VBN	B-PP	O
every	every	e1060	DT	B-NP	O
21	21	0000	CD	I-NP	O
days	day	d020	NNS	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
maximum	maximum	m020505	NN	I-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
cycles	cycle	c02402	NNS	I-NP	O
,	,	,000	,	O	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
by	by	b000	IN	B-PP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
followed	follow	f0403	VBD	B-VP	O
the	the	t000	DT	B-NP	O
next	next	n023	JJ	I-NP	O
day	day	d000	NN	I-NP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
fixed	fix	f0203	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cisplatin	cisplatin	c02140305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
incorporate	incorporate	i5206106030	JJ	B-ADJP	O
escalating	escalate	e20403052	VBG	B-VP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
intrapatient	intrapatient	i5360103053	JJ	B-NP	O
escalations	escalation	e20403052	NNS	I-NP	O
within	within	w0305	IN	B-PP	O
a	a	a000	DT	B-NP	O
given	give	g0105	VBN	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
are	be	a600	VBP	B-VP	O
permitted	permit	p0650303	VBN	I-VP	O
if	if	i100	IN	B-SBAR	O
toxicity	toxicity	t0202030	NN	B-NP	B-Disease
permits	permit	p065032	NNS	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
writing	writing	w603052	NN	I-NP	O
,	,	,000	,	I-NP	O
dose	dose	d020	NN	I-NP	O
level	level	l0104	NN	I-NP	O
4	4	4000	CD	I-NP	O
(	(	(000	(	O	O
260	260	0000	CD	B-NP	O
,	,	,000	,	I-NP	O
270	270	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
280	280	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
being	be	b052	VBG	I-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
;	;	;000	:	O	O
three	three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
this	this	t020	DT	B-NP	O
level	level	l0104	NN	I-NP	O
are	be	a600	VBP	B-VP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
.	.	.000	.	O	O

With	With	w030	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
,	,	,000	,	I-NP	O
granulocyte	granulocyte	g6050402030	NN	I-NP	O
colony	colony	c04050	NN	I-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
factor	factor	f02306	NN	B-NP	O
5	5	5000	CD	B-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
d	d	d000	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
given	give	g0105	VBN	I-VP	O
(	(	(000	(	O	O
days	day	d020	NNS	B-NP	O
4	4	4000	CD	B-NP	O
through	through	t06020	IN	B-PP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
18	18	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
evaluable	evaluable	e1040140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
response	response	r0210520	NN	B-NP	O
,	,	,000	,	O	O
seven	seven	s0105	CD	B-NP	O
(	(	(000	(	O	O
39	39	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
(	(	(000	(	O	O
33	33	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
achieved	achieve	a20103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
partial	partial	p06304	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
and	and	a530	CC	I-NP	O
disease	disease	d02020	NN	I-NP	O
progressed	progress	p60260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
two	two	t000	CD	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
72	72	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Eleven	Eleven	e40105	CD	B-NP	O
responding	respond	r021053052	VBG	I-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
subsequent	subsequent	s01202053	JJ	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
/	/	/000	SYM	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
or	or	o600	CC	O	O
radical	radical	r030204	JJ	B-NP	O
radiotherapy	radiotherapy	r030306010	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
pathologic	pathologic	p03040202	JJ	I-NP	O
complete	complete	c0514030	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
responses	response	r02105202	NNS	I-NP	O
.	.	.000	.	O	O

Alopecia	Alopecia	a401020	NNP	B-NP	B-Disease
,	,	,000	,	O	O
paresthesias	paresthesia	p060230202	NNS	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
arthralgias	arthralgia	a630604202	NNS	B-NP	B-Disease
/	/	/000	SYM	B-NP	O
myalgias	myalgia	m04202	NNS	I-NP	B-Disease
have	have	h010	VBP	B-VP	O
occurred	occur	o20603	VBN	I-VP	O
frequently	frequently	f60205340	RB	B-ADVP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
with	with	w030	IN	B-PP	O
one	one	o500	CD	B-NP	O
exception	exception	e201305	NN	I-NP	O
(	(	(000	(	O	O
a	a	a000	DT	B-NP	O
grade	grade	g6030	NN	I-NP	O
3	3	3000	CD	I-NP	O
myalgia	myalgia	m0420	NN	I-NP	B-Disease
)	)	)000	)	O	O
they	they	t000	PRP	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
grade	grade	g6030	NN	B-NP	O
1	1	1000	CD	I-NP	O
or	or	o600	CC	I-NP	O
2	2	2000	CD	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	O	O
limiting	limit	l0503052	VBG	B-VP	O
hematologic	hematologic	h0503040202	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

Paclitaxel	Paclitaxel	p024030204	NN	B-NP	B-Chemical
/	/	/000	SYM	I-NP	O
cisplatin	cisplatin	c02140305	NN	I-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
for	for	f060	IN	B-PP	O
locoregionally	locoregionally	l02060205040	RB	B-NP	O
advanced	advanced	a3105203	JJ	I-NP	O
head	head	h030	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
neck	neck	n020	NN	I-NP	I-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
and	and	a530	CC	O	O
continued	continued	c0530503	JJ	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
warranted	warrant	w0605303	VBN	I-VP	O
.	.	.000	.	O	O

Results	Result	r020432	NNS	B-NP	O
thus	thus	t020	RB	B-ADVP	O
far	far	f060	RB	B-VP	O
suggest	suggest	s02023	VBP	I-VP	O
no	no	n000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
response	response	r0210520	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
for	for	f060	IN	B-PP	O
paclitaxel	paclitaxel	p024030204	NN	B-NP	B-Chemical
doses	dose	d0202	NNS	I-NP	O
above	above	a1010	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

Improvement	Improvement	i5160105053	NN	B-NP	O
of	of	o100	IN	B-PP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
propranolol	propranolol	p6016050404	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
suffering	suffer	s0106052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
Parkinson	Parkinson	p06205205	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
PD	PD	p300	NN	B-NP	B-Disease
)	)	)000	)	O	O
with	with	w030	IN	B-PP	O
severely	severely	s0106040	RB	B-ADVP	O
disabling	disable	d02014052	VBG	B-VP	O
dyskinesia	dyskinesia	d0205020	NN	B-NP	B-Disease
received	receive	r020103	VBD	B-VP	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
propranolol	propranolol	p6016050404	NN	I-NP	B-Chemical
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
adjunct	adjunct	a320523	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
currently	currently	c0605340	RB	I-NP	O
used	use	u203	VBN	I-NP	O
medical	medical	m030204	JJ	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
40	40	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
score	score	s2060	NN	I-NP	O
without	without	w0303	IN	B-PP	O
increase	increase	i526020	NN	B-NP	O
of	of	o100	IN	B-PP	O
parkinsonian	parkinsonian	p0620520505	JJ	B-NP	B-Disease
motor	motor	m0306	NN	I-NP	B-Disease
disability	disability	d020104030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Ballistic	Ballistic	b0402302	JJ	B-NP	O
and	and	a530	CC	I-NP	O
choreic	choreic	c0602	JJ	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
markedly	markedly	m0620340	RB	I-VP	O
ameliorated	ameliorate	a504060303	VBN	I-VP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
dystonia	dystonia	d023050	NN	B-NP	B-Disease
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
beta	beta	b030	SYM	O	O
-	-	-000	HYPH	O	O
blockers	blocker	b402062	NNS	B-NP	O
may	may	m000	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
levodopa	levodopa	l0103010	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
ballistic	ballistic	b0402302	JJ	I-NP	O
and	and	a530	CC	I-NP	O
choreic	choreic	c0602	JJ	I-NP	O
dyskinesia	dyskinesia	d0205020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
PD	PD	p300	NN	B-NP	B-Disease
.	.	.000	.	O	O

Habitual	Habitual	h010304	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
with	with	w030	IN	B-PP	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Six	Six	s020	CD	B-NP	O
epidemiologic	epidemiologic	e10305040202	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
United	United	u50303	NNP	I-NP	O
States	State	s30302	NNPS	I-NP	O
and	and	a530	CC	O	O
Europe	Europe	e06010	NNP	B-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
habitual	habitual	h010304	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
end	end	e530	NN	I-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
stage	stage	s3020	NN	I-NP	I-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
(	(	(000	(	O	O
ESRD	ESRD	e263	NN	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
4	4	4000	CD	B-NP	O
to	to	t000	TO	B-PP	O
19	19	0000	CD	B-NP	O
.	.	.000	.	O	O

As	As	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
and	and	a530	CC	I-NP	O
other	other	o306	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
now	now	n000	RB	I-VP	O
been	be	b050	VBN	I-VP	O
withdrawn	withdraw	w0303605	VBN	I-VP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
market	market	m06203	NN	I-NP	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
countries	country	c053602	NNS	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
case	case	c020	NN	I-NP	O
control	control	c053604	NN	I-NP	O
studies	study	s30302	NNS	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
each	each	e020	DT	B-NP	O
in	in	i500	IN	B-PP	O
North	North	n0630	NNP	B-NP	O
Carolina	Carolina	c0604050	NNP	I-NP	O
,	,	,000	,	O	O
northern	northern	n063065	JJ	B-NP	O
Maryland	Maryland	m0604053	NNP	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
West	West	w023	NNP	B-NP	O
Berlin	Berlin	b06405	NNP	I-NP	O
,	,	,000	,	O	O
Germany	Germany	g065050	NNP	B-NP	O
,	,	,000	,	O	O
showed	show	s030	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
habitual	habitual	h010304	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
also	also	a420	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
chronic	chronic	c060502	JJ	B-NP	B-Disease
renal	renal	r0504	JJ	I-NP	I-Disease
failure	failure	f04060	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
ESRD	ESRD	e263	NN	I-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
to	to	t000	TO	B-PP	O
4	4	4000	CD	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
studies	study	s30302	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
both	both	b030	CC	O	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
acetaminophen	acetaminophen	a20305050105	NN	I-NP	B-Chemical
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
burden	burden	b06305	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
latter	latter	l0306	JJ	I-NP	O
being	be	b052	VBG	B-VP	O
somewhat	somewhat	s0503	RB	B-ADJP	O
less	less	l020	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
former	former	f06506	JJ	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
risk	risk	r020	NN	B-NP	O
may	may	m000	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
due	due	d000	JJ	B-ADVP	O
to	to	t000	TO	B-PP	O
differences	difference	d010605202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	B-NP	B-Disease
potential	potential	p0305304	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
themselves	themselves	t05204102	PRP	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
relative	relative	r0403010	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
would	would	w043	MD	B-VP	O
be	be	b000	VB	I-VP	O
expected	expect	e2102303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
if	if	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
higher	high	h0206	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
either	either	e0306	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
alone	alone	a4050	RB	B-ADVP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
used	use	u203	VBN	I-VP	O
both	both	b030	CC	O	O
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
with	with	w030	IN	B-PP	O
other	other	o306	JJ	B-NP	O
analgesics	analgesic	a50420202	NNS	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
phenacetin	phenacetin	p05020305	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
available	available	a1040140	JJ	B-ADJP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
combinations	combination	c0510503052	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
habitual	habitual	h010304	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ESRD	ESRD	e263	NNP	B-NP	B-Disease
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
clearly	clearly	c40640	RB	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
cannot	cannot	c0503	MD	B-VP	O
be	be	b000	VB	I-VP	O
dismissed	dismiss	d0250203	VBN	I-VP	O
.	.	.000	.	O	O

Acetaminophen	Acetaminophen	a20305050105	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Through	Through	t06020	IN	B-PP	O
30	30	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
widespread	widespread	w03021603	JJ	B-NP	O
use	use	u200	NN	I-NP	O
,	,	,000	,	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
shown	show	s050	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
remarkably	remarkably	r050620140	RB	I-NP	O
safe	safe	s010	JJ	I-NP	O
medication	medication	m03020305	NN	I-NP	O
in	in	i500	IN	B-PP	O
therapeutic	therapeutic	t06010302	JJ	B-NP	O
dosages	dosage	d020202	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
potential	potential	p0305304	NN	I-NP	O
for	for	f060	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
produce	produce	p603020	VB	I-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
toxicities	toxicity	t02020302	NNS	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
very	very	v060	RB	B-ADJP	O
low	low	l000	JJ	I-ADJP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
produce	produce	p603020	VB	I-VP	O
symptoms	symptom	s0513052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
anaphylaxis	anaphylaxis	a501040202	NN	B-NP	B-Disease
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
sensitive	sensitive	s05203010	JJ	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
article	article	a630240	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
two	two	t000	CD	B-NP	O
critically	critically	c60302040	RB	I-NP	B-Disease
ill	ill	i400	JJ	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
whom	whom	w050	WP	B-NP	O
transient	transient	t6052053	JJ	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
reproducibly	reproducibly	r01603020140	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Other	Other	o306	JJ	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
allergic	allergic	a406202	JJ	B-NP	B-Disease
reactions	reaction	r023052	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
clinically	clinically	c40502040	RB	B-ADJP	O
detectable	detectable	d030230140	JJ	I-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
hypotensive	hypotensive	h0103052010	JJ	I-NP	B-Disease
episodes	episode	e1020302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
severe	severe	s01060	JJ	B-ADJP	O
enough	enough	e5020	RB	I-ADJP	O
to	to	t000	TO	B-VP	O
require	require	r02060	VB	I-VP	O
vasopressor	vasopressor	v020160206	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
reports	report	r010632	NNS	I-NP	O
illustrate	illustrate	i40236030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
need	need	n030	NN	I-NP	O
for	for	f060	IN	B-SBAR	O
clinicians	clinician	c40502052	NNS	B-NP	O
to	to	t000	TO	B-VP	O
consider	consider	c0520306	VB	I-VP	O
acetaminophen	acetaminophen	a20305050105	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
unknown	unknown	u52505	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
.	.	.000	.	O	O

Reduction	Reduction	r0302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
heparan	heparan	h010605	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
anionic	anionic	a50502	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
.	.	.000	.	O	O

Heparan	Heparan	h010605	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-VP	O
anionic	anionic	a50502	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
induction	induction	i5302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
diabetes	diabetes	d010302	NN	B-NP	B-Disease
by	by	b000	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
age	age	a200	NN	B-NP	O
-	-	-000	HYPH	O	O
adn	adn	a350	NN	B-NP	O
sex	sex	s020	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
matched	match	m03203	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
employing	employ	e514052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cationic	cationic	c030502	JJ	I-NP	O
dye	dye	d000	NN	I-NP	O
cuprolinic	cuprolinic	c016040502	JJ	I-NP	B-Chemical
blue	blue	b400	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Morphometric	Morphometric	m0610503602	JJ	B-NP	O
analysis	analysis	a5040202	NN	I-NP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
computerized	computerized	c05103060203	JJ	I-NP	O
image	image	i5020	NN	I-NP	O
processor	processor	p6020206	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
heparan	heparan	h010605	NN	I-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
specificity	specificity	s1020102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cuprolinic	cuprolinic	c016040502	JJ	I-NP	B-Chemical
blue	blue	b400	JJ	I-NP	I-Chemical
staining	staining	s305052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
demonstrated	demonstrate	d05052360303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
glycosaminoglycan	glycosaminoglycan	g4020205050240205	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
degrading	degrade	d02603052	VBG	B-VP	O
enzymes	enzyme	e520502	NNS	B-NP	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
pretreatment	pretreatment	p6036035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
sections	section	s023052	NNS	I-NP	O
with	with	w030	IN	B-PP	O
heparitinase	heparitinase	h01060305020	NN	B-NP	O
abolished	abolish	a1040203	VBD	B-VP	O
all	all	a400	DT	B-NP	O
staining	staining	s305052	NN	I-NP	O
,	,	,000	,	O	O
whereas	whereas	w0602	IN	O	O
chondroitinase	chondroitinase	c05360305020	NN	B-NP	O
ABC	ABC	a120	NNP	B-NP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
majority	majority	m0206030	NN	I-NP	O
of	of	o100	IN	B-PP	O
anionic	anionic	a50502	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
(	(	(000	(	O	O
74	74	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-ADJP	B-Disease
and	and	a530	CC	O	O
81	81	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
in	in	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
within	within	w0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
rara	rara	r060	NN	I-NP	O
externa	externa	e230650	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
minority	minority	m0506030	NN	I-NP	O
of	of	o100	IN	B-PP	O
anionic	anionic	a50502	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
scattered	scatter	s2030603	VBN	I-VP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
densa	densa	d0520	NN	I-NP	O
and	and	a530	CC	O	O
lamina	lamina	l05050	NN	B-NP	O
rara	rara	r060	NN	I-NP	O
interna	interna	i530650	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADJP	O
smaller	small	s50406	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
rara	rara	r060	NN	I-NP	O
externa	externa	e230650	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
and	and	a530	CC	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-NP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
01	01	0000	CD	I-NP	O
for	for	f060	IN	B-PP	O
diabetic	diabetic	d010302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	O
control	control	c053604	NN	I-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Diabetic	Diabetic	d010302	JJ	B-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
progressively	progressively	p60260201040	RB	B-ADVP	O
developed	develop	d01040103	VBD	B-VP	O
albuminuria	albuminuria	a410505060	NN	B-NP	B-Disease
reaching	reach	r02052	VBG	B-VP	O
40	40	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
(	(	(000	(	O	O
32	32	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	:	O	O
62	62	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	O	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
after	after	a1306	IN	B-PP	O
8	8	8000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
8	8	8000	CD	B-NP	O
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	O	O
)	)	)000	)	O	O
mg	mg	m200	NN	B-NP	O
/	/	/000	SYM	O	O
24	24	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
002	002	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
time	time	t050	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
heparan	heparan	h010605	NN	B-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
anionic	anionic	a50502	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
total	total	t0304	JJ	I-NP	O
anionic	anionic	a50502	JJ	I-NP	O
site	site	s030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
(	(	(000	(	O	O
number	number	n05106	NN	B-NP	O
of	of	o100	IN	B-PP	O
anionic	anionic	a50502	JJ	B-NP	O
sites	site	s0302	NNS	I-NP	O
x	x	x000	VBP	B-VP	O
mean	mean	m050	JJ	B-NP	O
anionic	anionic	a50502	JJ	I-NP	O
site	site	s030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
rara	rara	r060	NN	I-NP	O
externa	externa	e230650	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
reduced	reduce	r030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
19	19	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
021	021	0000	CD	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
by	by	b000	IN	B-PP	O
26	26	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
02	02	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Number	Number	n05106	NN	B-NP	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
anionic	anionic	a50502	JJ	I-NP	O
site	site	s030	NN	I-NP	O
surface	surface	s061020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
part	part	p063	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
(	(	(000	(	O	O
lamina	lamina	l05050	NN	B-NP	O
densa	densa	d0520	NN	I-NP	O
and	and	a530	CC	O	O
lamina	lamina	l05050	NN	B-NP	O
rara	rara	r060	NN	I-NP	O
interna	interna	i530650	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	I-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
changed	change	c05203	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
streptozotocin	streptozotocin	s3601302030205	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
diabetic	diabetic	d010302	JJ	I-NP	B-Disease
rats	rat	r032	NNS	I-NP	O
with	with	w030	IN	B-PP	O
an	an	a500	DT	B-NP	O
increased	increase	i5260203	VBN	I-NP	O
urinary	urinary	u605060	JJ	I-NP	O
albumin	albumin	a410505	NN	I-NP	O
excretion	excretion	e260305	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
reduced	reduce	r030203	VBN	I-NP	O
heparan	heparan	h010605	NN	I-NP	B-Chemical
sulphate	sulphate	s041030	NN	I-NP	I-Chemical
charge	charge	c0620	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
/	/	/000	SYM	B-NP	O
density	density	d052030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
found	find	f053	VBN	I-VP	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
lamina	lamina	l05050	NN	I-NP	O
rara	rara	r060	NN	I-NP	O
externa	externa	e230650	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
glomerular	glomerular	g405060406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
membrane	membrane	m0516050	NN	I-NP	O
.	.	.000	.	O	O

Mediation	Mediation	m030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
enhanced	enhance	e505203	VBN	B-NP	O
reflex	reflex	r01402	NN	I-NP	O
vagal	vagal	v0204	JJ	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
by	by	b000	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
via	via	v000	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
formation	formation	f0650305	NN	I-NP	O
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Dopa	Dopa	d010	NN	B-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
extracerebral	extracerebral	e236020601604	JJ	B-NP	O
decarboxylase	decarboxylase	d020610204020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
with	with	w030	IN	B-PP	O
MK	MK	m200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
486	486	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
anesthetize	anesthetize	a502303020	NN	B-NP	O
MAO	MAO	m000	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
inhibited	inhibit	i5010303	VBN	I-NP	O
dogs	dog	d020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
reflex	reflex	r01402	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
injected	inject	i5202303	VBN	B-NP	O
norepinephrine	norepinephrine	n0601050106050	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
enhanced	enhance	e505203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dopa	dopa	d010	NN	I-NP	I-Chemical
,	,	,000	,	O	O
DL	DL	d400	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
Threo	Threo	t060	AFX	O	I-Chemical
-	-	-000	HYPH	O	I-Chemical
dihydroxyphenylserine	dihydroxyphenylserine	d03602010504206050	NN	B-NP	I-Chemical
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
or	or	o600	CC	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
responses	response	r02105202	NNS	I-NP	O
to	to	t000	TO	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

FLA	FLA	f400	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
63	63	0000	CD	B-NP	I-Chemical
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
beta	beta	b030	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
oxidase	oxidase	o203020	NN	I-NP	O
inhibitor	inhibitor	i5010306	NN	I-NP	O
,	,	,000	,	O	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
have	have	h010	VB	I-VP	O
any	any	a500	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
,	,	,000	,	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
or	or	o600	CC	I-NP	O
reflex	reflex	r01402	NN	I-NP	O
-	-	-000	HYPH	O	O
enhancing	enhance	e5052052	VBG	B-VP	O
effect	effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
.	.	.000	.	O	O

Pimozide	Pimozide	p0502030	NNP	B-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
affect	affect	a1023	VB	I-VP	O
the	the	t000	DT	B-NP	O
actions	action	a23052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
on	on	o500	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
but	but	b030	CC	O	O
completely	completely	c051403040	RB	B-VP	O
blocked	block	b40203	VBD	I-VP	O
the	the	t000	DT	B-NP	O
enhancement	enhancement	e505205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
reflexes	reflex	r0140202	NNS	B-NP	O
.	.	.000	.	O	O

Removal	Removal	r050104	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
carotid	carotid	c060303	NN	I-NP	O
sinuses	sinus	s050202	NNS	I-NP	O
caused	cause	c0203	VBD	B-VP	O
an	an	a500	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
abolished	abolish	a1040203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
negative	negative	n0203010	JJ	I-NP	O
chronotropic	chronotropic	c06050360102	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
restored	restore	r0230603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
to	to	t000	TO	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	O	O
heart	heart	h063	NN	B-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HTP	HTP	h310	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
decreased	decrease	d0260203	VBD	B-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
and	and	a530	CC	I-NP	O
heart	heart	h063	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
reflex	reflex	r01402	NN	I-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
to	to	t000	TO	B-PP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
L	L	l000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
dopa	dopa	d010	NN	B-NP	I-Chemical
enhances	enhance	e505202	VBZ	B-VP	O
reflex	reflex	r01402	NN	B-NP	O
bradycardia	bradycardia	b603020630	NN	I-NP	B-Disease
through	through	t06020	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
alpha	alpha	a410	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
.	.	.000	.	O	O

Furthermore	Furthermore	f063065060	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
rather	rather	r0306	RB	B-CONJP	O
than	than	t050	IN	I-CONJP	O
norepinephrine	norepinephrine	n0601050106050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
do	do	d000	VBP	B-VP	O
not	not	n030	RB	I-VP	O
require	require	r02060	VB	I-VP	O
the	the	t000	DT	B-NP	O
carotid	carotid	c060303	NN	I-NP	O
sinus	sinus	s0502	NN	I-NP	O
baroreceptors	baroreceptor	b060602013062	NNS	I-NP	O
.	.	.000	.	O	O

Microangiopathic	Microangiopathic	m026052010302	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
complicating	complicate	c05140203052	VBG	B-VP	O
FK506	FK506	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
3	3	3000	CD	B-NP	O
episodes	episode	e1020302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
microangiopathic	microangiopathic	m026052010302	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
(	(	(000	(	O	O
MAHA	MAHA	m000	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
solid	solid	s0403	JJ	I-NP	O
organ	organ	o6205	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
FK506	FK506	0000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
)	)	)000	)	O	O
therapy	therapy	t06010	NN	B-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
,	,	,000	,	O	O
discontinuation	discontinuation	d02053050305	NN	B-NP	O
of	of	o100	IN	B-PP	O
FK506	FK506	0000	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
exchange	exchange	e20520	NN	I-NP	O
,	,	,000	,	O	O
fresh	fresh	f6020	JJ	B-NP	O
frozen	freeze	f60205	VBN	I-NP	O
plasma	plasma	p40250	NN	I-NP	O
replacement	replacement	r0140205053	NN	I-NP	O
,	,	,000	,	O	O
corticosteroids	corticosteroid	c0630202306032	NNS	B-NP	B-Chemical
,	,	,000	,	O	O
aspirin	aspirin	a210605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
resolution	resolution	r02040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MAHA	MAHA	m000	NN	B-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
one	one	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
,	,	,000	,	O	O
reintroduction	reintroduction	r05360302305	NN	B-NP	O
of	of	o100	IN	B-PP	O
FK506	FK506	0000	NN	B-NP	B-Chemical
led	lead	l030	VBD	B-VP	O
to	to	t000	TO	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
recurrence	recurrence	r02060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
MAHA	MAHA	m000	NN	B-NP	B-Disease
.	.	.000	.	O	O

FK506	FK506	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
MAHA	MAHA	m000	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
probably	probably	p6010140	RB	B-ADVP	O
rare	rare	r060	JJ	B-ADJP	O
but	but	b030	CC	O	O
physicians	physician	p0202052	NNS	B-NP	O
must	must	m023	MD	B-VP	O
be	be	b000	VB	I-VP	O
aware	aware	a060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
severe	severe	s01060	JJ	I-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
and	and	a530	CC	O	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
,	,	,000	,	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
seem	seem	s050	VB	I-VP	O
to	to	t000	TO	B-PP	O
cross	cross	c602	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
react	react	r023	NN	I-NP	O
with	with	w030	IN	B-PP	O
cyclosporin	cyclosporin	c0240210605	NN	B-NP	B-Chemical
A	A	a000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
CyA	CyA	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
an	an	a500	DT	B-NP	O
immuno	immuno	i5050	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
suppressive	suppressive	s01602010	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
already	already	a46030	RB	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
induce	induce	i53020	VB	I-VP	O
MAHA	MAHA	m000	NN	B-NP	B-Disease
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
anticancer	anticancer	a530205206	JJ	I-NP	O
drugs	drug	d602	NNS	I-NP	O
and	and	a530	CC	O	O
combined	combined	c0510503	JJ	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
nephrotoxic	nephrotoxic	n0106030202	JJ	I-NP	B-Disease
action	action	a2305	NN	I-NP	O
of	of	o100	IN	B-PP	O
anticancer	anticancer	a530205206	JJ	B-NP	O
drugs	drug	d602	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
nitrogranulogen	nitrogranulogen	n03602605040205	NN	B-NP	B-Chemical
(	(	(000	(	O	O
NG	NG	n200	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
methotrexate	methotrexate	m0303602030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MTX	MTX	m320	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
cyclophosphamide	cyclophosphamide	c0240102105030	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CY	CY	c000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
administered	administer	a35050230603	VBN	B-VP	O
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
[	[	[000	(	O	O
MTX	MTX	m320	NN	B-NP	B-Chemical
+	+	+000	SYM	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
+	+	+000	SYM	O	O
CY	CY	c000	NN	B-NP	B-Chemical
(	(	(000	(	O	O
CMF	CMF	c510	NN	B-NP	O
)	)	)000	)	O	O
]	]	]000	)	O	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
experiments	experiment	e2106050532	NNS	B-NP	O
on	on	o500	IN	B-PP	O
Wistar	Wistar	w02306	NNP	B-NP	O
rats	rat	r032	NNS	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
,	,	,000	,	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
urine	urine	u6050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
.	.	.000	.	O	O

Histopathologic	Histopathologic	h0230103040202	JJ	B-NP	O
evaluation	evaluation	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
MTX	MTX	m320	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0228	0228	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
plasma	plasma	p40250	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
decrease	decrease	d026020	NN	B-NP	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
NG	NG	n200	NN	B-NP	B-Chemical
,	,	,000	,	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
CY	CY	c000	NN	I-NP	B-Chemical
neither	neither	n0306	CC	O	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
nor	nor	n060	CC	O	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
compared	compare	c0510603	VBN	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
group	group	g601	NN	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
no	no	n000	DT	B-NP	O
cytostatics	cytostatic	c030230302	NNS	I-NP	O
.	.	.000	.	O	O

Following	Follow	f04052	VBG	B-PP	O
polytherapy	polytherapy	p040306010	NN	B-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
CMF	CMF	c510	NN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
statistically	statistically	s30302302040	RB	I-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	SYM	I-NP	O
0343	0343	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
clearance	clearance	c4060520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
creatinine	creatinine	c60305050	NN	B-NP	B-Chemical
concentration	concentration	c05205360305	NN	I-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
increase	increase	i526020	VB	I-VP	O
significantly	significantly	s025010205340	RB	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

CY	CY	c000	NN	B-NP	B-Chemical
caused	cause	c0203	VBD	B-VP	O
hemorrhagic	hemorrhagic	h05060202	JJ	B-NP	B-Disease
cystitis	cystitis	c0230302	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
cause	cause	c020	VB	I-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
when	when	w050	WRB	B-ADVP	O
combined	combine	c0510503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
MTX	MTX	m320	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Histologic	Histologic	h023040202	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
kidneys	kidney	k03502	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
administration	administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
MTX	MTX	m320	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
CY	CY	c000	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
NG	NG	n200	NN	I-NP	B-Chemical
,	,	,000	,	O	O
while	while	w040	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
such	such	s020	JJ	I-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	O	O
joint	joint	j053	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
MTX	MTX	m320	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
+	+	+000	SYM	B-NP	O
CY	CY	c000	NN	I-NP	B-Chemical
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
studies	study	s30302	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
MTX	MTX	m320	NN	B-NP	B-Chemical
+	+	+000	SYM	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
+	+	+000	SYM	B-NP	O
CY	CY	c000	NN	I-NP	B-Chemical
administered	administer	a35050230603	VBN	B-VP	O
jointly	jointly	j05340	RB	B-ADVP	O
is	be	i200	VBZ	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
interpeduncular	interpeduncular	i53061030520406	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
regulates	regulate	r02040302	VBZ	B-VP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
'	'	'000	''	I-NP	O
s	s	s000	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
free	free	f600	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
field	field	f043	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Partial	Partial	p06304	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
made	make	m030	VBN	I-VP	O
with	with	w030	IN	B-PP	O
kainic	kainic	k0502	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interpeduncular	interpeduncular	i53061030520406	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
ventral	ventral	v053604	JJ	I-NP	O
midbrain	midbrain	m031605	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Compared	Compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
sham	sham	s050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
operated	operate	o1060303	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
,	,	,000	,	O	O
lesions	lesion	l02052	NNS	B-NP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
25	25	0000	CD	I-NP	O
)	)	)000	)	O	O
blunted	blunt	b405303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
early	early	e0640	JJ	I-NP	O
(	(	(000	(	O	O
<	<	<000	SYM	O	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
free	free	f600	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
field	field	f043	NN	I-NP	O
locomotor	locomotor	l02050306	NN	I-NP	B-Disease
hypoactivity	hypoactivity	h0102301030	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
m	m	m000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
enhanced	enhance	e505203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
)	)	)000	)	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
raised	raise	r0203	VBD	B-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
nocturnal	nocturnal	n02306504	JJ	I-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Lesions	Lesion	l02052	NNS	B-NP	O
reduced	reduce	r030203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
extent	extent	e23053	NN	I-NP	O
of	of	o100	IN	B-PP	O
immunohistological	immunohistological	i50502304020204	JJ	B-NP	O
staining	staining	s305052	NN	I-NP	O
for	for	f060	IN	B-PP	O
choline	choline	c04050	NN	B-NP	B-Chemical
acetyltransferase	acetyltransferase	a2030436052106020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
interpeduncular	interpeduncular	i53061030520406	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
(	(	(000	(	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
025	025	0000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
not	not	n030	RB	O	O
for	for	f060	IN	B-PP	O
tyrosine	tyrosine	t0602050	NN	B-NP	B-Chemical
hydroxylase	hydroxylase	h0360204020	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
surrounding	surround	s06053052	VBG	I-NP	O
catecholaminergic	catecholaminergic	c030204050506202	JJ	I-NP	O
A10	A10	0000	NN	I-NP	O
region	region	r0205	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
interpeduncular	interpeduncular	i53061030520406	JJ	I-NP	O
nucleus	nucleus	n02402	NN	I-NP	O
mediates	mediate	m030302	VBZ	B-VP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
dampens	dampen	d051052	VBZ	B-VP	O
nicotinic	nicotinic	n02030502	JJ	B-NP	O
arousal	arousal	a60204	JJ	I-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
located	locate	l020303	VBN	B-VP	O
elsewhere	elsewhere	e42060	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
.	.	.000	.	O	O

Lithium	Lithium	l0305	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
functional	functional	f05230504	JJ	I-NP	I-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
reduced	reduce	r030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
switch	switch	s0320	NN	I-NP	O
to	to	t000	TO	B-PP	O
divalproex	divalproex	d01041602	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
series	series	s0602	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Lithium	Lithium	l0305	NN	B-NP	B-Chemical
remains	remain	r05052	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
and	and	a530	CC	I-NP	O
maintenance	maintenance	m053050520	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
disorder	disorder	d0206306	NN	I-NP	I-Disease
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
much	much	m020	JJ	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
written	write	w60305	VBN	I-VP	O
about	about	a103	IN	B-PP	O
the	the	t000	DT	B-NP	O
management	management	m050205053	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
more	more	m060	RBR	I-NP	O
common	common	c0505	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
polyuria	polyuria	p04060	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
tremor	tremor	t60506	NN	I-NP	B-Disease
,	,	,000	,	O	O
more	more	m060	RBR	B-NP	O
subtle	subtle	s01340	JJ	I-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
such	such	s020	JJ	B-PP	O
as	as	a200	IN	I-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
creativity	creativity	c60301030	NN	B-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	B-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
remain	remain	r0505	VBP	B-VP	O
understudied	understudied	u5306230303	JJ	B-ADJP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
report	report	r01063	NN	I-NP	O
summarizes	summarize	s05060202	VBZ	B-VP	O
our	our	o060	PRP$	B-NP	O
experience	experience	e21060520	NN	I-NP	O
in	in	i500	IN	B-PP	O
switching	switch	s032052	VBG	B-VP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
from	from	f605	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
to	to	t000	TO	B-PP	O
divalproex	divalproex	d01041602	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
to	to	t000	TO	B-VP	O
alleviate	alleviate	a401030	VB	I-VP	O
such	such	s020	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
functional	functional	f05230504	JJ	I-NP	I-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
Open	Open	o105	NN	B-NP	O
,	,	,000	,	O	O
case	case	c020	NN	B-NP	O
series	series	s0602	NN	I-NP	O
design	design	d02025	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
seven	seven	s0105	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
substitution	substitution	s0123030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
,	,	,000	,	O	O
either	either	e0306	CC	O	O
fully	fully	f040	RB	B-ADVP	O
or	or	o600	CC	I-ADVP	O
partially	partially	p063040	RB	I-ADVP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
divalproex	divalproex	d01041602	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
extremely	extremely	e23605040	RB	B-ADJP	O
helpful	helpful	h04104	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	B-Disease
,	,	,000	,	I-NP	I-Disease
motivational	motivational	m0301030504	JJ	I-NP	I-Disease
,	,	,000	,	I-NP	I-Disease
or	or	o600	CC	I-NP	I-Disease
creative	creative	c603010	JJ	I-NP	I-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
attributed	attribute	a36010303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
bipolar	bipolar	b010406	JJ	I-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSION	CONCLUSION	c05240205	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
preliminary	preliminary	p6040505060	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
,	,	,000	,	O	O
divalproex	divalproex	d01041602	NN	B-NP	B-Chemical
sodium	sodium	s0305	NN	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
superior	superior	s010606	JJ	I-NP	O
alternative	alternative	a4306503010	NN	I-NP	O
to	to	t000	TO	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
bipolar	bipolar	b010406	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
experiencing	experience	e2106052052	VBG	B-VP	O
cognitive	cognitive	c02503010	JJ	B-NP	B-Disease
deficits	deficit	d0102032	NNS	I-NP	I-Disease
,	,	,000	,	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
creativity	creativity	c60301030	NN	B-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
functional	functional	f05230504	JJ	B-NP	B-Disease
impairments	impairment	i510650532	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Effect	Effect	e1023	NN	B-NP	O
of	of	o100	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
between	between	b0305	IN	B-PP	O
January	January	j05060	NNP	B-NP	O
1992	1992	0000	CD	I-NP	O
and	and	a530	CC	O	O
January	January	j05060	NNP	B-NP	O
1996	1996	0000	CD	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
receiving	receive	r0201052	VBG	B-VP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
over	over	o106	IN	B-PP	O
a	a	a000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
year	year	y060	NN	I-NP	O
,	,	,000	,	O	O
one	one	o500	CD	B-NP	O
group	group	g601	NN	I-NP	O
comprising	comprise	c051602052	VBG	B-VP	O
hypertensive	hypertensive	h01063052010	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
comprising	comprising	c051602052	JJ	I-NP	O
nonhypertensive	nonhypertensive	n0501063052010	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
not	not	n030	RB	B-VP	O
receiving	receive	r0201052	VBG	I-VP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
from	from	f605	IN	B-PP	O
transplant	transplant	t605214053	NN	B-NP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
was	be	w020	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Nifedipine	Nifedipine	n010301050	NN	B-NP	B-Chemical
significantly	significantly	s025010205340	RB	B-ADVP	O
improved	improve	i5160103	VBD	B-VP	O
kidney	kidney	k0350	NN	B-NP	O
function	function	f052305	NN	I-NP	O
as	as	a200	IN	B-SBAR	O
indicated	indicate	i53020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
lowering	lowering	l06052	NN	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
at	at	a300	IN	B-PP	O
6	6	6000	CD	B-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
observed	observe	o1206103	VBN	I-NP	O
positive	positive	p0203010	JJ	I-NP	O
impact	impact	i51023	NN	I-NP	O
of	of	o100	IN	B-PP	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
reducing	reduce	r0302052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
liver	liver	l0106	NN	B-NP	O
transplant	transplant	t605214053	NN	I-NP	O
recipients	recipient	r02010532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
in	in	i500	IN	B-PP	O
selecting	select	s04023052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
to	to	t000	TO	B-VP	O
treat	treat	t603	VB	I-VP	O
hypertension	hypertension	h0106305205	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Alpha	Alpha	a410	NN	B-NP	O
and	and	a530	CC	I-NP	O
beta	beta	b030	NN	I-NP	O
coma	coma	c050	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
intoxication	intoxication	i5302020305	NN	I-NP	O
uncomplicated	uncomplicate	u520514020303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
cerebral	cerebral	c0601604	JJ	B-NP	B-Disease
hypoxia	hypoxia	h01020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Four	Four	f060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
rendered	render	r0530603	VBN	I-VP	O
comatose	comatose	c0503020	NN	B-NP	B-Disease
or	or	o600	CC	O	O
stuporous	stuporous	s3010602	JJ	B-ADJP	B-Disease
by	by	b000	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
intoxication	intoxication	i5302020305	NN	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
hypoxic	hypoxic	h010202	JJ	B-ADJP	O
,	,	,000	,	O	O
are	be	a600	VBP	B-VP	O
described	describe	d0260103	VBN	I-VP	O
.	.	.000	.	O	O

Three	Three	t060	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
received	receive	r020103	VBD	B-VP	O
high	high	h020	JJ	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
chlormethiazole	chlormethiazole	c040650302040	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
alcohol	alcohol	a4204	NN	B-NP	B-Chemical
withdrawal	withdrawal	w0303604	NN	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
one	one	o500	CD	B-NP	O
took	take	t020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
suicidal	suicidal	s020304	JJ	I-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
nitrazepam	nitrazepam	n036020105	NN	B-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
nitrazepam	nitrazepam	n036020105	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
chlormethiazole	chlormethiazole	c040650302040	NN	B-NP	B-Chemical
intoxication	intoxication	i5302020305	NN	I-NP	O
conformed	conform	c05106503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
of	of	o100	IN	B-PP	O
'	'	'000	``	O	O
alpha	alpha	a410	NN	B-NP	O
coma	coma	c050	NN	I-NP	B-Disease
'	'	'000	''	O	O
,	,	,000	,	O	O
showing	show	s052	VBG	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
reactive	reactive	r023010	JJ	I-NP	O
generalized	generalize	g0506040203	VBN	B-VP	O
or	or	o600	CC	O	O
frontally	frontally	f6053040	RB	B-NP	O
predominant	predominant	p6030505053	JJ	I-NP	O
alpha	alpha	a410	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
EEG	EEG	e020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fourth	fourth	f0630	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
was	be	w020	VBD	B-VP	O
unconscious	unconscious	u5205202	JJ	B-ADJP	O
after	after	a1306	IN	B-SBAR	O
chlormethiazole	chlormethiazole	c040650302040	NN	B-NP	B-Chemical
administration	administration	a350502360305	NN	I-NP	O
exhibite	exhibite	e201030	NN	I-NP	O
generalized	generalize	g0506040203	VBN	B-VP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
reactive	reactive	r023010	JJ	B-NP	O
activity	activity	a2301030	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
slow	slow	s400	JJ	I-NP	O
beta	beta	b030	NN	I-NP	O
range	range	r0520	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
recovered	recover	r02010603	VBD	B-VP	O
completely	completely	c051403040	RB	B-ADVP	O
without	without	w0303	IN	B-PP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
sequelae	sequela	s02040	NNS	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
withdrawal	withdrawal	w0303604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
offending	offend	o1053052	VBG	I-NP	O
agents	agent	a20532	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
similarities	similarity	s0504060302	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
and	and	a530	CC	O	O
pharmacological	pharmacological	p0650204020204	JJ	B-NP	O
depression	depression	d0160205	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
brain	brain	b605	NN	I-NP	O
stem	stem	s305	NN	I-NP	O
reticular	reticular	r03020406	JJ	I-NP	O
formation	formation	f0650305	NN	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
suggested	suggest	s0202303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
situations	situation	s0303052	NNS	I-NP	O
disturbed	disturb	d02306103	VBD	B-VP	O
reticulo	reticulo	r0302040	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
thalamic	thalamic	t040502	JJ	B-NP	O
interactions	interaction	i5306023052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
important	important	i51063053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
alpha	alpha	a410	NN	B-NP	O
coma	coma	c050	NN	I-NP	B-Disease
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
when	when	w050	WRB	B-ADVP	O
this	this	t020	DT	B-NP	O
electroencephalographic	electroencephalographic	e4023605201040260102	JJ	I-NP	O
and	and	a530	CC	I-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
picture	picture	p023060	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
seen	see	s050	VBN	I-VP	O
in	in	i500	IN	B-PP	O
drug	drug	d602	NN	B-NP	O
intoxication	intoxication	i5302020305	NN	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
absence	absence	a120520	NN	I-NP	O
of	of	o100	IN	B-PP	O
significant	significant	s0250102053	JJ	B-NP	O
hypoxaemia	hypoxaemia	h0102050	NN	I-NP	B-Disease
,	,	,000	,	O	O
a	a	a000	DT	B-NP	O
favourable	favourable	f01060140	JJ	I-NP	O
outcome	outcome	o032050	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
anticipated	anticipate	a5302010303	VBN	I-VP	O
.	.	.000	.	O	O

Magnetic	Magnetic	m0250302	JJ	B-NP	O
resonance	resonance	r02050520	NN	I-NP	O
volumetry	volumetry	v04050360	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
in	in	i500	IN	B-PP	O
epileptic	epileptic	e10401302	JJ	B-NP	B-Disease
patients	patient	p030532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
overdosages	overdosage	o1063020202	NNS	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
relationship	relationship	r040305201	NN	I-NP	O
between	between	b0305	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
and	and	a530	CC	O	O
cerebellar	cerebellar	c06010406	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
experienced	experience	e210605203	VBN	I-VP	O
clinical	clinical	c4050204	JJ	B-NP	O
intoxication	intoxication	i5302020305	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
females	female	f050402	NNS	I-NP	O
and	and	a530	CC	O	O
6	6	6000	CD	B-NP	O
males	male	m0402	NNS	I-NP	O
,	,	,000	,	O	O
21	21	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
59	59	0000	CD	I-NP	O
years	year	y062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
age	age	a200	NN	B-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	SYM	I-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
T	T	t000	NN	I-NP	O
whole	whole	w040	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
body	body	b030	NN	I-NP	O
system	system	s02305	NN	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
circular	circular	c0620406	JJ	I-NP	O
polarized	polarize	p04060203	VBN	I-NP	O
head	head	h030	NN	I-NP	O
coil	coil	c040	NN	I-NP	O
.	.	.000	.	O	O

Conventional	Conventional	c0510530504	JJ	B-NP	O
spin	spin	s105	NN	I-NP	O
echo	echo	e200	NN	I-NP	O
images	image	i50202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
acquired	acquire	a20603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
sagittal	sagittal	s020304	JJ	I-NP	O
and	and	a530	CC	I-NP	O
transverse	transverse	t605210620	JJ	I-NP	O
orientation	orientation	o60530305	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
performed	perform	p06106503	VBD	B-VP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
resolution	resolution	r02040305	NN	I-NP	O
3D	3D	3000	NN	I-NP	O
gradient	gradient	g603053	NN	I-NP	O
echo	echo	e200	NN	I-NP	O
,	,	,000	,	O	O
T1	T1	0000	NN	B-NP	O
-	-	-000	HYPH	O	O
weighted	weight	w020303	VBN	B-VP	O
sequences	sequence	s0205202	NNS	B-NP	O
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
1	1	1000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
mm	mm	m500	NN	I-NP	O
slice	slice	s4020	NN	I-NP	O
thickness	thickness	t02502	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
images	image	i50202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
subsequently	subsequently	s0120205340	RB	I-VP	O
processed	process	p6020203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
obtain	obtain	o1305	VB	I-VP	O
volumetric	volumetric	v040503602	JJ	B-NP	O
data	datum	d030	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
.	.	.000	.	O	O

Cerebellar	Cerebellar	c06010406	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
group	group	g601	NN	I-NP	O
ranged	range	r05203	VBD	B-VP	O
between	between	b0305	IN	B-PP	O
67	67	0000	CD	B-NP	O
.	.	.000	.	O	O
66	66	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
131	131	0000	CD	I-NP	O
.	.	.000	.	O	O
08	08	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
(	(	(000	(	O	O
mean	mean	m050	NN	B-NP	O
108	108	0000	CD	I-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
3D	3D	3000	NN	I-NP	O
gradient	gradient	g603053	NN	I-NP	O
echo	echo	e200	JJ	I-NP	O
data	datum	d030	NNS	I-NP	O
sets	set	s032	NNS	I-NP	O
from	from	f605	IN	B-PP	O
10	10	0000	CD	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
and	and	a530	CC	I-NP	O
10	10	0000	CD	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
female	female	f05040	JJ	I-NP	O
age	age	a200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
matched	match	m03203	VBN	I-NP	O
volunteers	volunteer	v04053062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
used	use	u203	VBN	I-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
volumes	volume	v040502	NNS	I-NP	O
.	.	.000	.	O	O

Using	Use	u2052	VBG	B-VP	O
linear	linear	l0506	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
no	no	n000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
exists	exist	e20232	VBZ	B-VP	O
between	between	b0305	IN	B-PP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
duration	duration	d060305	NN	I-NP	O
,	,	,000	,	O	O
elevation	elevation	e4010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
serum	serum	s0605	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
and	and	a530	CC	O	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
multiple	multiple	m0430140	JJ	B-NP	O
regression	regression	r0260205	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
daily	daily	d040	JJ	I-NP	O
dosage	dosage	d02020	NN	I-NP	O
,	,	,000	,	O	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
and	and	a530	CC	O	O
cerebellar	cerebellar	c06010406	JJ	B-NP	O
volume	volume	v04050	NN	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
a	a	a000	DT	B-NP	O
correlation	correlation	c06040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
conclude	conclude	c0524030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
overdosage	overdosage	o106302020	NN	I-NP	B-Disease
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
necessarily	necessarily	n020206040	RB	I-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
unlikely	unlikely	u5402040	JJ	B-ADJP	O
that	that	t030	IN	B-SBAR	O
phenytoin	phenytoin	p050305	NN	B-NP	B-Chemical
medication	medication	m03020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	B-Disease
atrophy	atrophy	a36010	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
remaining	remain	r0505052	VBG	I-NP	O
patients	patient	p030532	NNS	I-NP	O
.	.	.000	.	O	O

Quantitative	Quantitative	q0530303010	JJ	B-NP	O
morphometric	morphometric	m0610503602	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
provide	provide	p601030	VBP	B-VP	O
valuable	valuable	v040140	JJ	B-NP	O
insights	insight	i5202032	NNS	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
cerebellar	cerebellar	c06010406	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Late	Late	l030	JJ	B-NP	O
recovery	recovery	r0201060	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
reported	report	r0106303	VBN	I-VP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hemolytic	hemolytic	h05040302	JJ	I-NP	B-Disease
uremic	uremic	u60502	JJ	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
(	(	(000	(	O	O
HUS	HUS	h020	NN	B-NP	B-Disease
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
woman	woman	w0505	NN	I-NP	O
taking	take	t02052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	B-Chemical
contraceptives	contraceptive	c0536020130102	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
heparin	heparin	h010605	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
dipyridamole	dipyridamole	d01060305040	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
hemodialysis	hemodialysis	h0503040202	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
after	after	a1306	IN	B-SBAR	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
three	three	t060	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
urinary	urinary	u605060	JJ	I-NP	O
output	output	o03103	NN	I-NP	O
rose	rise	r020	VBD	B-VP	O
above	above	a1010	IN	B-PP	O
500	500	0000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
six	six	s020	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
anuria	anuria	a5060	NN	B-NP	B-Disease
,	,	,000	,	O	O
dialysis	dialysis	d040202	NN	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
stopped	stop	s30103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
emphasizes	emphasize	e51020202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
possibility	possibility	p020104030	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
HUS	HUS	h020	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
invariably	invariably	i51060140	RB	B-ADJP	O
irreversible	irreversible	i6010620140	JJ	I-ADJP	O
and	and	a530	CC	O	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
despite	despite	d021030	IN	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
oliguria	oliguria	o402060	NN	I-NP	B-Disease
,	,	,000	,	O	O
recovery	recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
obtained	obtain	o130503	VBN	I-VP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
adult	adult	a3043	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
affected	affect	a102303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
HUS	HUS	h020	NN	B-NP	B-Disease
,	,	,000	,	O	O
dialysis	dialysis	d040202	NN	B-NP	O
should	should	s043	MD	B-VP	O
not	not	n030	RB	I-VP	O
be	be	b000	VB	I-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
prematurely	prematurely	p6050306040	RB	B-ADVP	O
;	;	;000	:	O	O
moreover	moreover	m060106	RB	B-ADVP	O
,	,	,000	,	O	O
bilateral	bilateral	b04030604	JJ	B-NP	O
nephrectomy	nephrectomy	n0106023050	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	O	O
microangiopathic	microangiopathic	m026052010302	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
.	.	.000	.	O	O

Morphological	Morphological	m06104020204	JJ	B-NP	O
features	feature	f030602	NNS	I-NP	O
of	of	o100	IN	B-PP	O
encephalopathy	encephalopathy	e52010401030	NN	B-NP	B-Disease
after	after	a1306	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
valproate	valproate	v0416030	NN	I-NP	B-Chemical
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopic	microscopic	m026020102	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
of	of	o100	IN	B-PP	O
capillaries	capillary	c01040602	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
intragastric	intragastric	i53602023602	JJ	I-NP	O
application	application	a14020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
antiepileptic	antiepileptic	a53010401302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
valproate	valproate	v0416030	NN	I-NP	I-Chemical
(	(	(000	(	O	O
Vupral	Vupral	v01604	JJ	B-NP	O
"	"	"000	``	I-NP	O
Polfa	Polfa	p0410	NNP	I-NP	O
"	"	"000	''	O	O
)	)	)000	)	O	O
at	at	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
200	200	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
b	b	b000	NN	I-NP	O
.	.	.000	.	O	O

w	w	w000	LS	B-LST	O
.	.	.000	.	O	O
once	once	o520	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
for	for	f060	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	I-NP	O
6	6	6000	CD	I-NP	O
,	,	,000	,	I-NP	O
9	9	9000	CD	I-NP	O
and	and	a530	CC	I-NP	O
12	12	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
revealed	reveal	r010403	VBD	B-VP	O
neurological	neurological	n0604020204	JJ	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
indicating	indicate	i530203052	VBG	B-VP	O
cerebellum	cerebellum	c06010405	NN	B-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
(	(	(000	(	O	O
"	"	"000	``	O	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
"	"	"000	''	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
ultrastructural	ultrastructural	u43602360230604	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
structural	structural	s360230604	JJ	B-NP	O
elements	element	e4050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
brain	brain	b605	NN	I-NP	O
-	-	-000	HYPH	O	O
barrier	barrier	b0606	NN	B-NP	O
(	(	(000	(	O	O
BBB	BBB	b100	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
were	be	w060	VBD	B-VP	O
detectable	detectable	d030230140	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
3	3	3000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
became	become	b02050	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
later	later	l0306	JJ	I-NP	O
months	month	m05302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
experiment	experiment	e210605053	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
were	be	w060	VBD	B-VP	O
most	most	m023	RBS	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
after	after	a1306	IN	B-PP	O
12	12	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
,	,	,000	,	O	O
located	located	l020303	JJ	B-ADJP	O
mainly	mainly	m0540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
molecular	molecular	m04020406	JJ	I-NP	O
layer	layer	l060	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
.	.	.000	.	O	O

Lesions	Lesion	l02052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
capillary	capillary	c0104060	NN	I-NP	O
included	include	i5240303	VBD	B-VP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
endothelial	endothelial	e53030404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Organelles	Organelle	o62050402	NNS	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
in	in	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
the	the	t000	DT	B-NP	O
mitochondria	mitochondrion	m030205360	NNS	I-NP	O
(	(	(000	(	O	O
increased	increase	i5260203	VBN	B-NP	O
number	number	n05106	NN	I-NP	O
and	and	a530	CC	I-NP	O
size	size	s020	NN	I-NP	O
,	,	,000	,	O	O
distinct	distinct	d0230523	JJ	B-NP	O
degeneration	degeneration	d0205060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
their	their	t060	PRP$	B-NP	O
matrix	matrix	m03602	NN	I-NP	O
and	and	a530	CC	I-NP	O
cristae	cristae	c60230	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
Golgi	Golgi	g0420	NNP	B-NP	O
apparatus	apparatus	a1060302	NN	I-NP	O
were	be	w060	VBD	B-VP	O
altered	alter	a430603	VBN	I-VP	O
.	.	.000	.	O	O

Reduced	Reduce	r030203	VBN	B-NP	O
size	size	s020	NN	I-NP	O
of	of	o100	IN	B-PP	O
capillary	capillary	c0104060	JJ	B-NP	O
lumen	lumen	l0505	NN	I-NP	O
and	and	a530	CC	I-NP	O
occlusion	occlusion	o240205	NN	I-NP	O
were	be	w060	VBD	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
swollen	swell	s0405	VBN	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
luminal	luminal	l050504	JJ	B-NP	B-Chemical
protrusions	protrusion	p603602052	NNS	I-NP	O
and	and	a530	CC	O	O
swollen	swollen	s0405	JJ	B-NP	O
microvilli	microvilli	m02601040	NNS	I-NP	O
.	.	.000	.	O	O

Pressure	Pressure	p602060	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vessel	vessel	v0204	NN	I-NP	O
wall	wall	w040	NN	I-NP	O
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
enlarged	enlarged	e5406203	JJ	B-NP	O
perivascular	perivascular	p0601020406	JJ	I-NP	O
astrocytic	astrocytic	a236020302	JJ	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

Fragments	Fragment	f60250532	NNS	B-NP	O
of	of	o100	IN	B-PP	O
necrotic	necrotic	n0260302	JJ	B-NP	B-Disease
endothelial	endothelial	e53030404	JJ	I-NP	O
cells	cell	c042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
lumens	lumen	l05052	NNS	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
loosening	loosen	l0205052	VBG	I-VP	O
and	and	a530	CC	O	O
breaking	breaking	b602052	NN	B-NP	O
of	of	o100	IN	B-PP	O
tight	tight	t0203	JJ	B-NP	O
cellular	cellular	c040406	JJ	I-NP	O
junctions	junction	j0523052	NNS	I-NP	O
.	.	.000	.	O	O

Damage	Damage	d05020	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
vascular	vascular	v020406	JJ	I-NP	O
basement	basement	b0205053	NN	I-NP	O
lamina	lamina	l05050	NN	I-NP	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
observed	observe	o1206103	VBN	I-VP	O
.	.	.000	.	O	O

Damage	Damage	d05020	NN	B-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
capillary	capillary	c0104060	NN	I-NP	O
was	be	w020	VBD	B-VP	O
accompanied	accompany	a20510503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
to	to	t000	TO	B-PP	O
neuroglial	neuroglial	n0602404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
perivascular	perivascular	p0601020406	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
proliferation	proliferation	p60401060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
(	(	(000	(	O	O
Bergmann	Bergmann	b062505	NNP	B-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
in	in	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-ADJP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
occasionally	occasionally	o20205040	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
oligodendrocytes	oligodendrocyte	o402030536020302	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
.	.	.000	.	O	O

Alterations	Alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
structural	structural	s360230604	JJ	I-NP	O
elements	element	e4050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NNP	I-NP	O
coexisted	coexist	c0202303	VBD	B-VP	O
with	with	w030	IN	B-PP	O
marked	marked	m06203	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
neurons	neuron	n06052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellum	cerebellum	c06010405	NN	I-NP	O
(	(	(000	(	O	O
Purkinje	Purkinje	p0620520	NN	B-NP	O
cells	cell	c042	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
earliest	early	e064023	JJS	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
electron	electron	e4023605	NN	B-NP	O
micrographs	micrograph	m0260260102	NNS	I-NP	O
both	both	b030	CC	O	O
luminal	luminal	l050504	JJ	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
antiluminal	antiluminal	a5304050504	JJ	I-NP	O
sides	side	s0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
BBB	BBB	b100	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cerebellar	cerebellar	c06010406	JJ	I-NP	O
cortex	cortex	c06302	NN	I-NP	O
had	have	h030	VBD	B-VP	O
similar	similar	s050406	JJ	B-NP	O
lesions	lesion	l02052	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
possible	possible	p020140	JJ	I-NP	O
influence	influence	i5140520	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	B-Disease
damage	damage	d05020	NN	I-NP	I-Disease
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-NP	O
hyperammonemia	hyperammonemia	h01060505050	NN	I-NP	B-Disease
,	,	,000	,	O	O
upon	upon	u105	IN	B-PP	O
the	the	t000	DT	B-NP	O
development	development	d0104015053	NN	I-NP	O
of	of	o100	IN	B-PP	O
valproate	valproate	v0416030	NN	B-NP	B-Chemical
encephalopathy	encephalopathy	e52010401030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Fatal	Fatal	f0304	JJ	B-NP	O
intracranial	intracranial	i5360260504	JJ	I-NP	B-Disease
bleeding	bleeding	b403052	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
prehospital	prehospital	p60210304	NN	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
paramedic	paramedic	p06050302	JJ	B-NP	O
misjudgment	misjudgment	m020325053	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
execution	execution	e2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
protocol	protocol	p6030204	NN	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
allergic	allergic	a406202	JJ	B-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
pulmonary	pulmonary	p04505060	JJ	B-NP	B-Disease
edema	edema	e3050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
wheezing	wheeze	w02052	VBG	B-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
sudden	sudden	s0305	JJ	I-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
respiratory	respiratory	r0210603060	JJ	B-NP	B-Disease
distress	distress	d023602	NN	I-NP	I-Disease
,	,	,000	,	O	O
rash	rash	r020	NN	B-NP	B-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
history	history	h023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
medicine	medicine	m0302050	NN	I-NP	O
led	lead	l030	VBD	B-VP	O
the	the	t000	DT	B-NP	O
two	two	t000	CD	I-NP	O
paramedics	paramedic	p06050302	NNS	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
scene	scene	s2050	NN	I-NP	O
to	to	t000	TO	B-VP	O
administer	administer	a350502306	VB	I-VP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Subsequently	Subsequently	s0120205340	RB	B-ADVP	O
,	,	,000	,	O	O
acute	acute	a2030	JJ	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
and	and	a530	CC	O	O
fatal	fatal	f0304	JJ	B-NP	O
subarachnoid	subarachnoid	s0106020503	JJ	I-NP	B-Disease
hemorrhage	hemorrhage	h0506020	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Epinephrine	Epinephrine	e1050106050	NN	B-NP	B-Chemical
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
proven	proven	p60105	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
prehospital	prehospital	p60210304	NN	B-NP	O
care	care	c060	NN	I-NP	O
;	;	;000	:	O	O
however	however	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
use	use	u200	NN	B-NP	O
by	by	b000	IN	B-PP	O
paramedics	paramedic	p06050302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
suspected	suspect	s02102303	VBN	B-NP	O
allergic	allergic	a406202	JJ	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
severe	severe	s01060	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
viewed	view	v030	VBN	I-VP	O
with	with	w030	IN	B-PP	O
caution	caution	c0305	NN	B-NP	O
.	.	.000	.	O	O

Role	Role	r040	NN	B-NP	O
of	of	o100	IN	B-PP	O
activation	activation	a23010305	NN	B-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
B2	B2	0000	NN	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Cellular	Cellular	c040406	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
account	account	a2053	VBP	B-VP	O
for	for	f060	IN	B-PP	O
disruption	disruption	d02601305	NN	B-NP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
are	be	a600	VBP	B-VP	O
not	not	n030	RB	O	O
clear	clear	c406	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
synthesis	synthesis	s0530202	NN	B-NP	O
/	/	/000	SYM	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
activate	activate	a2301030	VB	I-VP	O
B2	B2	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
.	.	.000	.	O	O

Permeability	Permeability	p0650104030	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
was	be	w020	VBD	B-VP	O
quantitated	quantitate	q053030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
clearance	clearance	c4060520	NN	B-NP	O
of	of	o100	IN	B-PP	O
fluorescent	fluorescent	f40602053	NN	B-NP	O
-	-	-000	HYPH	O	O
labeled	label	l010403	VBN	B-VP	O
dextran	dextran	d023605	NN	B-NP	B-Chemical
before	before	b01060	IN	B-PP	O
and	and	a530	CC	I-PP	O
during	during	d06052	IN	I-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
acute	acute	a2030	JJ	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
vehicle	vehicle	v0240	NN	B-NP	O
and	and	a530	CC	I-NP	O
Hoe	Hoe	h000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
140	140	0000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
1	1	1000	CD	B-NP	O
microM	microM	m02605	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Phenylephrine	Phenylephrine	p05040106050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
increased	increase	i5260203	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
,	,	,000	,	O	O
arteriolar	arteriolar	a63060406	JJ	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
and	and	a530	CC	I-NP	O
clearance	clearance	c4060520	NN	I-NP	O
of	of	o100	IN	B-PP	O
fluorescent	fluorescent	f40602053	JJ	B-NP	O
dextran	dextran	d023605	NN	I-NP	B-Chemical
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
magnitude	magnitude	m02503030	NN	I-NP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
findings	finding	f053052	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
disruption	disruption	d02601305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
blood	blood	b403	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
brain	brain	b605	NN	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
during	during	d06052	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	O	O
related	related	r040303	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
/	/	/000	SYM	B-NP	O
release	release	r04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bradykinin	bradykinin	b603020505	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
activate	activate	a2301030	VB	I-VP	O
B2	B2	0000	NN	B-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Risk	Risk	r020	NN	B-NP	O
factors	factor	f023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sensorineural	sensorineural	s05206050604	JJ	B-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
preterm	preterm	p603065	JJ	B-NP	O
infants	infant	i510532	NNS	I-NP	O
.	.	.000	.	O	O

Among	Among	a5052	IN	B-PP	O
547	547	0000	CD	B-NP	O
preterm	preterm	p603065	JJ	I-NP	O
infants	infant	i510532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
<	<	<000	SYM	B-NP	O
or	or	o600	CC	O	O
=	=	=000	SYM	B-VP	O
34	34	0000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
gestation	gestation	g0230305	NN	I-NP	O
born	bear	b065	VBN	B-VP	O
between	between	b0305	IN	B-PP	O
1987	1987	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1991	1991	0000	CD	I-NP	O
,	,	,000	,	O	O
8	8	8000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
46	46	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
developed	develop	d01040103	VBD	B-VP	O
severe	severe	s01060	JJ	B-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
bilateral	bilateral	b04030604	JJ	I-NP	O
sensorineural	sensorineural	s05206050604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Perinatal	Perinatal	p06050304	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
infants	infant	i510532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
control	control	c053604	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
matched	match	m03203	VBN	B-VP	O
for	for	f060	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
and	and	a530	CC	I-NP	O
birth	birth	b0630	NN	I-NP	O
weight	weight	w0203	NN	I-NP	O
and	and	a530	CC	B-PP	O
for	for	f060	IN	B-PP	O
perinatal	perinatal	p06050304	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Our	Our	o060	PRP$	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
demonstrated	demonstrate	d05052360303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
higher	high	h0206	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
perinatal	perinatal	p06050304	JJ	B-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Ototoxicity	Ototoxicity	o3030202030	NN	B-NP	B-Disease
appeared	appear	a10603	VBD	B-VP	O
closely	closely	c402040	RB	B-ADJP	O
related	related	r040303	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
administration	administration	a350502360305	NN	I-NP	O
and	and	a530	CC	O	O
higher	high	h0206	JJR	B-NP	O
total	total	t0304	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
ototoxic	ototoxic	o3030202	JJ	B-NP	B-Disease
drugs	drug	d602	NNS	I-NP	O
,	,	,000	,	O	O
particularly	particularly	p06302040640	RB	B-ADVP	O
aminoglycosides	aminoglycosides	a50502402020302	IN	B-ADVP	B-Chemical
and	and	a530	CC	O	O
furosemide	furosemide	f060205030	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
strongly	strongly	s3605240	RB	B-ADVP	O
recommend	recommend	r0205053	VBP	B-VP	O
to	to	t000	TO	B-PP	O
prospectively	prospectively	p602102301040	RB	B-VP	O
and	and	a530	CC	I-VP	O
regularly	regularly	r02040640	RB	I-VP	O
perform	perform	p061065	VB	I-VP	O
audiologic	audiologic	a03040202	JJ	B-NP	O
assessment	assessment	a2025053	NN	I-NP	O
in	in	i500	IN	B-PP	O
sick	sick	s020	JJ	B-NP	O
preterm	preterm	p603065	JJ	I-NP	O
children	child	c043605	NNS	I-NP	O
as	as	a200	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
delayed	delay	d0403	VBN	B-NP	O
onset	onset	o5203	NN	I-NP	O
and	and	a530	CC	O	O
in	in	i500	IN	B-PP	O
most	most	m023	JJS	B-NP	O
cases	case	c0202	NNS	I-NP	O
bilateral	bilateral	b04030604	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
.	.	.000	.	O	O

Seizure	Seizure	s02060	NN	B-NP	B-Disease
resulting	result	r02043052	VBG	B-VP	O
from	from	f605	IN	B-PP	O
a	a	a000	DT	B-NP	O
venlafaxine	venlafaxine	v0540102050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-VP	O
report	report	r01063	VB	I-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
.	.	.000	.	O	O

CASE	CASE	c020	NN	B-NP	O
SUMMARY	SUMMARY	s05060	NN	I-NP	O
:	:	:000	:	O	O
A	A	a000	DT	B-NP	O
40	40	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
woman	woman	w0505	NN	I-NP	O
with	with	w030	IN	B-PP	O
major	major	m0206	JJ	B-NP	B-Disease
depression	depression	d0160205	NN	I-NP	I-Disease
took	take	t020	VBD	B-VP	O
an	an	a500	DT	B-NP	O
overdose	overdose	o1063020	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
apparent	apparent	a106053	JJ	I-NP	O
suicide	suicide	s02030	NN	I-NP	O
attempt	attempt	a30513	NN	I-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
ingestion	ingestion	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
26	26	0000	CD	B-NP	O
venlafaxine	venlafaxine	v0540102050	NN	I-NP	B-Chemical
50	50	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
mg	mg	m200	NN	I-NP	O
tablets	tablet	t014032	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
experienced	experience	e210605203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
witnessed	witness	w0350203	VBN	I-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
.	.	.000	.	O	O

She	She	s000	PRP	B-NP	O
was	be	w020	VBD	B-VP	O
admitted	admit	a350303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
medical	medical	m030204	JJ	I-NP	O
intensive	intensive	i53052010	JJ	I-NP	O
care	care	c060	NN	I-NP	O
unit	unit	u503	NN	I-NP	O
,	,	,000	,	O	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
discontinued	discontinue	d020530503	VBN	I-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
seen	see	s050	VBN	I-VP	O
.	.	.000	.	O	O

DISCUSSION	DISCUSSION	d020205	NN	B-NP	O
:	:	:000	:	O	O
To	To	t000	TO	B-PP	O
our	our	o060	PRP$	B-NP	O
knowledge	knowledge	k5040320	NN	I-NP	O
,	,	,000	,	O	O
this	this	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
reported	report	r0106303	VBN	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
that	that	t030	WDT	B-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
generalized	generalize	g0506040203	VBN	I-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
nonoverdose	nonoverdose	n0501063020	JJ	B-NP	O
pharmacokinetics	pharmacokinetic	p0650202050302	NNS	I-NP	O
and	and	a530	CC	I-NP	O
pharmacodynamics	pharmacodynamic	p0650203050502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
venlafaxine	venlafaxine	v0540102050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
risks	risk	r020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
available	available	a1040140	JJ	B-NP	O
interventions	intervention	i53061053052	NNS	I-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
emergent	emergent	e5062053	JJ	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
was	be	w020	VBD	B-VP	O
instituted	institute	i523030303	VBN	I-VP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
venlafaxine	venlafaxine	v0540102050	NN	I-NP	B-Chemical
overdose	overdose	o1063020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
our	our	o060	PRP$	B-NP	O
patient	patient	p03053	NN	I-NP	O
resulted	result	r0204303	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
single	single	s05240	JJ	I-NP	O
episode	episode	e102030	NN	I-NP	O
of	of	o100	IN	B-PP	O
generalized	generalize	g0506040203	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
but	but	b030	CC	O	O
elicited	elicit	e4020303	VBD	B-VP	O
no	no	n000	DT	B-NP	O
further	further	f06306	JJ	I-NP	O
sequelae	sequela	s02040	NNS	I-NP	O
.	.	.000	.	O	O

Combined	Combine	c0510503	VBN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
E1	E1	0000	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
haemodilution	haemodilution	h0503040305	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Combined	Combine	c0510503	VBN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
prolonged	prolong	p60405203	VBN	B-NP	O
prostaglandin	prostaglandin	p602302405305	NN	I-NP	B-Chemical
E1	E1	0000	NN	I-NP	I-Chemical
(	(	(000	(	O	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
haemodilution	haemodilution	h0503040305	NN	I-NP	B-Disease
on	on	o500	IN	B-PP	O
hepatic	hepatic	h010302	JJ	B-NP	O
function	function	f052305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
undergoing	undergo	u53062052	VBG	B-VP	O
hip	hip	h010	NN	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
;	;	;000	:	O	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
A	A	a000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
subjected	subject	s01202303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
controlled	control	c05360403	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
alone	alone	a4050	RB	B-ADVP	O
,	,	,000	,	O	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
B	B	b000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
haemodilution	haemodilution	h0503040305	NN	B-NP	B-Disease
alone	alone	a4050	RB	B-ADVP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
10	10	0000	CD	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
controlled	controlled	c05360403	JJ	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
haemodilution	haemodilution	h0503040305	NN	I-NP	B-Disease
.	.	.000	.	O	O

Haemodilution	Haemodilution	h0503040305	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
B	B	b000	NN	B-NP	O
and	and	a530	CC	O	O
C	C	c000	NN	B-NP	O
was	be	w020	VBD	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
withdrawing	withdraw	w03036052	VBG	B-VP	O
approximately	approximately	a16020503040	RB	B-NP	O
1000	1000	0000	CD	I-NP	O
mL	mL	m400	NN	I-NP	O
of	of	o100	IN	B-PP	O
blood	blood	b403	NN	B-NP	O
and	and	a530	CC	O	O
replacing	replace	r01402052	VBG	B-VP	O
it	it	i300	PRP	B-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
dextran	dextran	d023605	NN	B-NP	B-Chemical
solution	solution	s040305	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
final	final	f0504	JJ	B-NP	O
haematocrit	haematocrit	h050302603	NN	I-NP	O
values	value	v0402	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
21	21	0000	CD	B-NP	O
or	or	o600	CC	I-NP	O
22	22	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Controlled	Control	c05360403	VBN	B-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	I-NP	O
C	C	c000	NN	I-NP	O
was	be	w020	VBD	B-VP	O
induced	induce	i530203	VBN	I-VP	O
with	with	w030	IN	B-PP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
to	to	t000	TO	B-VP	O
maintain	maintain	m05305	VB	I-VP	O
mean	mean	m050	JJ	B-NP	O
arterial	arterial	a630604	JJ	I-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
at	at	a300	IN	B-PP	O
55	55	0000	CD	B-NP	O
mmHg	mmHg	m502	NN	I-NP	O
for	for	f060	IN	B-PP	O
180	180	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
.	.	.000	.	O	O

Measurements	Measurement	m0206050532	NNS	B-NP	O
included	include	i5240303	VBD	B-VP	O
arterial	arterial	a630604	JJ	B-NP	O
ketone	ketone	k03050	NN	I-NP	O
body	body	b030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
(	(	(000	(	O	O
AKBR	AKBR	a216	NN	B-NP	O
,	,	,000	,	O	O
aceto	aceto	a2030	AFX	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
acetate	acetate	a203030	NN	I-NP	I-Chemical
/	/	/000	SYM	B-NP	O
3	3	3000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxybutyrate	hydroxybutyrate	h03602010306030	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
clinical	clinical	c4050204	JJ	B-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
parameters	parameter	p060503062	NNS	I-NP	O
.	.	.000	.	O	O

AKBR	AKBR	a216	NN	B-NP	O
and	and	a530	CC	I-NP	O
biological	biological	b04020204	JJ	I-NP	O
hepatic	hepatic	h010302	JJ	I-NP	O
function	function	f052305	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
change	change	c0520	NN	I-NP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
time	time	t050	NN	I-NP	O
course	course	c0620	NN	I-NP	O
in	in	i500	IN	B-PP	O
groups	group	g6012	NNS	B-NP	O
A	A	a000	NN	I-NP	O
and	and	a530	CC	I-NP	O
B	B	b000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
group	group	g601	NN	B-NP	O
C	C	c000	NN	I-NP	O
,	,	,000	,	O	O
AKBR	AKBR	a216	NN	B-NP	O
showed	show	s030	VBD	B-VP	O
a	a	a000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
decrease	decrease	d026020	NN	I-NP	O
at	at	a300	IN	B-PP	O
120	120	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
at	at	a300	IN	B-PP	O
180	180	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
49	49	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
start	start	s3063	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotension	hypotension	h010305205	NN	B-NP	B-Disease
and	and	a530	CC	B-PP	O
at	at	a300	IN	B-PP	O
60	60	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
(	(	(000	(	O	O
-	-	-000	SYM	B-NP	O
32	32	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
after	after	a1306	IN	B-PP	O
recovery	recovery	r0201060	NN	B-NP	O
of	of	o100	IN	B-PP	O
normotension	normotension	n0650305205	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
SGOT	SGOT	s203	NN	B-NP	O
,	,	,000	,	O	O
SGPT	SGPT	s213	NN	B-NP	O
,	,	,000	,	O	O
LDH	LDH	l300	NN	B-NP	O
and	and	a530	CC	O	O
total	total	t0304	JJ	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
showed	show	s030	VBD	B-VP	O
significant	significant	s0250102053	JJ	B-NP	O
increases	increase	i5260202	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
operation	operation	o1060305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
prolonged	prolong	p60405203	VBN	I-NP	O
combination	combination	c051050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
120	120	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
of	of	o100	IN	B-PP	O
PGE1	PGE1	0000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypotension	hypotension	h010305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
moderate	moderate	m0306030	JJ	I-NP	O
haemodilution	haemodilution	h0503040305	NN	I-NP	B-Disease
would	would	w043	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
impairment	impairment	i51065053	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
hepatic	hepatic	h010302	JJ	B-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Cardiovascular	Cardiovascular	c06301020406	JJ	B-NP	B-Disease
alterations	alteration	a430603052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
.	.	.000	.	O	O

Preclinical	Preclinical	p6024050204	JJ	B-NP	O
toxicologic	toxicologic	t0202040202	JJ	I-NP	O
investigation	investigation	i51023020305	NN	I-NP	O
suggested	suggest	s0202303	VBD	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blocker	blocker	b40206	NN	I-NP	O
,	,	,000	,	O	O
Ro	Ro	r000	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
5967	5967	0000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
induced	induce	i530203	VBD	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
alterations	alteration	a430603052	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
fetuses	fetus	f030202	NNS	I-NP	O
exposed	expose	e210203	VBN	B-VP	O
to	to	t000	TO	B-PP	O
this	this	t020	DT	B-NP	O
agent	agent	a2053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
organogenesis	organogenesis	o620502050202	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
designed	design	d0202503	VBN	I-VP	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
the	the	t000	DT	B-NP	O
hypothesis	hypothesis	h01030202	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
in	in	i500	IN	B-PP	O
general	general	g050604	JJ	B-NP	O
induce	induce	i53020	VBP	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
indicating	indicate	i530203052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
pharmacologic	pharmacologic	p06502040202	JJ	I-NP	O
class	class	c402	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
three	three	t060	CD	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
structure	structure	s36023060	NN	I-NP	O
,	,	,000	,	O	O
nifedipine	nifedipine	n010301050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
diltiazem	diltiazem	d0430205	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
,	,	,000	,	O	O
along	along	a4052	IN	B-PP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
new	new	n000	JJ	I-NP	O
agent	agent	a2053	NN	I-NP	O
.	.	.000	.	O	O

Pregnant	Pregnant	p6025053	JJ	B-NP	O
rats	rat	r032	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
administered	administer	a35050230603	VBN	I-VP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
period	period	p0603	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	O
morphogenesis	morphogenesis	m06102050202	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
offspring	offspring	o1216052	NN	I-NP	O
examined	examine	e2050503	VBN	B-VP	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
20	20	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
gestation	gestation	g0230305	NN	B-NP	O
for	for	f060	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
malformations	malformation	m04106503052	NNS	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
exposure	exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-PP	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
four	four	f060	CD	I-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
this	this	t020	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
significant	significant	s0250102053	JJ	I-ADJP	O
only	only	o540	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
nifedipine	nifedipine	n010301050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
four	four	f060	CD	I-NP	O
agents	agent	a20532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
aortic	aortic	a06302	JJ	B-NP	O
arch	arch	a620	NN	I-NP	O
branching	branching	b6052052	NN	I-NP	O
variants	variant	v060532	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
significantly	significantly	s025010205340	RB	B-ADJP	O
increased	increase	i5260203	VBN	I-ADJP	O
only	only	o540	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
Ro	Ro	r000	NN	B-NP	B-Chemical
40	40	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
5967	5967	0000	CD	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
verapamil	verapamil	v06010504	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
common	common	c0505	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
sumatriptan	sumatriptan	s0503601305	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Atypical	Atypical	a3010204	JJ	B-NP	B-Disease
sensations	sensation	s05203052	NNS	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
subcutaneous	subcutaneous	s012030502	JJ	B-NP	O
sumatriptan	sumatriptan	s0503601305	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
common	common	c0505	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
of	of	o100	IN	B-PP	O
uncertain	uncertain	u5206305	JJ	B-NP	O
origin	origin	o60205	NN	I-NP	O
.	.	.000	.	O	O

They	They	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
almost	almost	a45023	RB	B-ADJP	O
always	always	a402	RB	I-ADJP	O
benign	benign	b05025	JJ	I-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
mistaken	mistake	m0230205	VBN	I-VP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
serious	serious	s0602	JJ	I-NP	O
adverse	adverse	a310620	JJ	I-NP	O
event	event	e1053	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
presented	present	p60205303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
tingling	tingle	t0524052	VBG	B-VP	B-Disease
or	or	o600	CC	I-VP	I-Disease
burning	burn	b065052	VBG	I-VP	I-Disease
sensations	sensation	s05203052	NNS	B-NP	I-Disease
limited	limit	l050303	VBN	B-VP	O
to	to	t000	TO	B-PP	O
areas	area	a602	NNS	B-NP	O
of	of	o100	IN	B-PP	O
heat	heat	h030	NN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
or	or	o600	CC	I-NP	O
sunburn	sunburn	s051065	NN	I-NP	B-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
these	these	t020	DT	B-NP	O
individuals	individual	i530103042	NNS	I-NP	O
,	,	,000	,	O	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	I-VP	O
likely	likely	l02040	RB	I-VP	O
generated	generate	g05060303	VBN	I-VP	O
superficially	superficially	s0106102040	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
skin	skin	s205	NN	I-NP	O
.	.	.000	.	O	O

Macula	Macula	m02040	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
after	after	a1306	IN	B-PP	O
intravitreal	intravitreal	i5360103604	JJ	B-NP	O
amikacin	amikacin	a5020205	NN	I-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Although	Although	a43020	IN	B-SBAR	O
intravitreal	intravitreal	i5360103604	JJ	B-NP	O
aminoglycosides	aminoglycoside	a50502402020302	NNS	I-NP	B-Chemical
have	have	h010	VBP	B-VP	O
substantially	substantially	s0123053040	RB	I-VP	O
improved	improve	i5160103	VBN	I-VP	O
visual	visual	v0204	JJ	B-NP	O
prognosis	prognosis	p60250202	NN	I-NP	O
in	in	i500	IN	B-PP	O
endophthalmitis	endophthalmitis	e5301030450302	NN	B-NP	B-Disease
,	,	,000	,	O	O
macular	macular	m020406	JJ	B-NP	O
infarction	infarction	i51062305	NN	I-NP	B-Disease
may	may	m000	MD	B-VP	O
impair	impair	i5106	VB	I-VP	O
full	full	f040	JJ	B-NP	O
visual	visual	v0204	JJ	I-NP	O
recovery	recovery	r0201060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
present	present	p602053	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
presumed	presume	p6020503	VBN	B-NP	O
amikacin	amikacin	a5020205	NN	I-NP	B-Chemical
retinal	retinal	r030504	NN	I-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
with	with	w030	IN	B-PP	O
amikacin	amikacin	a5020205	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
vancomycin	vancomycin	v052050205	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
alpha	alpha	a410	SYM	B-NP	O
-	-	-000	HYPH	B-NP	O
haemolytic	haemolytic	h05040302	JJ	I-NP	O
streptococcal	streptococcal	s36013020204	JJ	I-NP	B-Disease
endophthalmitis	endophthalmitis	e5301030450302	NN	I-NP	I-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Endophthalmitis	Endophthalmitis	e5301030450302	NN	B-NP	B-Disease
resolved	resolve	r0204103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
improvement	improvement	i5160105053	NN	B-NP	O
in	in	i500	IN	B-PP	O
visual	visual	v0204	JJ	B-NP	O
acuity	acuity	a2030	NN	I-NP	O
to	to	t000	TO	B-PP	O
6	6	6000	CD	B-NP	O
/	/	/000	SYM	B-NP	O
24	24	0000	CD	I-NP	O
at	at	a300	IN	B-PP	O
three	three	t060	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Fundus	Fundus	f05302	NN	B-NP	O
fluorescein	fluorescein	f4060205	NN	I-NP	B-Chemical
angiography	angiography	a52026010	NN	I-NP	O
confirmed	confirm	c05106503	VBD	B-VP	O
macular	macular	m020406	JJ	B-NP	O
capillary	capillary	c0104060	JJ	I-NP	O
closure	closure	c402060	NN	I-NP	O
and	and	a530	CC	I-NP	O
telangiectasis	telangiectasis	t040520230202	NN	I-NP	B-Disease
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Currently	Currently	c0605340	RB	B-NP	O
accepted	accept	a201303	VBN	I-NP	O
intravitreal	intravitreal	i5360103604	JJ	I-NP	O
antibiotic	antibiotic	a53010302	JJ	I-NP	O
regimens	regimen	r0205052	NNS	I-NP	O
may	may	m000	MD	B-VP	O
cause	cause	c020	VB	I-VP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
and	and	a530	CC	O	O
macular	macular	m020406	JJ	B-NP	O
ischaemia	ischaemia	i2050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
aimed	aim	a0503	VBN	B-VP	O
at	at	a300	IN	B-PP	O
avoiding	avoid	a103052	VBG	B-VP	O
retinal	retinal	r030504	JJ	B-NP	B-Disease
toxicity	toxicity	t0202030	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
role	role	r040	NN	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
smoking	smoking	s502052	NN	B-NP	O
-	-	-000	HYPH	O	O
related	relate	r040303	VBN	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
activates	activate	a23010302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
sympathetic	sympathetic	s051030302	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
and	and	a530	CC	B-PP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
way	way	w000	NN	I-NP	O
could	could	c043	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Animal	Animal	a50504	NN	B-NP	O
studies	study	s30302	NNS	I-NP	O
and	and	a530	CC	O	O
mechanistic	mechanistic	m020502302	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
could	could	c043	MD	B-VP	O
play	play	p400	VB	I-VP	O
a	a	a000	DT	B-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
accelerating	accelerate	a2040603052	VBG	B-NP	O
atherosclerosis	atherosclerosis	a306024060202	NN	I-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
evidence	evidence	e1030520	NN	B-NP	O
among	among	a5052	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
is	be	i200	VBZ	B-VP	O
too	too	t000	RB	B-ADJP	O
inadequate	inadequate	i50302030	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
definitive	definitive	d010503010	JJ	B-ADJP	O
about	about	a103	IN	B-PP	O
such	such	s020	JJ	B-NP	O
an	an	a500	DT	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

Almost	Almost	a45023	RB	B-ADVP	O
certainly	certainly	c0630540	RB	I-ADVP	O
,	,	,000	,	O	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
hemodynamic	hemodynamic	h0503050502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
contributes	contribute	c0536010302	VBZ	B-VP	O
to	to	t000	TO	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
current	current	c06053	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
much	much	m020	RB	B-ADJP	O
less	less	l020	RBR	I-ADJP	O
important	important	i51063053	JJ	I-ADJP	O
than	than	t050	IN	B-SBAR	O
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
prothrombotic	prothrombotic	p603060510302	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cigarette	cigarette	c0206030	NN	B-NP	O
smoking	smoking	s502052	NN	I-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
carbon	carbon	c06105	NN	B-NP	B-Chemical
monoxide	monoxide	m0502030	NN	I-NP	I-Chemical
.	.	.000	.	O	O

Nicotine	Nicotine	n0203050	NN	B-NP	B-Chemical
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
enhance	enhance	e50520	VB	I-VP	O
thrombosis	thrombosis	t060510202	NN	B-NP	B-Disease
among	among	a5052	IN	B-PP	O
humans	human	h05052	NNS	B-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pipe	pipe	p010	NN	B-NP	O
smokers	smoker	s502062	NNS	I-NP	O
and	and	a530	CC	O	O
people	people	p0140	NNS	B-NP	O
using	use	u2052	VBG	B-VP	O
transdermal	transdermal	t6052306504	JJ	B-NP	O
nicotine	nicotine	n0203050	NN	I-NP	B-Chemical
support	support	s01063	VBP	B-VP	O
the	the	t000	DT	B-NP	O
idea	idea	i300	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
toxins	toxin	t02052	NNS	B-NP	O
other	other	o306	JJ	B-ADJP	O
than	than	t050	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
are	be	a600	VBP	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
important	important	i51063053	JJ	I-NP	O
causes	cause	c0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
cardiovascular	cardiovascular	c06301020406	JJ	I-NP	O
events	event	e10532	NNS	I-NP	O
.	.	.000	.	O	O

Finally	Finally	f05040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
response	response	r0210520	NN	I-NP	O
for	for	f060	IN	B-PP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
events	event	e10532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
flat	flat	f403	JJ	B-ADJP	O
,	,	,000	,	O	O
suggesting	suggest	s02023052	VBG	B-VP	O
that	that	t030	IN	B-SBAR	O
if	if	i100	IN	B-SBAR	O
nicotine	nicotine	n0203050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
,	,	,000	,	O	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
seen	see	s050	VBN	I-VP	O
with	with	w030	IN	B-PP	O
relatively	relatively	r040301040	RB	B-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
level	level	l0104	NN	I-NP	O
cigarette	cigarette	c0206030	NN	I-NP	O
exposures	exposure	e21020602	NNS	I-NP	O
.	.	.000	.	O	O

Iatrogenically	Iatrogenically	i036020502040	RB	B-NP	O
induced	induce	i530203	VBN	I-NP	O
intractable	intractable	i5360230140	JJ	I-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
reentrant	reentrant	r0536053	JJ	I-NP	I-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
catheter	catheter	c030306	NN	I-NP	O
ablation	ablation	a140305	NN	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
Wolff	Wolff	w041	NNP	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
Parkinson	Parkinson	p06205205	NNP	I-NP	I-Disease
-	-	-000	HYPH	I-NP	I-Disease
White	White	w030	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
idiopathic	idiopathic	i3010302	JJ	I-NP	B-Disease
dilated	dilated	d040303	JJ	I-NP	I-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
with	with	w030	IN	B-PP	O
WPW	WPW	w100	NN	B-NP	B-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
idiopathic	idiopathic	i3010302	JJ	B-NP	B-Disease
dilated	dilated	d040303	JJ	I-NP	I-Disease
cardiomyopathy	cardiomyopathy	c0630501030	NN	I-NP	I-Disease
,	,	,000	,	O	O
intractable	intractable	i5360230140	JJ	B-NP	O
atrioventricular	atrioventricular	a36010536020406	JJ	I-NP	B-Disease
reentrant	reentrant	r0536053	NN	I-NP	I-Disease
tachycardia	tachycardia	t02020630	NN	I-NP	I-Disease
(	(	(000	(	O	O
AVRT	AVRT	a163	NN	B-NP	B-Disease
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
iatrogenically	iatrogenically	i036020502040	RB	I-VP	O
induced	induce	i530203	VBN	I-VP	O
.	.	.000	.	O	O

QRS	QRS	q620	NNS	B-NP	O
without	without	w0303	IN	B-PP	O
preexcitation	preexcitation	p602030305	NN	B-NP	O
,	,	,000	,	O	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
junctional	junctional	j05230504	JJ	B-NP	O
escape	escape	e2010	NN	I-NP	O
beats	beat	b032	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
verapamil	verapamil	v06010504	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
unidirectional	unidirectional	u503060230504	JJ	B-NP	O
antegrade	antegrade	a53026030	NN	I-NP	O
block	block	b402	NN	I-NP	O
of	of	o100	IN	B-PP	O
accessory	accessory	a202060	JJ	B-NP	O
pathway	pathway	p030	NN	I-NP	O
after	after	a1306	IN	B-PP	O
catheter	catheter	c030306	NN	B-NP	O
ablation	ablation	a140305	NN	I-NP	O
,	,	,000	,	O	O
established	establish	e230140203	VBN	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
AVRT	AVRT	a163	NN	I-NP	B-Disease
attack	attack	a302	NN	I-NP	O
.	.	.000	.	O	O

Epidemic	Epidemic	e1030502	JJ	B-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
hydrochlorofluorocarbons	hydrochlorofluorocarbon	h0360204060140602061052	NNS	B-NP	B-Chemical
used	use	u203	VBN	B-VP	O
as	as	a200	IN	B-PP	O
ozone	ozone	o2050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
sparing	spar	s106052	VBG	B-VP	O
substitutes	substitute	s0123030302	NNS	B-NP	O
of	of	o100	IN	B-PP	O
chlorofluorocarbons	chlorofluorocarbon	c04060140602061052	NNS	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Hydrochlorofluorocarbons	Hydrochlorofluorocarbon	h0360204060140602061052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
HCFCs	HCFC	h212	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
are	be	a600	VBP	B-VP	O
used	use	u203	VBN	I-VP	O
increasingly	increasingly	i5260205240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
industry	industry	i5302360	NN	B-NP	O
as	as	a200	IN	B-PP	O
substitutes	substitute	s0123030302	NNS	B-NP	O
for	for	f060	IN	B-PP	O
ozone	ozone	o2050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
depleting	deplete	d01403052	VBG	B-VP	O
chlorofluorocarbons	chlorofluorocarbon	c04060140602061052	NNS	B-NP	B-Chemical
(	(	(000	(	O	O
CFCs	CFC	c120	NNS	B-NP	B-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

Limited	Limited	l050303	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
potential	potential	p0305304	JJ	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
investigated	investigate	i51023020303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
epidemic	epidemic	e1030502	NN	I-NP	O
of	of	o100	IN	B-PP	O
liver	liver	l0106	NN	B-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
nine	nine	n050	CD	B-NP	O
industrial	industrial	i53023604	JJ	I-NP	O
workers	worker	w062062	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
had	have	h030	VBN	I-VP	O
repeated	repeat	r010303	VBN	I-VP	O
accidental	accidental	a20305304	JJ	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
mixture	mixture	m023060	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
,	,	,000	,	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
dichloro	dichloro	d0204060	AFX	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trifluoroethane	trifluoroethane	t60140603050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
HCFC	HCFC	h212	NN	B-NP	B-Chemical
123	123	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloro	chloro	c04060	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tetrafluoroethane	tetrafluoroethane	t0360140603050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
HCFC	HCFC	h212	NN	B-NP	B-Chemical
124	124	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
nine	nine	n050	CD	I-NP	O
exposed	expose	e210203	VBN	I-NP	O
workers	worker	w062062	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
affected	affect	a102303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
various	various	v0602	JJ	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
.	.	.000	.	O	O

Both	Both	b030	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
metabolised	metabolise	m0301040203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
way	way	w000	NN	I-NP	O
as	as	a200	IN	B-PP	O
1	1	1000	CD	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
bromo	bromo	b6050	AFX	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
1	1	1000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chloro	chloro	c04060	NN	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
trifluoroethane	trifluoroethane	t60140603050	NN	B-NP	I-Chemical
(	(	(000	(	O	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
form	form	f065	VB	I-VP	O
reactive	reactive	r023010	JJ	B-NP	O
trifluoroacetyl	trifluoroacetyl	t601406020304	NN	I-NP	B-Chemical
halide	halide	h04030	NN	I-NP	O
intermediates	intermediate	i53065030302	NNS	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
implicated	implicate	i514020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	I-NP	B-Disease
of	of	o100	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
aimed	aim	a0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
test	test	t023	VB	I-VP	O
whether	whether	w0306	IN	B-SBAR	O
HCFCs	HCFC	h212	NNS	B-NP	B-Chemical
123	123	0000	CD	B-NP	I-Chemical
and	and	a530	CC	I-NP	I-Chemical
124	124	0000	CD	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
For	For	f060	IN	O	O
one	one	o500	CD	B-NP	O
severely	severely	s0106040	RB	B-VP	O
affected	affect	a102303	VBD	I-VP	O
worker	worker	w06206	NN	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
and	and	a530	CC	O	O
immunohistochemical	immunohistochemical	i50502302050204	JJ	B-NP	O
stainings	staining	s305052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
presence	presence	p6020520	NN	I-NP	O
of	of	o100	IN	B-PP	O
trifluoroacetyl	trifluoroacetyl	t601406020304	NN	B-NP	B-Chemical
protein	protein	p60305	NN	I-NP	O
adducts	adduct	a30232	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
done	do	d050	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
of	of	o100	IN	B-PP	O
six	six	s020	CD	B-NP	O
affected	affect	a102303	VBN	I-NP	O
workers	worker	w062062	NNS	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
controls	control	c0536042	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
tested	test	t02303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
autoantibodies	autoantibody	a03053010302	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
react	react	r023	VBP	B-VP	O
with	with	w030	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	O
cytochrome	cytochrome	c030206050	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
P450	P450	0000	NN	I-NP	O
2E1	2E1	0000	NN	I-NP	O
(	(	(000	(	O	O
P450	P450	0000	NN	B-NP	O
2E1	2E1	0000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
P58	P58	0000	NN	B-NP	O
protein	protein	p60305	NN	I-NP	O
disulphide	disulphide	d02041030	NN	I-NP	O
isomerase	isomerase	i20506020	NN	I-NP	O
isoform	isoform	i201065	NN	I-NP	O
(	(	(000	(	O	O
P58	P58	0000	NN	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

FINDINGS	FINDINGS	f053052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
sample	sample	s05140	NN	I-NP	O
showed	show	s030	VBD	B-VP	O
hepatocellular	hepatocellular	h010302040406	JJ	B-NP	O
necrosis	necrosis	n0260202	NN	I-NP	B-Disease
which	which	w020	WDT	B-NP	O
was	be	w020	VBD	B-VP	O
prominent	prominent	p60505053	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
perivenular	perivenular	p0601050406	JJ	B-NP	O
zone	zone	z050	NN	I-NP	O
three	three	t060	CD	I-NP	O
and	and	a530	CC	O	O
extended	extend	e2305303	VBD	B-VP	O
focally	focally	f02040	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
portal	portal	p06304	JJ	B-NP	O
tracts	tract	t60232	NNS	I-NP	O
to	to	t000	TO	B-PP	O
portal	portal	p06304	JJ	B-NP	O
tracts	tract	t60232	NNS	I-NP	O
and	and	a530	CC	O	O
centrilobular	centrilobular	c053604010406	JJ	B-NP	O
areas	area	a602	NNS	I-NP	O
(	(	(000	(	O	O
bridging	bridge	b6032052	VBG	B-VP	O
necrosis	necrosis	n0260202	NN	B-NP	B-Disease
)	)	)000	)	O	O
.	.	.000	.	O	O

Trifluoroacetyl	Trifluoroacetyl	t601406020304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
adducted	adduct	a302303	VBN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
surviving	survive	s06101052	VBG	B-VP	O
hepatocytes	hepatocyte	h0103020302	NNS	B-NP	O
.	.	.000	.	O	O

Autoantibodies	Autoantibody	a03053010302	NNS	B-NP	O
against	against	a20523	IN	B-PP	O
P450	P450	0000	NN	B-NP	O
2E1	2E1	0000	NN	I-NP	O
or	or	o600	CC	I-NP	O
P58	P58	0000	NN	I-NP	O
,	,	,000	,	O	O
previously	previously	p6010240	RB	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
halothane	halothane	h0403050	NN	B-NP	B-Disease
hepatitis	hepatitis	h01030302	NN	I-NP	I-Disease
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
detected	detect	d0302303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
of	of	o100	IN	B-PP	O
five	five	f010	CD	B-NP	O
affected	affect	a102303	VBN	I-NP	O
workers	worker	w062062	NNS	I-NP	O
.	.	.000	.	O	O

INTERPRETATION	INTERPRETATION	i530616030305	NN	B-NP	O
:	:	:000	:	O	O
Repeated	Repeat	r010303	VBN	B-NP	O
exposure	exposure	e2102060	NN	I-NP	O
of	of	o100	IN	B-PP	O
human	human	h0505	JJ	B-NP	O
beings	being	b052	NNS	I-NP	O
to	to	t000	TO	B-PP	O
HCFCs	HCFC	h212	NNS	B-NP	B-Chemical
123	123	0000	CD	B-NP	I-Chemical
and	and	a530	CC	I-NP	I-Chemical
124	124	0000	CD	I-NP	I-Chemical
can	can	c050	MD	B-VP	O
result	result	r02043	VB	I-VP	O
in	in	i500	IN	B-PP	O
serious	serious	s0602	JJ	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
proportion	proportion	p60106305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
exposed	expose	e210203	VBN	I-NP	O
population	population	p01040305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
exact	exact	e2023	JJ	I-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatotoxicity	hepatotoxicity	h0103030202030	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
is	be	i200	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
known	know	k505	VBN	I-VP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
trifluoroacetyl	trifluoroacetyl	t601406020304	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-VP	O
altered	alter	a430603	VBN	B-NP	O
liver	liver	l0106	NN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
involved	involve	i5104103	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
view	view	v000	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
potentially	potentially	p03053040	RB	I-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
compounds	compound	c0510532	NNS	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
urgent	urgent	u62053	JJ	I-NP	O
need	need	n030	NN	I-NP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
safer	safe	s0106	JJR	B-NP	O
alternatives	alternative	a43065030102	NNS	I-NP	O
.	.	.000	.	O	O

Bile	Bile	b040	NN	B-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
hamartoma	hamartoma	h05063050	NN	I-NP	I-Disease
occurring	occur	o206052	VBG	B-VP	O
in	in	i500	IN	B-PP	O
association	association	a2020305	NN	B-NP	O
with	with	w030	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
with	with	w030	IN	B-PP	O
danazol	danazol	d050204	NN	B-NP	B-Chemical
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
report	report	r01063	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
bile	bile	b040	NN	B-NP	B-Disease
duct	duct	d023	NN	I-NP	I-Disease
hamartoma	hamartoma	h05063050	NN	I-NP	I-Disease
which	which	w020	WDT	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
on	on	o500	IN	B-PP	O
long	long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
danazol	danazol	d050204	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Such	Such	s020	JJ	B-NP	O
patients	patient	p030532	NNS	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
under	under	u5306	IN	B-PP	O
close	close	c4020	JJ	B-ADJP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
,	,	,000	,	O	O
preferably	preferably	p601060140	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
periodic	periodic	p060302	JJ	B-NP	O
ultrasound	ultrasound	u43602053	NN	I-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
.	.	.000	.	O	O

If	If	i100	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
develops	develop	d0104012	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	B-Disease
mass	mass	m020	NN	I-NP	I-Disease
,	,	,000	,	O	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
non	non	n050	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
specific	specific	s1020102	JJ	I-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
features	feature	f030602	NNS	I-NP	O
and	and	a530	CC	O	O
imaging	imaging	i502052	NN	B-NP	O
appearances	appearance	a10605202	NNS	I-NP	O
,	,	,000	,	O	O
biopsy	biopsy	b0120	NN	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
way	way	w000	NN	I-NP	O
to	to	t000	TO	B-VP	O
achieve	achieve	a2010	VB	I-VP	O
a	a	a000	DT	B-NP	O
definitive	definitive	d010503010	JJ	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
.	.	.000	.	O	O

Endocrine	Endocrine	e53026050	JJ	B-NP	O
screening	screening	s2605052	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
022	022	0000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
with	with	w030	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
:	:	:000	:	O	O
clinical	clinical	c4050204	JJ	B-NP	O
significance	significance	s02501020520	NN	I-NP	O
and	and	a530	CC	I-NP	O
cost	cost	c023	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
strategy	strategy	s3603020	NN	I-NP	O
.	.	.000	.	O	O

PURPOSE	PURPOSE	p061020	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
reviewed	review	r0103	VBD	B-VP	O
the	the	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
of	of	o100	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
prolactin	prolactin	p60402305	NN	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
022	022	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
referred	refer	r010603	VBD	B-VP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
compared	compare	c0510603	VBD	B-VP	O
the	the	t000	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
with	with	w030	IN	B-PP	O
history	history	h023060	NN	B-NP	O
,	,	,000	,	O	O
results	result	r020432	NNS	B-NP	O
of	of	o100	IN	B-PP	O
physical	physical	p020204	JJ	B-NP	O
examination	examination	e205050305	NN	I-NP	O
,	,	,000	,	O	O
other	other	o306	JJ	B-NP	O
etiological	etiological	e304020204	JJ	I-NP	O
investigations	investigation	i510230203052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
endocrine	endocrine	e53026050	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
to	to	t000	TO	B-VP	O
refine	refine	r01050	VB	I-VP	O
the	the	t000	DT	B-NP	O
rules	rule	r0402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
cost	cost	c023	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
endocrine	endocrine	e53026050	JJ	I-NP	O
screening	screening	s2605052	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
pinpoint	pinpoint	p051053	VB	I-VP	O
actual	actual	a2304	JJ	B-NP	O
responsibility	responsibility	r0210520104030	NN	I-NP	O
for	for	f060	IN	B-PP	O
hormonal	hormonal	h0650504	JJ	B-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
.	.	.000	.	O	O

MATERIALS	MATERIALS	m0306042	NNS	B-NP	O
AND	AND	a530	CC	I-NP	O
METHODS	METHODS	m03032	NNS	I-NP	O
:	:	:000	:	O	O
Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
by	by	b000	IN	B-PP	O
radioimmunoassay	radioimmunoassay	r030505020	NN	B-NP	O
.	.	.000	.	O	O

Every	Every	e1060	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
was	be	w020	VBD	B-VP	O
screened	screen	s260503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
451	451	0000	CD	B-NP	O
were	be	w060	VBD	B-VP	O
screened	screen	s260503	VBN	I-VP	O
for	for	f060	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	B-Disease
sexual	sexual	s0204	JJ	I-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
,	,	,000	,	O	O
gynecomastia	gynecomastia	g0502050230	NN	B-NP	B-Disease
or	or	o600	CC	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
4	4	4000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Determination	Determination	d03065050305	NN	B-NP	O
was	be	w020	VBD	B-VP	O
repeated	repeat	r010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
case	case	c020	NN	B-NP	O
of	of	o100	IN	B-PP	O
abnormal	abnormal	a1506504	JJ	B-NP	O
first	first	f0623	JJ	I-NP	O
results	result	r020432	NNS	I-NP	O
.	.	.000	.	O	O

Prolactin	Prolactin	p60402305	NN	B-NP	O
results	result	r020432	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
previous	previous	p60102	JJ	I-NP	O
personal	personal	p0620504	JJ	I-NP	O
cohort	cohort	c063	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
340	340	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
and	and	a530	CC	O	O
systematic	systematic	s023050302	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
.	.	.000	.	O	O

Main	Main	m050	NNP	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
criteria	criterion	c603060	NNS	I-NP	O
tested	test	t02303	VBN	B-VP	O
regarding	regard	r02063052	VBG	B-PP	O
efficiency	efficiency	e1020520	NN	B-NP	O
in	in	i500	IN	B-PP	O
hormone	hormone	h065050	NN	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
were	be	w060	VBD	B-VP	O
low	low	l000	JJ	B-NP	B-Disease
sexual	sexual	s0204	JJ	I-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
,	,	,000	,	O	O
small	small	s504	JJ	B-NP	O
testes	testis	t02302	NNS	I-NP	O
and	and	a530	CC	O	O
gynecomastia	gynecomastia	g0502050230	NN	B-NP	B-Disease
.	.	.000	.	O	O

Endocrine	Endocrine	e53026050	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
heptylate	heptylate	h01304030	NN	I-NP	I-Chemical
or	or	o600	CC	O	O
human	human	h0505	JJ	B-NP	O
chorionic	chorionic	c060502	JJ	I-NP	O
gonadotropin	gonadotropin	g05030360105	NN	I-NP	O
for	for	f060	IN	B-PP	O
hypogonadism	hypogonadism	h01020503025	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
bromocriptine	bromocriptine	b605026013050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
hyperprolactinemia	hyperprolactinemia	h0106160402305050	NN	B-NP	B-Disease
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
3	3	3000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
in	in	i500	IN	B-PP	O
107	107	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
but	but	b030	CC	O	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
prevalence	prevalence	p601040520	NN	I-NP	O
of	of	o100	IN	B-PP	O
repeatedly	repeatedly	r01030340	RB	B-NP	O
low	low	l000	JJ	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
increased	increase	i5260203	VBD	B-VP	O
with	with	w030	IN	B-PP	O
age	age	a200	NN	B-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
%	%	%000	NN	I-NP	O
before	before	b01060	IN	B-PP	O
age	age	a200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
and	and	a530	CC	O	O
9	9	9000	CD	B-NP	O
%	%	%000	NN	I-NP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
or	or	o600	CC	O	O
older	old	o4306	JJR	B-ADJP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
discovered	discover	d02010603	VBN	I-VP	O
after	after	a1306	IN	B-PP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
determination	determination	d03065050305	NN	I-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
low	low	l000	JJ	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
result	result	r02043	VB	I-VP	O
from	from	f605	IN	B-PP	O
nonorganic	nonorganic	n050620502	JJ	B-NP	O
hypothalamic	hypothalamic	h0103040502	JJ	I-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
normal	normal	n06504	JJ	B-NP	O
serum	serum	s0605	NN	I-NP	O
luteinizing	luteinize	l030502052	VBG	B-VP	O
hormone	hormone	h065050	NN	B-NP	O
and	and	a530	CC	I-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
only	only	o540	RB	B-NP	O
a	a	a000	DT	I-NP	O
small	small	s504	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
(	(	(000	(	O	O
definite	definite	d0105030	JJ	B-NP	O
improvement	improvement	i5160105053	NN	I-NP	O
in	in	i500	IN	B-PP	O
only	only	o540	RB	B-NP	O
16	16	0000	CD	I-NP	O
of	of	o100	IN	B-PP	O
44	44	0000	CD	B-NP	O
[	[	[000	(	O	O
36	36	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
]	]	]000	)	O	O
after	after	a1306	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
morning	morning	m065052	NN	I-NP	O
or	or	o600	CC	O	O
nocturnal	nocturnal	n02306504	JJ	B-NP	O
erections	erection	e6023052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	I-NP	O
definite	definite	d0105030	JJ	I-NP	O
vasculogenic	vasculogenic	v0204020502	JJ	I-NP	O
contributions	contribution	c05360103052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Determining	Determine	d0306505052	VBG	B-VP	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	B-Disease
sexual	sexual	s0204	JJ	I-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
or	or	o600	CC	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
physical	physical	p020204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
would	would	w043	MD	B-VP	O
have	have	h010	VB	I-VP	O
missed	miss	m0203	VBN	I-VP	O
40	40	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
37	37	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
those	those	t020	DT	B-NP	O
subsequently	subsequently	s0120205340	RB	B-VP	O
improved	improve	i5160103	VBN	I-VP	O
by	by	b000	IN	B-PP	O
androgen	androgen	a5360205	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Prolactin	Prolactin	p60402305	NN	B-NP	O
exceeded	exceed	e20303	VBD	B-VP	O
20	20	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
in	in	i500	IN	B-PP	O
5	5	5000	CD	B-NP	O
men	man	m050	NNS	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
normal	normal	n06504	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
2	2	2000	CD	B-NP	O
at	at	a300	IN	B-PP	O
repeat	repeat	r0103	NN	B-NP	O
determination	determination	d03065050305	NN	I-NP	O
.	.	.000	.	O	O

Only	Only	o540	RB	B-NP	O
1	1	1000	CD	I-NP	O
prolactinoma	prolactinoma	p60402305050	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
discovered	discover	d02010603	VBN	I-VP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
lower	low	l060	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
we	we	w000	PRP	B-NP	O
found	find	f053	VBD	B-VP	O
during	during	d06052	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
2	2	2000	CD	I-NP	O
decades	decade	d020302	NNS	I-NP	O
(	(	(000	(	O	O
overall	overall	o10604	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
greater	great	g60306	JJR	B-NP	O
than	than	t050	IN	I-NP	O
20	20	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
in	in	i500	IN	B-PP	O
1	1	1000	CD	B-NP	O
.	.	.000	.	O	O
86	86	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
,	,	,000	,	O	O
821	821	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
,	,	,000	,	O	O
prolactinomas	prolactinoma	p604023050502	NNS	B-NP	B-Disease
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
,	,	,000	,	I-NP	O
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
38	38	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Bromocriptine	Bromocriptine	b605026013050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
definitely	definitely	d010503040	RB	B-ADJP	O
effective	effective	e1023010	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
35	35	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
8	8	8000	CD	B-NP	O
of	of	o100	IN	B-PP	O
12	12	0000	CD	B-NP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
only	only	o540	RB	B-NP	O
9	9	9000	CD	I-NP	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
cases	case	c0202	NNS	I-NP	O
with	with	w030	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
between	between	b0305	IN	B-PP	O
20	20	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
35	35	0000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Testosterone	Testosterone	t02302306050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
low	low	l000	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
with	with	w030	IN	B-PP	O
prolactin	prolactin	p60402305	NN	B-NP	O
greater	great	g60306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
35	35	0000	CD	B-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Low	Low	l000	JJ	B-NP	O
prevalences	prevalence	p6010405202	NNS	I-NP	O
and	and	a530	CC	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
prolactin	prolactin	p60402305	NN	I-NP	O
in	in	i500	IN	B-PP	O
erectile	erectile	e6023040	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
cannot	cannot	c0503	MD	B-VP	O
justify	justify	j023010	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
routine	routine	r03050	JJ	I-NP	O
determination	determination	d03065050305	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
cost	cost	c023	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
screening	screening	s2605052	NN	I-NP	O
strategies	strategy	s36030202	NNS	I-NP	O
recommended	recommend	r020505303	VBD	B-VP	O
so	so	s000	RB	B-ADVP	O
far	far	f060	RB	I-ADVP	O
missed	miss	m0203	VBN	B-VP	O
40	40	0000	CD	B-NP	O
to	to	t000	TO	I-NP	O
50	50	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
of	of	o100	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
improved	improve	i5160103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
endocrine	endocrine	e53026050	JJ	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
pituitary	pituitary	p0303060	JJ	I-NP	B-Disease
tumors	tumor	t05062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
now	now	n000	RB	B-ADVP	O
advocate	advocate	a3102030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
before	before	b01060	IN	B-PP	O
age	age	a200	NN	B-NP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
testosterone	testosterone	t02302306050	NN	I-NP	B-Chemical
be	be	b000	VB	B-VP	O
determined	determine	d030650503	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	B-Disease
sexual	sexual	s0204	JJ	I-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
and	and	a530	CC	O	O
abnormal	abnormal	a1506504	JJ	B-NP	O
physical	physical	p020204	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
but	but	b030	CC	O	O
that	that	t030	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
be	be	b000	VB	B-VP	O
measured	measure	m020603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
all	all	a400	DT	B-NP	O
men	man	m050	NNS	I-NP	O
older	old	o4306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
50	50	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
.	.	.000	.	O	O

Prolactin	Prolactin	p60402305	NN	B-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
determined	determine	d030650503	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
cases	case	c0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
low	low	l000	JJ	B-NP	B-Disease
sexual	sexual	s0204	JJ	I-NP	I-Disease
desire	desire	d02060	NN	I-NP	I-Disease
,	,	,000	,	O	O
gynecomastia	gynecomastia	g0502050230	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
testosterone	testosterone	t02302306050	NN	B-NP	B-Chemical
less	less	l020	JJR	B-NP	O
than	than	t050	IN	I-NP	O
4	4	4000	CD	I-NP	O
ng	ng	n200	NN	I-NP	O
.	.	.000	.	O	O
/	/	/000	SYM	B-NP	O
ml	ml	m400	NN	I-NP	O
.	.	.000	.	O	O

Extrapyramidal	Extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
at	at	a300	IN	B-PP	O
comparable	comparable	c051060140	JJ	B-NP	O
D2	D2	0000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

Risperidone	Risperidone	r0210603050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
with	with	w030	IN	B-PP	O
high	high	h020	JJ	B-NP	O
affinity	affinity	a105030	NN	I-NP	O
at	at	a300	IN	B-PP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
and	and	a530	CC	O	O
serotonin	serotonin	s06030505	NN	B-NP	B-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
HT2	HT2	0000	NN	I-NP	I-Chemical
receptors	receptor	r02013062	NNS	I-NP	O
.	.	.000	.	O	O

Previous	Previous	p60102	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
proposed	propose	p6010203	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
pharmacologic	pharmacologic	p06502040202	JJ	B-NP	O
profile	profile	p601040	NN	I-NP	O
may	may	m000	MD	B-VP	O
produce	produce	p603020	VB	I-VP	O
improved	improved	i5160103	JJ	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
for	for	f060	IN	B-PP	O
negative	negative	n0203010	JJ	B-NP	O
psychotic	psychotic	p2020302	JJ	I-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
decreased	decrease	d0260203	VBD	B-VP	O
propensity	propensity	p601052030	NN	B-NP	O
for	for	f060	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
;	;	;000	:	O	O
features	feature	f030602	NNS	B-NP	O
shared	share	s0603	VBN	B-VP	O
by	by	b000	IN	B-PP	O
so	so	s000	RB	O	O
-	-	-000	HYPH	O	O
called	call	c0403	VBN	B-VP	O
'	'	'000	``	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
'	'	'000	''	I-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
if	if	i100	IN	B-SBAR	O
routine	routine	r03050	JJ	B-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
unique	unique	u5020	JJ	I-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
D2	D2	0000	NN	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
and	and	a530	CC	I-NP	O
pattern	pattern	p03065	NN	I-NP	O
of	of	o100	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
[	[	[000	(	B-LST	O
123I	123I	0000	LS	I-LST	O
]	]	]000	)	O	O
IBZM	IBZM	i125	NN	B-NP	O
SPECT	SPECT	s1023	NN	I-NP	O
to	to	t000	TO	B-VP	O
determine	determine	d03065050	VB	I-VP	O
D2	D2	0000	NN	B-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
routine	routine	r03050	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
12	12	0000	CD	B-NP	O
)	)	)000	)	O	O
or	or	o600	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
7	7	7000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
produced	produce	p6030203	VBD	B-VP	O
D2	D2	0000	NN	B-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
levels	level	l01042	NNS	I-NP	O
between	between	b0305	IN	B-PP	O
approximately	approximately	a16020503040	RB	B-NP	O
60	60	0000	CD	I-NP	O
and	and	a530	CC	I-NP	O
90	90	0000	CD	I-NP	O
%	%	%000	NN	I-NP	O
at	at	a300	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
no	no	n000	DT	B-NP	O
significant	significant	s0250102053	JJ	I-NP	O
difference	difference	d01060520	NN	I-NP	O
between	between	b0305	IN	B-PP	O
occupancy	occupancy	o2010520	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
or	or	o600	CC	I-NP	O
risperidone	risperidone	r0210603050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
induced	induce	i530203	VBN	I-NP	I-Disease
parkinsonism	parkinsonism	p06205205025	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
subjects	subject	s0120232	NNS	B-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
42	42	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
(	(	(000	(	O	O
29	29	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
at	at	a300	IN	B-PP	O
occupancy	occupancy	o2010520	NN	B-NP	O
levels	level	l01042	NNS	I-NP	O
above	above	a1010	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
observations	observation	o1206103052	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
HT2	HT2	0000	NN	I-NP	O
blockade	blockade	b402030	NN	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
with	with	w030	IN	B-PP	O
risperidone	risperidone	r0210603050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
D2	D2	0000	NN	B-NP	O
occupancy	occupancy	o2010520	NN	I-NP	O
rates	rate	r0302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
above	above	a1010	IN	B-NP	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
appear	appear	a106	VB	I-VP	O
to	to	t000	TO	I-VP	O
protect	protect	p603023	VB	I-VP	O
against	against	a20523	IN	B-PP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
for	for	f060	IN	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
of	of	o100	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
treated	treat	t60303	VBN	I-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
mitoxantrone	mitoxantrone	m03020536050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
48	48	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
hour	hour	h060	NN	I-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
and	and	a530	CC	I-NP	O
leucovorin	leucovorin	l02010605	NN	I-NP	B-Chemical
(	(	(000	(	O	O
MFL	MFL	m140	NN	B-NP	B-Chemical
)	)	)000	)	O	O
:	:	:000	:	O	O
low	low	l000	JJ	B-NP	O
palliative	palliative	p0403010	JJ	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
and	and	a530	CC	O	O
high	high	h020	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
treated	treat	t60303	VBN	I-NP	O
advanced	advanced	a3105203	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
is	be	i200	VBZ	B-VP	O
no	no	n000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
second	second	s02053	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
line	line	l050	NN	I-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Combination	Combination	c051050305	NN	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
with	with	w030	IN	B-PP	O
mitoxantrone	mitoxantrone	m03020536050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
high	high	h020	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
fluorouracil	fluorouracil	f406060204	NN	I-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
)	)	)000	)	O	O
and	and	a530	CC	O	O
leucovorin	leucovorin	l02010605	NN	B-NP	B-Chemical
(	(	(000	(	O	O
MFL	MFL	m140	NN	B-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	I-Chemical
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
effective	effective	e1023010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
well	well	w040	RB	I-NP	O
tolerated	tolerate	t04060303	VBN	I-NP	O
regimen	regimen	r020505	NN	I-NP	O
.	.	.000	.	O	O

From	From	f605	IN	B-PP	O
October	October	o230106	NNP	B-NP	O
1993	1993	0000	CD	I-NP	O
to	to	t000	TO	B-PP	O
November	November	n0105106	NNP	B-NP	O
1995	1995	0000	CD	I-NP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
treated	treat	t60303	VBD	B-VP	O
13	13	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
previously	previously	p6010240	RB	B-NP	O
chemotherapy	chemotherapy	c050306010	NN	I-NP	O
-	-	-000	HYPH	O	O
treated	treat	t60303	VBN	B-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
breast	breast	b6023	NN	I-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
mitoxantrone	mitoxantrone	m03020536050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
m2	m2	0000	NN	B-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
continuous	continuous	c0530502	JJ	B-NP	O
infusion	infusion	i510205	NN	I-NP	O
of	of	o100	IN	B-PP	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
FU	FU	f000	NN	I-NP	I-Chemical
,	,	,000	,	O	O
3000	3000	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	O	O
m2	m2	0000	NN	B-NP	O
,	,	,000	,	O	O
together	together	t020306	RB	B-ADVP	O
with	with	w030	IN	B-PP	O
leucovorin	leucovorin	l02010605	NN	B-NP	B-Chemical
,	,	,000	,	O	O
300	300	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
48	48	0000	CD	B-NP	O
h	h	h000	NN	I-NP	O
from	from	f605	IN	B-PP	O
day	day	d000	NN	B-NP	O
1	1	1000	CD	I-NP	O
to	to	t000	TO	B-PP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O

Each	Each	e020	DT	B-NP	O
course	course	c0620	NN	I-NP	O
of	of	o100	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
every	every	e1060	DT	B-NP	O
4	4	4000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Most	Most	m023	JJS	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
two	two	t000	CD	I-NP	O
metastatic	metastatic	m030230302	JJ	I-NP	O
sites	site	s0302	NNS	I-NP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
lung	lung	l052	NN	B-NP	O
metastasis	metastasis	m030230202	NN	I-NP	O
predominant	predominant	p6030505053	JJ	B-ADJP	O
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
anthracycline	anthracycline	a530602024050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Seven	Seven	s0105	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
received	receive	r020103	VBN	I-VP	O
radiotherapy	radiotherapy	r030306010	NN	B-NP	O
and	and	a530	CC	O	O
seven	seven	s0105	CD	B-NP	O
had	have	h030	VBD	B-VP	O
received	receive	r020103	VBN	I-VP	O
hormone	hormone	h065050	NN	B-NP	O
therapy	therapy	t06010	NN	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
courses	course	c06202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
MFL	MFL	m140	NN	B-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	I-Chemical
given	give	g0105	VBN	B-VP	O
was	be	w020	VBD	B-VP	O
six	six	s020	CD	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
cumulative	cumulative	c050403010	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
mitoxantrone	mitoxantrone	m03020536050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
68	68	0000	CD	B-NP	O
.	.	.000	.	O	O
35	35	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
m2	m2	0000	NN	I-NP	O
.	.	.000	.	O	O

One	One	o500	CD	B-NP	O
patient	patient	p03053	NN	I-NP	O
had	have	h030	VBD	B-VP	O
complete	complete	c0514030	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
,	,	,000	,	O	O
seven	seven	s0105	CD	B-NP	O
had	have	h030	VBD	B-VP	O
stable	stable	s30140	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
,	,	,000	,	O	O
none	none	n050	NN	B-NP	O
had	have	h030	VBD	B-VP	O
partial	partial	p06304	JJ	B-NP	O
response	response	r0210520	NN	I-NP	O
and	and	a530	CC	O	O
five	five	f010	CD	B-NP	O
had	have	h030	VBD	B-VP	O
progressive	progressive	p602602010	JJ	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
overall	overall	o10604	JJ	I-NP	O
objective	objective	o12023010	JJ	I-NP	O
response	response	r0210520	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
6	6	6000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
median	median	m0305	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
period	period	p0603	NN	B-NP	O
was	be	w020	VBD	B-VP	O
14	14	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
16	16	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Median	Median	m0305	JJ	B-NP	O
progression	progression	p60260205	NN	I-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
was	be	w020	VBD	B-VP	O
5	5	5000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
complete	complete	c0514030	JJ	I-NP	O
responder	responder	r02105306	NN	I-NP	O
had	have	h030	VBD	B-VP	O
relapse	relapse	r040120	NN	B-NP	O
-	-	-000	HYPH	O	O
free	free	f600	JJ	B-NP	O
survival	survival	s0610104	NN	I-NP	O
up	up	u100	IN	B-NP	O
to	to	t000	TO	I-NP	O
17	17	0000	CD	I-NP	O
months	month	m05302	NNS	I-NP	O
.	.	.000	.	O	O

Major	Major	m0206	JJ	B-NP	O
toxicities	toxicity	t02020302	NNS	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
cardiotoxicity	cardiotoxicity	c063030202030	NN	B-NP	B-Disease
and	and	a530	CC	I-NP	O
leukopenia	leukopenia	l0201050	NN	I-NP	B-Disease
.	.	.000	.	O	O

Eight	Eight	e0203	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
dead	dead	d030	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
follow	follow	f040	VB	I-NP	O
-	-	-000	HYPH	B-ADJP	O
up	up	u100	RP	B-PRT	O
;	;	;000	:	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
died	die	d030	VBD	B-VP	O
of	of	o100	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
related	relate	r040303	VBN	I-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
MFL	MFL	m140	NNP	I-NP	B-Chemical
regimen	regimen	r020505	NN	I-NP	I-Chemical
achieves	achieve	a20102	VBZ	B-VP	O
little	little	l0340	JJ	B-NP	O
palliative	palliative	p0403010	JJ	I-NP	O
benefit	benefit	b050103	NN	I-NP	O
and	and	a530	CC	O	O
induces	induce	i530202	VBZ	B-VP	O
severe	severe	s01060	JJ	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
at	at	a300	IN	B-PP	O
a	a	a000	DT	B-NP	O
fairly	fairly	f0640	RB	I-NP	O
high	high	h020	JJ	I-NP	O
rate	rate	r030	NN	I-NP	O
.	.	.000	.	O	O

Administration	Administration	a350502360305	NN	B-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
regimen	regimen	r020505	NN	I-NP	O
to	to	t000	TO	B-PP	O
breast	breast	b6023	NN	B-NP	B-Disease
cancer	cancer	c05206	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
treated	treat	t60303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
chemotherapy	chemotherapy	c050306010	NN	B-NP	O
and	and	a530	CC	O	O
those	those	t020	DT	B-NP	O
with	with	w030	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	B-Disease
heart	heart	h063	NN	I-NP	I-Disease
function	function	f052305	NN	I-NP	I-Disease
requires	require	r020602	VBZ	B-VP	O
careful	careful	c060104	JJ	B-NP	O
attention	attention	a305305	NN	I-NP	O
.	.	.000	.	O	O

Ticlopidine	Ticlopidine	t0240103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
:	:	:000	:	O	O
report	report	r01063	NN	B-NP	O
of	of	o100	IN	B-PP	O
three	three	t060	CD	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
and	and	a530	CC	O	O
review	review	r010	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
literature	literature	l030603060	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
,	,	,000	,	O	O
three	three	t060	CD	B-NP	O
Chinese	Chinese	c05020	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
were	be	w060	VBD	B-VP	O
reported	report	r0106303	VBN	I-VP	O
and	and	a530	CC	O	O
another	another	a50306	DT	B-NP	O
13	13	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
English	English	e524020	JJ	I-NP	O
literature	literature	l030603060	NN	I-NP	O
were	be	w060	VBD	B-VP	O
reviewed	review	r0103	VBN	I-VP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
attempted	attempt	a3051303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
find	find	f053	VB	I-VP	O
underlying	underlying	u53064052	JJ	B-NP	O
similarities	similarity	s0504060302	NNS	I-NP	O
,	,	,000	,	O	O
evaluate	evaluate	e104030	VBP	B-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
identify	identify	i3053010	VB	B-VP	O
appropriate	appropriate	a16016030	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
for	for	f060	IN	B-PP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
but	but	b030	IN	B-PP	O
one	one	o500	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
over	over	o106	IN	B-PP	O
60	60	0000	CD	B-NP	O
years	year	y062	NNS	I-NP	O
old	old	o430	JJ	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
6	6	6000	CD	I-NP	O
who	who	w000	WP	B-NP	O
died	die	d030	VBD	B-VP	O
were	be	w060	VBD	B-VP	O
all	all	a400	DT	O	O
older	old	o4306	JJR	B-ADJP	O
than	than	t050	IN	B-PP	O
65	65	0000	CD	B-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
old	old	o430	JJ	B-NP	O
age	age	a200	NN	I-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
for	for	f060	IN	B-PP	O
developing	develop	d010401052	VBG	B-VP	O
this	this	t020	DT	B-NP	O
complication	complication	c0514020305	NN	I-NP	O
.	.	.000	.	O	O

Agranulocytosis	Agranulocytosis	a26050402030202	NN	B-NP	B-Disease
occurred	occur	o20603	VBD	B-VP	O
3	3	3000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
initiation	initiation	i5030305	NN	B-NP	O
of	of	o100	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
so	so	s000	RB	B-NP	O
frequent	frequent	f602053	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
white	white	w030	JJ	B-NP	O
cell	cell	c040	NN	I-NP	O
count	count	c053	NN	I-NP	O
during	during	d06052	IN	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

There	There	t060	EX	B-NP	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
no	no	n000	DT	B-NP	O
direct	direct	d06023	JJ	I-NP	O
correlation	correlation	c06040305	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
or	or	o600	CC	I-NP	O
duration	duration	d060305	NN	I-NP	O
used	use	u203	VBN	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
bone	bone	b050	NN	B-NP	B-Disease
marrow	marrow	m060	NN	I-NP	I-Disease
suppression	suppression	s0160205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Treatment	Treatment	t6035053	NN	B-NP	O
for	for	f060	IN	B-PP	O
ticlopidine	ticlopidine	t0240103050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
aplastic	aplastic	a1402302	JJ	I-NP	B-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
with	with	w030	IN	B-PP	O
colony	colony	c04050	NN	B-NP	O
-	-	-000	HYPH	O	O
stimulating	stimulate	s3050403052	VBG	B-VP	O
factors	factor	f023062	NNS	B-NP	O
seemed	seem	s0503	VBD	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
little	little	l0340	JJ	B-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
fact	fact	f023	NN	I-NP	O
that	that	t030	IN	B-SBAR	O
5	5	5000	CD	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
6	6	6000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
received	receive	r020103	VBD	B-VP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
channel	channel	c0504	NN	I-NP	O
blockers	blocker	b402062	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
,	,	,000	,	O	O
should	should	s043	MD	B-VP	O
alert	alert	a4063	VB	I-VP	O
clinicians	clinician	c40502052	NNS	B-NP	O
to	to	t000	TO	B-VP	O
be	be	b000	VB	I-VP	O
more	more	m060	RBR	B-ADJP	O
cautious	cautious	c0302	JJ	I-ADJP	O
when	when	w050	WRB	B-ADVP	O
using	use	u2052	VBG	B-VP	O
these	these	t020	DT	B-NP	O
two	two	t000	CD	I-NP	O
drugs	drug	d602	NNS	I-NP	O
simultaneously	simultaneously	s05043050240	RB	B-ADVP	O
.	.	.000	.	O	O

Upregulation	Upregulation	u1602040305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
vasopressin	vasopressin	v020160205	NN	B-NP	B-Chemical
gene	gene	g050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
paraventricular	paraventricular	p06010536020406	JJ	I-NP	O
and	and	a530	CC	I-NP	O
supraoptic	supraoptic	s01601302	JJ	I-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
lithium	lithium	l0305	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
arginine	arginine	a6205050	NN	B-NP	B-Chemical
vasopressin	vasopressin	v020160205	NN	I-NP	I-Chemical
(	(	(000	(	O	O
AVP	AVP	a100	NN	B-NP	B-Chemical
)	)	)000	)	O	O
gene	gene	g050	NN	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
paraventricular	paraventricular	p06010536020406	JJ	I-NP	O
(	(	(000	(	O	O
PVN	PVN	p150	NN	B-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
supraoptic	supraoptic	s01601302	JJ	B-NP	O
nuclei	nucleus	n0240	NNS	I-NP	O
(	(	(000	(	O	O
SON	SON	s050	NN	B-NP	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
investigated	investigate	i51023020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
with	with	w030	IN	B-PP	O
lithium	lithium	l0305	NN	B-NP	B-Chemical
(	(	(000	(	O	O
Li	Li	l000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
,	,	,000	,	O	O
using	use	u2052	VBG	B-VP	O
in	in	i500	FW	B-NP	O
situ	situ	s030	FW	I-NP	O
hybridization	hybridization	h01603020305	NN	I-NP	O
histochemistry	histochemistry	h023020502360	NN	I-NP	O
and	and	a530	CC	I-NP	O
radioimmunoassay	radioimmunoassay	r030505020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
male	male	m040	JJ	I-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
consuming	consume	c05205052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
diet	diet	d030	NN	I-NP	O
that	that	t030	WDT	B-NP	O
contained	contain	c0530503	VBD	B-VP	O
LiCl	LiCl	l024	NN	B-NP	B-Chemical
(	(	(000	(	O	O
60	60	0000	CD	B-NP	O
mmol	mmol	m504	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
marked	marked	m06203	JJ	B-NP	O
polyuria	polyuria	p04060	NN	I-NP	B-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
Li	Li	l000	NNP	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
produced	produce	p6030203	VBD	B-VP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
volume	volume	v04050	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypotonic	hypotonic	h01030502	JJ	B-NP	O
urine	urine	u6050	NN	I-NP	O
with	with	w030	IN	B-PP	O
low	low	l000	JJ	B-NP	O
ionic	ionic	i0502	JJ	I-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
sodium	sodium	s0305	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
slightly	slightly	s4020340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Li	Li	l000	NNP	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

Plasma	Plasma	p40250	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
transcripts	transcript	t605260132	NNS	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
gene	gene	g050	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PVN	PVN	p150	NN	I-NP	O
and	and	a530	CC	I-NP	O
SON	SON	s050	NN	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
increased	increase	i5260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Li	Li	l000	NNP	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
treated	treat	t60303	VBN	I-NP	O
rats	rat	r032	NNS	I-NP	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
controls	control	c0536042	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
dehydration	dehydration	d0360305	NN	B-NP	B-Disease
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
the	the	t000	DT	B-NP	O
activation	activation	a23010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
visceral	visceral	v020604	JJ	B-NP	O
afferent	afferent	a106053	JJ	I-NP	O
inputs	input	i51032	NNS	I-NP	O
may	may	m000	MD	B-VP	O
contribute	contribute	c053601030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
elevation	elevation	e4010305	NN	I-NP	O
of	of	o100	IN	B-PP	O
plasma	plasma	p40250	NN	B-NP	O
AVP	AVP	a100	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
upregulation	upregulation	u1602040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
AVP	AVP	a100	NN	B-NP	B-Chemical
gene	gene	g050	NN	I-NP	O
expression	expression	e2160205	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
PVN	PVN	p150	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
SON	SON	s050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
Li	Li	l000	NNP	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
diabetes	diabetes	d010302	NN	I-NP	B-Disease
insipidus	insipidus	i52010302	NN	I-NP	I-Disease
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

Antinociceptive	Antinociceptive	a53050202013010	JJ	B-NP	O
and	and	a530	CC	I-NP	O
antiamnesic	antiamnesic	a53050202	JJ	I-NP	O
properties	property	p60106302	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
presynaptic	presynaptic	p6020501302	JJ	I-NP	O
cholinergic	cholinergic	c040506202	JJ	I-NP	O
amplifier	amplifier	a5140106	NN	I-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
3	3	3000	CD	B-NP	B-Chemical
alpha	alpha	a410	SYM	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
tropyl	tropyl	t60104	NN	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
p	p	p000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
bromophenyl	bromophenyl	b605010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
propionate	propionate	p60105030	NN	B-NP	I-Chemical
[	[	[000	(	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
]	]	]000	)	O	O
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
s	s	s000	NN	I-NP	O
.	.	.000	.	I-NP	O
c	c	c000	NN	I-NP	O
.	.	.000	.	O	O
;	;	;000	:	O	O
30	30	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
60	60	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	I-NP	O
o	o	o000	NN	I-NP	O
.	.	.000	.	O	O
;	;	;000	:	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
;	;	;000	:	O	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
micrograms	microgram	m026026052	NNS	I-NP	O
/	/	/000	SYM	O	O
mouse	mouse	m020	NN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
examined	examine	e2050503	VBN	I-VP	O
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
rats	rat	r032	NNS	B-NP	O
and	and	a530	CC	O	O
guinea	guinea	g050	NN	B-NP	O
pigs	pig	p020	NNS	I-NP	O
by	by	b000	IN	B-PP	O
use	use	u200	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
hot	hot	h030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
plate	plate	p4030	NN	I-NP	O
,	,	,000	,	O	O
abdominal	abdominal	a13050504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
constriction	constriction	c0523602305	NN	I-NP	O
,	,	,000	,	O	O
tail	tail	t040	NN	B-NP	O
-	-	-000	HYPH	I-NP	O
flick	flick	f402	NN	I-NP	O
and	and	a530	CC	I-NP	O
paw	paw	p000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
tests	test	t0232	NNS	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
antinociception	antinociception	a5305020201305	NN	I-NP	O
peaked	peak	p0203	VBD	B-VP	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
and	and	a530	CC	O	O
then	then	t050	RB	B-VP	O
slowly	slowly	s4040	RB	I-VP	O
diminished	diminish	d05050203	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
antinociception	antinociception	a5305020201305	NN	I-NP	O
produced	produce	p6030203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
prevented	prevent	p60105303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
unselective	unselective	u5204023010	JJ	I-NP	O
muscarinic	muscarinic	m02060502	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
atropine	atropine	a3601050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
M1	M1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
antagonists	antagonist	a5302050232	NNS	I-NP	O
pirenzepine	pirenzepine	p0605201050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
dicyclomine	dicyclomine	d0202405050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
depletor	depletor	d0140306	NN	I-NP	O
hemicholinium	hemicholinium	h0502040505	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
3	3	3000	CD	I-NP	I-Chemical
,	,	,000	,	O	O
but	but	b030	CC	B-PP	O
not	not	n030	RB	I-PP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
opioid	opioid	o103	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
naloxone	naloxone	n0402050	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
gamma	gamma	g050	SYM	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminobutyric	aminobutyric	a50501030602	JJ	I-NP	I-Chemical
acidB	acidB	a2031	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
3	3	3000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
aminopropyl	aminopropyl	a5050160104	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
diethoxy	diethoxy	d03020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methyl	methyl	m0304	NN	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
phosphinic	phosphinic	p0210502	JJ	B-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
H3	H3	0000	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
R	R	r000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
alpha	alpha	a410	SYM	O	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
methylhistamine	methylhistamine	m030402305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
D2	D2	0000	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
quinpirole	quinpirole	q05106040	NN	I-NP	B-Chemical
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine4	hydroxytryptamine4	0000	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
2	2	2000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxy	methoxy	m03020	NN	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
amino	amino	a5050	JJ	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
5	5	5000	CD	I-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
chlorobenzoic	chlorobenzoic	c04060105202	JJ	I-NP	I-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
diethylamino	diethylamino	d030405050	NN	B-NP	I-Chemical
)	)	)000	)	O	I-Chemical
ethyl	ethyl	e304	NN	B-NP	I-Chemical
ester	ester	e2306	NN	I-NP	I-Chemical
hydrochloride	hydrochloride	h036020406030	NN	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamin1A	hydroxytryptamin1A	0000	NN	I-NP	I-Chemical
antagonist	antagonist	a530205023	NN	I-NP	O
1	1	1000	CD	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
methoxyphenyl	methoxyphenyl	m0302010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
[	[	[000	(	B-NP	I-Chemical
4	4	4000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
2	2	2000	CD	B-NP	I-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
phthalimido	phthalimido	p030405030	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
butyl	butyl	b0304	NN	B-NP	I-Chemical
]	]	]000	)	O	I-Chemical
piperazine	piperazine	p010602050	NN	B-NP	I-Chemical
hydrobromide	hydrobromide	h03601605030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
polyamines	polyamine	p04050502	NNS	I-NP	O
depletor	depletor	d0140306	NN	I-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Based	Base	b0203	VBN	B-PP	O
on	on	o500	IN	B-PP	O
these	these	t020	DT	B-NP	O
data	datum	d030	NNS	I-NP	O
,	,	,000	,	O	O
it	it	i300	PRP	B-NP	O
can	can	c050	MD	B-VP	O
be	be	b000	VB	I-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
exerted	exert	e206303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
effect	effect	e1023	NN	I-NP	O
mediated	mediate	m030303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
potentiation	potentiation	p030530305	NN	I-NP	O
of	of	o100	IN	B-PP	O
cholinergic	cholinergic	c040506202	JJ	B-NP	O
transmission	transmission	t605250205	NN	I-NP	O
.	.	.000	.	O	O

(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
(	(	(000	NN	I-NP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
40	40	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
scopolamine	scopolamine	s2010405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
dicyclomine	dicyclomine	d0202405050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
passive	passive	p02010	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

Affinity	Affinity	a105030	NN	B-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
for	for	f060	IN	B-PP	O
muscarinic	muscarinic	m02060502	JJ	B-NP	O
receptor	receptor	r0201306	NN	I-NP	O
subtypes	subtype	s0130102	NNS	I-NP	O
,	,	,000	,	O	O
determined	determine	d030650503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
functional	functional	f05230504	JJ	B-NP	O
studies	study	s30302	NNS	I-NP	O
(	(	(000	(	O	O
rabbit	rabbit	r0103	NN	B-NP	O
vas	vas	v020	NN	I-NP	O
deferens	deferen	d0106052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
M1	M1	0000	NN	B-NP	O
,	,	,000	,	O	O
guinea	guinea	g050	NN	B-NP	O
pig	pig	p020	NN	I-NP	O
atrium	atrium	a3605	NN	I-NP	O
for	for	f060	IN	B-PP	O
M2	M2	0000	NN	B-NP	O
,	,	,000	,	O	O
guinea	guinea	g050	NN	B-NP	O
pig	pig	p020	NN	I-NP	O
ileum	ileum	i405	NN	I-NP	O
for	for	f060	IN	B-PP	O
M3	M3	0000	NN	B-NP	O
and	and	a530	CC	O	O
immature	immature	i503060	JJ	B-NP	O
guinea	guinea	g050	NN	I-NP	O
pig	pig	p020	NN	I-NP	O
uterus	uterus	u30602	NN	I-NP	O
for	for	f060	IN	B-PP	O
putative	putative	p0303010	JJ	B-NP	O
M4	M4	0000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
have	have	h010	VBP	B-VP	O
shown	show	s050	VBN	I-VP	O
an	an	a500	DT	B-NP	O
M4	M4	0000	NN	I-NP	O
/	/	/000	SYM	B-VP	O
M1	M1	0000	NN	B-NP	O
selectivity	selectivity	s0402301030	NN	I-NP	O
ratio	ratio	r030	NN	I-NP	O
of	of	o100	IN	B-PP	O
10	10	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
that	that	t030	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
antinociception	antinociception	a5305020201305	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
anti	anti	a530	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
amnesic	amnesic	a50202	JJ	I-NP	B-Disease
effect	effect	e1023	NN	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
through	through	t06020	IN	B-PP	O
an	an	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
acetylcholine	acetylcholine	a20304204050	NN	B-NP	B-Chemical
extracellular	extracellular	e23602040406	JJ	I-NP	O
levels	level	l01042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
antinociceptive	antinociceptive	a53050202013010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
antiamnesic	antiamnesic	a53050202	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
range	range	r0520	NN	I-NP	O
,	,	,000	,	O	O
(	(	(000	(	O	O
+	+	+000	SYM	B-NP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
impair	impair	i5106	VB	I-VP	O
mouse	mouse	m020	NN	B-NP	O
performance	performance	p0610650520	NN	I-NP	O
evaluated	evaluate	e1040303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
rota	rota	r030	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
rod	rod	r030	NN	I-NP	O
test	test	t023	NN	I-NP	O
and	and	a530	CC	O	O
Animex	Animex	a50502	NNP	B-NP	O
apparatus	apparatus	a1060302	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
different	different	d0106053	JJ	B-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
in	in	i500	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

Up	Up	u100	IN	B-PP	O
until	until	u5304	IN	B-PP	O
now	now	n000	RB	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
only	only	o540	JJ	I-NP	O
factor	factor	f02306	NN	I-NP	O
studied	study	s30303	VBN	B-ADJP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
diameter	diameter	d050306	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
needle	needle	n0340	NN	I-NP	O
on	on	o500	IN	B-PP	O
post	post	p023	AFX	B-NP	O
-	-	-000	HYPH	I-NP	O
operative	operative	o10603010	JJ	I-NP	O
sensorineural	sensorineural	s05206050604	JJ	I-NP	B-Disease
hearing	hearing	h06052	NN	I-NP	I-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
describe	describe	d026010	VB	I-VP	O
this	this	t020	DT	B-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
investigate	investigate	i5102302030	VB	I-VP	O
other	other	o306	JJ	B-NP	O
factors	factor	f023062	NNS	I-NP	O
influencing	influence	i514052052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
degree	degree	d0260	NN	I-NP	O
of	of	o100	IN	B-PP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Two	Two	t000	CD	B-NP	O
groups	group	g6012	NNS	I-NP	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
similar	similar	s050406	JJ	I-NP	O
patients	patient	p030532	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
:	:	:000	:	O	O
one	one	o500	CD	B-NP	O
group	group	g601	NN	I-NP	O
received	receive	r020103	VBD	B-VP	O
6	6	6000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
prilocaine	prilocaine	p60402050	NN	I-NP	B-Chemical
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
;	;	;000	:	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
received	receive	r020103	VBD	B-VP	O
3	3	3000	CD	B-NP	O
mL	mL	m400	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
.	.	.000	.	O	O

Patients	Patient	p030532	NNS	B-NP	O
given	give	g0105	VBN	B-PP	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
develop	develop	d010401	VB	I-VP	O
hearing	hearing	h06052	NN	B-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
given	give	g0105	VBN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
out	out	o030	IN	B-PP	O
of	of	o100	IN	B-PP	O
22	22	0000	CD	B-NP	O
)	)	)000	)	O	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
average	average	a106020	JJ	I-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
for	for	f060	IN	B-PP	O
speech	speech	s1020	NN	B-NP	O
frequencies	frequency	f60205202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
about	about	a103	IN	B-NP	O
10	10	0000	CD	I-NP	O
dB	dB	d100	NN	I-NP	O
after	after	a1306	IN	B-PP	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
dB	dB	d100	NN	I-NP	O
after	after	a1306	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

None	None	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
complained	complain	c05140503	VBD	B-VP	O
of	of	o100	IN	B-PP	O
subjective	subjective	s012023010	JJ	B-NP	O
hearing	hearing	h06052	NN	I-NP	B-Disease
loss	loss	l020	NN	I-NP	I-Disease
.	.	.000	.	O	O

Long	Long	l052	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
term	term	t065	NN	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
not	not	n030	RB	O	O
possible	possible	p020140	JJ	B-ADJP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
following	follow	f04052	VBG	B-PP	O
intrathecal	intrathecal	i536030204	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
hyperbaric	hyperbaric	h010610602	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
describe	describe	d026010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
transient	transient	t6052053	JJ	B-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
that	that	t030	WDT	B-NP	O
occurred	occur	o20603	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
8	8	8000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
%	%	%000	NN	I-NP	O
hyperbaric	hyperbaric	h010610602	JJ	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
slowly	slowly	s4040	RB	B-VP	O
injected	inject	i5202303	VBN	I-VP	O
through	through	t06020	IN	B-PP	O
a	a	a000	DT	B-NP	O
25	25	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
gauge	gauge	g020	NN	I-NP	O
pencil	pencil	p05204	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
point	point	p053	NN	I-NP	O
spinal	spinal	s10504	JJ	I-NP	O
needle	needle	n0340	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
surgery	surgery	s062060	NN	I-NP	O
and	and	a530	CC	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
uneventful	uneventful	u501053104	JJ	B-ADJP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
3	3	3000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
surgery	surgery	s062060	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
reported	report	r0106303	VBD	B-VP	O
an	an	a500	DT	B-NP	O
area	area	a600	NN	I-NP	O
of	of	o100	IN	B-PP	O
hypoaesthesia	hypoaesthesia	h01023020	NN	B-NP	O
over	over	o106	IN	B-PP	O
L3	L3	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
L4	L4	0000	NN	I-NP	O
dermatomes	dermatome	d065030502	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
leg	leg	l020	NN	I-NP	O
which	which	w020	WDT	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
operated	operate	o1060303	VBN	I-VP	O
on	on	o500	IN	B-PP	O
(	(	(000	(	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
pinprick	pinprick	p051602	NN	B-NP	I-Disease
sensation	sensation	s0520305	NN	I-NP	I-Disease
)	)	)000	)	O	O
without	without	w0303	IN	B-PP	O
reduction	reduction	r0302305	NN	B-NP	O
in	in	i500	IN	B-PP	O
muscular	muscular	m020406	JJ	B-NP	O
strength	strength	s3605230	NN	I-NP	O
.	.	.000	.	O	O

Sensation	Sensation	s0520305	NN	B-NP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
area	area	a600	NN	I-NP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
normal	normal	n06504	JJ	B-ADJP	O
over	over	o106	IN	B-PP	O
the	the	t000	DT	B-NP	O
following	follow	f04052	VBG	I-NP	O
2	2	2000	CD	I-NP	O
weeks	week	w020	NNS	I-NP	O
.	.	.000	.	O	O

Prospective	Prospective	p6021023010	JJ	B-NP	O
multicentre	multicentre	m0430205360	JJ	I-NP	O
studies	study	s30302	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
large	large	l0620	JJ	I-NP	O
population	population	p01040305	NN	I-NP	O
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
long	long	l052	JJ	I-NP	O
follow	follow	f040	VB	B-VP	O
-	-	-000	HYPH	O	O
up	up	u100	RP	B-PRT	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
performed	perform	p06106503	VBN	I-VP	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
evaluate	evaluate	e104030	VB	I-VP	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
solution	solution	s040305	NN	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
preferred	prefer	p6010603	VBN	I-VP	O
for	for	f060	IN	B-PP	O
unilateral	unilateral	u504030604	JJ	B-NP	O
spinal	spinal	s10504	JJ	I-NP	O
anaesthesia	anaesthesia	a5023020	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
hyperbaric	hyperbaric	h010610602	JJ	I-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
solution	solution	s040305	NN	I-NP	O
(	(	(000	(	O	O
if	if	i100	IN	B-SBAR	O
pencil	pencil	p05204	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
point	point	p053	NN	I-NP	O
needle	needle	n0340	NN	I-NP	O
and	and	a530	CC	O	O
slow	slow	s400	JJ	B-NP	O
injection	injection	i5202305	NN	I-NP	O
rate	rate	r030	NN	I-NP	O
are	be	a600	VBP	B-VP	O
employed	employ	e51403	VBN	I-VP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
in	in	i500	IN	B-SBAR	O
order	order	o6306	NN	O	O
to	to	t000	TO	B-VP	O
minimize	minimize	m0505020	VB	I-VP	O
the	the	t000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
localized	localized	l02040203	JJ	I-NP	O
high	high	h020	JJ	I-NP	O
peak	peak	p020	NN	I-NP	O
anaesthetic	anaesthetic	a50230302	JJ	I-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
transient	transient	t6052053	JJ	I-NP	O
neurological	neurological	n0604020204	JJ	I-NP	B-Disease
deficit	deficit	d010203	NN	I-NP	I-Disease
.	.	.000	.	O	O

Transient	Transient	t6052053	JJ	B-NP	B-Disease
neurologic	neurologic	n06040202	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
after	after	a1306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
:	:	:000	:	O	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
with	with	w030	IN	B-PP	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
than	than	t050	IN	B-PP	O
with	with	w030	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
Recent	Recent	r02053	JJ	B-NP	O
evidence	evidence	e1030520	NN	I-NP	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
transient	transient	t6052053	JJ	B-NP	B-Disease
neurologic	neurologic	n06040202	JJ	I-NP	I-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
TNSs	TNS	t520	NNS	B-NP	B-Disease
)	)	)000	)	O	O
frequently	frequently	f60205340	RB	B-ADVP	O
follow	follow	f040	VBP	B-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
spinal	spinal	s10504	JJ	I-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
but	but	b030	CC	O	O
are	be	a600	VBP	B-VP	O
infrequent	infrequent	i51602053	JJ	B-ADJP	O
with	with	w030	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

However	However	h0106	RB	B-ADVP	O
,	,	,000	,	O	O
identification	identification	i305301020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
a	a	a000	DT	B-NP	O
short	short	s063	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
acting	act	a23052	VBG	B-VP	O
local	local	l0204	JJ	B-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
to	to	t000	TO	B-VP	O
substitute	substitute	s012303030	VB	I-VP	O
for	for	f060	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
brief	brief	b601	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
remains	remain	r05052	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
important	important	i51063053	JJ	I-NP	O
goal	goal	g040	NN	I-NP	O
.	.	.000	.	O	O

Prilocaine	Prilocaine	p60402050	NN	B-NP	B-Chemical
is	be	i200	VBZ	B-VP	O
an	an	a500	DT	B-NP	O
amide	amide	a5030	NN	I-NP	O
local	local	l0204	JJ	I-NP	O
anesthetic	anesthetic	a50230302	NN	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
that	that	t030	DT	B-NP	O
of	of	o100	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Accordingly	Accordingly	a206305240	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
,	,	,000	,	I-NP	O
prospective	prospective	p6021023010	JJ	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
compares	compare	c0510602	VBZ	B-VP	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
with	with	w030	IN	B-PP	O
respect	respect	r021023	NN	B-NP	O
to	to	t000	TO	B-PP	O
duration	duration	d060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
and	and	a530	CC	O	O
relative	relative	r0403010	JJ	B-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
TNSs	TNS	t520	NNS	B-NP	B-Disease
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Ninety	Ninety	n05030	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
classified	classify	c4020103	VBN	B-VP	O
as	as	a200	IN	B-PP	O
American	American	a5060205	NNP	B-NP	O
Society	Society	s02030	NNP	I-NP	O
of	of	o100	IN	B-PP	O
Anesthesiologists	Anesthesiologist	a50230204020232	NNPS	B-NP	O
physical	physical	p020204	JJ	I-NP	O
status	status	s30302	NN	I-NP	O
I	I	i000	CD	B-NP	O
or	or	o600	CC	I-NP	O
II	II	i000	CD	I-NP	O
who	who	w000	WP	B-NP	O
were	be	w060	VBD	B-VP	O
scheduled	schedule	s2030403	VBN	I-VP	O
for	for	f060	IN	B-PP	O
short	short	s063	JJ	B-NP	O
gynecologic	gynecologic	g0502040202	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
under	under	u5306	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
anesthesia	anesthesia	a5023020	NN	I-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
allocated	allocate	a4020303	VBN	I-VP	O
to	to	t000	TO	I-VP	O
receive	receive	r02010	VB	I-VP	O
2	2	2000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
ml	ml	m400	NN	I-NP	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
lidocaine	lidocaine	l0302050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
%	%	%000	NN	I-NP	O
prilocaine	prilocaine	p60402050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
bupivacaine	bupivacaine	b010102050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
7	7	7000	CD	B-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
%	%	%000	NN	I-NP	O
glucose	glucose	g402020	NN	I-NP	B-Chemical
.	.	.000	.	O	O

All	All	a400	DT	B-NP	O
solutions	solution	s0403052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
provided	provide	p6010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
blinded	blinded	b405303	JJ	B-NP	O
vials	vial	v042	NNS	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
hospital	hospital	h0210304	NN	I-NP	O
pharmacy	pharmacy	p065020	NN	I-NP	O
.	.	.000	.	O	O

Details	Detail	d03042	NNS	B-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
puncture	puncture	p0523060	NN	I-NP	O
,	,	,000	,	O	O
extension	extension	e2305205	NN	B-NP	O
and	and	a530	CC	I-NP	O
regression	regression	r0260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
spinal	spinal	s10504	JJ	B-NP	O
block	block	b402	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
times	time	t0502	NNS	I-NP	O
to	to	t000	TO	B-VP	O
reach	reach	r020	VB	I-VP	O
discharge	discharge	d020620	NN	B-NP	O
criteria	criterion	c603060	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
noted	note	n0303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
evening	evening	e105052	NN	I-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	O
day	day	d000	NN	I-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
for	for	f060	IN	B-PP	O
TNSs	TNS	t520	NNS	B-NP	B-Disease
by	by	b000	IN	B-PP	O
a	a	a000	DT	B-NP	O
physician	physician	p020205	NN	I-NP	O
unaware	unaware	u5060	JJ	B-ADJP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
drug	drug	d602	NN	I-NP	O
administered	administer	a35050230603	VBN	B-VP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
details	detail	d03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
anesthetic	anesthetic	a50230302	JJ	I-NP	O
procedure	procedure	p60203060	NN	I-NP	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
Nine	Nine	n050	CD	B-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
experienced	experienced	e210605203	JJ	I-NP	O
TNSs	TNS	t520	NNS	I-NP	B-Disease
,	,	,000	,	O	O
1	1	1000	CD	B-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
03	03	0000	CD	B-NP	O
)	)	)000	)	O	O
had	have	h030	VBD	B-VP	O
them	them	t050	PRP	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
none	none	n050	NN	B-NP	O
of	of	o100	IN	B-PP	O
30	30	0000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
receiving	receive	r0201052	VBG	B-VP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
had	have	h030	VBD	B-VP	O
TNSs	TNS	t520	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Times	Time	t0502	NNS	B-NP	O
to	to	t000	TO	B-VP	O
ambulate	ambulate	a5104030	VB	I-VP	O
and	and	a530	CC	O	O
to	to	t000	TO	B-PP	O
void	void	v030	NN	B-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
after	after	a1306	IN	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
prilocaine	prilocaine	p60402050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
150	150	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
165	165	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
and	and	a530	CC	O	O
238	238	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
253	253	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
but	but	b030	CC	O	O
prolonged	prolong	p60405203	VBD	B-VP	O
after	after	a1306	IN	B-PP	O
bupivacaine	bupivacaine	b010102050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
200	200	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
299	299	0000	CD	I-NP	O
min	min	m050	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
;	;	;000	:	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
05	05	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
Prilocaine	Prilocaine	p60402050	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
preferable	preferable	p601060140	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
lidocaine	lidocaine	l0302050	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
short	short	s063	JJ	B-NP	O
surgical	surgical	s0620204	JJ	I-NP	O
procedures	procedure	p602030602	NNS	I-NP	O
because	because	b02020	IN	B-SBAR	O
it	it	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
similar	similar	s050406	JJ	I-NP	O
duration	duration	d060305	NN	I-NP	O
of	of	o100	IN	B-PP	O
action	action	a2305	NN	B-NP	O
but	but	b030	CC	O	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
TNSs	TNS	t520	NNS	B-NP	B-Disease
.	.	.000	.	O	O

Suxamethonium	Suxamethonium	s0205030505	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	O
induced	induce	i530203	VBN	B-NP	O
cardiac	cardiac	c06302	JJ	I-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
death	death	d030	NN	I-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
5	5	5000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
of	of	o100	IN	B-PP	O
immobilization	immobilization	i50104020305	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
report	report	r01063	NN	I-NP	O
describes	describe	d0260102	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
and	and	a530	CC	O	O
subsequent	subsequent	s01202053	JJ	B-NP	O
death	death	d030	NN	I-NP	B-Disease
as	as	a200	IN	B-PP	O
a	a	a000	DT	B-NP	O
result	result	r02043	NN	I-NP	O
of	of	o100	IN	B-PP	O
hyperkalaemia	hyperkalaemia	h0106204050	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
23	23	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	O	O
old	old	o430	JJ	B-NP	O
Malawian	Malawian	m0405	JJ	I-NP	O
woman	woman	w0505	NN	I-NP	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
days	day	d020	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
the	the	t000	DT	B-NP	O
onset	onset	o5203	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
meningitis	meningitis	m050520302	NN	B-NP	B-Disease
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
aspirated	aspirate	a21060303	VBD	B-VP	O
stomach	stomach	s305020	NN	B-NP	O
contents	content	c0530532	NNS	I-NP	O
and	and	a530	CC	O	O
needed	need	n0303	VBN	B-NP	O
endotracheal	endotracheal	e530360204	JJ	I-NP	O
intubation	intubation	i53010305	NN	I-NP	O
.	.	.000	.	O	O

Forty	Forty	f0630	CD	B-NP	O
seconds	second	s020532	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
injection	injection	i5202305	NN	B-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
bradycardia	bradycardia	b603020630	NN	B-NP	B-Disease
and	and	a530	CC	O	O
cardiac	cardiac	c06302	JJ	B-NP	B-Disease
arrest	arrest	a6023	NN	I-NP	I-Disease
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Attempts	Attempt	a305132	NNS	B-NP	O
to	to	t000	TO	B-VP	O
resuscitate	resuscitate	r020203030	VB	I-VP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
were	be	w060	VBD	B-VP	O
not	not	n030	RB	O	O
successful	successful	s0202104	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
potassium	potassium	p030205	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
4	4	4000	CD	B-NP	O
mequiv	mequiv	m0201	NN	I-NP	O
L	L	l000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

Apart	Apart	a1063	RB	B-ADVP	O
from	from	f605	IN	B-PP	O
the	the	t000	DT	B-NP	O
reduction	reduction	r0302305	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	JJ	I-NP	O
level	level	l0104	NN	I-NP	O
of	of	o100	IN	B-PP	O
consciousness	consciousness	c05202502	NN	B-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
were	be	w060	VBD	B-VP	O
no	no	n000	DT	B-NP	O
signs	sign	s0252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
motor	motor	m0306	NN	B-NP	O
neurone	neurone	n06050	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
or	or	o600	CC	B-PP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
known	know	k505	VBN	I-NP	O
predisposing	predispose	p60302102052	VBG	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
for	for	f060	IN	B-PP	O
hyperkalaemia	hyperkalaemia	h0106204050	NN	B-NP	B-Disease
following	follow	f04052	VBG	B-PP	O
the	the	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
is	be	i200	VBZ	B-VP	O
postulated	postulate	p023040303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
her	her	h060	PRP$	B-NP	O
death	death	d030	NN	I-NP	B-Disease
was	be	w020	VBD	B-VP	O
caused	cause	c0203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	B-NP	B-Disease
to	to	t000	TO	B-PP	O
suxamethonium	suxamethonium	s0205030505	NN	B-NP	B-Chemical
,	,	,000	,	O	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
her	her	h060	PRP	B-NP	O
5	5	5000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
day	day	d000	NN	I-NP	O
immobilization	immobilization	i50104020305	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
,	,	,000	,	O	O
autoimmune	autoimmune	a0305050	JJ	B-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
erythroblastocytopenia	erythroblastocytopenia	e60306014023020301050	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
ceftriaxone	ceftriaxone	c013602050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
80	80	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
yr	yr	y600	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
man	man	m050	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
hepatitis	hepatitis	h01030302	NN	I-NP	B-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
ingesting	ingest	i52023052	VBG	B-VP	O
oral	oral	o604	JJ	B-NP	O
ceftriaxone	ceftriaxone	c013602050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
transaminases	transaminase	t605205050202	NNS	I-NP	O
gradually	gradually	g603040	RB	B-ADVP	O
returned	return	r0306503	VBD	B-VP	O
to	to	t000	TO	B-PP	O
baseline	baseline	b0204050	NN	B-NP	O
after	after	a1306	IN	B-PP	O
withholding	withhold	w03043052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
beta	beta	b030	NN	I-NP	B-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotic	antibiotic	a53010302	NN	I-NP	O
,	,	,000	,	O	O
there	there	t060	EX	B-NP	O
was	be	w020	VBD	B-VP	O
a	a	a000	DT	B-NP	O
gradual	gradual	g60304	JJ	I-NP	O
increase	increase	i526020	NN	I-NP	O
in	in	i500	IN	B-PP	O
serum	serum	s0605	NN	B-NP	O
bilirubin	bilirubin	b04060105	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
a	a	a000	DT	B-NP	O
decrease	decrease	d026020	NN	I-NP	O
in	in	i500	IN	B-PP	O
hemoglobin	hemoglobin	h050240105	NN	B-NP	O
concentration	concentration	c05205360305	NN	I-NP	O
caused	cause	c0203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
autoimmune	autoimmune	a0305050	JJ	I-NP	B-Disease
hemolytic	hemolytic	h05040302	JJ	I-NP	I-Disease
anemia	anemia	a5050	NN	I-NP	I-Disease
and	and	a530	CC	I-NP	O
erythroblastocytopenia	erythroblastocytopenia	e60306014023020301050	NN	I-NP	B-Disease
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
responded	respond	r02105303	VBD	B-VP	O
to	to	t000	TO	B-PP	O
systemic	systemic	s0230502	JJ	B-NP	O
steroids	steroid	s306032	NNS	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
immunoglobulins	immunoglobulin	i5050240104052	NNS	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
the	the	t000	DT	B-NP	O
widespread	widespread	w03021603	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
agents	agent	a20532	NNS	I-NP	O
this	this	t020	DT	B-NP	O
triad	triad	t603	NN	I-NP	O
of	of	o100	IN	B-PP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
previously	previously	p6010240	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
connection	connection	c0502305	NN	B-NP	O
with	with	w030	IN	B-PP	O
beta	beta	b030	SYM	B-NP	B-Chemical
lactam	lactam	l02305	NN	I-NP	I-Chemical
antibiotics	antibiotic	a53010302	NNS	I-NP	O
.	.	.000	.	O	O

Thyroxine	Thyroxine	t0602050	NN	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
:	:	:000	:	O	O
an	an	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
case	case	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
thyrotoxicosis	thyrotoxicosis	t060302020202	NN	B-NP	B-Disease
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

Eating	Eat	e03052	VBG	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
behavioural	behavioural	b010604	JJ	I-NP	O
problems	problem	p6014052	NNS	I-NP	O
and	and	a530	CC	I-NP	O
drug	drug	d602	NN	I-NP	B-Disease
abuse	abuse	a1020	NN	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
uncommon	uncommon	u520505	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
.	.	.000	.	O	O

When	When	w050	WRB	B-ADVP	O
they	they	t000	PRP	B-NP	O
do	do	d000	VBP	B-VP	O
occur	occur	o206	VB	I-VP	O
they	they	t000	PRP	B-NP	O
are	be	a600	VBP	B-VP	O
often	often	o1305	RB	B-ADVP	O
unrecognized	unrecognized	u56020250203	JJ	B-ADJP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
denial	denial	d0504	NN	B-NP	O
but	but	b030	CC	O	O
when	when	w050	WRB	B-ADVP	O
significant	significant	s0250102053	JJ	B-NP	O
may	may	m000	MD	B-VP	O
pose	pose	p020	VB	I-VP	O
a	a	a000	DT	B-NP	O
risk	risk	r020	NN	I-NP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
mother	mother	m0306	NN	I-NP	O
and	and	a530	CC	O	O
her	her	h060	PRP$	B-NP	O
fetus	fetus	f0302	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
number	number	n05106	NN	I-NP	O
of	of	o100	IN	B-PP	O
problems	problem	p6014052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
encountered	encounter	e520530603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
women	woman	w0505	NNS	B-NP	O
with	with	w030	IN	B-PP	O
eating	eat	e03052	VBG	B-VP	B-Disease
disorders	disorder	d02063062	NNS	B-NP	I-Disease
in	in	i500	IN	B-PP	O
pregnancy	pregnancy	p60250520	NN	B-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
prolonged	prolonged	p60405203	JJ	B-NP	O
and	and	a530	CC	I-NP	O
recurrent	recurrent	r0206053	JJ	I-NP	O
metabolic	metabolic	m03010402	JJ	I-NP	O
disturbances	disturbance	d02306105202	NNS	I-NP	O
and	and	a530	CC	O	O
diuretic	diuretic	d060302	JJ	B-NP	O
abuse	abuse	a1020	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
particular	particular	p063020406	JJ	B-NP	O
it	it	i300	PRP	B-NP	O
illustrates	illustrate	i402360302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
derangements	derangement	d06052050532	NNS	I-NP	O
of	of	o100	IN	B-PP	O
thyroid	thyroid	t0603	NN	B-NP	O
function	function	f052305	NN	I-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
pregnant	pregnant	p6025053	JJ	B-NP	O
women	woman	w0505	NNS	I-NP	O
with	with	w030	IN	B-PP	O
eating	eat	e03052	VBG	B-NP	B-Disease
disorders	disorder	d02063062	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
reminds	remind	r050532	VBZ	B-VP	O
us	us	u200	PRP	B-NP	O
that	that	t030	IN	B-SBAR	O
when	when	w050	WRB	B-ADVP	O
a	a	a000	DT	B-NP	O
cause	cause	c020	NN	I-NP	O
for	for	f060	IN	B-PP	O
thyrotoxicosis	thyrotoxicosis	t060302020202	NN	B-NP	B-Disease
remains	remain	r05052	VBZ	B-VP	O
obscure	obscure	o12060	JJ	B-ADJP	O
,	,	,000	,	O	O
thyroxine	thyroxine	t0602050	NN	B-NP	B-Chemical
abuse	abuse	a1020	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
considered	consider	c052030603	VBN	I-VP	O
and	and	a530	CC	I-VP	O
explored	explore	e2140603	VBN	I-VP	O
.	.	.000	.	O	O

Repeated	Repeat	r010303	VBN	B-NP	O
trimipramine	trimipramine	t60501605050	NN	I-NP	B-Chemical
induces	induce	i530202	VBZ	B-VP	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
/	/	/000	SYM	B-NP	O
D3	D3	0000	NN	I-NP	O
and	and	a530	CC	I-NP	O
alpha1	alpha1	0000	NN	I-NP	O
-	-	-000	HYPH	O	O
adrenergic	adrenergic	a360506202	JJ	B-ADJP	O
up	up	u100	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
.	.	.000	.	O	O

Trimipramine	Trimipramine	t60501605050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
TRI	TRI	t600	NN	B-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
shows	show	s020	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
chemically	chemically	c0502040	RB	B-ADJP	O
related	relate	r040303	VBN	I-ADJP	O
to	to	t000	TO	B-PP	O
imipramine	imipramine	i501605050	NN	B-NP	B-Chemical
but	but	b030	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
inhibit	inhibit	i50103	VB	I-VP	O
the	the	t000	DT	B-NP	O
reuptake	reuptake	r013020	NN	I-NP	O
of	of	o100	IN	B-PP	O
noradrenaline	noradrenaline	n060360504050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
5	5	5000	CD	B-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptamine	hydroxytryptamine	h0360203601305050	NN	I-NP	I-Chemical
,	,	,000	,	O	O
nor	nor	n060	CC	O	O
does	do	d020	VBZ	O	O
it	it	i300	PRP	B-NP	O
induce	induce	i53020	VB	B-VP	O
beta	beta	b030	SYM	B-NP	O
-	-	-000	HYPH	O	O
adrenergic	adrenergic	a360506202	JJ	B-ADJP	O
down	down	d050	RB	B-ADVP	O
-	-	-000	HYPH	B-NP	O
regulation	regulation	r02040305	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
mechanism	mechanism	m0205025	NN	I-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
activity	activity	a2301030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
still	still	s304	RB	B-ADVP	O
unknown	unknown	u52505	JJ	B-ADJP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
aim	aim	a050	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
present	present	p602053	JJ	I-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
find	find	f053	VB	I-VP	O
out	out	o030	RP	B-PRT	O
whether	whether	w0306	IN	B-SBAR	O
TRI	TRI	t600	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
was	be	w020	VBD	B-VP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
adaptive	adaptive	a3013010	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
dopaminergic	dopaminergic	d01050506202	JJ	I-NP	O
and	and	a530	CC	I-NP	O
alpha1	alpha1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
systems	system	s023052	NNS	I-NP	O
,	,	,000	,	O	O
demonstrated	demonstrate	d05052360303	VBN	B-VP	O
by	by	b000	IN	B-PP	O
us	us	u200	PRP	B-NP	O
previously	previously	p6010240	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
various	various	v0602	JJ	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	B-Chemical
.	.	.000	.	O	O

TRI	TRI	t600	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
given	give	g0105	VBN	I-VP	O
to	to	t000	TO	B-PP	O
male	male	m040	JJ	B-NP	O
Wistar	Wistar	w02306	NNP	I-NP	O
rats	rat	r032	NNS	I-NP	O
and	and	a530	CC	O	O
male	male	m040	JJ	B-NP	O
Albino	Albino	a41050	NNP	I-NP	O
Swiss	Swiss	s020	JJ	I-NP	O
mice	mouse	m020	NNS	I-NP	O
perorally	perorally	p0606040	RB	B-ADVP	O
twice	twice	t020	RB	B-ADVP	O
daily	daily	d040	RB	I-ADVP	O
for	for	f060	IN	B-PP	O
14	14	0000	CD	B-NP	O
days	day	d020	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
acute	acute	a2030	JJ	I-NP	O
experiment	experiment	e210605053	NN	I-NP	O
TRI	TRI	t600	NN	I-NP	B-Chemical
(	(	(000	(	O	O
given	give	g0105	VBN	B-NP	O
i	i	i000	NN	I-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
antagonize	antagonize	a530205020	VB	I-VP	O
the	the	t000	DT	B-NP	O
reserpine	reserpine	r02061050	NN	I-NP	B-Chemical
hypothermia	hypothermia	h01030650	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
and	and	a530	CC	O	O
does	do	d020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
potentiate	potentiate	p03053030	VB	I-VP	O
the	the	t000	DT	B-NP	O
5	5	5000	CD	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	I-Chemical
hydroxytryptophan	hydroxytryptophan	h036020360130105	NN	I-NP	I-Chemical
head	head	h030	NN	I-NP	O
twitches	twitch	t03202	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

TRI	TRI	t600	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
to	to	t000	TO	B-PP	O
rats	rat	r032	NNS	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
locomotor	locomotor	l02050306	JJ	I-NP	O
hyperactivity	hyperactivity	h010602301030	NN	I-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
amphetamine	amphetamine	a510305050	NN	B-NP	I-Chemical
,	,	,000	,	O	O
quinpirole	quinpirole	q05106040	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
(	(	(000	(	O	O
+	+	+000	SYM	O	O
)	)	)000	)	O	O
-	-	-000	HYPH	B-NP	O
7	7	7000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
hydroxy	hydroxy	h036020	NN	I-NP	O
-	-	-000	HYPH	O	O
dipropyloaminotetralin	dipropyloaminotetralin	d01601040505030360405	NN	B-NP	O
(	(	(000	(	O	O
dopamine	dopamine	d0105050	NN	B-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
and	and	a530	CC	O	O
D3	D3	0000	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
stereotypies	stereotypy	s306030102	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
d	d	d000	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
amphetamine	amphetamine	a510305050	NN	I-NP	I-Chemical
or	or	o600	CC	I-NP	O
apomorphine	apomorphine	a105061050	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
not	not	n030	RB	I-VP	O
potentiated	potentiate	p030530303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
TRI	TRI	t600	NN	B-NP	B-Chemical
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
behaviour	behaviour	b0106	NN	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
phenylephrine	phenylephrine	p05040106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
given	give	g0105	VBN	B-VP	O
intraventricularly	intraventricularly	i53601053602040640	RB	B-ADVP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
,	,	,000	,	O	O
evaluated	evaluate	e1040303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
open	open	o105	JJ	I-NP	O
field	field	f043	NN	I-NP	O
test	test	t023	NN	I-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
the	the	t000	DT	B-NP	O
aggressiveness	aggressiveness	a2602010502	NN	I-NP	B-Disease
evoked	evoke	e10203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
clonidine	clonidine	c40503050	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
mice	mouse	m020	NNS	B-NP	O
,	,	,000	,	O	O
both	both	b030	DT	B-NP	O
these	these	t020	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
being	be	b052	VBG	B-VP	O
mediated	mediate	m030303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
an	an	a500	DT	B-NP	O
alpha1	alpha1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
may	may	m000	MD	B-VP	O
be	be	b000	VB	I-VP	O
concluded	conclude	c05240303	VBN	I-VP	O
that	that	t030	IN	B-SBAR	O
,	,	,000	,	O	O
like	like	l020	IN	B-PP	O
other	other	o306	JJ	B-NP	O
tricyclic	tricyclic	t60202402	JJ	I-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	B-Chemical
studied	study	s30303	VBN	B-VP	O
previously	previously	p6010240	RB	B-ADVP	O
,	,	,000	,	O	O
TRI	TRI	t600	NN	B-NP	B-Chemical
given	give	g0105	VBN	B-VP	O
repeatedly	repeatedly	r01030340	RB	B-ADVP	O
increases	increase	i5260202	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
responsiveness	responsiveness	r021052010502	NN	I-NP	O
of	of	o100	IN	B-PP	O
brain	brain	b605	NN	B-NP	O
dopamine	dopamine	d0105050	NN	I-NP	B-Chemical
D2	D2	0000	NN	I-NP	O
and	and	a530	CC	O	O
D3	D3	0000	NN	B-NP	O
(	(	(000	(	O	O
locomotor	locomotor	l02050306	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
but	but	b030	CC	B-CONJP	O
not	not	n030	RB	I-CONJP	O
stereotypy	stereotypy	s30603010	JJ	B-ADJP	O
)	)	)000	)	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
alpha1	alpha1	0000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
adrenergic	adrenergic	a360506202	JJ	I-NP	O
receptors	receptor	r02013062	NNS	I-NP	O
to	to	t000	TO	B-PP	O
their	their	t060	PRP$	B-NP	O
agonists	agonist	a2050232	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
question	question	q02305	NN	I-NP	O
arises	arise	a60202	VBZ	B-VP	O
whether	whether	w0306	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
reuptake	reuptake	r013020	NN	I-NP	O
inhibition	inhibition	i5010305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
any	any	a500	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
adaptive	adaptive	a3013010	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
repeated	repeat	r010303	VBN	B-NP	O
antidepressants	antidepressant	a5303016020532	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
suggested	suggest	s0202303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
antidepressant	antidepressant	a530301602053	NN	I-NP	B-Chemical
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

Pethidine	Pethidine	p0303050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
adolescent	adolescent	a30402053	JJ	I-NP	O
receiving	receive	r0201052	VBG	I-NP	O
pethidine	pethidine	p0303050	NN	I-NP	B-Chemical
for	for	f060	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
healthy	healthy	h0430	JJ	I-NP	O
17	17	0000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
year	year	y060	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
old	old	o430	JJ	I-NP	O
male	male	m040	JJ	I-NP	O
received	receive	r020103	VBN	I-NP	O
standard	standard	s3053063	JJ	I-NP	O
intermittent	intermittent	i5306503053	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
a	a	a000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
-	-	-000	HYPH	O	O
controlled	control	c05360403	VBN	B-VP	O
analgesia	analgesia	a5042020	NN	B-NP	O
(	(	(000	(	O	O
PCA	PCA	p200	NN	B-NP	O
)	)	)000	)	O	O
pump	pump	p051	NN	B-NP	O
for	for	f060	IN	B-PP	O
management	management	m050205053	NN	B-NP	O
of	of	o100	IN	B-PP	O
postoperative	postoperative	p023010603010	JJ	B-NP	B-Disease
pain	pain	p050	NN	I-NP	I-Disease
control	control	c053604	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
h	h	h000	NN	I-NP	O
postoperatively	postoperatively	p02301060301040	RB	B-ADVP	O
he	he	h000	PRP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
self	self	s041	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
limited	limit	l050303	VBN	B-NP	O
seizure	seizure	s02060	NN	I-NP	B-Disease
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
plasma	plasma	p40250	NN	B-NP	O
pethidine	pethidine	p0303050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
norpethidine	norpethidine	n0610303050	NN	B-NP	B-Chemical
were	be	w060	VBD	B-VP	O
elevated	elevate	e4010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
range	range	r0520	NN	I-NP	O
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
clinical	clinical	c4050204	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
central	central	c053604	JJ	B-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
excitation	excitation	e2030305	NN	I-NP	O
.	.	.000	.	O	O

No	No	n000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
risk	risk	r020	NN	I-NP	O
factors	factor	f023062	NNS	I-NP	O
for	for	f060	IN	B-PP	O
CNS	CNS	c520	NN	B-NP	O
toxicity	toxicity	t0202030	NN	I-NP	B-Disease
were	be	w060	VBD	B-VP	O
identified	identify	i30530103	VBN	I-VP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
method	method	m0303	NN	I-NP	O
allowed	allow	a403	VBD	B-VP	O
frequent	frequent	f602053	JJ	B-NP	O
self	self	s041	AFX	I-NP	O
-	-	-000	HYPH	I-NP	O
dosing	dosing	d02052	NN	B-NP	O
of	of	o100	IN	B-PP	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
at	at	a300	IN	B-PP	O
short	short	s063	JJ	B-NP	O
time	time	t050	NN	I-NP	O
intervals	interval	i53061042	NNS	I-NP	O
and	and	a530	CC	O	O
rapid	rapid	r0103	JJ	B-NP	O
accumulation	accumulation	a205040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
norpethidine	norpethidine	n0610303050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
routine	routine	r03050	JJ	I-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
pethidine	pethidine	p0303050	NN	B-NP	B-Chemical
via	via	v000	IN	B-PP	O
PCA	PCA	p200	NN	B-NP	O
even	even	e105	RB	B-ADVP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
brief	brief	b601	JJ	I-NP	O
postoperative	postoperative	p023010603010	JJ	I-NP	O
analgesia	analgesia	a5042020	NN	I-NP	O
should	should	s043	MD	B-VP	O
be	be	b000	VB	I-VP	O
reconsidered	reconsider	r02052030603	VBN	I-VP	O
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
unusual	unusual	u50204	JJ	I-NP	O
toxic	toxic	t0202	JJ	I-NP	O
reaction	reaction	r02305	NN	I-NP	O
to	to	t000	TO	B-PP	O
axillary	axillary	a204060	JJ	B-NP	O
block	block	b402	NN	I-NP	O
by	by	b000	IN	B-PP	O
mepivacaine	mepivacaine	m010102050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

An	An	a500	DT	B-NP	O
increase	increase	i526020	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	I-Disease
blood	blood	b403	NN	B-NP	I-Disease
pressure	pressure	p602060	NN	I-NP	I-Disease
,	,	,000	,	O	O
accompanied	accompany	a20510503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
,	,	,000	,	O	O
agitation	agitation	a2030305	NN	B-NP	B-Disease
,	,	,000	,	O	O
incomprehensible	incomprehensible	i5205160520140	JJ	B-NP	B-Disease
shouts	shout	s032	NNS	I-NP	I-Disease
and	and	a530	CC	O	O
loss	loss	l020	NN	B-NP	B-Disease
of	of	o100	IN	B-PP	I-Disease
consciousness	consciousness	c05202502	NN	B-NP	I-Disease
,	,	,000	,	O	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
elderly	elderly	e430640	JJ	I-NP	O
,	,	,000	,	I-NP	O
ASA	ASA	a200	NN	I-NP	O
classification	classification	c40201020305	NN	I-NP	O
group	group	g601	NN	I-NP	O
II	II	i000	CD	I-NP	O
,	,	,000	,	O	O
cardiovascularly	cardiovascularly	c0630102040640	RB	B-NP	O
medicated	medicate	m03020303	VBN	I-NP	O
male	male	m040	NN	I-NP	O
,	,	,000	,	O	O
12	12	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
after	after	a1306	IN	B-PP	O
performance	performance	p0610650520	NN	B-NP	O
of	of	o100	IN	B-PP	O
axillary	axillary	a204060	JJ	B-NP	O
block	block	b402	NN	I-NP	O
with	with	w030	IN	B-PP	O
mepivacaine	mepivacaine	m010102050	NN	B-NP	B-Chemical
850	850	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
containing	contain	c05305052	VBG	B-VP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
0	0	0000	CD	I-NP	O
.	.	.000	.	O	O
225	225	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
,	,	,000	,	O	O
for	for	f060	IN	B-PP	O
correction	correction	c0602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
Dupuytren	Dupuytren	d0103605	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
contracture	contracture	c0536023060	NN	I-NP	I-Disease
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
intravenous	intravenous	i536010502	JJ	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
labetalol	labetalol	l01030404	NN	B-NP	B-Chemical
,	,	,000	,	I-NP	O
metoprolol	metoprolol	m030160404	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
midazolam	midazolam	m03020405	NN	I-NP	B-Chemical
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
condition	condition	c0530305	NN	I-NP	O
improved	improve	i5160103	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
15	15	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
later	later	l0306	RB	B-ADVP	O
he	he	h000	PRP	B-NP	O
woke	wake	w020	VBD	B-VP	O
up	up	u100	RP	B-PRT	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
block	block	b402	NN	I-NP	O
was	be	w020	VBD	B-VP	O
successful	successful	s0202104	JJ	B-ADJP	O
and	and	a530	CC	O	O
surgery	surgery	s062060	NN	B-NP	O
was	be	w020	VBD	B-VP	O
conducted	conduct	c05302303	VBN	I-VP	O
as	as	a200	IN	B-SBAR	O
scheduled	schedule	s2030403	VBN	B-VP	O
despite	despite	d021030	IN	B-PP	O
persisting	persist	p062023052	VBG	B-VP	O
atrial	atrial	a3604	JJ	B-NP	B-Disease
fibrillation	fibrillation	f016040305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Postoperatively	Postoperatively	p02301060301040	RB	B-ADVP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
refused	refuse	r010203	VBD	B-VP	O
DC	DC	d200	NN	B-NP	O
cardioversion	cardioversion	c0630106205	NN	I-NP	O
and	and	a530	CC	O	O
was	be	w020	VBD	B-VP	O
treated	treat	t60303	VBN	I-VP	O
medically	medically	m0302040	RB	B-ADVP	O
.	.	.000	.	O	O

Both	Both	b030	CC	O	O
the	the	t000	DT	B-NP	O
temporal	temporal	t0510604	JJ	I-NP	O
relationship	relationship	r040305201	NN	I-NP	O
of	of	o100	IN	B-PP	O
events	event	e10532	NNS	B-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
response	response	r0210520	NN	I-NP	O
to	to	t000	TO	B-PP	O
treatment	treatment	t6035053	NN	B-NP	O
suggest	suggest	s02023	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
rapid	rapid	r0103	JJ	I-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
absorption	absorption	a12061305	NN	I-NP	O
of	of	o100	IN	B-PP	O
mepivacaine	mepivacaine	m010102050	NN	B-NP	B-Chemical
with	with	w030	IN	B-PP	O
adrenaline	adrenaline	a360504050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
/	/	/000	SYM	B-NP	O
or	or	o600	CC	O	O
interaction	interaction	i530602305	NN	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
drugs	drug	d602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
patient	patient	p03053	NN	I-NP	O
'	'	'000	''	O	O
s	s	s000	VBZ	B-VP	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
medications	medication	m030203052	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
responsible	responsible	r0210520140	JJ	B-ADJP	O
for	for	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
perioperative	perioperative	p06010603010	JJ	I-NP	O
complications	complication	c05140203052	NNS	I-NP	O
.	.	.000	.	O	O

Drug	Drug	d602	NN	B-NP	O
-	-	-000	HYPH	O	O
associated	associate	a2020303	VBN	B-NP	O
acute	acute	a2030	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
onset	onset	o5203	NN	I-NP	O
vanishing	vanish	v0502052	VBG	B-VP	B-Disease
bile	bile	b040	NN	B-NP	I-Disease
duct	duct	d023	NN	I-NP	I-Disease
and	and	a530	CC	O	O
Stevens	Stevens	s301052	NNP	B-NP	B-Disease
-	-	-000	HYPH	B-NP	I-Disease
Johnson	Johnson	j05205	NNP	I-NP	I-Disease
syndromes	syndrome	s05360502	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
child	child	c043	NN	I-NP	O
.	.	.000	.	O	O

Acute	Acute	a2030	JJ	B-NP	O
vanishing	vanish	v0502052	VBG	I-NP	B-Disease
bile	bile	b040	NN	I-NP	I-Disease
duct	duct	d023	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
but	but	b030	CC	I-NP	O
established	established	e230140203	JJ	I-NP	O
cause	cause	c020	NN	I-NP	O
of	of	o100	IN	B-PP	O
progressive	progressive	p602602010	JJ	B-NP	O
cholestasis	cholestasis	c040230202	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
adults	adult	a30432	NNS	B-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
most	most	m023	RBS	B-ADVP	O
often	often	o1305	RB	I-ADVP	O
drug	drug	d602	NN	B-NP	O
or	or	o600	CC	I-NP	O
toxin	toxin	t0205	NN	I-NP	O
related	relate	r040303	VBN	B-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
is	be	i200	VBZ	B-VP	O
of	of	o100	IN	B-PP	O
unknown	unknown	u52505	JJ	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
.	.	.000	.	O	O

It	It	i300	PRP	B-NP	O
has	have	h020	VBZ	B-VP	O
not	not	n030	RB	I-VP	O
been	be	b050	VBN	I-VP	O
reported	report	r0106303	VBN	I-VP	O
previously	previously	p6010240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
.	.	.000	.	O	O

Stevens	Stevens	s301052	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Johnson	Johnson	j05205	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
well	well	w040	RB	I-NP	O
-	-	-000	HYPH	I-NP	O
recognized	recognize	r020250203	VBN	B-VP	O
immune	immune	i5050	JJ	B-NP	O
complex	complex	c051402	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
mediated	mediate	m030303	VBN	B-NP	O
hypersensitivity	hypersensitivity	h010620520301030	NN	I-NP	B-Disease
reaction	reaction	r02305	NN	I-NP	O
that	that	t030	WDT	B-NP	O
affects	affect	a10232	VBZ	B-VP	O
all	all	a400	DT	B-NP	O
age	age	a200	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
is	be	i200	VBZ	B-VP	O
drug	drug	d602	NN	B-NP	O
or	or	o600	CC	I-NP	O
infection	infection	i5102305	NN	I-NP	B-Disease
induced	induce	i530203	VBD	B-VP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
has	have	h020	VBZ	B-VP	O
classic	classic	c40202	JJ	B-NP	O
systemic	systemic	s0230502	JJ	I-NP	O
,	,	,000	,	I-NP	O
mucosal	mucosal	m020204	JJ	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
dermatologic	dermatologic	d06503040202	JJ	B-NP	O
manifestations	manifestation	m050102303052	NNS	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
previously	previously	p6010240	RB	I-NP	O
healthy	healthy	h0430	JJ	I-NP	O
child	child	c043	NN	I-NP	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
,	,	,000	,	I-NP	O
severe	severe	s01060	JJ	I-NP	O
,	,	,000	,	I-NP	O
rapidly	rapidly	r010340	RB	I-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
vanishing	vanish	v0502052	VBG	I-NP	B-Disease
bile	bile	b040	NN	I-NP	I-Disease
duct	duct	d023	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
shortly	shortly	s06340	RB	B-ADVP	O
after	after	a1306	IN	B-PP	O
Stevens	Stevens	s301052	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Johnson	Johnson	j05205	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
described	describe	d0260103	VBN	I-VP	O
;	;	;000	:	O	O
this	this	t020	DT	B-NP	O
was	be	w020	VBD	B-VP	O
temporally	temporally	t05106040	RB	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
ibuprofen	ibuprofen	i10160105	NN	B-NP	B-Chemical
use	use	u200	NN	I-NP	O
.	.	.000	.	O	O

Despite	Despite	d021030	IN	B-PP	O
therapy	therapy	t06010	NN	B-NP	O
with	with	w030	IN	B-PP	O
ursodeoxycholic	ursodeoxycholic	u620302020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
prednisone	prednisone	p603502050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
then	then	t050	RB	B-ADVP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
,	,	,000	,	O	O
her	her	h060	PRP$	B-NP	O
cholestatic	cholestatic	c040230302	JJ	I-NP	B-Disease
disease	disease	d02020	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
unrelenting	unrelente	u5604053052	VBG	I-VP	O
,	,	,000	,	O	O
with	with	w030	IN	B-PP	O
cirrhosis	cirrhosis	c060202	NN	B-NP	B-Disease
shown	show	s050	VBN	B-VP	O
by	by	b000	IN	B-PP	O
biopsy	biopsy	b0120	NN	B-NP	O
6	6	6000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
presentation	presentation	p6020530305	NN	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
case	case	c020	NN	I-NP	O
documents	document	d02050532	NNS	I-NP	O
acute	acute	a2030	JJ	B-NP	O
drug	drug	d602	NN	I-NP	O
-	-	-000	HYPH	B-VP	O
related	relate	r040303	VBN	I-VP	O
vanishing	vanish	v0502052	VBG	B-VP	B-Disease
bile	bile	b040	NN	B-NP	I-Disease
duct	duct	d023	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pediatric	pediatric	p0303602	JJ	I-NP	O
age	age	a200	NN	I-NP	O
group	group	g601	NN	I-NP	O
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
shared	share	s0603	VBN	I-VP	O
immune	immune	i5050	JJ	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
pathogenesis	pathogenesis	p0302050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
both	both	b030	CC	O	O
Stevens	Stevens	s301052	NNP	B-NP	B-Disease
-	-	-000	HYPH	I-NP	I-Disease
Johnson	Johnson	j05205	NNP	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
and	and	a530	CC	O	O
vanishing	vanish	v0502052	VBG	B-VP	B-Disease
bile	bile	b040	NN	B-NP	I-Disease
duct	duct	d023	NN	I-NP	I-Disease
syndrome	syndrome	s0536050	NN	I-NP	I-Disease
.	.	.000	.	O	O

High	High	h020	JJ	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
in	in	i500	IN	B-PP	O
Belgium	Belgium	b04205	NNP	B-NP	O
.	.	.000	.	O	O

Primary	Primary	p605060	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
rare	rare	r060	JJ	I-NP	O
,	,	,000	,	I-NP	O
progressive	progressive	p602602010	JJ	I-NP	O
and	and	a530	CC	I-NP	O
incurable	incurable	i52060140	JJ	I-NP	O
disease	disease	d02020	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
intake	intake	i53020	NN	I-NP	O
of	of	o100	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressant	suppressant	s01602053	NN	I-NP	I-Chemical
drugs	drug	d602	NNS	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
importance	importance	i510630520	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
association	association	a2020305	NN	I-NP	O
was	be	w020	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
Belgium	Belgium	b04205	NNP	B-NP	O
while	while	w040	IN	B-SBAR	O
this	this	t020	DT	B-NP	O
country	country	c05360	NN	I-NP	O
still	still	s304	RB	B-ADVP	O
had	have	h030	VBD	B-VP	O
no	no	n000	DT	B-NP	O
restriction	restriction	r023602305	NN	I-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
prescription	prescription	p602601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

Thirty	Thirty	t0630	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
five	five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
and	and	a530	CC	O	O
85	85	0000	CD	B-NP	O
matched	match	m03203	VBN	I-NP	O
controls	control	c0536042	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
recruited	recruit	r0260303	VBN	I-VP	O
over	over	o106	IN	B-PP	O
32	32	0000	CD	B-NP	O
months	month	m05302	NNS	I-NP	O
(	(	(000	(	O	O
1992	1992	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
1994	1994	0000	CD	I-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
Belgium	Belgium	b04205	NNP	B-NP	O
.	.	.000	.	O	O

Exposure	Exposure	e2102060	NN	B-NP	O
to	to	t000	TO	B-VP	O
appetite	appetite	a103030	VB	I-VP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
basis	basis	b0202	NN	I-NP	O
of	of	o100	IN	B-PP	O
hospital	hospital	h0210304	NN	B-NP	O
records	record	r020632	NNS	I-NP	O
and	and	a530	CC	O	O
standardized	standardized	s30530630203	JJ	B-NP	O
interview	interview	i530610	NN	I-NP	O
.	.	.000	.	O	O

Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
three	three	t060	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
had	have	h030	VBD	B-VP	O
previously	previously	p6010240	RB	I-VP	O
taken	take	t0205	VBN	I-VP	O
appetite	appetite	a103030	NN	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
,	,	,000	,	O	O
mainly	mainly	m0540	RB	B-NP	O
fenfluramines	fenfluramine	f051406050502	NNS	I-NP	B-Chemical
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
compared	compare	c0510603	VBN	B-PP	O
with	with	w030	IN	B-PP	O
only	only	o540	RB	B-NP	O
5	5	5000	CD	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
controls	control	c0536042	NNS	I-NP	O
(	(	(000	(	O	O
66	66	0000	CD	B-NP	O
versus	versus	v06202	CC	I-NP	O
6	6	6000	CD	I-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
p	p	p000	NN	B-NP	O
<	<	<000	SYM	B-VP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
0001	0001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Five	Five	f010	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
died	die	d030	VBD	B-VP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
interview	interview	i530610	NN	I-NP	O
,	,	,000	,	O	O
all	all	a400	DT	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
8	8	8000	CD	B-NP	O
patients	patient	p030532	NNS	I-NP	O
the	the	t000	DT	B-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
of	of	o100	IN	B-PP	O
primary	primary	p605060	JJ	B-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
was	be	w020	VBD	B-VP	O
uncertain	uncertain	u5206305	JJ	B-ADJP	O
,	,	,000	,	O	O
5	5	5000	CD	B-NP	O
of	of	o100	IN	B-PP	O
them	them	t050	PRP	B-NP	O
had	have	h030	VBD	B-VP	O
taken	take	t0205	VBN	I-VP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
had	have	h030	VBD	B-VP	O
been	be	b050	VBN	I-VP	O
exposed	expose	e210203	VBN	I-VP	O
to	to	t000	TO	I-VP	O
appetite	appetite	a103030	VB	I-VP	B-Chemical
suppressants	suppressant	s016020532	NNS	B-NP	I-Chemical
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
on	on	o500	IN	B-PP	O
average	average	a106020	NN	B-NP	O
more	more	m060	RBR	B-ADJP	O
severely	severely	s0106040	RB	I-ADJP	O
ill	ill	i400	JJ	I-ADJP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
to	to	t000	TO	B-VP	O
have	have	h010	VB	I-VP	O
a	a	a000	DT	B-NP	O
shorter	short	s06306	JJR	I-NP	O
median	median	m0305	JJ	I-NP	O
delay	delay	d040	NN	I-NP	O
between	between	b0305	IN	B-PP	O
onset	onset	o5203	NN	B-NP	O
of	of	o100	IN	B-PP	O
symptoms	symptom	s0513052	NNS	B-NP	O
and	and	a530	CC	I-NP	O
diagnosis	diagnosis	d0250202	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
policy	policy	p04020	NN	I-NP	O
of	of	o100	IN	B-PP	O
unrestricted	unrestricted	u56023602303	JJ	B-NP	O
prescription	prescription	p602601305	NN	I-NP	O
of	of	o100	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
a	a	a000	DT	B-NP	O
high	high	h020	JJ	I-NP	O
incidence	incidence	i52030520	NN	I-NP	O
of	of	o100	IN	B-PP	O
associated	associate	a2020303	VBN	B-NP	O
primary	primary	p605060	JJ	I-NP	B-Disease
pulmonary	pulmonary	p04505060	JJ	I-NP	I-Disease
hypertension	hypertension	h0106305205	NN	I-NP	I-Disease
.	.	.000	.	O	O

Intake	Intake	i53020	NN	B-NP	O
of	of	o100	IN	B-PP	O
appetite	appetite	a103030	JJ	B-NP	B-Chemical
suppressants	suppressant	s016020532	NNS	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
accelerate	accelerate	a20406030	VB	I-VP	O
the	the	t000	DT	B-NP	O
progression	progression	p60260205	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
disease	disease	d02020	NN	I-NP	O
.	.	.000	.	O	O

Inappropriate	Inappropriate	i5016016030	JJ	B-NP	O
use	use	u200	NN	I-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
vigabatrin	vigabatrin	v020103605	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
typical	typical	t010204	JJ	B-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Carbamazepine	Carbamazepine	c061050201050	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
vigabatrin	vigabatrin	v020103605	NN	I-NP	B-Chemical
are	be	a600	VBP	B-VP	O
contraindicated	contraindicate	c0536053020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
typical	typical	t010204	JJ	B-NP	O
absence	absence	a120520	NN	I-NP	B-Disease
seizures	seizure	s020602	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
18	18	0000	CD	B-NP	O
consecutive	consecutive	c0520203010	JJ	I-NP	O
referrals	referral	r0106042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
children	child	c043605	NNS	B-NP	O
with	with	w030	IN	B-PP	O
resistant	resistant	r02023053	JJ	B-NP	O
typical	typical	t010204	JJ	I-NP	O
absences	absence	a1205202	NNS	I-NP	O
only	only	o540	RB	B-ADVP	O
,	,	,000	,	O	O
eight	eight	e0203	CD	B-NP	O
were	be	w060	VBD	B-VP	O
erroneously	erroneously	e6050240	RB	I-VP	O
treated	treat	t60303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
either	either	e0306	CC	B-PP	O
as	as	a200	IN	B-PP	O
monotherapy	monotherapy	m050306010	NN	B-NP	O
or	or	o600	CC	B-PP	O
as	as	a200	IN	B-PP	O
an	an	a500	DT	B-NP	O
add	add	a300	NN	I-NP	O
-	-	-000	HYPH	B-ADVP	O
on	on	o500	RP	I-ADVP	O
.	.	.000	.	O	O

Vigabatrin	Vigabatrin	v020103605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	I-VP	O
used	use	u203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
.	.	.000	.	O	O

Frequency	Frequency	f6020520	NN	B-NP	O
of	of	o100	IN	B-PP	O
absences	absence	a1205202	NNS	B-NP	O
increased	increase	i5260203	VBD	B-VP	O
in	in	i500	IN	B-PP	O
four	four	f060	CD	B-NP	O
children	child	c043605	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
and	and	a530	CC	O	O
two	two	t000	CD	B-NP	O
of	of	o100	IN	B-PP	O
these	these	t020	DT	B-NP	O
developed	develop	d01040103	VBN	I-NP	O
myoclonic	myoclonic	m0240502	JJ	I-NP	B-Disease
jerks	jerk	j062	NNS	I-NP	I-Disease
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
resolved	resolve	r0204103	VBD	B-VP	O
on	on	o500	IN	B-PP	O
withdrawal	withdrawal	w0303604	NN	B-NP	O
of	of	o100	IN	B-PP	O
carbamazepine	carbamazepine	c061050201050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Absences	Absence	a1205202	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
aggravated	aggravate	a26010303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
both	both	b030	DT	B-NP	O
cases	case	c0202	NNS	I-NP	O
where	where	w060	WRB	B-ADVP	O
vigabatrin	vigabatrin	v020103605	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
on	on	o500	RP	B-PRT	O
to	to	t000	TO	B-PP	O
concurrent	concurrent	c05206053	JJ	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
.	.	.000	.	O	O

Optimal	Optimal	o130504	JJ	B-NP	O
control	control	c053604	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
absences	absence	a1205202	NNS	I-NP	O
was	be	w020	VBD	B-VP	O
achieved	achieve	a20103	VBN	I-VP	O
with	with	w030	IN	B-PP	O
sodium	sodium	s0305	NN	B-NP	B-Chemical
valproate	valproate	v0416030	NN	I-NP	I-Chemical
,	,	,000	,	O	O
lamotrigine	lamotrigine	l0503602050	NN	B-NP	B-Chemical
,	,	,000	,	O	O
or	or	o600	CC	O	O
ethosuximide	ethosuximide	e3020205030	NN	B-NP	B-Chemical
alone	alone	a4050	RB	B-ADVP	O
or	or	o600	CC	O	O
in	in	i500	IN	B-PP	O
combination	combination	c051050305	NN	B-NP	O
.	.	.000	.	O	O

Choreoathetoid	Choreoathetoid	c06030303	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
associated	associate	a2020303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
to	to	t000	TO	B-PP	O
methadone	methadone	m0303050	NN	B-NP	B-Chemical
.	.	.000	.	O	O

Choreatiform	Choreatiform	c060301065	NN	B-NP	B-Disease
hyperkinesias	hyperkinesia	h01062050202	NNS	I-NP	I-Disease
are	be	a600	VBP	B-VP	O
known	know	k505	VBN	I-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
occasional	occasional	o2020504	JJ	B-NP	O
movement	movement	m0105053	NN	I-NP	B-Disease
abnormalities	abnormality	a15065040302	NNS	I-NP	I-Disease
during	during	d06052	IN	B-PP	O
intoxications	intoxication	i53020203052	NNS	B-NP	O
with	with	w030	IN	B-PP	O
cocaine	cocaine	c02050	NN	B-NP	B-Chemical
but	but	b030	CC	B-NP	O
not	not	n030	RB	I-NP	O
opiates	opiate	o10302	NNS	B-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
case	case	c020	NN	I-NP	O
report	report	r01063	NN	I-NP	O
of	of	o100	IN	B-PP	O
euphoria	euphoria	e01060	NN	B-NP	O
and	and	a530	CC	O	O
choreoathetoid	choreoathetoid	c06030303	JJ	B-NP	B-Disease
movements	movement	m01050532	NNS	I-NP	I-Disease
both	both	b030	CC	O	O
transiently	transiently	t605205340	RB	B-VP	O
induced	induce	i530203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
rapid	rapid	r0103	JJ	B-NP	O
adjustment	adjustment	a320235053	NN	I-NP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
mu	mu	m000	SYM	I-NP	O
-	-	-000	HYPH	I-NP	O
opioid	opioid	o103	JJ	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
agonist	agonist	a205023	NN	I-NP	O
methadone	methadone	m0303050	NN	I-NP	B-Chemical
in	in	i500	IN	B-PP	O
an	an	a500	DT	B-NP	O
inpatient	inpatient	i5103053	NN	I-NP	O
previously	previously	p6010240	RB	B-NP	O
abusing	abuse	a102052	VBG	I-NP	O
heroine	heroine	h06050	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
cocaine	cocaine	c02050	NN	I-NP	B-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
minor	minor	m0506	JJ	B-NP	O
EEG	EEG	e020	NN	I-NP	O
abnormalities	abnormality	a15065040302	NNS	I-NP	O
occurred	occur	o20603	VBD	B-VP	O
.	.	.000	.	O	O

Possible	Possible	p020140	JJ	B-NP	O
underlying	underlie	u53064052	VBG	I-NP	O
neurobiological	neurobiological	n060104020204	JJ	I-NP	O
phenomena	phenomenon	p0505050	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
discussed	discuss	d020203	VBN	I-VP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
.	.	.000	.	O	O

Collaborative	Collaborative	c04010603010	JJ	B-NP	O
Working	Working	w062052	NNP	I-NP	O
Group	Group	g601	NNP	I-NP	O
on	on	o500	IN	B-PP	O
Clinical	Clinical	c4050204	NNP	B-NP	O
Trial	Trial	t604	NNP	I-NP	O
Evaluations	Evaluation	e10403052	NNPS	I-NP	O
.	.	.000	.	O	O

Adverse	Adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
antipsychotics	antipsychotic	a53012020302	NNS	B-NP	O
often	often	o1305	RB	B-ADVP	O
lead	lead	l030	VBP	B-VP	O
to	to	t000	TO	B-PP	O
noncompliance	noncompliance	n05205140520	NN	B-NP	O
.	.	.000	.	O	O

Thus	Thus	t020	RB	B-ADVP	O
,	,	,000	,	O	O
clinicians	clinician	c40502052	NNS	B-NP	O
should	should	s043	MD	B-VP	O
address	address	a3602	VB	I-VP	O
patients	patient	p030532	NNS	B-NP	O
'	'	'000	POS	B-NP	O
concerns	concern	c0520652	NNS	I-NP	O
about	about	a103	IN	B-PP	O
adverse	adverse	a310620	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
and	and	a530	CC	O	O
attempt	attempt	a30513	NN	B-NP	O
to	to	t000	TO	B-VP	O
choose	choose	c020	VB	I-VP	O
medications	medication	m030203052	NNS	B-NP	O
that	that	t030	WDT	B-NP	O
will	will	w040	MD	B-VP	O
improve	improve	i516010	VB	I-VP	O
their	their	t060	PRP$	B-NP	O
patients	patient	p030532	NNS	I-NP	O
'	'	'000	POS	B-NP	O
quality	quality	q04030	NN	I-NP	O
of	of	o100	IN	B-PP	O
life	life	l010	NN	B-NP	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
overall	overall	o10604	JJ	B-NP	O
health	health	h0430	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
side	side	s030	NN	I-NP	O
effect	effect	e1023	NN	I-NP	O
profiles	profile	p6010402	NNS	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
antipsychotics	antipsychotic	a53012020302	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
more	more	m060	RBR	B-ADJP	O
advantageous	advantageous	a310530202	JJ	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
conventional	conventional	c0510530504	JJ	I-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
.	.	.000	.	O	O

Conventional	Conventional	c0510530504	JJ	B-NP	O
agents	agent	a20532	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
with	with	w030	IN	B-PP	O
unwanted	unwanted	u505303	JJ	B-NP	O
central	central	c053604	JJ	I-NP	O
nervous	nervous	n06102	JJ	I-NP	O
system	system	s02305	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
including	include	i52403052	VBG	B-PP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
symptoms	symptom	s0513052	NNS	I-NP	I-Disease
(	(	(000	(	O	O
EPS	EPS	e120	NNS	B-NP	B-Disease
)	)	)000	)	O	O
,	,	,000	,	O	O
tardive	tardive	t063010	JJ	B-NP	B-Disease
dyskinesia	dyskinesia	d0205020	NN	I-NP	I-Disease
,	,	,000	,	O	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
possible	possible	p020140	JJ	B-NP	O
impairment	impairment	i51065053	NN	I-NP	O
of	of	o100	IN	B-PP	O
some	some	s050	DT	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
measures	measure	m020602	NNS	I-NP	O
,	,	,000	,	O	O
as	as	a200	RB	B-CONJP	O
well	well	w040	RB	I-CONJP	O
as	as	a200	IN	I-CONJP	O
cardiac	cardiac	c06302	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
orthostatic	orthostatic	o630230302	JJ	B-NP	B-Disease
hypotension	hypotension	h010305205	NN	I-NP	I-Disease
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
changes	change	c05202	NNS	I-NP	O
,	,	,000	,	O	O
anticholinergic	anticholinergic	a5302040506202	JJ	B-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
and	and	a530	CC	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
newer	new	n060	JJR	I-NP	O
atypical	atypical	a3010204	JJ	I-NP	O
agents	agent	a20532	NNS	I-NP	O
have	have	h010	VBP	B-VP	O
a	a	a000	DT	B-NP	O
lower	low	l060	JJR	I-NP	O
risk	risk	r020	NN	I-NP	O
of	of	o100	IN	B-PP	O
EPS	EPS	e120	NNP	B-NP	B-Disease
,	,	,000	,	O	O
but	but	b030	CC	O	O
are	be	a600	VBP	B-VP	O
associated	associate	a2020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
varying	vary	v06052	VBG	B-NP	O
degrees	degree	d02602	NNS	I-NP	O
with	with	w030	IN	B-PP	O
sedation	sedation	s030305	NN	B-NP	O
,	,	,000	,	O	O
cardiovascular	cardiovascular	c06301020406	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
anticholinergic	anticholinergic	a5302040506202	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
weight	weight	w0203	NN	B-NP	B-Disease
gain	gain	g050	NN	I-NP	I-Disease
,	,	,000	,	O	O
sexual	sexual	s0204	JJ	B-NP	B-Disease
dysfunction	dysfunction	d021052305	NN	I-NP	I-Disease
,	,	,000	,	O	O
hepatic	hepatic	h010302	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
,	,	,000	,	O	O
lowered	lower	l0603	VBD	B-VP	O
seizure	seizure	s02060	NN	B-NP	B-Disease
threshold	threshold	t0602043	NN	I-NP	O
(	(	(000	(	O	O
primarily	primarily	p60506040	RB	B-NP	O
clozapine	clozapine	c40201050	NN	I-NP	B-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
agranulocytosis	agranulocytosis	a26050402030202	NN	B-NP	B-Disease
(	(	(000	(	O	O
clozapine	clozapine	c40201050	NN	B-NP	B-Chemical
only	only	o540	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Since	Since	s0520	IN	B-SBAR	O
the	the	t000	DT	B-NP	O
incidence	incidence	i52030520	NN	I-NP	O
and	and	a530	CC	I-NP	O
severity	severity	s0106030	NN	I-NP	O
of	of	o100	IN	B-PP	O
specific	specific	s1020102	JJ	B-NP	O
adverse	adverse	a310620	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
differ	differ	d0106	VBP	B-VP	O
among	among	a5052	IN	B-PP	O
the	the	t000	DT	B-NP	O
various	various	v0602	JJ	I-NP	O
atypicals	atypical	a30102042	NNS	I-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
clinician	clinician	c4050205	NN	I-NP	O
should	should	s043	MD	B-VP	O
carefully	carefully	c0601040	RB	I-VP	O
consider	consider	c0520306	VB	I-VP	O
which	which	w020	WDT	B-NP	O
side	side	s030	NN	B-NP	O
effects	effect	e10232	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
most	most	m023	RBS	B-ADJP	O
likely	likely	l02040	JJ	I-ADJP	O
to	to	t000	TO	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
individual	individual	i53010304	NN	I-NP	O
'	'	'000	POS	B-NP	O
s	s	s000	NNS	I-NP	O
dissatisfaction	dissatisfaction	d020302102305	NN	I-NP	O
and	and	a530	CC	I-NP	O
noncompliance	noncompliance	n05205140520	NN	I-NP	O
before	before	b01060	IN	B-PP	O
choosing	choose	c02052	VBG	B-VP	O
an	an	a500	DT	B-NP	O
antipsychotic	antipsychotic	a53012020302	JJ	I-NP	O
for	for	f060	IN	B-PP	O
a	a	a000	DT	B-NP	O
particular	particular	p063020406	JJ	I-NP	O
patient	patient	p03053	NN	I-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
randomized	randomize	r053050203	VBN	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
comparison	comparison	c051060205	NN	I-NP	O
trial	trial	t604	NN	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
for	for	f060	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
disruptive	disruptive	d026013010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

OBJECTIVE	OBJECTIVE	o12023010	NN	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
goal	goal	g040	NN	I-NP	O
of	of	o100	IN	B-PP	O
this	this	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
was	be	w020	VBD	B-VP	O
to	to	t000	TO	B-VP	O
compare	compare	c051060	VB	I-VP	O
the	the	t000	DT	B-NP	O
efficacy	efficacy	e102020	NN	I-NP	O
and	and	a530	CC	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
two	two	t000	CD	B-NP	O
doses	dose	d0202	NNS	I-NP	O
of	of	o100	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
treatment	treatment	t6035053	NN	I-NP	O
of	of	o100	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
disruptive	disruptive	d026013010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
in	in	i500	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
with	with	w030	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

METHOD	METHOD	m0303	NN	B-NP	O
:	:	:000	:	O	O
In	In	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
random	random	r05305	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
assignment	assignment	a2025053	NN	I-NP	O
,	,	,000	,	O	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
,	,	,000	,	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
controlled	control	c05360403	VBN	B-VP	O
trial	trial	t604	NN	B-NP	O
(	(	(000	(	O	O
phase	phase	p020	NN	B-NP	O
A	A	a000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
standard	standard	s3053063	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
,	,	,000	,	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
50	50	0000	CD	B-NP	O
-	-	-000	:	O	O
0	0	0000	CD	B-NP	O
.	.	.000	.	O	O
75	75	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
(	(	(000	(	O	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
compared	compare	c0510603	VBN	I-VP	O
in	in	i500	IN	B-PP	O
71	71	0000	CD	B-NP	O
outpatients	outpatient	o031030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	JJ	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
.	.	.000	.	O	O

For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
subsequent	subsequent	s01202053	JJ	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	I-NP	O
week	week	w020	NN	I-NP	O
double	double	d0140	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
blind	blind	b4053	JJ	I-NP	O
crossover	crossover	c6020106	NN	I-NP	O
phase	phase	p020	NN	I-NP	O
(	(	(000	(	O	O
phase	phase	p020	NN	B-NP	O
B	B	b000	NN	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
standard	standard	s3053063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
or	or	o600	CC	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
were	be	w060	VBD	B-VP	O
switched	switch	s03203	VBN	I-VP	O
to	to	t000	TO	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
patients	patient	p030532	NNS	B-NP	O
taking	take	t02052	VBG	B-VP	O
placebo	placebo	p402010	NN	B-NP	O
were	be	w060	VBD	B-VP	O
randomly	randomly	r0530540	RB	I-VP	O
assigned	assign	a202503	VBN	I-VP	O
to	to	t000	TO	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
or	or	o600	CC	I-NP	O
low	low	l000	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
For	For	f060	IN	B-PP	O
the	the	t000	DT	B-NP	O
60	60	0000	CD	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
completed	complete	c05140303	VBD	B-VP	O
phase	phase	p020	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
standard	standard	s3053063	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
was	be	w020	VBD	B-VP	O
efficacious	efficacious	e1020202	JJ	B-ADJP	O
and	and	a530	CC	I-ADJP	O
superior	superior	s010606	JJ	I-ADJP	O
to	to	t000	TO	B-PP	O
both	both	b030	CC	O	O
low	low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
and	and	a530	CC	I-NP	O
placebo	placebo	p402010	NN	I-NP	O
for	for	f060	IN	B-PP	O
scores	score	s20602	NNS	B-NP	O
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
Brief	Brief	b601	NNP	I-NP	O
Psychiatric	Psychiatric	p20203602	NNP	I-NP	O
Rating	Rating	r03052	NNP	I-NP	O
Scale	Scale	s2040	NNP	I-NP	O
psychosis	psychosis	p2020202	NN	I-NP	B-Disease
factor	factor	f02306	NN	I-NP	O
and	and	a530	CC	B-PP	O
on	on	o500	IN	B-PP	O
psychomotor	psychomotor	p202050306	NN	B-NP	B-Disease
agitation	agitation	a2030305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Response	Response	r0210520	NN	B-NP	O
rates	rate	r0302	NNS	I-NP	O
according	accord	a2063052	VBG	B-PP	O
to	to	t000	TO	B-PP	O
three	three	t060	CD	B-NP	O
sets	set	s032	NNS	I-NP	O
of	of	o100	IN	B-PP	O
criteria	criterion	c603060	NNS	B-NP	O
were	be	w060	VBD	B-VP	O
greater	great	g60306	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
60	60	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
than	than	t050	IN	B-PP	O
the	the	t000	DT	B-NP	O
low	low	l000	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
35	35	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
placebo	placebo	p402010	NN	B-NP	O
(	(	(000	(	O	O
25	25	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
-	-	-000	HYPH	O	O
30	30	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
advantage	advantage	a31053020	NN	I-NP	O
of	of	o100	IN	B-PP	O
standard	standard	s3053063	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
over	over	o106	IN	B-PP	O
low	low	l000	JJ	B-NP	O
dose	dose	d020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
replicated	replicate	r014020303	VBN	I-VP	O
in	in	i500	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
B	B	b000	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
phase	phase	p020	NN	B-NP	O
A	A	a000	NN	I-NP	O
,	,	,000	,	O	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	B-NP	B-Disease
signs	sign	s0252	NNS	I-NP	I-Disease
tended	tend	t05303	VBD	B-VP	O
to	to	t000	TO	I-VP	O
be	be	b000	VB	I-VP	O
greater	great	g60306	JJR	B-ADJP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
standard	standard	s3053063	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
than	than	t050	IN	B-PP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
two	two	t000	CD	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
primarily	primarily	p60506040	RB	B-ADVP	O
because	because	b02020	IN	B-PP	O
of	of	o100	IN	I-PP	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
(	(	(000	(	O	O
20	20	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
)	)	)000	)	O	O
who	who	w000	WP	B-NP	O
developed	develop	d01040103	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
signs	sign	s0252	NNS	I-NP	O
.	.	.000	.	O	O

Low	Low	l000	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
dose	dose	d020	NN	I-NP	O
haloperidol	haloperidol	h0401060304	NN	I-NP	B-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
differ	differ	d0106	VB	I-VP	O
from	from	f605	IN	B-PP	O
placebo	placebo	p402010	NN	B-NP	O
on	on	o500	IN	B-PP	O
any	any	a500	DT	B-NP	O
measure	measure	m02060	NN	I-NP	O
of	of	o100	IN	B-PP	O
efficacy	efficacy	e102020	NN	B-NP	O
or	or	o600	CC	I-NP	O
side	side	s030	NN	I-NP	O
effects	effect	e10232	NNS	I-NP	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicated	indicate	i53020303	VBD	B-VP	O
a	a	a000	DT	B-NP	O
favorable	favorable	f01060140	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
profile	profile	p601040	NN	I-NP	O
for	for	f060	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
in	in	i500	IN	B-PP	O
doses	dose	d0202	NNS	B-NP	O
of	of	o100	IN	B-PP	O
2	2	2000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
3	3	3000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
,	,	,000	,	O	O
although	although	a43020	IN	B-SBAR	O
a	a	a000	DT	B-NP	O
subgroup	subgroup	s012601	NN	I-NP	O
developed	develop	d01040103	VBD	B-VP	O
moderate	moderate	m0306030	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
severe	severe	s01060	JJ	B-NP	O
extrapyramidal	extrapyramidal	e2360106050304	JJ	I-NP	B-Disease
signs	sign	s0252	NNS	I-NP	I-Disease
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
starting	start	s3063052	VBG	I-NP	O
dose	dose	d020	NN	I-NP	O
of	of	o100	IN	B-PP	O
1	1	1000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
day	day	d000	NN	I-NP	O
with	with	w030	IN	B-PP	O
gradual	gradual	g60304	JJ	B-NP	O
,	,	,000	,	I-NP	O
upward	upward	u1063	JJ	I-NP	O
dose	dose	d020	NN	I-NP	O
titration	titration	t0360305	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
recommended	recommend	r020505303	VBN	I-VP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
narrow	narrow	n060	JJ	I-NP	O
therapeutic	therapeutic	t06010302	JJ	I-NP	O
window	window	w0530	NN	I-NP	O
observed	observe	o1206103	VBN	B-VP	O
with	with	w030	IN	B-PP	O
haloperidol	haloperidol	h0401060304	NN	B-NP	B-Chemical
may	may	m000	MD	B-VP	O
also	also	a420	RB	I-VP	O
apply	apply	a140	VB	I-VP	O
to	to	t000	TO	B-PP	O
other	other	o306	JJ	B-NP	O
neuroleptics	neuroleptic	n060401302	NNS	I-NP	O
used	use	u203	VBN	B-VP	O
in	in	i500	IN	B-PP	O
Alzheimer	Alzheimer	a420506	NNP	B-NP	B-Disease
'	'	'000	POS	B-NP	I-Disease
s	s	s000	NN	I-NP	I-Disease
disease	disease	d02020	NN	I-NP	I-Disease
patients	patient	p030532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
psychosis	psychosis	p2020202	NN	B-NP	B-Disease
and	and	a530	CC	O	O
disruptive	disruptive	d026013010	JJ	B-NP	B-Disease
behaviors	behavior	b01062	NNS	I-NP	I-Disease
.	.	.000	.	O	O

Effects	Effect	e10232	NNS	B-NP	O
of	of	o100	IN	B-PP	O
acetylsalicylic	acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
on	on	o500	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
in	in	i500	IN	B-PP	O
dogs	dog	d020	NNS	B-NP	O
.	.	.000	.	O	O

A	A	a000	DT	B-NP	O
reproducible	reproducible	r01603020140	JJ	I-NP	O
model	model	m0304	NN	I-NP	O
for	for	f060	IN	B-PP	O
producing	produce	p60302052	VBG	B-VP	O
diffuse	diffuse	d01020	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
injury	injury	i52060	NN	I-NP	I-Disease
(	(	(000	(	O	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
)	)	)000	)	O	O
has	have	h020	VBZ	B-VP	O
been	be	b050	VBN	I-VP	O
developed	develop	d01040103	VBN	I-VP	O
to	to	t000	TO	I-VP	O
study	study	s3030	VB	I-VP	O
the	the	t000	DT	B-NP	O
cardioprotective	cardioprotective	c06301603023010	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
agents	agent	a20532	NNS	B-NP	O
or	or	o600	CC	I-NP	O
maneuvers	maneuver	m0501062	NNS	I-NP	O
which	which	w020	WDT	B-NP	O
might	might	m0203	MD	B-VP	O
alter	alter	a4306	VB	I-VP	O
the	the	t000	DT	B-NP	O
evolution	evolution	e1040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
acute	acute	a2030	JJ	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	B-Disease
infarction	infarction	i51062305	NN	I-NP	I-Disease
.	.	.000	.	O	O

Infusions	Infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
epinephrine	epinephrine	e1050106050	NN	B-NP	B-Chemical
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
mug	mug	m020	NN	I-NP	O
per	per	p060	IN	B-PP	O
kilogram	kilogram	k0402605	NN	B-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
for	for	f060	IN	B-PP	O
6	6	6000	CD	B-NP	O
hours	hour	h062	NNS	I-NP	O
)	)	)000	)	O	O
increased	increase	i5260203	VBN	B-NP	O
radiocalcium	radiocalcium	r030204205	NN	I-NP	B-Chemical
uptakes	uptake	u130202	VBZ	B-VP	O
into	into	i530	IN	B-PP	O
intact	intact	i53023	JJ	B-NP	O
myocardium	myocardium	m0206305	NN	I-NP	O
and	and	a530	CC	O	O
each	each	e020	DT	B-NP	O
of	of	o100	IN	B-PP	O
its	its	i320	PRP$	B-NP	O
subcellular	subcellular	s012040406	JJ	I-NP	O
components	component	c051050532	NNS	I-NP	O
with	with	w030	IN	B-PP	O
the	the	t000	DT	B-NP	O
mitochondrial	mitochondrial	m0302053604	JJ	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
showing	show	s052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
most	most	m023	RBS	I-NP	O
consistent	consistent	c052023053	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
compared	compare	c0510603	VBN	B-VP	O
to	to	t000	TO	B-PP	O
saline	saline	s04050	NN	B-NP	O
-	-	-000	HYPH	O	O
infused	infuse	i510203	VBN	B-NP	O
control	control	c053604	NN	I-NP	O
animals	animal	a505042	NNS	I-NP	O
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
,	,	,000	,	O	O
957	957	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
827	827	0000	CD	B-NP	O
counts	count	c0532	NNS	I-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
per	per	p060	IN	B-PP	O
gram	gram	g605	NN	B-NP	O
of	of	o100	IN	B-PP	O
dried	dry	d603	VBN	B-NP	O
tissue	tissue	t020	NN	I-NP	O
or	or	o600	CC	I-NP	O
fraction	fraction	f602305	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
also	also	a420	RB	B-ADVP	O
increased	increase	i5260203	VBD	B-VP	O
significantly	significantly	s025010205340	RB	B-ADVP	O
(	(	(000	(	O	O
12	12	0000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
vs	v	v200	NNS	I-NP	O
.	.	.000	.	O	O
5	5	5000	CD	B-NP	O
.	.	.000	.	O	O
0	0	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
per	per	p060	IN	B-PP	O
100	100	0000	CD	B-NP	O
Gm	Gm	g500	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
fat	fat	f030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
free	free	f600	JJ	I-NP	O
dry	dry	d600	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Infusions	Infusion	i5102052	NNS	B-NP	O
of	of	o100	IN	B-PP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
chloride	chloride	c0406030	NN	I-NP	I-Chemical
sufficient	sufficient	s0102053	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
raise	raise	r020	VB	I-VP	O
serum	serum	s0605	NN	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
2	2	2000	CD	B-NP	O
mEq	mEq	m020	NN	I-NP	O
.	.	.000	.	O	O
per	per	p060	IN	B-PP	O
liter	liter	l0306	NN	B-NP	O
failed	fail	f0403	VBD	B-VP	O
to	to	t000	TO	I-VP	O
increase	increase	i526020	VB	I-VP	O
calcium	calcium	c04205	NN	B-NP	B-Chemical
influx	influx	i51402	NN	I-NP	O
into	into	i530	IN	B-PP	O
the	the	t000	DT	B-NP	O
myocardial	myocardial	m0206304	JJ	I-NP	O
cell	cell	c040	NN	I-NP	O
.	.	.000	.	O	O

Mitochondrial	Mitochondrial	m0302053604	JJ	B-NP	O
radiocalcium	radiocalcium	r030204205	NN	I-NP	B-Chemical
uptakes	uptake	u130202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
in	in	i500	IN	B-PP	O
animals	animal	a505042	NNS	B-NP	O
pretreated	pretreate	p60360303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
acetylsalicylic	acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
or	or	o600	CC	O	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
or	or	o600	CC	O	O
when	when	w050	WRB	B-ADVP	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
was	be	w020	VBD	B-VP	O
added	add	a303	VBN	I-VP	O
to	to	t000	TO	B-PP	O
the	the	t000	DT	B-NP	O
epinephrine	epinephrine	e1050106050	NN	I-NP	B-Chemical
infusion	infusion	i510205	NN	I-NP	O
(	(	(000	(	O	O
2	2	2000	CD	B-NP	O
,	,	,000	,	I-NP	O
682	682	0000	CD	I-NP	O
,	,	,000	,	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
803	803	0000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
3	3	3000	CD	B-NP	O
,	,	,000	,	I-NP	O
424	424	0000	CD	I-NP	O
counts	count	c0532	NNS	I-NP	O
per	per	p060	IN	B-PP	O
minute	minute	m05030	NN	B-NP	O
per	per	p060	IN	B-PP	O
gram	gram	g605	NN	B-NP	O
of	of	o100	IN	B-PP	O
dried	dry	d603	VBN	B-NP	O
fraction	fraction	f602305	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Myocardial	Myocardial	m0206304	JJ	B-NP	O
calcium	calcium	c04205	NN	I-NP	B-Chemical
concentrations	concentration	c052053603052	NNS	I-NP	O
also	also	a420	RB	B-ADVP	O
were	be	w060	VBD	B-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
2	2	2000	CD	I-NP	O
,	,	,000	,	I-NP	O
8	8	8000	CD	I-NP	O
.	.	.000	.	I-NP	O
3	3	3000	CD	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
8	8	8000	CD	B-NP	O
.	.	.000	.	O	O
9	9	9000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O
per	per	p060	IN	B-PP	O
100	100	0000	CD	B-NP	O
Gm	Gm	g500	NN	I-NP	O
.	.	.000	.	O	O
of	of	o100	IN	B-PP	O
fat	fat	f030	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
free	free	f600	JJ	I-NP	O
dry	dry	d600	JJ	I-NP	O
weight	weight	w0203	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
,	,	,000	,	O	O
being	be	b052	VBG	B-VP	O
significantly	significantly	s025010205340	RB	I-VP	O
decreased	decrease	d0260203	VBN	I-VP	O
only	only	o540	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
last	last	l023	JJ	I-NP	O
two	two	t000	CD	I-NP	O
.	.	.000	.	O	O

Evidence	Evidence	e1030520	NN	B-NP	O
of	of	o100	IN	B-PP	O
microscopic	microscopic	m026020102	JJ	B-NP	O
damage	damage	d05020	NN	I-NP	O
was	be	w020	VBD	B-VP	O
graded	grade	g60303	VBN	I-VP	O
as	as	a200	IN	B-PP	O
less	less	l020	RBR	B-ADJP	O
severe	severe	s01060	JJ	I-ADJP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
three	three	t060	CD	I-NP	O
treatment	treatment	t6035053	NN	I-NP	O
groups	group	g6012	NNS	I-NP	O
.	.	.000	.	O	O

Acetylsalicylic	Acetylsalicylic	a20304204020402	JJ	B-NP	B-Chemical
acid	acid	a203	NN	I-NP	I-Chemical
,	,	,000	,	O	O
dipyridamole	dipyridamole	d01060305040	NN	B-NP	B-Chemical
,	,	,000	,	O	O
and	and	a530	CC	O	O
hydrocortisone	hydrocortisone	h0360206302050	NN	B-NP	B-Chemical
all	all	a400	DT	O	O
appear	appear	a106	VBP	B-VP	O
to	to	t000	TO	I-VP	O
have	have	h010	VB	I-VP	O
cardioprotective	cardioprotective	c06301603023010	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
when	when	w050	WRB	B-ADVP	O
tested	test	t02303	VBN	B-VP	O
in	in	i500	IN	B-PP	O
this	this	t020	DT	B-NP	O
model	model	m0304	NN	I-NP	O
.	.	.000	.	O	O

Clinical	Clinical	c4050204	JJ	B-NP	O
and	and	a530	CC	I-NP	O
histopathologic	histopathologic	h0230103040202	JJ	I-NP	O
examination	examination	e205050305	NN	I-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
allografts	allograft	a40260132	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
at	at	a300	IN	B-NP	O
least	least	l023	JJS	I-NP	O
one	one	o500	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

BACKGROUND	BACKGROUND	b026053	NN	B-NP	O
:	:	:000	:	O	O
We	We	w000	PRP	B-NP	O
clinically	clinically	c40502040	RB	B-ADVP	O
and	and	a530	CC	I-ADVP	O
pathologically	pathologically	p03040202040	RB	I-ADVP	O
analyzed	analyze	a5040203	VBN	B-VP	O
renal	renal	r0504	JJ	B-NP	O
allografts	allograft	a40260132	NNS	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
9	9	9000	CD	I-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
treated	treat	t60303	VBN	B-VP	O
with	with	w030	IN	B-PP	O
tacrolimus	tacrolimus	t026040502	NN	B-NP	B-Chemical
(	(	(000	(	O	O
FK506	FK506	0000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
for	for	f060	IN	B-PP	O
more	more	m060	JJR	B-NP	O
than	than	t050	IN	I-NP	O
1	1	1000	CD	I-NP	O
year	year	y060	NN	I-NP	O
.	.	.000	.	O	O

METHODS	METHODS	m03032	NNS	B-NP	O
:	:	:000	:	O	O
Twenty	Twenty	t0530	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
six	six	s020	CD	I-NP	O
renal	renal	r0504	JJ	I-NP	O
allograft	allograft	a4026013	NN	I-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
specimens	specimen	s10205052	NNS	I-NP	O
from	from	f605	IN	B-PP	O
1	1	1000	CD	B-NP	O
9	9	9000	CD	I-NP	O
renal	renal	r0504	JJ	I-NP	O
transplant	transplant	t605214053	NN	I-NP	O
patients	patient	p030532	NNS	I-NP	O
who	who	w000	WP	B-NP	O
underwent	undergo	u5306053	VBD	B-VP	O
transplantations	transplantation	t60521405303052	NNS	B-NP	O
between	between	b0305	IN	B-PP	O
1991	1991	0000	CD	B-NP	O
and	and	a530	CC	I-NP	O
1993	1993	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

Thirteen	Thirteen	t06305	CD	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
performed	perform	p06106503	VBN	I-VP	O
from	from	f605	IN	B-PP	O
stable	stable	s30140	JJ	B-NP	O
functioning	function	f052305052	VBG	I-NP	O
renal	renal	r0504	JJ	I-NP	O
allografts	allograft	a40260132	NNS	I-NP	O
with	with	w030	IN	B-PP	O
informed	inform	i5106503	VBN	B-NP	O
consent	consent	c052053	NN	I-NP	O
(	(	(000	(	O	O
nonepisode	nonepisode	n050102030	JJ	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
other	other	o306	JJ	I-NP	O
13	13	0000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
from	from	f605	IN	B-PP	O
dysfunctional	dysfunctional	d02105230504	JJ	B-NP	O
renal	renal	r0504	JJ	I-NP	O
allografts	allograft	a40260132	NNS	I-NP	O
with	with	w030	IN	B-PP	O
a	a	a000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
indication	indication	i53020305	NN	I-NP	O
for	for	f060	IN	B-PP	O
biopsy	biopsy	b0120	NN	B-NP	O
(	(	(000	(	O	O
episode	episode	e102030	NN	B-NP	O
biopsy	biopsy	b0120	NN	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

RESULTS	RESULTS	r020432	NNS	B-NP	O
:	:	:000	:	O	O
The	The	t000	DT	B-NP	O
main	main	m050	JJ	I-NP	O
pathologic	pathologic	p03040202	JJ	I-NP	O
diagnoses	diagnosis	d0250202	NNS	I-NP	O
(	(	(000	(	O	O
some	some	s050	DT	B-NP	O
overlap	overlap	o106401	NN	I-NP	O
)	)	)000	)	O	O
were	be	w060	VBD	B-VP	O
acute	acute	a2030	JJ	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
(	(	(000	(	O	O
AR	AR	a600	NN	B-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
chronic	chronic	c060502	JJ	B-NP	O
rejection	rejection	r0202305	NN	I-NP	O
(	(	(000	(	O	O
CR	CR	c600	NN	B-NP	O
;	;	;000	:	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
AR	AR	a600	NN	B-NP	O
+	+	+000	SYM	O	O
CR	CR	c600	NN	B-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
4	4	4000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
recurrent	recurrent	r0206053	JJ	B-NP	O
IgA	IgA	i200	NN	I-NP	B-Disease
nephropathy	nephropathy	n010601030	NN	I-NP	I-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
5	5	5000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
normal	normal	n06504	JJ	B-NP	O
findings	finding	f053052	NNS	I-NP	O
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
2	2	2000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
minimal	minimal	m050504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
9	9	9000	CD	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
mild	mild	m043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
(	(	(000	(	O	O
n	n	n000	NN	B-NP	O
=	=	=000	SYM	B-VP	O
11	11	0000	CD	B-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Of	Of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
nonepisode	nonepisode	n050102030	JJ	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
,	,	,000	,	O	O
7	7	7000	CD	B-NP	O
and	and	a530	CC	I-NP	O
4	4	4000	CD	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
showed	show	s030	VBD	B-VP	O
minimal	minimal	m050504	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
and	and	a530	CC	I-NP	O
mild	mild	m043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
.	.	.000	.	O	O

Chronic	Chronic	c060502	JJ	B-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
consisted	consist	c05202303	VBD	B-VP	O
of	of	o100	IN	B-PP	O
rough	rough	r020	JJ	B-NP	O
and	and	a530	CC	I-NP	O
foamy	foamy	f050	JJ	I-NP	O
tubular	tubular	t010406	JJ	I-NP	O
vacuolization	vacuolization	v0204020305	NN	I-NP	O
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
arteriolopathy	arteriolopathy	a63060401030	NN	B-NP	O
(	(	(000	(	O	O
angiodegeneration	angiodegeneration	a52030205060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arteriolar	arteriolar	a63060406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
;	;	;000	:	O	O
20	20	0000	CD	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
focal	focal	f0204	JJ	B-NP	B-Disease
segmental	segmental	s02505304	JJ	I-NP	I-Disease
glomerulosclerosis	glomerulosclerosis	g4050604024060202	NN	I-NP	I-Disease
(	(	(000	(	O	O
4	4	4000	CD	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
)	)	)000	)	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
striped	strip	s360103	VBN	I-NP	O
form	form	f065	NN	I-NP	O
of	of	o100	IN	B-PP	O
interstitial	interstitial	i5306230304	JJ	B-NP	B-Disease
fibrosis	fibrosis	f0160202	NN	I-NP	I-Disease
(	(	(000	(	O	O
11	11	0000	CD	B-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
serum	serum	s0605	NN	I-NP	O
creatinine	creatinine	c60305050	NN	I-NP	B-Chemical
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
patients	patient	p030532	NNS	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mild	mild	m043	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
,	,	,000	,	O	O
which	which	w020	WDT	B-NP	O
included	include	i5240303	VBD	B-VP	O
7	7	7000	CD	B-NP	O
episode	episode	e102030	NN	I-NP	O
biopsies	biopsy	b01202	NNS	I-NP	O
,	,	,000	,	O	O
were	be	w060	VBD	B-VP	O
statistically	statistically	s30302302040	RB	B-ADJP	O
higher	high	h0206	JJR	I-ADJP	O
than	than	t050	IN	B-PP	O
those	those	t020	DT	B-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
minimum	minimum	m050505	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
-	-	-000	HYPH	I-NP	O
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
group	group	g601	NN	I-NP	O
(	(	(000	(	O	O
P	P	p000	NN	B-NP	O
<	<	<000	SYM	B-ADJP	O
0	0	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
001	001	0000	CD	I-NP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

CONCLUSIONS	CONCLUSIONS	c052402052	NNS	B-NP	O
:	:	:000	:	O	O
This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
demonstrates	demonstrate	d05052360302	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
chronic	chronic	c060502	JJ	B-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
consists	consist	c0520232	VBZ	B-VP	O
primarily	primarily	p60506040	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
arteriolopathy	arteriolopathy	a63060401030	NN	B-NP	O
manifesting	manifest	m0501023052	VBG	B-VP	O
as	as	a200	IN	B-SBAR	O
insudative	insudative	i520303010	JJ	B-NP	O
hyalinosis	hyalinosis	h04050202	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
arteriolar	arteriolar	a63060406	JJ	I-NP	O
wall	wall	w040	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
mild	mild	m043	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
chronic	chronic	c060502	JJ	I-NP	O
FK506	FK506	0000	NN	I-NP	B-Chemical
nephropathy	nephropathy	n010601030	NN	I-NP	B-Disease
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
condition	condition	c0530305	NN	I-NP	O
which	which	w020	WDT	B-NP	O
may	may	m000	MD	B-VP	O
lead	lead	l030	VB	I-VP	O
to	to	t000	TO	B-PP	O
deterioration	deterioration	d0306060305	NN	B-NP	O
of	of	o100	IN	B-PP	O
renal	renal	r0504	JJ	B-NP	O
allograft	allograft	a4026013	NN	I-NP	O
function	function	f052305	NN	I-NP	O
.	.	.000	.	O	O

Different	Different	d0106053	JJ	B-NP	O
lobular	lobular	l010406	JJ	I-NP	O
distributions	distribution	d02360103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
altered	altered	a430603	JJ	B-NP	O
hepatocyte	hepatocyte	h010302030	NN	I-NP	O
tight	tight	t0203	JJ	I-NP	O
junctions	junction	j0523052	NNS	I-NP	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intrahepatic	intrahepatic	i536010302	JJ	B-NP	B-Disease
and	and	a530	CC	I-NP	I-Disease
extrahepatic	extrahepatic	e236010302	JJ	I-NP	I-Disease
cholestasis	cholestasis	c040230202	NN	I-NP	I-Disease
.	.	.000	.	O	O

Hepatocyte	Hepatocyte	h010302030	NN	B-NP	O
tight	tight	t0203	JJ	I-NP	O
junctions	junction	j0523052	NNS	I-NP	O
(	(	(000	(	O	O
TJs	TJ	t200	NNS	B-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
only	only	o540	RB	I-NP	O
intercellular	intercellular	i53062040406	JJ	I-NP	O
barrier	barrier	b0606	NN	I-NP	O
between	between	b0305	IN	B-PP	O
the	the	t000	DT	B-NP	O
sinusoidal	sinusoidal	s05020304	JJ	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
canalicular	canalicular	c0504020406	JJ	I-NP	O
spaces	space	s10202	NNS	I-NP	O
,	,	,000	,	O	O
play	play	p400	VBP	B-VP	O
a	a	a000	DT	B-NP	O
key	key	k000	JJ	I-NP	O
role	role	r040	NN	I-NP	O
in	in	i500	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
formation	formation	f0650305	NN	I-NP	O
.	.	.000	.	O	O

Although	Although	a43020	IN	B-SBAR	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
TJs	TJ	t200	NNS	I-NP	O
are	be	a600	VBP	B-VP	O
impaired	impaired	i510603	JJ	B-ADJP	O
in	in	i500	IN	B-PP	O
cholestasis	cholestasis	c040230202	NN	B-NP	B-Disease
,	,	,000	,	O	O
attempts	attempt	a305132	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
localize	localize	l0204020	VB	I-VP	O
the	the	t000	DT	B-NP	O
precise	precise	p602020	JJ	I-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
TJ	TJ	t200	NN	I-NP	O
damage	damage	d05020	NN	I-NP	O
by	by	b000	IN	B-PP	O
freeze	freeze	f6020	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
fracture	fracture	f6023060	NN	I-NP	O
electron	electron	e4023605	NN	I-NP	O
microscopy	microscopy	m02602010	NN	I-NP	O
have	have	h010	VBP	B-VP	O
produced	produce	p6030203	VBN	I-VP	O
limited	limited	l050303	JJ	B-NP	O
information	information	i510650305	NN	I-NP	O
.	.	.000	.	O	O

Recently	Recently	r0205340	RB	B-ADVP	O
,	,	,000	,	O	O
several	several	s010604	JJ	B-NP	O
TJ	TJ	t200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
associated	associate	a2020303	VBN	I-NP	O
proteins	protein	p603052	NNS	I-NP	O
like	like	l020	IN	B-PP	O
ZO	ZO	z000	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
7H6	7H6	0000	CD	I-NP	O
have	have	h010	VBP	B-VP	O
been	be	b050	VBN	I-VP	O
identified	identify	i30530103	VBN	I-VP	O
and	and	a530	CC	O	O
characterized	characterize	c06023060203	VBN	B-VP	O
.	.	.000	.	O	O

Immunolocalization	Immunolocalization	i505040204020305	NN	B-NP	O
of	of	o100	IN	B-PP	O
7H6	7H6	0000	NN	B-NP	O
appears	appear	a1062	VBZ	B-VP	O
to	to	t000	TO	I-VP	O
closely	closely	c402040	RB	I-VP	O
correlate	correlate	c0604030	VB	I-VP	O
with	with	w030	IN	B-PP	O
paracellular	paracellular	p0602040406	JJ	B-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
.	.	.000	.	O	O

We	We	w000	PRP	B-NP	O
used	use	u203	VBD	B-VP	O
rat	rat	r030	NN	B-NP	O
models	model	m03042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
intrahepatic	intrahepatic	i536010302	JJ	B-NP	B-Disease
cholestasis	cholestasis	c040230202	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
ethinyl	ethinyl	e30504	NN	B-NP	B-Chemical
estradiol	estradiol	e2360304	NN	I-NP	I-Chemical
(	(	(000	(	O	O
EE	EE	e000	NN	B-NP	B-Chemical
)	)	)000	)	O	O
treatment	treatment	t6035053	NN	B-NP	O
and	and	a530	CC	O	O
extrahepatic	extrahepatic	e236010302	JJ	B-NP	B-Disease
cholestasis	cholestasis	c040230202	NN	I-NP	I-Disease
by	by	b000	IN	B-PP	O
bile	bile	b040	NN	B-NP	O
duct	duct	d023	NN	I-NP	O
ligation	ligation	l020305	NN	I-NP	O
(	(	(000	(	O	O
BDL	BDL	b340	NN	B-NP	O
)	)	)000	)	O	O
to	to	t000	TO	B-VP	O
precisely	precisely	p60202040	RB	I-VP	O
determine	determine	d03065050	VB	I-VP	O
the	the	t000	DT	B-NP	O
site	site	s030	NN	I-NP	O
of	of	o100	IN	B-PP	O
TJ	TJ	t200	NN	B-NP	O
damage	damage	d05020	NN	I-NP	O
.	.	.000	.	O	O

Alterations	Alteration	a430603052	NNS	B-NP	O
in	in	i500	IN	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
TJs	TJ	t200	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
assessed	assess	a20203	VBN	I-VP	O
by	by	b000	IN	B-PP	O
double	double	d0140	JJ	B-NP	O
-	-	-000	HYPH	I-NP	O
immunolabeling	immunolabeling	i505040104052	NN	I-NP	O
for	for	f060	IN	B-PP	O
7H6	7H6	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
ZO	ZO	z000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
using	use	u2052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
confocal	confocal	c0510204	JJ	I-NP	O
laser	laser	l0206	NN	I-NP	O
scanning	scanning	s205052	NN	I-NP	O
microscope	microscope	m02602010	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
control	control	c053604	NN	B-NP	O
rats	rat	r032	NNS	I-NP	O
,	,	,000	,	O	O
immunostaining	immunostaining	i50502305052	NN	B-NP	O
for	for	f060	IN	B-PP	O
7H6	7H6	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
ZO	ZO	z000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
colocalized	colocalize	c0402040203	VBD	B-VP	O
to	to	t000	TO	I-VP	O
outline	outline	o034050	VB	I-VP	O
bile	bile	b040	NN	B-NP	O
canaliculi	canaliculus	c050402040	NNS	I-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
continuous	continuous	c0530502	JJ	I-NP	O
fashion	fashion	f0205	NN	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
contrast	contrast	c0536023	NN	B-NP	O
,	,	,000	,	O	O
7H6	7H6	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
ZO	ZO	z000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
immunostaining	immunostaining	i50502305052	NN	I-NP	O
was	be	w020	VBD	B-VP	O
more	more	m060	RBR	B-ADJP	O
discontinuous	discontinuous	d020530502	JJ	I-ADJP	O
,	,	,000	,	O	O
outlining	outline	o03405052	VBG	B-VP	O
the	the	t000	DT	B-NP	O
bile	bile	b040	NN	I-NP	O
canaliculi	canaliculus	c050402040	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
BDL	BDL	b340	NN	B-NP	O
.	.	.000	.	O	O

Immunostaining	Immunostaining	i50502305052	NN	B-NP	O
for	for	f060	IN	B-PP	O
7H6	7H6	0000	NN	B-NP	O
,	,	,000	,	O	O
not	not	n030	RB	B-NP	O
ZO	ZO	z000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
,	,	,000	,	O	O
decreased	decrease	d0260203	VBN	B-VP	O
and	and	a530	CC	O	O
predominantly	predominantly	p603050505340	RB	B-VP	O
appeared	appear	a10603	VBD	I-VP	O
as	as	a200	IN	B-PP	O
discrete	discrete	d026030	JJ	B-NP	O
signals	signal	s025042	NNS	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
submembranous	submembranous	s01505160502	JJ	I-NP	O
cytoplasm	cytoplasm	c03014025	NN	I-NP	O
of	of	o100	IN	B-PP	O
periportal	periportal	p060106304	JJ	B-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
BDL	BDL	b340	NN	B-NP	O
.	.	.000	.	O	O

After	After	a1306	IN	B-PP	O
EE	EE	e000	NN	B-NP	B-Chemical
treatment	treatment	t6035053	NN	I-NP	O
,	,	,000	,	O	O
changes	change	c05202	NNS	B-NP	O
in	in	i500	IN	B-PP	O
immunostaining	immunostaining	i50502305052	NN	B-NP	O
for	for	f060	IN	B-PP	O
7H6	7H6	0000	NN	B-NP	O
and	and	a530	CC	I-NP	O
ZO	ZO	z000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
were	be	w060	VBD	B-VP	O
similar	similar	s050406	JJ	B-ADJP	O
to	to	t000	TO	B-PP	O
those	those	t020	DT	B-NP	O
seen	see	s050	VBN	B-VP	O
in	in	i500	IN	B-PP	O
periportal	periportal	p060106304	JJ	B-NP	O
hepatocytes	hepatocyte	h0103020302	NNS	I-NP	O
after	after	a1306	IN	B-PP	O
BDL	BDL	b340	NN	B-NP	O
,	,	,000	,	O	O
but	but	b030	CC	O	O
distributed	distribute	d0236010303	VBD	B-VP	O
more	more	m060	RBR	B-ADVP	O
diffusely	diffusely	d0102040	RB	I-ADVP	O
throughout	throughout	t060203	IN	B-PP	O
the	the	t000	DT	B-NP	O
lobule	lobule	l01040	NN	I-NP	O
.	.	.000	.	O	O

This	This	t020	DT	B-NP	O
study	study	s3030	NN	I-NP	O
is	be	i200	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
first	first	f0623	JJ	I-NP	O
to	to	t000	TO	B-VP	O
demonstrate	demonstrate	d0505236030	VB	I-VP	O
that	that	t030	IN	B-SBAR	O
impairment	impairment	i51065053	NN	B-NP	O
of	of	o100	IN	B-PP	O
hepatocyte	hepatocyte	h010302030	NN	B-NP	O
TJs	TJ	t200	NNS	I-NP	O
occurs	occur	o2062	VBZ	B-VP	O
heterogenously	heterogenously	h030602050240	RB	B-ADVP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
liver	liver	l0106	NN	I-NP	O
lobule	lobule	l01040	NN	I-NP	O
after	after	a1306	IN	B-PP	O
BDL	BDL	b340	NN	B-NP	O
and	and	a530	CC	O	O
suggests	suggest	s020232	VBZ	B-VP	O
that	that	t030	IN	B-SBAR	O
BDL	BDL	b340	NN	B-NP	O
and	and	a530	CC	I-NP	O
EE	EE	e000	NN	I-NP	B-Chemical
treatments	treatment	t60350532	NNS	I-NP	O
produce	produce	p603020	VBP	B-VP	O
different	different	d0106053	JJ	B-NP	O
lobular	lobular	l010406	JJ	I-NP	O
distributions	distribution	d02360103052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
increased	increase	i5260203	VBN	B-NP	O
paracellular	paracellular	p0602040406	JJ	I-NP	O
permeability	permeability	p0650104030	NN	I-NP	O
.	.	.000	.	O	O

Memory	Memory	m05060	NN	B-NP	O
facilitation	facilitation	f0204030305	NN	I-NP	O
and	and	a530	CC	I-NP	O
stimulation	stimulation	s305040305	NN	I-NP	O
of	of	o100	IN	B-PP	O
endogenous	endogenous	e53020502	JJ	B-NP	O
nerve	nerve	n0610	NN	I-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
releaser	releaser	r040206	NN	I-NP	O
PG	PG	p200	NN	I-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
3alpha	3alpha	30410	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
tropyl	tropyl	t60104	NN	B-NP	I-Chemical
2	2	2000	CD	I-NP	I-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
p	p	p000	NN	B-NP	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
bromophenyl	bromophenyl	b605010504	NN	I-NP	I-Chemical
)	)	)000	)	O	I-Chemical
propionate	propionate	p60105030	NN	B-NP	I-Chemical
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
acetylcholine	acetylcholine	a20304204050	NN	I-NP	B-Chemical
releaser	releaser	r040206	NN	I-NP	O
,	,	,000	,	O	O
on	on	o500	IN	B-PP	O
memory	memory	m05060	NN	B-NP	O
processes	process	p6020202	NNS	I-NP	O
and	and	a530	CC	O	O
nerve	nerve	n0610	NN	B-NP	O
growth	growth	g6030	NN	I-NP	O
factor	factor	f02306	NN	I-NP	O
(	(	(000	(	O	O
NGF	NGF	n210	NN	B-NP	O
)	)	)000	)	O	O
synthesis	synthesis	s0530202	NN	B-NP	O
were	be	w060	VBD	B-VP	O
evaluated	evaluate	e1040303	VBN	I-VP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mouse	mouse	m020	NN	I-NP	O
passive	passive	p02010	JJ	I-NP	O
-	-	-000	HYPH	I-NP	O
avoidance	avoidance	a1030520	NN	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
(	(	(000	NN	I-NP	O
10	10	0000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
30	30	0000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
/	/	/000	SYM	B-NP	O
kg	kg	k200	NN	I-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	I-NP	O
p	p	p000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
,	,	,000	,	O	O
administered	administer	a35050230603	VBN	B-VP	O
20	20	0000	CD	B-NP	O
min	min	m050	NN	I-NP	O
before	before	b01060	IN	B-PP	O
the	the	t000	DT	B-NP	O
training	training	t605052	NN	I-NP	O
session	session	s0205	NN	I-NP	O
,	,	,000	,	O	O
prevented	prevent	p60105303	VBD	B-VP	O
amnesia	amnesia	a5020	NN	B-NP	B-Disease
induced	induce	i530203	VBN	B-VP	O
by	by	b000	IN	B-PP	O
both	both	b030	CC	O	O
the	the	t000	DT	B-NP	O
non	non	n050	JJ	I-NP	O
selective	selective	s04023010	JJ	I-NP	O
antimuscarinic	antimuscarinic	a530502060502	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
scopolamine	scopolamine	s2010405050	NN	I-NP	B-Chemical
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
M1	M1	0000	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
selective	selective	s04023010	JJ	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
S	S	s000	NN	I-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
(	(	(000	(	O	I-Chemical
-	-	-000	SYM	O	I-Chemical
)	)	)000	)	O	I-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
ET	ET	e300	NN	I-NP	I-Chemical
-	-	-000	SYM	B-NP	I-Chemical
126	126	0000	CD	B-NP	I-Chemical
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
same	same	s050	JJ	I-NP	O
experimental	experimental	e21060505304	JJ	I-NP	O
conditions	condition	c05303052	NNS	I-NP	O
,	,	,000	,	O	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
(	(	(000	(	O	O
5	5	5000	CD	B-NP	O
-	-	-000	HYPH	I-NP	O
20	20	0000	CD	I-NP	O
microg	microg	m02602	NN	I-NP	O
per	per	p060	IN	B-PP	O
mouse	mouse	m020	NN	B-NP	O
,	,	,000	,	O	O
i	i	i000	NN	B-NP	O
.	.	.000	.	O	O
c	c	c000	NN	B-NP	O
.	.	.000	.	I-NP	O
v	v	v000	NN	I-NP	O
.	.	.000	.	O	O
)	)	)000	)	O	O
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
prevent	prevent	p601053	VB	I-VP	O
antimuscarine	antimuscarine	a53050206050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
amnesia	amnesia	a5020	NN	I-NP	B-Disease
,	,	,000	,	O	O
demonstrating	demonstrate	d050523603052	VBG	B-VP	O
a	a	a000	DT	B-NP	O
central	central	c053604	JJ	I-NP	O
localization	localization	l0204020305	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
activity	activity	a2301030	NN	I-NP	O
.	.	.000	.	O	O

At	At	a300	IN	B-PP	O
the	the	t000	DT	B-NP	O
highest	high	h02023	JJS	I-NP	O
effective	effective	e1023010	JJ	I-NP	O
doses	dose	d0202	NNS	I-NP	O
,	,	,000	,	O	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
produce	produce	p603020	VB	I-VP	O
any	any	a500	DT	B-NP	O
collateral	collateral	c04030604	JJ	I-NP	O
symptoms	symptom	s0513052	NNS	I-NP	O
as	as	a200	IN	B-SBAR	O
revealed	reveal	r010403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
Irwin	Irwin	i605	NNP	I-NP	O
test	test	t023	NN	I-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
it	it	i300	PRP	B-NP	O
did	do	d030	VBD	B-VP	O
not	not	n030	RB	I-VP	O
modify	modify	m03010	VB	I-VP	O
spontaneous	spontaneous	s10530502	JJ	B-NP	O
motility	motility	m0304030	NN	I-NP	O
and	and	a530	CC	I-NP	O
inspection	inspection	i52102305	NN	I-NP	O
activity	activity	a2301030	NN	I-NP	O
,	,	,000	,	O	O
as	as	a200	IN	B-SBAR	O
revealed	reveal	r010403	VBN	B-VP	O
by	by	b000	IN	B-PP	O
the	the	t000	DT	B-NP	O
hole	hole	h040	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
board	board	b063	NN	I-NP	O
test	test	t023	NN	I-NP	O
.	.	.000	.	O	O

PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
was	be	w020	VBD	B-VP	O
also	also	a420	RB	B-ADVP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
increase	increase	i526020	VB	I-VP	O
the	the	t000	DT	B-NP	O
amount	amount	a5053	NN	I-NP	O
of	of	o100	IN	B-PP	O
NGF	NGF	n210	NN	B-NP	O
secreted	secrete	s0260303	VBN	B-VP	O
in	in	i500	FW	B-ADVP	O
vitro	vitro	v0360	FW	I-ADVP	O
by	by	b000	IN	B-PP	O
astrocytes	astrocyte	a236020302	NNS	B-NP	O
in	in	i500	IN	B-PP	O
a	a	a000	DT	B-NP	O
dose	dose	d020	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
dependent	dependent	d01053053	JJ	I-NP	O
manner	manner	m0506	NN	I-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
maximal	maximal	m020504	JJ	I-NP	O
NGF	NGF	n210	NN	I-NP	O
contents	content	c0530532	NNS	I-NP	O
obtained	obtain	o130503	VBN	B-VP	O
by	by	b000	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
were	be	w060	VBD	B-VP	O
17	17	0000	CD	B-NP	O
.	.	.000	.	I-NP	O
6	6	6000	CD	I-NP	O
-	-	-000	HYPH	B-VP	O
fold	fold	f043	RB	B-ADVP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
control	control	c053604	NN	I-NP	O
value	value	v040	NN	I-NP	O
.	.	.000	.	O	O

During	During	d06052	IN	B-PP	O
culture	culture	c043060	NN	B-NP	O
,	,	,000	,	O	O
no	no	n000	DT	B-NP	O
morphological	morphological	m06104020204	JJ	I-NP	O
changes	change	c05202	NNS	I-NP	O
were	be	w060	VBD	B-VP	O
found	find	f053	VBN	I-VP	O
at	at	a300	IN	B-PP	O
effective	effective	e1023010	JJ	B-NP	O
concentrations	concentration	c052053603052	NNS	I-NP	O
of	of	o100	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	B-NP	I-Chemical
9	9	9000	CD	I-NP	I-Chemical
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
current	current	c06053	JJ	I-NP	O
work	work	w062	NN	I-NP	O
indicates	indicate	i53020302	VBZ	B-VP	O
the	the	t000	DT	B-NP	O
ability	ability	a104030	NN	I-NP	O
of	of	o100	IN	B-PP	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
to	to	t000	TO	B-VP	O
induce	induce	i53020	VB	I-VP	O
beneficial	beneficial	b05010204	JJ	B-NP	O
effects	effect	e10232	NNS	I-NP	O
on	on	o500	IN	B-PP	O
cognitive	cognitive	c02503010	JJ	B-NP	O
processes	process	p6020202	NNS	I-NP	O
and	and	a530	CC	O	O
stimulate	stimulate	s30504030	VBP	B-VP	O
activity	activity	a2301030	NN	B-NP	O
of	of	o100	IN	B-PP	O
NGF	NGF	n210	NN	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
astroglial	astroglial	a23602404	JJ	B-NP	O
cells	cell	c042	NNS	I-NP	O
.	.	.000	.	O	O

Therefore	Therefore	t0601060	RB	B-ADVP	O
,	,	,000	,	O	O
PG	PG	p200	NN	B-NP	B-Chemical
-	-	-000	HYPH	O	I-Chemical
9	9	9000	CD	B-NP	I-Chemical
could	could	c043	MD	B-VP	O
represent	represent	r01602053	VB	I-VP	O
a	a	a000	DT	B-NP	O
potential	potential	p0305304	JJ	I-NP	O
useful	useful	u20104	JJ	I-NP	O
drug	drug	d602	NN	I-NP	O
able	able	a140	JJ	B-ADJP	O
to	to	t000	TO	B-VP	O
improve	improve	i516010	VB	I-VP	O
the	the	t000	DT	B-NP	O
function	function	f052305	NN	I-NP	O
of	of	o100	IN	B-PP	O
impaired	impaired	i510603	JJ	B-NP	O
cognitive	cognitive	c02503010	JJ	I-NP	O
processes	process	p6020202	NNS	I-NP	O
.	.	.000	.	O	O

Mechanisms	Mechanism	m02050252	NNS	B-NP	O
of	of	o100	IN	B-PP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
rat	rat	r030	NN	I-NP	O
.	.	.000	.	O	O

-	-	-000	HYPH	B-NP	O
Tacrolimus	Tacrolimus	t026040502	NN	I-NP	B-Chemical
(	(	(000	(	O	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
)	)	)000	)	O	O
is	be	i200	VBZ	B-VP	O
a	a	a000	DT	B-NP	O
powerful	powerful	p06104	JJ	I-NP	O
,	,	,000	,	O	O
widely	widely	w03040	RB	B-VP	O
used	use	u203	VBN	I-VP	O
immunosuppressant	immunosuppressant	i5050201602053	NN	B-NP	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
clinical	clinical	c4050204	JJ	I-NP	O
utility	utility	u304030	NN	I-NP	O
of	of	o100	IN	B-PP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
is	be	i200	VBZ	B-VP	O
complicated	complicate	c0514020303	VBN	I-VP	O
by	by	b000	IN	B-PP	O
substantial	substantial	s012305304	JJ	B-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
and	and	a530	CC	I-NP	O
nephrotoxicity	nephrotoxicity	n0106030202030	NN	I-NP	B-Disease
.	.	.000	.	O	O

To	To	t000	TO	B-VP	O
clarify	clarify	c406010	VB	I-VP	O
the	the	t000	DT	B-NP	O
mechanisms	mechanism	m02050252	NNS	I-NP	O
of	of	o100	IN	B-PP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
,	,	,000	,	O	O
we	we	w000	PRP	B-NP	O
studied	study	s30303	VBD	B-VP	O
the	the	t000	DT	B-NP	O
chronic	chronic	c060502	JJ	I-NP	O
effects	effect	e10232	NNS	I-NP	O
of	of	o100	IN	B-PP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
the	the	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
endothelin	endothelin	e53030405	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
mRNA	mRNA	m650	NN	B-NP	O
of	of	o100	IN	B-PP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	I-NP	O
endothelin	endothelin	e53030405	NN	I-NP	O
-	-	-000	HYPH	O	O
converting	convert	c051063052	VBG	B-VP	O
enzyme	enzyme	e52050	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
(	(	(000	(	O	O
ECE	ECE	e200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
)	)	)000	)	O	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
endothelial	endothelial	e53030404	JJ	I-NP	O
nitric	nitric	n03602	JJ	I-NP	B-Chemical
oxide	oxide	o2030	NN	I-NP	I-Chemical
synthase	synthase	s053020	NN	I-NP	O
(	(	(000	(	O	O
eNOS	eNOS	e502	NN	B-NP	O
)	)	)000	)	O	O
activity	activity	a2301030	NN	B-NP	O
,	,	,000	,	O	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
mRNA	mRNA	m650	NN	B-NP	O
of	of	o100	IN	B-PP	O
eNOS	eNOS	e502	NN	B-NP	O
and	and	a530	CC	I-NP	O
C	C	c000	NN	I-NP	O
-	-	-000	HYPH	I-NP	O
type	type	t010	NN	I-NP	O
natriuretic	natriuretic	n036060302	JJ	I-NP	O
peptide	peptide	p013030	NN	I-NP	O
(	(	(000	(	O	O
CNP	CNP	c510	NN	B-NP	O
)	)	)000	)	O	O
in	in	i500	IN	B-PP	O
rat	rat	r030	NN	B-NP	O
blood	blood	b403	NN	I-NP	O
vessels	vessel	v02042	NNS	I-NP	O
.	.	.000	.	O	O

In	In	i500	IN	B-PP	O
addition	addition	a30305	NN	B-NP	O
,	,	,000	,	O	O
the	the	t000	DT	B-NP	O
effect	effect	e1023	NN	I-NP	O
of	of	o100	IN	B-PP	O
the	the	t000	DT	B-NP	O
specific	specific	s1020102	JJ	I-NP	O
endothelin	endothelin	e53030405	NN	I-NP	O
type	type	t010	NN	I-NP	O
A	A	a000	NN	I-NP	O
receptor	receptor	r0201306	NN	I-NP	O
antagonist	antagonist	a530205023	NN	I-NP	O
FR	FR	f600	NN	I-NP	B-Chemical
139317	139317	0000	CD	I-NP	I-Chemical
on	on	o500	IN	B-PP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
was	be	w020	VBD	B-VP	O
studied	study	s30303	VBN	I-VP	O
.	.	.000	.	O	O

FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
,	,	,000	,	I-NP	O
5	5	5000	CD	I-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	.	O	O

kg	kg	k200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	O	O

d	d	d000	SYM	B-NP	O
-	-	-000	:	O	O
1	1	1000	CD	B-NP	O
given	give	g0105	VBN	B-VP	O
for	for	f060	IN	B-PP	O
4	4	4000	CD	B-NP	O
weeks	week	w020	NNS	I-NP	O
,	,	,000	,	O	O
elevated	elevated	e4010303	JJ	B-NP	O
blood	blood	b403	NN	I-NP	O
pressure	pressure	p602060	NN	I-NP	O
from	from	f605	IN	B-PP	O
102	102	0000	CD	B-NP	O
+	+	+000	SYM	B-ADJP	O
/	/	/000	SYM	O	O
-	-	-000	SYM	O	O
13	13	0000	CD	B-NP	O
to	to	t000	TO	B-PP	O
152	152	0000	CD	B-NP	O
+	+	+000	SYM	O	O
/	/	/000	SYM	B-NP	O
-	-	-000	SYM	B-NP	O
15	15	0000	CD	I-NP	O
mm	mm	m500	NN	I-NP	O
Hg	Hg	h200	NN	I-NP	O
and	and	a530	CC	O	O
increased	increase	i5260203	VBD	B-VP	O
the	the	t000	DT	B-NP	O
synthesis	synthesis	s0530202	NN	I-NP	O
of	of	o100	IN	B-PP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
mesenteric	mesenteric	m020530602	JJ	I-NP	O
artery	artery	a63060	NN	I-NP	O
(	(	(000	(	O	O
240	240	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
230	230	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

Little	Little	l0340	JJ	B-NP	O
change	change	c0520	NN	I-NP	O
was	be	w020	VBD	B-VP	O
observed	observe	o1206103	VBN	I-VP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
expression	expression	e2160205	NN	I-NP	O
of	of	o100	IN	B-PP	O
ECE	ECE	e200	NN	B-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
and	and	a530	CC	I-NP	O
CNP	CNP	c510	NN	I-NP	O
mRNA	mRNA	m650	NN	I-NP	O
.	.	.000	.	O	O

FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
decreased	decrease	d0260203	VBD	B-VP	O
eNOS	eNOS	e502	NN	B-NP	O
activity	activity	a2301030	NN	I-NP	O
and	and	a530	CC	O	O
the	the	t000	DT	B-NP	O
levels	level	l01042	NNS	I-NP	O
of	of	o100	IN	B-PP	O
eNOS	eNOS	e502	NN	B-NP	O
mRNA	mRNA	m650	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
aorta	aorta	a0630	NN	I-NP	O
(	(	(000	(	O	O
48	48	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
and	and	a530	CC	O	O
55	55	0000	CD	B-NP	O
%	%	%000	NN	I-NP	O
,	,	,000	,	O	O
respectively	respectively	r02102301040	RB	B-ADVP	O
)	)	)000	)	O	O
.	.	.000	.	O	O

The	The	t000	DT	B-NP	O
administration	administration	a350502360305	NN	I-NP	O
of	of	o100	IN	B-PP	O
FR	FR	f600	NN	B-NP	B-Chemical
139317	139317	0000	CD	I-NP	I-Chemical
(	(	(000	(	O	O
10	10	0000	CD	B-NP	O
mg	mg	m200	NN	I-NP	O
.	.	.000	SYM	I-NP	O
kg	kg	k200	NN	I-NP	O
-	-	-000	HYPH	B-NP	O
1	1	1000	CD	I-NP	O
.	.	.000	.	I-NP	O
d	d	d000	NN	I-NP	O
-	-	-000	:	O	O
1	1	1000	CD	B-NP	O
)	)	)000	)	O	O
prevented	prevent	p60105303	VBD	B-VP	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
-	-	-000	HYPH	B-NP	O
induced	induce	i530203	VBN	I-NP	O
hypertension	hypertension	h0106305205	NN	I-NP	B-Disease
in	in	i500	IN	B-PP	O
rats	rat	r032	NNS	B-NP	O
.	.	.000	.	O	O

These	These	t020	DT	B-NP	O
results	result	r020432	NNS	I-NP	O
indicate	indicate	i5302030	VBP	B-VP	O
that	that	t030	IN	B-SBAR	O
FK	FK	f200	NN	B-NP	B-Chemical
506	506	0000	CD	I-NP	I-Chemical
may	may	m000	MD	B-VP	O
increase	increase	i526020	VB	I-VP	O
blood	blood	b403	NN	B-NP	O
pressure	pressure	p602060	NN	I-NP	O
not	not	n030	RB	B-CONJP	O
only	only	o540	RB	I-CONJP	O
by	by	b000	IN	B-PP	O
increasing	increase	i52602052	VBG	B-VP	O
ET	ET	e300	NN	B-NP	O
-	-	-000	HYPH	O	O
1	1	1000	CD	B-NP	O
production	production	p60302305	NN	I-NP	O
but	but	b030	CC	B-CONJP	O
also	also	a420	RB	I-CONJP	O
by	by	b000	IN	B-PP	O
decreasing	decrease	d02602052	VBG	B-VP	O
NO	NO	n000	NN	B-NP	B-Chemical
synthesis	synthesis	s0530202	NN	I-NP	O
in	in	i500	IN	B-PP	O
the	the	t000	DT	B-NP	O
vasculature	vasculature	v020403060	NN	I-NP	O
.	.	.000	.	O	O

